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	Foreword
Richard	A.C.	Hughes
Arthur	K.	Asbury
The	lifetime	risk	of	Guillain-Barré	syndrome	(GBS)	is	one	in	a	thousand,	not	common,	but	not	rare	either.
It	 punches	 above	 its	 weight	 in	 the	 hierarchy	 of	 diseases	 because	 its	 onset	 is	 dramatic,	 its	 effects
potentially	devastating,	its	pathology	fascinating,	its	mechanisms	tantalising	and	its	treatment	so	far	only
partly	satisfactory.	One	of	us	(AKA)	studied	a	large	number	of	cases	postmortem	and	noted	the	similarity
of	the	usual	pathology	to	the	animal	model,	experimental	autoimmune	neuritis	[1].	This	prompted	the	other
(RACH)	to	search	for	the	antigen	responsible	for	the	animal	model	[2]	and	to	look	for	better	treatments
[3].	 Interest	 in	 GBS	 grew	 to	 the	 extent	 that	 by	 the	 early	 1990s	 two	 books	 on	 GBS	 appeared	 almost
simultaneously,	one	with	one	author	and	the	other	with	three	[4,5].	A	generation	later	and	a	century	since
the	famous	description	by	Guillain,	Barré	and	Strohl	in	1916,	this	new	book	commands	63	chapters	and
over	100	authors.	It	is	a	fascinating	read.
In	the	1800s,	the	site	of	pathology	in	acute	ascending	paralysis	was	still	unclear.	In	the	first	two-thirds
of	 the	 1900s,	 pathological	 studies	 showed	 inflammation	 and	 tissue	 damage	 throughout	 the	 nerves	 and
spinal	roots.	The	clinical	picture	appeared	rather	uniform.	In	the	mid-1950s,	C.	Miller	Fisher	described
his	 eponymous	 syndrome	 of	 eye	 movement	 paralysis,	 loss	 of	 tendon	 reflexes	 and	 ataxia	 which	 may
overlap	with	GBS	[6].	In	the	last	quarter	of	the	1900s,	American	and	Chinese	investigators	identified	a
paralytic	syndrome	due	to	predominantly	motor	neuropathy	[7].	Others	have	described	formes	frustes	and
more	 chronic	 clinical	 courses.	 Increasingly	 sophisticated	 electrophysiology	 has	 distinguished
predominantly	demyelinating	disease	 from	 forms	due	 to	primary	 axonal	degeneration	or,	most	 recently,
forms	 due	 to	 nodal	 conduction	 block	 without	 either	 demyelination	 or	 axonal	 degeneration.	 With
increasingly	refined	diagnostic	criteria	[8],	epidemiological	studies	have	shown	that	GBS	is	a	worldwide
problem	 but	 with	 a	 preponderance	 of	 different	 clinical	 forms	 in	 different	 geographical	 regions.	 The
ongoing	massive	international	GBS	outcome	study	(IGOS),	with	more	than	1,000	records,	will	give	new
insights	into	these	variations.
The	 first	 pathological	 studies	 emphasized	 cellular	 infiltration	 by	 macrophages	 as	 responsible	 for
damaging	the	myelin	sheaths	with	T	cells	directed	against	myelin	proteins	as	instigating	the	process.	This
mechanism	 is	 certainly	 the	 cause	 of	 experimental	 autoimmune	 neuritis.	 It	 arises	 spontaneously	 in	mice
lacking	specific	genes	which	control	T	cell	regulation.	However,	some	human	pathological	studies	have
shown	 deposition	 of	 immunoglobulin	 and	 complement	 on	 the	 surface	 of	 myelin	 sheaths,	 suggesting
antibody	rather	 than	T-cell	mechanisms	 in	GBS.	In	mouse	and	rabbit	models,	antibodies	 to	glycolipids,
especially	 gangliosides,	 cause	 conduction	 block	 and	 axonal	 degeneration	 closely	 mimicking	 the
predominantly	motor	axonal	neuropathy	form	of	GBS.	Although	there	is	little	evidence	of	T-cell	responses
to	myelin	proteins,	antibodies	to	gangliosides	are	present	in	the	acute	phase	of	GBS,	and	their	antigenic
target	defines	the	clinical	pattern	of	the	disease.	Thus	antibodies	to	glycolipids	have	become	the	favoured
mechanism	 causing	 GBS.	 With	 the	 latest	 microarray	 technology,	 antibodies	 to	 complex	 arrays	 of
glycolipids	are	detectable	in	the	more	common	demyelinating	form	of	GBS	as	well	as	in	the	axonal	forms
of	the	disease	and	Fisher	syndrome.
Campylobacter	 jejuni	 infection	 is	 the	 commonest	 of	 several	 known	 antecedent	 events	 precipitating
GBS.	Some	genetic	strains	of	this	bacterium	have	lipopolysaccharides	in	their	membranes	which	trigger
antibody	responses	in	genetically	susceptible	individuals.	The	antibodies	react	with	gangliosides	on	the
surface	of	the	axolemma	or	myelin	sheaths	in	parts	of	the	peripheral	nervous	system	accessible	to	soluble
factors.	One	of	the	intriguing	mysteries	about	GBS	is	that	so	many	different	infections	trigger	a	clinically
similar	 disease.	 Case	 reports	 and	 small	 series	 report	 hundreds	 of	 preceding	 illnesses.	 Case	 control
studies	implicate	cytomegalovirus,	Epstein-Barr	virus	and	hepatitis	E	as	well	as	Campylobacter	 jejuni,
and	the	IGOS	study	is	likely	to	add	more.	Are	all	these	diseases	the	same?	Or	does	the	peripheral	nervous
system	have	only	a	limited	number	of	ways	of	expressing	a	disease	due	to	an	inflammatory	reaction?	Does
the	occurrence	of	disease	reflect	the	specific	virulence	of	the	organism	or	the	failure	of	immune	regulation
by	the	patient?	Or,	more	likely,	both?	This	book	should	bring	us	closer	to	answering	these	questions.
Even	in	the	absence	of	a	full	understanding	of	the	mechanisms	of	GBS,	neurologists	have	been	testing
empirical	treatments.	Spontaneous	improvement	is	usual,	which	has	made	it	impossible	to	judge	whether
many	 claims	 of	 successful	 treatment	 reflect	 anything	 other	 than	 the	 natural	 history	 of	 the	 disease.
However,	 recovery	 is	 often	 slow	 and	 incomplete,	 which	 has	 stimulated	 the	 launch	 of	 randomised
controlled	 trials.	 Cochrane	 systematic	 reviews	 contain	 convenient	 meta-analyses	 of	 their	 results.
Surprisingly,	 corticosteroids,	 the	panacea	 for	many	 inflammatory	diseases,	 turned	out	 to	be	 ineffective.
The	 first	 treatment	 shown	 to	be	able	 to	hasten	 recovery	and	 shorten	 the	disease	was	plasma	exchange.
Intravenous	immunoglobulin	is	as	effective	and	more	convenient	and	so	more	commonly	used	where	it	is
available.	The	 success	of	 these	 two	 treatments	has	made	 further	progress	more	difficult	because	 it	 has
become	unacceptable	to	omit	treatment	with	one	of	them.	It	is	encouraging	that	there	is	an	ongoing	trial	of
the	complement	inhibitor	eculizumab	founded	on	observations	in	a	relevant	animal	model.	We	hope	that
this	 book	will	 stimulate	 others	 to	 test	 some	 of	 the	many	 available	 newer	 immunomodulatory	 agents	 to
provide	 the	 improvement	 in	 treatment	 which	 our	 patients	 need.	 Our	 patients	 and	 their	 support
organisations	constantly	remind	us	that	they	need	more	consistent	rapid	diagnosis,	prompter	treatment	and
greater	attention	to	the	disability,	pain	and	fatigue	which	GBS	may	leave	behind.	This	book	will	set	the
stage	but	much	remains	to	be	done.
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	GBS	Centenary
Hugh	J.	Willison,	John	A.	Goodfellow	and	David	R.	Cornblath
It	 has	 been	 a	 century	 since	 the	 famous	 description	was	 first	 published	 in	 1916	by	Guillain,	Barré	 and
Strohl	of	an	acute	onset	polyneuropathy	with	albumino-cytologic	dissociation	 in	 the	cerebrospinal	 fluid
(CSF)	and	clinical	 recovery.	This	new	disorder	was	distinguished	from	acute	poliomyelitis	which	also
caused	acute	onset	weakness	but	exhibited	asymmetry,	variable	recovery,	and	an	inflammatory	CSF.	As
time	passed,	 the	disease	became	best	known	by	 the	names	of	 its	 first	2	authors.	Strohl’s	name	receded
from	 the	 roll-call,	 and	 Landry’s	 prior	 description	 also	 became	 increasingly	 overlooked	 as	 the	 current
eponym	 took	 its	 place	 in	 the	 medical	 hall	 of	 fame.	 Thus	 the	 Landry-Guillain-Barré-Strohl	 syndrome
became	 the	 Guillain-Barré	 syndrome,	 more	 commonly	 referred	 to	 just	 as	 GBS.	 GBS	 today	 is	 known
worldwide	where	the	incidence	is	a	steady	2	cases	per	100,000	of	population	per	year.	On	this	basis,	we
estimate	 there	 are	 over	 100,000	 cases	 per	 annum	worldwide.	GBS	 is	 now	 the	most	 common	 cause	 of
onset	flaccid	paralysis,	as	polio	has	receded	due	to	vaccination.
As	 part	 of	 the	 Inflammatory	Neuropathy	Consortium/Peripheral	Nerve	Society	meeting	 in	Glasgow,
22–23	June	2016,	it	was	decided	to	have	a	GBS	Centenary	Symposium	and	celebration	on	24	June	2016
and	to	publish	this	book.	Rather	 than	a	conventional	 textbook,	a	more	reflective	format	was	considered
appropriate.	Modern	bibliographic	databases	make	access	to	the	primary	literature	a	click	of	the	mouse
away,	and	there	was	no	particular	desire	to	create	a	comprehensive	summary	of	100	years	of	published
work.	 Authors	 were	 thus	 assigned	 the	 brief	 of	 choosing	 roughly	 10	 publications,	 their	 ‘Top	 10’,	 that
influenced	their	thinking	around	the	subject	of	GBS.	A	wide	range	of	authors	from	emeritus	professors	to
junior	medical	 students	 from	 around	 the	 world	 were	 invited	 to	 contribute	 their	 thoughts	 on	 particular
topics,	each	in	their	writing	style.	The	result	is	a	collection	of	63	essays	from	110	authors	presented	in	a
highly	 eclectic	 format.	 Some	 contributors	 have	 stuck	 firmly	 to	 the	 Top	 10	 format,	 while	 others	 have
written	 conventional	 accounts	 of	 their	 topic.	 Some	 are	 poetic,	 yet	 others	 prosaic.	Contents	 range	 from
history	 of	 the	 syndrome	 to	 the	 future	 of	GBS.	There	 are	many	 personal	 reflections	 by	 those	who	 have
made	important	contributions	to	the	understanding	and	treatment	of	the	disease.	The	reader	can	take	in	one
or	more	chapters	of	special	interest	or	just	read	any	chapter	for	pleasure.	The	book	is	readily	accessible
to	those	with	highly	specialized	interests	in	selected	areas	of	research,	the	general	neurologist	looking	for
an	update,	and	the	patients	and	their	families	trying	to	understand	this	mysterious	illness.	For	all,	it	should
be	a	road	map	for	the	next	100	years.
The	 book’s	 foreword	was	written	 by	 2	 of	 the	most	 important	GBS	 researchers,	 Professors	 R.A.C.
Hughes	 and	 A.K.	 Asbury,	 who	 have	 made	 seminal	 contributions	 to	 the	 field	 over	 a	 lifetime	 of
achievement.	 It	 provides	 an	 overview	of	 the	 first	 100	years	 in	 a	 few	pages.	We	open	with	 an	English
translation	of	the	original	1916	paper.	A	facsimile	reprint	and	re-typed	French	version	are	included	as	an
appendix.	The	History	section	includes	reflections	from	the	Hôpital	de	la	Pitié-Salpêtrière,	the	home	of
many	famous	French	neurologists,	and	moves	through	a	timeline	of	both	famous	and	forgotten	papers.
The	Epidemiology	section	includes	a	broad	worldwide	view	of	GBS.	Highlighted	is	the	International
GBS	 Outcome	 Study	 (IGOS)—a	 multinational	 collaborative	 effort	 led	 by	 the	 Rotterdam	 GBS	 group
involving	 over	 1,000	 GBS	 patients,	 all	 contributing	 to	 a	 massive	 collection	 of	 clinical,
electrophysiological,	biospecimens,	and	outcomes	data.	This	will	be	a	rich	source	of	study	for	years	to
come.	 Important	 advances	 in	GBS	have	 come	 from	studies	 in	 the	 Indian	 subcontinent,	China,	Asia	 and
Japan,	and	these	are	well	covered.
The	Clinical	section	highlights	those	disorders	that	originally	were	not	thought	to	be	classic	GBS,	an
acute	 ascending	 sensory-motor	 polyneuropathy,	 but	 that	 were	 eventually	 realized	 to	 be	 part	 of	 the
spectrum	 of	 GBS.	 These	 disorders,	 ranging	 from	 Miller	 Fisher	 syndrome	 to	 acute	 motor	 axonal
neuropathy,	 and	 lesser-known	 syndromes	 have	 indeed	 taught	 us	 much	 about	 the	 classic	 syndrome.
Investigations	 of	 these	 ‘variants’	 have	 provided	 important	 clues	 about	 epidemiology	 and	 pathogenesis,
and	we	await	more	from	further	study	of	them.
The	Clinical	Investigation	section	shows	how	understanding	the	many	areas	that	confirm	the	clinical
diagnosis	of	GBS,	shown	in	the	Clinical	section,	have	advanced	our	knowledge.	Pathological	studies	led
to	 the	 first	 inkling	 that	 this	was	 an	 autoimmune	 disorder	 and	 supported	 both	 the	 humoral	 and	 cellular
hypotheses	 of	 the	 disease.	 Physiology	 has	 helped	 refine	 the	 pathophysiological	 understanding	 of	GBS,
leading	to	the	more	recent	concepts	of	the	node	of	Ranvier	as	a	major	site	of	action	in	the	evolution	of	the
disease.	 Imaging	 promises	 to	 provide	 new	 insights,	 as	 it	 can	 look	 at	 the	 whole	 nervous	 system	 or
concentrate	on	specific	areas	of	 interest.	Lastly,	 there	 remains	great	 interest	 in	what	we	can	 learn	from
CSF	aside	from	disease	confirmation.
The	sections	on	the	many	aspects	of	more	basic	research	(animal	models,	basic	science,	antibodies,
and	antecedent	events	and	susceptibility)	show	how	much	has	been	done	but	also	how	much	more	there	is
to	do.	Taken	together,	these	sections	begin	with	the	observations	from	the	1950s	in	experimental	allergic
neuritis	and	move	through	an	enormous	research	effort.	These	studies	include	important	observations	on
diarrhoea,	 Campylobacter	 jejuni	 and	 GBS,	 gangliosides	 and	 GBS,	 auto-antibodies	 and	 GBS,	 and
genetics	 and	GBS.	 These	 and	 others	 have	 led	 to	 the	 current	 understanding	 of	 GBS	 as	 an	 autoimmune
disorder	 in	which	a	genetically	susceptible	 individual	comes	 into	contact	with	a	specific	 inciting	agent
and	then	develops	antibodies	against	that	agent	which	mistakenly	identify	the	nerve	as	similar	and	attack
it.
The	 Treatment	 section	 discusses	 the	 current	 standards	 of	 care:	 plasma	 exchange	 and	 intravenous
immunoglobulins.	Importance	is	given	to	the	role	of	supportive	care	as	critically	necessary	in	the	overall
management.	Noted	is	the	fact	that	no	new	treatment	has	been	approved	for	GBS	since	the	1990s.	There
are	several	clinical	trials	now	underway	and	hopefully,	by	the	printing	of	this	book,	their	results	will	be
known	and	new	treatment	options	will	be	available.
The	Outcome	section	shows	how	far	we	have	come	in	the	provision	of	rehabilitation	services	and	our
ability	to	predict	outcomes.	But	we	also	need	better	outcome	measures	for	our	clinical	trials	that	mimic
what	patients	think	about	themselves	and	their	recovery.
The	last	section	is	a	potpourri	of	Top	10,	from	bibliographical	citations	to	images	to	views	of	medical
students	and	Ph.D.	candidates	to	the	patient	perspective.	It	ends	with	a	view	to	the	future.
We	 wish	 to	 thank	 the	 GBS	 CIDP	 Foundation	 International	 for	 their	 continuous	 support	 and	 for
providing	the	funds	for	publication.	We	thank	our	many	colleagues	around	the	world	for	embracing	this
project	 with	 such	 enthusiasm	 and	 demonstrating	 a	 remarkable	 array	 of	 talent.	 Last	 we	 dedicate	 this
publication	 to	 all	 those	who	have	had	GBS	and	 their	 families,	who	provide	 the	 inspiration	 to	do	 ever
more	to	alleviate	the	natural	course	of	Guillain-Barré	syndrome.
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On	a	Radiculo-Neuritis	Syndrome	with
Hyperalbuminosis	of	the	Cerebrospinal	Fluid
without	Cell	Reaction.	Notes	on	Clinical	and
Graphical	Characteristics	of	Tendon	Reflexes
MM.	Georges	Guillain,	J.-A.	Barré	and	A.	Strohl
We	draw	 attention,	 in	 this	 note,	 to	 a	 clinical	 syndrome	which	we	have	 observed	 in	 two	patients.	This
syndrome	is	characterized	by	motor	disturbance,	abolition	of	the	tendon	reflexes	with	preservation	of	the
cutaneous	 reflexes,	paraesthesia	with	mild	disorders	of	objective	sensation,	pain	at	pressure	of	muscle
masses,	 slightly	 accentuated	 changes	 of	 the	 electric	 reactions	 of	 nerves	 and	muscles	 and	 very	 notable
hyperalbuminosis	of	 the	cerebrospinal	 fluid	with	absence	of	cytological	 reaction	 (albumino-cytological
dissociation).	This	syndrome	appeared	 to	depend	on	a	concomitant	 involvement	of	spinal	 roots,	nerves
and	muscles,	most	probably	of	infectious	or	toxic	nature.	It	must	be	differentiated	from	simple	radiculitis,
pure	polyneuritis	and	polymyalgia.	Experimental	research	using	a	graphic	method	on	the	speed	of	reflexes
and	 their	 delayed	 time,	 on	 the	 modalities,	 the	 muscular	 contractility,	 show	 that,	 in	 reality,	 the	 whole
peripheral	 neuro-muscular	 system	 is	 involved	 in	 the	 syndrome.	 We	 also	 particularly	 insist	 on	 the
hyperalbuminosis	 of	 the	 cerebrospinal	 fluid	without	 cytological	 reaction,	which	 to	 our	 knowledge	 has
never	been	mentioned	in	similar	cases.
OBS.	1.	The	soldier	D	…,	of	the	hussars,	twenty-five-years	old,	arrived
on	the	20th	of	August	1916,	at	the	neurological	Centre	of	the	VIth	Army
because	of	motor	disturbances	of	the	lower	and	upper	limb	members.
The	affliction	affected	him	beginning	in	July	the	25th	with	tingling	of
feet	and	weakness	of	the	lower	limbs,	such	that	he	had	to	stop
walking	every	200	to	300	meters.	Then	during	the	following	days,
tingling	appeared	in	the	upper	limbs	and	on	the	lower	part	of	the	face;
the	muscular	strength	weakened	in	the	upper	limbs.
These	 various	 disorders	 evolved	 without	 obvious	 cause:	 the	 patient	 didn’t	 have	 a	 recent	 infectious
disease	 or	 any	 pharyngitis	 (even	 mild).	 He	 didn’t	 have	 symptoms	 of	 food	 poisoning	 and	 no	 major
tiredness.	We	shall	add	that,	in	his	past	medical	history,	we	didn’t	find	any	important	facts;	the	sick	person
denied	any	syphilitic	infection	and	any	alcoholic	habit.	The	first	examination	of	August	25th	allowed	us	to
notice	the	following	symptomatology.
The	 muscular	 strength	 was	 globally	 decreased	 in	 the	 upper	 and	 lower	 limbs	 but	 without	 a	 total
paralysis;	 this	decrease	of	 the	muscular	 strength	was	especially	prominent	 in	 the	extremities	where	we
noticed	an	extreme	weakness	of	the	flexion	and	the	extension	of	toes,	foot,	fingers	and	hands.
The	 muscles	 of	 the	 trunk	 were	 also	 weak,	 so	 that	 the	 patient	 could	 not	 sit	 independently	 without
support.
Walking	was	possible	for	a	few	steps;	we	then	noticed	a	certain	gait	instability	and	the	upright	posture
of	the	foot	could	not	be	maintained.
There	was	no	disorder	of	facial	muscle	power.
The	electric	examination	showed	that	in	the	upper	limbs,	the	faradic	excitability	was	normal	and	the
galvanic	excitability	was	good	for	all	the	muscles	with	lively	shocks;	there	was	no	polar	inversion;	we
only	remarked	on	a	light	hypo-excitability	of	the	finger	extensor;	sometimes	the	shock	was	slightly	slowed
down;	we	noticed	polar	 inversion	for	 the	 lateral	gastrocnemius,	but	 the	degeneration	reaction	was	very
incomplete.
The	patellar,	Achilles	and	medio-plantar	reflexes	investigated	with	the	hammer	were	absent,	as	well
as	the	bicep,	radio-and	cubito-pronator,	and	olecranon	reflexes.
The	plantar	cutaneous	reflexes	led	to	obvious	flexion	of	the	toes	with	a	contraction	at	distance	of	the
tensor	fascia	latae.	Cremasteric	and	cutaneous	abdominal	reflexes	were	normal.	We	noted	no	withdrawal
reflexes,	either	plucking	of	the	instep,	or	by	hyperflexion	of	the	toes.
The	 neuro-muscular	 excitability	 brought	 about	 by	 direct	 percussion	 of	 the	 muscle	 mass	 with	 the
hammer	was	maintained.
The	patient	still	reported	tingling	in	both	feet	up	to	the	top	of	malleolus	and	in	both	hands	up	to	over
the	wrist.	There	was	no	clear	disorder	of	objective	sensibility,	but	we	found	a	mild	hypoesthesia	to	touch,
heat	and	pain	in	the	feet	and	hands.	The	muscle	mass	of	the	upper	and	lower	limbs	ached	upon	pressure.
Pupils	reacted	to	light	and	accommodation.
There	was	no	sphincter	dysfunction.
There	was	no	fever,	and	no	respiratory	or	gastro-intestinal	disorder,	and	the	pulse	was	normal.
Urine,	examined	at	the	Laboratory	of	Bacteriology	and	Chemistry	of	the	Army,	did	not	contain	either
sugar,	nor	albumin,	nor	indoxyl;	the	chemical	elements	were	in	their	normal	proportion.
Lumbar	 puncture	 showed	 clear	 cerebrospinal	 fluid,	 not	 hypertensive,	 with	 hyperalbuminosis	 (2.5
grams	of	albumin	per	litre)	without	a	leukocyte	reaction	(2–4	cells	per	field).
The	Wassermann	reaction	in	the	blood	was	negative.
Specimens	from	the	pharynx	and	nasal	mucus	showed	the	absence	of	any	diphtheria	bacilli.
Treatment	 consisted	 of	 absolute	 rest,	 massage	 of	 the	 upper	 and	 lower	 limbs,	 and	 injections	 of
strychnine	and	soda	of	phenylsalicylate.
On	August	the	27th,	tingling	decreased	in	the	lower	limbs.
On	September	 the	2nd,	some	improvement	 in	muscle	strength	was	observed,	and	there	was	no	more
tingling	 in	 the	 feet,	 but	 it	 persisted	 in	 the	 hands.	 Tendon	 reflexes	 were	 still	 absent.	 A	 repeat	 lumbar
puncture	 showed	 a	 very	 marked	 hyperalbuminosis	 without	 appreciable	 leukocyte	 reaction	 as	 in	 the
previous	examination.
On	September	the	19th,	motor	disturbance	was	improving;	the	patient	was	able	to	walk	for	an	hour;	he
could	stand	on	one	foot.	Paresthesia	had	completely	disappeared	in	the	lower	limbs	but	persisted	in	the
hands	 although	 this	was	 attenuated.	 Tendon	 reflexes	were	 clinically	 absent,	 there	were	 no	withdrawal
reflexes,	 and	 cutaneous	 reflexes	 were	 normal.	 With	 direct	 percussion	 of	 the	 muscle	 masses	 with	 the
hammer,	neuromuscular	excitability	seemed	normal	in	the	upper	and	lower	limbs	and	in	the	face.
The	patient,	gradually	improving,	was	sent	to	convalesce	on	the	30th	of	September.
OBS.	II.	The	soldier	D	…,	from	the	…	Infantry	Regiment,	thirty-five-years
old,	arrived	on	the	5th	of	September	1916,	at	the	Neurological	Centre
of	the	VIth	Army	because	of	motor	disturbance	in	the	lower	limbs
which	were	shown	in	the	following	circumstances.
On	the	28th	of	August,	after	a	walk	of	15	kilometres,	he	felt	an	abnormal	fatigue,	headache,	erratic	pain	in
the	upper	and	lower	limbs.	He	lay	down,	could	not	sleep	and	shivered	part	of	the	night.	The	next	morning
he	 walked	 with	 huge	 difficulty	 to	 go	 to	 the	 examination;	 he	 was	 exempted	 from	 service	 for	 four
consecutive	days.	The	paretic	state	began	with	the	lower	limbs	and	then	reached	the	upper	limbs.	On	the
fourth	day	he	wanted	to	 leave	at	five	o’clock	with	his	comrades,	got	dressed,	but	fell	with	his	bag	and
could	not	get	up.	Transported	to	an	aid	station,	he	was	then	discharged	to	the	neurological	centre	of	the
Army.	These	deficits	had	developed	without	an	apparent	cause:	he	had	had	no	recent	infectious	disease,
had	 no	 symptoms	 of	 food	 poisoning	 or	 other;	 moreover,	 he	 was	 very	 convinced	 that	 he	 had	 never
contracted	syphilis.
On	the	5th	of	September,	we	noted	the	following	findings.
The	patient	 could	do,	with	effort,	 small	 flexion	and	extension	movements	of	 the	 toes,	 flexion	of	 the
knee	and	of	the	hip.	The	same	difficulty	existed	for	movements	of	the	upper	limbs,	especially	distally.	The
head	was	usually	rotated	to	the	left	and	the	patient	encountered	difficulty	turning	it	to	the	right;	he	could
open	and	close	the	mouth,	but	slowly	and	incompletely.
The	examination	of	 electrical	 reactions	 showed	a	 slight	hyper-excitability	of	nerves	and	muscles	 to
faradic	 current.	With	 galvanic	 current,	 excitability	 increased	 slightly,	 especially	 for	 the	 nerves	 of	 the
upper	limb;	there	was	no	reaction	of	degeneration.
The	patellar	reflexes	were	very	difficult	to	elicit	due	to	muscle	hypertonia;	they	seemed	to	be	present.
The	Achilles	 and	medio-plantar	 reflexes	were	 absent.	 The	 upper	 limb	 reflexes	 could	 not	 be	 assessed
because	 of	 the	 hypertonia	 and	 the	 impossibility	 of	 a	 complete	 muscular	 relaxation.	 Plantar	 cutaneous
reflexes	 brought	 a	 frank	 flexion	 of	 toes;	 cremasteric	 and	 abdominal	 cutaneous	 reflexes	 were	 normal.
There	was	no	withdrawal	reflex	either	when	the	back	of	the	foot	was	pinched	or	by	hyperflexion	of	the
toes,	but	the	patient	perceived	the	sensations	caused	by	these	excitations.
The	 neuromuscular	 excitability	 brought	 about	 by	 direct	 percussion	 of	 the	 muscle	 mass	 with	 the
percussion	hammer	was	present.
The	patient	complained	of	 tingling	in	the	extremities.	There	was	no	disorder	of	objective	sensitivity
and	only	a	light	touch,	pain	and	temperature	hypo-aesthesia	in	the	feet	and	hands.
Muscles	of	the	calf	and	forearm	were	painful	upon	pressure.
The	pupils	reacted	equally	to	light	and	accommodation.	The	patient	urinated	independently;	he	knew
when	he	needed	to	but	could	not	feel	the	flow	of	urine.
He	had	no	fever,	no	Kernig’s	sign,	no	nausea,	no	vomiting.	The	urine	examined	by	 the	Bacteriology
and	 Chemistry	 Laboratory	 of	 the	 army	 contained	 neither	 sugar	 nor	 albumin	 or	 indoxyl;	 the	 chemical
elements	were	in	their	normal	proportion.
It	is	necessary	to	note	that	a	skin	rash	appeared	3	or	4	days	previously,	mainly	localized	in	the	upper
thorax	 and	 in	 the	 lower	 abdominal	 region.	 The	 eruption	was	 characterized	 by	 erythema	 and	 papulous
spots.	Except	for	these	regions	the	eruptive	elements	were	disseminated	on	the	rest	of	the	thorax	and	the
abdomen,	whilst	 no	 component	was	 seen	 on	 the	 lower	 and	 upper	 limbs.	The	 lumbar	 puncture	 showed
clear	cerebrospinal	liquid,	not	apparently	hypertensive,	with	hyperalbuminosis	(more	than	0.85	grams	of
albumin	with	the	albuminimetry	of	Sicard),	without	leukocyte	reaction	(3–4	lymphocytes	per	field).
The	findings	noted	during	the	first	examination	had	a	slight	tendency	towards	improvement.	However,
on	the	20th	of	September,	we	still	noticed	the	muscles’	weakness	in	the	distal	limbs,	the	absence	of	all	the
tendon	reflexes	apart	 from	the	 left	biceps	reflex,	 the	maintenance	of	cutaneous	reflexes,	muscle	pain	on
pressure,	 and	 parasthesia	 of	 the	 extremities	 with	 a	 light	 hypoesthesia.	 We	 also	 observed	 intermittent
myoclonic	jerks	in	the	muscles	of	the	calf	and	of	the	thigh.	A	repeat	lumbar	puncture	was	unchanged	from
the	previous	examination:	clear	 liquid,	not	hypertensive,	with	an	accentuated	hyperalbuminosis	without
leukocyte	reaction	(3–4	lymphocytes	per	field).
The	patient	was	evacuated	to	the	back	lines	on	the	1st	of	October.
Discussion
Both	 observations	 which	 we	 have	 just	 recounted	 are	 completely	 similar.	 These	 two	 patients,	 without
detectable	visible	cause,	developed	a	clinical	syndrome,	characterized	by	disorders	of	all	the	muscles	of
the	 upper	 and	 lower	 limbs,	 worse	 distally,	 the	 loss	 of	 tendon	 reflexes	 with	 preservation	 of	 all	 the
cutaneous	 reflexes,	 paresthesia	 with	 mild	 disorders	 of	 objective	 sensation,	 pain	 when	 pressure	 was
applied	 to	muscle	masses,	 small	modifications	 of	 the	 electric	 reactions	 of	 nerves	 and	muscles	 and	 the
distinct	finding	in	the	cerebrospinal	fluid	of	a	marked	hyperalbuminosis	without	cytological	reaction.
The	 hyperalbuminosis	 of	 the	 cerebrospinal	 fluid	without	 cellular	 reaction	 is	 a	 peculiarity	which	 is
important	to	emphasize.	This	albumino-cytological	dissociation	(Sicard	and	Foix)	is	observed	most	of	the
time	 in	 certain	medullary	 compression,	 in	Pott’s	 disease	 and	 in	 certain	 cases	of	 syphilis	 of	 the	 central
nervous	 system,	 but	we	 do	 not	 believe	 these	 apply	 here,	 as	 it	 seems	 to	 us	 that	 our	 patients	 have	 pure
radiculitis	and	polyneuritis.
In	the	second	patient,	 it	 is	also	important	to	note	that	a	certain	hypertonia	accompanied	the	paralytic
state	of	certain	muscles.	When	the	patient	was	resting,	the	muscle	tone	was	clearly	higher	than	that	of	a
healthy	 individual	 in	 the	 same	 situation.	 Passive	movements	 remained	 normal.	 The	 limited	 number	 of
voluntary	movements,	as	described	above,	were	rigid	and	marked	with	a	certain	lethargy.	Examination	of
the	tendinous	reflexes	proved	difficult	since	the	required	stretching	of	the	relevant	muscles	was	prevented
by	 the	 ongoing	 contraction	 taking	 place	 in	 the	 antagonists.	Despite	 these	 findings,	which	we	 encounter
frequently	enough	in	meningitis	cases,	the	patient	was	able	to	assume	a	seated	position	by	stretching	the
arms	 out	 almost	 completely,	 whilst	 simultaneously	 applying	 light	 support	 to	 the	 knees	 to	 prevent	 any
bending.	The	lower	limbs	could	rise	almost	to	a	right	angle	with	the	trunk,	and	bend	like	those	of	a	normal
subject.	 Consequently,	 the	 sign	 of	 Kernig	 did	 not	 exist	 in	 our	 patient.	 This	 state	 of	 hypertonia	 was
consequently	in	no	way	attributable	to	meningitis,	but	rather	a	particular	state	of	the	muscular	contractility
apparently	caused	by	damage	to	the	peripheral	nerve.
We	have	already	highlighted	the	fact	that	states	of	hypertonia	can	occur	during	some	peripheral	neuritis
and	in	incomplete	nerve	injuries,	and	specify	at	this	opportunity	that	spasms	frequently	observed	during
certain	 facial	 palsies	 are	 not	 an	 exception	 to	 the	 peripheral	wounds	 of	 the	 nerves,	 as	 it	 is	 classically
believed.
All	 the	disorders	observed	in	these	two	patients	belong	to	a	simultaneous	pathology	of	spinal	roots,
peripheral	 nerves	 and	 muscles.	 The	 major	 hyperalbuminosis	 in	 the	 cerebrospinal	 fluid	 testifies	 to
meningeal	 involvement;	 the	 character	 of	 the	 paralytic	 disorder	 prevailing	 distally	 in	 the	 limbs	 and	 the
muscle	pain	on	pressure	indicate	the	involvement	of	the	peripheral	nerves	and	of	the	muscles.	Moreover,
it	seems	to	us	that	it	is	a	too	great	a	simplification	in	neurology	to	segregate	polyneuritis	and	polymyositis;
in	one	very	large	series	of	cases	of	infectious	or	toxic	polyneuritis,	the	intramuscular	nerve	endings,	the
muscular	 fibres	 can	 themselves	 be	 affected	 and	 in	 reality	 it	 is	more	 often	polyneuromyositis	 than	pure
polyneuritis.
In	the	first	patient,	the	experimental	findings	made	by	the	graphic	method	allowed	us	to	identify	certain
new	characteristics	in	the	study	of	reflexes	and	muscular	contractility.	The	graphic	method	can	inform	the
interpretation	of	symptoms	and	injuries.
Figure	1.1		R,	R,	Myographic	curve	of	quadriceps	femoris	during	the	patellar	reflex,	with	a	Desprez	signal	indicating	the	time	of
percussion	and	time	in	1/100	second.	I,	I,	I,	The	same	plots	for	direct	percussion	of	the	quadriceps	femoris	muscle.	Recorded	on
21	August	1916.	Note	the	almost	total	absence	of	contraction	‘reflex’	following	percussion	of	the	patellar	tendon,	while	it	is	clearly
present	for	direct	percussion	of	the	muscle.
Figure	1.2		(A)	Myographic	curve	of	the	gastrocnemius	muscle	in	the	ankle	reflexes.	(M)	The	same	appears	in	the	medial	plantar
reflex.	Recorded	on	21	August	1916.	The	first	rise	of	the	curve	(A)	is	a	mechanical	shock;	the	second	is	a	‘muscular’	contraction.
The	‘reflex’	part,	which	does	not	exist	in	the	case	of	ankle	reflexes,	is,	however,	very	visible	low	on	the	curve	of	the	medial	plantar
reflex.
In	 this	patient,	while	 the	 tendon	 reflexes	appeared	absent	during	clinical	examination	 throughout	 the
course	 of	 the	 disease,	 the	 graphic	 inscription	 showed	 some	 contraction	 of	 quadriceps,	 femoral	 and
gastrocnemius	muscles	under	the	influence	of	direct	muscle	percussion;	the	tendons	of	these	muscles	and
their	muscle	masses	 showed	 interesting	peculiarities.	 From	 the	 onset	 of	 the	 disease,	 the	 search	 for	 the
patellar	 reflex	 brought	 a	 contraction	 after	 mechanical	 shock	 which	 we	 see	 clearly	 in	 Figure	 1.	 This
contraction,	 strikingly	 weaker	 than	 that	 obtained	 in	 a	 healthy	 subject,	 occurs	 after	 a	 delay	 of
approximately	0.056s,	and	 is	not	 followed	by	 the	 second,	more	ample	and	 longer	contraction	normally
seen	 as	 part	 of	 a	 delayed	 reflex.	We	 noticed	 0.152s	 after	 the	 beginning	 of	 the	 excitement	 a	 very	 light
uprising	of	 the	curve,	 indicating	 the	vestige	of	 the	 reflex	contraction.	The	patellar	 reflex	 is	also	almost
completely	 reduced	 to	 an	 idiomuscular	 reflex	 until	 the	 cure	 of	 the	 disease.	 During	 this	 period	 the
percussion	of	the	mass	of	quadriceps	provoked	a	beautiful	muscular	contraction	occurring	with	a	delay	of
0.051s,	 followed	 by	 the	 second	 contraction,	 having	 all	 the	 characters	 of	 a	 contraction	 of	 reflex	 origin
(Figure	1)	and	occurring	0.150s	after	the	beginning	of	the	excitement.
The	muscles	partially	respond	to	mechanical	excitement	of	the	tendon,	which	is	transmitted	by	spread
via	the	muscular	fibres,	and	results	in	a	nearly	normal	double	contraction	when	it	is	directly	percussed.	It
seems	to	be	affected	by	a	mechanical	hypo-excitability	which	makes	 it	excitable	only	for	abrupt	blows
directly	on	the	body	of	the	muscle.
The	Achilles	reflex,	at	the	beginning,	was	also	greatly	modified	and	reduced	almost	completely	at	the
mechanical	shock.	That	shown	in	Figure	2	is	of	very	low	amplitude,	occurs	after	an	extreme	delay—that
is	approximately	0.110s—and	is	not	 followed	by	 the	normal	delayed	reflex	contraction.	But,	 instead	of
what	occurred	for	the	patellar	reflex,	these	changes	partially	reversed,	and,	already	on	September	5th	(see
Figure	3),	repeat	testing	revealed	a	more	ample,	brisker,	faster	muscular	shock	(0.055s),	followed	by	a
delayed	 second	 reflex	 contraction	 arising	 after	 a	 delay	 of	 0.140s.	 The	 direct	mechanical	 shock	 of	 the
gastrocnemius	followed	a	parallel	evolution	and	gradually	resumed	a	shape	closer	to	normal.
Figure	1.3		An	external	myographic	curve	in	the	ankle	reflexes.	Recorded	on	5	September	1916.	The	reflex	is	present	with	its
three	characteristic	elevations.	However	the	‘muscle’	contraction	and	especially	the	‘reflex’	contraction	are	lower	than	in	a	normal
subject.
It	 is	worth	 noting	 that,	 at	 the	 beginning	 of	 the	 disease,	 although	 the	 percussion	 of	 the	Achilles	 and
gastrocnemius	 tendons	 didn’t	 provoke	 any	muscular	 contraction,	 the	 investigation	 of	 the	medio-plantar
reflex	 brought	 the	 second	 contraction,	with	 a	 0.144s	 delay	 constituting	what	we	 have	 to	 consider	 as	 a
reflex	contraction	of	low	intensity	(see	Figure	2).
Furthermore,	 whereas	 a	 simple	 clinical	 examination	 revealed	 only	 the	 abolition	 of	 the	 tendinous
reflexes,	 a	 detailed	 analysis	 of	 the	myographic	 curves,	 by	 revealing	which	 elements	 of	 the	 reflex	 are
abnormal,	 leads	us	to	a	series	of	worthwhile	remarks.	Firstly,	 the	complete	disappearance	of	 the	reflex
part	of	 the	myographic	curve	or,	when	 it	 remains,	 its	 extreme	delay	and	 reduced	amplitude	and	 speed,
shows	 us	 the	 deep	 and	 dominant	 change	 of	 the	 nervous	 drivers	 or	 of	 the	 central	 part	 of	 the	 reflex.	 In
addition,	the	muscular	shock	is	also	modified,	decreased	in	height,	slowed,	and	delayed	in	its	appearance;
this	causes	us	to	think	that	the	muscular	element	was	also	touched	by	the	process	of	poisoning.	Finally,	the
comparison	 of	 curves	 obtained	 after	 percussion	 of	 the	 patellar	 tendon	 and	 from	 the	 Achilles’	 tendon
allows	us	to	notice	a	different	evolution	for	these	reflexes.	Whereas	the	first	one	was	quickly	abolished
and	 didn’t	 return	 until	 the	 the	 patient	 had	 left	 the	 hospital,	 the	 second,	 although	 seeming	 abolished
clinically,	was	 detectable	 using	 the	 graphic	method	 and	 had	 characteristics	 getting	 gradually	 closer	 to
normal	 earlier.	We	 insist	 on	 this	 important	 fact	 that	 the	 graphic	 method	 allows	much	more	 precise
assessment	of	the	state	of	tendon	reflex	than	an	examination	with	the	hammer.
The	 pathogenesis	 of	 the	 syndrome	 of	 radiculoneuritis	 observed	 in	 our	 patients	 was	 not	 able	 to	 be
determined.	An	infection	or	poisoning	must	without	doubt	be	suspected,	but	we	were	not	able	to	identify
them.	The	prognosis	did	not	appear	to	be	very	grave,	if	we	judge	it	by	the	evolution	of	the	affliction	in	our
two	patients:	the	first	one	was	almost	cured	and	the	second	in	the	process	of	improvement	when	they	were
evacuated	by	the	Army.
(1)	This	observation	was	briefly	analyzed	by	one	of	us	in	a	medical	meeting	of	VI	Army	at	Villers-
Cotterets	in	August	1915.
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GBS:	The	Early	Years	in	Paris
Jacques	Philippon	and	Jean-Marc	Léger
The	19th	Century:	Landry,	Stohl	and	Others
Landry’s	Acute	Ascending	Paralysis
Jean	 Baptiste	 Octave	 Landry,	 born	 in	 1826	 (a	 year	 before	 J.M.	 Charcot),	 as	 a	 young	medical	 student
voluntarily	 treated	patients	 during	 the	 cholera	 epidemic	of	 1850,	 and	 then	 trained	during	his	 residency
alternatively	in	medicine	and	surgery.	However,	his	medical	thesis	in	1854,	General	considerations	on
pathogenesis	and	therapeutic	indications	of	nervous	diseases,	showed	a	decided	interest	in	neurology
[1].	 In	 1859	 he	 published	 a	 paper	 entitled	Acute	ascending	paralysis	 in	which	 he	 gave	 the	 following
description.
The	 sensory	 and	 motor	 systems	 may	 be	 equally	 affected.	 However	 the	 main	 problem	 is	 usually	 a	 motor	 disorder
characterised	by	a	gradual	diminution	of	muscular	strength	with	flaccid	limbs	without	contractures.…	The	paralysis	moves
rapidly	from	lower	to	upper	areas.	The	progression	can	be	more	or	less	rapid.	When	the	paralysis	reaches	its	maximum
intensity,	the	danger	of	asphyxia	is	always	imminent.	However	in	eight	out	of	ten	cases	death	was	avoided.	When	there	is	a
reversal	of	the	paralysis,	the	recovery	period	involves	phenomena	opposite	to	those	indicated	in	the	development	period.
Patients	then	either	recover	very	quickly,	or	the	disease	becomes	chronic	with	slow	improvement	[2].
What	Should	Be	the	Exact	Name	of	the	Syndrome?	Guillain-Barré	or	Landry-Guillain-
Barré?
The	description	of	a	neurological	disease	as	provided	by	Octave	Landry	in	1859	is	very	close	to	that	set
forth	by	Guillain	and	Barré	57	years	later.	The	main	difference	is	related	to	the	fact	that	biological	and
cytological	studies	of	the	cerebrospinal	fluid	(CSF)	were	not	possible	in	Landry’s	time,	the	first	lumbar
puncture	 having	 been	 introduced	 in	 1891	 by	 Quincke	 in	 his	 search	 for	 a	 method	 of	 draining
hydrocephalus.	If	the	hallmark	is	indeed	albumino-cytological	dissociation,	it	is	evident	that	the	syndrome
described	 by	 Landry	 cannot	 fulfil	 this	 definition.	 G.	 Guillain	 and	 J.A.	 Barré,	 when	 completing	 their
description	in	1936,	added,	“We	do	not	accept	to	include	in	our	syndrome	the	acute	ascending	paralysis
described	by	Landry	considering	that	the	Landry	cases	mixed	diagnoses	which	may	have	included	other
causes	of	paralysis	such	as	poliomyelitis	or	acute	encephalomyelitis”	[3,4].	Today,	however,	it	seems	fair
to	recognize	that	the	clear	description	offered	by	Landry	is	very	similar	to	the	clinical	entity	of	GBS.	The
importance	of	Landry’s	work	has	been	underlined	by	Haymaker	and	Schiller,	considering	in	their	book	[5]
that	he	was	among	the	133	founding	fathers	of	neurology.
Confirmation	 of	 the	 importance	 of	 the	 work	 of	 Landry	 was	 given	 by	 Jules	 Dejerine	 (1849–1917),
future	professor	of	neurology	at	the	Salpêtrière	Hospital,	who	wrote	in	his	medical	thesis	(1879),	Studies
on	nervous	system	lesions	in	the	acute	ascending	paralysis,	“Landry	was	the	first	to	draw	attention	to	a
specific	 form	 of	 paralysis	 that	 he	 called	 extenso-progressive.…	 Based	 on	 certain	 symptomatic
particularities,	including	the	fact	that	sensation	was	relatively	unaffected,	he	proposed	designating	these
paralyses	by	the	general	name	of	acute	centripetal	or	ascending	paralysis”.
And	Strohl?
Why	did	the	name	of	André	Strohl	appear	only	in	the	first	paper	and	disappear	in	the	later	publications?
Had	he	been	forgotten	on	purpose	because	he	was	the	youngest	(29	years	old)	and	less	known	than	the	2
other	co-authors?	There	is	a	more	rational	explanation:	Strohl’s	participation	was	limited	to	the	study	of
reflex	and	nerve	conduction,	and	did	not	concern	the	clinical	aspects.	His	academic	career	(professor	in
Paris	in	1925)	was	mainly	concerned	with	physical	medicine,	a	subject	in	which	he	published	more	than
200	papers	[6].
Dumenil	and	Chronic	Ascending	Neuritis
In	1864	Louis	Stanislas	Dumenil	(1823–1890),	a	surgeon	working	in	Rouen,	described	one	case	(and	3
more	in	1866)	of	acute	and	symmetrical	ascending	paralysis	which	according	to	him	might	be	caused	by
an	atrophy	of	 the	peripheral	nerves.	He	said,	“Not	 least	 important	nor	 least	 interesting	in	 the	history	of
these	peripheral	paralyses	 is	 their	extension	 to	a	 large	part	of	 the	nervous	system—one	could	speak	of
generalisation—to	the	point	of	compromising	life	through	the	invasion	of	the	most	essential	nerves	such	as
the	vagus	nerve”	[7].	He	was	the	first	to	carry	out	an	electric	exploration,	using	Duchenne	de	Boulogne’s
new	 machine,	 noting	 that	 after	 a	 phase	 of	 depression,	 the	 excitability	 of	 the	 nervous	 trunk	 improved
progressively	from	the	centre	to	the	periphery.	It	demonstrated	the	existence	of	peripheral	paralysis,	with
the	possibility	of	extension	to	the	nervous	centres:	for	Dumenil,	 they	could	be	called	chronic	ascending
neuritis.
Even	if	some	observations	of	similar	patients	appear	by	the	end	of	the	century,	nothing	new	concerning
clinical	 or	 pathological	 aspects	was	worthy	of	 note	 until	 the	 description	of	Guillain,	Barré	 and	Strohl
[8,9].
Neurology	in	Paris	at	the	Turn	of	the	Century
After	 the	 death	 of	Charcot	 in	 1893,	 the	main	 subject	 of	 discussion	 among	 neurologists	 remained	what
constituted	 the	 true	 nature	 of	 hysteria.	Within	 this	 debate	 a	 turning	 point	 appeared	with	 the	 studies	 of
Joseph	 Babinski	 (1857–1932).	 Babinski	 had	 been	 a	 senior	 resident	 under	 Charcot,	 and	 his	 first
conception	was	directly	inspired	by	his	master,	but	he	progressively	drew	away	from	the	Charcot	school
of	thought,	creating	a	new	definition	of	hysteria	(1901)	and	suggesting	as	a	substitute	the	term	‘pithiatism.’
At	the	same	time,	he	pursued	his	own	work	on	organic	symptoms,	but	returned	to	psychological	problems
during	the	war,	writing	Hysteria-Pithiatism	and	reflex	nervous	disorders	in	the	neurology	of	war	 [10]
with	J.	Froment	(1878–1946).
After	 the	 death	 of	Charcot,	 the	 chair	 for	 nervous	 diseases	 at	 the	Salpêtrière	was	 held	 by	Raymond
(1844–1910),	then	by	Jules	Dejerine	(1849–1917).	Married	to	an	American	student,	Dejerine	would	have
an	efficient	teammate	in	his	wife,	especially	on	their	masterpiece	Anatomy	of	the	central	nervous	system.
Among	their	other	numerous	papers,	2	are	eponymous:	the	description	of	the	Dejerine-Roussy	syndrome,
caused	by	a	lesion	in	the	posterior	thalamus,	and	Dejerine-Sottas	neuropathy.
Pierre	Marie	 (1853–1940)	 succeeded	Dejerine	 in	 1917	 until	 his	 retirement	 in	 1923.	He	 described
acromegaly	and	hereditary	cerebellar	ataxia.	He	worked	on	aphasia,	 though	his	 ideas	were	opposed	 to
those	of	Paul	Broca	and	Karl	Wernicke.	He	started	the	Revue	Neurologique	 in	1893	and	the	Société	de
Neurologie,	being	its	first	general	secretary.
French	Neurology	during	the	First	World	War
More	than	half	of	the	members	of	the	Société	de	Neurologie	served	in	the	armed	forces;	some	continued
their	activities	in	their	department	partially	militarised,	like	Babinski	and	Froment	at	the	Pitié	Hospital	or
Dejerine	and	A.	Thomas	at	the	Salpêtrière.	Others	were	posted	in	neurological	military	centres,	such	as
G.	Roussy	at	the	centre	of	the	10th	Army	or	G.	Guillain	and	J.A.	Barré	at	the	6th.
Besides	 a	 heavy	 traumatic	 pathology	 affecting	 the	 central	 nervous	 system	 and	 peripheral	 nerves,
combat	 conditions	 and	 social	 attitudes	 during	 the	 war	 resulted	 in	 a	 considerable	 number	 of	 mental
disorders.	The	distinction	between	emotional	 stress	 and	psychic	 trauma	directly	 related	 to	 fighting	and
simulation	was	a	major	concern	for	army	physicians.	The	Société	de	Neurologie	and	representatives	of
allied	medical	centres	held	a	joint	meeting	in	1916.	Many	of	the	works	from	this	meeting	were	published
after	 the	war,	 such	as	 the	book	by	Babinski	 and	Froment,	Hysteria	 and	pithiatism	and	 reflex	 nervous
disorders	 in	 the	 neurology	 of	 war	 (1917)	 or	Neurological	 works	 during	 war	 by	 Guillain	 and	 Barré
(1920).	It	is	remarkable	that	in	such	conditions,	just	after	the	Battle	of	the	Somme,	the	3	authors	were	able
to	publish	a	short	note	on	2	paralysed	soldiers	they	encountered	in	1916	[8].
The	Academic	Careers	of	G.	Guillain	and	A.	Barré
Georges	Guillain	 classed	 first	 at	 the	 resident	 exam	 in	 1898	 and	 had	 the	 possibility	 of	working	 among
prestigious	mentors	in	neurology,	completing	his	residency	with	P.	Marie.	It	was	under	Marie’s	direction
that	Guillain	carried	out	his	anatomical	works	(on	the	pyramidal	tracts	and	internal	capsule),	emphasising
in	 a	 special	 lecture	 the	 importance	 for	 a	 neurologist	 to	 think	 as	 an	 anatomist,	 a	 physiologist	 and	 a
biologist.	In	this	way	he	started	with	the	study	of	cerebrospinal	fluid	(focusing	on	the	benzoin	colloidal
reaction	in	nervous	syphilis).
Jean	 Alexandre	 Barré,	 a	 resident	 under	 Babinski	 in	 1909–1910,	 defended	 his	 thesis	 on	 tabes
arthropathies.	He	started	a	long	collaboration	with	Guillain	during	the	war	and	became	his	friend.	While
a	professor	of	neurology	 in	Strasbourg,	beginning	 in	1919,	Barré	published	several	hundred	papers.	 In
1925	he	welcomed	Joseph	Babinski	 in	Strasbourg	with	great	warmth,	ensuring	a	 large	audience	for	his
conference	on	the	importance	of	asking	the	right	questions	and	in	detecting	subjective	symptoms;	he	was
responsible	for	the	introduction	of	Guillain	to	Babinski.
The	Conception	of	GBS	after	the	War
After	the	original	description	of	the	syndrome	in	1916,	no	other	mention	of	GBS	appeared	until	Guillain
and	Barré	published	Neurological	Work	in	War	Conditions	in	1920.	This	relative	reserve	persisted	until
1936	 with	 a	 complete	 clarification	 at	 the	 Société	 de	 Neurologie,	 following	 a	 paper	 by	 Théophile
Alajouanine	on	a	case	of	‘acute	polyneuritis	followed	by	death’.	Guillain	and	Barré	clearly	defined	the
nosographic	limits	of	their	syndrome,	insisting	particularly	on	the	importance	of	the	albuminocytological
dissociation	in	the	CSF,	otherwise	encountered	only	in	spinal	compressions,	Pott	disease	and	syphilis	of
the	 nervous	 system.	 This	 characteristic	 was	 for	 them	 absolutely	 different	 from	 infectious	 polyneuritis.
They	rejected	the	hypothesis	of	any	similarity	with	the	acute	febrile	neuritis	recognised	by	Osler	in	1892
and	 Holmes	 in	 1917,	 due	 to	 the	 presence	 of	 fever	 in	 their	 syndrome.	 They	 admitted,	 however,	 with
additional	experience,	to	some	modifications	in	the	original	description:	cranial	nerves	may	be	involved
and	difficulty	with	micturition	can	occur.	Furthermore,	some	clinical	subdivisions	may	be	described	such
as	spinal,	spinal	and	brain	stem,	brainstem,	mental	signs.	They	added	ataxia	with	cerebellar	involvement
but	rejected	definitively	polyneuritis	with	normal	CSF	protein	and	high	cellular	count	[3,4].
The	Unknown	but	Well-known	Patient
Harvey	Cushing,	along	with	many	other	American	physicians,	took	part	in	the	First	World	War.	In	August
1918,	after	an	episode	of	flu,	he	suffered	from	an	illness	characterised	by	a	progressive	weakness	of	the
legs	with	paraesthesia,	then	his	hands,	and	lastly	associated	with	bilateral	facial	paresis.	He	wrote	on	the
3rd	of	November	(cited	by	J.F.	Fulton):	“My	hands	now	caught	up	with	my	feet—so	numb	and	clumsy	that
shaving’s	 a	 danger	 and	 buttoning	 laborious”.	 At	 the	 end	 of	 the	 war,	 Cushing	 showed	 some	 signs	 of
improvement.	 Back	 in	 Boston	 in	 February	 1919,	 he	 resumed	 his	 operative	 schedule,	 but	 remained
exhausted	after	operations.	He	attributed	this	fatigue	to	his	previous	‘polyneuritis’.
The	 exact	 diagnosis	 of	 his	 illness	 was	 unknown	 and	 particularly	 difficult	 to	 establish	 due	 to	 an
association	 with	 peripheral	 vascular	 disorder.	 For	 S.C.	 Reich	 [11],	 the	 combination	 of	 progressive
weakness	of	the	limbs,	together	with	areflexia	and	bilateral	facial	paralysis	substantiates	the	diagnosis	of
GBS.	 This	 seems	 to	 be	 confirmed	 by	 the	 evolution:	 rapid	 deterioration,	 plateau	 phase	 and	 slow
improvement	albeit	incomplete.
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GBS	100:	The	Eponym
Alastair	Compston
When,	 in	 1916,	Georges	Guillain	 (1876–1961),	 Jean-Alexandre	Barré	 (1880–1967)	 and	André	 Strohl
(1887–1977)	 described	 2	 soldiers	 admitted	 to	 the	 ‘Centre	 neurologique’	 of	 the	 6th	 Army	 based	 near
Amiens	with	tingling	and	progressive	weakness	in	the	limbs,	electrical	inexcitability	of	the	reflexes	and
‘hyperalbuminose	 …	 sans	 reaction	 cellulaire’	 in	 the	 cerebrospinal	 fluid,	 the	 condition	 was	 initially
known	as	‘acute	febrile	or	ascending	polyneuritis’	 [1].	Abe	(AB)	Baker	(1908–1988)	responded	to	 the
hint	 dropped	 by	 Guillain,	 who	 soon	 started	 referring	 to	 ‘our	 syndrome’,	 and	 described	 cases	 of
encephalomyeloradiculitis	 as	 the	 ‘Guillain-Barré	disease’.	Generally	 left	 out	 in	 the	 cold	 thereafter,	 the
1977	obituary	notice	of	Strohl	refers	to	the	syndrome	of	‘Guillain,	Strohl	and	Barré’.	Also	jostling	for	a
place	 on	 the	 podium	when	 speaking	 of	 ‘acute	 ascending	 paralysis’	 is	 the	 description	 in	 1859	 by	 Jean
Baptiste	 Octave	 Landry	 (1826–1865)	 [2]—an	 omission	 partly	 corrected	 by	 Webb	 Haymaker	 (1902–
1984)	and	James	Kernohan	(1911–1981)	when	reviewing	their	experience	of	the	‘Landry-Guillain-Barré
syndrome’	[3].	(Sir)	William	Osler	(1849–1919)	wrote	on	acute	ascending	(Landry’s)	paralysis	[4]	and
drew	attention	to	the	series	reported	by	(James)	Ross	(1837–1892)resolving	the	ambiguity	of	whether	this
is	 primarily	 a	 disease	 of	 the	 spinal	 cord	 or	 peripheral	 nerve	 [5].	 But,	 in	 recent	 years,	 neurology	 has
settled	 for	 the	 abbreviated	 GBS	 (Guillain-Barré	 syndrome)	 when	 referring	 to	 acute	 post-infectious
polyneuritis.
Thomas	Willis	entitled	the	last	of	his	12	treatises	Pharmacutice	rationalis	(1674–1675),	emphasising
that	 treatment	 in	 medicine	 should	 be	 mechanism-based	 [6].	 But	 that	 ideal	 presupposed	 a	 concept	 of
disease	 and	 a	 system	 for	 nomenclature	 [7].	By	 the	 late	 17th	 century,	 as	 far	 as	 the	nervous	 system	was
concerned,	not	much	had	changed	for	over	2	millennia	since	the	Greeks	and	Romans	rationalized	existing
concepts.	Magic	medicine	 ignored	 the	 sick	 individual	 as	 a	 source	 of	 information.	 Plato	 (427–327	BC)
believed	in	health	as	a	state	of	harmony;	disease	was	an	excess,	alteration	or	relocation	of	body	(earth,
fire,	 air	 and	water)	 and	 soul.	Hippocrates	 (460–377	BC)	 internalized	medicine,	 relating	 disease	 to	 the
individual	 and	 illustrated	 his	 ideas	 with	 case	 histories	 describing	 the	 onset,	 duration	 and	 outcome	 of
symptoms.	 For	 Galen	 (AD	 130–200),	 disease	 had	 a	 locus	 and	 a	 pathological	 process;	 function	 was
affected	 first	 and	 alterations	 in	 structure	 then	 followed.	 It	 was	 a	 short	 step	 to	 extend	 the	 concept	 of
physiology	 (Francis	Glisson,	 1597–1677)	 to	 that	 of	 a	 pathological	 process	 that	 encapsulated	 primitive
origins	of	the	concept	of	immunology	(Girolamo	Frascatoro,	1478–1553).	Although	previous	images	had
shown	appendages	attached	to	the	brain	and	spinal	cord,	Andreas	Vesalius	(1514–1564)	first	accurately
depicted	the	nervous	system—brain,	spinal	cord	and	peripheral	nerves—as	one	structure	in	his	“drawing
of	the	nerves,	which	shows	the	origin	of	the	7	pairs	of	nerves	that	arise	from	the	brain	and	the	beginning
of	the	spinal	cord,	and	superbly	explains	the	ordering	and	succession	of	all	the	pairs	that	take	their	origin
from	 the	 spinal	 cord	 that	 is	 contained	 in	 the	 bones	 of	 the	 back”.	 Thomas	 Sydenham	 (1624–1689)
advanced	 the	 concept	of	natural	history,	detected	by	observation	of	untreated	disease	over	 time.	There
followed	 studies	 on	 the	 anatomical	 seat	 of	 disease	 (Giovanni	 Morgagni,	 1682–1771);	 and	 the	 final
transition	 to	 the	 notion	 of	 cellular	 (dis)organization	 as	 the	 basis	 of	 all	 pathology	 (Rudolph	 Virchow,
1821–1902).	Thus,	when	Guillain,	Barré	and	Strohl	studied	medicine,	disease	consisted	of	a	pathological
process	affecting	one	or	more	parts	of	the	body,	with	a	natural	history	and	a	cellular	basis	for	alterations
in	physiology	underlying	the	characteristic	symptoms	and	signs.
But	how	best	could	one	disease	be	distinguished	from	another,	and	appropriately	named?	As	clinical
descriptions	proliferated,	nomenclature	switched	from	reference	to	the	most	obvious	manifestations—the
‘falling	sickness’,	 the	‘sick	headache’,	 the	‘scrofulous	palsy’—to	hagiography	and	the	medical	eponym.
Famous	 doctors	 were	 remembered	 through	 diseases	 named	 after	 them.	 Later,	 a	 mechanism-based
taxonomy	 seemed	 preferable,	 and	 pathology	 started	 contributing	 to	 the	 classification	 of	 disease.	Now,
acronym	 competed	with	 eponym	 inmedical	 nosology.	 In	 the	 present	 context,	 a	 variety	 of	 abbreviations
emerged	for	the	Guillain-Barré	syndrome	based	on	different	patterns	of	the	natural	history	and	variations
in	 the	 pathology	 responsible	 for	 acute,	 recurrent	 and	 chronic	 inflammatory	 demyelinating	 and	 axonal
polyneuropathies—the	family	of	AIDP,	CIDP,	AMAN,	AMSAN	and	their	many	first-,	second-	and	third-
degree	 relatives.	 Nonetheless,	 custodians	 of	 the	 eponym	 fought	 back,	 as	 the	 celebration	 of	 this	 book
concedes.	In	the	preface	to	Neurological	Eponyms,	Peter	Koehler,	George	Bruyn	(1928–2002)	and	John
Pearce	 argue	 that	medical	 eponyms	 are	 again	 in	 vogue,	 and	 the	 feeble	 attempt	 of	 would-be	 scientific
doctors	to	emulate	the	‘real’	sciences	of	mathematics	and	physics	has	suffered	a	volte	face	 in	which	the
silent	revolution	of	molecular	biology	in	identifying	mutations,	deletions	and	frame-shifts	has	reconciled
the	inferiority	complex	allowing	medicine,	once	again,	to	luxuriate	in	the	eponym	[8].
It	usually	takes	a	while	for	eponyms	to	settle	down	and	the	designated	heroes	to	emerge.	Inevitably,
many	 eponymous	 attributions	 attract	 rival	 claims	 for	 priority	 on	behalf	 of	 others	who	provided	 earlier
accounts	 of	 that	 particular	 disorder.	 Indeed,	 a	 brief	 wander	 through	 any	 reasonable	 library	 easily
identifies	examples	appearing	before	the	eponym-defining	publication(s).	In	writing	A	Practical	Treatise
of	Painful	Distempers	with	Some	Effectual	Methods	of	Curing	Them,	Exemplified	in	a	Great	Variety	of
Histories	 (1739),	 Theophilus	 Lobb	 (1678–1763)	 considered	 “some	 of	 the	most	 frequent	 and	 common
painful	distempers	which	afflict	human	bodies:	 they	are	many,	and	some	of	them	very	dreadful,	both	on
account	of	the	exquisite	torment	they	give,	and	the	hazard	into	which	they	put	the	lives	of	those	who	fall
under	them”	[9].	Mrs	M-y	W—r,	aged	24	years,	seen	on	26	April	1733,	complained	that	for	several	days
she	had	noticed	pains	in	the	bottom	of	her	feet	and	pricking	in	the	ankles	such	that	she	could	not	tell	how
to	 walk.	 A	 complete	 cure	 of	 the	 complaint,	 caused	 ‘by	 acrid	 particles	 brought	 into	 contact	 with	 the
extremities	of	 the	nerves	of	her	feet’,	was	soon	effected	through	the	judicious	administration	of	various
tinctures.	 As	 a	 general	 conclusion,	 Dr	 Lobb	 anticipated	 subsequent	 elucidation	 of	 the	 pathology	 and
mechanisms	of	demyelinating	peripheral	neuropathies:	‘If	the	covering	membrane	of	the	nerves	happens	to
be	corroded,	and	the	extremities	of	them	made	naked,	acrid	particles	…	by	striking	thro’(ugh)	the	common
covering	membrane	of	the	nerves,	may	…	excite	pain’.
John	Pearce	[10]	has	drawn	attention	to	the	epidemic	of	acute	sensorimotor	polyneuropathy	in	Paris,
described	by	Auguste	François	Chomel	(1788–1858)	[11],	and	observed	by	Robert	Graves	(1796–1853)
during	his	Parisian	visit	in	the	summer	of	1828—the	illness	characterised	by	“sensations	of	pricking	and
severe	pain	in	the	integuments	of	the	hands	and	feet,	accompanied	by	so	acute	a	degree	of	sensibility	that
the	patients	could	not	bear	these	parts	to	be	touched	by	the	bed-clothes	…	[followed	by]	a	diminution	or
even	absence	of	sensation	…	the	power	of	motion	declined	…	advancing	with	progressive	pace	..	over
the	 whole	 of	 both	 extremities	 …	 and	 finally	 …	 to	 become	 altogether	 paralytic”	 [12].	 This	 and	 the
subsequent	work	 of	 Louis	Duménil	 (1823–1890)	 of	Rouen	 [13]	went	 largely	 unnoticed.	 (Sir)	William
Gowers	 (1845–1915)	 considered	 that	 only	when	 “fresh	 facts	were	 brought	 forward	 by	 [Alex]	 Joffroy
[1844–1908],	 (Ernst	 von)	 Leyden	 [1832–1910]	 and	 [Sir]	 Thomas	Grainger	 Stewart	 [1837–1900]	was
attention	 generally	 directed	 to	 the	 subject	 of	 peripheral	 neuritis”	 [14].	 Grainger	 Stewart	 reported	 3
examples	of	 the	 illness	already	described	by	Graves	[15].	He	noted	 loss	of	 the	 tendon	reflexes	 (which
Grainger	 Stewart	 had	 introduced	 into	 routine	medical	 practice	 in	 the	United	Kingdom),	 and	 electrical
inexcitability	of	the	limbs.	One	patient	died.	Whereas	the	brachial	plexus	was	normal,	the	axis	cylinders
in	 nerves	 of	 the	 forearms	 had	 undergone	 degeneration.	 Between	 1861	 and	 1876,	 Grainger	 Stewart
progressed	steadily	from	lecturer	and	consultant	in	pathology	and	medicine	to	professor	of	physic	at	the
Royal	Infirmary	of	Edinburgh.	His	most	influential	books	were	The	Teaching	of	Medicine	in	Edinburgh
(1877)	and	An	Introduction	to	Disease	of	the	Nervous	System	 (1884).	Attendance	grew	steadily	at	his
lectures	 in	 the	Extra-Academical	School	 in	Edinburgh.	The	2	manuscript	 notebooks	 in	which	Grainger
Stewart	drafted	these	141	lectures	cover	594	pages	[16].	Lecture	98	includes	a	section	on	“Paralysis	and
other	conditions	due	to	disease	of	nerve	endings	or	nerves	(neuritis,	peripheral	neuritis,	multiple	neuritis,
alcoholic	paralysis)”.	Amongst	other	details,	the	attentive	medical	students	were	told:
Paralysis	and	other	cond[i]t[ions]	due	to	dis[ease]	of	n[erve]	endings	or	nerves.	We	noted	that	there	was	paralysis	in	hands
&	feet	spread	up	to	arms	and	legs	&	that	there	was	interference	of	sensation	and	motion.	There	is	no	change	in	brain	and
cord.	1.	Very	often	the	dis[ease]	affects	the	fib[rous]	tiss[tissue]	bet[ween]	the	fibres	accounting	for	the	parenchymatous
changes.	 2.	 There	 is	 a	 change	 in	 the	 n[erve]	 medullary	 sheath	 centre	 of	 n[erve]	 and	 sens[ory]	 struct[ure].	 Often	 the
changes	proper	 to	 the	n[erve]	begin	at	periphery	and	spread	up	 towards	centre.	Occasionally	 there	are	patches	on	 the
n[erve]	 involved,	normal	p[ar]ts	and	then	 involved	portions.	The	proc[ess]	may	originate	 in	 the	nse	(sic)	or	 in	 the	 trophic
cells.	Symptoms.	It	very	seldom	happens	that	peripheral	n[erve]	is	confined	to	one	n[erve]	but	gener[erally]	occurs	in	hands
and	feet—spreads	up.	There	is	a	peculiar	sensation	in	hands	at	first	there	is	awkwardness	in	the	hands	at	first.	Hands	get
glossy,	nails	and	hair	get	altered.	There	are	changes	in	bl[ood]	distribution,	eg	pallor	or	congestion.	These	cases	go	on	till
pat[ient]	is	unable	to	help	himself	but	with	treat	some	good	improve	sets	in	always	and	then	there	are	felt	various	morbid
sensations	and	espec[ially]	tenderness	on	press[ure]	along	line	of	nerves.	Often	serious	sym[toms]	arise	viz	by	involving
vital	n[erve];	h[ear]t	and	resp[iratory]	nerves	may	be	attacked	&	death.
Pasted	 alongside	 is	 the	 printed	 galley	 summarising	 the	 lecture	 with	 the	 annotation:	 “Some	 get	 a
peripheral	 neuritis	 recurring	 y[ea]r	 after	 y[ea]r”.	Despite	 this	 emphatic	 formulation	 of	 the	 diseases	 of
peripheral	nerve,	Lecture	56	(pages	220–21)	describes	“acute	ascending	paralysis	(Landry)”	as	a	disease
of	the	spinal	cord.
This	account	of	competitors	for	the	GBS	‘victor	ludorum’	is	incomplete,	and	not	all	the	descriptions
provide	information	on	natural	history	with	recovery	and	pathological	findings	sufficient	to	distinguish	the
disorder	named	after	Guillain	and	Barré	from	other	forms	of	rapid	onset	multiple	neuritis.	Wijdicks	and
Ropper	 credit	 James	Wardrop	 (1782–1869)	 and	Charles-Prosper	Ollivier	 d’Angers	 (1796–1845)	with
original	 contributions	 to	 the	 subject	 [17].	Readers	 of	 this	 book	will	 have	 little	 difficulty	 in	 identifying
additional,	equally	deserving	celebrants.	But	if	we	are	to	stick	with	eponym	for	describing	patients	with
acute	 post-infectious	 polyneuropathy,	 why	 not	 the	 ‘Lobb-Wardrop-Ollivier-Chomel-Graves-Landry-
Duménil-Grainger	Stewart-Ross-Guillain-Barré-Strohl	syndrome’?
[This	text	is	based	partly	on	passages	that	appeared	in	various	editorials	for	issues	of	Brain	written
between	2004	and	2015.]
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GBS100:	Some	Literary	and	Historical	Accounts
A.J.	Larner
Introduction
The	 importance	of	hearing	patient	narratives	of	disease—‘hearing	 the	patient’s	voice’—is	 increasingly
recognised	 as	 a	 complement	 to	 the	 technical	 narratives	 of	 disease	 produced	 by	 clinicians.	As	well	 as
being	of	intrinsic	interest,	the	patient	perspective	may	broaden	medical	sensibility	to,	and	perception	of,
the	experiential	aspects	of	disease,	and	rightly	give	the	impression	that	clinicians	are	actually	listening	to
their	patients	rather	than	simply	shaping	their	narratives	for	their	own	purposes.
As	for	other	neurological	diseases,	there	are	many	patient	accounts	of	GBS	(see,	for	example,	patient
accounts	on	www.gaincharity.org.uk),	only	a	few	of	which	are	discussed	here,	alongside	some	fictional
accounts	and	some	possible	historical	cases.
Patient	Narratives	of	GBS
The	American	author	Joseph	Heller	 (1923–1999),	most	noted	 for	his	1961	novel	Catch-22,	 developed
GBS	in	late	1981	and	subsequently	wrote	an	account	of	his	illness,	No	Laughing	Matter	(1986)	[1].	The
book	 consists	 of	 alternating	 chapters	 by	 Heller	 and	 his	 friend	 Speed	 Vogel,	 so	 that	 both	 patient	 and
collateral	 narratives	 are	 provided,	 although	 it	might	 be	 argued	 that	Vogel	 is	 simply	Heller’s	 alter	 ego
(page	 220),	 since	 during	 the	 author’s	 illness	 Vogel	 lived	 in	 his	 house,	 wore	 his	 clothes,	 forged	 his
signature	on	cheques,	dealt	with	his	fan	mail,	and	‘more	or	less	assumed	his	identity’	(page	72).
In	 the	Heller/Vogel	 account,	 neurological	 problems	 began	with	weakness	 (difficulty	 pulling	 open	 a
door,	removing	a	heavy	sweater	over	his	head),	along	with	dysphagia	(trouble	swallowing	a	meal	after
the	first	few	mouthfuls,	a	symptom	calculated	to	ring	alarm	bells	in	a	‘prodigious	eater’)	and	cacogeusia
(food	tasting	metallic).	At	the	gym,	simple	stretching	exercises	proved	difficult:
Lying	supine	on	a	mat.…	Bending	each	 leg	 in	succession,	 I	was	supposed	to	wrap	my	arms	about	 the	shin	and	 lift	my
head	to	touch	my	chin	to	my	knee.	I	could	not	come	close,	on	either	side.	(page	22)
Heller	could	only	do	7	of	his	usual	15	push-ups.	The	following	day,	a	Sunday,	Heller	again	noted	food
tasted	metallic,	as	well	as	chewing	his	food	more	slowly	than	usual,	and	he	reflected	that
something	neurologically	unpleasant	was	taking	place	inside	me,	something	I	could	not	control	and	could	not	fathom.	All	of
my	limbs	felt	tired.	(page	19)
He	 spoke	 to	 his	 physician	 to	 report	 his	 symptoms,	 who	 diagnosed	 GBS	 over	 the	 telephone	 and
arranged	to	see	him,	followed	shortly	 thereafter	by	a	neurological	consult	 (with	Dr	Walter	Sencer)	and
admission	to	the	medical	intensive	care	unit	of	the	Mount	Sinai	Hospital	in	New	York	(Sencer	published	a
number	 of	 articles	 in	 the	 Journal	 of	 the	 Mount	 Sinai	 Hospital,	 later	 the	 Mount	 Sinai	 Journal	 of
Medicine,	in	the	1950s	and	1960s	but	none	relate	to	GBS).	At	no	time	did	Heller	experience	numbness	or
pain	(page	21).
During	his	22-day	ICU	admission	he	did	not	require	ventilation,	although	a	tracheostomy	was	mooted
at	one	point.	His	weakness	was	profound,	with	dysarthria	and	dysphagia	requiring	a	nasogastric	tube,	and
respiratory	and	cardiac	monitoring.	His	major	gripe	was	sleep	deprivation,	and	then	a	fear	of	not	waking
from	 sleep,	 which	 led	 to	 low	mood	 and	 psychiatric	 consultations.	 Treatment	 was	 entirely	 supportive,
Heller’s	illness	predating	effective	immunotherapies	for	GBS.
There	was	some	doubt	about	the	diagnosis	because	2	lumbar	punctures	returned	normal	results	and	it
was	with	relief	(according	to	Heller)	 that	a	 third	puncture	(all	were	reported	to	be	painless)	showed	a
raised	protein,	confirming	the	suspected	clinical	diagnosis.
Despite	a	weakness	so	profound	that	he	could	not	lift	his	head	or	roll	over,	Heller	commented	that
I	never	once	throughout	the	entire	experience	thought	of	myself	as	weak.…	I	was	paralyzed,	not	weak.	And	in	truth,	I	wasn’t
weak.	My	muscles	were	weak.	(page	162;	italics	in	original)
The	corner	was	turned	shortly	after	Christmas	1981,	with	gradual	neurological	improvement	thereafter
such	 that	 after	3	months	and	3	days	he	 left	Mount	Sinai	Hospital	 for	 a	 rehabilitation	 facility	 (the	Rusk
Institute	at	the	New	York	University	Medical	Center)	until	mid-May	1982.
In	 passing,	 Vogel	 gives	 an	 answer	 to	 the	 perennial	 question	 of	 why	 we	 refer	 to	 ‘Guillain-Barré
syndrome’	and	not	‘Guillain-Barré-Strohl	syndrome’,	despite	the	tripartite	authorship	of	the	original	1916
paper.	 One	 of	 Heller’s	 friends	 was	 the	 novelist	 Mario	 Puzo	 (1920–1999),	 author	 of	 The	 Godfather
(1969),	 later	 made	 into	 a	 celebrated	 film.	 Informed	 of	 Heller’s	 diagnosis	 by	 a	 mutual	 friend,	 Puzo
apparently	blurted	out
“My	God,	that’s	terrible!”
“Hey	Mario,	you	know	about	Guillain-Barré?”
“No,	I	never	heard	nothing	about	it	[sic],”	Mario	replied.	“But	when	they	name	any	disease	after	two	guys,	it’s	got	to	be
terrible!”	(page	44)
By	extrapolation,	then,	perhaps	naming	a	disease	after	3	guys	(Guillain-Barré-Strohl)	rather	than	2	would
render	it	simply	too	awful	to	contemplate	(e.g.,	Gerstmann-Straussler-Schenker	disease?).
It	was	 also	 in	 1981	 that	Tony	Benn	 (1925–2014),	 an	English	Labour	Party	 politician	 and	 socialist,
developed	 GBS	 just	 at	 the	 time	 that	 he	 was	 campaigning	 (ultimately	 unsuccessfully)	 for	 the	 deputy
leadership	of	his	party.	Brief	notes	on	his	 illness	appear	 in	his	political	diaries	 [2],	beginning	with	an
entry	on	5th	May:
I	wasn’t	feeling	very	well	today.	I	have	had	this	tingling	in	my	legs	and	now	my	hands,	and	my	face	has	been	very	hot	and
my	skin	has	been	rough.
After	 consulting	 a	 fellow	member	of	Parliament	who	was	medically	qualified	 and	being	 reassured,
Benn	then	consulted	his	general	practitioner	on	14th	May:
I	reported	the	fact	that	I	have	got	this	tingling	in	my	legs.	At	the	moment,	walking	is	like	having	on	wellington	boots	full	of
water	with	a	sponge	in	the	feet.	I	don’t	have	any	feeling	in	my	feet	and	my	hands	tingle.…	He	thinks	it	might	be	some	nerve
condition.
By	1st	June,	referral	to	a	neurologist	was	made,	and	on	4th	June
I	was	taken	to	see	Dr	Clifford	Rose	[1926–2012],	who	examined	me.	I	hadn’t	got	reflexes	in	my	legs	or	arms.
He	 told	me,	 “I	 think	 I	know	what	 this	 is.	 If	 this	was	only	a	medical	consideration,	 I	would	 recommend	you	came	 into
hospital	at	once.”
I	said,	“Well,	I’m	perfectly	happy	to	do	that	because	I	am	simply	incapacitated.”
Benn	 was	 then	 in	 hospital	 from	 6th	 to	 17th	 June,	 when	 there	 are	 no	 diary	 entries	 [2].	 Following
discharge	from	hospital,	he	noted	on	24th	June	that	“I	have	to	rest	in	the	afternoon,	and	it’s	still	painful	to
walk”,	but	there	do	not	seem	to	be	any	other	comments	on	possible	sequelae	in	the	abridged	diary	entries,
other	 than	 “very	 tired”	 on	 26th	 September,	 although	 this	 could	 have	 been	 related	 to	 his	 political
campaigning	prior	to	the	party	conference	which	started	that	day.	Overall,	therefore,	it	seems	that	Benn’s
GBS	was	a	mild	episode,	with	prominent	sensory	symptoms,	unlike	Heller	who	seems	not	to	have	had	any
sensory	features.
An	account	of	recovery	from	‘Guillain-Barré	disease’	by	an	ex-patient,	Lucile	Marie	Hoerr	Charles,
PhD,	 a	 college	 professor,	 appeared	 in	 1961	 in	 the	 journal	Psychosomatic	Medicine	 [3].	 Her	 illness
followed	a	routine	smallpox	vaccination	(and	was	indeed	written	up	and	published	as	such	[4]).	She	had
been	affected	2	years	earlier	and	was	paralysed	for	6	weeks.	Looking	back,	she	said
It	has	been	a	 tremendous	experience	of	both	body	and	soul;	a	slow,	painful,	miserable,	uncertain,	 frightening	business;
often	wonderful,	and	full	of	amusement	and	beauty	also.
Pain	was	a	significant	factor	in	this	illness:
In	a	few	days	my	hands	became	numb	and,	when	I	held	them	under	the	faucet,	I	could	not	tell	the	difference	between	hot
and	cold	water.	Soon,	severe	pain	came.	My	whole	body	seemed	to	be	just	one	cramp.
Despite	making	a	good	physical	recovery,	she	found
convalescence	after	leaving	the	hospital	was	also	a	dark,	trying	period—in	some	ways	worse	than	acute	illness.	No	more
support	by	institutional	routine,	nor	by	the	constant	bustle,	energy,	authority	and	tender-loving-care	of	medical	people	who
were	pushing	hard	to	make	me	well.
I	am	sure	many	if	not	all	neurologists	have	encountered	GBS	patients	who	report	feeling	‘abandoned’
after	hospital	discharge,	despite	good	or	excellent	neurological	recovery.
Fictional	Accounts	of	GBS
Paralysis	and	the	recovery	from	it	are	subjects	calculated	to	attract	writers	for	their	dramatic	potential.
Although	not	perhaps	amounting	to	a	genre,	a	number	of	classic	novels,	primarily	intended	for	children
(‘improving	literature’),	feature	characters	who	develop	paralysis:	Katy	Carr	in	What	Katy	Did	 (1872)
by	Susan	Coolidge;	Clara	Sessman	in	Heidi	(1880)	by	Johanna	Spyri;	Colin	Craven	in	The	Secret	Garden
(1909)	by	Frances	Hodgson	Burnett;	 and	Pollyanna	Whittier	 in	Pollyanna	 (1913)	by	Eleanor	H	Porter
[5,6].	 All	 these	 novels	 predate	 the	 original	 description	 of	 GBS,	 but	 the	 fictional	 possibilities	 of	 this
paralysing	disorder	have	subsequently	been	exploited	on	occasion.
Likewise,	 playwrights	 have	 sometimes	 featured	 characters	with	 paralysis,	 for	 example	The	 Sacred
Flame	 (1928)	 by	W	Somerset	Maugham	 (himself	medically	 qualified),	 and	Whose	 Life	 Is	 It	 Anyway?
(1978)	by	Brian	Clark,	featuring	post-traumatic	paraplegia	and	quadriplegia,	respectively.
In	Solomon’s	Porch:	The	Story	of	Ben	and	Rose	by	Jane	Riley	[7],	Ben	Windham,	a	college	professor
in	his	50s,	develops	a	neurological	illness	which	is	labelled	Guillain-Barré	syndrome.	Whether	the	author
had	any	experience	of	the	disease,	firsthand	or	otherwise,	is	not	clear,	but	there	are	certainly	elements	in
the	 description	 of	 the	 disease	 within	 the	 novel	 which	 jar	 the	 clinical	 reader.	 The	 patient	 suffers
progressive	weakness	over	a	few	weeks	(contrary	to	the	blurb,	“…	gone	to	a	party	…	when	he	left,	he
was	crippled”),	but	despite	his	seeing	numbers	of	clinicians	and	undergoing	a	lumbar	puncture,	no	clear
diagnosis	 emerges,	 other	 than	 polyneuropathy,	 possibly	 related	 to	 his	 underlying	 diabetes.	Despite	 this
lack	of	diagnostic	clarity,	a	referral	to	rehabilitation	services	is	made,	before	transfer	to	another	medical
centre	 where	 the	 diagnosis	 is	 immediately	 made	 by	 a	 physician	 and	 confirmed	 by	 a	 neurologist	 who
labels	 some	 of	 the	 previously	 consulted	 professionals	 ‘irresponsible’.	 However,	 the	 timeframe	 of	 the
novel	is	a	little	difficult	to	follow	and	it	may	be	that	neurological	decline	has	been	going	on	for	more	than
8	 weeks;	 indeed	 the	 neurologist	 considers	 that	 this	 is	 the	 ‘slow	 kind’	 of	 GBS,	 and	 “considers	 yours
chronic	inflammatory	demyelinating	polyneuropathy”	(pages	67–68);	so,	not	GBS	at	all!	This	may	explain
the	 treatment	with	prednisolone	 (pages	67,	81)	as	well	as	plasma	exchange.	The	patient’s	wife	 is	 still,
perhaps	justifiably,	a	little	baffled:
I	don’t	really	understand	the	difference	between	GBS	and	CIDP.	You	seem	to	be	somewhere	in	between	the	symptoms	for
those	two.	(page	88;	also	206)
So,	subacute	demyelinating	polyradiculoneuropathy	(SIDP),	perhaps?
When	the	patient	weakens	again,	nearly	18	months	later,	the	prednisolone	still	seems	to	be	continuing
(page	106),	prior	to	more	plasma	exchange,	IVIg,	and	cyclophosphamide.	More	perplexingly,	the	patient
complains	of	 loss	of	sensation	from	the	chest	down,	suggesting	a	sensory	level	(pages	41,	54,	85),	and
eventually	is	found	to	have	cervical	spine	stenosis	(page	115)	requiring	surgical	intervention,	presumably
some	form	of	decompression.	Whilst	the	concurrence	of	2	neurological	diseases	is	not	impossible,	it	 is
implausible.	Furthermore,	the	patient’s	wife	is	informed	by	the	physician	shortly	after	the	GBS	diagnosis
that	 the	 “leading	 cause	 of	 death	 related	 to	GBS	 is	 suicide”	 (page	69),	 though	how	a	 paralysed	patient
might	achieve	this	is	not	made	clear.
Although	 accuracy	 or	 consistency	 is	 not	 necessarily	 to	 be	 anticipated	 in	 a	 work	 of	 fiction,	 one
seriously	worries	for	any	GBS	patient	or	family	who	might	use	this	book	as	a	source	of	information	about
the	 disease;	 the	 frontispiece	 disclaimer,	 with	 direction	 to	 Guillain-Barré	 Foundation	 International	 for
information	regarding	the	disease,	is	a	welcome	inclusion.
In	 Thaw	 by	 Monica	 Roe	 [8],	 the	 narrating	 voice	 is	 that	 of	 Dane	 Rafferty,	 an	 18-year-old	 skier
recovering	 from	 GBS	 in	 a	 rehabilitation	 centre	 in	 Florida,	 far	 distant	 from	 his	 family	 and	 friends	 in
upstate	New	York.	The	action	takes	place	over	a	2-month	period,	with	flashbacks	to	premorbid	days	and
disease	 onset.	 Hence	 the	 focus	 is	 more	 on	 the	 recovery	 phase,	 particularly	 the	 input	 from	 a
physiotherapist,	 Anya,	 and	 an	 occupational	 therapist	 (no	 doctor	 ever	 darkens	 these	 pages!);	 this	 is
concordant	with	 the	 author	 being	 a	 “travelling	 physical	 therapist”	 (according	 to	 the	 blurb)	 presumably
with	experience	of	treating	GBS	patients:
Recovery	from	Guillain-Barré	is	a	strange	process.	After	you	get	to	the	totally	helpless	point	and	hang	out	there	for	a	while,
the	whole	thing	begins	to	reverse	itself.…	Trouble	is,	during	all	that	time	when	you	can’t	move,	your	joints	start	to	tighten	up,
so	by	the	time	you	can	actually	tell	your	muscles	to	move	on	their	own,	the	joints	may	be	too	stiff	to	let	it	happen.	(page	56)
As	Dane’s	recovery	progresses	(relatively	quickly),	some	of	the	techniques	of	neurorehabilitation	are
mentioned,	for	example	the	tilt	table,	and	the	patient’s	perspective	on	this:
This	 table	 contraption	 that	 can	 be	 cranked	 from	 horizontal	 to	 completely	 vertical,	 bringing	 the	 person	 on	 it	 along	 like
Frankenstein’s	monster	 rising	 from	 the	slab.	Supposedly,	being	upright	and	putting	weight	on	your	 feet	 is	good	 for	your
bones	and	joints	even	if	you	can’t	do	it	yourself.…	It	also	makes	you	dizzy	if	you	do	it	for	too	long	at	first.	(pages	69–70)
Later	Anya	sets	Dane	to	work	with	the	inflatable	ball	(“It	makes	my	muscles	burn	like	hell	…	but	it’s
really	been	helping	my	balance	and	torso	strength”;	page	192),	and	standing	using	the	parallel	bars:
The	 sequence	 of	 steps	 that	 we	 always	 go	 through	 to	 get	me	 standing:	 plant	 both	 feet	 on	 the	 ground,	 as	 far	 back	 as
possible;	shift	weight	forward	through	my	legs.	At	this	point,	[Anya]	usually	pulls	my	hips	forward	and	up,	giving	just	a	little
extra	power	to	my	upward	push.	(pages	193–95)
There	is	something	heartfelt	and,	one	senses,	personal	about	the	battles	of	the	physiotherapist,	Anya,
with	her	recalcitrant	patient,	Dane,	and	patient	relatives	complaining	about	lack	of	recovery.	When	Dane
is	refusing	physiotherapy	Anya	tells	him
You	all	want	to	be	fixed,	want	us	to	perform	miracles	we	can’t	guarantee	and	provide	answers	we	can’t	give.…	You’ll	still
turn	right	around	and	blame	us	if	it	doesn’t	end	up	exactly	the	way	you	hoped	it	would.	(page	207)
This	 lament	 sounds	 like	 the	 voice	 of	 experience,	 but,	 like	 the	 other	 passages	 quoted,	 is	 seamlessly
assumed	 within	 the	 narrative.	 Most	 readers	 will	 probably	 be	 more	 concerned	 with	 whether	 Dane
recovers	 fully,	gets	back	 to	 skiing,	 and	makes	 it	 up	with	his	girlfriend	 (who	ditched	him	when	he	was
paralysed,	 intubated	 and	 ventilated—some	 girls	 surely	 know	 how	 to	 pick	 their	moment!).	 But	 there	 is
much	to	enjoy	in	this	book	if	reading	with	neurological	spectacles	on.
Historical	Diagnoses	of	GBS
Appeal	 to	 the	historical	 record	may	help	 to	answer	 the	question	as	 to	whether	 cases	of	GBS	occurred
before	1916.	However,	since	CSF	findings	were	part	of	the	diagnostic	characterisation	by	Guillain	and
his	 colleagues,	 and	 lumbar	 puncture	was	 only	 performed	 after	 1897,	 cases	 conforming	 to	 the	 original
clinical	and	 investigational	description	(dissociation	albumino-cytologique)	occurring	before	 the	1916
publication	would	 seem	unlikely.	Hence	 inferences	 based	 on	 clinical	 features	 are	 the	 only	 recourse	 to
answer	the	question	of	historical	cases.
For	 example,	 Reich	 suggested	 that	 the	 renowned	 American	 neurosurgeon	 Harvey	 Cushing	 (1869–
1939)	suffered	 from	GBS	in	1918	when	an	undiagnosed	 illness	characterised	 (in	Cushing’s	diaries)	by
symmetrical	 weakness,	 numbness	 and	 paresthesias	 of	 the	 hands	 and	 feet,	 areflexia,	 bilateral	 facial
paresis,	diplopia,	and	fever	prevented	him	from	operating	[9].
Another,	more	formalised,	example	of	this	diagnostic	revisionism	relates	to	the	diagnosis	of	Franklin
Delano	 Roosevelt	 (1882–1945),	 32nd	 president	 of	 the	 United	 States	 of	 America	 (1933–1945),	 who
suffered	a	paralytic	illness	in	1921	which	is	widely	believed	to	have	been	due	to	poliomyelitis.	Goldman
and	colleagues	re-examined	the	clinical	features	as	recorded	in	biographies	of	FDR	(he	never	underwent
lumbar	 puncture	 or	 neurophysiological	 testing	 as	 far	 as	 is	 known)	 and	 undertook	 a	 Bayesian	 (i.e.,
probabilistic)	 analysis	 of	 8	 key	 symptoms	 [10].	 By	 multiplying	 prior	 probabilities	 by	 symptom
probabilities,	Goldman	and	colleagues	calculated	that	6	out	of	the	8	symptoms	had	posterior	probabilities
which	 favoured	 a	 diagnosis	 of	 GBS	 over	 poliomyelitis.	 It	 is	 an	 interesting	 analysis,	 which	 certainly
attracted	widespread	attention	when	first	published,	but	essentially	inferential.	The	exact	determination	of
FDR’s	diagnosis	is	never	likely	to	be	established.
Could	other	previous	fictional	accounts	of	paralysis	in	fact	be	describing	GBS?	Any	such	claim	would
of	 course	 be	 entirely	 speculative.	 Since	 both	 Katy	 Carr	 and	 Pollyanna	 Whittier	 develop	 paralysis
following	traumatic	accidents,	GBS	would	not	seem	to	be	a	likely	diagnosis.	Few	details	are	given	about
the	onset	of	illness	in	Clara	Sessman	and	Colin	Craven,	but	as	they	both	subsequently	recover	from	these
illnesses	it	might	be	wondered	whether	they	had	GBS,	in	Colin’s	case	sufficient	to	produce	lower	limb
atrophy.
Conclusion
It	 seems	 implausible	 that	 GBS	 did	 not	 exist	 before	 Guillain,	 Barré,	 and	 Strohl	 took	 to	 print,	 thus
characterising	GBS	as	a	disease	entity.	This	same	condition	seems	to	be	described,	for	example,	 in	 the
reports	 by	 Landry	 [11]	 (1859),	Wardrop	 [12,13]	 (1834),	 and	Warrington	 (1903)	 [14].	 Thus	 a	 ‘100th
anniversary’	of	GBS	is	in	some	ways	a	cultural	construct.	Clinical	knowledge	of	GBS	which	has	accrued
over	the	century	has	sometimes	transferred	into	the	literary	domain,	spawning	both	personal	and	fictional
(or	possibly	 ‘factional’)	 accounts	of	 the	disease,	 as	well	 as	 attempts	 at	 retrospective	diagnosis,	which
may	 inform	 or	 frustrate	 readers,	 depending	 on	 the	 perspective	 (lay,	 professional)	 from	 which	 they
approach	these	documents.	At	best,	these	narratives	may	allow	clinicians	to	hear	the	patient	voice	which
may	ultimately	inform	their	approach	to	the	management	of	sick	patients.
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10	Papers	Illustrating	the	Guillain-Barré	Syndrome
Timeline
Michael	P.T.	Lunn
Brilliant	minds	 have	 peppered	 the	 history	 of	Guillain-Barré	 syndrome	 (GBS)	 and	 brilliant	 thought	 has
advanced	both	GBS	and	wider	humanity	to	where	we	find	ourselves	in	2016.	Quite	frequently	serendipity,
time	or	simply	posthumous	recognition	have	identified	the	important	moments	in	the	history	of	GBS	and
the	world.	I	have	chosen	papers	that	illustrate	some	of	the	key	GBS	developments	and	juxtaposed	these
against	important	(and	less	important)	contemporaneous	scientific	discoveries.
1849–1881:	Charles	Darwin	discovers	worms	are	unable	to	hear	the
bassoon
In	 1849,	Octave	Landry	published	 examples	 of	 the	 subsequently	 eponymous	 ascending	paralysis	 in	 his
paper	‘La	paralysie	ascendante	aiguë’	[1].	In	the	same	year,	Charles	Robert	Darwin	was	asking	his	ten-
year-old	son	to	play	his	bassoon	as	loudly	as	possible	to	garden	worms	to	see	if	they	could	hear	or	not.	In
his	1881	treatise	‘The	Formation	of	Vegetable	Mould	through	the	Action	of	Worms,	with	Observations	of
their	Habits’	Darwin	wrote,	“Worms	do	not	possess	any	sense	of	hearing.	They	took	not	the	least	notice	of
the	shrill	notes	from	a	metal	whistle,	which	was	repeatedly	sounded	near	them;	nor	did	they	of	the	deepest
and	loudest	tones	of	a	bassoon.	They	were	indifferent	to	shouts	…	[and]	…	when	placed	on	a	table	close
to	the	keys	of	a	piano,	which	was	played	as	loudly	as	possible,	they	remained	perfectly	quiet	[2].’	Clearly
greater	 science	 was	 to	 come	 from	 his	 serendipitous,	 prior	 trip	 on	 the	 Beagle.	 Landry’s	 eloquent
description	 of	 10	 cases	 of	 ascending	 paralysis,	 however,	 was	 the	 nidus	 from	 which	 our	 subsequent
understanding	of	Guillain-Barré	syndrome	derives.	He	clearly	describes	acute	ascending	paralysis	with
paraesthesia,	normal	intellect,	the	absence	of	bladder	or	bowel	involvement	but	respiratory	involvement
leading	to	2	deaths.	There	was	no	identified	abnormality	at	postmortem.
Whilst	Charles	Darwin	brooded	uncomfortably	on	the	Origin	of	Species,	biding	his	time,	studying	his
worms,	Landry	married	a	destitute	aristocratic	beauty,	switched	his	focus	to	a	very	lucrative	hydrotherapy
business	and	died	of	cholera	aged	39,	with	Charcot	at	his	bedside.	Arguably	his	scientific	observation
was	far	in	excess	of	Darwin’s,	his	greatness	recognised	by	Charcot.	His	life	was	cruelly	cut	short;	what
more	might	there	have	been?
1870—James	Clerk	Maxwell—Discovery	of	Electromagnetism—1873
In	the	timeline	of	GBS,	Westphal	[3]	and	Erb	[4]	are	credited	with	the	simultaneous	description	of	deep
tendon	 reflexes	 in	patients	with	 spinal	cord	disease.	The	 recognition	and	diagnosis	of	GBS	 in	 the	21st
century	remains	clinical,	and	the	history	and	examination	are	key.	Westphal	described	the	exaggeration	of
the	knee	jerk	in	a	patient	with	multiple	sclerosis	and	in	his	paper	reports	that	the	same	phenomenon	had
been	observed	by	Erb	in	a	paper	which	he	was	reviewing.	Although	Landry	had	described	the	‘flaccid
limbs	without	…	reflex	movements	of	any	kind’	[1],	he	did	not	recognise	reflexes	as	such.	Mitchell	and
Lewis	are	probably	 the	first	 to	score	reduced	reflexes	[5].	Their	nomenclature	graded	0	as	absent,	and
then	=	as	very	slight,	−	slight,	N	normal,	+	marked	and	++	as	very	marked.	One	might	think	that	with	3
grades	 of	 reduced	 reflexes	 they	were	 keener	 on	 lower	motor	 neurone	 lesions	 than	 those	 of	 the	 central
nervous	system.	It	was	left	to	Guillain,	Barré	and	Strohl	to	emphasise	the	loss	of	reflexes	30	years	later.
1910–1915:	Einstein	and	the	Theory	of	General	Relativity
The	war	gave	Guillain,	Barré	and	Strohl	the	opportunity	to	describe	the	cases	of	2	paralysed	soldiers	in
the	1916	paper	that	has	seeded	this	publication	[6].	Rather	like	Landry	shifting	his	focus	to	hydrotherapy,
Strohl	decided	his	career	was	better	placed	in	physical	medicine	than	neurology.	It	is	said	that	as	a	result
his	name	was	left	off	the	subsequent	eponym	for	our	disease.	One	would	hope	that	today	such	a	lack	of
acknowledgement	would	not	occur.	However,	the	3	authors	drew	attention	to	the	doubling	of	the	latency
of	the	knee	and	ankle	reflexes,	and	deduced	therefore	that	there	must	be	a	delay	in	the	conduction	time	of
the	 reflex	 arc.	 They	 also	 emphasised	 the	 albuminocytological	 dissociation	 in	 the	 cerebrospinal	 fluid
(CSF)	 of	 the	 2	 soldiers,	 both	 of	whom	 had	 raised	 CSF	 protein.	 The	 authors	 of	 this	 paper,	mentioned
innumerable	times	in	this	book,	had	no	idea	of	the	causation	of	their	illness.	They	were	very	insistent	that
the	soldiers	did	not	have	venereal	disease,	despite	syphilis	being	rife	in	the	trenches,	and	they	remained
unsure	whether	 the	cause	was	intoxication	or	 infection.	What	we	remain	sure	about	 is	 that	syphilis	still
doesn’t	 cause	 a	 peripheral	 neuropathy	 (although	 of	 course	 it	 is	 in	 the	 differential	 diagnosis	 for	 a
radiculitis).
1940–1941:	Howard	Florey	and	the	First	Use	of	Penicillin	in	Humans
Despite	the	recognition	of	GBS	as	an	entity,	and	a	number	of	treatises	on	GBS	from	Guillain	and	others,
the	pathogenesis	remained	elusive.	Infection	remained	a	strong	candidate	for	the	causation	of	GBS	in	the
early	 part	 of	 the	 20th	 century.	 Leyden	 [7]	 had	 described	 an	 intense	 cellular	 nerve	 infiltration,	 but
Haymaker	and	Kernohan,	 in	a	highly	influential	paper	[8],	commenced	thoughts	on	processes	other	than
infectious	inflammation.	They	described	the	‘limited	pathological	material’	of	50	fatal	cases.	Oedema	and
nerve	 root	 swelling,	 possibly	 secondary	 to	 infection,	were	 blamed	 for	 the	 pathology	 seen	 and	 a	 cell-
mediated	 pathogenesis	 fell	 out	 of	 favour.	 Perhaps	 this	 was	 the	 beginning	 of	 thoughts	 of	 a	 humoral
pathogenesis,	 before	 any	 knowledge	 of	 antibodies.	 They	 also	 heralded	 the	 future	 heterogeneity	 of	 the
Guillain-Barré	 syndromes	 with	 the	 statement	 that	 ‘from	 the	 clinical	 standpoint	 all	 forms	 are	 initially
polyradiculoneuritis’,	many	forms	existed	broadly	classified	 into	4,	but	 that	 ‘the	majority	…	bridge	 the
gaps	between.’
1950–1953:	Francis	Crick	and	James	Watson	Describe	the	Helical
Structure	of	DNA
In	1956	Charles	Miller	Fisher	described	3	cases	of	an	acute	syndrome	consisting	of	ataxia,	areflexia	and
external	 ophthalmoplegia,	 without	 long	 tract	 signs	 or	 central	 nervous	 system	 involvement	 and	 with
albumin-cytological	 dissociation	 in	 one	 case	 [9].	 Guillain	 himself	 probably	 described	 a	 similar	 case
much	earlier	 [10].	Miller	Fisher	 syndrome	 is	now	recognised	as	a	distinct	clinical	entity,	with	varying
amounts	of	overlap	to	GBS,	part	of	 the	heterogeneity	recognised	by	others.	Perhaps	 the	other	 important
milestone	 associated	 with	 Miller	 Fisher	 syndrome	 is	 its	 association	 with	 antibodies	 to	 gangliosides,
thought	to	be	key	to	the	pathogenesis.	We	now	recognise	that	IgG1	antibodies	to	GQ1b	are	found	in	almost
all	 cases	 of	Miller	 Fisher	 syndrome	 and	 related	 or	 overlapping	 syndromes	 (e.g.	 acute	 oropharyngeal
palsy	and	Bickerstaff’s	brainstem	encephalitis)	[11].
1970–1971:	Federico	Faggin	and	Intel	4004,	the	First	Commercial
Microprocessor
One	of	the	most	influential	papers	in	our	GBS	timeline	covers	just	3	succinct	pages	in	The	Lancet	[12].	In
it	Richard	Hughes	describes	a	randomised	placebo-controlled	trial	of	prednisolone	treatment	for	GBS	in
40	participants.	His	conclusion	was	negative:	“Our	results	provide	no	grounds	for	the	use	of	steroids	in
the	 management	 of	 acute	 inflammatory	 neuropathy	 since	 the	 prognosis	 is	 not	 improved,	 the	 rate	 of
recovery	is	slowed	and	the	chance	of	relapse	may	be	increased”.	Looked	at	simply,	this	paper	sets	out	a
negative	 trial	 suggesting	 that	 prednisolone	 is	 ineffective	 and	 possibly	 harmful.	 Looking	 back	 now,	 the
paper	 has	 had	 a	much	 further	 range	 of	 influence,	 still	 reaching	 into	 the	 21st	 century.	 Firstly,	 it	 sets	 a
benchmark	 for	 randomised	controlled	 trials	 in	GBS.	 It	 stimulated	 the	need	 for	other	effective	 therapies
beyond	supportive	care.	Lastly,	it	described	a	clinimetric	approach	to	GBS	studies	that	became	known	as
the	Hughes	scale,	which	some	authors	continue	to	use.	However,	Professor	Hughes	recognised	the	scale’s
inadequacies	from	an	early	stage,	spawning	the	Inflammatory	Neuropathy	Cause	and	Treatment	(INCAT)
studies	 and,	 subsequently,	 the	 Peripheral	 Neuropathy	 Outcome	 Measures	 Standardisation	 (PeriNomS)
Rasch-built	scales	that	benchmark	influential	investigation	in	the	21st	century.
1980–1981:	The	First	Flight	of	the	NASA	Space	Shuttle
Guy	McKhann	is	the	only	person	who	appears	twice	in	my	timeline.	In	1985	the	Guillain-Barré	Syndrome
Study	 Group,	 under	 Dr	 McKhann’s	 guidance,	 published	 the	 first	 really	 significant	 trial	 of	 effective
treatment	for	GBS	[13].	This	trial	was	massive	for	its	time,	including	245	adults	and	children	with	GBS
within	 30	 days	 of	 diagnosis.	 This	 sort	 of	 study	 size	 in	 GBS	 has	 only	 recently	 been	 exceeded	 with
IGOS1000,	 which	 has	 already	 included	 more	 than	 1,000	 participants	 in	 2016.	 The	 paper	 is	 widely
misquoted	and	misunderstood,	especially	when	it	comes	to	the	use	of	IVIg,	shown	later	to	be	of	equivalent
efficacy	 to	plasma	exchange.	What	 is	 seldom	recognised	 is	 that	neither	plasma	exchange	nor	 IVIg	have
been	shown	to	terminate	the	progress	of	GBS,	reduce	disability	or	abort	the	nadir	of	disease.	The	GBS
Study	 Group	 trial	 clearly	 demonstrated	 a	 more	 rapid	 recovery,	 approximately	 halving	 the	 time	 to	 1
Hughes	 grade	 improvement	 or	 to	 be	 extubated	 if	 ventilated.	 This	 translates	 of	 course	 into	 a	 massive
reduction	in	complications	of	GBS.
1990–1994:	Andrew	Wiles	Proves	Fermat’s	Last	Theorem
Guy	 McKhann	 and	 colleagues	 from	 Johns	 Hopkins	 and	 China	 described	 a	 fascinating	 epidemic
neuromuscular	paralysis	in	their	Lancet	paper	of	1991	[14].	So	frequently	in	science	it	is	the	things	that
are	not	 expected	 that	 are	 the	most	 interesting.	They	observed,	 “On	 the	basis	of	 clinical	 features	 alone,
many	 of	 the	 children	 and	 young	 adults	 in	 China	 would	 be	 considered	 to	 have	 GBS.”	 but	 the
electrophysiological	and	epidemic	features	were	not	those	seen	in	Western	GBS—this	was	a	new,	GBS-
like	 disease.	 From	 this	 paper	 acute	 motor	 axonal	 neuropathy	 (AMAN)	 and	 acute	 motor	 and	 sensory
axonal	neuropathy	(AMSAN)	were	conceived.	A	common	infectious	initiation	with	Campylobacter	jejuni
was	 identified.	 The	 involvement	 of	 activated	 complement	 and	 targeted	 macrophage	 destruction	 was
visualised,	and	antibodies	in	the	serum	of	patients	to	gangliosides	and	ganglioside	like	epitopes	resulting
in	immunological	molecular	mimicry	were	described.	The	findings	and	pathological	knowledge	from	this
critical	paper	opened	the	door	to	multiple	avenues	of	investigation,	paving	the	way	to	our	understanding
of	GBS	as	an	autoimmune	disease.	The	Chinese	Paralytic	Syndrome	was	a	sensational	discovery.
2000–2001:	DONUT	Collaboration	and	the	Discovery	of	the	Neutrino
For	 the	 last	40	years	 the	study	of	GBS	has	been	 littered	with	attempts	 to	produce	a	disease	model	 that
reproduced	 an	 acute	 inflammatory	 peripheral	 nerve	 disease	 in	 animals.	 Kadlubowski	 and	 Hughes’
description	of	EAN	 in	1979	by	 immunisation	with	bovine	myelin	protein	 antigens	 (mainly	P2)	was	 an
early	successful	attempt.	Adoptive	transfer	EAN	produced	a	T-cell	model	of	the	disease.	More	latterly	the
beautiful	 demonstration	 of	 the	 development	 of	 a	 spontaneous	 neuropathy	 by	 subverting	 immunological
tolerance	with	a	transgenic	mouse	producing	P0-specific	T	cells	in	2009	added	a	key	piece	to	the	jigsaw
to	 join	 up	 the	 immunological	 ‘dot	 to	 dot’	 puzzle	 from	 instigation	 to	 completion	 of	 disease	 in	 GBS.
Arguably	 the	most	striking	model	description,	however,	was	by	Nobuhiro	Yuki	and	colleagues	 in	2001
[15],	with	a	rabbit	animal	model	caused	by	sensitisation	with	GM1	ganglioside.	This	paper	re-ignited	the
quest	 for	models	which	 had	 been	 fallow	 for	 some	 years	 and	 re-engaged	 the	 anti-ganglioside	 antibody
hypothesis.
2010–2009	Grunting	Causes	Diplocardia	Earthworms	to	Emerge	from
the	Soil
So	 the	world	 of	worm	 science	 turned	 full	 circle,	 and	 in	 2009	Mitra	 and	 colleagues	 demonstrated	 that
exposing	 earthworms	 to	 vibratory	 frequencies	 of	 less	 than	 500Hz	 caused	 them	 to	 emerge	 from	 their
burrows.	Darwin,	 in	 his	 paper	 on	 the	 ‘Formation	 of	Vegetable	Mould’,	 had	 actually	 demonstrated	 that
worms	were	very	sensitive	to	the	vibrations	of	the	piano	when	they	were	placed	on	the	sounding	board
and	middle	C	(256Hz)	was	sounded.	So	over	170	years	we	have	discovered	that	worms	can’t	hear	but
they	can	feel	middle	C!	GBS	has	gone	far	further.	My	key	paper	for	this	decade	is	not	yet	published	but
derives	 from	 the	 work	 of	 Hugh	 Willison	 with	 complement	 inhibition.	 Halstead	 and	 colleagues
demonstrated	 the	 complete	 abrogation	 of	 an	 antibody-mediated	 acute	 inflammatory	 neuropathy	 in	mice
[16].	Although	 the	 human	 pilot	 study	 in	multifocal	motor	 neuropathy	was	 negative	 [17],	 at	 the	 time	 of
publication	2	 trials	of	eculizumab	in	GBS	are	ongoing.	 If	 these	fulfil	 their	promise	and	eculizumab	can
bring	to	an	abrupt	halt	the	damage	ongoing	at	the	time	of	patients	presenting	with	GBS	we	will	have	the
first	‘cure’	for	this	most	fascinating	of	diseases.
Conclusion
Man	has	been	to	the	moon,	antibiotics	have	come	(and	perhaps	are	now	going),	the	mystery	of	our	DNA
has	been	solved	and	the	laws	of	the	universe	have	been	cracked	open.	Worms	still	can’t	hear!	Many,	many
great	minds	have	contributed	to	these	developments	and	in	GBS	research	has	not	fallen	behind.	We	should
be	 proud	 of	 our	 discoveries,	 sometimes	 serendipitous,	 sometimes	 deliberate.	 The	 unusual	 is	 often	 the
most	rewarding.	We	should	continue	to	pursue	our	goal	to	cure	this	disease—we	have	not	done	so	badly
thus	far.
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10	Papers	the	World	Forgot:	A	Critical	Analysis	of
Scientific	Progress	in	GBS
Stephen	W.	Reddel,	Todd	A.	Hardy	and	Stefan	Blum
Introduction
The	centenary	of	Guillain,	Barré	and	Strohl’s	 landmark	description	of	Guillain-Barré	 syndrome	 (GBS)
provides	 an	 opportunity	 to	 celebrate	 the	 key	 papers	 that	 have	 advanced	 our	 understanding	 of	 the
condition.	It	is	equally	a	time	to	contemplate	some	of	the	lesser-appreciated	observations	about	GBS.	In
this	chapter,	using	esoteric	and	poorly	understood	techniques,	we	have	identified	10	GBS	papers	which	in
some	aspect	are	forgotten,	but	which	the	authors	feel	are	worthy	of	renewed	reflection.	We	apologise	if
there	 are	 even	more	worthy	 forgotten	 papers	 that	we	 have	 overlooked,	 especially	 gems	 hidden	within
other	languages.	We	hope	that	by	reappraising	the	past	we	and	the	reader	can	progress	from	it.
Gardner	WJ,	et	al.	Increased	intracranial	pressure	caused	by	increased
protein	content	in	the	cerebrospinal	fluid;	an	explanation	of
papilledema	in	certain	cases	of	small	intracranial	and	intraspinal
tumors,	and	in	the	Guillain-Barré	syndrome.	The	New	England	Journal
of	Medicine,	1954
The	 literature	 on	 GBS	 reports	 several	 cases	 of	 patients	 with	 concomitant	 papilloedema,	 but	 the
association	 is	 not	 widely	 known.	 In	 1954,	 Gardner	 and	 colleagues	 hypothesized	 that	 papilloedema	 in
GBS	 and	 in	 other	 conditions,	 such	 as	 ependymoma	 of	 the	 cauda	 equina,	 acoustic	 tumour	 and
poliomyelitis,	 arises	as	a	 result	of	 elevated	CSF	protein.	 In	elegant	 experiments	 in	anaesthetized	dogs,
they	 demonstrated	 that	 elevated	 CSF	 protein	 can	 slow	 absorption	 of	 CSF,	 presumably	 by	 partially
obstructing	the	arachnoid	villi,	leading	to	increased	intracranial	pressure	(ICP)	and	papilloedema	[1].
This	finding	accorded	with	an	earlier	postmortem	observation	in	a	GBS	patient	who	had	elevated	ICP,
papilloedema,	 a	 normal	 ventriculogram	 and	 a	 tendency	 for	CSF	 fluid	 to	 clot	 after	 lumbar	 puncture,	 of
deposition	 of	 ‘amorphous	 material’	 at	 the	 Pacchionian	 granulation	 of	 the	 arachnoid	 villi	 [2].	 Further
support	 for	 impaired	CSF	absorption	 leading	 to	raised	ICP	and	papilloedema	comes	from	a	 later	study
showing	deranged	CSF	flow	in	a	patient	with	GBS	who	also	had	elevated	CSF	protein	and	hydrocephalus
[3].
Other	 reports	 have	 disputed	 the	 hypothesis	 of	 impaired	 CSF	 absorption	 for	 various	 reasons,	 chief
among	 them	 being	 that,	 in	 individual	 patients,	 the	 level	 of	 elevated	 protein	 does	 not	 necessarily
correspond	 to	 papilloedema	 [4].	 Case	 reports	 of	 isotype-labelled	 albumin	 absorption	 from	 the
subarachnoid	space	in	patients	with	GBS	also	failed	to	demonstrate	a	major	defect	in	CSF	reabsorption
[5].	Moreover,	the	observation	that	not	all	patients	with	GBS	and	papilloedema	have	hydrocephalus	has
also	been	used	to	argue	against	the	impaired	CSF	absorption	hypothesis.
Amit	R,	et	al.	Acute,	severe,	central	and	peripheral	nervous	system
combined	demyelination.	Pediatric	Neurology,	1986.
Historically,	 numerous	 cases	 have	 been	 described	 recognizing	 central	 nervous	 system	 (CNS)
demyelination	 in	 patients	 with	 GBS	 [6,7],	 but	 the	 association	 is	 rare.	 GBS	 and	 acute	 disseminated
encephalomyelitis	 (ADEM)	 are	 distinct,	 monophasic,	 acquired,	 multifocal,	 demyelinating	 diseases	 of
subacute	onset	which	 follow	 in	 the	days	 to	weeks	after	 infection	or	vaccination.	Both	are	presumed	 to
have	 an	 autoimmune	 basis	 and	 seemingly	 respond	 to	 immunotherapies	 such	 as	 plasma	 exchange	 or
intravenous	 immunoglobulin	 (IVIg).	Similarly,	 cases	of	 chronic	peripheral	 and	central	 demyelination—
i.e.	CIDP	and	MS—have	been	described	[8].
The	similarity	between	GBS	and	ADEM,	and	the	fact	that	they	can	occur	simultaneously	in	the	same
patient	has	implications	for	their	immunopathogenesis.	The	monophasic	nature	of	these	diseases	implies
that	they	arise	due	to	a	transient	breakdown	in	immune	self-tolerance	to	a	common	epitope	on	the	myelin
of	 both	 the	 peripheral	 nervous	 system	 (PNS)	 and	 CNS.	 Presently,	 the	 identity	 of	 this	 common	myelin
epitope	is	unknown,	but	myelin	protein	P1	in	the	PNS	is	identical	to	myelin	basic	protein	in	the	CNS,	so
an	epitope	shared	between	the	PNS	and	CNS	is	conceivable	[9].
If	 a	 shared	 epitope	 hypothesis	 is	 correct,	 then	 a	 pertinent	 question	 is	why	 do	 so	 few	 patients	who
contract	GBS	also	acquire	ADEM?
Bickerstaff	ER,	Cloake	PC.	Mesencephalitis	and	rhombencephalitis.
British	Medical	Journal,	1951;	Bickerstaff	ER.	Brain-stem	encephalitis;
further	observations	on	a	grave	syndrome	with	benign	prognosis.
British	Medical	Journal,	1975.
Bickerstaff’s	 original	 description	 of	what	 came	 to	 be	 known	 as	 ‘Bickerstaff’s	 brainstem	 encephalitis’
(BBE),	 includes	 the	 characteristic	 symptoms	 of	 subacute	 onset	 oculomotor	 and	 facial	 palsy,	 bulbar
impairment	and	ataxia,	followed	by	obtundation	with	mixed	upper	motor	and	lower	motor	neurone	signs.
While	these	papers,	and	the	syndrome	they	describe,	are	far	from	forgotten,	it	is	usually	not	appreciated
that	as	many	as	7	of	Bickerstaff’s	11	patients	also	experienced	nausea	and	vomiting	prior	 to	becoming
obtunded	[10,11].
The	 reason	why	BBE	patients	 should	 complain	 of	 nausea	 is	 not	 clear.	One	 explanation	 is	 that	 it	 is
caused	 by	 GQ1b	 antibodies	 gaining	 access	 to	 the	 cerebrospinal	 fluid	 (CSF)	 at	 sites	 where	 there	 is
increased	‘leakiness’	of	the	blood	brain	barrier,	such	as	at	the	level	of	the	chemoreceptor	trigger	zone	in
the	area	postrema	of	the	medulla	[12].
If	this	is	correct,	then	it	provides	further	evidence	that	BBE	not	only	affects	the	PNS	but	the	CNS	as
well	 [13].	Observations	 in	support	of	CNS	involvement,	at	 least	 in	a	proportion	of	patients	with	BBE,
include	abnormal	EEG	findings	with	encephalopathy,	increased	infratentorial	T2	signal	changes	on	MRI,
inflammatory	 brainstem	 lesions	 at	 postmortem,	 absent	 cortical-evoked	 responses,	 and	 the	 finding	 that
GQ1b	antibodies	in	the	CSF	decline	as	patients	with	BBE	recover	[14,15].
Stewart	G,	et	al.	HLA	antigens	in	the	Landry-Guillain-Barré	syndrome
and	chronic	relapsing	polyneuritis.	Annals	of	Neurology,	1978
Numerous	 publications	 on	 GBS	 refer	 to	 the	 concept	 of	 molecular	 mimicry	 converting	 an	 allo-antigen
response	 to	 an	 auto-antigen	 response,	 suggesting	 an	 infection	 triggering	 an	 initial	 adaptive	 immune
response,	followed	by	a	cross	reactivity	to	a	neural	antigen	in	the	context	of	an	interaction	between	the
infection	and	the	individual’s	HLA	characteristics.
Confounding	 this	 hypothesis	 is	 the	 lack	 of	 a	 general	 association	 of	 HLA	 with	 GBS,	 unlike	 most
autoimmune	 diseases.	 This	 lack	 of	 association	 in	 GBS	 is	 unlike	 the	 situation	 in	 chronic	 relapsing
polyneuritis	 /	 CIDP	 [16].	 A	 lack	 of	 association	 in	 GBS	 was	 confirmed	 in	 a	 number	 of	 other	 studies
[17,18].
Presuming	that	GBS	is	still	caused	by	the	broader	immune	system	and	is	not	directly	infectious,	 this
engenders	several	possible	considerations.
1.	 Each	subform	of	GBS	may	have	HLA	associations	specific	to	the	trigger	and	ethnicity	that	are	lost	in
any	general	 study.	This	 is	 intellectually	 the	easiest	 consideration	because	 it	 accepts	 the	hypothesis.
There	 is	 some	 limited	 support	 for	 this	 idea	 of	 subgroup	 analysis	 in	 the	 context	 of	 the	 1976–1977
influenza	vaccine,	or	for	certain	infections	[18,19,20].
2.	 Major	 HLA	 are	 not	 the	 determinants	 of	 this	 molecular	 mimicry	 and	 other	 adaptive	 systems
determining	 nonpeptide	 antibodies	 or	 NK	 pathways	 transduce	 this	 response.	 This	 is	 discussed	 in
Yoshi	(see	below).
3.	 The	 cross-reactive	 response	 may	 be	 the	 norm,	 but	 only	 certain	 individuals	 open	 the	 blood	 nerve
barrier,	permitting	the	development	of	a	clinical	rather	than	just	an	immunological	process.	In	EAN
the	use	of	a	nonspecific	approach	to	opening	the	blood	nerve	barrier	facilitates	the	entry	of	a	specific
response	to	a	target	antigen	[21].
As	it	currently	stands	the	lack	of	HLA	association	for	GBS	casts	some	doubt	on	the	molecular	mimicry
hypothesis.	This	 is,	however,	 in	keeping	with	 the	 idea	 that	GBS	 is	not—or	at	 least	 is	not	 substantially
different	from—a	standard	autoimmune	disease	[18,22].
Yoshii	F	and	Shinohara	Y.	Natural	killer	cells	in	patients	with	Guillain-
Barré	syndrome.	Journal	of	the	Neurological	Sciences,	1998
GBS	differs	 in	a	number	of	aspects	 from	most	classic	autoimmune	diseases,	with	 lack	of	a	clear	HLA
association,	 poor	 response	 to	 corticosteroids	 and	 a	 short-lived	monophasic	 course.	 These	 differences
could	indicate	a	deviation	of	the	usual	immune	response	very	early	after	the	initial	trigger	in	GBS,	raising
the	possibility	that	the	innate	immune	system	plays	a	role.
In	spite	of	this,	study	of	the	innate	immune	system	in	GBS	has	been	neglected.	Natural	killer	cells	are
an	integral	part	of	the	cellular	innate	immune	system,	with	important	links	to	the	adaptive	immune	system.
Yoshii	and	Shinohara	describe	decreased	natural	killer	cell	function	early	in	the	disease	course	in	GBS
patients	 compared	 with	 healthy	 controls	 [23].	 After	 plasmapheresis,	 they	 found,	 NK	 cell	 function
recovered	to	normal	range.	In	contrast,	NK	cell	numbers	did	not	change.
The	 role	 of	 the	 innate	 immune	 system	 in	 GBS	 pathogenesis	 has	 been	 recently	 re-explored.	 The
response	of	dendritic	cells	of	patients	with	GBS	secondary	to	Campylobacter	jejuni	have	been	found	to
have	an	increased	activation	to	lipopolysaccharides	(LOS)	[24]	.	Macrophage	migration	inhibitory	factor
(MIF),	a	cytokine-inhibiting	random	migration	of	macrophages,	has	been	found	to	be	upregulated	 in	 the
serum	and	CSF	of	GBS	patients,	with	upregulated	Toll-like	receptor	4,	a	receptor	of	LOS	on	monocytes
[25].	 Furthermore,	 genetic	 differences	 in	 killer-immunoglobulin-like	 receptors	 (KIR)	 in	 GBS	 patients
compared	to	healthy	controls	have	been	found	[26].
Exley	AR,	et	al.	Tumour	necrosis	factor-alpha	and	other	cytokines	in
Guillain-Barré	syndrome.	Journal	of	Neurology,	Neurosurgery	and
Psychiatry,	1994
A	 role	 for	 cytokines	 in	 the	 pathogenesis	 of	 GBS	 has	 been	 proposed	 ever	 since	 the	 detection	 of	 the
therapeutic	effect	of	plasma	exchange,	which	suggested	soluble	factors	are	involved.	The	role	of	TNF-α
in	 GBS	 pathogenesis	 had	 been	 suspected	 based	 on	 the	 observation	 of	 TNF-α	 mediated	 changes	 after
intraneural	injection	in	mice	as	well	as	the	detection	of	TNF-α	positive	macrophages	around	nerves	at	the
time	of	disease	onset	in	EAN	[27,28].
Exley	and	colleagues	studied	a	range	of	cytokines	in	GBS	patients	undergoing	plasma	exchange.	They
found	no	difference	in	IL-1	and	IFN-γ	in	GBS	patients	versus	controls.	In	contrast,	TNF-α	concentrations
were	increased	in	GBS	patients,	including	correlation	with	severity	[29].
More	 recently	 TNF-α	 polymorphisms	 showed	 genetic	 differences	 in	 GBS	 patients	 versus	 healthy
controls.	A	meta-analysis	examining	12	 studies	 from	diverse	geographical	 areas	confirmed	 that	TNF-α
polymorphism	308	A/G	was	significantly	associated	with	 the	 risk	of	developing	GBS	[30].	Parallel	 to
this,	 clinical	 observations	 linked	 demyelinating	 neuropathies	 with	 use	 of	 TNF-α	 inhibitors,	 such	 as
infliximab	or	etanercept.	A	range	of	demyelinating	neuropathies,	including	AIDP,	MFS,	CIDP	and	MMN
have	been	described	in	the	context	of	TNF-α	inhibition	therapy	[31].	Confusingly,	TNF-α	inhibition	was
also	reported	as	therapy	for	CIDP	[32].
This	points	 towards	a	 complex	 role	of	TNF-α	 in	 the	pathogenesis	of	GBS;	 indeed,	 such	a	 role	has
been	 proposed	 for	 a	 number	 of	 other	 autoimmune	 diseases	 [33].	 Possibly,	 this	 could	 be	 explained	 by
interaction	of	TNF-α	with	its	diverse	receptors	or	downstream	effects	thereof.	TNF-α	can	act	as	a	pro-
inflammatory	and	activate	macrophages	by	binding	to	a	specific	cell	surface	receptor,	TNFR1.	However,
binding	to	TNFR2	has	been	linked	to	anti-inflammatory	and	neuroprotective	effects	[34].
Prineas	JW.	Pathology	of	the	Guillain-Barré	syndrome.	Annals	of
Neurology,	1981;	Schonberger	LB,	et	al.	Guillain-Barré	syndrome.	Its
epidemiology	and	associations	with	influenza	vaccination.	Annals	of
Neurology,	1981.
We	 include	 2	 papers,	 but	 commend	 the	whole	 edition	 on	GBS,	 the	 very	 first	 supplement	 of	Annals	 of
Neurology.	It	reported	on	a	GBS	conference	sponsored	by	the	Kroc	Foundation,	endowed	by	the	founder
of	the	McDonald’s	hamburger	chain.
Prineas’	 paper	 provides	 a	 fascinating	 review	 of	 the	 early	 pathological	 studies	 of	GBS	 and	 related
diseases	 [35].	 Initially	 such	 cases	were	 not	 accepted	 as	 being	 a	 disorder	 of	 the	 peripheral	 nerves,	 as
anterior	 horn	 cell	 changes	were	 present,	 suggesting	 this	was	 spinal	 in	 aetiology.	 Charcot’s	 strength	 of
opinion	contributed.	Slowly	this	evolved	into	acceptance	that	 the	peripheral	nerves	were	involved,	and
the	anterior	horn	cell	changes	were	a	postmortem	artefact.
Later	 studies	 reviewed	 indicated	 that	 pathological	 changes	 were	 patchy	 and	 particularly	 where
anterior	 and	 posterior	 roots	 join	 to	 form	 the	 spinal	 nerves.	 These	 dissections	 of	 large	 numbers	 of
necropsy	GBS	cases	early	in	the	disease	course	are	unlikely	to	be	repeated.	These	demonstrated	that	the
time	 from	onset	 to	death	 is	an	 important	contributor	 to	 the	pathological	changes	present.	Earliest	 is	 the
presence	of	oedema	and	irregularity	of	the	myelin	sheaths,	with	cellular	infiltration	only	9–11	days	after
onset.
The	paper	concludes	with	a	review	of	Prineas’	electron	microscopy	studies	of	GBS	with	wonderful
figures	of	macrophage	processes	insinuating	into	the	myelin	sheaths.
Schonberger	and	colleagues	provide	a	comprehensive	review	of	the	evidence	supporting	a	significant
excess	of	GBS	after	the	A/New	Jersey	influenza	vaccinations	administered	in	the	United	States	in	1976
and	 1977.	 This	 resulted	 in	 the	 American	 Academy	 of	 Neurology	 collaborating	 with	 a	 national	 GBS
surveillance	system	initiated	by	the	Centers	for	Disease	Control.	Their	paper	confirms	that	the	additional
GBS	cases	 after	 the	 1976–1977	vaccination	 program	occurred	 in	 the	 first	 5	weeks	 and	peaked	 at	 2–3
weeks	 after	 vaccination,	 and	 that	 this	 was	 not	 the	 case	 in	 subsequent	 years	 [36].	 The	 same	 temporal
association	of	GBS	following	any	other	triggering	infection,	whether	respiratory	or	gastrointestinal,	was
also	shown.
Guillain	G,	et	al.	Sur	un	syndrome	de	radiculo-névrite	avec
hyperalbuminose	du	liquide	céphalo-rachidien	sans	réaction
cellulaire:	remarques	sur	les	caractères	cliniques	et	graphiques	des
réflexes	tendineux.	Bulletins	et	mémoires	de	la	Société	médicale	des
hôpitaux	de	Paris.	Translation	by	Brody	IA	and	Wilkins	RH,	Archives	of
Neurology,	1968	(Brody	and	Wilkins,	1968).
It	may	seem	strange	to	end	a	chapter	on	things	forgotten	with	a	paper	that	started	the	book!	However,	the
historical	context	is	now	dim.	When	authors	newly	describe	a	syndrome,	a	distinction	is	being	made	from
what	 is	already	known.	Guillain,	Barré	and	Strohl’s	paper	stressed	that	 there	was	no	fever	or	venereal
disease	 [37].	 So	 when	 they	 wrote	 “’the	 striking	 hyperalbuminosis	 of	 the	 cerebrospinal	 fluid	 without
cellular	reaction	is	a	feature	…	of	signal	 importance	…	it	has	not	been	described	…	in	radiculitis	and
polyneuritis”	[38],	what	were	those	other	cases	of	sometimes	febrile	radiculitis	and	polyneuritis	with	a
cellular	reaction?
These	were	doctors	working	in	an	army	hospital	in	the	Great	War,	seeing	soldiers	from	the	trenches,	in
northern	 France.	 In	 addition	 to	 the	 war	 wounds	 there	 were	 numerous	 infections,	 arising	 from	 poor
hygiene,	as	well	as	zoonoses,	with	endemic	rats	and	 lice	 in	 the	fields	and	forests	behind	 the	front,	and
Ixodes	ricinus	 ticks,	 the	European	vector	for	Lyme	neuroborreliosis,	even	now	prevalent	in	this	part	of
France	[39].
Febrile	 polyneuritis	 was	 discussed	 contemporaneously,	 by	 Lieutenant-Colonel	 Gordon	 Holmes,
Consultant	Neurologist,	British	Armies	 in	France	 [40].	Richard	Hughes	writes,	 “It	 is	puzzling	 to	know
what	modern	disease	Osler	and	Holmes	were	describing	since	absence	of	fever	is	 the	rule	in	Guillain-
Barré	 Syndrome”	 [41].	 Polio	 and	 diphtheria	 are	 discussed	 therein;	 syphilis	 and	 spinal	 compressions
and/or	 Pott’s	 disease	 (tuberculosis)	 were	 discussed	 by	 Guillain	 and	 his	 colleagues.	 However,	 Lyme
disease	and	trench	fever	may	be	forgotten	differentials	for	the	historical	context.	Holmes’	paper	noted	an
association	with	trench	fever.
True	nervous	 system	Lyme	disease	 can	present	 as	 rapidly	progressive	 radiculoneuritis	 akin	 to	GBS
[42].	Facial	nerve	involvement	is	common,	and	indeed	was	noted	by	Holmes[40].	Fever	may	be	absent,
but	a	cellular	pleocytosis	is	characteristic.	It	is	still	the	case	that	“a	lumbar	puncture	is	usually	performed
…	to	rule	out	infectious	diseases,	such	as	Lyme	disease”	[43].
Trench	fever,	a	systemic	infection	of	Bartonella	quintana	transmitted	by	the	body	louse,	was	rife	and
may	 cause	meningoencephalitis	with	 cellular	 pleocytosis.	 Trench	 fever	 caused	marked	 loss	 of	 fighting
man	power	and	consequent	investigation	[44]:	“It	 is	curious	that	 the	sniffing	up	the	nose	of	the	infected
excreta	of	lice	did	not	give	rise	to	infection,	whereas	the	placing	of	the	same	material	in	the	conjunctival
sac	 did	 give	 rise	 to	 positive	 results	 in	 2	 cases.	 The	 attempt	 to	 infect	 by	 way	 of	 the	 urethra	 was
unsuccessful.”
The	initial	presentation	can	be	similar	to	GBS,	although	the	later	course	is	not.	“The	men	affected	by
trench	fever	began	…	with	a	faintness	that	dropped	them	in	their	tracks,	headache	and	backache,	with	pain
and	stiffness	in	the	legs.…	Many	could	not	bear	the	pressure	of	the	bedclothes”	[45]	(Herringham,	1917).
Neurologists	will	 recall	 such	 histories,	 and	while	many	 cases	will	 be	 parainfectious	myalgia	 or	 some
other	 cause	 of	 pain,	 some	 will	 be	 a	 pain-predominant	 presentation	 of	 GBS,	 with	 initially	 preserved
reflexes.
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The	Global	Epidemiology	of	Guillain-Barré
Syndrome	and	the	Relationship	to	Vaccines
James	J.	Sejvar
Introduction
Although	 relatively	 uncommon	 compared	 to	many	 other	 neurologic	 illnesses,	Guillain-Barré	 syndrome
(GBS)	has	been	 the	 focus	of	 some	of	 the	most	 intense	and	extensive	epidemiologic	assessments	of	any
illness.	This	has	primarily	been	driven	by	an	apparent	causal	association	between	GBS	and	a	particular
formulation	of	the	influenza	vaccine.	As	such,	our	understanding	of	the	epidemiology	of	GBS	is	intimately
intertwined	with	 the	 concern	 about	GBS	 and	 vaccines.	As	 a	 result,	 this	 chapter	will	 discuss	what	we
currently	know	about	the	global	epidemiology	of	GBS,	and	how	its	relationship	to	a	single	vaccine	has
driven	much	of	the	overall	understanding	of	GBS	epidemiology.
Global	Epidemiology	of	GBS:	The	Basics
Shortly	after	the	recognition	and	description	of	the	specific	clinical	entity	of	GBS	(whether	you	are	in	the
‘Landry	(1859)’	camp	or	the	‘Guillain,	Barré,	and	Strohl	(1916)’	camp),	there	was	a	great	deal	of	focus
on,	and	rapid	increase	in	understanding	of	the	clinical,	laboratory	and	electrophysiologic	aspects	of	this
newly	 recognized	 syndrome.	 However,	 the	 epidemiology	 of	 the	 syndrome	 was	 poorly	 understood;
epidemiology	as	a	distinct	medical	discipline	was	 still	 in	 its	 early	 stages	at	 this	 time,	 and	 the	 relative
rarity	 of	 the	 condition	made	 epidemiologic	 studies	 challenging.	 Nevertheless,	 over	 time,	 case	 reports
began	 to	 trickle	 into	 small	 case	 series,	 and	 from	 this	 trickle,	 several	 epidemiologic	 factors	 of	 GBS
seemed	to	emerge:	it	was	relatively	uncommon;	it	seemed	to	affect	males	more	commonly	than	females;	it
could	 occur	 at	 any	 age;	 and	 it	 was	 often	 associated	 with	 some	 antecedent	 prodrome	 suggestive	 of
infection,	 particularly	 upper	 respiratory	 tract	 infections.	 Information	 on	 incidence,	 demographics,	 and
other	basic	epidemiologic	data	were	gleaned	from	larger	studies	on	the	occurrence	of	neurologic	disease
in	general.
Early	 assessments	 of	 the	 epidemiology	 of	 GBS	were	 hampered	 primarily	 by	 one	 thing—lack	 of	 a
standardized	 set	 of	 criteria	 or	 common	 case	 definition,	 by	which	 cases	 could	 be	 accurately	 compared
with	each	other	and	reliable	estimates	of	incidence	obtained.	So	many	different	systems	of	classification
and	characterization	of	the	syndrome	began	to	evolve	that	it	eventually	prompted	Guillain	himself	to	state,
“I	no	longer	recognize	the	syndrome	J.A.	Barré	and	I	described”	[1].
The	 first	 true	 descriptive	 epidemiologic	 study	 of	 GBS	 was	 published	 in	 1973	 by	 Lesser	 and
colleagues,	 who	 utilized	 the	 composite	 medical	 diagnostic	 file	 of	 the	 Mayo	 Clinic	 in	 Rochester,
Minnesota	[2];	this	is	a	database	that	allows	for	the	collection	of	longitudinal	data	from	a	circumscribed
population	over	a	long	duration.	This	study	retrospectively	identified	all	GBS	cases	occurring	in	Olmsted
County,	Minnesota	between	1935	and	1968.	The	case	definition	used	was	a	clinical	history	of	acute	or
subacute	onset	of	bilateral	weakness	with	or	without	cranial	nerve	abnormalities	or	sensory	findings,	in
the	absence	of	concurrent	febrile	illness;	cyto-albuminologic	dissociation	was	assessed	for	but	was	not	a
requisite.	This	was	 the	 first	comprehensive	study	 to	validate,	 in	a	 systematic	and	standardized	 fashion,
many	of	the	epidemiologic	features	of	GBS	that	we	now	take	for	granted.	During	that	34-year	period,	29
patients	 meeting	 the	 case	 criteria	 were	 identified,	 resulting	 in	 a	 mean	 annual	 incidence	 of	 1.6
cases/100,000	population/year;	males	were	slightly	more	likely	to	be	affected	than	females.	Rates	were
highest	in	the	40–59	age	group	(though,	notably,	due	to	small	sample	size	the	standard	errors	in	each	age
group	 were	 large).	 Cases	 were	 not	 clustered	 in	 any	 season,	 or	 in	 any	 given	 year.	 An	 antecedent
respiratory	 or	 infectious	 illness	 closely	 preceding	 neurologic	 illness	 onset	 was	 reported	 in	 16	 (55%)
cases.
The	Lesser	 study	was	 followed	up	by	a	subsequent	assessment	using	 the	same	methodology	and	 the
same	database,	extending	the	investigation	period	through	1976,	and	included	a	case-control	component
[3].	 In	 order	 to	 evaluate	 the	 possible	 association	 between	 antecedent	 infections	 and	 GBS,	 controls
consisting	of	persons	with	acute	neurologic	illness	but	not	GBS	(including	meningitis,	herpes	zoster	and
idiopathic	Bell’s	palsy)	were	identified.	The	additional	8	years	yielded	11	additional	cases,	with	a	total
of	40	cases	identified	between	1935	and	1976.	The	findings	of	this	assessment	were	largely	the	same	as
the	first	assessment:	overall	mean	annual	incidence	of	1.7/100,000	persons;	slight	male	predominance;	no
detectable	trends	by	age,	sex,	season	or	year;	and	an	increase	in	incidence	in	the	40–59	age	group.	The
case	control	study	suggested	that	GBS	patients	were	statistically	more	likely	to	report	a	febrile	or	other
infectious	 illness	 in	 the	 4	weeks	 preceding	GBS	 onset	 than	 the	 age-	 and	 sex-matched	 controls,	 but	 no
differences	in	terms	of	exposure	to	prior	immunizations,	allergic	or	metabolic	disorders,	or	exposure	to
toxins,	suggesting	an	important	relationship	between	prior	infections	and	GBS.
Together,	 these	 papers	 solidified	 many	 of	 the	 basic	 epidemiologic	 tenets	 of	 GBS	 that	 had	 been
reported	 to	 that	 time—at	 least	 in	 a	 white,	 homogeneous,	 largely	 middle	 class	 population	 in	 the
Midwestern	United	States.	Even	the	authors	of	these	studies	cautioned	against	generalizing	these	findings
to	the	entire	United	States,	let	alone	the	world.	A	population-based	study	assessing	the	incidence	of	GBS
in	San	Joaquin	County	in	California	was	published	at	approximately	the	same	time	as	the	publication	of
the	Olmsted	County	papers	 [4];	 the	 findings	 in	 this	 study	were	commensurate	with	 the	Olmsted	County
data	with	the	exception	that	the	San	Joaquin	evaluation	failed	to	demonstrate	a	male	predominance,	most
likely	due	to	small	sample	size	(n	=	18).
Aside	 from	 these	 assessments,	 surprisingly	 little	 work	 on	 the	 basic	 epidemiology	 of	 GBS	 was
conducted	 from	 identification	of	 the	 syndrome	until	 the	 swine	 flu	 (H1N1)	campaign	of	1976.	Globally,
what	work	was	being	 conducted	 consisted	of	 case	 reports	 and	 case	 series	 using	varying	 classification
schemes,	case	ascertainment	methodologies,	and	denominators	resulting	in	a	vertigo-inducing	variety	of
estimates	of	incidence,	seasonality	versus	no	seasonality,	age	distributions	and	other	basic	epidemiologic
parameters.	 Essentially,	 the	 only	 consistent	 feature	 of	 these	 various	 estimates	 and	 assessments	 was
inconsistency.	This	heterogeneity	was	demonstrated	eloquently	in	an	article	by	McGrogan	and	colleagues,
who	undertook	the	heroic	task	of	performing	a	systematic	literature	review	of	the	epidemiology	of	GBS
worldwide	between	1980	and	2008	[5].	An	initial	review	of	the	literature	yielded	511	papers;	these	were
winnowed	down	to	include	only	epidemiologically	sound	studies	with	sufficient	data	and	that	conformed
to	 one	 of	 the	 relatively	 widely	 accepted	 case	 definitions/case	 criteria	 for	 GBS.	 After	 this	 laborious
process,	a	resultant	63	papers	survived	to	the	point	of	full	review.
To	review	the	results	of	McGrogan’s	assessment	is	to	appreciate	the	immense	diversity	of	fundamental
epidemiologic	 features	of	GBS	worldwide.	Much	of	 this	diversity,	however,	 is	 ‘man-made’,	driven	by
differences	in	case	ascertainment,	case	definitions/classifications	and	reporting	methods,	rather	than	true
fluctuations	in	GBS	epidemiology.	These	differences	resulted	in	a	vast	range	of	incidence	estimates	with
incidence	rates	varying	between	0.38/100,000/year	(95%	CI	0.25–0.56)	in	Finland	to	2.53/100,000/year
(95%	CI	1.87–3.35)	in	Curaçao.	McGrogan’s	review	of	the	literature	also	highlighted	that	most	of	what
we	know	about	the	epidemiology	of	GBS	is	based	upon	populations	in	North	America	and	Europe,	where
the	vast	majority	 (89%	of	 the	63	 studies)	of	 studies	were	conducted;	 for	 the	 rest	of	 the	world,	 so	 few
assessments	 had	 been	 conducted	 as	 to	 preclude	 comment	 on	 geographical	 trends.	 An	 important
observation	 from	 McGrogan’s	 paper	 was	 the	 influence	 of	 study	 method	 had	 on	 incidence	 estimates.
Invariably,	incidence	estimates	provided	by	prospective	studies	and	database	searches	were	higher	than
those	found	by	retrospective	studies	relying	on	medical	record	review.
In	an	effort	to	streamline	the	heterogeneous	results	of	McGrogan’s	work,	several	colleagues	from	the
U.S.	Centers	for	Disease	Control	and	Prevention	(CDC),	including	myself,	performed	a	meta-analysis	to
further	 refine	 these	 incidence	 estimates	 in	North	America	 and	 Europe	 [6].	 Beginning	with	 the	 articles
cited	by	McGrogan,	and	inclusive	of	several	other	studies	published	subsequent	to	McGrogan’s	article,
we	conducted	a	meta-analysis	of	the	most	thorough	epidemiologic	papers	published	up	to	2009.	To	obtain
the	 most	 accurate	 incidence	 estimates,	 we	 applied	 specific	 and	 tight	 criteria.	 Because	 so	 little	 was
understood	 about	 the	 epidemiology	 of	 GBS	 elsewhere,	 we	 included	 only	 articles	 estimating	 GBS
incidence	in	North	American	and	European	countries;	studies	had	to	include	at	least	20	cases;	data	had	to
be	 population-based;	 and	 a	 diagnosis	 of	GBS	 had	 to	 be	 confirmed	 by	 a	 subject	matter	 expert	 using	 a
widely	 accepted	 case	 definition	 for	 GBS.	 This	 study	 identified	 1,683	 nonduplicative	 publications,	 of
which	 16	met	 the	 inclusion	 criteria.	Using	 regression	 analysis,	we	were	 able	 to	 derive	 an	 equation	 to
calculate	average	GBS	rate	per	100,000	person-years	as	a	function	of	age	(exp[−12.0771	+	0.01813	(age
in	years)]	×	100,000);	this	equation	provides	a	utilitarian	method	of	ascertaining	‘expected’	rates	of	GBS
by	age	in	any	given	population	in	North	America	or	Europe,	which	we	hoped	would	be	a	useful	tool.	Our
calculation	resulted	in	a	median	crude	incidence	rate	for	GBS	of	1.11	cases	per	100,000	person-years.
GBS	 incidence	 increased	by	20%	for	every	10-year	 increase	 in	age,	and	consistent	with	other	 studies,
was	slightly	higher	for	males	than	females.	This	study	was	able	to	harness	the	power	of	the	meta-analysis
not	only	to	calculate	a	robust	GBS	incidence	estimate,	but	to	provide	a	tool	to	estimate	background	age-
specific	rates	of	GBS	incidence	in	comparable	populations.
As	mentioned,	McGrogan’s	article	highlighted	the	disappointing	paucity	of	good,	solid	incidence	and
epidemiologic	 estimates	 of	GBS	 outside	 of	North	America	 and	Europe	 that	 still	 persists	 today.	 These
estimates	are	plagued	by	less-than-reliable	case	ascertainment	methods	(e.g.	use	of	ICD	codes	only),	lack
of	validation	of	cases	by	applicable	criteria	and	other	limitations.	A	notable	exception	to	this	general	lack
of	understanding	is	an	assessment	of	GBS	incidence	in	China	published	in	2002[7].	Cheng	and	colleagues
were	able	to	perform	a	prospective,	population-based	assessment	of	GBS	in	Harbin,	China	(population
5.4	million	 as	of	2001)	over	 a	1-year	period.	The	authors	performed	enhanced	active	 surveillance	 for
GBS	amongst	a	network	of	physicians,	included	a	component	of	admission	record	review	at	all	hospitals
in	Harbin	to	identify	GBS	patients	who	may	have	been	missed	by	the	prospective	surveillance,	and	had
each	GBS	diagnosis	confirmed	by	examination	by	senior	neurologists.	The	authors	identified	36	patients
in	Harbin,	resulting	in	a	crude	incidence	of	0.67	(95%	CI	0.47–0.92)	for	both	sexes;	male:female	ratio
was	1.4.	Interestingly,	when	assessing	age-specific	incidence,	the	lowest	GBS	rate	per	100,000	person-
years	was	 in	 the	30–39	age	group,	while	 the	highest	was	 in	 the	youngest	age	group	(<10	years	of	 age;
1.15/100,000/year).	The	2	notable	findings	from	this	study	were	the	relatively	low	crude	incidence	when
compared	 to	 other	 studies	 using	 such	 robust	 case-finding	 methodologies,	 and	 the	 finding	 of	 a	 high
incidence	among	children	and	lower	incidence	in	adults.
The	 findings	 of	 this	 study	 continue	 to	 perplex	 me;	 their	 study	 design	 was	 sound,	 they	 were	 well-
powered	 to	 detect	 their	 cases,	 but	 the	 age-specific	 data	 differs	 from	 nearly	 every	 other	 GBS
epidemiologic	 study.	 The	 authors	make	 several	 suggestions	 as	 to	why	 this	 finding	might	 be,	 including
more	 complete	 case	 ascertainment	 among	 children,	misdiagnosis	 of	GBS	 in	 this	 age	 group	 and	 a	 true
difference	 in	 GBS	 epidemiology	 in	 Harbin	 due	 to	 genetic	 or	 environmental	 differences	 between
populations;	however,	I’m	still	left	with	questions.
Of	note,	a	similar	finding	of	high	incidence	of	GBS	among	children	was	observed	in	a	well-designed
assessment	of	GBS	epidemiology	in	Bangladesh	performed	by	Islam	and	colleagues	[8].	By	applying	a
standardized	case	definition	to	identified	acute	flaccid	paralysis	(AFP)	cases	for	2	consecutive	calendar
years	 (2006	 and	 2007),	 they	 calculated	 a	 crude	 incidence	 rate	 fell	 between	 1.5	 and	 2.5	 per	 100,000
population	 /year.	Seasonality	was	noted,	with	a	peak	 in	early	spring	 (May)	and	nadir	 in	February.	The
high	incidence	of	GBS	in	children	in	Bangladesh	has	been	hypothesized	to	be	related	to	a	larger	burden	of
exposure	to	enteric	pathogens,	specifically	Campylobacter	jejuni.	This	study	assessed	incidence	only	in
children	<15	years,	precluding	a	comparison	of	 incidence	between	children	and	older	age	groups	as	 in
the	 Harbin	 paper.	 Both	 these	 studies	 demonstrate,	 however,	 that	 it	 is	 probable,	 even	 likely,	 that	 the
epidemiology	of	GBS	in	other	parts	of	the	world	differ	substantially	from	that	described	and	well	known
in	North	America	and	Europe.	This	highlights	the	need	for	further,	well-designed	investigations	into	the
epidemiology	of	GBS	in	South	and	Southeast	Asia,	Africa,	Central	and	South	America,	and	the	Middle
East	in	order	to	truly	obtain	a	global	comprehension	of	the	epidemiology	of	GBS	worldwide,	as	well	as
risk	factors	for	GBS	in	these	areas.
GBS	and	Vaccines
The	issue	of	GBS	epidemiology	and	the	association	of	GBS	and	vaccines	are	intimately	intertwined.	This
is	because,	due	to	one	singular	event,	GBS	went	from	being	an	interesting	but	rare	neurologic	disorder	to
a	 syndrome	 that	 has	 undergone	 some	 of	 the	 most	 extensive	 epidemiologic	 scrutiny	 of	 human	 medical
conditions	 (at	 least	 in	 North	 America	 and	 Europe).	 More	 is	 understood	 about	 the	 epidemiology	 and
incidence	of	GBS	than	about	many	far	more	common	diseases.	However,	the	apparent	causal	association
between	GBS	and	a	formulation	of	the	vaccine	against	so-called	swine	flu	had	far-reaching	implications
for	our	understanding	of	GBS.
An	important	concept	in	the	discussion	of	potential	adverse	events	following	immunizations	(AEFI)	is
the	concept	of	causality.	It	is	possible	to	find	case	reports	or	case	series	of	the	development	of	nearly	any
neurologic	illness	following	nearly	any	vaccine;	reports	of	‘X	illness	following	Y	vaccine’	permeate	the
literature.	However,	 substantiation	of	an	etiologic	or	causal	nature	of	 such	associations	with	data	 from
clinical	trials	or	large	epidemiologic	studies	is	generally	lacking.	Thus,	the	occurrence	of	many	clinical
events	 that	 are	 associated	 with	 a	 particular	 vaccine	 by	 virtue	 of	 temporal	 proximity	 is	 substantially
different	than	demonstrating	a	causal	relationship.
GBS	and	Vaccines:	The	Early	Years
Since	 its	 initial	 recognition	 and	 description,	 it	 was	 observed	 that	 GBS	 could	 occasionally	 occur
following	a	vaccination.	In	a	review	of	over	1,100	case	reports	and	case	series	conducted	by	Leneman
and	colleagues	[1],	vaccines	were	included	among	the	literal	litany	of	events	temporally	associated	with
development	of	GBS	(other	conditions	‘associated’	with	GBS	in	this	review	included	penicillin,	recent
emotional	stress,	falls	and	fractures	and	lightning	strikes).	However,	even	in	this	list,	it	was	recognized
that	some	vaccines	anecdotally	seemed	to	be	more	strongly	associated	with	subsequent	GBS	than	others,
on	the	basis	of	more	GBS	cases	apparently	reported	following	particular	vaccines.	The	most	common	of
these	 anecdotal	GBS-inducing	 vaccines	 seemed	 to	 be	 neurally	 derived	 rabies	 vaccine;	 other	 vaccines,
including	tetanus,	smallpox,	the	Salk	poliomyelitis	and	seasonal	influenza	vaccines	were	also	included	in
this	comprehensive	list.	However,	like	every	other	association	noted	at	that	time,	the	association	between
vaccines	and	GBS	was	temporal	only,	and	a	causal	association	was	unable	to	be	demonstrated,	primarily
because	 these	 investigations	 lacked	appropriate	 controls	 against	which	 to	 compare	 the	 experience	of	 a
given	series	of	cases.
GBS	and	the	1976	U.S.	Swine	Flu	Vaccination	Campaign:	The	Shot	Heard	’Round	the
World
GBS	began	 to	be	viewed	specifically	 through	a	vaccine-filtered	 lens	 in	1976.	This	was	 the	year	of	 the
U.S.	 bicentennial—1976	marked	 the	 200th	 birthday	 of	 the	 nation.	Against	 this	 backdrop	 of	 patriotism,
fireworks	and	celebration,	the	understanding	of	GBS	was	about	to	be	changed	forever.
In	early	February	of	1976,	the	New	Jersey	Department	of	Health	obtained	isolates	of	influenza	viruses
from	military	 recruits	 at	Fort	Dix	 in	New	Jersey,	who	were	 suffering	 from	 influenza-like	 illness	 (ILI).
Testing	at	the	CDC	indicated	that	most	of	these	influenza	virus	isolates	were	of	a	seasonal	strain	that	was
commonly	circulating	at	that	time.	Several	of	the	isolates,	however,	were	determined	to	be	an	H1N1	virus
of	swine	origin	(A/NJ/76[H1N1]).	These	isolates	were	antigenically	similar	to	the	virus	responsible	for
the	catastrophic	1918	‘swine	flu’	pandemic	 that	 resulted	 in	millions	of	deaths	worldwide.	Surveillance
around	 the	 Fort	 Dix	 area	 failed	 to	 identify	 the	 presence	 of	 the	 H1N1	 virus	 outside	 of	 the	 base;
surveillance	among	 the	Fort	Dix	military	personnel,	however,	demonstrated	 sustained	person-to-person
transmission.	In	March	1976,	a	panel	of	experts	was	emergently	convened,	and	recommended	widespread
H1N1	vaccination	in	anticipation	of	another	epidemic	of	‘swine	flu’.	Within	weeks,	a	presidential	order
was	issued	creating	the	National	Influenza	Immunization	Program	(NIIP),	and	the	CDC	was	charged	with
its	implementation.	During	that	summer,	the	U.S.	government	contracted	with	4	pharmaceutical	companies
to	 produce	 enough	 H1N1	 vaccine	 to	 immunize	 the	 entire	 U.S.	 population;	 the	 manufacturers	 balked,
agreeing	 to	manufacture	 the	 vaccine	 on	 such	 short	 order	 only	 if	 they	were	 deemed	 ‘immune’	 from	 any
litigation	from	possible	adverse	events.	The	U.S.	government	agreed,	and	the	manufacturers	quickly	went
to	work	formulating	millions	of	doses	of	vaccine	(predominantly	monovalent	inactivated	vaccine).	On	1
October	1976,	the	NIIP	was	launched,	with	great	fanfare.	Keep	in	mind,	to	this	point,	the	H1N1	virus	had
not	been	identified	off	of	the	Fort	Dix	base,	and	no	one	had	died	or	fallen	severely	ill	from	the	virus.	Over
the	subsequent	11	weeks,	about	45	million	persons	were	administered	the	vaccine.
Before	 the	 campaign	 was	 launched,	 a	 nationwide	 passive	 surveillance	 system	 was	 established	 to
evaluate	 any	 possible	 adverse	 events	 following	 this	 immunization.	 A	 young	 CDC	 epidemiologist,	 Dr
Larry	 Schonberger,	 was	 put	 in	 charge	 of	 overseeing	 and	monitoring	 this	 program.	 Trained	 in	 internal
medicine	and	just	arriving	as	a	CDC	staff	member	after	his	studies	in	epidemiology	at	Johns	Hopkins	and
anxious	 to	 begin	 applying	 his	 epidemiologic	 knowledge,	 Dr	 Schonberger	 took	 on	 the	 project,	 never
anticipating	the	storm	that	was	to	come.	By	2	December,	2	clusters	of	GBS	were	reported	to	CDC	from	2
different	 U.S.	 states.	 Out	 of	 an	 abundance	 of	 caution,	 these	 clusters	 led	 to	 the	 initiation	 of	 active
surveillance	for	GBS	cases	 in	 these	2	states	and	2	additional	states,	and	shortly	 thereafter	7	additional
states,	to	evaluate	the	possibility	of	a	causal	relationship	between	GBS	and	the	influenza	vaccinations.	As
Dr	Schonberger	crunched	the	numbers,	he	became	intrigued;	as	more	GBS	cases	came	in,	intrigue	turned
into	 concern.	 In	 this	 pre-desktop	 computer	 era,	 Dr	 Schonberger	 spent	 hours	 comparing	 rates	 of	 GBS
among	vaccinees	and	nonvaccinees,	and	became	convinced	that	something	was	out	of	the	ordinary—there
appeared	 to	 be	 a	 plausible	 association	 between	 the	 vaccine	 and	GBS.	Using	person-time	 analysis,	 the
data	suggested	that	recent	vaccinees	had	a	7-fold	greater	incidence	of	GBS	compared	with	those	who	had
not	received	the	vaccine.	On	the	basis	of	these	preliminary	findings,	and	the	weakening	evidence	that	a
swine	 flu	 pandemic	 was	 actually	 going	 to	 emerge,	 the	 vaccination	 campaign	 was	 suspended	 on	 16
December	 1976	 (Dr	 Schonberger	 recalls	 the	 secretary	 of	Health	 and	Human	Services	 telling	 him	 in	 a
stern	and	somewhat	irritated	voice,	“You	better	be	right	about	this.”)
The	 preliminary	 findings	 were	 published	 in	 CDC’s	 Morbidity	 and	 Mortality	 Weekly	 Report
(MMWR)	on	24	December	[9].	All	personnel	who	were	originally	deployed	to	oversee	and	administer
the	vaccine	were	reassigned	to	conduct	active	surveillance	for	GBS	nationally	to	determine	as	quickly	as
possible	whether	the	influenza	vaccinations	were	in	fact	related	to	GBS	and,	if	so,	to	determine	the	risk.
CDC	and	state	health	departments	performed	active	outreach	to	neurologists	throughout	the	United	States
to	request	reporting	of	all	cases	of	GBS	with	an	onset	between	1	October	1976	(the	commencement	of	the
immunization	 program)	 and	 31	 January	 1977.	 This	 focused	 surveillance	 on	 GBS	 identified	 a	 total	 of
1,098	 cases;	 532	 (48.5%)	 occurred	 sometime	 after	 receipt	 of	 a	 swine	 flu	 vaccine.	 Many	 notable
epidemiologic	 features	were	 identified,	 including	several	 that	provided	strong	evidence	of	an	etiologic
association	between	the	vaccinations	and	GBS:
1.	 The	attack	rates	of	GBS	among	adults	were	significantly	higher	in	vaccinees	compared	to	the	rates	in
the	unvaccinated	population.
2.	 The	 distribution	 of	 cases	 occurring	 by	 week	 after	 vaccination	 clustered	 in	 the	 first	 5	 weeks,
particularly	in	weeks	2	and	3	after	vaccination.	Compared	to	the	expected	rates,	the	relative	risks	for
GBS	 during	 weeks	 2	 and	 3	 after	 vaccination	 exceeded	 12.	 This	 pattern	 of	 occurrence	 was
biologically	consistent	with	the	development	of	an	immune-mediated	condition	such	as	GBS.
3.	 Compared	to	the	unvaccinated	GBS	patients,	the	proportion	of	the	vaccinated	patients	with	a	history
of	an	acute	 illness	within	4	weeks	before	onset	of	GBS	was	markedly	 lower—33%	versus	62%—
suggesting	that	vaccine	and	not	another	antigenic	stimulus	was	resulting	in	the	increased	incidence	of
GBS.
4.	 The	 reported	 relative	 risk	 (RR)	of	GBS	 for	 the	6-week	period	 after	 vaccination	 in	 adults	was	7.6
(95%	 CI	 6.7–8.6),	 resulting	 in	 an	 attributable	 risk	 (AR)	 during	 this	 period	 of	 0.88	 GBS
cases/100,000	vaccinees.
5.	 About	 98%	 of	 the	 vaccinations	 were	 administered	 to	 adults.	 During	 the	 6-week	 period	 after
vaccination,	the	attack	rates	in	each	of	the	4	adult	age	groups,	(18–24,	25–44,	45–64	and	65+	years)
but	not	for	children	(0–17	years),	were	significantly	elevated	compared	to	the	background	rates.
Summary	conclusions	of	this	study	were	that	many	cases	of	GBS	were	directly	related	to	vaccination,
with	 those	 recently	vaccinated	having	a	significantly	elevated	attack	 rate	 in	every	adult	age	group.	The
total	 vaccine	 AR	 in	 adults	 was	 reported	 as	 just	 under	 1	 case	 of	 GBS	 per	 100,000	 vaccinations.	 Dr
Schonberger	published	his	final	results	in	the	American	Journal	of	Epidemiology	[10].
Criticisms	and	Reanalysis
Despite	these	studies	suggesting	an	epidemiologic	link	between	the	1976	influenza	vaccine	and	GBS,	the
results	were	questioned	on	a	number	of	different	bases:	cases	of	GBS	were	ascertained	and	classified	by
state	and	local	public	health	officials	who	may	have	not	have	familiarity	with	the	complicated	diagnosis
of	GBS;	 full	 evaluation	 of	 cases	 by	 a	 trained	 neurologist	was	 not	 required,	 and	many	 non-neurologist
practitioners	may	not	have	had	enough	familiarity	with	the	syndrome	to	arrive	at	a	correct	diagnosis;	and
the	 intense	 publicity	 surrounding	 the	 swine	 flu	 immunization	 effort	may	have	 led	many	practitioners	 to
over-diagnose	any	peripheral	neuropathy	among	vaccinees	as	GBS.	Similarly,	 the	CDC	did	not	conduct
an	 independent	 medical	 record	 review	 of	 the	 1,098	 cases	 submitted	 as	 GBS.	 It	 was	 noted	 that	 the
characteristics	of	a	number	of	cases	accepted	by	the	CDC	did	not	conform	to	accepted	diagnostic	criteria
for	GBS.	Finally,	 the	 publicity	 surrounding	 the	 campaign	may	have	biased	practitioners	 towards	 over-
reporting	 GBS	 among	 vaccinees,	 or	 alternatively	 under-reporting	 GBS	 among	 unvaccinated	 patients.
These	points	were	summarized	in	a	scathing	editorial	published	in	the	Archives	of	Neurology	by	Kurland
and	colleagues	[11].
As	 legal	 claims	 against	 the	U.S.	 government	 for	 damage	 caused	by	 the	H1N1	vaccine	mounted,	 the
pressure	on	Dr	Schonberger	similarly	increased.	Schonberger	and	others	at	the	CDC	were	deposed,	and
Schonberger	 found	 himself	 trying	 to	 explain	 the	 epidemiologic	 principles	 behind	 the	 association	 to
litigious	lawyers	and	patients.	“It	was	the	most	stressful	time	of	my	life”,	he	recalls.	Ultimately,	the	U.S.
Justice	Department	 insisted	on	an	 independent	assessment	of	 the	original	CDC	data	by	an	expert	panel
comprised	of	epidemiologists	and	neurologists.	This	expert	panel	was	convened	in	1982	and	chaired	by
Dr	Alexander	Langmuir,	one	of	the	legends	of	public	health	epidemiology	and	a	former	CDC	director.	The
CDC	was	forced	to	hand	over	all	of	the	raw	data	and	calculations.	In	determining	risk,	the	panel	decided
after	analysing	available	data	to	exclude	many	cases	that	were	included	in	the	original	study,	and	to	base
its	 risk	 assessment	 on	 the	 most	 definite	 and	 severely	 affected	 cases	 (those	 with	 ‘extensive	 motor
involvement’).	 It	 also	 decided	 to	 use	 2	 different	 estimates	 of	 the	 expected	 background	 rates	 of	 GBS.
Based	 on	 the	 ‘extensive	 motor	 involvement’	 cases,	 the	 panel	 confirmed	 the	 original	 findings	 of	 a
significantly	elevated	risk	of	GBS	among	vaccinees	that	peaked	at	weeks	2–3	following	vaccination	and
lasted	for	at	least	6	weeks.	The	panel	reported	that	this	vaccine	effect	possibly	lasted	for	8–10	weeks,	but
not	 longer.	 Depending	 upon	 the	 estimated	 baseline	 used,	 the	 panel	 concluded	 that	 the	 total	 vaccine
attributable	risk	of	GBS	was	0.49	to	0.59	cases	per	100,000	adult	vaccinees	over	a	6-	or	8-week	period
after	vaccination	respectively;	thus,	although	the	estimated	attributable	risk	was	somewhat	lower	than	that
estimated	by	original	study	due	to	more	conservative	case	selection,	this	investigation	again	substantiated
a	causal	association	between	the	vaccine	and	GBS;	results	were	published	 in	 the	American	Journal	of
Epidemiology	[12].
The	1976	Swine	Flu	Vaccine	and	GBS:	Biological	Evidence
The	multiple	assessments	demonstrating	the	link	between	the	swine	flu	vaccination	and	GBS	essentially
proved	causality	by	epidemiologic	means.	What	remained	unclear,	however,	was	why	this	would	be	the
case,	biologically.	One	study	assessing	the	possible	association	of	human	leukocyte	antigen	(HLA)	types
among	cases	of	GBS	identified	during	the	1976	vaccine	surveillance	effort	[13].	This	study	identified	no
specific	 HLA	 haplotypes	 amongst	 92	 GBS	 cases	 and	 100	 controls	 that	 were	 clearly	 associated	 with
development	of	GBS	following	the	1976	influenza	vaccine.
Perhaps	 the	 most	 creative	 attempt	 to	 establish	 a	 biological	 underpinning	 to	 this	 association	 was
performed	by	Nachamkin	and	colleagues	[14].	This	study	assessed	the	potential	association	of	influenza
vaccines	with	anti-ganglioside	antibodies.	Particular	Campylobacter	jejuni	serotypes	have	been	found	to
have	a	 strong	association	with	 the	development	of	GBS,	which	 is	hypothesized	 to	be	due	 to	molecular
mimicry	between	bacterial	surface	lipooligosaccharides	which	express	peripheral	nerve	ganglioside-like
epitopes,	resulting	in	the	production	of	cross-reactive	antibodies.	It	has	been	hypothesized	that,	since	C.
jejuni	 is	 frequently	 present	 in	 poultry,	 and	 since	 influenza	 vaccine	 is	 produced	 in	 chicken	 eggs,
contamination	of	vaccine-production	eggs	with	C.	jejuni	may	have	resulted	in	an	association	of	GBS	with
the	1976	vaccine	or	other	formulations.
Nachamkin	tested	this	latter	hypothesis	by	obtaining	archived	lots	of	the	swine	flu	vaccines	as	well	as
several	 other	 influenza	 vaccine	 formulations	 that	 had	 not	 been	 associated	with	 increased	 risk	 of	GBS.
Mice	were	inoculated	with	vaccine;	additional	mice	were	inoculated	with	C.	 jejuni—one	serotype	 that
displays	GM1	ganglioside	mimicry	as	a	positive	control,	and	one	with	no	GM1	ganglioside	mimicry	as	a
negative	 control.	 The	 immunized	mice	 were	 found	 to	 have	 no	 antibodies	 to	C.	 jejuni,	 suggesting	 that
Campylobacter	 antigens	 were	 not	 present	 in	 the	 vaccine	 formulations.	 However,	 all	 immunized	 mice
developed	anti-GM1	IgM	and	IgG	antibodies,	with	significant	increases	in	such	antibodies	observed	over
time.	 While	 the	 authors	 offered	 a	 possible	 hypothesis	 as	 to	 how	 these	 antibodies	 might	 have	 been
generated	(involving	an	interaction	between	vaccine	epitopes	and	neural	sialic	acid	moeities),	the	ability
of	all	tested	vaccine	formulations,	even	those	with	no	apparent	association	with	GBS,	to	induce	anti-GM1
antibodies	calls	into	question	the	biological	significance	of	this	finding.	Additional	exploration	of	the	role
of	vaccine	proteins,	including	use	of	negative	controls	of	a	type	not	utilized	in	the	study,	would	be	needed
to	further	substantiate	these	findings.
Subsequent	Assessments	of	the	GBS	Risk	after	Receipt	of	Influenza	Vaccines	Not
Containing	the	1976	Swine	Flu	Antigens
The	 association	 of	 the	 1976	 influenza	 vaccine	 with	 GBS	 obviously	 led	 to	 great	 concern	 about	 the
potential	of	subsequent	seasonal	 influenza	vaccines	 to	 lead	 to	a	similar	association.	Between	1977	and
2009,	at	least	9	published	assessments	of	the	risk	of	GBS	following	influenza	vaccines	were	conducted
(Table	7.1)	[15–24].	Of	these	9	studies,	2	involved	active,	population-based	surveillance,	medical	record
reviews	 and	 patient	 interviews	 [19,24].	 Three	 used	 searches	 of	 large	 datasets	 that	 enabled	 linking	 of
disease	 codes	 and	 vaccination	 information	 and	 the	 comparison	 of	 GBS	 attack	 rates	 in	 different	 time
windows	 after	 vaccination	 [20,22,23].	Two	 involved	 active	 sentinel	 neurologist	 surveillance	 [17,	 25].
One	used	hospital	discharge	data	without	a	link	to	vaccination	information	[18]	and	one	assessed	reports
to	a	national	passive	vaccine-adverse	event	surveillance	system	[21].	Two	of	 these	studies	suggested	a
small	 but	 statistically	 significant	 increase	 in	 risk	 of	 GBS	 following	 various	 formulations	 of	 influenza
vaccine,	 on	 the	 order	 of	 relative	 risks	 of	 about	 1.6	 to	 1.7—statistically	 significant	 but	 not	 particularly
concerning,	from	a	clinical	standpoint	[19,	20].	The	other	7	studies	did	not	find	a	statistically	significant
overall	vaccine-related	increase	in	GBS	risk	(Table	7.1).
Overall,	the	preponderance	of	epidemiologic	evidence	on	the	risk	of	GBS	following	influenza	vaccine
formulations	 since	 1976	 would	 suggest	 that	 this	 risk,	 if	 any,	 is	 much	 smaller	 than	 that	 observed	 in
association	with	 the	1976	vaccination	campaign.	Hence,	 any	 risk	of	GBS	 following	 influenza	vaccines
would	likely	be	greatly	outweighed	in	any	particular	season	by	the	benefits	of	the	vaccinations	in	reducing
influenza	morbidity	and	mortality.
Table	7.1		Epidemiologic	features	and	incidence	of	Guillain-Barré	syndrome	following	the	1976	swine	influenza	vaccine,	and
various	formulations	of	seasonal	influenza	vaccine,	1976–2009




I	think	it	is	also	important	to	point	out	that,	in	1976,	had	an	influenza	pandemic	actually	occurred,	the
GBS	risk	associated	with	the	vaccine	would	have	become	a	minor	issue,	as	the	morbidity	and	mortality
prevented	by	the	vaccine	would	have	undoubtedly	eclipsed	the	small	but	real	risk	of	post-vaccine	GBS.	It
is	because	the	pandemic	never	materialized	that	this	association	with	GBS	took	on	the	focus	that	it	did.
2009	pH1N1	Influenza	Virus:	Déjà	vu	All	Over	Again
During	 the	 spring	of	 2009,	 the	world	witnessed	 the	 emergence	of	 yet	 another	H1N1	 influenza	virus	 of
swine	origin.	Unfortunately,	unlike	the	1976	H1N1	influenza	virus,	the	2009	virus	was	definitely	a	serious
public	 health	 threat;	 in	 April	 2009,	 the	 virus	 was	 identified	 in	 specimens	 obtained	 from	 2
epidemiologically	 unlinked	 patients	 in	 the	 United	 States.	 Similar	 viruses	 were	 rapidly	 identified	 in
Mexico,	 Canada,	 and	 subsequently	 other	 countries	 throughout	 the	 world;	 by	 the	 summer	 of	 that	 year,
94,512	confirmed	cases	with	429	deaths	were	reported	to	the	World	Health	Organization	(WHO),	leading
to	the	declaration	of	a	pandemic.
The	 global	 emergence	 of	 the	 pandemic	 (H1N1)	 2009	 virus	 (pH1N1),	 and	 its	 rapid	 global	 spread
associated	with	community-wide	outbreaks,	hospitalizations	and	deaths	prompted	rapid	development	of
new	influenza	A	(H1N1)	2009	monovalent	vaccine	that	could	be	produced	in	sufficient	quantities	 to	be
used	globally.	The	association	of	GBS	with	 the	1976	swine	 flu	vaccine	had	 left	public	health	officials
shell-shocked,	and	 immediately	 led	 to	questions	about	a	similar	association	of	neurologic	disease	with
vaccines	against	the	p(H1N1)	2009	virus,	also	partially	of	swine	origin.
Although	 the	 safety	 and	 efficacy	 of	 the	 influenza	 A	 (H1N1)	 2009	 monovalent	 vaccine	 was	 to	 be
assessed	 through	 a	 small	 number	 of	 limited	 clinical	 trials,	 the	 interval	 between	 vaccine
development/manufacturing	and	widespread	use	of	the	vaccine	was	extremely	short,	pre-licensure	safety
data	was	quite	limited,	and	post-licensure	safety	surveillance	was	going	to	take	many	months	to	collect
and	assess.	Such	was	 the	angst	about	a	 repeat	of	 the	1976	situation	 that	a	group	of	us	at	CDC	huddled
together	 on	 a	 Saturday	 afternoon	 shortly	 after	 recognition	 of	 the	 pandemic,	 deliberating	 the	 need	 to
conduct	 surveillance	 for	GBS	 in	 the	 face	 of	 the	 vaccination	 campaign,	 and	 if	 so,	 how.	Ultimately,	we
decided	to	implement	real-time,	active,	population-based	surveillance	for	GBS	following	p(H1N1)	2009
monovalent	vaccine	in	order	to	inform	public	health	recommendations	regarding	the	relative	benefit	and
harm	 associated	 with	 the	 vaccination	 program.	 Several	 other	 countries,	 recounting	 the	 1976	 incident,
decided	to	do	the	same.
In	the	United	States,	in	rapid	fashion	an	active,	population-based	surveillance	system	for	GBS	cases
was	implemented	(published	by	Wise	and	colleagues)	[26].	This	study	differed	from	the	1976	assessment
in	that	it	primarily	compared	risk	of	GBS	following	p(H1N1)	vaccine	to	regular	seasonal	vaccine	and	to
estimated	 baseline	 rates	 of	 GBS.	 Surveillance	 commenced	 on	 1	 October	 2009	 (coincident	 with	 the
introduction	of	the	U.S.	vaccine),	and	continued	through	31	May	2010.	The	assessment	was	overseen	by
the	 CDC,	 and	 conducted	 amongst	 CDC’s	 10	 Emerging	 Infections	 Program	 (EIP)	 sites;	 the	 EIP	 sites
constitute	 a	 platform	 to	 perform	 population-based	 real-time	 surveillance	 for	 a	 number	 of	 different
conditions	in	10	U.S.	states,	encompassing	a	population	of	approximately	49	million	residents.	Learning
from	the	criticisms	of	the	1976	evaluation,	each	EIP	site	established	a	surveillance	network	comprised	of
neurologists	 and	 other	 healthcare	 providers	 that	 was	 queried	weekly	 to	 stimulate	 reporting	 of	 suspect
GBS	cases;	hospital	discharge	data	were	also	reviewed	(ICD-9	code	357.0)	to	capture	additional	cases
not	reported	through	the	provider	network.	Cases	were	stratified	into	2	broad	age	groups	(0–24	years;	≥
25	 years)	 to	 ensure	 ascertainment	 of	 sufficient	 person-time.	 Trained	 surveillance	 officers	 reviewed
medical	records	and	conducted	telephone	interviews	with	suspected	cases	to	obtain	basic	demographics,
risk	 factors	 and	 vaccination	 status,	 and	 determined	 date	 of	 receipt	 of	 p(H1N1)	 and	 seasonal	 influenza
vaccines.	Cases	were	then	classified	according	to	Brighton	criteria	case	definitions	for	GBS	(Appendix)
[27];	patients	meeting	Brighton	Levels	1–3	(akin	 to	suspect,	probable	and	confirmed)	were	 included	 in
analysis.	The	observed	number	of	GBS	cases	was	compared	with	the	number	of	expected	cases,	which
we	 estimated	 by	 applying	 age-specific	GBS	 background	 rates	 to	 the	 EIP	 population.	GBS	 background
rates	were	estimated	by	modelling	published	population-based	GBS	rates.
Among	 44.9	 million	 persons	 under	 surveillance	 from	 1	 October	 2009	 to	 31	 May	 31	 2010,	 study
personnel	identified	707	suspect	GBS	cases,	with	411	cases	ultimately	meeting	inclusion	criteria.	Eighty-
four	percent	of	GBS	cases	were	≥	25	years,	52%	were	male,	68%	were	white,	15%	required	mechanical
ventilation,	and	3%	died.	The	median	weekly	number	of	GBS	cases	by	date	of	onset	was	12	(range	1	to
19);	the	frequency	of	cases	was	similar	across	the	surveillance	period	for	both	age	groups.
The	 411	GBS	 cases	 in	 the	 EIP	 catchment	was	 similar	 to	 the	 expected	 number	 for	 the	 surveillance
population	(age-adjusted	observed/expected	ratio:	1.21,	95%	CI	0.91–1.74),	as	well	as	among	persons
0–24	and	≥	25	years	old.	Data	suggested	11	total	excess	GBS	cases	during	the	surveillance	period	and	an
estimated	 0.74	 (95%	 CI:	 0.04–1.56)	 excess	 cases	 of	 GBS	 per	 million	 p(H1N1)	 vaccine	 doses.	 GBS
incidence	was	not	significantly	elevated	following	receipt	of	seasonal	vaccine.	Antecedent	events	were
less	common	among	cases	who	received	p(H1N1)	vaccine	in	the	42	days	prior	to	onset	compared	with
those	who	did	not	(59%	vs.	79%,	p	=	0.02).	Examination	of	specific	antecedent	event	types	showed	that
upper	respiratory	or	influenza-like	symptoms	were	the	only	category	that	was	significantly	less	common
among	cases	receiving	p(H1N1)	vaccine	than	those	who	did	not	(38%	vs.	67%,	p	<	0.01).
Thus,	the	estimated	excess	occurrence	of	GBS	associated	with	p(H1N1)	vaccine,	less	than	one	case
per	million	 p(H1N1)	 doses	 administered,	was	 similar	 to	 that	 associated	with	 some	 previous	 seasonal
influenza	 vaccine	 formulations	 and	 was	 10-fold	 lower	 than	 the	 excess	 risk	 associated	 with	 the	 1976
vaccine.
In	 contrast	 to	 the	 finding	 of	 less	 than	 one	 excess	GBS	 case	 per	million	 doses	 of	 p(H1N)1	 vaccine
administered,	 numerous	 studies	 have	 demonstrated	 the	 effectiveness	 of	 p(H1N1)	 vaccine	 in	 preventing
pandemic	 influenza	 A	 (H1N1)	 2009	 infections;	 the	 CDC	 estimated	 that	 the	 use	 of	 p(H1N1)	 vaccine
prevented	713,000	 to	1.5	million	cases,	3,900	 to	10,400	hospitalizations,	and	200	 to	520	deaths	 in	 the
United	States	during	the	same	time	period	[28].	Thus,	the	small	but	real	increased	risk	of	developing	GBS
following	the	p(H1N1)	vaccine	was	dwarfed	by	the	benefits	of	receiving	the	vaccine	[29–31].
Multiple	 additional	 analyses	 of	 the	 potential	 association	 between	 p(H1N1)	 vaccine	 and	GBS	were
performed	in	various	countries,	and	included	at	least	one	international	consortium	study	[32–35].	Results
of	course	varied	between	country	and	study,	but	none	demonstrated	a	risk	of	GBS	vastly	different	from	the
U.S.	surveillance	results.
The	bottom	line,	then,	regarding	GBS	and	influenza	vaccines	is	that	the	1976	swine	influenza	vaccine
was	 associated	 with	 a	 small	 but	 real	 increased	 risk	 of	 developing	 GBS	 in	 the	 6–8	 weeks	 following
receipt	of	vaccine.	Subsequent	seasonal	influenza	vaccines,	including	the	2009	p(H1N1)	swine	influenza
vaccine,	have	not	demonstrated	such	 increased	risk,	with	rare	exceptions.	 In	 the	3	assessments	 that	did
demonstrate	a	slightly	increased	GBS	risk,	the	risk	was	many	magnitudes	lower	than	that	associated	with
the	1976	vaccine.	In	any	given	season,	the	small	but	potential	risk	of	GBS	is	greatly	outweighed	by	the
morbidity	and	mortality	associated	with	influenza	illness.
…	And	Everything	Else:	Association	between	Other	Vaccines	and	GBS
To	 this	 point,	 as	 you	 may	 have	 noticed,	 the	 entire	 discussion	 of	 GBS	 and	 vaccines	 has	 centred	 on
influenza	vaccine.	That	is	because	nearly	every	other	vaccine	that	has	been	associated	with	GBS	has	been
done	so	on	a	temporal	basis	only—a	person	receives	a	vaccine,	several	weeks	later	GBS	occurs—and
that	 is	about	all	we	can	say.	These	‘temporal’	associations	are	made	even	more	challenging	by	the	fact
that	it	is	nearly	impossible	to	exclude	the	possibility	that	another	antigenic	stimulus	(e.g.	a	clinically	silent
infection)	 was	 not	 the	 triggering	 factor	 for	 the	 GBS.	 Attempts	 have	 been	 made	 to	 demonstrate	 an
association	between	GBS	and	other	vaccines,	if	one	exists,	but	unlike	the	1976	swine	flu	vaccine,	to	date
no	other	vaccine	has	been	convincingly	demonstrated	to	have	a	causal	association	with	GBS.	I’ll	provide
a	few	of	the	more	interesting	examples	of	‘other’	vaccines	and	GBS:
Earlier	 formulations	 of	 rabies	 vaccine,	which	 entailed	 inoculation	 of	 live	 rabies	 virus	 into	mature
sheep	 or	 goat	 brain	 and	 inactivated	 with	 phenol,	 appeared	 to	 be	 associated	 with	 a	 higher-than-
expected	incidence	of	‘neuroparalytic	adverse	events’	thought	to	be	GBS	[36,37].	This	was	presumed
to	be	due	to	the	presence	of	brain	protein	in	the	formulated	vaccine,	with	the	possible	generation	of
antibodies	 cross-reactive	 to	 peripheral	 nerve	 proteins.	 Newer	 formulations	 of	 the	 rabies	 vaccine,
which	are	derived	from	chick	embryo	cells,	do	not	appear	to	be	causally	associated	with	GBS,	though
brain-derived	rabies	vaccine	continues	to	be	used	throughout	much	of	the	resource-poor	world.
Early	concerns	about	an	association	between	oral	polio	vaccine	(OPV)	and	GBS	were	raised	due	to	a
situation	in	Finland	in	1985,	at	which	time	94%	of	the	Finnish	population	was	vaccinated	with	OPV
over	a	5-week	period	between	10	February	and	15	March	due	to	an	outbreak	of	wild-type	poliovirus.
During	 and	 shortly	 after	 the	 immunization	 campaign,	 several	 hospitals	 reported	 admitting	 unusually
large	numbers	of	suspected	GBS	patients,	with	10	cases	admitted	during	the	first	quarter	and	6	cases
during	 the	second	quarter	of	1985,	corresponding	 to	 the	 immunization	campaign	[38–40].	However,
later	 studies	 assessing	monthly	 reports	 of	GBS	between	 1981	 and	 1986	 suggest	 that	 the	 number	 of
GBS	 cases	 started	 to	 rise	 prior	 to	 the	OPV	 campaign;	 since	 there	 had	 been	 an	 influenza	 epidemic
between	December	and	April	of	 that	year,	 the	authors	concluded	that	 the	small	apparent	 increase	 in
GBS	 observed	 during	 that	 time	 could	 have	 been	 associated	 with	 the	 circulation	 of	 wild-type
poliovirus	or	 influenza	virus	 in	 addition	 to	OPV;	 it	was	 just	 not	 possible	 to	 say	with	 certainty.	No
other	assessments	have	supported	an	association	between	OPV	or	 injected	polio	vaccine	(IPV)	and
GBS	[38].
A	suspected	association	between	GBS	and	a	formulation	of	meningococcal	polysaccharide	diphtheria
toxoid	 conjugate	vaccine	 (Menactra;	MCV4)	 appears	 to	have	been	 a	 false	 alarm.	The	vaccine	was
licenced	in	January	2005	for	use	in	the	United	States	for	persons	aged	11–55;	in	February	2005	a	U.S.
immunization	advisory	committee	recommended	MCV4	vaccination	for	11-	12-year-old	children	and
before	 high	 school	 entry	 for	 individuals	 not	 previously	 vaccinated,	 in	 addition	 to	 the	 ongoing
recommendations	 for	 routine	 vaccination	 for	 persons	 living	 in	 college	 dormitories,	 army	 bases,
prisons	 or	 other	 crowded	 living	 conditions.	 By	 October	 2005,	 5	 cases	 of	 GBS	 following	MCV4
vaccination	had	been	reported	to	the	Vaccine	Adverse	Events	Reporting	System	(VAERS),	a	national
passive	 reporting	 system	 that	 collects	 reports	 of	 potential	 adverse	 events	 following	 immunizations
from	both	clinicians	and	the	lay	public	[41].	By	September	2006,	17	suspected	cases	of	GBS	had	been
identified	among	vaccinees	aged	11–19	within	6	weeks	of	vaccination.	Based	upon	these	17	cases,	a
calculated	IRR	of	1.78	(95%	CI	1.02,	2.85)	was	found,	representing	a	bit	less	than	1	additional	GBS
case	per	million	vaccines	[42].	This	estimate,	however,	needed	to	be	interpreted	with	caution,	given
the	 passive	 nature	 of	 VAERS	 reporting	 and	 the	 imprecise	 estimated	 background	 rate	 of	 GBS	 in
adolescents	 at	 that	 time.	 Subsequent	 evaluations	 of	 GBS	 risk	 following	 MCV4	 using	 controlled
studies	 and	 other	 systematic	 methodologies	 have	 failed	 to	 substantiate	 any	 increased	 risk	 of	 GBS
following	MCV4	[43].
Tetanus	toxoid	vaccine,	in	the	form	of	tetanus-diphtheria	(Td)	vaccine,	has	been	associated	with	one
apparent	 case	 of	 challenge/rechallenge	 in	which	 a	 42-year-old	male	 developed	GBS	 following	Td
vaccine	 on	 3	 separate	 occasions	 over	 a	 13-year	 period,	 raising	 the	 possibility	 of	 causality	 in	 this
individual	 [44].	However,	 larger	 assessments	 of	GBS	 following	 tetanus	 toxoid-containing	vaccines
have	failed	to	substantiate	an	increased	risk	[45].
The	 fundamental	 fact,	 as	 stated	 earlier,	 that	 one	 can	 find	 a	 case	 report	 of	 nearly	 any	 vaccine	 being
followed	temporally	by	onset	of	GBS	does	not	equate	to	‘causality’.	Vaccines	have	truly	been	one	of	the
miracles	 of	 modern	 medicine.	 Countless	 millions	 of	 lives	 have	 been	 saved	 by	 development	 and
implementation	of	vaccines,	and	in	many	ways,	vaccines	have	become	a	victim	of	their	own—people	are
concerned	about	potential	‘complications’	of	vaccines	largely	because	they	do	not	recall	the	tremendous
morbidity	and	mortality	from	the	very	illnesses	that	vaccines	prevent.	Any	theoretical	risk	of	development
of	 GBS,	 or	 any	 other	 neurologic	 illness,	 for	 that	 matter,	 following	 vaccines	 is	 far	 outweighed	 by	 the
benefits	of	receipt	of	the	vaccine.
During	 the	 next	 100	 years,	 hopefully,	 we	 will	 gain	 a	 better	 understanding	 of	 the	 incidence,
epidemiology	 and	 risk	 factors	 for	GBS	 in	Africa,	Asia,	 the	Middle	East	 and	 other	 areas	 of	 the	 globe.
Continued	 pharmacovigilance	 should	 be	 conducted	 to	 assess	 for	 any	 additional	 causal	 associations
between	vaccines	or	other	immunomodulating	products	and	GBS.
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	Appendix:	Brighton	Collaboration	Case	Definition,	Guillain-Barré
Syndrome	[27]
Level	1	of	Diagnostic	Certainty
Presence	of:
1.	 Acute	 onset	 of	 bilateral	 and	 relatively	 symmetric	 flaccid	weakness/paralysis	 of	 the	 limbs	with	 or
without	involvement	of	respiratory	or	cranial	nerve	innervated	muscles
2.	 Decreased	or	absent	deep	tendon	reflexes	at	least	in	affected	limbs
3.	 Monophasic	illness	pattern	with	weakness	nadir	reached	between	12	hours	and	28	days,	followed	by
clinical	plateau	and	subsequent	improvement	or	death
4.	 Electrophysiologic	findings	consistent	with	GBS
5.	 Presence	of	albuminocytologic	dissociation	(elevation	of	CSF	protein	level	above	laboratory	normal
value	and	CSF	total	white	cell	count	<	50	cells/mm3)
6.	 Absence	of	an	alternative	diagnosis	for	weakness
Level	2	of	Diagnostic	Certainty
Presence	of:
1.	 Acute	 onset	 of	 bilateral	 and	 relatively	 symmetric	 flaccid	weakness/paralysis	 of	 the	 limbs	with	 or
without	involvement	of	respiratory	or	cranial	nerve	innervated	muscles
2.	 Decreased	or	absent	deep	tendon	reflexes	at	least	in	affected	limbs
3.	 Monophasic	illness	pattern,	with	weakness	nadir	reached	between	12	hours	and	28	days,	followed	by
clinical	plateau	and	subsequent	improvement	or	death
4.	 CSF	with	 a	 total	 white	 cell	 count	<	 50	 cells/mm3	 (with	 or	 without	 CSF	 protein	 elevation	 above
laboratory	 normal	 value)	 or	 if	 CSF	 not	 collected	 or	 results	 not	 available,	 and	 electrodiagnostic
studies	consistent	with	GBS
5.	 Absence	of	an	alternative	diagnosis	for	weakness
Level	3	of	Diagnostic	Certainty	(clinical	case	definition)
Presence	of:
1.	 Acute	 onset	 of	 bilateral	 and	 relatively	 symmetric	 flaccid	weakness/paralysis	 of	 the	 limbs	with	 or
without	involvement	of	respiratory	or	cranial	nerve	innervated	muscles
2.	 Decreased	or	absent	deep	tendon	reflexes	at	least	in	affected	limbs
3.	 Monophasic	illness	pattern,	with	weakness	nadir	reached	between	12	hours	and	28	days,	followed	by
clinical	plateau	and	subsequent	improvement	or	death
4.	 Absence	of	an	alternative	diagnosis	for	weakness
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Introduction
Guillain-Barré	 syndrome	 (GBS)	 is	 a	 disorder	with	 no	 boundaries.	Reports	 have	 been	 published	 about
patients	 from	 all	 geographical	 areas,	 including	 males	 and	 females	 of	 all	 ages.	 With	 a	 current	 world
population	 of	 7.4	 billion	 people	 and	 an	 incidence	 rate	 of	 1	 to	 2	 per	 100,000	 per	 year,	 the	 estimated
number	of	persons	 that	yearly	develop	GBS	 is	about	100,000.	However,	GBS	 is	also	a	 relatively	 rare
disease	for	clinicians	and	researchers	and	it	may	be	difficult	to	develop	sufficient	clinical	expertise	or	to
collect	sufficient	data	for	research.
The	 current	 chapter	 is	 a	 plea	 that	 patients,	 clinicians	 and	 researchers	 would	 all	 benefit	 from
international	collaboration	in	their	general	aim	to	reduce	the	worldwide	burden	of	disease.	We	would	like
to	 illustrate	 this	 by	 indicating	 several	 topics	 in	 research	 which	 strongly	 benefit	 from	 international
collaboration.
Compare	Incidence	Rates	to	Identify	Risk	Factors	for	Developing	GBS
GBS	 is	 probably	 caused	 by	 a	 combination	 of	 host	 and	 environmental	 susceptibility	 factors	which	may
differ	 per	 geographical	 area.	To	be	 able	 to	 identify	 these	 factors	 it	will	 be	 important	 to	 conduct	 large
incidence	studies	that	use	the	same	case	definitions	and	study	design.	The	incidence	of	GBS	worldwide
has	 been	 reported	 between	 0.4	 and	 3.25	 per	 100,000	 person-years.	 In	 one	 meta-analysis	 in	 North
American	and	European	countries,	the	incidence	was	0.81–1.89	(median	1.11)	per	100,000	person-years
[1,2].	Although	this	range	could	be	considered	to	be	wide,	it	is	even	more	variable	when	incidence	rates
of	 non-Western	 countries	 are	 considered.	 For	 example,	 the	 lowest	 incidence	 rate	 of	 0.4	 per	 100,000
persons	has	been	 reported	 in	one	hospital-based	 study	 in	Brazil,	whereas	 the	highest	 incidence	 rate	of
3.25	has	 been	 reported	 in	 children	 from	Bangladesh	 (<15	years	 if	 age)	 (see	Table	8.1)	 [3,4,5].	 These
results	are	based	on	a	relatively	small	number	of	patients	and	have	not	been	confirmed	in	larger	studies
but	 theymay	 indicate	 that	 the	 exposure	 to	 infections	 as	 well	 as	 host	 factors	 may	 influence	 the	 risk	 of
developing	GBS.
Another	variability	 regarding	 the	epidemiology	of	GBS	worldwide	 is	whether	 seasonal	 fluctuations
are	observed.	Some	studies	report	a	peak	in	the	winter,	others	in	the	summer	and	the	remaining	report	no
seasonal	fluctuations	whatsoever.	One	meta-analysis	concluded	that	in	Western	countries,	the	Middle	East
and	Far	East,	 there	 seems	 to	 be	 a	 14%	higher	 incidence	 of	GBS	 in	 the	wintertime,	while	 in	Northern
China,	the	Indian	subcontinent	and	Latin	America	there	seems	to	be	a	predominance	of	GBS	in	summer.
This	difference	could	be	explained	by	a	different	type	of	antecedent	event,	being	upper	respiratory	tract
infections	in	Western	countries	and	gastroenteritis	in	the	latter	[6].
Table	8.1		Incidence	of	GBS	by	country
Many	observations	regarding	the	incidence	of	GBS	worldwide	have	been	published	but	connections
and	 explanations	 about	 the	 reason	 for	 the	 differences	 are	 difficult	 to	 make,	 due	 to	 different	 research
designs	and	descriptions	(Table	8.1).	More	international	research	is	 therefore	needed	for	 improving	the
understanding	of	the	geographical	differences	in	GBS	incidences.
Specific	Antecedent	Events	Triggering	GBS
About	 two-third	of	patients	 report	symptoms	of	a	 respiratory	or	gastrointestinal	 tract	 infection	within	3
weeks	beforeonset	of	GBS.	A	specific	infectious	cause	has	been	identified	in	about	half	of	patients,	with
Campylobacter	jejuni	being	the	predominant	cause.	Other	infectious	agents	which	have	been	identified	in
relation	 to	 GBS	 are	 cytomegalovirus,	 Epstein-Barr	 virus,	 Mycoplasma	 pneumonia,	 Haemophilus
influenzae,	 influenza	 A	 virus	 and	 recently	 hepatitis	 E	 virus	 [7].	 The	 frequencies	 of	 these	 preceding
infections,	 however,	 highly	 differ	 between	 various	 geographical	 areas.	 Without	 international
collaboration	it	will	be	difficult	 to	define	 if	 these	differences	are	real	or	represent	differences	 in	study
design	 and	 techniques	 used	 to	 demonstrate	 such	 infections.	 There	 are	 various	 examples	 of	 such
comparative	 and	 international	 studies.	 One	 example	 is	 the	 collaborative	 study	 between	 Japan	 and	 the
Netherlands	 investigating	 the	 frequency	 of	 preceding	 infections	 with	 C.	 jejuni	 and	 2	 serological
techniques	 to	 demonstrate	 such	 infections	 in	 patients	 with	 GBS	 [8].	 This	 study	 indicated	 that	 the
proportion	of	patients	with	preceding	C.	jejuni	infections	was	similar.	However,	the	distribution	of	anti-
ganglioside	antibodies	(against	GM1,	GM1b	and	Ga1Nac-GD1a)	actually	differed	between	the	countries,
indicating	that	geographical	determining	factors	(either	of	the	host	or	the	triggering	infectious	agent)	play
a	role	in	determining	the	antibody	response	in	individuals	[9].
A	second	example	is	a	collaboration	between	the	United	Kingdom	and	the	Netherlands	which	resulted
in	the	discovery	that	hepatitis	E	infection	is	associated	with	GBS	in	5%	of	cases,	and	in	10%	of	neuralgic
amyotrophy	 [10,11].	 The	 combination	 of	 patient	 cohorts	 and	 techniques	 was	 crucial	 to	 making	 these
discoveries.
Various	 types	 of	 infection	 are	 known	 to	 precipitate	 GBS	 but	 the	 type	 of	 infections	 may	 differ	 per
geographical	 area.	 By	 collecting	 data	 and	 biosamples	 from	 patients	 in	 various	 areas	 using	 the	 same
standard	 protocol	 and	 testing	 these	 samples	 in	 a	 uniform	 way	 it	 will	 be	 possible	 to	 determine	 the
differences	between	countries	and	the	role	infections	play	in	the	pathogenesis	of	GBS.
Histopathological	Subtype	Differences	in	GBS
Initially	GBS	was	considered	to	be	a	primarily	demyelinating	disorder	of	the	peripheral	nerves,	in	which
some	 patients	 may	 develop	 secondary	 axonal	 degeneration.	 Tom	 Feasby	 challenged	 this	 concept	 by
describing	 the	 first	 patients	 fulfilling	 the	 diagnostic	 criteria	 for	 GBS	 and	 showing	 initial	 features	 of
axonal	degeneration	[12].
In	the	1990s,	a	striking	increase	in	acute	flaccid	paralysis	was	observed	in	children	and	young	adults
at	rural	areas	in	Northern	China.	Researchers	from	the	United	States	visited	this	region	to	study	together
with	local	researchers	this	endemic	‘Chinese	paralytic	syndrome’.	They	found	that	 the	major	difference
between	it	and	the	classic	GBS	known	in	that	time,	was	that	these	patients	did	not	have	sensory	loss	and
that	a	motor	axonal	polyneuropathy	was	found	on	electrophysiological	studies	 [13,14].	They	concluded
that	 these	 patients	 did	 have	 a	 different	 form	 of	 GBS	 with	 predominantly	 motor	 signs	 and	 an	 axonal
polyneuropathy,	the	so-called	acute	motor	axonal	neuropathy	(AMAN).
Later	 studies	 have	 shown	 that	 there	 is	 a	 distinct	 geographical	 variation	 in	 frequency	 of	AMAN.	 In
Europe	and	North	America,	AMAN	accounts	for	only	3–17%	of	GBS	cases,	whereas	this	proportion	is
much	 higher	 in	 Asia	 and	 South	 America	 (30%	 to	 65%).	 The	 opposite	 applies	 to	 the	 demyelinating
subtype,	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP),	 which	 is	 present	 in	 69–90%	 of
Western	GBS	patients	and	in	only	20–40%	of	Asian	and	South	American	patients	[15].	One	international
collaborative	study	between	Japan	and	Italy	confirmed	these	findings	[16].	The	cause	of	the	geographical
difference	 in	AIDP	 and	AMAN	 frequencies	 is	 not	 yet	 clear.	Most	 probably,	 it	 is	 associated	with	 both
internal	(host	factors)	as	external	factors	(infectious	agents).	As	illustrated	in	this	paragraph,	international
collaboration	is	crucial	to	further	unravelling	this	phenomenon.
Electrodiagnostic	Criteria	for	GBS	Subtypes
Research	on	location	is	not	always	obligatory.	In	2012,	Antonino	Uncini	from	Italy	and	Satoshi	Kuwabara
from	Japan	combined	their	expertise	and	published	a	wonderful	review	on	electrodiagnostic	criteria	for
GBS	[17].	In	this	review	they	give	a	historical	overview	of	the	development	of	electrodiagnostic	criteria
for	AIDP,	AMAN	and	AMSAN.	They	also	explain	very	clearly	the	observations	of	conduction	slowing	in
AMAN	 patients	 without	 excessive	 temporal	 dispersion	 (reversible	 conduction	 failure	 or	 conduction
blocks).	This	may	result	in	fallaciously	diagnosing	AMAN	patients	with	reversible	conduction	failure	as
AIDP	 patients.	 Despite	 attempts	 to	 include	 diagnostic	 criteria	 to	 identify	 this	 reversible	 conduction
failure,	 there	 still	 was	 a	 shift	 from	AIDP	 to	AMAN	with	 serial	 nerve	 conduction	 studies.	 Uncini	 and
Kuwabara	also	show	that	on	top	of	this	difficulty,	there	are	numerous	terms	to	describe	this	phenomenon,
making	 the	 confusion	 complete.	 Moreover,	 electrophysiological	 departments	 frequently	 use	 their	 own
standards	 and	 protocols.	 For	 these	 reasons,	 comparing	 study	 results	 from	 different	 countries	 about
electrophysiological	 studies	 in	GBS	patients	may	be	difficult	and	confusing.	 International	collaboration
will	be	essential	to	developing	a	worldwide	consensus	on	electrophysiological	protocols	for	examination
and	criteria	for	diagnosing	the	different	electrophysiological	subtypes.
Differences	in	Health	Care
Too	 many	 patients	 with	 GBS	 are	 living	 in	 low-income	 countries	 where	 the	 majority	 only	 receive
supportive	 care	 at	 the	most.	But	 patients	 from	high-income	 countries	who	 are	 treated	with	 intravenous
immunoglobulins	(IVIg)	or	plasma-exchange	(PE)	also	show	a	considerable	mortality	of	about	3%	to	7%,
and	about	10–20%	of	the	patients	remain	permanently	severely	disabled	[7].
We	would	 like	 to	 illustrate	 the	difference	 in	 outcome	of	GBS	 in	 low-	versus	 high-income	areas	 by
comparing	2	 studies.	The	 first	 study	was	carried	out	 in	 the	Netherlands	 in	 a	 cohort	of	527	patients,	of
which	 the	majority	weretreated	with	either	 IVIg	or	PE,	with	mortality	 rate	of	2.8%	[18].	Most	patients
died	 from	 cardiovascular	 or	 autonomic	 complications	 and	 death	 occurred	 most	 frequently	 during	 the
recovery	phase.
A	second	study	from	Bangladesh,	with	a	prospective	study	design	similar	 to	 that	of	 the	Dutch	study,
showed	that	only	one-quarter	of	the	patients	were	treated	with	IVIg	and	that	the	mortality	rate	was	14%.
Several	patients	died	because	of	 respiratory	 failure	and	 lack	of	 facilities	 to	offer	ventilation	at	an	 ICU
[19].
These	results	show	the	alarming	difference	in	health	care	and	outcome	of	GBS	between	Western	and
developing	 countries.	 Hopefully,	 international	 collaboration,	 not	 only	 of	 researchers	 but	 also	 from
governments	and	medical	services,	can	eliminate	the	global	differences	in	outcome	after	GBS.
International	Collaboration	on	Treatment	Trials
Despite	 the	 increase	 in	 general	 health	 care	 and	 number	 of	 potentially	 effective	 immune	 modulatory
treatments,	it	is	becoming	increasingly	difficult	to	conduct	international	therapeutic	studies	in	GBS.	In	part
this	is	caused	by	the	more	complex	regulations	for	conducting	such	trials.	But	GBS	is	also	relatively	rare
and	highly	variable	in	disease	course	and	outcome,	making	it	difficult	to	demonstrate	a	general	therapeutic
effect.
In	 earlier	 decades,	 there	 were	 only	 2	 studies	 on	 PE	 or	 IVIg	 with	 international	 collaboration:	 the
French	 Cooperative	 Group	 on	 plasma-exchange	 in	 1987	 and	 1997	 (collaboration	 of	 France	 and
Switzerland)	[20,21],	and	the	Plasma	Exchange/Sandoglobulin	Guillain-Barré	Syndrome	Trial	Group	in
1997	(collaboration	of	United	States	of	America,	Canada,	United	Kingdom,	Germany,	Belgium,	Portugal,
Norway,	Switzerland,	Italy,	Israel	and	Australia)	[22].
Currently,	there	are	only	3	national	randomized	controlled	trials	running	in	3	different	countries:	the
Inhibition	 of	 complement	 activation	 (eculizumab)	 in	 Guillain-Barré	 study	 (ICA-GBS)	 in	 the	 United
Kingdom,	the	Japanese	eculizumab	trial	for	GBS	(JET-GBS)	in	Japan,	and	the	Second	IVIg	dose	in	GBS
patients	with	poor	prognosis	(SID-GBS	trial)	in	the	Netherlands.
Ethical	committees	demand	more	and	more	strict	regulations	on	carrying	out	RCTs,	and	the	problem	is
that	 every	 nation	 has	 its	 own	 regulations.	 This	 makes	 it	 difficult	 to	 set	 up	 international	 RCTs.	 An
infrastructure	and	network	of	dedicated	centres	 for	conducting	 therapeutic	 studies	may	strongly	support
the	conduct	of	therapeutic	studies.	Less	strict	rules	apply	for	observational	studies	and	the	International
GBS	Outcome	Study	(IGOS)	is	currently	running	in	18	countries.	The	main	aim	of	IGOS	is	to	be	better
able	 to	 predict	 disease	 course	 and	 outcome	 in	 individual	 patients,	 but	 it	 also	 provides	 a	 platform	 for
evaluating	different	 therapeutic	 strategies	 internationally.	Hopefully,	 these	 results	 could	be	a	 stepup	 for
further	(international)	RCTs	to	confirm	the	observational	findings.
InternationalOrganizations
The	 GBS-CIDP	 Foundation	 International	 (http://www.gbs-cidp.org/)	 is	 an	 international	 patient
organization,	currently	represented	in	43	countries.	Their	aim	is	to	provide	“access	to	early	and	accurate
diagnosis,	appropriate	and	affordable	treatment,	and	knowledgeable	support	devices”.	The	organization
consists	of	 a	global	network	of	volunteers,	healthcare	professionals,	 researchers	 and	 industry	partners.
This	organization	already	plays	an	 important	 role	 in	 international	collaboration	between	clinicians	and
researchers.
In	 2007	 the	 Inflammatory	Neuropathy	Consortium	 (INC)	was	 raised	 by	Richard	Hughes	 to	 support
international	 research	 in	GBS	 and	 other	 neuropathies.	 This	 consortium	made	 it	 possible	 to	 initiate	 the
International	GBS	Outcome	Study	(IGOS)	(www.gbsstudies.org).	The	aim	of	the	prospective	longitudinal
cohort	study	is	to	define	all	biological	and	clinical	determinants	and	predictors	of	the	clinical	course	and
outcome	of	 individual	patients	with	GBS.	The	strength	of	 IGOS	is	 the	highly	detailed	and	standardized
collections	 of	 clinical	 data	 and	 biomaterials	 in	 18	 different	 countries	 from	 6	 continents.	 This	 way	 of
collection	 will	 ensure	 that	 the	 results	 from	 different	 countries	 are	 highly	 comparable.	 Moreover,	 by
combining	 forces	 the	 IGOS	consortium	has	been	able	 to	 include	currently	1,146	patients	with	GBS,	an
unprecedentedly	 large	 number	 of	 well-defined	 patients.	 The	 consortium	 of	 about	 100	 clinicians	 and
researchers	will	 collaboratively	 approach	many	 of	 the	most	 important	 remaining	 research	 questions	 in
GBS,	including	the	ones	described	above.	The	collected	materials	will	also	be	used	to	compare	different
techniques	for	demonstrating	preceding	infections,	anti-neural	antibodies	and	genes	potentially	involved
in	the	pathogenesis	of	GBS.	Bangladesh	is	one	of	the	countries	participating,	coordinated	by	Dr.	Zhahir
Islam,	Badrul	 Islam	and	Professor	Deen	Mohammed,	providing	 the	opportunity	 to	compare	for	 the	first
time	data	and	materials	derived	from	high-	and	 low-income	countries.	Last	but	not	 least	 the	IGOS	will
provide	a	unique	opportunity	to	train	young	clinicians	in	treating	patients	with	GBS	and	young	researchers
in	conducting	research	in	GBS.	Dedicated	clinicians	and	researchers	from	all	over	the	world	are	invited
to	join	the	consortium.
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The	Chinese	Paralytic	Syndrome—Recollections	of
2	Participants
Guy	McKhann	and	Tony	W.	Ho
Guy’s	Narrative
First	Observations
“I	didn’t	think	you	still	had	so	much	polio.”
I	made	that	statement	in	November,	1986,	while	standing	in	the	middle	of	a	paediatric	ward	of	the	Beijing
Children’s	Hospital,	surrounded	by	4-	to	6-year-old	children,	all	partially	paralyzed,	some	on	respirators.
My	hosts	quickly	assured	me	that	this	was	not	polio,	it	was	the	Guillain-Barré	syndrome	(GBS),	and	they
had	epidemics	every	summer.	Clearly	this	was	different	than	my	concept	of	GBS.	Thus	began	a	20-plus-
year	 collaboration	 between	 a	 team	 of	 colleagues	 from	 Johns	 Hopkins	 University,	 the	 University	 of
Pennsylvania,	and	colleagues	in	Beijing	and	Shijiazhuang.
I	made	a	 longer	visit	 to	Beijing	 in	October	1988.	At	 that	 time	 I	 saw	about	30	children	and	had	 the
opportunity	 to	 examine	 10	 thoroughly.	 I	 also	 had	 the	 opportunity	 to	 discuss	 this	 form	 of	 GBS	 with
Professor	Zhu	Fu-Tang,	a	90-year-old	paediatrician	and	founder	of	 the	Beijing	Children’s	Hospital.	Dr
Zhu	 Fu-Tang	 had	 been	 a	 student	 of	 my	 father’s	 at	 the	 Boston	 Children’s	 Hospital	 in	 the	 1930s.	 In
discussing	the	epidemiology,	I	was	also	fortunate	to	be	able	to	speak,	at	a	later	date,	with	Professor	Jun-
Xiong	Mao,	the	former	head	of	Neurology	at	the	2nd	Teaching	Hospital	of	Hebei	Medical	University.
Was	This	a	New	Disease?
Both	of	these	senior	clinicians	felt	that	this	was	a	new	condition,	first	occurring	in	the	1970s.	Prior	to	that
they	had	seen	GBS,	primarily	in	adults,	similar	 to	what	we	have	in	North	America	and	Europe.	At	that
time,	they	suddenly	began	seeing	an	influx	of	paediatric	patients,	so	much	so	that	in	both	hospitals	(at	least
150	kilometres	apart)	they	would	have	to	take	over	wards	from	other	services,	because	their	neurology
services	 were	 overwhelmed.	 The	 cases	 were	 almost	 exclusively	 in	 the	 summer,	 starting	 in	May,	 and
dropping	off	by	October.	There	were	more	boys	than	girls	(60/40).	The	cases	came	from	rural	areas,	not
from	the	cities.	There	was	no	clustering	of	cases;	no	multiple	cases	from	a	single	village;	only	1	instance
of	2	cases	 in	 the	 same	 family;	 and	no	 involvement	of	exposed	medical	personnel.	The	age	distribution
was	 strikingly	 different	 from	 ‘western	 GBS’,	 being	 predominantly	 children.	 A	 prodromal	 illness	 was
sometimes	 present,	 but	 varied.	 In	 view	 of	 the	 subsequent	 association	with	Campylobacter	 jejuni,	 we
asked	particularly	about	gastrointestinal	symptoms,	but	found	these	occurring	in	only	15%	to	20%.
I	decided	that	we	should	evaluate	this	problem	further,	and	that	I	needed	some	help.	So	I	put	together	a
team	from	Hopkins	(Drs	Jack	Griffin,	David	Cornblath,	Tony	Ho	and	myself)	and	from	Penn	(initially	Dr
Art	Asbury	and	then	later	added	Dr	Irv	Nachamkin—an	expert	on	Campylobacter	jejuni).	We	were	able
to	 get	 some	 funding	 from	 the	 Rockefeller	 Foundation	 and	 were	 prepared	 to	 go	 when	 things	 were
disrupted,	in	June	1989,	by	the	events	at	Tiananmen	Square	and	other	areas.	In	the	meantime,	Dr	Chun-Yun
Li,	 from	Shijiazhuang	 in	Hebei	 province,	 came	 to	work	with	 us	 in	Baltimore,	 primarily	with	Dr	 Jack
Griffin.	Dr	Li	had	seen	several	hundred	cases	or	more	of	GBS	in	China,	so	it	was	not	entirely	clear	who
was	teaching	whom.	After	a	year	with	Dr	Griffin,	Dr	Li	returned	to	Shijiazhuang,	where	he	became	head
of	Neurology	at	the	2nd	Teaching	Hospital	in	Hebei,	the	site	of	most	of	our	future	work.
In	August	1990,	we	finally	got	to	Dr	Li’s	hospital.	The	results	were	outstanding.	Dr	Li	had	arranged
for	20	patients	to	be	available,	all	in	one	large	room.	The	clinical	histories	were	quite	stereotyped.	Most
patients	had	been	previously	healthy.	The	 first	 symptom,	particularly	 in	children,	was	unsteadiness	and
falling,	 followed	 quickly	 by	 bilateral,	 symmetrical	 leg	 weakness.	 The	 disease	 then	 might	 skip	 to	 the
cranial	nerves,	with	facial	weakness	and	swallowing	difficulties	and	then	breathing	difficulties.	The	last
phase	would	be	bilateral	weakness	of	the	arms.	The	duration	of	onset	could	be	as	short	as	2	to	3	days,	or,
rarely,	 up	 to	 a	 week.	 There	 were	 no	 sensory	 complaints	 or	 pain	 as	 part	 of	 the	 disease	 process.	 A
tracheostomy	or	intubation	was	often	performed	in	part	to	aid	respiratory	weakness	and	also	to	overcome
swallowing	difficulties.	The	patients	were	afebrile.	If	CSF	was	obtained,	it	showed	a	few	cells	(up	to	8–
10	monocytes)	and	elevated	protein.
In	one	corner	of	the	large	room	was	our	first	patient,	‘H-1’,	a	young	man	about	10	years	old	who	was
intubated	and	being	ventilated	by	his	father	compressing	an	anaesthesia	bag	(Figure	9.1).	I	hurried	through
my	exam	and	told	Tony,	who	was	from	Taiwan	and	who	was	acting	as	our	interpreter,	to	tell	them	to	take
the	 patient	 upstairs	 and	 put	 him	 back	 on	 his	 respirator.	 (I	 was	 afraid	 he	 might	 die	 while	 we	 were
examining	him.)	Tony	came	back	a	few	minutes	later	and	said	‘Don’t	embarrass	them—they	have	run	out
of	 respirators	due	 to	 the	number	of	patients	 that	 had	come	 in.’	Later	we	went	up	 to	 the	ward	 and	 saw
several	other	patients	being	kept	alive	by	family	members	constantly	‘bagging’	them.	This	could	go	on	for
weeks.
In	another	part	of	the	room,	Dave	Cornblath	had	set	up	his	EMG	machine,	which	he	had	brought	from
Hopkins.	After	about	 the	second	patient,	he	came	over	and	quietly	said,	‘Boss—I	think	we	have	a	new
disease!’	He	showed	us	the	EMG	tracing,	and	the	EMG	clearly	pointed	towards	a	motor	axonal	disease
with	reduced	motor	amplitudes,	little	or	no	reduction	of	conduction	velocity,	and	preserved	sensory	nerve
action	 potentials.	 This	 finding	 was	 very	 different	 from	 the	 typical	 understanding	 of	 Guillain-Barré
syndrome	 at	 that	 time	 [1,2].	 GBS	 was	 thought	 to	 be	 mostly	 demyelinating	 affecting,	 both	 motor	 and
sensory	nerves.
To	skip	ahead	a	year	(1991),	we	returned	to	Shijiazhuang,	and	particularly	asked	Dr	Li	if	we	could	see
some	of	the	patients	that	we	had	seen	the	year	before.	Who	should	be	there	waiting	for	us,	but	‘H-1’	and
his	father.	He	had	not	only	survived,	but	also	made	a	miraculous	recovery.	He	stood	up,	walked	over	to
us,	and	shook	hands.	He	was	not	completely	normal.	He	had	some	distal	atrophy	of	his	hands	and	feet,	and
perhaps	his	tongue.	The	remainder	of	his	exam	was	normal.	His	pattern	of	recovery	was	a	long,	gradual
one.	He	was	 on	 respiratory	 support	 for	 at	 least	 a	month.	The	 physicians	 at	 the	 2nd	Teaching	Hospital
were,	and	are,	justifiably	proud	of	their	low	mortality	rate.	They	know	if	they	can	get	patients	through	the
acute	phase,	they	will	gradually	recover.
Figure	9.1		A	child	with	AMAN	is	ventilated	by	hand	by	his	father
What	Is	This	Disease?
We	had	a	lot	of	discussion,	both	among	ourselves	and	with	others,	about	what	this	disease	might	be	(see
Figure	 9.2).	Was	 it	 polio?	 The	 patients	 were	 afebrile,	 had	 symmetrical	 disease,	 and	 had	 no	 signs	 of
inflammation	in	their	CSF.	Polio	seemed	untenable.	Was	it	related	to	the	polio	vaccine?	I	was	contacted
by	both	Albert	Sabin	(see	The	Mexican	Connection,	below)	and	Jonas	Salk	about	 this	possibility,	each
pointing	to	the	other’s	vaccine.	For	most	patients,	polio	vaccination	had	occurred	months	or	years	prior	to
the	onset	of	 this	 illness.	Further,	 there	was	no	clustering	of	cases.	A	polio	vaccine-related	 illness	also
seemed	untenable.	Was	this	some	toxin	or	pesticide?	We	seriously	considered	this	possibility,	but	were
put	off	by	the	sporadic	nature	of	the	disease.
The	Pathology
The	 Chinese	 do	 very	 few	 autopsies.	 However,	 Dr	 Li	 was	 able	 to	 perform	 limited	 autopsies	 on	 12
patients.	He	removed	the	lower	spinal	cord,	anterior	and	posterior	roots,	peripheral	nerve,	and	muscle.
The	tissue	was	fixed	for	immunocytochemistry	and	electron	microscopy	and	brought	to	Hopkins	after	our
visits.	At	that	point,	Art	Asbury	and	Jack	Griffin	took	over.
Figure	9.2		What	is	the	possible	relationship	between	this	new	disease	‘Chinese	paralytic	syndrome’	(CPS)	and	Guillain-Barré
syndrome?	This	hand-drawn	note	dates	from	the	original	discussions	in	1992.
To	begin	with,	it	was	clear	what	this	was	not:	an	inflammatory	demyelinating	polyneuropathy	(AIDP)
as	 Dr	 Asbury	 and	 colleagues	 had	 described	 in	 1969	 [3].	 Rather,	 in	 fatal	 cases,	 there	 was	 extensive
Wallerian–like	degeneration	of	motor	axons	(thus	called	acute	motor	axonal	neuropathy	[AMAN]),	and,	in
some	 cases,	 involvement	 of	 both	 sensory	 and	 motor	 axons	 (thus	 called	 acute	 sensory-motor	 axonal
neuropathy	[AMSAN]).	In	both	instances	a	prominent	feature	was	the	presence	of	macrophages	within	the
periaxonal	 space,	 displacing	 the	 axon	 (Figure	 9.3).	 The	 movement	 of	 macrophages	 to	 the	 axon	 was
defined	[4–6].	These	clues	suggested	that	the	macrophages	were	attracted	to	something	in	the	paranodal
or	nodal	regions.	Under	Jack’s	leadership,	Charlene	Macko,	Kazim	Sheikh	and	Tony	Ho	later	carried	out
detailed	 work	 on	 these	 precious	 samples	 and	 demonstrated	 the	 presence	 of	 IgG	 and	 the	 complement
activation	product	C3d	bound	to	the	axolemma	of	motor	fibres,	especially	in	the	nodal	axolemma.	This	is
in	contrast	to	the	AIDP	cases	in	which	the	complement	activation	products	were	on	the	outer	surface	of
Schwann	cells	[7,8]	(see	Figure	9.3).
Figure	9.3	 	 (A)	Deposition	of	 the	complement	product	C3d	on	outer	surface	of	 two	 fibres	 from	an	AIDP	case.	 (B)	Extensive
vesiculation	of	the	myelin	sheath	in	the	same	case.	(C)	Foamy	macrophages	associated	with	a	fibre	from	the	same	AIDP	case.
(D)	Schematic	illustrating	antibody,	complement	and	macrophage	attack	directed	against	the	outer	surface	of	the	myelin	sheath
in	AIDP.	(E)	C3d	deposition	at	the	node	of	Ranvier	in	ventral	root	in	an	AMAN	case.	(F)	Node	of	Ranvier	on	ventral	root	with	nodal
lengthening	and	 two	overlying	macrophages	 in	a	case	of	AMAN.	(G)	A	macrophage	 in	 the	 internodal	axon	beginning	 to	extend
processes	 towards	 the	periaxonal	space.	 (H)	Schematic	 illustrating	a	macrophage	 inserting	 itself	at	a	node	of	Ranvier	where
there	is	antibody	and	complement	deposition.	AIDP	images	(A,	B,	C)	adapted	with	permission	from	[7].	AMAN	images	(F	and	G)
adapted	with	permission	from	[5].	Images	D,	E	and	H	work	of	McKhann	G,	originally	published	in	[18].
Tony’s	Narrative
The	Relationship	to	Chickens	and	to	Campylobacter	jejuni	(C.	jejuni)
Our	first	trip	was	in	1990.	As	a	medical	student,	it	was	an	exciting	trip	for	me	accompanying	4	world-
famous	neurologists	to	investigate	this	new	disease.	Guy	took	us	to	Beijing	Children’s	Hospital	and	we
met	Dr	Zhu	Fu-tang	(Figure	9.4).	Guy	was	very	 interested	 in	his	observation	 that	 this	disease	suddenly
increased	in	prevalence	in	the	1970s.	We	did	not	get	any	real	clues	on	the	first	day	we	visited	him.	During
the	next	day,	Guy	asked	him	the	same	question,	‘What	happened	twenty	years	ago?’	again	to	no	avail.	On
the	 third	day,	Guy	asked	 the	 same	question	again!	 I	 thought	 to	myself,	 ‘Haven’t	we	asked	 this	question
before?’	To	my	surprise,	we	got	some	very	useful	clues.	As	it	turns	out,	Dr	Zhu	Fu-tang	had	been	carefully
thinking	about	Guy’s	question	for	the	past	3	days.	He	recollected	that	most	of	these	children	were	from	the
countryside	and	usually	appeared	after	rainfalls.	This	disease	only	occurred	in	children	who	were	older
than	1	year,	and	many	got	sick	after	drinking	unboiled	water	or	eating	raw	eggs.	These	clues	pointed	us	to
possibility	that	a	diarrheal	illness	was	the	potential	trigger	to	the	disease.	After	returning	from	our	first
trip,	given	some	reported	association	of	Campylobacter	with	GBS	in	Australia	by	Kaldor	and	Speed	[9],
we	 decided	 to	 follow	 up	 on	 this	 lead.	 We	 first	 contacted	 Dr	 Martin	 Blaser	 of	 Vanderbilt,	 given	 his
expertise	in	Campylobacter	serology.	The	initial	data	showed	promising	results;	many	of	Chinese	patients
did	indeed	have	elevated	anti-Campylobacter	antibody	titres,	suggesting	antecedent	infection	[10].
After	the	1991	trip,	the	focus	of	our	research	was	now	on	Campylobacter	and	gangliosides.	One	day,
Art	came	in	and	said,	‘Guess	what,	we	had	the	world	expert	on	Campylobacter	in	our	backyard	all	this
time!’	We	quickly	enlisted	Dr	Irving	Nachamkin	from	Penn	to	the	research	team.	He	told	us	we	needed	to
culture	these	bacteria	from	the	patients.	Under	Irv’s	direction,	I	started	spending	my	post-call	days	during
my	 internship	 at	Massachusetts	General	Hospital	 in	 the	 basement	 bacteriological	 lab,	 learning	 how	 to
grow	Campylobacter	under	microaerophilic	conditions.	This	turned	out	to	be	a	good	investment.	After	my
internship,	 I	 spent	 the	 summer	 of	 1992	 at	 Shijiazhuang	 seeing	 these	 patients,	 doing	 nerve	 conduction
studies,	and	teaching	our	Chinese	colleagues	how	to	culture	Campylobacter.	This	is	when	we	found	the
striking	association	with	chickens.	A	14-year-old	girl	came	 in	with	advancing	disease.	She	 told	us	 that
she	was	studying	in	the	city.	Her	mother	had	called	her	and	asked	her	to	come	back	to	the	village	to	take
care	of	a	‘sick’	chicken.	After	feeding	the	chicken	with	some	form	of	medicine	(presumably	vitamins),	she
fell	 ill	 and	became	paralyzed.	We	 sent	 a	 team	 to	her	 village	 to	 examine	 these	 chickens	 and	 took	 stool
cultures.	The	pictures	were	striking:	several	chickens	had	their	heads	drooped	to	one	side	(Figure	9.5).
The	 nerve	 pathology	 in	 the	 chickens	 showed	 the	 typical	 axonal	 damage	we	 had	 seen	 in	 humans.	 In
addition,	we	were	able	 to	 isolate	Campylobacter	 jejuni	 from	 the	girl	 and	 these	 chickens.	We	 took	 the
natural	next	step.	Dr	Li	bought	some	live	chickens	from	the	market	and	fed	them	Campylobacter.	To	our
surprise,	in	the	first	batch	of	33,	all	got	diarrhoea	and	half	became	weak.	In	the	second	batch,	a	quarter
developed	 paralysis.	 These	 weak	 chickens	 had	 pathology	 in	 their	 sciatic	 nerves	 similar	 to	 AMAN
patients.	 An	 animal	 model	 of	 Campylobacter-associated	 AMAN	 had	 been	 developed	 [11].	 Most
interestingly,	the	chickens	were	housed	next	to	6	monkeys	that	had	been	in	the	animal	facility	for	almost
10	years.	Four	monkeys	came	down	with	diarrhoea,	followed	by	paralysis!	(Presumably	they	were	able
to	reach	out	from	their	cage	and	play	with	the	chickens	or	their	stools).	The	first	paralyzed	monkey	was
cultured	positive	for	C.	jejuni.	By	the	fifth	day,	he	was	quite	sick.	Fearing	his	imminent	demise,	he	was
sacrificed,	and	the	subsequent	autopsy	material	showed	essentially	no	findings	except	minor	changes	in
the	ventral	roots	(looking	back,	maybe	the	paralysis	was	mainly	due	to	conduction	blocks).	The	second
monkey	also	came	down	with	paralysis	but	slowly,	over	1–2	months.	His	teased	fibres	showed	extensive
axonal	damage	consistent	with	AMAN.	Examining	 these	monkeys’	nerves	showed	 that	 they	 indeed	also
had	motor	axonal	damage.
Figure	9.4		Top	from	right	to	left:	Dr	Zhu	Fu-Tang	(centre),	Dr	Hu-sheng	Wu	(left),	Dr	Arthur	Asbury,	Dr	Guy	McKhann,	Dr	Tony
Ho,	 Dr	 Jack	 Griffin	 at	 Beijing	 Children	 Hospital;	 Bottom:	 Dr	 Chun-Yun	 Li,	 Dr	 Arthur	 Asbury,	 Dr	 Jack	 Griffin	 in	 front	 of	 New
Research	Laboratory	at	2nd	Affiliated	Hospital	of	Hebei	Medical	University
Figure	9.5		Naturally	occurring	animal	model	of	GBS	in	the	chicken.	The	chicken	on	the	left	displays	a	flaccid	weakness	following
Campylobacter	jejuni	enteritis.
We	were	very	encouraged	with	these	results	and	were	eager	to	establish	similar	models	in	the	United
States.	We	tried	to	repeat	similar	experiments	with	a	number	of	chicken	species	at	Penn.	Art	revealed	his
Kentucky	 roots,	 adeptly	 showing	Nachamkin	and	 I	how	 to	handle	 these	chickens	and	how	 to	 feed	 them
with	Campylobacter.	 We	 were	 never	 successful	 in	 establishing	 the	 model—but	 in	 retrospect,	 these
chickens	may	not	have	been	C.	jejuni	naïve.	If	they	were	colonized	with	other	strains	of	C.	jejuni,	we	may
have	had	difficulty	infecting	them	with	the	pathological	strain	of	C.	jejuni.
Ganglioside	Epitopes:	Connection	to	C.	jejuni
Many	anti-glycoconjugate	antibodies	have	been	described	in	GBS	patients.	The	strongest	association	is
between	 the	 Fisher	 syndrome	 and	 IgG	 anti-GQ1b.	 Our	 initial	 investigation	 had	 focused	 on	 anti-GM1
antibody	 because	 there	 were	 reports	 of	 its	 association	 with	 GBS.	 Later,	 collaborating	 with	 Professor
Hugh	Willison,	we	were	able	to	investigate	the	anti-glycoconjugate	profile	and	to	correlate	with	different
subtypes	 of	 GBS.	 What	 we	 found	 was	 that	 both	 AMAN	 and	 AIDP	 patients	 had	 elevated	 anti-
glycoconjugate	antibody	to	GM1,	GD1b	and	GA1.	However,	only	the	AMAN	patients	had	elevated	GD1a
[12],	suggesting	that	this	may	be	the	pathogenic	epitopes	for	AMAN.	Because	C.	jejuni’s	liposaccharides
shared	sugar	structures	similar	 to	 those	of	gangliosides,	 the	question	arose	as	 to	whether	 the	antibodies
were	generated	against	these	epitopes.	The	investigation	turned	out	to	be	very	fruitful.	Irving	was	able	to
show	 that	 the	pathogenic	strain	of	C.	 jejuni	 (mostly	Penner	19)	did	contain	GM1,	GD1a-like	epitopes,
suggesting	that	‘molecular	mimicry’	may	be	the	underlying	pathogenesis.	Further	evidence	suggested	that
motor	axons	were	particularly	enriched	with	GD1a	epitopes,	which	may	explain	the	predominant	motor
axonal	 damage.	Working	with	 Professor	 Yuki,	 we	 have	 found	 additional	 ganglioside	 epitopes	 such	 as
GM1b	and	GalNAc-GD1a	[13].
Recovery	from	Axonal	Damage
One	of	the	most	important	questions	was	how,	if	this	was	true	axonal	damage,	patients	could	recover.	As
mentioned	above,	we	were	shocked	when	we	saw	these	completely	paralyzed	patients	who	had	no	or	low
amplitude	distal	motor-evoked	potentials	 return	a	year	 later	walking	with	only	 limited	 residual	muscle
atrophy.	 The	 observation	 by	 Jack	 and	 Art	 that	 the	 focus	 of	 immune	 attacks	 is	 the	 nodal	 or	 paranodal
regions	suggested	that	these	patients	could	have	reversible	nodal	blocks	without	significant	axon	damage.
Nobuhiro	Yuki	has	since	further	substantiated	these	observations	[14].	Another	possible	explanation	for
the	rapid	reversibility	was	very	distal	axonal	degeneration.	The	evidence	of	this	actually	came	from	the
United	 States,	 not	 China.	We	 saw	 a	 woman	 with	Campylobacter-associated	 AMAN	 at	 Hopkins.	 She
improved	 quickly	 following	 plasmapheresis.	 Motor-point	 biopsy	 showed	 denervated	 neuromuscular
junctions	 and	 reduced	 fibre	 numbers	 in	 intramuscular	 nerves,	 showing	 that	 distal	 axonal	 degeneration
could	explain	the	rapid	improvement	[15].
The	Mexican	Connection
Who	better	a	person	to	ask	about	acute	paralysis	in	children	than	Dr	Albert	Sabin?	Guy	and	I	made	a	trip
to	Washington,	DC	 to	visit	Albert	after	we	got	back	 from	China	 in	1990.	 It	was	an	 interesting	 trip.	As
soon	as	we	sat	down,	Albert	said,	‘I	know	why	you	are	here.	I	have	seen	those	kids	in	Beijing.	They	are
very	similar	 to	the	patients	we	saw	in	Mexico	City.’	He	handed	us	a	paper	from	1969	in	which	he	and
Manuel	Ramos-Alveraz	were	the	lead	authors	describing	an	epidemic	of	acute	flaccid	paralysis	that	they
named	‘nuclear	neuronopathy	and	cytoplasmic	neuronopathy’,	describing	the	ballooned	anterior	horn	cells
they	 saw	 [16].	 At	 that	 time	 they	 were	 testing	 a	 live	 polio	 vaccine	 in	 Mexico	 when	 these	 children
developed	acute	flaccid	paralysis.	Even	though	the	children	had	non-inflammatory	CSF,	both	Manuel	and
Albert	were	 blamed	 for	 the	 outbreak.	Albert	was	 forced	 to	 leave	Mexico	 and	Manuel	was	 ostracized
from	the	Mexico	medical	community.
We	followed	up	this	lead	and	tracked	down	Manuel	in	a	little	alley	in	Mexico	City.	To	our	surprise,	he
had	 kept	 all	 the	 original	 pathology	 from	 these	 children.	 We	 brought	 these	 pathology	 blocks	 back	 to
Hopkins.	 With	 modern	 techniques,	 we	 were	 able	 to	 confirm	 that	 these	 children	 indeed	 had	 similar
pathology.	While	Albert	and	Manuel	had	focused	on	the	anterior	horn	cells,	Jack	and	Art	focused	attention
to	the	anterior	roots	which	showed	similar	Wallerian-like	degeneration	of	motor	roots.	What	Albert	and
Manuel	observed	was	chromatolysis	from	the	motor	nerve	damage.
We	 then	made	 several	 trips	 to	Mexico	 and	 discovered	 that	 there	were	 still	 children	 suffering	 from
acute	 motor	 axonal	 neuropathy,	 and	 that	 AMAN	was	 occurring	 in	 the	 summer,	 as	 in	 China.	We	 were
successful	 in	 culturing	 Campylobacter	 jejuni	 from	 these	 children.	 When	 these	 Campylobacter	 were
analysed	 for	 their	 genetic	 linkage,	 to	 our	 surprise,	 these	Campylobacter	 were	 closely	 related	 to	 the
Chinese	strains	and	carried	similar	ganglioside-like	epitopes	[17].
Current	Status	of	AMAN	in	China
In	2012,	Tony	made	another	visit	 to	Shijiazhuang.	China	had	completely	changed	since	we	were	 there.
They	now	have	a	bullet	train	from	Beijing	to	Shijiazhuang	which	cut	the	travel	time	from	6	hours	to	about
an	hour.	Dr	Li	is	now	a	member	of	the	Chinese	Academy	and	has	built	a	state-of-the-art	research	institute
at	 the	2nd	Teaching	Hospital.	AMAN	and	AIDP	still	occur	every	summer	after	 rainfalls.	However,	 the
physicians	in	Shijiazhuang	now	have	modern	and	ample	respirators,	and	treat	these	patients	with	IVIg.
We	are	writing	this	report	almost	30	years	after	we	first	started	looking	into	a	strange	form	of	GBS	in
China.	We	would	summarize	our	group’s	contributions	as	follows:
1.	 Characterization	of	the	clinical	form	of	acute	motor	axonal	neuropathy	(AMAN)
2.	 The	delineation	of	the	differences	in	electrophysiology	between	AIDP	and	AMAN
3.	 The	delineation	of	the	distinctive	pathology	of	AMAN
4.	 The	association	of	AMAN	and	Campylobacter	jejuni
5.	 The	development	of	a	chicken	model	of	AMAN
6.	 The	association	of	ganglioside	epitopes	with	AMAN,	and	the	development	of	the	theory	of	molecular
mimicry	as	applied	to	AMAN
We	dedicate	this	report	to	our	all-important	colleague,	Jack	Griffin.
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GBS	in	the	Indian	Subcontinent:	Sitting	on	the
Other	Side	of	the	Fence
Ansh	Mehta,	Zhahir	Islam	and	Govind	Chavada
Introduction
Since	the	launch	of	the	global	polio	eradication	drive	by	the	World	Health	Organisation	in	1988,	there	has
been	 a	 significant	 reduction	 in	 the	 incidence	 of	 poliomyelitis	 worldwide,	 and,	 indeed,	 most	 Indian
subcontinent	countries	except	Pakistan	became	polio	free	in	2014.	In	the	pre-eradication	era,	polio	was
the	major	cause	of	infective	acute	flaccid	paralysis	(AFP),	so	it	comes	as	no	surprise	that	it	has	remained
a	major	focus	of	attention	for	the	past	50	years	on	the	Indian	subcontinent.	Whilst	active	surveillance	for
polio	 still	 continues,	 focus	has	now	shifted	 to	other,	non-polio	virus-related	causes	of	AFP	 (NP-AFP).
There	are	number	of	conditions	that	may	lead	to	NP-AFP,	which	include	toxic,	metabolic,	infective	and
inflammatory	conditions.	Amongst	all,	Guillain-Barré	syndrome	 is	 the	 leading	cause	of	NP-AFP	 in	 this
region.
In	the	context	of	the	resource-poor	Indian	subcontinent,	GBS	represents	a	major	health	care	challenge
to	improving	outcomes.	GBS	continues	to	remain	a	clinical	diagnosis	and	therefore	clinical	differentiation
between	GBS	 and	 other	NP-AFP	 can	 be	 difficult.	 Correct	 identification	 of	GBS	 cases	 help	 guide	 the
appropriate	management	of	patients,	especially	when	resources	are	limited	and	the	cost	of	immunotherapy
is	a	major	factor.	There	is	extensive	literature	available	describing	GBS	incidence	rates	in	the	Western
world,	 but	 similar	 data	 from	 developing	 countries	 are	 lacking.	 Availability	 of	 these	 data	 is	 hugely
important,	not	only	for	the	better	understanding	of	the	disease	pattern	in	this	region	but	also	for	resource
allocation	 and	 formulation	of	 national	 health	 policies.	 Similarly,	 from	Western	 literature	we	know	 that
most	patients	with	GBS	make	a	good	recovery	but	about	20%	remain	disabled	after	a	year;	however,	the
overall	 burden	 of	 GBS	 in	 developing	 countries	 is	 not	 known,	 especially	 when	 there	 is	 no	 universal
availability	of	immunotherapy	and	rehabilitation	facilities	in	these	countries.	Conducting	comprehensive
epidemiological	 and	 sophisticated	 clinical	 studies	 in	 such	 a	 diverse	 and	 largely	 rural	 subcontinent
population	poses	the	greatest	challenge	in	these	regions.
Subcontinent	countries	are	perfect	examples	of	the	inverse	care	law,	whereby	those	with	the	greatest
need	have	the	greatest	difficulty	in	accessing	health	care	facilities.	For	example,	 in	a	country	like	India
with	a	population	of	1.3	billion,	70%	live	in	rural	areas	with	a	ratio	of	3–5	primary	care	physicians	per
100,000	 inhabitants.	 When	 it	 comes	 to	 specialist	 neurology	 care,	 as	 of	 2013	 there	 were	 only	 1,100
practising	 neurologists,	 of	 which	 half	 were	 based	 in	 big	 cities,	 which	 effectively	 equates	 to	 one
neurologist	per	1	million	inhabitants.	In	comparison,	the	United	Kingdom	has	10	neurologists	per	million.
Thus,	availability	of	specialist	neurology	care	is	grossly	inadequate	and	the	vast	majority	of	GBS	cases
are	managed	 by	 general	 physicians	 in	 peripheral	 hospitals	 [1].	 Grossly	 inadequate	 public	 health	 care
resources	force	patients	to	use	private	health	care	facilities,	which	provide	up	to	80%	of	patient	care	in
these	countries	 [2].	 In	most	GBS	cases,	diagnosis	 is	made	clinically	and	additional	 tests	such	as	nerve
conduction	 studies	 and	 CSF	 examination	 are	 performed	 only	 if	 the	 patient	 can	 afford	 them	 and	 the
resources	are	available.	Often	the	diagnosis	is	delayed,	especially	in	rural	settings	where	patients	have	to
travel	a	long	distance,	the	cost	of	health	care	is	an	obstacle	and	clinical	expertise	even	in	regional	centres
is	lacking.	Treatment	of	GBS	in	these	countries	largely	depends	on	what	patients	can	afford	and	whether
treatment	 facilities	 such	 as	 plasma	 exchange	 (PE)	 and	 mechanical	 ventilators	 are	 available.	 On	 an
average,	PE	costs	 around	1,200	USD,	while	 indigenous	 IVIg	costs	 around	2,400	USD;	 therefore	PE	 is
frequently	 preferred	 over	 IVIg	 treatment.	Often	 poorer	 patients	 are	 treated	with	mechanical	 ventilation
without	 IVIg	 or	 plasmapheresis,	 especially	 in	 government	 hospitals	 where	 plasma	 exchange	 is	 not
available.	 Rehabilitation	 of	 GBS	 patients	 poses	 a	 further	 challenge	 due	 to	 the	 inadequate	 numbers	 of
specialist	centres,	which	in	turn	contributes	to	poor	outcome.
Due	 to	 huge	 socioeconomic	 and	 cultural	 constraints	 and	 various	 other	 health	 care	 priorities,
subcontinent	countries	are	far	behind	in	GBS	care	and	research.
While	literature	from	some	countries	is	limited	to	case	reports	and	retrospective	studies,	countries	like
India	and	Bangladesh	have	made	considerable	progress	and	 the	vast	majority	of	publications	 from	 this
region	come	from	these	two	countries.	The	purpose	of	this	‘Top	10’	is	to	highlight	the	contributions	of	the
region’s	scientific	community,	in	chronological	order.	Certainly,	this	list	is	not	comprehensive,	and	by	no
means	detracts	from	the	contributions	of	others,	whom	we	unfortunately	have	not	the	space	to	mention	in
this	brief	chapter.
Seth	RK.	Landry-Guillain-Barré	syndrome	in	children.	Indian	Journal	of
Pediatrics,	1965
Seth’s	was	probably	the	first	comprehensive	case	series	of	GBS	from	this	region	[3].	In	this	article	Seth
describes	 8	 paediatric	 GBS	 cases.	 What	 is	 striking	 in	 this	 case	 series	 is	 that	 one	 GBS	 patient	 was
wrongly	 diagnosed	 and	 treated	 as	 having	 ‘post	 diphtheritic	 polyneuropathy’	 and	 3	 patients	 died	 of
respiratory	failure	due	to	the	unavailability	of	mechanical	ventilators.	Interestingly,	6	out	of	the	8	cases	in
this	 series	 were	 treated	 with	 steroids,	 which	 at	 the	 time	 was	 ‘widely	 acceptable’.	 This	 article	 also
highlights	the	diagnostic	and	therapeutic	challenges	faced	by	developing	countries,	where	other	causes	of
AFP	such	as	poliomyelitis	and	post-diphtheritic	polyneuropathy	were	a	common	problem.
Tharakan	J,	et	al.	Small	volume	plasma	exchange	in	Guillain-Barré
syndrome:	experience	in	25	patients.	Journal	of	the	Association	of
Physicians	of	India,	1990
Encouraged	by	the	first-ever	case	report	by	Brettle	and	colleagues	[4]	and	subsequent	anecdotal	reports
showing	the	efficacy	of	plasma	exchange	in	GBS,	in	1984	Osterman	and	colleagues	conducted	the	first-
ever	randomised	controlled	trial	showing	the	efficacy	of	PE	in	GBS	patients	[5].	Keeping	pace	with	the
Western	 world,	 Tharakan	 and	 colleagues	 published	 their	 experience	 of	 25	 GBS	 patients	 treated	 with
small-volume	plasma	exchange	(SVPE),	with	promising	results	[6].	However,	what	is	surprising	is	 that
despite	being	a	cheap	alternative	 to	conventional	PE,	very	 little	effort	has	been	made	 to	validate	 these
results,	which	otherwise	could	potentially	 transform	GBS	treatment	 in	 the	developing	world,	where	the
cost	of	immunotherapy	is	a	major	limiting	factor.
Gupta	SK	et	al.	Acute	idiopathic	axonal	neuropathy	(AIAN):	a	clinical
and	electrophysiological	observation.	Acta	Neurolica	Scandinavica,
1994
Controversy	surrounding	underlying	pathological	processes	in	GBS	continued	to	dominate	the	1980s	and
1990s.	 GBS	 was	 traditionally	 considered	 to	 be	 a	 demyelinating	 disease	 until	 Feasby	 and	 colleagues
challenged	 this	 view	 and	 published	 the	 first	 report	 of	 ‘acute	 axonal	GBS’	 in	 1986	 [7].	McKhann	 and
colleagues	 later	 substantiated	 this	 view	 and	 described	 a	 case	 series	 of	 Chinese	 GBS	 patients	 with
predominant	axonal	degeneration	as	an	underlying	pathology	[8].	Not	far	behind,	within	a	year,	Gupta	and
colleagues	published	 the	 first	AMAN	case	series	 in	 India,	describing	clinical	and	electrophysiological
features	 of	 20	 axonal	GBS	patients	with	 poor	 recovery	 patterns,	 reinforcing	 the	 idea	 that	 axonal	GBS
should	be	considered	a	distinct	entity	[9].
Kalita	J,	et	al.	Neurophysiological	criteria	in	the	diagnosis	of	different
clinical	types	of	Guillain-Barré	syndrome.	Journal	of	Neurology,
Neurosurgery	and	Psychiatry,	2008
Electrophysiological	(EP)	criteria	of	GBS	has	remained	a	topic	of	major	controversy	in	the	field.	Most
initial	 criteria	was	 designed	 according	 to	 the	 traditional	 thinking	 that	GBS	 represents	 a	 demyelinating
disorder	of	peripheral	nerves;	however,	when	this	view	was	challenged,	new	criteria	were	designed	to
accommodate	 ‘axonal	 GBS’.	 One	 of	 the	 issues	 regarding	 these	 criteria	 is	 the	 ‘EP	 definition	 of
demyelination’,	 which	 is	 completely	 arbitrary	 without	 any	 laboratory	 evidence.	 Kalita	 and	 colleagues
conducted	 a	 study	 comparing	 the	 diagnostic	 sensitivity	 of	 6	 different	 criteria	 and	 found	 significant
variation	 in	diagnostic	sensitivity	of	 these	criteria,	underscoring	 the	 importance	of	consensus-based	EP
diagnostic	criteria	[10].
Gupta	A,	et	al.	Guillain-Barré	Syndrome:	rehabilitation	outcome,
residual	deficits	and	requirement	of	lower	limb	orthosis	for
locomotion	at	1	year	follow-up.	Disability	and	Rehabilitation,	2010
‘Neurological	rehabilitation’,	which	is	an	integral	part	of	neurology	care	in	the	Western	world,	remains	a
luxury	 in	 the	developing	world.	 In	 the	 context	 of	GBS,	 this	 interesting	 report	 by	Gupta	 and	 colleagues
describes	the	overall	rehabilitation	outcomes	of	35	GBS	patients	[11].	The	study	showed	that	only	14%	of
patients	diagnosed	with	GBS	were	admitted	 to	a	 rehabilitation	unit,	which	 is	well	below	 the	 figure	of
40%	 in	 some	 earlier	 studies.	 It	 also	 showed	 that	 while	 most	 patients	 make	 a	 very	 good	 functional
recovery,	about	34%	of	patients	 required	 foot	orthosis	 to	walk	and	about	25%	of	patients	continued	 to
complain	of	neuropathic	pain,	highlighting	the	need	to	develop	effective	neuro-rehabilitation	facilities	in
low-income	countries.
Sendhilkumar	R,	et	al.	Effect	of	pranayama	and	meditation	as	an	add-
on	therapy	in	rehabilitation	of	patients	with	Guillain-Barré	syndrome—
a	randomized	control	pilot	study.	Disability	and	Rehabilitation,	2013
Over	the	past	few	decades	the	ancient	Indian	practice	of	yoga	has	gained	tremendous	attention	around	the
world.	 Integrated	 yoga	 programmes,	 in	 addition	 to	 traditional	 physiotherapy,	 have	 been	 shown	 to	 be
effective	in	long-term	rehabilitation	of	various	rheumatologic	disorders.	In	this	fascinating	pilot	study,	the
authors	conducted	a	single	blind	randomised	control	trial	of	22	GBS	patients,	comparing	the	efficacy	of
yoga	 with	 conservative	 treatment,	 and	 although	 the	 study	 failed	 to	 show	 any	 beneficial	 effect	 of
pranayama	 and	 meditation	 on	 patients’	 pain,	 anxiety	 and	 depression	 level,	 it	 showed	 significant
improvement	 in	 quality	 of	 sleep	 [12].	Clearly,	 sleep-related	 issues	 are	 very	 common	 in	GBS	 and	 can
affect	the	overall	quality	of	life;	therefore,	if	these	findings	are	substantiated	by	further	large	RCTs,	yoga
may	have	a	place	in	GBS	rehabilitation.
Islam	Z,	et	al.	High	incidence	of	Guillain-Barré	syndrome	in	children,
Bangladesh.	Emerging	Infectious	Diseases,	2011
This	article	reinforces	the	idea	that,	as	the	most	developing	countries	are	inching	closer	to	achieving	the
complete	eradication	of	poliomyelitis,	GBS	is	emerging	as	a	major	cause	of	AFP	[13].	Not	only	that,	it
also	highlights	an	 interesting	 fact	 that	 in	countries	 like	Bangladesh,	GBS	rates	are	at	 least	2	 to	3	 times
higher	than	what	has	been	reported	in	the	Americas	and	Europe,	and	the	burden	of	this	disabling	disease
could	be	much	higher	 than	we	 all	 think.	 In	 this	 study	 Islam	and	 colleagues	 systematically	 analysed	 the
surveillance	 data	 on	 reported	AFP	 cases	 from	Bangladesh	 and	 have	 shown	 that	while	Bangladesh	 has
been	successful	in	eradicating	poliomyelitis	since	2000,	non-polio	AFP	cases	are	continue	to	occur,	with
an	 incidence	 rate	of	3.25	per	100,000	children	 less	 than	15	year	of	age,	and	 that	a	great	proportion	of
these	non-polio	AFP	cases	are	diagnosed	as	GBS,	with	crude	incidence	rates	of	GBS	in	children	varying
from	1.5	to	5	per	100,000	per	year	in	Bangladesh.
Islam	Z,	et	al.	Axonal	variant	of	Guillain-Barré	syndrome	associated
with	Campylobacter	infection	in	Bangladesh.	Neurology,	2010
This	 fascinating	 article	 by	 Islam	 and	 colleagues	 portrays	 a	 real-time	 picture	 of	 GBS	 in	 developing
countries	 like	Bangladesh	 [14].	 This	 prospective	 case-control	 study	 from	 the	Dhaka	 area	 showed	 that
most	GBS	cases	were	axonal	variant.	What	stands	out	from	this	study	is	the	fact	that	most	patients	did	not
receive	any	specific	immunotherapy	and	about	43%	of	these	patients	had	poor	outcome	as	defined	by	an
“inability	to	walk	unaided	at	6	months”	after	disease	onset.	Studies	like	this	clearly	show	the	real	gap	in
availability	 of	 treatment	 and	 outcome	 of	 GBS,	 between	 developing	 and	 developed	 nations.	 The
international	GBS	community	needs	to	make	concerted	efforts	to	tackle	this	potentially	disabling	disease.
Islam	Z,	et	al.	Guillain-Barré	syndrome-related	Campylobacter	jejuni	in
Bangladesh:	ganglioside	mimicry	and	cross-reactive	antibodies.	PLoS
One,	2012
Many	studies	on	the	pathogenesis	of	GBS	report	findings	that	are	consistent	with	the	mimicry	hypothesis,
but	none	of	these	studies	originated	from	a	developing	country.	In	this	study,	Islam	and	colleagues	provide
evidence	in	support	of	the	hypothesis	that	even	in	the	developing	world,	C.	jejuni	infections	induce	GBS
in	 these	 patients	 by	 molecular	 mimicry	 and	 induction	 of	 a	 cross-reactive	 immune	 response	 to	 nerve
gangliosides	 [15].	The	authors	 found	evidence	of	 IgG	antibodies	 to	certain	 strains	of	C.	 jejuni	LOS	 in
GBS	patients’	sera,	following	which,	they	showed	that	anti-GM1	and	GD1a	monoclonal	antibodies	react
to	C.	jejuni	LOS.	Further,	they	closed	the	loop	by	performing	a	mass	spectroscopy	analysis	showing	GM1
and	GD1a	gangliosides-like	structures	on	certain	strains	of	C.	Jejuni	LOS.
Islam	MB,	et	al.	Small	volume	plasma	exchange	(SVPE)	for	Guillain-
Barré	syndrome	(GBS)	patients	in	Bangladesh:	a	phase	2	clinical	trial.
7th	Meeting	of	the	Inflammatory	Neuropathy	Consortium	(INC)	of	the
Peripheral	Nerve	Society;	Dusseldorf,	Germany,	2014
Access	 to	costly	 immune	 therapy	such	as	 IVIG	and	PE	for	GBS	patients	 remains	a	major	challenge	for
most	low-income	developing	countries.	A	full	course	of	intravenous	immunoglobulin,	for	an	adult	of	60
kg,	 costs	 around	 12,000–16,000	USD,	 and	 a	 conventional	 PE	 for	 5	 days	 costs	 around	 4,500	 to	 5,000
USD,	which	makes	these	treatments	inaccessible	to	the	majority	of	patients.	Therefore	cheap	alternatives
must	be	sought.	One	such	attempt	is	this	ongoing	combined	Dutch-Bangladesh	study	hoping	to	show	that
SVPE	has	can	change	the	therapeutic	landscape	in	most	developing	countries	[16].
Conclusion
GBS	continues	 to	remain	a	 leading	cause	of	AFP	in	subcontinent	countries.	While	 the	 true	 incidence	of
GBS	in	these	countries	is	not	known,	there	are	very	good	reasons	to	believe	that	the	incidence	is	higher
than	 previously	 thought.	 Lack	 of	 systematic	 epidemiological	 and	 outcome	 studies,	 and	 poor	 research
infrastructure	to	perform	such	studies,	remain	major	challenges	in	this	area.	The	outcome	of	GBS,	which
is	otherwise	thought	to	be	very	favourable	in	the	majority	of	cases	in	the	Western	world,	may	not	be	so	in
the	developing	world	due	to	inaccessibility	of	highly	expensive	immunotherapy	and	lack	of	rehabilitation
facilities.
Concerted	 efforts	 by	 the	 international	 GBS	 community	 are	 needed	 to	 bridge	 this	 gap	 between	 the
developing	 and	 developed	 world.	With	 recent	 globalisation,	 the	 socio-economic	 landscape	 is	 rapidly
changing	 in	 this	 region	and	with	 it	 the	availability	of	health	care	 resources	and	 research	 infrastructure.
Today	countries	like	India	and	Bangladesh	are	developing	close	links	with	international	research	centres,
a	trend	we	hope	will	continue	and	that	will	contribute	further	in	understanding	this	disease.
The	100th	anniversary	of	GBS	reminds	me	of	a	great	man,	scientist,	mathematician	and	inventor	of	the
first	solar	cooker	of	India,	my	grandfather	Chandra	Mehta,	the	person	whom	I	was	not	fortunate	enough	to
meet	as	we	lost	him	to	GBS	before	my	birth.	I	am	sure	there	are	many	like	me	and	who	wish	to	find	better
treatment	for	this	potentially	disabling	and	life-threatening	illness.
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Clinical	Diversities	of	Guillain-Barré	Syndrome	in
Korea:	A	Wondering	Stranger’s	View	from	the	Far
East:	Is	the	Dawn	Coming	to	Him?
Jong	Kuk	Kim
A	man	seeking	the	ultimate	truth	left	his	home	on	a	long	journey.	Finally	he	arrived	at	Scotland,	the	land	of
folktales.	 Could	 he	 find	 the	 legendary	 sword	 here?	He	 is	 trying	 to	 get	 answers	 to	 questions	 that	 have
troubled	him	for	many	years.
My	quest	began	when	I	was	a	young	resident	 in	neurology	training.	I	met	a	college	student	suffering
from	 acute	 onset	 dysarthria	 and	 dysphagia.	 There	was	 no	 evidence	 of	 other	 neurological	 symptoms	 or
signs,	but	he	had	had	an	upper	respiratory	tract	infection	(URI)	in	the	preceding	days.	All	investigations,
including	 a	 brain	 MRI,	 electrophysiology	 and	 blood	 work,	 including	 for	 acetylcholine	 receptor
antibodies,	 did	 not	 reveal	 the	 answer.	 I	 could	 do	 nothing	 for	 that	 young	 patient.	Although	 the	 patient’s
symptoms	improved	spontaneously	over	time,	a	question	still	remained.	What	was	the	true	cause	of	acute
dysphagia?
Time	 passed	 and	 I	 entered	 a	 fellowship	 training	 course	 in	 the	 neuromuscular	 division.	 I	 met	 3
consecutive	 cases	 with	 diplopia	 within	 2	 months.	 Two	 of	 them	 had	 preceding	 URIs.	 The	 interesting
features	 were	 that	 they	 all	 had	 asymmetric	 and	 incomplete	 bilateral	 oculomotor	 palsy	 with	 internal
ophthalmoplegia,	 without	 apparent	 gait	 disorders,	 falling	 or	 ataxia.	 “How	 should	 I	 conceive	 of	 and
differentiate	 this	kind	of	case	when	I	meet	 it?	What	can	I	do	for	 them?”	I	 thought.	A	test	for	anti-GQ1b
antibodies	was	strongly	positive	in	the	acute	phase	serum	in	all	these	patients	[1].	If	this	antibody	was	not
positive	 or	 even	 if	 we	 could	 not	 perform	 a	 study	 for	 this	 antibody,	 should	 we	 interpret	 this	 kind	 of
problem	as	a	variant	form	of	autoimmune	neuropathy?	What	if	we	did	not	know	whether	this	antibody	had
a	very	close	relationship	with	Miller	Fisher	syndrome	(MFS)	[2]?	If	so,	MFS	could	appear	with	various
features	other	 than	 the	 classical	 triad.	 In	 addition,	 the	 anti-GQ1b	antibody	 syndrome	can	manifest	with
various	features	overlapping	those	of	Guillain-Barré	syndrome	(GBS)	and	MFS	[3].
After	 several	 months,	 I	 met	 another	 interesting	 case,	 a	 22-year-old	 man	 suffering	 from	 acute
quadriparesis	after	several	days	of	diarrhoea.	There	was	apparent	evidence	of	peripheral	neuropathy	in
his	 nerve	 conduction	 study.	But	 in	 neurological	 examination	 his	muscle	 stretch	 reflex	was	 exacerbated
rather	 than	 depressed.	 I	 thought,	 “Can	 I	 regard	 this	 as	 a	 typical	 finding	 for	 GBS?”	 I	 decided	 to	 get
immunological	information.	I	asked	Professor	Susumu	Kusunoki,	who	was	the	first	to	find	the	significance
of	anti-GQ1b	antibody	in	MFS	when	the	serum	was	positive	for	auto-antibody	against	a	rare	ganglioside
GalNAc-GD1a.	I	learned	that	deep-tendon	reflex	can	be	preserved	or	exacerbated	in	some	types	of	GBS
with	positive	anti-ganglioside	antibodies	[4].	And	I	also	learned	that	this	hyperreflexia	is	mostly	found	in
an	acute	motor	axonal	neuropathy	subtype	of	GBS	in	Asia,	including	China	and	Japan	[5].	This	GalNAc-
GD1a	ganglioside	is	located	in	paranodal	axonal	membranes	and	appears	to	be	a	target	for	autoimmune
peripheral	neuropathy	[6].	But	the	result	of	electrophysiology	in	the	previous	case	was	curious.	Although
there	was	 conduction	block	 and	 abnormal	 temporal	 dispersion,	 including	prolonged	 terminal	 latencies,
motor	conduction	velocity	was	absolutely	normal.	Most	of	the	abnormal	findings	were	limited	to	motor
nerves	and	parameters	of	sensory	nerve	were	quite	normal.	Did	these	findings	represent	demyelinating	or
axonal	neuropathy?
Subsequently,	 I	 learned	 that	 interpreting	electrophysiological	 findings	 in	GBS	 is	complicated	by	 the
dynamic	 changes	 in	 these	 patients.	 Many	 neurologists	 in	 my	 home	 country	 thought	 that	 GBS	 mainly
damaged	 the	 peripheral	 nerve	 myelin.	 Finally	 I	 found	 that	 not	 all	 electrophysiological	 studies	 will
necessarily	reveal	the	correct	underlying	pathophysiological	mechanism.	Evidence	was	accumulating	that
some	of	the	patients’	real	problems	lay	in	the	peripheral	nerve	axon,	even	though	in	electrophysiological
studies	 they	 displayed	 the	 traditional	 features	 of	 demyelination	 [7].	 In	 addition,	 anti-ganglioside
antibodies	 showed	 apparent	 differences	 between	 GBS	 in	 Eastern	 and	 Western	 countries,	 and	 they
provided	the	critical,	determining	pathophysiology	[8].
What	was	the	situation	in	my	home	country?	Does	demyelinating	GBS	predominate	there,	as	it	does	in
Western	countries,	or	is	axonal	GBS	as	prevalent	in	Korea	as	it	is	in	China	and	Japan?	Until	that	time,	it
was	 a	 very	 confusing	 situation	 with	 2	 studies	 producing	 completely	 contradictory	 results	 [9,10].	 If
electrophysiological	classifications	cannot	determine	this,	it	would	be	better	to	find	the	presence	of	auto-
antibodies.	So	I	decided	to	get	some	additional	help	from	the	expert	of	a	neighbouring	country	and	visited
Professor	 Kusunoki’s	 laboratory,	 which	 had	 sera	 from	 many	 Korean	 GBS	 patients.	 We	 found	 very
interesting	results	from	the	analysis	of	anti-ganglioside	antibodies	and	clinical	information.	Various	kinds
of	anti-ganglioside	antibodies	were	positive	in	more	than	50%	of	Korean	GBS	patients,	and	the	patients
with	 positive	 antibodies	 associated	 with	 the	 axonal	 subtype	 were	 classified	 as	 having	 demyelinating
neuropathy	 according	 to	 electrophysiological	 criteria.	But	most	 of	 those	 exhibiting	 demyelinating	GBS
with	positive	antibodies	showed	pure	motor	presentation	with	conduction	block	and	normal	conduction
velocity.	This	meant	 that	 the	antibodies	could	determine	 the	underlying	pathophysiology	[11].	We	found
that	studying	the	anti-ganglioside	antibodies	was	essential	to	understanding	the	disease.
I	wondered	 how	many	 variant	 types	 of	GBS	 existed	 in	my	 home	 country.	What	 could	we	 learn	 by
finding	anti-ganglioside	antibodies	 from	 these	various	 types	of	GBS?	 In	MFS,	we	 identified	a	delayed
facial	 palsy	 [12].	 Even	 though	 it	 was	 rare,	 there	 was	 another	 variant	 of	 GBS	 presenting	 with	 facial
diplegia	without	 prominent	 limb	weakness.	These	 patients	 showed	minor	 changes	 in	 electrophysiology
with	 tingling	hands	and	negative	anti-ganglioside	antibodies	 [13].	 In	addition,	ophthalmoplegia	 in	GBS
was	more	closely	associated	with	anti-GT1a	antibodies	than	was	MFS	[11].	Finally,	there	was	a	group	of
patients	who	could	not	be	classified	as	a	representing	subtype	according	to	criteria.	They	apparently	had
a	 type	 of	GBS	with	 acute	 bulbar	 palsy	 accompanied	 by	 various	 degrees	 of	 ophthalmoplegia	 or	 ataxia
[14].	Anti-ganglioside	antibodies	would	be	 the	 important	clue	 to	diagnosis	 in	 these	unusual	variants	or
subtypes	of	GBS.
Figure	11.1		Korean	neurologists	participating	in	the	2014	Inflammatory	Neuropathy	Consortium	at	Düsseldorf
GBS	has	many	faces	in	my	home	country.	Can	we	make	an	accurate	diagnosis	if	we	use	only	limited
information	during	 assessment?	Recently,	 there	was	 an	 interesting	 article	 about	whether	U.S.	President
Roosevelt	suffered	from	poliomyelitis	or	GBS.	According	to	this	story,	he	was	frequently	misdiagnosed
as	 having	 poliomyelitis,	 despite	 a	 lack	 of	 firm	 evidence.	 Other	 evidence	 apparently	 showed	 that	 his
problem	was	closer	to	GBS	[15].	This	taught	me	that	we	have	to	use	as	much	information	as	possible	to
classify	and	understand	the	variations	of	GBS.	This	is	very	important	in	Asian	countries,	including	Korea
(figure	11.1).
Which	 criteria	 should	 we	 use	 for	 defining	 GBS?	 Are	 there	 any	 universal	 standards?	 How	 do
antibodies	contribute	to	our	diagnostic	search?	How	are	they	valuable	in	determining	the	various	forms	of
GBS	encountered	in	my	home	country?	Have	all	 the	important	antibodies	been	found,	and	if	not,	where
can	I	explore	more?	A	new	level	of	complexity	has	emerged	in	this	context:	Antigen/antibody	reaction	is
not	a	two-dimensional	picture	drawn	on	a	piece	of	paper	but	a	three-dimensional	interaction	existing	in
space,	and	in	a	variety	of	combinations	and	interactions	[16].	So	we	need	a	new	way	to	explore	this	more
complex	antibody-antigen	relationship	[17].	New	subsets	of	antibodies	 to	ganglioside-complex	may	yet
shed	light	on	the	pathophysiology	of	this	disease,	including	even	demyelinating	GBS.
Someday	we	may	have	a	more	complete	understanding	and	explanation	of	the	clinical	and	pathological
heterogeneity	of	GBS	in	my	home	country.	For	now,	I	am	walking	in	the	highlands	in	hope	of	a	new	dawn.
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The	Evolution	of	the	Diagnostic	Criteria	for	GBS
Christiaan	Fokke	and	Bart	C.	Jacobs
Introduction
The	Guillain-Barré	 syndrome	 (GBS)	 consists	 of	 a	 heterogeneous	 group	 or	 spectrum	 of	 acute	 immune-
mediated	 polyradiculoneuropathies.	 In	 classical	 textbook	 cases,	 a	 patient	 will	 present	 with	 ascending
bilateral	weakness	and	sensory	disturbances	of	 the	 legs	and	arms,	 in	a	proportion	combined	with	pain,
cranial	 and	 autonomic	 nerve	 involvement,	 or	 respiratory	 weakness.	 The	 rapid	 development	 of	 these
symptoms	combined	with	 a	 flaccid	paresis	 and	 reduced	 tendon	 reflexes	 at	 neurological	 examination	 in
absence	of	other	causes	will	usually	lead	to	the	early	diagnosis	of	GBS.	In	other	cases,	the	diagnosis	may
be	 less	 straightforward.	 Diagnosis	 in	 patients	 at	 the	 boarders	 of	 the	 GBS	 spectrum	 or	 with	 ‘overlap
syndromes’	may	 be	more	 challenging.	A	 continuous	 spectrum	 from	paraparetic	 to	 pharyngeal-cervical-
brachial	variant	is	recognized,	although	international	discussion	remains	whether	purely	sensory	deficits,
hyperreflexia	 or	 spinal	 cord	 involvement	 should	 be	 considered	 as	 a	 part	 of	 the	GBS	 spectrum.	 These
diagnostic	 dilemmas	 also	 apply	 to	 clinical	 overlap	 syndromes	 with	 Miller	 Fisher	 and	 Bickerstaff
encephalitis.	Another	 diagnostic	 dilemma	may	occur	 in	 the	 acute	 phase	when	 a	 specific	 symptom,	 like
pain,	 predominates	 or	 when	 it	 is	 less	 evident	 that	 causes	 other	 than	 GBS	 should	 be	 considered	 and
excluded.	Accurate	and	early	diagnosis,	however,	is	essential,	considering	that	patients	require	treatment
and	 monitoring	 to	 prevent	 life-threatening	 complications.	 In	 addition,	 proper	 diagnostic	 criteria	 are
required	to	conduct	therapeutic	trials	and	epidemiological	studies.
From	First	Case	Descriptions	to	Diagnostic	Criteria
Reports	of	progressive	numbness	and	weakness	over	a	short	period	exist	in	medical	literature	since	the
early	19th	century.	In	1859	Jean	Baptiste	Octave	Landry	was	the	first	to	describe	a	neurologic	condition
characterized	 by	 ascending	 motor	 paralysis	 with	 poor	 prognosis	 that	 he	 referred	 to	 as	 “ascending
paralysis”	[1].	One	hundred	years	ago,	2	soldiers	with	acute	areflexic	paralysis	and	raised	protein	levels
with	normal	cell	count	in	cerebrospinal	fluid	(CSF)	were	described	by	Georges	Guillain,	Jean-Alexander
Barré	and	André	Strohl	[2].	These	remarkable	CSF	findings	set	the	condition	apart	from	infectious	causes
of	 limb	 paralysis	 including	 syphilis,	 tuberculosis	 and	 poliomyelitis.	 Around	 40	 years	 later	 an	 unusual
variant	 of	 acute	 idiopathic	 polyneuritis	 with	 ophthalmoplegia,	 ataxia	 and	 areflexia	 was	 described	 by
Charles	Miller	Fisher	[3]	and	a	combination	with	hypersomnolence	by	Edwin	Robert	Bickerstaff	[4].
Table	12.1		Diagnostic	criteria	for	Guillain-Barré	syndrome	developed	by	the	NINDS	(based	on	the	criteria	set	forth	in	Asbury	and
Cornblath	[6])
The	question	about	accurate	criteria	for	the	diagnosis	became	apparent	after	the	swine	flu	vaccination
campaign	 of	 1976–1977	 when	 there	 was	 a	 suspected	 increase	 in	 the	 incidence	 of	 GBS	 after	 this
vaccination.	This	diagnostic	problem	led	 to	 the	 introduction	of	more	strictly	defined	diagnostic	criteria
for	 GBS	 in	 1978	 by	 the	 US	 National	 Institute	 Neurological	 Disorders	 and	 Stroke	 (NINDS)	 [5].	 The
criteria	 were	 reaffirmed	 in	 1990	 and	 are	 still	 the	 most	 widely	 used	 for	 GBS	 to	 date,	 especially	 in
scientific	 research	(Table	12.1)	 [6].	The	key	 features	 in	 these	 criteria	 are	 the	presence	of	 symmetrical
flaccid	weakness	and	decreased	reflexes	and	the	absence	of	alternative	causes.
Additional	attempt	has	been	made	 to	classify	GBS	patients	 into	different	subgroups,	 for	example	by
incorporating	 nerve	 conduction	 studies	 (NCS)	 and	 anti-ganglioside	 results	 [7].	 The	 Brighton
collaboration	developed	different	 levels	of	diagnostic	certainty	 in	order	 to	standardize	case	definitions
with	the	aim	of	improving	vaccine	safety	(Table	12.2)	[8].	Development	of	new	criteria	continued,	with
detailed	descriptions	of	the	different	subgroups	[9].	An	important	limitation	of	most	of	these	criteria	for
current	 clinical	 practice	 is	 that	 the	 monophasic	 course	 becomes	 evident	 after	 a	 follow-up	 of	 days	 to
months.	 In	 addition,	GBS	 has	 an	 extensive	 differential	 diagnosis	 but	 it	 remains	 unclear	 to	what	 extent
additional	tests	should	be	performed	in	the	acute	phase	to	exclude	other	causes.
Table	12.2		Brighton	criteria	and	case	definitions	for	GBS	(based	on	the	criteria	set	forth	in	Sejvar	et	al.	[8]	and	used	with
permission	from	Fokke	et	al.	[10]).	+	=	present,	−	=	absent,	+/−	=	present	or	absent.
Additional	Investigations
GBS	 is	 still	 considered	 to	 be	 a	 syndrome,	 because	 there	 are	 at	 present	 no	 diagnostic	 and	 pathogenic
markers	available	with	 sufficient	 sensitivity	and	specificity.	There	are,	however,	 several	 investigations
that	can	be	helpful	to	support	the	clinical	diagnosis.
Cerebrospinal	Fluid	Examination
The	original	publication	 from	1916	 suggested	 that	 an	albuminocytological	dissociation	 in	 the	CSF	 is	 a
typical	finding	for	GBS.	We	now	recognize	that	elevated	CSF	protein	levels	are	found	in	approximately	in
only	50%	of	patients	in	the	first	3	days	after	onset	of	weakness	[10].	This	is	usually	also	the	time	window
in	which	the	patient	presents	to	the	emergency	department	and	has	therefore	diagnostic	limitations.	More
important	is	the	investigation	of	the	number	of	cells	in	CSF,	especially	to	exclude	other	diagnoses.	A	mild
pleiocytosis	 is	found	in	15%	of	patients	with	GBS	and	doesn’t	exclude	the	diagnosis.	According	to	the
Asbury	and	Cornblath	criteria,	only	CSF	cell	counts	>	50	cells	per	μl	should	cast	doubt	on	the	diagnosis
of	GBS.
Anti-Ganglioside	Antibodies
Many	different	antibodies	 to	single,	or	combinations	of,	gangliosides	have	been	 identified	 in	 the	serum
from	 patients	 in	 the	 acute	 phase	 of	 GBS.	 In	 specific	 clinical	 situations,	 testing	 for	 some	 of	 these
antibodies	 may	 be	 helpful	 to	 finding	 support	 for	 a	 diagnosis	 of	 GBS.	 Up	 to	 now,	 the	 most	 clinically
relevant	 anti-ganglioside	 tests	 are	 for	 patients	 suspected	 of	 having	 MFS	 (anti-GQ1b)	 or	 acute	 motor
axonal	neuropathy	(AMAN)	(anti-GM1	and	anti-GD1a	IgG).	The	general	low	frequency	of	each	specific
antibody	in	other	patients	with	GBS	results	in	a	low	negative	predictive	value.	Moreover,	the	presence	of
anti-gangliosides	 could	 also	 occur	 in	 other	 diseases.	 Another	 disadvantage	 of	 using	 anti-ganglioside
serology	 for	 the	diagnosis	of	GBS	 is	 that	 a	 test	 result	may	only	occur	 at	 a	 later	 stage,	when	 important
clinical	decisions	about	monitoring	and	 treatment	have	already	been	 taken.	Research	 into	antibodies	 to
gangliosides	 and	other	 peripheral	 nerve	 targets,	 however,	 is	 rapidly	progressing,	 and	 faster	 techniques
supporting	more	sensitive	and	more	specific	tests	may	emerge	in	the	near	future.
Nerve	Conduction	Studies
NCS	 can	 help	 to	 support	 the	 clinical	 diagnosis	 of	 GBS	 and	 to	 discriminate	 between	 axonal	 and
demyelinating	 subtypes	 of	 GBS.	Unfortunately,	 there	 are	 2	 important	 diagnostic	 limitations	 of	 NCS	 in
GBS.	 First,	 GBS	 is	 also	 highly	 heterogeneous	 with	 respect	 to	 NCS	 findings	 and	 various	 criteria	 for
demyelination	and	axonal	degeneration	have	been	developed.	A	related	problem	is	that	in	the	acute	phase
of	the	disease	a	considerable	proportion	of	patients	with	GBS	present	with	abnormalities	in	NCS	but	do
not	fulfil	the	criteria	of	one	of	the	GBS	subtypes	[10].	Unfortunately,	there	are	no	criteria	to	support	the
diagnosis	of	GBS	in	general	nor	to	set	GBS	apart	from	other	peripheral	nerve	disorders.	Second,	GBS	is
a	 highly	 dynamic	 disorder	 in	 which	 the	 NCS	 findings	 may	 change	 significantly	 over	 time.	 The
classification	of	demyelinating	and	axonal	forms	of	GBS	based	on	the	NCS	may	change	during	the	disease
course	of	an	individual	patient.	The	NCS	abnormalities	in	most	patients	tend	to	peak	around	2	weeks	after
the	onset	of	weakness,	which	makes	this	test	unsuitable	in	the	majority	of	patients	in	the	acute	phase.
MRI	Scanning
This	 underappreciated	 diagnostic	 test	 in	 GBS	 is	 pointed	 out	 by	 the	 fact	 that	 the	 only	 prospective
evaluation	 of	MRI	 lumbosacral	 nerve	 root	 enhancement	 was	 performed	 20	 years	 ago.	 This	 relatively
small	study	in	24	consecutive	GBS	patients	showed	that	18	out	of	19	with	‘typical’	GBS	had	nerve	root
enhancement,	compared	with	2	of	5	with	a	variant	presentation	[11].
Interestingly,	no	relation	was	found	between	nerve	root	enhancement	and	the	timing	of	the	MRI	or	CSF
protein	level.	Whether	this	is	due	to	the	small	number	of	patients	or	the	possibility	that	MRI	nerve	root
enhancement	 is	an	additional	and	 independent	 factor	 is	not	clear	at	 this	point.	The	 importance	of	nerve
root	 enhancement	 is	 supported	 by	 the	 correlation	 with	 pain,	 GBS	 disability	 grade	 and	 duration	 of
recovery.	For	patients	with	a	variant	GBS	it	might	be	more	useful	to	image	the	clinically	relevant	area,
but	 it	 is	 essential	 that	 contrast	 is	 administered	 if	 the	 diagnosis	 is	 suspected,	 as	 noncontrast	 sequences
appear	essentially	normal.	The	increasing	availability	of	MRI	scans	and	the	ability	to	see	results	within	a
few	hours	make	this	a	potential	important	diagnostic	test	in	the	acute	phase.	It	has	the	possibility	to	show
a	positive	finding	suggestive	of	GBS	and	to	exclude	important	differential	diagnoses.
Future	Directions
Now	we	are	celebrating	the	100-year	anniversary	of	GBS,	although	we	doubt	whether	this	name	will	still
be	in	use	in	the	100	years	to	come.	As	soon	as	we	better	understand	the	pathogenesis	and	heterogeneity	of
GBS,	it	may	not	be	required	to	use	a	syndrome	diagnosis.	Instead,	GBS	may	be	replaced	by	more	specific
sets	 of	 diagnostic	 criteria	 for	 an	 acute	 monophasic	 immune-mediated	 disease.	 Regarding	 the	 future
diagnostic	criteria	for	this	spectrum	of	immune-mediated	neuropathies,	2	aspects	are	very	relevant.
First,	 the	 diagnostic	 criteria	 should	 be	 pragmatic	 and	 support	 the	 clinician	 at	 the	 emergency
department	confronted	with	a	patient	with	rapidly	progressive	symmetrical	limb	weakness.	These	criteria
should	be	a	combination	of	neurological	and	additional	investigations	of	which	results	are	available	on
the	 same	 day	 to	 prevent	 delay	 of	 treatment.	 If	 no	 ideal	 diagnostic	 biomarker	 becomes	 available,	 a
combination	of	major	and	minor	criteria	would	be	able	to	cover	the	extensive	variety	of	symptoms	within
this	clinical	spectrum.	Importantly,	diagnostic	criteria	also	provide	the	diagnostic	boundary	of	GBS	when
a	patient	doesn’t	 fulfil	 these	criteria	and	 the	clinician	 is	encouraged	 to	continue	 the	search	for	 the	right
diagnosis.
Improvement	 of	 these	 criteria	 could	 be	 achieved	 by	 incorporating	 additional	 investigations	 in	 the
future,	 for	example,	development	of	a	diagnostic	 test	which	screens	patient	 sera	 for	a	whole	battery	of
different	antibodies.	Also,	prospective	clinical	trials	should	include	MRI	data	of	clinical	relevant	areas
of	 patients	 and	 investigate	 the	 relation	 between	 nerve	 root	 enhancement	 and	 onset	 of	 symptoms.	 It	 is
possible	that	nerve	root	enhancement	on	MRI	with	normal	cell	count	in	CSF	might	be	very	specific	for	an
‘acute	 immune	mediated	neuropathy’.	Future	 investigation	 should	also	point	out	 the	diagnostic	value	of
biomarkers	and	ultrasound.
The	 second	 should	 be	 classification	 criteria,	 to	 divide	 the	 broad	 spectrum	 of	 GBS	 patients	 into
homogenous	groups.	Where	the	diagnostic	criteria	should	look	for	the	common	pathway	of	acute	immune
neuropathies,	the	classification	criteria	should	point	out	the	differences	in	this	clinical	spectrum.	These
different	 subgroups	 are	 not	 only	 formed	 by	 similarities	 regarding	 signs	 and	 symptoms	 but	 also	 by
retrospective	clinical	data,	like	disease	course.	Also,	different	additional	tests	could	be	incorporated	into
these	 classification	 criteria,	 for	 example	 NCS	 results	 or	 future	 biomarkers	 which	 may	 take	 days	 to
process.	 Currently,	 the	 aim	 of	 this	 classification	would	 be	mainly	 for	 research	 purposes,	 as	 treatment
regimens	 are	 still	 similar	 between	 all	 patients	 with	 an	 acute	 immune	 mediated	 neuropathy.	 However,
further	investigation	into	pathological	pathways	of	different	subtypes	could	provide	important	insight	and
might	result	in	specific	therapies	in	the	future.
Summary	and	Conclusions
One	 hundred	 years	 since	 Guillain,	 Barré	 and	 Strohl’s	 publication,	 the	 diagnosis	 of	 the	 GBS	 is	 still
challenging	 due	 to	 a	 broad	 clinical	 spectrum	 without	 specified	 boarders	 and	 the	 lack	 of	 specific
diagnostic	tests.	Future	investigations	should	provide	the	diagnostic	value	of	biomarkers,	ultrasound	and
especially	MRI	with	gadolinium.	One	option	 is	 to	develop	diagnostic	and	classification	criteria	for	 the
acute	 immune	mediated	neuropathy	by	 combining	major	 and	minor	 criteria	 consisting	of	 clinical	 signs,
symptoms	and	results	from	additional	investigations.
Key	Outstanding	Questions
What	are	the	clinical	boundaries	defining	the	full	GBS	spectrum,	compared	to	other	diseases?
What	are	the	common	pathological	pathways	in	the	GBS	spectrum	and	can	this	knowledge	be	used	for
diagnosis?
What	 is	 the	optimal	and	most	cost-effective	diagnostic	workup	 in	 individual	patients	 to	confirm	 the
GBS	diagnosis	and	exclude	other	diagnoses?
What	is	a	better	name	for	this	disorder	than	Guillain-Barré	syndrome?
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Miller	Fisher	Syndrome
Atsuro	Chiba
Introduction
Miller	 Fisher	 syndrome	 (MFS)	 has	 attracted	 the	 interest	 of	 many	 neurologists	 because	 of	 its	 unique
combination	of	core	manifestations—ophthalmoplegia,	ataxia,	and	areflexia—that	do	not	initially	appear
to	be	easily	linked.	The	pathological	mechanisms	and	the	nosology	of	the	syndrome	had	been	discussed
for	several	decades,	but	the	arguments	lacked	a	cornerstone—a	disease-specific	biomarker.	Along	with
the	progression	of	research	on	anti-glycolipid	antibodies	related	to	Guillain-Barré	syndrome	(GBS),	an
IgG	antibody	against	ganglioside	GQ1b	was	discovered	 in	MFS.	 In	 this	 top-10	 story,	many	papers	are
from	Japan,	perhaps	because	Japanese	research	groups	have	some	advantages	in	this	field:	a	fairly	high
incidence	of	MFS	in	Japan	compared	with	other	countries	(27%	of	all	GBS	cases	 including	MFS	[1]),
and	 a	 long	 history	 of	 research	 into	 nervous	 system	 glycolipids	 originating	 from	 professor	 Tamio
Yamakawa’s	laboratory	at	the	University	of	Tokyo.
The	Origin	of	the	Story
Fisher	M.	An	unusual	variant	of	acute	idiopathic	polyneuritis	(syndrome	of
ophthalmoplegia,	ataxia	and	areflexia).	The	New	England	Journal	of	Medicine,	1956
There	is	an	aphorism	in	clinical	research	called	the	‘three-case	rule’	in	the	neurological	department	of	my
alma	mater:	‘Note	the	first	case	in	your	mind,	suspect	a	trend	after	the	second,	and	believe	after	the	third’.
Fisher’s	penetrating	original	paper	[2]	embodies	 this	rule.	He	had	met	2	patients	within	a	few	years	of
each	 other	 in	 the	 early	 1950s,	 and	might	 have	 been	waiting	 for	 the	 third	 one,	 the	Case	 1	 in	 the	 ‘Case
Reports’,	who	was	fully	studied	in	Massachusetts	General	Hospital	(MGH)	and	must	have	prompted	him
to	 this	paper	finally.	Fisher	seemed	to	already	have	some	idea	even	 in	 the	first	patient	 (the	Case	3),	 in
whom	 “although	 no	 diagnosis	 was	 made,	 a	 rise	 in	 the	 cerebrospinal-fluid	 protein	 was	 looked	 for”
because	 of	 polyneuropathic	 symptoms,	 the	 numbness	 of	 the	 fingers	 and	 areflexia.	 Albuminocytologic
dissociation,	 however,	 was	 not	 detected	 in	 a	 lumber	 tap	 at	 the	 end	 of	 6	weeks.	 The	 detailed	 clinical
information	on	the	second	patient	(the	Case	2)	came	from	a	hospital	file.	He	saw	this	patient	because	of
an	 unrelated	matter,	 and	 the	 patient	 recounted	 a	 past	 history	 of	 total	 ophthalmoplegia.	One	of	 the	most
important	 points	 that	 made	 him	 conclude	 that	 this	 syndrome	 was	 a	 variant	 of	 GBS,	 would	 be	 the
albuminocytological	dissociation	 in	 the	 cerebrospinal	 fluid,	 and	 this	was	 eventually	 detected	 from	 the
serial	spinal	tap	in	the	third	patient	at	MGH.	The	biochemical	feature	common	to	GBS	might	be	needed
for	 the	conclusion.	 Interestingly,	 episodes	of	 an	antecedent	 infection,	which	 is	now	 in	 the	centre	of	 the
pathogenesis	of	GBS	and	MFS,	were	not	so	emphasized.
This	 paper	 established	 the	 concept	 of	 the	 syndrome	 almost	 by	 itself.	 Atypical	 features	 obviously
attributed	to	the	central	nervous	system	(CNS)	were	also	described,	such	as	changes	in	arousal	level	and
a	preserved	Bell’s	phenomenon	in	a	state	of	total	external	ophthalmoplegia,	implying	the	true	extent	of	the
disorder.	Despite	 these	 and	 other	 features	 that	 could	 not	 be	 easily	 attributed	 to	 peripheral	 lesions,	 his
reluctant	conclusion	with	respect	to	the	core	manifestations	was	a	variant	of	GBS	with	“an	unusual	and
unique	 disturbance	 of	 peripheral	 neurons”.	 This	 conclusion	 might	 be	 owed	 to	 Fisher’s	 career	 in
cerebrovascular	disease.	Before	Fisher,	patients	with	 this	 syndrome	could	have	been	 thought	 to	have	a
stroke	in	the	brainstem,	but	as	a	leading	stroke	neurologist,	he	would	not	be	able	to	agree	with	this	idea.
Every	phenomenon	has	a	cause.	To	answer	riddles,	we	first	have	to	notice	their	presence.
Disease-Specific	Biomarker,	IgG	Anti-GQ1b	Antibody
Chiba	A,	et	al.	Serum	anti-GQ1b	IgG	antibody	is	associated	with	ophthalmoplegia	in	Miller
Fisher	syndrome	and	Guillain-Barré	syndrome:	clinical	and	immunohistochemical	studies.
Neurology,	1993
IgG	 anti-GQ1b	 antibody	 in	 MFS	 was	 first	 reported	 in	 1992	 [3].	 This	 antibody	 was	 identified	 in	 a
deductive	 screening	 approach.	 In	 the	 context	 of	 this	 research	 field,	 where	 Ilyas	 and	 colleagues	 first
reported	 anti-ganglioside	 antibodies	 in	 GBS	 in	 1988	 [4],	 it	 would	 be	 a	 matter	 of	 time	 before	 this
discovery,	and	the	antibody	was	soon	reported	independently	[5,6].	This	paper	in	Neurology	in	1993	[7]
demonstrated	 a	 possible	 relation	 between	 the	 antibody	 and	 ophthalmoplegia,	 one	 of	 the	 core
manifestations	in	MFS,	from	clinical,	immunohistochemical	and	biochemical	aspects.	Molecular	mimicry
theory,	the	core	theory	for	GBS	pathogenesis,	consists	of	2	parts:	(A)	antigenic	epitopes	on	the	agents	of
antecedent	infections	induce	antibodies	that	cross-react	with	antigens	that	mimic	molecular	structures	in
nervous	tissues;	and	(B)	the	localization	of	the	tissue	antigens	defines	the	clinical	features.	The	first	part
was	 demonstrated	 by	 the	 combination	 of	Campylobacter	 jejuni,	 anti-GM1	 antibody	 and	 acute	 motor
axonal	 neuropathy.	The	 story	of	MFS	and	GQ1b—a	high	positive	 rate	 of	 the	 antibody	 and	 consistency
between	 clinical	 findings	 and	 specific	 antigen	 distribution—is	 a	 good	 example	 of	 the	 second	 part.
Clinically,	IgG	anti-GQ1b	antibody	is	tightly	associated	with	acute	ophthalmoplegia	following	infectious
episodes:	MFS,	GBS	with	ophthalmoplegia,	and	acute	ophthalmoplegia	without	ataxia,	which	could	be	a
mild	 or	 incomplete	 form	 of	 MFS.	 Histochemically,	 GQ1b	 antigen	 accumulates	 specifically	 in	 the
paranodal	region	of	the	3	cranial	nerves	(oculomotor,	trochlear	and	abducens).	Biochemically,	the	amount
of	ganglioside	GQ1b	in	these	3	nerves	is	significantly	higher	than	in	the	other	cranial	nerves	or	peripheral
nervous	 tissues,	 except	 for	 the	 optic	 nerve	 [8].	 However,	 whether	 the	 antibody	 could	 physiologically
affect	nerve	conduction	was	still	unknown	at	this	point.
Ataxia	and	Areflexia
Kuwabara	S,	et	al.	Special	sensory	ataxia	in	Miller	Fisher	syndrome	detected	by	postural
body	sway	analysis.	Annals	of	Neurology,	1999
MFS	must	have	disclosed	a	special,	previously	unknown	type	of	ataxia.	Although	Fisher	described	it	as
cerebellar	in	type,	he	also	pointed	out	the	absence	of	‘cerebellar	speech’	even	in	severely	ataxic	cases.	In
his	original	description	he	speculated	on	an	alternate	cause,	saying	that	“if	the	cerebellar	system	is	not	to
be	 incriminated	 one	 must	 postulate	 that	 in	 the	 syndrome	 herein	 discussed,	 a	 unique,	 widespread	 and
selective	attack	on	the	sensory	neurons	underlying	postural	adjustment	must	be	occurring”.	An	abnormal
H-reflex	with	preserved	motor	conduction	was	reported,	suggesting	an	abnormality	in	1a	afferent	fibres
from	the	muscle	spindle	and	a	dysfunction	in	proprioception	[9,10].	Kuwabara	and	colleagues	performed
comprehensive	physiological	studies,	 including	analysis	of	 the	nature	of	 the	posture	 instability	 itself	by
body-sway	analysis,	and	concluded	that	the	condition	was	a	type	of	sensory	ataxia	probably	caused	by	the
selective	involvement	of	group	1a	muscle-spindle	afferents	[11].	Thus,	sensory	ataxia	with	a	preserved
sense	of	joint	position	is	what	makes	ataxia	in	MFS	unique.	This	can	also	explain	areflexia	in	MFS	in	a
manner	different	from	that	in	GBS,	in	which	areflexia	could	result	from	a	malfunction	of	1a	efferents.
Liu	IX.	Immunolocalization	of	GQ1b	and	related	gangliosides	in	human	extraocular
neuromuscular	junctions	and	muscle	spindles.	Investigative	Ophthalmology	and	Visual
Science,	2009
The	question	then	arises	as	to	where	anti-GQ1b	antibodies	might	bind	and	exert	their	pathological	effects
in	 human	 tissue.	 Considering	 the	 consistent	 combination	 of	 the	 triad	 in	 typical	MFS,	 it	 is	 simple	 and
natural	 to	 suppose	 that	 the	 antibody	 is	 related	 to	 each	 of	 them.	 Liu	 and	 colleagues	 used
immunohistochemistry	to	localize	the	epitopes	in	human	tissues,	focusing	especially	on	the	neuromuscular
junction	(NMJ)	and	the	muscle	spindles	[12].	Their	study	revealed	that	the	GQ1b/GT1a	epitope	was	more
richly	localized	in	the	NMJs	of	the	extraocular	muscles	(EOMs)	than	in	those	of	limb	muscles,	in	which
the	NMJs	were	rarely	stained.	This	finding	is	consistent	with	the	preferential	involvement	of	EOMs	and
with	a	study	of	single-fibre	electromyography	showing	that	transmission	at	neuromuscular	junctions	in	the
limbs	was	usually	unaffected	in	MFS	[13].	Liu	also	detected	the	GQ1b/GT1a	epitope	on	the	surface	of
individual	 intrafusal	 fibres	 of	 limb-muscle	 spindles	 at	 the	 equatorial	 region,	where	 abundant	 group	 1a
sensory	terminals	wrap	around	the	fibres.	This	observation	supports	the	involvement	of	group	1a	afferents
from	 the	 muscle	 spindles	 in	 ataxia	 and	 areflexia.	 This	 immunohistochemical	 study	 also	 revealed	 that
GD1b	 and	GQ1b/GT1a	were	 localized	 similarly,	 but	 that	 anti-GD1b	 antibody	 is	 not	 usually	 linked	 to
MFS.	Thus,	 other	 factors	would	be	 necessary	 for	 anti-GQ1b	 antibody	 to	 exert	 its	 pathogenic	 effect	 on
these	regions.
Pathological	Effect	of	Anti-GQ1b	Antibody
Halstead	SK,	et	al.	Anti-disialoside	antibodies	kill	perisynaptic	Schwann	cells	and	damage
motor	nerve	terminals	via	membrane	attack	complex	in	a	murine	model	of	neuropathy.
Brain,	2004
It	is	always	possible	that	autoantibodies,	including	anti-ganglioside	antibodies,	could	be	epiphenomena	or
secondary	to	tissue	injury.	To	rebut	this	possibility	in	a	clinical	setting,	detection	of	the	antibodies	before
onset	would	be	helpful,	especially	for	ruling	out	secondary	responses	to	injury.	Actually,	IgG	anti-GQ1b
antibody	was	also	detected	before	neurological	onset	of	MFS	in	patients	whose	sera	were	obtained	in	that
period	by	chance.	Although	a	more	effective	way	is	with	an	animal	model,	my	personal	search	in	many
animals,	 including	 up	 to	 crab-eating	 macaque,	 has	 failed	 to	 find	 an	 animal	 that	 expresses	 the	 GQ1b
epitope	in	the	ocular	motor	nerves	as	it	is	in	humans.	Willison’s	research	group	has	extensively	studied
the	 pathological	 effects	 of	 patient	 sera,	 their	 IgG	 fractions	 and	monoclonal	 antibodies	 (mAbs)	 against
GQ1b	using	an	ex-vivo	mouse	hemidiaphragm	preparation	[14].	Their	series	of	works	has	demonstrated:
(A)	patients’	 sera,	patients’	 IgG	and	 the	mAbs	cause	neuromuscular	block;	 (B)	 the	blocking	effect	was
complement-dependent	 and	 α-Latrotoxin-like;	 (C)	 the	 disialylgalactose	 epitope	 common	 to	 GQ1b	 is
expressed	in	the	NMJs	and	perisynaptic	Schwann	cells;	(D)	mAbs	destroyed	presynaptic	structure—both
nerve	terminals	and	perisynaptic	Schwann	cells,	with	deposition	of	a	membrane-attack	complex;	and	(E)
passive	transfer	of	mAbs	also	caused	morphological	change	in	NMJs.	These	findings	could	not	be	simply
expanded	 to	 the	 human	 disease,	 but	 the	 GQ1b-antigen	 was	 also	 detected	 in	 the	 NMJ	 of	 the	 human
extraocular	muscles	[12].	Neuromuscular	transmission	has	been	studied	in	MFS	patients	using	single	fibre
electromyography,	 but	 the	 results	 are	 contradictory.	 While	 Kuwabara	 and	 colleagues	 did	 not	 detect
transmission	defects	in	limb	muscles	[13],	Lo	and	colleagues	detected	those	in	the	orbicularis	oculi	[15].
This	disagreement	might	result	from	the	different	muscles	that	were	examined.
Clinical	Features	and	Related	Conditions
Mori	M,	et	al.	Neurology,	2001
Mori	and	colleagues	conducted	a	retrospective	clinical	analysis	of	50	consecutive	patients	with	typical
MFS	 in	Japan	 [16].	This	 remains	 the	 largest	case	series	 from	a	single	centre	so	 far	and	has	drawn	 the
clinical	 features	 of	 the	 syndrome	 representatively.	Table	13.1	 shows	 the	 specifications	 for	 the	 disease
described	in	their	paper.	Mori	and	colleagues	also	reported	the	effect	of	IVIg	and	plasmapheresis	in	MFS
patients,	showing	that	these	therapies	only	provided	limited	benefits	[17].
Yuki	N,	et	al.	An	immunologic	abnormality	common	to	Bickerstaff’s	brain	stem	encephalitis
and	Fisher’s	syndrome.	Journal	of	Neurological	Science,	1993
An	 ongoing	 debate	 is	 the	 nosological	 position	 of	MFS:	 is	 it	 a	 variant	 of	GBS	 or	 a	 kind	 of	 brainstem
encephalitis—the	 so-called	Bickerstaff	 brainstem	 encephalitis	 (BBE)?	 There	 have	 been	 2	 fundamental
limitations	contributing	to	this	debate.	One	was	that	pathophysiological	homogeneity	of	the	cohorts	could
not	be	determined	without	knowing	the	biomarkers	 involved	in	pathogenesis,	and	the	other	was	that,	as
shown	in	Fisher’s	original	paper,	MFS	itself	could	manifest	some	CNS	symptoms.	When	the	anti-GQ1b
antibody	was	 discovered,	 it	 appeared	 to	 be	 an	 attractive	 biomarker	 that	 could	 be	 used	 to	 answer	 the
debate.	 Yuki	 detected	 the	 antibody	 in	 all	 3	 patients	 diagnosed	 as	 BBE	 and	 revealed	 the	 common
immunological	features	in	MFS	and	BBE	[18].	His	research	group	then	increased	the	number	of	patients
to	53	BBE	and	466	MFS	patients,	and,	several	years	later,	compared	clinical,	serological,	radiological
and	 physiological	 features	 [19].	 Interesting	 observations	 in	 this	 study	 regarded	 the	 loss	 of	 soleus	 H-
reflexes	and	the	detection	of	1-Hz	power-spectrum	peak	on	the	postural	body-sway	analysis,	which	both
suggest	 dysfunction	 in	1a	 fibres.	These	were	 found	 in	 about	 70%	of	both	BBE	and	MFS	cases.	While
some	 patients	 with	 MFS	 do	 indeed	 show	 CNS	 signs,	 the	 majority	 of	 those	 diagnosed	 as	 BBE	 have
peripheral	features.	It	would	be	natural	to	suppose	that	BBE,	which	has	a	common	immunopathological
biomarker	with	MFS,	is	an	atypical	form	of	MFS	with	prominent	CNS	signs.
Koga	M,	et	al.	Nationwide	survey	of	patients	in	Japan	with	Bickerstaff	brainstem
encephalitis:	epidemiological	and	clinical	characteristics.	Journal	of	Neurology,
Neurosurgery	and	Psychiatry,	2012
To	 have	 an	 effective	 discussion	 about	 the	 relationship	 between	MFS	 and	 BBE,	we	 have	 to	 know	 the
makeup	of	the	groups	in	question.	A	Japanese	nationwide	survey	on	BBE	has	given	a	suggestion	regarding
this	 point	 [20].	 It	 revealed	 that	 BBE	 patients	with	 atypical	 neurological	 findings	 or	without	 IgG	 anti-
GQ1b	antibodies	had	features	different	from	those	with	typical	neurological	findings	with	the	antibodies.
Atypical	symptoms	were	linked	to	longer	duration	from	onset	to	nadir,	slower	recovery,	higher	frequency
of	 brain	 MRI	 abnormality,	 and	 increased	 protein	 concentration	 and	 marked	 pleocytosis	 in	 CSF.	 This
suggests	 that	BBE	 is	heterogeneous	 in	 terms	of	 the	pathomechanism.	BBE	patients	with	 IgG	anti-GQ1b
antibodies	could	be	the	true	variant	of	MFS,	and	BBE	without	the	antibody	may	be	the	true	‘-itis’	in	the
brainstem.
What	controls	whether	MFS	manifests	with	or	without	CNS	signs?	One	candidate	is	a	serum	factor	in
BBE	patients	that	increases	the	permeability	of	the	blood-brain	barrier	and	is	accompanied	by	autocrine
secretion	of	matrix	metalloproteinase-9	[21].	Research	in	this	direction	might	provide	new	methods	for
treatment	 other	 than	 those	 related	 to	 antibodies,	 especially	 in	 severe	 cases	 with	 profound	 CNS
manifestations.
Table	13.2	is	my	personal	arrangement	of	MFS-related	conditions.	They	are	divided	into	3	categories:
typical	 MFS	 (the	 prototype	 of	 these	 conditions);	 MFS-minus,	 in	 which	 ataxia	 or	 ophthalmoplegia	 is
absent	 throughout	 the	entire	clinical	 course	 (acute	ophthalmoplegia	and	acute	ataxia,	 respectively);	 and
MFS-plus,	in	which	motor	weakness	in	the	spinal	nerve	areas	or	CNS	symptoms	are	present	(GBS	with
ophthalmoplegia	and	BBE,	respectively).
Table	13.1		Epidemiological	and	clinical	features,	and	natural	prognosis	of	Miller	Fisher	syndrome	(modified	with	permission	from
Mori	et	al.,	2001	[16]).	Values	in	parentheses	are	ranges,	and	values	before	the	parentheses	are	medians.	a:	number	of	patients
examined;	b:	Yr	=	years,	Dy	=	days,	Mo	=	months;	c:	period	between	antecedent	infection	and	neurological	onset;	d:	these
include	dysesthesia	in	the	limb,	blepharoptosis	and	photophobia;	e:	gait	ability	in	the	Hughes	functional	grading	scale;	f:
symptoms	are	not	explained	by	or	dissociated	from	peripheral	disability;	g:	observation	in	patients	without	any	immunomodulatory
therapies;	h:	Op	=	ophthalmoplegia,	Ax	=	ataxia,	DTR	=	hyporeflexia
Table	13.2		Miller	Fisher	syndrome-related	conditions.
Antecedent	Infections	and	Antibody	Production
Koga	M,	et	al.	Antecedent	infections	in	Fisher	syndrome:	a	common	pathogenesis	of
molecular	mimicry.	Neurology,	2005
One	 patient	 in	 Fisher’s	 original	 paper	 developed	 the	 syndrome	 following	 pneumonia,	which	 probably
resulted	 from	 Haemophilus	 influenzae.	 This	 short	 but	 faithful	 description	 attracted	 the	 attention	 of
researchers	to	this	gram-negative	organism	in	the	respiratory	tract,	especially	after	the	historical	success
of	 molecular	 mimicry	 theory	 in	 the	 case	 of	 Campylobacter	 jejuni.	 Koga	 and	 colleagues	 performed
comprehensive	 studies	on	 antecedent	 infection	 in	MFS	and	 found	 serologically	 significant	 associations
between	the	disease	and	both	H.	influenzae	and	C.	jejuni	[22].	C.	jejuni	strains	isolated	from	MFS	were
significantly	associated	with	the	GQ1b	epitope	when	detected	using	antibodies,	and	biochemical	analyses
identified	a	possible	GT1a-mimicking	 tri-sialosyl	oligosaccharide	 structure	 in	 the	 lipooligosaccharides
(LOSs).	As	 for	H.	 influenzae,	 epitopes	 recognized	with	 anti-GQ1b	antibody	were	 also	detected	 in	 the
LOSs	extracted	from	clinical	isolates	of	MFS	patients.	Finally,	in	an	H.	influenzae	strain	isolated	from	an
MFS	patient,	Houliston	 and	 co-workers	biochemically	 identified	 a	novel	 disialosyl	 galactose	 structure
that	 is	 common	 to	 the	 nonreducing	 terminals	 of	 GQ1b	 and	GT1a	 [23].	 Although	 antecedent	 infectious
agents	have	not	been	identified	in	the	majority	of	MFS	patients,	the	molecular	mimicry	theory	could	also
be	applicable	in	MFS	related	to	both	C.	jejuni	and	H.	influenzae.
Heikema	P,	et	al.	Siglec-7	specifically	recognizes	Campylobacter	jejuni	strains	associated
with	oculomotor	weakness	in	Guillain-Barré	syndrome	and	Miller	Fisher	syndrome.	Clinical
Microbiology	and	Infection,	2013
Although	 tetra-sialosyl	 oligosaccharide	 structures	 in	 LOS	 that	 exactly	 mimic	 GQ1b	 have	 not	 been
identified,	 immunization	 of	 animals	with	 the	GT1a-mimicking	 LOS	 from	C.	 jejuni	 has	 been	 shown	 to
induce	 antibodies	 that	 react	 with	 both	 GQ1b	 and	 GT1a	 [24].	 In	 the	 human	 disease,	 those	 mimicking
molecules	 could	 induce	 anti-GQ1b/GT1a	 antibodies.	A	 group	 of	 I-type	 lectins	 primarily	 expressed	 on
hematopoietic	 cells—sialic	 acid-binding	 Ig-like	 lectins,	 or	 ‘siglecs’—are	 candidate	 molecules	 for
recognizing	sialylated	oligosaccharide	antigen.	Fifteen	siglecs	have	been	identified	in	humans,	and	each
member	is	unique	in	terms	of	expressed	cell	and	ligand	specificity.	Among	them,	siglec-7	strongly	binds
to	GT1a-mimic-bearing	LOS	from	C.	jejuni,	and	binding	to	disialo-oligosaccharide,	especially	the	α2–8
linkage,	causes	its	conformation	to	shift	dramatically	[25,26].	In	a	study	using	clinical	material,	Heikema
and	colleagues	showed	that	binding	between	siglec-7	and	C.	jejuni	LOS	(clinical	isolates	from	GBS	and
MFS	patients)	was	significantly	higher	in	the	patient	group	with	anti-GQ1b	[27].	This	finding	would	give
one	molecular	part	linking	between	the	antigens	on	the	pathogens	and	the	antibody	in	the	patients.	Siglec-7
expressed	on	monocyte-macrophages	could	bind	to	C.	jejuni	with	disialylated	LOS,	process	 it,	give	an
antigen-presentation,	and	induce	production	of	the	antibody	against	terminal	α2–8	disialylated	residues.
The	next	question	must	be	whether	polymorphisms	of	siglec-7	can	affect	anti-GQ1b	antibody	production
and	MFS,	as	has	been	reported	in	other	disorders	[28].
Key	Outstanding	Questions
1.	 What	are	the	pathogens	of	antecedent	infections	other	than	H.	influenzae	and	C.	jejuni?
2.	 How	do	the	pathogens	induce	the	antibody	production?
3.	 What	 are	 the	 immunological	 pathogenic	 factors	 in	 sero-negative	 cases,	 in	 whom	 anti-GQ1b/GT1a
antibodies	are	not	detected?
4.	 What	 is	 the	 difference	 in	 clinical	 phenotype,	 especially	 between	MFS	 and	 the	MFS-plus	 (BBE	or
GBS	with	ophthalmoplegia)?
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Axonal	Guillain-Barré	Syndrome
Thomas	E.	Feasby
Introduction
Guillain-Barré	 syndrome	 (GBS)	was	 thought	 of	 as	 the	 classic	 demyelinating	 disease	 of	 the	 peripheral
nervous	system	(PNS).	I	was	drawn	to	it	by	my	interest	in	demyelination	and	in	particular	by	my	interest
in	the	physiology	of	demyelination.	I	had	investigated	the	nature	of	nerve	conduction	in	regenerating	nerve
fibres	 in	 the	 laboratory	of	Professor	Tom	Sears	at	Queen	Square,	UK	and	observed	 the	 transition	 from
continuous	 to	 saltatory	 conduction	 in	 these	 fibres	 as	 they	 became	 myelinated.	 I	 published	 work	 on
conduction	 block	 in	 demyelinating	 GBS	 with	 my	 colleague	 Bill	 Brown.	 With	 my	 colleagues,	 I	 had
investigated	 passive	 transfer	 models	 of	 demyelination	 using	 both	 rabbit	 anti-galactocerebroside
antibodies	and	rat	T	cells.	 I	was	 thus	startled	when	I	came	upon	a	patient	with	GBS	who	didn’t	 fit	 the
model	of	demyelination	but	rather	turned	out	to	have	an	axonal	form	of	GBS.	Publication	of	this	work	was
controversial	 and	 began	 a	 10-year	 debate	 about	 this	 new	 concept	 which	 ultimately	 resulted	 in	 its
validation.
Background
The	pathology	of	GBS	has	been	discerned	over	the	years	through	the	lens	of	the	microscope	and	through
electrophysiological	recordings	of	responses	to	nerve	stimulation.	The	former	has	the	advantage	of	direct
observation	but	 the	 limitation	of	being	a	snapshot	 in	 time.	The	 latter	allows	 repeated	observations	but,
limited	by	its	indirect	nature,	requires	inferences.
The	 first	 major	 pathological	 study	 of	 GBS,	 by	 Haymaker	 and	 Kernohan	 [1],	 examined	 the	 central
nervous	system	and	the	nerve	roots,	but	not	the	peripheral	nerves,	in	50	autopsied	cases.	They	described
oedema	 in	 the	 nerve	 roots	 and	 adjacent	 spinal	 nerves	 and	 infiltration	 of	 lymphocytes	 and	 phagocytes,
which	 they	 thought	might	 be	 secondary.	They	 saw	demyelination	 and	what	 they	 thought	was	 secondary
axonal	degeneration.	In	their	last	case,	of	a	patient	who	died	after	46	days,	the	axonal	degeneration	was
very	 severe	 so	 that	 “by	 Bodian	 activated	 silver	 method,	 not	 a	 single	 normal	 axis	 cylinder	 was
encountered”.	Was	this	perhaps	a	case	of	‘axonal’	GBS?
Twenty	years	later,	Asbury,	Arnason	and	Adams	[2]	described	autopsy	results	in	19	GBS	cases.	Their
most	important	observation	was	the	lymphocytic	infiltration,	sometimes	very	extensive,	seen	in	all	cases,
including	 those	 at	 early	 stages	 of	 their	 illness.	 They	 observed	 demyelination	 of	 varying	 degrees	 in	 all
cases	as	well	as	axonal	injury/degeneration	in	most.	They	noted	that	“axonal	interruption	and	consequent
Wallerian	degeneration	was	observed	frequently,	most	commonly	and	to	a	more	marked	degree	in	cases
with	 the	 more	 intense	 inflammatory	 changes”.	 Like	 Haymaker	 and	 Kernohan,	 they	 considered	 axonal
degeneration	to	be	secondary,	but	in	their	case,	secondary	to	the	inflammation.
Waksman	and	Adams	[3]	described	experimental	allergic	neuritis	(EAN),	the	first	experimental	model
for	GBS	which	 they	 induced	 by	 immunization	 of	 rabbits	with	 sciatic	 nerve	 tissue	 plus	 adjuvants.	This
model	mimicked	human	GBS	and	was	analogous	to	experimental	allergic	encephalomyelitis	(EAE),	 the
experimental	 model	 of	 multiple	 sclerosis.	 They	 observed	 intense	 lymphocyte	 and	 mononuclear	 cell
inflammation,	 widespread	 demyelination	 and	 lesser	 degrees	 of	 axonal	 degeneration,	 again	 presumably
secondary.
Many	electrophysiological	studies	of	GBS,	by	McLeod	[4]	and	others,	have	detected	typical	signs	of
demyelination,	 including	 slowed	 conduction	 velocities,	 temporal	 dispersion	 of	 the	 compound	 muscle
action	potential	evoked	by	nerve	stimulation	and	delayed	‘F’	 responses.	 In	1984,	Bill	Brown	and	I	 [5]
described	the	significance	of	widespread	conduction	block	secondary	to	demyelination	as	the	major	cause
of	 acute	 weakness	 in	 most	 GBS	 patients.	 We	 also	 pointed	 out	 the	 common	 occurrence	 of	 axonal
degeneration	and	noted	 its	 role	 in	 the	residual	weakness	and	 limited	recovery	 in	some	patients.	At	 that
point	 we	 were	 unaware	 of	 the	 phenomenon	 of	 axonal	 degeneration	 occurring	 in	 the	 absence	 of
demyelination.
Axonal	Guillain-Barré	Syndrome
In	1985,	I	cared	for	a	64-year-old	woman	who,	2	weeks	after	a	bout	of	diarrhoea,	had	a	very	rapid	onset
of	 severe	GBS	 so	 that	 she	was	 quadriplegic	with	marked	 cranial	 nerve	 abnormalities	 and	 respiratory
failure	within	36	hours.	She	had	minor	sensory	findings.	Electrophysiological	studies	done	by	Bill	Brown
showed	 inexcitable	 motor	 nerves,	 a	 very	 unusual	 finding.	 She	 showed	 no	 improvement,	 developed
autonomic	instability	and	died	at	day	28	after	a	cardiac	arrest.
Joe	 Gilbert	 and	 I	 carried	 out	 an	 autopsy	 within	 hours	 of	 her	 death,	 on	 a	 Sunday,	 sampling	 the
peripheral	 nervous	 system	very	 extensively.	We	 found	widespread	 severe	 axonal	 degeneration	on	 light
microscopy	 from	 the	 nerve	 roots	 to	 the	 periphery,	 unaccompanied	 by	 evidence	 of	 demyelination	 or
lymphocytic	 inflammation.	This	was	confirmed	by	 teased	 fibre	 studies	and	electron	microscopy,	where
we	also	found	evidence	of	unmyelinated	fibre	loss.	My	colleagues	and	I	cared	for	4	more	very	acute	GBS
patients	who	also	had	 inexcitable	motor	nerves.	Three	of	 these	patients	had	very	 slow	and	 incomplete
recoveries.	We	had	much	internal	discussion	about	 the	meaning	of	 these	observations.	I	well	remember
debate	with	Charlie	Bolton,	who	was	concerned	that	the	one	case	with	reasonable	recovery,	his	patient,
didn’t	fit	and	might	have	had	AIDS.	Fortunately,	we	kept	that	case	in	the	series	and	Charlie	remained	a
co-author.
We	were	 convinced	 that	we	 had	 seen	 something	 new,	 and	we	 submitted	 an	 abstract	 describing	 our
findings	 for	 presentation	 at	 the	American	Academy	of	Neurology	meeting	 in	 1986	 entitled	 ‘Inexcitable
Motor	Nerves	in	GBS’.	Apparently,	the	selection	committee	was	not	excitable	either	and	they	rejected	our
submission.	 In	 the	meantime,	Brain,	 being	more	 receptive,	 published	 our	 description	 of	 these	 cases	 in
1986	with	the	title	of	‘An	acute	axonal	form	of	Guillain-Barré	polyneuropathy’	[6].	This	publication	led
to	almost	a	decade	of	controversy	over	whether	our	results	were	valid.
In	1987,	the	American	Academy	of	Neurology	accepted	our	more	excitingly	retitled	abstract,	‘Severe
acute	 axonal	 degeneration	 in	Guillain-Barré	 syndrome’,	 for	 presentation	 at	 the	 annual	meeting	 in	New
York	[7].	It	was	a	potentially	daunting	experience,	as	I	presented	the	paper	in	a	large,	very	full	room,	at	a
session	chaired	by	Arthur	Asbury	and	Barry	Arnason,	2	giants	of	the	GBS	and	neuroimmunology	world.
When	I	finished	my	presentation,	the	aisles	filled	with	questioners	queuing	at	the	microphones	to	engage
me	 in	 debate.	 But	 before	 they	 had	 their	 chance,	 the	 2	 chairmen	 challenged	 me	 on	 our	 findings	 and
interpretations.	The	main	points	of	criticism	were	 that	such	severe	axonal	degeneration	must	have	been
secondary	 to	 demyelination	 and	 inflammation,	 and	 that	 since	 our	 autopsied	 patient	 died	 after	 28	 days,
those	findings	could	have	subsided	and	hence	we	missed	them.	I	defended	our	position,	saying	that	if	the
axonal	 degeneration	 we	 observed	 had	 been	 secondary,	 the	 inflammation	 and	 demyelination	must	 have
been	extreme	and	widespread	and	we	couldn’t	possibly	have	missed	it.	We	were	quite	confident	that	we
had	sampled	 the	peripheral	nervous	system	 thoroughly.	 I	enjoyed	 this	 little	 joust	with	our	critics	and	 it
was	made	more	poignant	for	me	to	have	my	15-year-old	son	in	the	audience	to	see	his	dad	on	the	hot	seat.
My	colleague,	Angelika	Hahn,	and	I	turned	to	the	model	of	experimental	allergic	neuritis	in	the	Lewis
rat	to	respond	to	this	criticism.	In	a	1988	paper,	we	showed	that	EAN	became	more	severe	as	the	dose	of
antigen	 was	 increased	 and	 that	 the	 amount	 of	 axonal	 degeneration	 correlated	 with	 the	 amount	 of
inflammation	and	demyelination	[8].	This	supported	our	contention	that,	if	the	severe	axonal	degeneration
in	our	 case	had	been	 secondary,	we	could	not	have	missed	 inflammation	 and	demyelination	because	 it
would	have	been	equally	severe.
Important	support	for	the	concept	of	an	axonal	form	of	GBS	came	from	2	cases	reported	by	Yuki	and
colleagues	in	1990	[9].	Both	cases	had	severe	acute	motor	neuropathy	with	markedly	reduced	compound
muscle	action	potentials,	evidence	of	denervation	on	EMG	and	poor	recovery	suggestive	of	axonal	loss.
They	made	the	notable	observation	that	both	patients	had	a	preceding	diarrhoeal	illness,	had	serological
evidence	of	a	preceding	C.	jejuni	 infection,	and	had	positive	 titres	of	anti-GM1	antibodies.	Subsequent
work	by	their	group	and	others	established	the	principle	of	molecular	mimicry	in	these	cases	and	that	the
anti-GM1	 antibodies	 attached	 to	 the	 nodal	 axolemma	 and	 triggered	 complement-mediated	 destruction
facilitated	by	macrophages.
Nevertheless,	 the	controversy	continued,	with	major	 figures	 in	peripheral	nerve	 research	expressing
scepticism	 of	 our	 work.	 Two	 books	 on	 GBS	 failed	 to	 endorse	 us,	 although	 Richard	 Hughes	 was
supportive	in	his	1990	book	Guillain-Barré	Syndrome	[10].	Two	years	later,	P.K.	Thomas	said	that	GBS
was	“no	longer	a	simple	concept”	and	did	support	the	notion	of	an	axonal	form	of	the	disease	[11].	Cros
and	 Triggs	 in	 1993	 then	 argued	 that	 we	 failed	 to	 find	 evidence	 of	 demyelination	 and	 lymphocytic
inflammation	in	our	autopsied	case	because	the	lesions	might	have	been	focal	and	because	of	“incomplete
sampling”	 [12].	 They	 also	 said	 it	 “was	 possible	 that	 a	 fulminant	 but	 short-lived	 inflammatory-
demyelinating	process	was	no	longer	evident	at	autopsy”	after	28	days.	In	a	commentary	on	this	and	other
aspects	of	the	dispute,	Peter	Dyck	in	an	article	entitled	“Is	there	an	axonal	variety	of	GBS?”	weighed	the
evidence	and	suggested	that	there	likely	were	2	or	more	‘varieties’	of	GBS	and	suggested	the	collection
of	further	cases	to	delineate	these	types	[13].
In	 1993,	 my	 colleagues	 and	 I	 published	 a	 further	 study	 of	 4	 patients	 with	 acute	 severe	 GBS	with
inexcitable	motor	nerves	[14].	All	had	nerve	biopsies.	Three	patients	showed	pathological	evidence	of
acute	motor	sensory	axonal	neuropathy	(AMSAN),	including	one	studied	by	both	biopsy	and	autopsy.	The
autopsy	findings	were	similar	to	our	first	case,	described	in	1986.	The	fourth	patient	had	nerve	biopsies
at	days	15	and	75.	The	first	biopsy	showed	marked	inflammatory	demyelination	and	the	second	showed
an	almost	total	lack	of	myelinated	axons,	indicating	severe	secondary	axonal	degeneration.	This	showed
that	 axonal	 degeneration	 in	GBS	 can	 occur	 by	 2	 different	mechanisms.	 It	 also	 showed	 that	 inexcitable
motor	nerves	may	be	caused	by	severe	acute	demyelination.
Meanwhile,	Guy	McKhann,	Jack	Griffin,	David	Cornblath	and	colleagues	in	1993	described	a	series
of	cases	of	apparent	GBS	occurring	 in	northern	China	 in	children	which	were	predominantly	axonal	 in
nature	 but	 seemed	 to	 have	 a	 good	prognosis	 [15].	 I	 visited	Shijiazhuang	 in	China	 in	 1995	with	David
Cornblath	and	saw	a	ward	filled	with	these	young	patients,	many	of	them	being	ventilated	by	their	parents
by	hand.	Remarkably,	 the	outcome	was	very	good	 for	most.	This	new	form	of	GBS	was	different	 from
what	we	described	but	offered	strong	support	that	GBS	was	not	a	uniform	entity.
The	 most	 important	 support	 for	 our	 thesis	 came	 from	 the	 same	 Johns	 Hopkins	 group,	 led	 by	 Jack
Griffin	[16,17].	In	a	series	of	14	patients	who	died	with	GBS	in	Hebei	province	China,	4	had	pathology
consistent	 with	 acute	 axonal	 motor	 sensory	 neuropathy	 (AMSAN)	 [16,17],	 similar	 to	 what	 we	 had
described.	The	findings	were	of	extensive	axonal	degeneration	involving	nerve	roots	and	nerves,	without
significant	lymphocytic	infiltration	or	demyelination.	Furthermore,	activated	macrophages	were	found	in
the	periaxonal	space	in	perinodal	regions.	Two	cases	had	preceding	infection	with	C.	jejuni.	Of	note,	the
index	 case	 from	 our	 1986	 paper	 had	 diarrhoea	 of	 unknown	 cause	 2	 weeks	 before	 the	 onset	 of	 GBS,
perhaps	C.	jejuni.	Other	cases	in	the	Griffin	series	showed	evidence	of	axonal	involvement	restricted	to
motor	fibres,	hence	the	term	acute	motor	axonal	neuropathy	(AMAN).
Conclusion
It	turns	out	that	GBS	really	is	a	syndrome,	composed	of	several	subtypes	that	share	clinical	features	but
also	differ	 in	 important	ways	and	almost	certainly	differ	 in	pathogenesis.	What	has	been	a	very	healthy
debate	began	in	earnest	over	the	issue	of	‘axonal	GBS’.	A	PubMed	search	on	axonal	GBS	in	November
2015	yielded	805	articles,	all	published	in	1986	or	later.	We	now	have	a	much	deeper	understanding	of
the	basis	of	axonal	GBS	and	the	other	subtypes,	but	there	is	much	more	to	learn.	The	practical	value	of
this	 information	 is	 that,	 ultimately,	we	 should	 be	 able	 to	 identify	 patients	 by	 their	 subtype	 early	 in	 the
disease	 course,	 have	 good	 predictors	 of	 prognosis	 and	 provide	 a	 precision	 medicine	 approach	 to
treatment.
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The	Clinical	Semiology	of	GBS:	Formes	Frustes
and	What	They	Tell	Us
Allan	Ropper
I	 located	 and	 reviewed	 the	original	 notes	 and	papers	 that	 I	 used	 to	 assemble	 the	 two	brief	 articles	 on
variants	of	GBS	published	 in	1986	and	1994	 [1,2].	These	 stimulated	 several	 recollected	anecdotes.	 In
1980	[3]	I	had	reported	at	the	American	Academy	of	Neurology	meeting	four	of	the	earliest	cases	of	GBS
treated	with	plasma	exchange.	It	was	 the	subsequent	plasma	exchange	trial	and	the	prospect	of	a	useful
treatment	for	GBS	that	flooded	large	university	centres	with	these	cases	and	allowed	a	concentration	of
clinical	material.	Until	 then	steroids	were	used	but	with	 little	confidence	and	a	small	clinical	 trial	had
failed	 to	demonstrate	 efficacy.	 I	was	 at	 the	 right	 place	 at	 the	 right	 time	because	of	 our	well-organized
plasma	exchange	unit.	 I	 noticed	 these	 cases	 among	a	 series	of	what	became	about	100	patients	over	5
years	that	I	cared	for	in	our	neuro-ICU	and	a	subsequent	consecutive	prospective	series	that	I	accumulated
up	to	1991	after	the	trial.	The	latter	became	the	basis	of	a	monograph	with	Eelco	Wijdicks	and	Bradley
Truax	[4].
Just	as	I	had	begun	to	consider	writing	up	the	first	group	of	variant	cases	in	1985,	I	ran	into	Dr	John
(Jack)	 Griffin	 of	 Johns	 Hopkins	 as	 he	 was	 eating	 breakfast	 at	 the	 American	 Academy	 of	 Neurology
meeting.	He	 said,	 “You	 know,	 there	 are	 odd	 cases	 of	GBS	 that	we	 are	 seeing	 in	 the	 plasma	 exchange
trial.”	Just	in	the	weeks	before	I	had	formulated	the	pharyngeal-cervical-brachial	variant	in	my	mind	and
was	thinking	how	to	present	these	cases	in	a	paper.	As	Jack	was	an	open	and	generous	person,	I	told	him	I
was	working	on	the	problem	and	had	a	paper	in	mind.	I	had	the	impression	later	that	he	graciously	backed
off	on	writing	his	own.
In	writing	 the	 chapter	 on	 the	history	of	 the	 syndrome	 in	monograph	with	Truax	 and	Wijdicks	 I	was
sensitized	 to	 the	 failure	 by	 Guillain,	 Barré	 and	 Strohl	 to	 acknowledge	 earlier	 papers	 on	 the	 disease,
including	the	famous	one	by	Landry	in	1859.	In	looking	at	the	previously	published	papers	in	my	folder	it
was	clear	 that	others	had	come	across	similar	variants	 to	 the	ones	 I	was	seeing	and	described	 them	in
different	ways.	 In	particular,	 the	paper	by	Munsat	and	Barnes	 [5]	was	prominent.	That	paper	made	me
aware	that	there	are	few	truly	original	clinical	ideas	in	neurology;	most	are	the	reframing	of	older	notions
with	greater	clarity	so	they	can	be	used	as	handles	by	clinicians.
I	had	an	opportunity	to	discuss	the	variants	with	C.M.	Fisher,	himself	the	revealer	of	the	most	famed
variant.	 He	 was	 encouraging	 and	 suggested	 that	 I	 contrast	 them	 with	 alternative	 diagnoses	 such	 as
myasthenia	 gravis.	 He	 had	 earlier	 in	my	 career	 suggested	 that	 I	 keep	 a	 series	 of	 small	 notebooks	 on
interesting	cases,	and	also	on	major	errors	I	had	made	over	the	years.	The	former	was	the	repository	for
notes	on	the	clinical	variants	and	the	latter	has	become	the	basis	of	a	series	of	lectures	on	neurological
errors	that	we	published	and	that	I	often	give	as	a	visiting	professor.	But	the	most	useful	aspect	of	Fisher’s
career	example	was	to	collect	cases	of	a	similar	type	until	a	pattern	of	the	core	features	emerged.	This	is
how	he	advanced	the	study	of	cerebrovascular	disease—for	example	lacunar	strokes—and	articulated	not
only	the	diagnostic	features	 that	became	essential	 to	clinical	practice	but	variations	on	each	theme,	and
this	is	what	I	intended	to	do	with	the	initially	heterogeneous	variants	of	GBS	that	I	was	accumulating	in
the	ICU.
Table	15.1		Regional	and	Functional	Variants	of	Guillain-Barré	Syndrome	and	Their	Approximate	Frequency	in	My	Experience	in
Adult	Patients
Of	the	variants	described	in	the	two	aforementioned	papers	and	summarized	in	Table	15.1,	 the	most
interesting	 was	 the	 pharyngeal-cervical-brachial	 weakness	 that	 resembled	 botulism,	 diphtheria	 and
myasthenia	gravis.	Several	of	these	patients	had	been	referred	to	the	ICU	from	community	hospitals	with
specifically	one	of	these	alternative	diagnoses	on	the	admission	sheet	and	accompanying	notes,	making	it
clear	to	me	that	an	exposition	of	their	connection	to	GBS	might	be	useful.	I	recall	struggling	clinically	at
the	bedside	with	the	first	patient,	a	19-year-old	woman	with	blurred	vision	and	the	inability	to	raise	her
arms,	 who	 was	 thought	 by	 our	 senior	 clinicians	 (including	 Fisher!)	 to	 have	 botulism	 because	 of
ophthalmoparesis	and	ptosis.	Things	went	as	far	as	to	have	a	deltoid	muscle	biopsy	done,	but	deep	tendon
reflexes	were	 absent	 in	 the	 arms	 and	 she	did	not	 have	 iridoplegia.	The	 idea	 that	Bayes	 theorem	might
applied	 at	 the	 bedside	 had	 not	 yet	 permeated	 clinical	 work.	 The	 second	 variant,	 paraparesis	 that
resembled	a	cauda	equina	or	spinal	cord	lesion,	was	memorable	because	my	first	patient,	age	64,	began
to	have	leg	weakness	and	radicular	pain	while	she	was	bowling,	an	activity	she	undertook	avidly	even	at
her	age.	Rather	than	the	usual	complaint	in	GBS	of	inability	to	climb	stairs,	her	legs	buckled	as	she	tried
to	straighten	up	from	releasing	the	ball.	A	third	variant	was	certainly	alluded	to	in	earlier	papers	by	others
and	was	mainly	to	point	out	 that	ptosis	could	be	quite	severe	in	GBS	without	ophthalmoplegia,	 thereby
simulating	myasthenia.	The	same	ptosis	was	evident	in	the	pharyngeal-cervical-brachial	variant.	Finally,
in	the	first	paper	on	GBS	variants,	I	described	the	acute	severe	midline	back	pain	in	the	thoracic	region
that	preceded	or	accompanied	rare	cases	of	GBS	(‘coup	du	poignard’).	I	subsequently	saw	this	in	three
other	patients	who	had	been	on	orthopaedic	services	for	days	or	weeks	until	it	became	clear	their	more
serious	problem	was	quadriparesis,	but	it	also	resulted	in	one	of	the	worst	missed	diagnoses	in	my	career,
an	example	of	overconfidence	that	is	detailed	below.
Using	 the	 model	 of	 Fisher	 syndrome	 and	 its	 ostensible	 relationship	 to	 GBS,	 I	 looked	 for
commonalities	between	the	variant	syndromes	and	conventional	polyneuritis.	The	criteria	I	established	as
a	 working	 theory	 to	 determine	 if	 a	 syndrome	 was	 part	 of	 the	 GBS	 spectrum	 were	 (A)	 the	 clinical
syndrome	began	with	unusual	features	that	compelled	another	diagnosis	such	as	myasthenia	but	eventually
evolved	to	typical	GBS;	(B)	the	variant	syndrome	was	known	to	occur	as	a	component	of	fully	developed
GBS,	 for	 example	 ophthalmoplegia;	 (C)	 electrophysiologic	 tests	 showed	 conduction	 block,	 proximal
block,	absent	F-waves,	lost	sensory	potentials	or	other	features	typical	of	GBS,	but	these	might	be	present
only	in	one	region	of	 the	body;	(D)	the	CSF	protein	was	elevated	in	a	pattern	and	temporal	course	that
were	 consistent	with	GBS;	 (E)	 the	 illness	was	 acute	 or	 subacute	 and	monophasic,	 with	 recovery	 that
accorded	with	 the	 typical	course	of	GBS;	and	of	course,	(F)	other	causes	of	 the	syndrome,	particularly
myasthenia	gravis,	botulism,	diphtheria	and	myelitis,	were	excluded	with	as	much	precision	as	possible.
After	seeing	one	or	two	examples	of	a	variant,	it	became	possible	to	pick	them	out	of	the	larger	group	of
GBS	cases,	to	point	out	the	differences	to	residents	and	other	faculty,	and	thereby	to	redirect	treatment.
Moreover,	 regarding	 the	 clinical	 utility	 of	 knowing	 these	 variants,	 they	 should	 be	 viewed	 from	 the
perspective	of	Bayes’	theorem.	In	the	patients	I	see	in	a	teaching	hospital	in	Boston,	GBS	is	so	much	more
common	than	diphtheria	and	botulism	that	anything	appearing	to	simulate	these	rarer	diseases	clinically	is
still	 likely	 to	 be	 a	 GBS	 variant.	 This	 is	 even	 true	 when	 there	 is	 pupillary	 paralysis	 and	 dry	 mouth.
Myasthenia	gravis	only	superficially	imitates	the	cranial	and	the	pharyngeal-cervical-brachial	variant	of
GBS,	but	the	distinction	may	become	difficult	when	there	is	ptosis,	as	there	often	is.
These	 variants	 have	 taught	me	 several	 things	 about	 GBS.	 First,	 every	 disease	 process	 has	 to	 start
somewhere	in	the	body.	It	is	conceivable	that	there	is	inflammation	in	every	nerve	during	acute	GBS,	but
the	concentration	of	this	activity	in	a	few	regions	gives	rise	to	special	topographic	syndromes.	Since	some
regional	 variants	 remain	 persistent,	 pure	 and	 profound,	 there	 may	 be	 special	 epitopes,	 which	 are
distributed	 regionally	 in	 the	 peripheral	 nervous	 system,	 making	 the	 system	 immunologically	 far	 more
complex	than	anticipated.	Alternatively,	the	blood-nerve	barrier	may	be	opened	up	in	some	places	more
than	others,	and	this	allows	the	inflammatory	response	to	concentrate	in	one	region.	In	a	casual	article,	I
offered	the	observation	that	most	people	with	cranial	nerve	and	Fisher	variants	awakened	with	their	first
symptom,	 whereas	 more	 typical	 GBS	 came	 on	 during	 the	 active	 daytime	 hours.	 It	 is	 unlikely	 but
interesting	to	think	that	the	body	position	prior	to	the	onset	of	an	immune	reaction	could	have	an	influence
on	areas	of	blood-nerve	disruption.	This	is	probably	overly	simplistic.
It	 comes	 as	 little	 surprise	 therefore	 that	 Hugh	Willison	 and	 colleagues	 [6]	 and	 more	 profusely	 in
publications	from	Yuki’s	lab,	as	summarized	in	their	Medical	Progress	article	[7],	have	found	that	auto-
antibodies	 to	 certain	 gangliosides	 are	 disproportionately	 associated	 with	 certain	 variants	 but	 few	 are
specific.	The	relationship	between	anti-GQ1-b	antibodies	and	ophthalmoplegia	and	Fisher	syndrome	has
been	consistent,	but	others	such	as	GT1a	are	perhaps	less	so.	Except	for	GQ1b,	few	of	these	have	made	it
into	clinical	practice.
Second,	 familiarity	with	 the	variants	 created	 a	 risk	of	 the	misuse	of	 the	 availability	 heuristic	 [8].	 I
referred	above	to	one	glaring	example	of	a	patient	with	spinal	epidural	abscess	that	I	initially	mistook	for
GBS	because	of	quadriparesis	and	coup	du	poignard	between	his	scapulae.	He	was	areflexic	and	was
sent	 to	our	 ICU	 for	 IVIg	 treatments,	 having	had	 a	 lumbar	MRI	 that	was	normal.	 I	 examined	him	 in	 the
middle	of	 the	night	with	my	residents	and	he	was	 in	extreme	pain	 in	 the	back	and	 is	distal	extremities.
He’d	been	given	considerable	narcotics	and	was	intubated	for	respiratory	failure.	I	was	able	to	wake	him
up	enough	to	get	him	to	mouth	words,	close	his	eyes	and	purse	his	lips,	and	I	felt	all	of	these	movements
were	weak	and	 that	 therefore	 the	picture	was	consistent	with	GBS.	An	EMG	the	next	morning	showed
multiple	inexcitable	nerves	as	well	as	absent	late	responses	and	our	electrophysiologist	gave	a	diagnosis
of	GBS.	We	ordered	 the	 IVIg	 and	went	 about	 our	morning	 rounds.	Later	 in	 the	day,	 I	 asked	 to	 see	 the
lumbar	MRI	since	 the	patient	was	 febrile	and	 intermittently	hypotensive.	At	 the	very	upper	edge	of	 the
image	was	a	white	shadow.	It	quickly	became	clear	that	this	was	the	lower	edge	of	a	massive	epidural
abscess.	I	had	put	together	the	interscapular	pain,	with	quadriparesis,	areflexia,	respiratory	failure	and	a
too	 easily	 confirmatory	 EMG,	 all	 as	 GBS.	 We	 made	 the	 diagnosis	 about	 14	 hours	 after	 our	 initial
assessment	 and	 the	 patient	 went	 to	 the	 operating	 room	 but	 his	 spinal	 cord	 was	 already	 necrotic.	 At
autopsy,	there	was	a	massive	staphylococcal	epidural	abscess	extending	from	the	upper	cervical	through
the	 upper	 lumbar	 cord	 that	 I	 recounted	 in	 an	 entire	 chapter	 of	my	book	 for	 the	 public	 on	 neurological
problems,	Reaching	Down	the	Rabbit	Hole	[9].
This	points	out	 the	problem	of	having	 too	much	experience	with	unusual	 clinical	processes	 and	not
having	the	scepticism	and	simplicity	of	a	medical	student.	It	is	reminiscent	of	the	story	of	a	middle-aged
gentleman	who	was	 admitted	 to	 the	 hospital	 with	 severe	 back	 pain	 and	 progressive	wasting.	 He	was
examined	with	every	conceivable	test	and	seen	by	the	most	skilled	clinicians	in	the	hospital.	No	diagnosis
could	 be	made	 and	 he	 died.	 At	 autopsy,	 there	was	 an	 angiosarcoma	 of	 the	 spleen.	When	 the	 chief	 of
medicine	later	reviewed	the	chart,	he	noticed	that	a	medical	student	had	made	the	correct	diagnosis!	He
called	 the	 student	 to	 his	 office	 to	 congratulate	 him	 and	 asked	 how	he,	 a	 beginning	 student,	 could	 have
made	 this	 diagnosis	when	 every	 senior	 clinician	missed	 it.	 The	 student	 responded,	 “What	 else	 causes
back	pain?”	The	GBS	variants,	therefore,	have	made	me	both	a	better	and	a	worse	clinician.
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My	Top	10	GBS:	Pit	Stops	in	a	Sandstorm
Thirugnanam	Umapathi
Pit	Stops	in	a	Sandstorm
Strong	gusts.
Sands	whipped
Eyes	fail.
Spirits	sag
Directions	lost,
Weary	of,
Weary	from,
Pitfalls.
Pit	stops!
To	repose,
Re-Pose.
Convene,	confer.
Invigorate	and
Animate.
Ideational	oases
I	wonder	…
The	destination’s	form
1		Rag	Dolls,	No	More
Rows	of	weakened	children.
Flaccid	rag	dolls.
Iron-clad	lungs
Keeping	afloat,
From	near	certain	suffocation,
And	an	inevitable	life	of	poliotic	paralysis.
Oh,	but	…
One	child	recovers!
In	 1859	Octave	Landry	 published	 ‘Note	 sur	 la	 paralysie	 ascendante	 aiguë’	 [1],	 in	which	 he	 described
with	clarion	precision	5	personal	cases	and	5	from	the	literature	of	acute	ascending	paralysis:
The	main	problem	is	usually	a	motor	disorder	characterized	by	a	gradual	diminution	of	muscular	strength	with	flaccid	limbs
and	without	contractures,	convulsions	or	reflex	movements	of	any	kind.…
One	does	not	observe	any	symptoms	referable	to	the	nervous	system.…	The	intellectual	faculties	are	preserved	until
the	end.…
The	 weakness	 spread	 rapidly	 from	 the	 lower	 to	 the	 upper	 parts	 of	 the	 body	 with	 a	 universal	 tendency	 to	 become
generalized.…
The	progression	can	be	more	or	 less	 rapid.	 It	was	eight	days	 in	one	and	 fifteen	days	 in	another	case.…	When	 the
paralysis	reaches	its	maximum	intensity	the	danger	of	asphyxia	 is	always	imminent.…	In	two	cases,	death	occurred	at
this	stage	…	when	the	paralysis	recedes	it	demonstrates	the	reverse	of	the	phenomenon,	which	signaled	its	development.
…
On	the	day	before	dying	of	asphyxia	the	patient	was	lying	quietly	on	his	back	and	there	was	hollowing	of	the	abdomen
during	inspiration	and	outward	movement	during	expiration.
In	1916	Guillain,	Barré	and	Strohl	described	2	soldiers	with	an	acute	paralytic	 illness	 that	was	unlike
poliomyelitis	 [2].	 Besides	weakness	 and	 slight	 sensory	 loss,	 they	 emphasized	 the	 loss	 of	 deep	 tendon
reflexes.	They	also	directed	attention	to	the	increased	spinal	fluid	protein	with	normal	cell	count	using	the
technique	of	lumbar	puncture	developed	by	Heinrich	Quincke	in	1891.	The	2	patients	had	CSF	protein	of
2.5g/dl	and	0.85g/dl,	respectively,	with	normal	cell	counts.	Both	patients	started	improving	about	a	month
after	the	onset	of	illness.
2		To	the	Curious	Incident	of	the	Dog	in	the	Night-time
Gregory	(Scotland	Yard	detective):	“Is	there	any	other	point	to	which	you	would	wish	to	draw	my	attention?”
Holmes:	“To	the	curious	incident	of	the	dog	in	the	night-time.”
Gregory:	“The	dog	did	nothing	in	the	night-time.”
Holmes:	“That	was	the	curious	incident.”
“Silver	Blaze”,	Sir	Arthur	Conan	Doyle,	1892
Eyes	riveted	lock-still.
Gait	inebriated.
Tendons	insensate.
“This	is	acute	and	follows	an	infection.
Note	the	paralyzed	eyes.
And	it	all	fades	in	3	weeks.
What	is	missing?”	…
“The	cells!”
“Unmask	the	culprit	GBS”
Said	Charles	Miller	(Holmes)	Fisher
“There	flees	the	criminal’s	accomplice,	GQ1b!	Catch	him!”	shouted	Chiba	(Watson).
Miller	 Fisher	 described	 3	 patients	 with	 acute	 ophthalmoplegia,	 ataxia	 and	 absent	 tendon	 reflexes	 that
occurred	 acutely	 following	 an	 antecedent	 infection	 in	 1956	 [3].	 These	 patients	 had	 minimal	 or	 no
weakness.	All	 3	 recovered	 spontaneously.	One	out	 of	 the	2	patients	who	had	 spinal	 fluid	 analysis	 had
cyto-albuminogic	dissociation.	Fisher	hypothesized	a	common	etiopathological	link	between	this	disorder
and	Guillain-Barré	 syndrome	 (GBS).	Chiba	 and	 colleagues	 subsequently	 showed	 the	 close	 association
between	Miller	Fisher	syndrome	and	anti-GQ1b	antibody	[4].
3		Once	upon	a	Time	in	China
Doctor	McKhann	visits,
Perchance	the	summer	epidemic,
Of	acute	flaccid	weakness.
His	accessory	Jack
Muses	at	this	bizarre	cyclical	GBS.
Amidst	excited	shouts,	“Axonal	changes!”
Of	Cornblath	in	the	EMG	room.
Jack	demonstrates	indeed,
Macrophages	slip-sliding,
Below	plump	Schwann	cells,
Devouring	sweet-fatty	axolemma.
The	conspiracy	of	the	corkscrew	villain,
Campylobacter	jejuni,
Exposed!
Drs	McKhann	and	Griffin	led	a	team	to	China	and	delineated	the	AMAN	subtype	GBS	in	the	early	1990s
[5].	Eighty-eight	of	the	90	patients	they	saw	had	a	pattern	of	disease	characterized	by	reduced	compound
muscle	 action	potentials	with	normal	velocity	 and	 sensory-nerve	 action	potentials	 on	nerve-conduction
studies.	Two-thirds	of	 the	patients	had	serological	evidence	of	 recent	C.	 jejuni	 infection	 (compared	 to
16%	of	village	controls).	Likewise	a	greater	proportion	of	patients	had	IgG	anti-GM1	antibodies	[6].	In	6
axonal	 GBS	 cases	 that	 were	 autopsied,	 the	 pathological	 findings	 were	 Wallerian	 degeneration	 with
macrophages	within	the	periaxonal	space	that	were	surrounding	or	displacing	the	axons	that	had	an	intact
myelin	 sheath.	 The	 pathological	 changes	 were	 subtle	 in	 some	 of	 the	 patients	 that	 died	 from	 severe
paralysis,	 implying	 that	 functional	 abnormalities	 in	 the	 axolemma	 such	 as	 conduction	 block	 might	 be
responsible	for	the	paralysis	[7,8].	This	could	also	explain	the	relatively	rapid	recovery	of	some	patients;
the	median	time	to	regain	the	ability	to	walk	5	metres	with	assistance	was	31	days	in	the	AMAN	patients,
not	dissimilar	to	those	who	had	the	demyelinating	AIDP	subtype	[9].
4		Morpheus
Morphs	a	plenty,
Forms,	and	in	geography,
Blends	and	overlaps.
In	core-essence:	GBS.
Antecedence,
Nadir	in	weeks,
Proteinaceous-acellular	spinal	fluid.
And
Recuperating	convalescence.
Following	 the	 description	 of	 the	 Miller	 Fisher	 syndrome,	 other	 regional	 variants	 of	 GBS	 are	 being
continuously	 recognized.	 Pharyngeal-cervical-brachial	 weakness	 [10],	 acute	 ataxic	 neuropathy	 [11],
paraparetic	GBS	[12],	facial	diplegia	[10],	acute	ophthalmoplegia	[13],	polyneuritis	cranialis	[14],	acute
oropharyngeal	palsy	[15],	acute	ptosis	[12]	and	acute	mydriasis	[16]	are	some	of	the	sub-types	of	GBS
that	have	been	described.	They	are	usefully	named	after	 their	 cardinal	 features.	The	diagnosis	of	 these
regional	variants	can	be	challenging.	The	close	association	of	some	of	these	conditions	with	raised	anti-
ganglioside	antibodies,	such	as	anti	GQ1b	or	GT1a	antibodies,	can	aid	in	the	diagnosis.
Tendons	Frisky!
Suppressed	and	absent.
That’s	how	you	are.
You	do	sometimes	appear	intact.
Occasionally	florid,
And	even	flamboyant.
A	trickster,
In	the	malady	of	axons.
In	 1984,	 Pryor	 and	 colleagues	 reported	 a	 patient	who	developed	GBS	 after	 a	C.	 jejuni	 infection	with
remarkably	 intact	deep	 tendon	reflexes	 [17].	 In	 the	series	of	AMAN	patients	 from	China,	hyperreflexia
was	 noted	 during	 the	 early	 phase	 of	 recovery	 in	 some	 patients	 [5].	 Kuwabara	 and	 colleagues
corroborated	this	observation	in	13%	of	54	consecutive	GBS	patients.	Most	had	AMAN	and	had	raised
anti-GM1	 antibodies	 [18].	 Subsequently	 Yuki	 and	 colleagues	 demonstrated	 that	 up	 to	 10%	 of	 GBS
patients	can	have	normal	or	exaggerated	deep	tendon	reflexes	during	the	entire	course	of	illness	[19].
5		Double	Agent
Boundaries	apparently	regimented
Walls,	border-post,	customs
Man	and	material	separated.
Yet	GBS,	a	resident	of	the	PNS,
Spotted	dallying	in	CNS.
Somnolence,
Babinski,
Bells,
SIADH,
Are	guises	he	uses
In	his	forays
Bickerstaff	 and	 Cloake	 described	 3	 cases	 of	 ophthalmoplegia	 associated	 with	 ataxia	 and	 clouding	 of
consciousness	 in	1951	 [20].	They	drew	attention	 to	 the	 similarities	with	GBS,	 even	 though	 there	were
unequivocal	signs	suggestive	of	‘mesencephalitis	and	rhomboencephalitis’.	This	report	preceded	Miller
Fisher’s	report	on	the	ophthalmoplegia-ataxia-areflexia	triad	of	the	now-classic	Miller	Fisher	syndrome.
Remarkably,	one	of	the	3	patients	described	by	Miller	Fisher	did	have	drowsiness.	Yuki	and	colleagues
wrote	 the	 conclusive	 chapter	 in	 this	 saga	 in	 1997,	 proving	 the	 spectral	 relationship	 between	GBS	and
Bickerstaff	 [21].	 They	 described	 the	 presence	 of	 anti-GQ1b	 antibody	 in	 Bickerstaff	 encephalitis,	 an
antibody	that	by	then	had	been	well	associated	with	MFS.	This	serendipitous	discovery	was	made	when
they	were	attempting	 to	distinguish	a	single	case	of	apparent	Miller	Fisher	syndrome	that	 lapsed	 into	a
coma	from	Bickerstaff	encephalitis.
6		Mimics
O	hell!	What	have	we	here?
A	carrion	Death,	within	whose	empty	eye
There	is	a	written	scroll!	I’ll	read	the	writing.
All	that	weakens	rapidly	is	not	within	the	GBS	folda;
Often	have	you	heard	that	told:
Many	a	patient’s	life	hath	souleda.
But	my	outside	to	behold:
GBS	diagnoses	do	mimics	enfolda.
Had	you	been	as	wise	as	bold,
Young	in	limbs,	in	judgement	old
Your	answer	had	not	been	inscroll’d
Fare	you	well,	your	suit	is	cold.
Murphy	 and	 colleagues	 described	 a	 patient	 that	 presented	 with	 acute	 flaccid	 weakness	 of	 his	 limbs
associated	with	depressed	reflexes	that	evolved	over	3	weeks	[22].	These	features	were	consistent	with	a
diagnosis	of	GBS.	However,	 the	presence	of	unilateral	wrist	drop,	Horner’s	 syndrome,	normal	cranial
nerve	examination,	confusion,	normal	CSF	and	MR	changes	of	central	pontine	myelinolysis	were	atypical
for	GBS.	It	became	clear	then	that	the	patient	had	been	drinking	large	amounts	of	beer	and	spirits	for	more
than	 15	 years,	 and	 had	 stopped	 eating	 anything	 else	 for	 a	 week	 before	 admission.	 This	 was	 after	 an
apparent	upper	respiratory	infection	(which	further	confused	the	clinical	picture).	Nerve	conduction	study
showed	an	axonal	sensorimotor	polyneuropathy.	The	patient	improved	with	high-dose	thiamine	and	other
vitamin	 supplementation.	 Although	 the	 diagnostic	 serum	 pyruvate	 and	 red	 cell	 transketolase	 were	 not
tested	 (as	patient	had	already	received	high	doses	of	vitamins)	 the	patient	most	 likely	had	dry	beriberi
neuropathy	that	mimicked	GBS.
Bacchus	beckons
High	and	higher.
Ceres	grounds,
Cajoling	to	eat	her	grains	and	bread.
The	call	of	Bacchus	drowns	her	out.
Downed	in	spirits.
Hallucin-ens	many,
Is	that	you	darling,	Mnemosyne?
Don’t	leave	me.
I	can’t	chase	after	you.
For	I	am	losing	my	hands	and	feet
Other	 pertinent	GBS	mimics	 are	 acute	myelopathy,	 periodic	 paralysis,	HIV	 seroconversion,	 hereditary
neuropathy	with	 liability	 to	pressure	palsy,	 treatment-related	neuropathy	of	diabetes	 (previously	 termed
‘insulin	neuritis’),	acute	 intermittent	porphyria,	primary	meningeal	 lymphoma/carcinomatous	meningitis,
acute	cryoglobulinemic	neuropathy,	Lambert-Eaton	myasthenic	syndrome	and	acute	sensory	neuronopathy.
7		The	Long	Campaign
There	is	a	plaque	in	me
It	is	everywhere,
Suffocating	me	with	its	Fab	arms
Crushing	me	with	the	weight	of	its	Fc	pillars
Rid	me	of	this	enemy,	please!
Battle	cry!	Bugle	sounds!
No!	The	steroid-sword	is	ineffective!
Warns	Commander	Hughes.
We	need	another	weapon,
Lest	the	war	is	lost.
Voices	let	by	Jack
Rally	the	charge.
Exchange	the	milieu!
Clean	aliquots,
5	volumes	10	days,
Calls	out	the	command.
Patients	walk!
The	Dutch’s	kinship	of	the	Sea.
With	their	prescience
They	say	flood	and	wash	away,
With	pools	of	antibodies.
Patients	walk!
The	battle	is	won,	but
The	war	ravages	on.
Let’s	attack	on	both	fronts.
Exchange	and	flood,
Cajole	the	French.
But	patients	walk	the	same.
The	enemy	complements	the	attack,
MAC	is	their	key	weapon.
Masked	chimera	commandos,
Half	human	half	rodent,
Sneak	in	to	liquidate	MAC.
Can	they	shift	the	balance	of	the	war?
Hughes	 and	 co-workers	 demonstrated	 unequivocally	 the	 ineffectiveness	 of	 corticosteroids,	 used	 in
isolation,	 for	 the	 treatment	 of	 GBS	 [23].	 Subsequently	 2	 seminal	 studies	 have	 established	 the	 role	 of
plasma	exchange	 [24]	and	 intravenous	 immunoglobulin	 [25]	 in	hastening	 the	 recovery	of	GBS	patients,
while	another	showed	the	lack	of	additional	benefit	of	the	combination	[26].
Another	 promising	 therapeutic	 strategy	 is	 the	 inhibition	 of	 complement	 activity.	 Eculizumab	 is	 a
humanized	monoclonal	 antibody	 that	 blocks	 the	 formation	 of	 human	 C5a	 and	 C5b-9	 and	 consequently
interferes	 with	 action	 of	membrane	 attack	 complex	 (MAC).	 This	 ultimately	 inhibits	 antibody-induced,
complement-mediated	neuropathic	damage	of	GBS	[27].
8		A	Haiku	in	a	Kabuki
Sialated	ganglioside,
NOT	LPS	armoured	C-jejuni
Halt	antibodies!
The	Penner	19	serotype	(PEN	19)	is	an	organism	frequently	isolated	from	GBS	patients	and	rarely	found
in	C.	jejuni	enteritis	without	GBS.	In	a	case	of	AMAN	that	occurred	after	a	bout	of	diarrhoea,	Yuki	and
co-workers	demonstrated	elevated	 levels	of	 anti-GM1	antibody	and	a	4-fold	 increase	 in	 anti-C.	 jejuni
antibody	[28].	C.	jejuni	was	cultured	from	a	stool	sample	of	this	patient	and	identified	as	the	Penner	19
serotype.	The	 lipopolysaccharide	capsule	 (LPS)	of	 the	 isolated	C.	 jejuni	was	purified	and	analysed.	 It
showed	 binding	 activity	 of	 cholera	 toxin,	 which	 specifically	 recognizes	 the	 GM1-oligosaccharide.
Analysis	 using	 gas-liquid	 chromatography-mass	 spectrometry	 showed	 that	 the	 purified	 LPS	 contained
Gal,	GalNAc	and	NeuAC.	It	was	also	shown	that	this	oligosaccharide	structure	protrudes	from	the	LPS
core	and	its	configuration	is	identical	 to	the	terminal	tetrasaccharide	of	the	GM1	ganglioside.	This	was
the	 first	 study	 that	demonstrated	 the	 feasibility	of	molecular	mimicry	between	membrane	component	of
nerve	and	an	infectious	agent,	C.	jejuni,	that	precedes	GBS.
Kabuki	(歌舞伎)	dance
Sing	(歌),	dance	(舞),	skill	(伎)	mask	villain
Seduced	to	fratricide!
9		Axonal	Blocks
As	Schwann	cells	wither	away
Currents	leak,
Signals	bleak
Distal-nodes,	indifferent,	inexcited,
Wires	silent	…
The	celebrated	demyelinating	blocks.
Gangliosides	attract	trouble;
Antibodies	to	nodes	and	paranodes.
Squatting	on	sodium	channel	abodes.
Node-conduction	fails,
Wires	silent	…
The	overlooked	axonal	blocks.
Capasso	 and	 colleagues	 described	 2	 patients	with	 an	 acute	motor	 neuropathy,	 intact	 reflexes,	multiple
conduction	block	and	quick	spontaneous	recovery	[29].	These	patients	had	high	titres	of	anti-GD1a	and
GM1	antibodies,	and	one	had	recently	had	a	C.	jejuni	infection.	Both	recovered	within	a	few	weeks.	This
illness,	acute	motor	conduction	block	neuropathy	(AMCBN),	is	believed	to	be	a	subtype	of	GBS-AMAN.
It	is	 intriguing	that	it	appears	to	be	an	acute	equivalent	of	MMN,	analogous	at	 least	nosologically	to	an
AIDP-CIDP	relationship.	A	subsequent	report	by	Kokubun	and	colleagues	demonstrated	unequivocally	the
presence	of	conduction	block	in	axonal	GBS	[30].
10		Man’s	Best	Friend
In	health	and	sickness	you	are	my	ally
What	did	we	do	to	deserve	your	love	and	loyalty.
Wolves	you	may	have	been,
Threatening	my	father’s	sheep.
Tools	you	have	become;	and	my	buddy.
Count	the	ways	that	you	aid	me.
By	yet	another	act	of	serendipitous	sacrifice,
A	helping	paw	to	wipe	away	this	scourge.
GBS	too,
Your	service	leaves	untouched.
In	1967	Cummings	and	Haas	published	the	clinical	features	of	9	and	the	pathological	findings	of	5	dogs	of
various	breeds	with	coonhound	paralysis	[31].	This	is	an	acute	paralytic	illness	of	dogs	now	referred	to
as	acute	canine	paralysis	(ACP).	The	authors’	attempt	to	draw	parallels	with	GBS	occurring	in	humans
deserve	to	be	quoted	ad	verbatim:
In	both	entities	weakness	begins	acutely	in	the	lower	extremities	and	later	ascends	to	involve	the	upper	extremities	and	the
cranial	 nerves.	 The	 illness	 reaches	 its	 peak	 within	 several	 days,	 at	 which	 time	 flaccid	 weakness	 is	 extreme	 and
symmetrical,	 and	 some	 degree	 of	 respiratory	 embarrassment	 is	 present.	 Areflexia	 accompanies	 this	 loss	 of	 power.
Sensory	loss	is	mild	and	involves	the	acral	parts	of	the	extremities.	Bladder	and	bowel	function	are	unimpaired.	Pyrexia
due	to	the	disease	per	se	is	absent.	Recovery	is	slow,	but	good	return	of	power	is	achieved	within	several	months.
Distal	paraesthesiae,	a	symptom	undeterminable	in	the	dogs,	usher	in	the	human	illness	in	about	half	the	cases.
Certain	variations	are	common	to	both.	The	initial	site	of	weakness	may	be	the	upper	extremity.
Although	recovery	is	typical,	death	may	occur,	generally	due	to	respiratory	failure
On	the	other	hand,	the	degree	of	weakness	may	be	quite	mild,	hardly	preventing	ambulation.	Transient	impairment	of
bladder	and	bowel	function	is	not	uncommon.
A	difference	between	the	canine	and	human	syndromes	is	the	lack	of	cerebrospinal	fluid	protein	elevation	in	the	dogs
[although	only	2	dogs	had	lumbar	puncture].
Remarkably,	the	authors’	description	of	the	nerve	conduction	studies	in	these	animals	was	consistent
with	 an	 axonal	 neuropathy.	 Recently,	 Rupp	 and	 colleagues	 demonstrated	 the	 presence	 of	 anti-GM2
ganglioside	 antibodies	 in	 14	 out	 of	 25	 ACP	 dogs	 [32].	 Only	 one	 control	 dog	 (out	 of	 19	 with	 non-
neurological	illness,	and	15	with	epilepsy)	had	anti-glycolipid	antibodies.	The	authors	also	demonstrated
GM2	localization	in	the	abaxonal	Schwann	cell	membrane	of	canine	sciatic	nerve.	This	raises	the	exciting
possibility	of	ACP	as	a	naturally	occurring	animal	model	for	GBS.
Sand	Gets	into	the	Eye
The	bricked	homes	remain,
Walls	pocked,	tiles	loose,	leaking	pipes.
Such	was	the	vigour	of	the	sandstorm.
But	at	least	the	houses	stand,
Whilst	many	tents	lie	broken
Irreparably	damaged.
The	storm	has	shifted	the	sand	into	dunes.
I	climb	on	one	of	them.
Standing	on	its	shoulder,
The	sand,	as	dunes,
Lets	me	see	far	and	wide
The	same	sand,	as	storm,
A	while	ago,
Hampered	my	vision.
I	re-start	the	trek
With	enthused	spirits.
Sand	gets	in	my	eye.
Reminder	of	my	earlier	tryst.
Blink!	Blink!
Gaze	unwavering,
Fixed	on	the	horizon,	where
The	clear	blue	sky	embraces
Arms	out-stretched	in	an	arc	of
Sensuous	caress,
Conjugating	with	perfect	geometric	fit,
The	curves	of	the	hot	naked	desert	sand.
A	coital	embrace
Consummation	imminent.
Dedicated	 to	my	 teachers	 (in	 chronological	 order),	Drs	S.C.	Loong,	 Jack	Griffin,	Richard	Hughes	 and
Nobuhiro	Yuki.
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My	Top	10	Clinical	Pearls	in	GBS
Kenneth	C.	Gorson
Many	neurological	disorders	metaphorically	resemble	good	movies,	plays	and	books.	Allowing	for	new
characters	(symptoms	and	findings),	plot	twists	(a	multitude	of	confounding	and	complicating	factors	that
affect	 the	clinical	course),	and	occasionally	surprising	outcomes	(unanticipated	full	 recovery	or	death),
the	 neurological	 story	 weaves	 a	 fascinating	 narrative	 with	 a	 beginning,	 middle	 and	 end.	 GBS	 is	 no
different.	The	beginning	of	the	GBS	‘movie’	is	the	myriad	of	possible	clinical	presentations	and	missed
opportunities	for	accurate	diagnosis;	the	middle	represents	the	variable	evolution	of	new	symptoms	and
findings,	and	confounding	medical	complications	in	the	hospital;	and	the	end	of	the	story	can	be	viewed	as
the	 residual	 and	 often	 disabling	 features	 during	 recovery	 and	 plateau.	 Each	 segment	 poses	 unique
challenges.	Below	are	a	few	salient	clinical	pearls	I	have	accumulated	over	the	years.
The	Opening	Scene
Pain	and	Paresthesias	in	the	Emergency	Department
Missing	 GBS	 in	 the	 emergency	 department	 (ED)	 is	 common.	 The	 patient	 suddenly	 experiences	 acral
paresthesias	or	numbness,	and	often	back	and	radicular	leg	pain.	He	is	understandably	anxious	and	may
lead	a	clinician	to	a	diagnosis	of	panic	disorder	due	to	anchor	bias,	further	compounded	by	the	potential
for	 gender	 bias	 when	 the	 afflicted	 individual	 is	 an	 otherwise	 healthy	 young	 woman.	 A	 cursory
neurological	examination	is	deemed	‘nonfocal’,	and	the	patient	is	dismissed	with	a	diagnosis	of	anxiety,
hyperventilation	 syndrome,	 ‘neurasthenia’,	 or	 no	 diagnosis	 at	 all,	 and	 discharged	 home.	 Seldom	 is	 a
neurological	consultation	considered	in	those	without	overt	motor	deficits.	The	patient	returns	(often	to	a
different	ED)	days	to	a	week	later	with	progressive	generalized	weakness	and	ventilatory	failure,	and	the
diagnosis	 of	GBS	 is	 established.	McGillicuddy	 and	 colleagues	 have	 suggested	 that	 a	majority	 of	GBS
cases	are	misdiagnosed	at	the	first	ED	evaluation	and	delay	may	lead	to	a	worse	outcome	[1].	At	one	time
the	notion	of	‘ascending	paralysis’	as	a	hallmark	of	GBS	may	have	been	a	useful	oversimplification	for
teaching	purposes,	but	the	concept	has	outlived	its	utility.
Fully	one-third	of	patients	have	generalized	weakness	of	 the	arms	and	 legs	at	onset,	 and	15%	have
weakness	spreading	in	a	descending	pattern.	This	does	not	include	those	patients	with	the	Miller	Fisher
syndrome	or	pure	sensory	variants.	Sadly,	the	view	that	‘GBS	equals	ascending	paralysis’	is	steadfastly
fixed	 in	 the	 minds	 of	 many	 clinicians	 to	 the	 exclusion	 of	 the	 other	 diagnostic	 features	 of	 GBS.	 For
example,	 symptom	 onset	 is	 always	 acute,	 as	 the	 patient	 usually	 comments	 he	 has	 never	 experienced
anything	‘quite	like	this	before’,	and	although	paresthesias	and	numbness	may	fluctuate,	the	symptoms	are
constant	(not	episodic),	generally	symmetrical,	and,	at	least	initially,	distal	to	the	wrists	and	ankles.	The
discrepancy	between	prominent	sensory	symptoms	and	little	or	no	objective	sensory	loss	is	a	hallmark	of
early	GBS.	In	contrast	to	panic	disorder	with	hyperventilation,	facial	paresthesias	are	uncommon	in	GBS.
In	my	experience,	abnormal	deep	tendon	reflexes	are	too	often	overlooked.	In	those	without	a	pre-existing
neuropathic	disorder,	generalized	hyporeflexia,	or	isolated,	symmetrically	absent	Achilles	reflexes,	is	not
normal	 in	 an	 otherwise	 healthy	 individual	 with	 acute	 neuropathic	 symptoms;	 GBS	 always	 should	 be
considered.
Nothing	above	the	Neck
Not	 infrequently	 a	patient	with	 rapidly	progressive,	 flaccid,	 areflexic	quadriplegia	 and	 sensory	 loss	 is
transferred	 with	 ‘GBS’.	 Neurology	 trainees	 sometimes	 come	 to	 premature	 diagnostic	 closure	 in	 such
cases	 and	 initiate	 IVIg	 therapy.	 Although	 ophthalmoparesis,	 facial	 and	 oropharyngeal	 weakness,	 or
ventilatory	compromise	are	not	requisite	findings	in	severely	affected	GBS	patients,	I	always	reconsider
the	clinical	diagnosis	when	there	are	no	cranial	nerve	findings	in	quadriplegic	patients.	Acute	flaccid
paralysis	and	areflexia	also	may	be	seen	in	spinal	shock	below	the	level	of	the	lesion.	Acute	transverse
myelitis	is	the	primary	concern	and	my	diagnostic	rule	always	has	been	to	obtain	a	gadolinium-enhanced
MRI	of	the	cervical	and	thoracic	spinal	cord.	In	addition	to	the	absence	of	cranial	nerve	findings,	clinical
features	 that	 favour	 an	 acute	myelopathy	 include	 complaints	 of	 rapidly	 progressive	 sensory	 loss	 in	 the
legs	extending	proximally	to	the	trunk,	and	early	and	prominent	urinary	retention	or	incontinence	which	is
often	 overlooked,	 as	 virtually	 all	 patients	 now	 have	 urinary	 catheters	 placed	 upon	 ICU	 admission.	 A
bladder	ultrasound	performed	before	catheter	placement	which	demonstrates	high	post-void	residuals	is	a
useful	 clue.	 In	 acute	 thoracic	 transverse	myelitis,	 there	will	 be	 leg	 paralysis	with	 bladder	 and	 bowel
involvement	and	complete	sparing	of	the	upper	limbs.	In	such	cases	excruciating	upper-	or	mid-thoracic
pain	is	common	(le	coup	de	poignard)	and	rare	in	GBS.	Careful	sensory	examination	invariably	shows	a
spinal	sensory	level,	and	in	high	cervical	lesions	this	may	not	be	evident	unless	sensory	testing	extends	to
the	 clavicle;	 pinprick	 testing	 also	 should	 be	 performed	 just	 lateral	 to	 the	 spinous	 processes	 to	 avoid
confusion	with	 escutcheon	 sensory	 loss	 on	 the	 anterior	 trunk,	which	may	be	 present	 in	GBS	and	 acute
ganglionopathies.
What	Does	Not	Belong
Virtually	 all	 major	 reviews	 of	 GBS	 provide	 a	 regurgitation	 of	 a	 long	 list	 of	 diseases	 that	 mimic	 the
disorder.	This	usually	 falls	 into	 two	basic	 categories:	 the	 first	 are	 the	 acute	neuropathic	disorders	 that
share	 the	 rapid	 progression	 of	 a	 paralytic	 peripheral	 neuropathy,	 but	 are	 so	 strikingly	 rare	 as	 to	 be
discussed	almost	exclusively	for	pedagogic	purposes	and	then	promptly	dismissed.	Such	entities	include
diphtheria,	 arsenic	 and	 thallium	 intoxication,	 acute	 intermittent	 porphyria,	 etc.	 My	 mentors	 have
undoubtedly	encountered	a	case	or	two	of	these	oddities	during	their	half-century	careers,	but	I	personally
have	never	seen	a	case	of	diphtheric	demyelinating	polyneuropathy,	or	for	that	matter	arsenic	or	thallium
poisoning.	Additional	 examples	 are	 provided	 in	 Table	17.1.	 These	 exceptionally	 rare	 conditions	 have
less	 in	common	with	classical	and	even	atypical	 forms	of	GBS	due	 to	 the	panoply	of	non-neurological
features,	and	erudite	educators	talk	more	about	them	than	actually	see	them.
Table	17.1		Selected	examples	of	‘mimics’	in	the	differential	diagnosis	of	Guillain-Barré	syndrome	(GBS)
The	second	category	of	disorders	discussed	in	the	context	of	GBS	is	non-neuropathic	diseases	causing
acute,	 rapidly	 progressive	 weakness.	 Conditions	 other	 than	 transverse	 myelitis	 include	 basilar	 artery
thrombosis,	myasthenia	gravis,	botulism,	 tick	paralysis,	periodic	paralysis,	 acute	 fulminant	myopathies,
etc.	 (see	 Table	 17.1).	 These	 conditions	 should	 be	 considered	 when	 accompanied	 by	 the	 appropriate
associated	 symptoms	 or	 clinical	 findings,	 but	 the	 typical	GBS	 patient	 usually	 does	 not	 require	 routine
evaluation	 to	exclude	 these	disorders.	Two	of	my	mentors,	Louis	Caplan,	MD,	and	Allan	Ropper,	MD,
frequently	espoused	‘Fisher’s	rules’	on	teaching	rounds,	reflecting	the	clinical	genius	of	their	mentor,	C.
Miller	 Fisher.	 Rule	 5	 has	 suited	 me	 well	 in	 assessing	 patients	 with	 GBS:	 “In	 arriving	 at	 a	 clinical
diagnosis,	think	of	the	5	most	common	findings	(historical,	physical	findings,	or	laboratory)	found	in	the
disorder—if	at	least	3	are	not	present,	the	diagnosis	is	likely	to	be	wrong”	[2].	I	believe	the	converse	is
also	true:	If	there	are	too	many	features	that	do	not	belong,	consider	an	alternative	disorder.	For	example,
the	observations	of	a	fever	at	onset	of	symptoms,	prominent	gastrointestinal	or	other	organ	dysfunction,
psychiatric	 or	 cognitive	 impairment,	 seizures,	 skin	 or	 hair	 changes,	 central	 nervous	 system	 findings,
multifocality	or	prominent	asymmetry,	pain	disproportionate	to	sensory	findings,	CSF	pleocytosis	(>	50
white	 blood	 cells),	 and	 electrodiagnostic	 findings	 indicative	 of	 a	 primary	 axonopathy	 (allowing	 for
axonal	 forms	 of	GBS),	 neuromuscular	 junction	 disorder,	 or	myopathy	 all	warrant	 reconsideration	 of	 a
GBS	diagnosis.
The	Plot	Twists
How	Electrodiagnostic	Studies	and	Spinal	Fluid	Analysis	Help	and	Hurt
The	 value	 of	 electrodiagnostic	 and	 cerebrospinal	 fluid	 (CSF)	 studies	 are	 covered	 in	 greater	 depth
elsewhere	in	this	volume,	such	that	only	a	few	comments	are	provided.	Both	tests	are	crucial	objective
measures	 that	 establish	 the	 diagnosis	 in	 the	 majority	 of	 GBS	 patients.	 The	 anticipated	 findings	 are
acquired	 demyelination	 on	 nerve	 conduction	 studies	 (NCS)	 and	 cyto-albuminological	 dissociation	 on
CSF	 analysis,	 and	 yet	 these	 studies	 also	 are	 helpful	 when	 neither	 is	 present	 or	 other	 unexpected
abnormalities	are	found	that	point	to	an	alternative	diagnosis.	For	example,	in	paraparetic	patients	where
the	only	NCS	abnormalities	are	prolonged	or	absent	late	responses	limited	to	the	lower	extremities,	other
conditions	 that	 affect	 the	 nerve	 roots	 or	 motor	 neurons	 must	 be	 considered,	 such	 as	 neoplastic	 cell
infiltration,	sarcoidosis,	Lyme	disease,	and	rarely,	acute	infectious	polyradiculitis	due	to	herpes	zoster	or
simplex,	 HIV	 and	West	 Nile	 virus	 infection.	 In	 such	 scenarios	 there	 is	 usually	 a	 CSF	 pleocytosis	 in
addition	to	an	elevated	protein	level.	Conversely,	in	a	validation	study	of	the	Brighton	criteria	for	GBS,
Fokke	and	co-workers	[3]	observed	that	no	GBS	patient	had	a	pleocytosis	greater	 than	50	cells/µl,	but
approximately	 15%	 had	 a	 5	 to	 50	 cells/µl;	 therefore,	 although	 other	 conditions	 should	 be	 thoroughly
investigated,	a	moderate	pleocytosis	does	not	exclude	GBS	in	the	appropriate	clinical	context.	Similarly,
finding	 an	 elevated	 CSF	 protein	 concentration	 is	 dependent	 on	 the	 timing	 of	 the	 lumbar	 puncture.
Approximately	one-third	of	otherwise	classic	GBS	patients	have	a	normal	CSF	protein	level	during	the
first	week	of	symptoms,	such	that	a	normal	CSF	analysis	does	not	exclude	GBS.
There	are	NCS	findings	that	mimic	GBS,	and	atypical	cases	of	GBS	may	lack	classical	demyelinating
abnormalities.	 Multiple	 conduction	 blocks	 in	 named	 motor	 nerve	 territories	 correlate	 with	 clinical
weakness	 in	 GBS,	 but	 also	 may	 be	 an	 early	 finding	 in	 acute	 mononeuritis	 multiplex	 due	 to	 systemic
vasculitis.	 When	 the	 EMG	 shows	 normal	 sensory	 potentials	 and	 low	 or	 absent	 motor	 amplitudes
consistent	with	a	motor	axonopathy,	the	acute	motor	axonal	neuropathy	(AMAN)	variant	of	GBS	is	likely,
but	West	Nile	virus	infection	and	tick	paralysis	(especially	in	children	in	appropriate	geographic	areas)
also	should	be	considered.	Acute	ataxic	and	pure	sensory	variants	of	GBS	usually	demonstrate	absent	or
reduced	sensory	potentials	in	the	limbs	without	demyelinating	findings,	and	sometimes	are	confused	with
acute	 ganglionopathies	 due	 to	 paraneoplastic	 neuropathy	 or	 Sjögren’s	 syndrome.	 Fokke	 and	 colleagues
have	shown	that	40%	of	GBS	patients	may	not	fulfil	diagnostic	criteria	for	demyelination	on	the	initial
study,	and	approximately	1%	of	patients	have	a	normal	NCS	[3].	Sometimes	this	occurs	because	too	few
nerves	were	sampled,	and	Albers	and	associates	have	suggested	that	more	extensive	testing	detects	more
demyelinating	 abnormalities	 [4].	 In	 others,	 electrophysiological	 abnormalities	 evolve	 as	 the	 condition
advances	and	diagnostic	criteria	are	fulfilled	upon	follow-up	study.
When	to	Intubate?
GBS	patients	 are	 at	 high	 risk	 for	 developing	medical	 complications	 during	 the	 course	 of	 their	 illness,
most	commonly	pneumonia.	As	weakness	advances,	it	sometimes	can	be	difficult	to	determine	the	exact
cause	 of	 progressive	 respiratory	 decline	 and	 the	 indication	 for	 intubation.	 In	 those	 with	 developing
pneumonia	or	sepsis,	there	is	overt	dyspnoea	with	tachycardia,	findings	on	pulmonary	examination,	chest
X-ray	infiltrate	and	hypoxia	on	arterial	blood	gas	monitoring.	Intubation	in	these	patients	sometimes	may
be	avoided	with	proper	antibiotic	therapy	and	supplemental	oxygen.
In	 contrast,	 those	 with	 progressive	 ventilatory	 failure	 due	 to	 GBS	 have	 tachycardia	 without	 early
dyspnoea,	their	lung	fields	are	clear,	and	chest	X-ray	and	arterial	blood	gases	are	normal.	The	utility	of
sequential	measurement	of	respiratory	mechanics	(vital	capacity,	maximal	inspiratory	force)	cannot	be
over-emphasized.	Estimated	normal	vital	capacity	varies	as	a	 function	of	age,	gender	and	height,	but	a
reasonable	approximation	 is	60	cc/kg.	With	progressive	weakness	of	 the	diaphragmatic	and	 intercostal
muscles	 there	 is	a	steady	decline	of	 the	vital	capacity,	and	at	20	cc/kg	 the	patient	may	look	reasonably
well	 but	 should	 be	 electively	 intubated	 to	 reduce	 the	 risk	 of	 aspiration,	 prevent	 rapidly	 progressive
ventilatory	 failure	 with	 retention	 of	 carbon	 dioxide,	 and	 prevent	 hypoxia	 eventually	 leading	 to	 a
respiratory	 arrest.	 This	 is	 generally	 the	 reverse	 sequence	 of	 events	 that	 occurs	 in	 most	 patients	 with
parenchymal	lung	disease.	However,	there	are	useful	clinical	clues	that	predict	ventilatory	failure.	Lawn
and	colleagues	have	shown	that	there	seems	to	be	a	correlation	between	rapid	progression	of	GBS	(e.g.,
quadriplegia	 evolving	 over	 a	 few	 days),	 progressive	weakness	 of	 the	 neck	 flexors	 on	 bedside	 testing,
bifacial	 or	 tongue	weakness,	 bulbar	 impairment,	 and	 impending	 ventilatory	 failure	 requiring	 intubation
[5].
When	in	doubt,	intubate.	Intubate	early,	in	a	controlled	situation,	preferably	during	the	day,	when	the
staff	anaesthesiologist	may	leisurely	stroll	 to	 the	ICU	and	the	anxiety	of	 the	patient,	family	and	medical
staff	are	manageable.	I	have	heard	of	innumerable	cases	of	intubation	disasters:	The	patient	initially	looks
fine	on	a	floor	bed,	respiratory	mechanics	and	other	clinical	signs	are	not	followed	properly,	and	hours
later	 the	next	 ‘neuro	check’	 finds	 the	patient	cyanotic	and	not	breathing.	A	code	 is	called,	 followed	by
crash	 intubation	 (usually	 by	 a	 less	 skilful	 anaesthesiologist-in-training)	 and	 the	 requisite	 ventilatory
associated	pneumonia	follows	over	the	next	48	hours.	This	scenario	invariably	occurs	in	the	middle	of	the
night	 on	 a	 weekend,	 but	 on	 occasion	 I	 have	 seen	 it	 during	 the	 day	 if	 the	 medical	 caregivers	 are	 not
attentive.
Dysautonomia	from	GBS,	and	Attention	to	Medical	Management
Dysautonomia	is	common	in	GBS	patients,	particularly	resting	tachycardia	that	remains	invariant	despite
blood	pressure	fluctuations.	These	features	tend	to	occur	early	during	an	ICU	stay	and	are	concordant	with
rapidly	progressive	ventilatory	 failure	 and	quadriplegia.	However,	 in	 a	non-ventilated	patient	who	has
been	in	the	ICU	for	many	days	or	weeks,	with	a	sudden	onset	of	otherwise	unexplained	tachycardia	with
respiratory	 failure	 requiring	 intubation,	 or	 with	 worsening	 tachycardia	 and	 respiratory	 distress	 in	 an
intubated	patient,	pulmonary	embolus	is	the	leading	consideration.	A	knee-jerk	attribution	to	‘worsening
dysautonomia’	or	‘ventilatory	failure	due	to	late	progressive	GBS’	should	be	avoided	until	other	medical
explanations	have	been	excluded.	It	is	the	assiduous	attention	to	the	details	of	medical	management	in
the	ICU	that	leads	to	better	outcomes	in	GBS.
New	Onset	Paralysis	in	ICU	Patients
Over	the	years	I	have	had	frequent	consultations	for	paralyzed	patients	in	ICU,	to	‘rule	out	GBS’.	These
patients	 were	 critically	 ill	 and	 ventilated	 with	 multi-organ	 failure.	 Most	 were	 heavily	 sedated	 and
received	paralytic	agents	to	facilitate	ventilation.	These	cases	looked	like	severe	GBS;	there	was	severe,
generalized,	 flaccid	 symmetrical	 weakness	 of	 the	 limbs	 with	 areflexia	 and	 sensory	 loss.	 Bolton	 and
colleagues	clarified	our	 thinking	with	 their	 seminal	work	defining	critical	 illness	polyneuropathy	 (CIP)
and	distinguished	this	condition	from	GBS	acquired	in	the	ICU	[6].	In	contrast	to	GBS,	these	patients	are
neurologically	intact	upon	ICU	admission	and	weakness	develops	later	in	the	hospital	course.	The	NCS
show	a	primary	axonopathy	without	demyelinating	features	and	 the	spinal	 fluid	protein	concentration	 is
normal.	Another	related	paralytic	syndrome,	critical	illness	myopathy,	has	been	associated	with	the	use	of
corticosteroids	and	neuromuscular	blocking	agents.	Unlike	most	myopathies	which	have	a	predilection	for
proximal	muscles,	distal	and	proximal	muscles	may	be	affected	equally,	and	occasionally	distal	weakness
predominates.	Preserved	 sensation	helps	 to	differentiate	 critical	 illness	myopathy	 from	polyneuropathy,
but	both	can	occur	simultaneously	and	confound	the	clinical	evaluation.	Most	critical	care	physicians	are
now	aware	of	these	neuromuscular	syndromes	and	are	therefore	less	apt	to	confuse	them	with	GBS.	One
should	be	mindful	that	genuine	GBS	very	rarely	develops	in	the	ICU,	such	as	after	a	severe	viral	infection
or	surgery.
Does	CIP	contribute	to	the	secondary	axonal	loss	that	occurs	in	severely	affected	GBS	patients	in	the
ICU?	In	my	experience	this	does	not	appear	to	be	the	case.	Ho	and	co-workers	at	our	facility	found	that	of
those	GBS	patients	in	the	ICU	who	had	follow-up	NCS,	68%	developed	an	axonal	pattern	on	the	second
study,	and	although	their	prognosis	was	less	favourable	than	those	with	a	persistent	demyelinating	pattern
(greater	weakness,	disability,	and	prolonged	hospital	stay),	there	was	no	relationship	between	an	axonal
pattern	and	frequency	of	sepsis,	multi-organ	failure	or	Apache	II	scores	[7].
Recovery	and	Relapse
The	characteristic	course	of	GBS	is	progression	to	nadir	over	4	weeks,	 then	a	stable	plateau	phase	for
days,	weeks	or	months,	 followed	by	 a	 recovery	phase	 for	weeks	 to	years.	During	 the	plateau	or	 early
recovery	 phase,	 approximately	 10%	 of	 patients	 relapse	with	 recurrent	GBS	 symptoms	 and	 findings	 in
otherwise	 medically	 stable	 patients.	 This	 is	 termed	 a	 treatment-related	 fluctuation	 (TRF),	 and	 most
respond	to	retreatment	with	IVIg	or	plasma	exchange	and	resume	an	otherwise	uncomplicated	recovery.
TRFs	 should	 be	 distinguished	 from	 transient	 worsening	 triggered	 by	 a	 medical	 complication,	 e.g.,
pneumonia,	 urinary	 tract	 or	 other	 infection,	 bowel	 obstruction,	 pulmonary	 embolus,	 etc.	 In	 such
circumstances	 treatment	should	be	directed	at	 the	medical	problem,	not	more	 immunotherapy.	 These
patients	recover	once	the	medical	issue	is	resolved.
There	 are	 occasional	 patients	 who	 have	 multiple	 relapses	 in	 the	 weeks	 that	 follow	 nadir	 without
explanation.	 The	 first	 and	 second	 relapses	 might	 be	 attributed	 to	 TRFs,	 but	 by	 the	 third	 relapse,	 it
becomes	clear	something	else	is	happening.	These	patients	typically	respond	to	repeated	courses	of	IVIg
or	plasma	exchange,	but	recovery	is	not	sustained.	Eventually	it	is	apparent,	but	only	in	retrospect,	 that
these	patients	have	a	variant	of	chronic	 inflammatory	demyelinating	polyneuropathy	(CIDP)	manifest	as
acute	relapsing	GBS.	Their	course	is	punctuated	by	acute,	rapidly	progressive	relapses	of	recurrent	GBS
(in	contrast	to	most	CIDP	patients	that	progress	slowly	over	months).	This	CIDP	pattern	has	been	termed
acute-CIDP	 (A-CIDP)	 by	 Ruts	 and	 associates	 [8].	 Our	 Dutch	 colleagues	 have	 found	 that	 it	 occurs	 in
approximately	5–16%	of	patients	presenting	as	GBS.	This	variant	can	be	distinguished	from	those	with
GBS	and	TRFs	by	the	presence	of	3	or	more	relapses,	or	a	relapse	that	occurs	after	8	weeks.	A-CIDP
patients	are	less	severely	affected,	have	less	frequent	cranial	nerve	findings	and	respiratory	compromise,
and	have	slower	nerve	conduction	velocities	that	are	more	characteristic	of	CIDP.	Unfortunately,	none	of
these	features	are	useful	contemporaneously	to	predict	which	GBS	patient	with	a	TRF	has	A-CIDP.	In	my
GBS	 patients	 useful	 clinical	 clues	 associated	 with	 A-CIDP	 include	 the	 development	 of	 any	 new
neurological	findings	after	4	weeks—for	example,	new	weakness	in	muscles	previously	unaffected,	new
sensory	abnormalities,	or	the	onset	of	cranial	nerve	involvement	not	evident	at	nadir.	Once	the	diagnosis
of	A-CIDP	has	been	established,	the	patient	should	be	treated	according	to	published	treatment	protocols
for	CIDP.	It	also	should	be	remembered	that	in	contrast	to	typical	CIDP,	these	patients	relapse	quickly	and
may	decompensate	from	normal	to	bedbound	within	days.
The	Final	Act
Late	Fluctuations
Hickam’s	 dictum	 (“Patients	 can	 have	 as	 many	 diseases	 as	 they	 damn	 well	 please”)	 also	 applies	 to
recovered	 GBS	 patients.	 Such	 individuals	 are	 understandably	 anxious	 that	 any	 trivial	 change	 in	 their
residual	 symptoms	 represents	 an	 impending	 recurrence.	 However,	 fluctuations	 of	 paresthesias	 and
numbness	in	otherwise	stable,	recovered	patients	are	more	likely	due	to	unrelated	health	issues,	such	as
dehydration,	infections,	sleep	deprivation,	or	stress,	and	promptly	resolve	when	the	inciting	factors	have
been	 properly	 addressed.	 In	 contrast,	 patients	 are	 entitled	 to	 accumulate	 other	 neurological	 disorders
simulating	 their	 original	 GBS	 symptoms,	 such	 as	 a	 superimposed	 diabetic	 or	 B12	 deficiency-related
polyneuropathy	or	 cervical	 spondylotic	myelopathy.	These	 secondary	 conditions	usually	 evolve	 slowly
and	are	 clarified	with	 careful	 clinical	 assessment	 and	 judicious	 testing.	One	 should	be	mindful	not	 to
routinely	 attribute	 new,	 progressive	 neurological	 symptoms	 to	 a	 remote	 history	 of	 GBS.	 Lastly,
Kuitwaard	 and	 colleagues	 have	 observed	 that	 there	 are	 the	 unlucky	 few,	 as	 many	 at	 6%,	 who	 have
recurrent	GBS	[9].	Recurrences	range	from	2	to	7	attacks	over	years	or	decades,	with	clinical	features
similar	 to	 the	 first	 presentation	and	usually	 triggered	by	an	 infection.	Repeated	attacks	of	GBS	 tend	 to
occur	 in	 younger	 individuals	 and	 those	 with	 the	Miller	 Fisher	 variant,	 and	 are	 usually	milder	 with	 a
shorter	recovery	compared	to	the	first	episode.	The	cause	for	recurrences	remains	unknown	but	there	must
be	genetic	and	immunological	factors	unique	to	those	individuals.
The	Forgotten	Patient
I	have	become	aware	of	the	enormous	problem	of	a	lack	of	long-term	follow-up	for	GBS	patients	after
hospital	discharge	due	to	my	involvement	with	the	International	GBS	Outcomes	Study	(IGOS).	This	may
be	 related	 to	 the	nature	of	medical	care	 in	 the	United	States,	where	patients	are	often	 transferred	great
distances	 to	 medical	 centres	 with	 expertise	 in	 the	 care	 of	 patients	 with	 GBS	 and	 which	 precludes
subsequent	outpatient	follow-up	at	the	treating	facility.	However,	my	personal	observations	suggest	it	also
may	 be	 a	 phenomenon	 of	 ‘the	 forgotten	 patient’	 once	 the	 patient	 has	 been	 stabilized	 and	 transferred
elsewhere.	Many	have	 persistent	 symptoms,	 even	 if	 they	 have	made	 a	 ‘full	 recovery’	 by	 our	 limited
metrics.
Pain	is	common	in	the	recovery	phase,	characterized	as	neuropathic	burning	or	lancinating	pains	in	a
length-dependent	 distribution.	 Persistent	 fatigue	 causes	 substantial	 disability.	Afflicted	 individuals	may
have	normal	strength	but	have	great	trouble	completing	routine	activities	of	daily	living.	Severely	affected
patients	have	 fixed	motor	deficits	 (hand	weakness,	 foot	drop)	 that	may	benefit	 from	orthotics,	assistive
devices,	and	continued	physical	or	occupational	therapy.	Many	have	depression	and	anxiety	that	have	not
been	treated	after	hospital	discharge.	Virtually	all	patients	have	questions	about	the	nature	of	the	disease
and	their	prognosis	for	further	recovery.	Support	groups	such	as	the	GBS/CIDP	Foundation	International
are	 tremendously	 helpful.	 GBS	 patients	may	 continue	 to	 improve	 slowly	 years	 after	 onset.	 It	 is	 these
patients	 who	 benefit	 most	 from	 follow-up	 outpatient	 evaluations	 that	 provide	 practical	 treatment
interventions,	thoughtful	guidance,	support	and	hope.
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The	Spectrum	of	GBS	and	CIDP
Krista	Kuitwaard
Introduction
Guillain-Barré	 syndrome	 (GBS)	 is	 an	 acute	 polyneuropathy	 that	 reaches	 its	 maximum	 severity	 (by
definition)	 within	 4	 weeks,	 whereas	 the	 maximum	 severity	 in	 chronic	 inflammatory	 demyelinating
polyradiculoneuropathy	(CIDP)	is	reached	after	at	least	8	weeks.	Differentiating	between	GBS	and	CIDP
can	be	difficult	as	 it	 relies	on	arbitrary	clinical	criteria	and	this	separation	may	be	mainly	nosological.
Preceding	 infections,	 involvement	of	cranial	nerves	or	weakness	of	 respiratory	muscles	are	more	often
encountered	in	GBS	than	in	CIDP,	but	they	can	occur	in	both.	Although	GBS	is	generally	a	monophasic
disorder,	treatment-related	fluctuations	(TRFs)	and	recurrences	occur.	CIDP	usually	runs	a	progressive	or
relapsing	course	but	may	be	monophasic,	resembling	GBS	and	requiring	only	a	single	course	of	treatment.
Additionally,	CIDP	patients	with	an	acute	or	subacute	onset,	resembling	GBS,	exist.
GBS	and	CIDP	in	the	Same	Patients
A	46-year-old	man	developed	weakness	as	well	as	numbness	in	his	extremities	over	the	course	of	one	year.	He	responded
well	 to	 IV	 immunoglobulins	 (IVIg)	 once	 every	 2	weeks.	 Several	 attempts	 to	 reduce	 the	 dose	 resulted	 in	 an	 immediate
deterioration.	After	6	years	the	IVIg	could	be	stopped	and	he	remained	in	remission.	Twelve	years	later,	after	an	episode	of
diarrhoea,	he	developed	a	tetraparalysis	and	facial	palsy	within	48	hours.	He	was	treated	with	 IVIg	and	required	artificial
ventilation	for	2	months.	He	had	a	near-complete	recovery	and	no	new	episodes	occurred.
Kuitwaard	K,	et	al.	Individual	patients	who	experienced	both	Guillain-Barré	syndrome	and
CIDP.	The	Journal	of	the	Peripheral	Nervous	System,	2009
Four	separate	patients	are	described	as	having	separate	episodes	of	both	GBS	and	CIDP	[1].	All	fulfilled
the	clinical	and	diagnostic	criteria	for	both	GBS	and	CIDP	[2–3].	One	patient	had	CIDP	and	years	later
developed	 a	 monophasic	 episode	 of	 GBS	 with	 respiratory	 failure.	 Two	 patients	 had	 GBS	 and	 later
developed	CIDP,	and	1	patient	was	described	as	having	had	recurrent	GBS	with	TRFs	that	evolved	into
CIDP.	Although	such	case	series	are	rare,	this	one	suggests	that	GBS	and	CIDP	may	constitute	a	continuum
or	that	there	are	common	host	factors	that	influence	susceptibility	to	these	disorders.
Recurrent	GBS
A	42-year-old	woman	developed	progressive	weakness	and	sensory	disturbances	in	less	than	4	weeks,	and	complained	of
severe	pain.	Symptoms	were	maximal	within	4	weeks.	Seven	years	later	she	had	similar	symptoms	after	a	bout	of	flu,	that
developed	in	less	than	2	weeks.	Sixteen	years	thereafter	she	had	another	episode	after	a	flu-like	infection	that	developed	in
1	week.	Five	years	after	 the	previous	episode	she	developed	progressive	 tetraparesis	over	a	 few	hours	after	a	bout	of
diarrhoea,	for	which	she	was	treated	with	IVIg.	She	needed	artificial	ventilation	and	had	autonomic	dysfunction	complicated
by	an	asystole.	She	was	successfully	resuscitated	and	eventually	discharged	to	a	rehabilitation	centre.
Wijdicks	EF,	Ropper	AH.	Acute	relapsing	Guillain-Barré	syndrome	after	long
asymptomatic	intervals.	Archives	of	Neurology,	1990
Five	patients	that	recovered	from	an	initial	episode	of	GBS	were	described,	who	had	an	acute	relapse	4
to	36	years	later	[4].	The	clinical	features	(such	as	respiratory	insufficiency	and	facial	weakness),	return
of	their	reflexes	and	long	asymptomatic	intervals	distinguished	their	illnesses	from	CIDP.	The	patients	all
had	similar	antecedent	infectious	diseases	as	well	as	similar	symptoms	each	time.	Asbury	[5]	speculated
that	 residual	 inflammation	may	 remain	 between	 episodes,	 accounting	 for	 the	 similar	 symptoms	 during
every	episode,	although	the	long	asymptomatic	intervals	make	this	hypothesis	less	likely.	This	case	series
suggests	that	some	patients	have	an	immunological	susceptibility	that	makes	them	prone	to	develop	GBS.
Grand’Maison	F,	et	al.	Recurrent	Guillain-Barré	syndrome.	Clinical	and	laboratory
features.	Brain,	1992
The	features	of	recurrent	GBS	were	defined	and	their	clinical	characteristics	were	compared	with	those
described	for	chronic	relapsing	polyneuropathy	[6].	Recurrent	GBS	was	defined	as	2	or	more	episodes	of
acute	 idiopathic	 demyelinating	 polyneuropathy	with	 an	 onset	<	 8	 weeks	 (fulfilling	 the	 criteria	 for	 the
diagnosis	of	GBS	[2])	followed	by	a	complete	or	near-complete	recovery.	Because	the	authors	found	a
progressive	phase	of	<	4	weeks	too	restrictive,	 it	 is	 likely	that	some	of	these	patients	had	CIDP	with	a
subacute	onset.	Over	a	time	period	when	270	monophasic	GBS	patients	were	admitted,	12	recurrent	GBS
patients	with	a	total	of	32	episodes	(1–6	recurrences)	were	identified.	The	mean	age	at	onset	of	the	initial
episode	was	28.9	years	and	the	mean	interval	between	episodes	9.7	years.	In	67%	of	patients	an	infection
was	noted	preceding	 the	 first	 episode.	All	patients	were	asymptomatic	or	had	mild	 symptoms	between
episodes.	CSF	protein	level	was	normal	or	only	mildly	elevated	when	obtained	within	1	week	of	onset	of
the	 recurrence	 or	 in	 the	 recovery	 phase.	 In	 all	 patients	 the	 protein	 level	was	 elevated	when	CSF	was
obtained	more	than	1	week	after	onset	of	symptoms	during	a	symptomatic	phase.	One	of	these	12	patients
had	 several	 pregnancy	 or	 post-partum	 related	 triggers.	 In	 patients	 with	 the	Miller	 Fisher	 variant,	 the
presence	of	ophthalmoparesis	and	ataxia	was	constant	from	episode	to	episode,	although	the	nature	of	the
preceding	infection	or	trigger	tended	to	differ.	The	time	to	reach	maximum	deficit	(nadir),	the	disability	at
nadir	and	the	time	between	recurrences	varied	considerably	and	unpredictably	between	episodes.	It	was
mentioned	that	it	remains	unclear	whether	recurrent	GBS	and	chronic	relapsing	polyneuropathy	represent
different	conditions.
Treatment-Related	Fluctuations	in	GBS
A	twenty-year-old	man	complained	of	muscle	aches	after	a	flu	infection.	Two	days	later	he	had	tingling	in	his	limbs.	At	the
general	practitioner’s	office	he	fell	off	the	examination	couch	and	could	not	get	up	by	himself.	At	hospital	admission	he	had
tetraparesis	and	areflexia.	CSF	showed	a	normal	protein	 level.	He	was	 treated	with	 IVIg	and	muscle	strength	 improved
quickly	thereafter.	Just	a	few	days	later	he	developed	a	bilateral	facial	palsy	and	muscle	strength	decreased,	and	he	was
successfully	re-treated	with	another	IVIg	course.
Ropper	AH,	et	al.	Limited	relapse	in	Guillain-Barré	syndrome	after	plasma	exchange.
Archives	of	Neurology,	1988
Although	 relapses	 in	 patients	who	 improved	 after	 plasma	 exchange	had	been	 reported	 earlier,	 the	 first
detailed	description	of	10	GBS	patients	with	a	relapse	after	plasma	exchange	was	from	the	Boston	group
[7].	Ten	out	of	94	GBS	patients	(10%)	showed	mild	to	moderate	worsening	after	an	initial	improvement
following	plasma	exchange.	Eight	of	these	patients	were	treated	with	another	course	of	plasma	exchange,
which	was	followed	by	clinical	improvement.	Although	the	authors	mention	that	this	improvement	could
have	been	the	natural	course,	the	beneficial	effects	of	re-treatment	were	likely.	During	follow-up	none	of
these	patients	developed	CIDP.	It	was	hypothesised	that	early	start	and	cessation	from	treatment	may	lead
to	continued	production	of	a	pathogenic	factor.	This	paper	showed	that	about	10%	of	GBS	patients	can
have	 an	 early	 relapse	 after	 successful	 treatment,	 currently	 defined	 as	 treatment-related	 fluctuations
(TRFs).
Kleyweg	RP,	van	der	Meché	FG.	Treatment	related	fluctuations	in	Guillain-Barré	syndrome
after	high-dose	immunoglobulins	or	plasma-exchange.	Journal	of	Neurology,
Neurosurgery	&	Psychiatry,	1991
As	TRFs	were	described	in	GBS	patients	treated	with	steroids	it	seemed	plausible	that	these	fluctuations
would	 also	 occur	 after	 treatment	 with	 IVIg.	 This	 paper	 showed	 that	 these	 TRFs	 were	 not	 treatment
specific	[8].	A	TRF	was	defined	as
1.	 Improvement	in	functional	score	(GBS	disability	scale)	of	≥	1	grade	or	improvement	>5	points	on	the
MRC	sum	score	within	4	weeks,	followed	by	a	decrease	in	the	MRC	>5	points	or	a	worsening	of	≥	1
grade	in	functional	score	or:
2.	 Stabilization	of	the	clinical	course	for	more	than	1	week	followed	by	a	worsening	in	MRC	sum	score
of	>5	points	or	at	least	1	grade	in	functional	score.
In	 the	Dutch	GBS	trial,	high-dose	IVIg	was	compared	with	plasma	exchange.	Fourteen	out	of	147	GBS
patients	showed	a	TRF	(10%),	a	percentage	similar	to	what	has	been	found	by	Ropper	[7].	Of	these	14
patients,	6	were	treated	with	plasma	exchange	and	8	with	IVIg.	Six	received	another	treatment	course	and
4	 received	multiple	 courses.	All	 patients	 that	were	 re-treated	 showed	 an	 improvement	 or	 stabilization
after	 treatment.	Four	patients	were	not	re-treated	for	no	specific	reason	and	still	showed	a	spontaneous
improvement	after	the	relapse,	indicating	that	not	all	TRF	patients	need	repeated	treatment.	Although	not
formally	investigated,	re-treatment	of	TRF	patients	is	generally	recommended	[9].	The	hypothesis	is	that
the	 pathogenic	 process,	 suppressed	 by	 treatment,	 is	 still	 active	 or	 reactivated	 after	 treatment.	 An
explanation	 for	 the	 fact	 that	 not	 all	 patients	 show	 TRFs	might	 be	 that	 some	 are	 treated	 earlier	 in	 the
disease	course	when	 they	are	still	 in	 the	active	disease	phase.	Another	explanation	could	be	 that	 some
patients	have	a	 longer	 active	disease	course	or	more	prolonged	 immune	attack	 than	others,	 requiring	a
higher	dose	or	longer	treatment	period.
Acute	and	Subacute	CIDP
A	 52-year-old	 woman	 developed	 sensory	 disturbances	 after	 a	 flu	 infection.	 Two	 days	 later	 she	 was	 unable	 to	 walk.
Maximum	disability	was	reached	in	6	days.	In	the	period	thereafter	she	had	several	exacerbations	needing	IVIg	treatment,
and	was	treated	subsequently	with	IVIg	once	every	month	for	the	next	7	years.
Hughes	R,	et	al.	Subacute	idiopathic	demyelinating	polyradiculoneuropathy.	Archives	of
Neurology,	1992
Seven	cases	with	a	subacute	idiopathic	demyelinating	polyradiculoneuropathy	(SIDP)	were	described	as
having	a	monophasic	episode	of	progressive	weakness	over	the	course	of	4–8	weeks	[10].	Three	patients
reported	 a	 respiratory	 infection	 before	 onset	 of	 neurological	 symptoms.	 None	 of	 these	 patients	 had
autonomic	dysfunction	or	required	artificial	ventilation.	All	patients	clearly	responded	to	prednisone	or
showed	a	spontaneous	recovery.	Six	out	of	7	patients	had	an	increased	CSF	protein	level.	Patients	had	a
predominantly	 motor	 polyradiculoneuropathy	 of	 both	 proximal	 as	 well	 as	 distal	 muscles	 and	 were
relatively	mildly	affected.	In	the	spectrum	of	GBS	and	CIDP,	SIDP	occupies	a	middle	position.
McCombe	PA,	et	al.	Chronic	inflammatory	demyelinating	polyradiculoneuropathy.	Brain,
1987
In	this	report	the	clinical	features,	course	and	electrophysiology	is	described	from	92	CIDP	patients	[11].
Sixty	 patients	 (65%)	 had	 a	 relapsing	 course,	 whereas	 32	 patients	 (35%)	 showed	 a	 progressive	 or
monophasic	 course.	 CIDP	 patients	with	 a	 relapsing	 course	 had	 a	 significant	 earlier	 age	 of	 onset.	 The
disability	 of	 the	 relapsing	 patients	was	 similar	 to	 that	 of	 the	 non-relapsing	 ones.	 Twenty-nine	 patients
(32%)	reported	an	illness	or	vaccination	in	the	6	weeks	prior	to	onset,	which	is	considerably	lower	than
in	GBS,	where	two-thirds	reported	such	a	trigger.	They	found	a	rapid	rate	of	onset	in	15	patients	(16%).
These	patients	reached	their	nadir	within	4	weeks.	However,	they	were	distinguished	from	GBS	by	their
subsequent	relapsing	or	progressive	course.	The	authors	excluded	recurrent	GBS	patients.
Molín	J,	et	al.	Acute	clinical	onset	chronic	inflammatory	demyelinating	polyneuropathy	in	a
dog.	Muscle	&	Nerve,	2011
A	5-year-old	Rottweiler	dog	was	evaluated	for	an	acute-onset	tetraparesis	and	hyporeflexia	developing
over	 the	 course	 of	 1	 week	 [12].	 Electrophysiology	 showed	 clear	 evidence	 of	 demyelination.
Electromyography	 showed	 fibrillations	 as	 well	 as	 positive	 sharp	 waves	 in	 all	 muscles.	 The	 clinical
findings	 were	 fully	 compatible	 with	 acute	 canine	 idiopathic	 polyneuropathy	 (ACIP).	 Euthanasia	 was
performed	 because	 of	 rapid	 deterioration.	 On	 postmortem	 examination,	 severe	 enlargement	 and
demyelination	 of	 the	 cervical	 nerve	 roots	 was	 seen.	 Pathology	 showed	 hypertrophic	 changes	 with
formation	 of	 onion	 bulbs,	 and	 hypomyelinated	 fibres	 indicating	 chronic	 de-	 and	 remyelination.
Furthermore,	other	chronic	signs	were	found.	The	owner	of	the	dog	did	not	recall	any	previous	episodes
and	 the	 diagnosis	 of	 acute-CIDP	 (A-CIDP)	was	made.	 This	 report	 illustrates	 that	 differentiating	 acute
from	chronic	forms	of	inflammatory	polyneuropathy	on	clinical	characteristics	can	be	difficult	not	only	in
humans	but	also	in	animals.	Differentiating	between	the	two	is	important	because	corticosteroids	are	not
effective	in	the	acute	form	either	in	humans	or	in	animals.
Differentiation	between	A-CIDP	and	GBS	with	or	without	TRFs
A	33-year-old	man	developed	progressive	weakness	and	paraesthesia	in	his	limbs	over	the	course	of	1	week.	Three	days
later	he	was	unable	to	walk.	He	improved	after	IVIg,	but	9	days	later	he	developed	facial	palsy	and	ophthalmoplegia	and
was	again	treated	with	IVIg.	He	became	tetraplegic	and	needed	artificial	ventilation.	Initially	it	was	thought	he	had	TRFs,	but
after	5	exacerbations,	all	rapidly	responding	to	IVIg,	a	diagnosis	of	acute-onset	CIDP	(A-CIDP)	was	made.
Ruts	L,	et	al.	Distinguishing	acute-onset	CIDP	from	fluctuating	Guillain-Barré	syndrome:	a
prospective	study.	Neurology,	2010
Distinguishing	 between	 GBS-TRF	 and	 A-CIDP	 early	 in	 the	 course	 of	 the	 disease	 can	 be	 important
because	prognosis	and	treatment	strategy	can	be	different.	Out	of	164	GBS	or	MFS	patients	enrolled	in	a
prospective	study,	16	patients	had	1	or	more	TRFs	(10%)	[13].	The	definition	of	a	TRF	or	exacerbation
was	 similar	 to	 the	one	used	by	Kleyweg	and	colleagues	 [8].	Eight	patients	 initially	diagnosed	as	GBS
appeared	to	have	A-CIDP	(5%).	The	first	TRF	always	occurred	within	8	weeks	from	onset	of	weakness,
and	most	TRFs	occurred	within	4	weeks.	None	of	the	GBS	patients	had	more	than	2	TRFs.	Patients	with
GBS-TRFs	were	more	severely	affected	compared	to	A-CIDP	patients	at	all	time	points.
Patients	having	A-CIDP	were	less	likely	to	have	cranial	nerve	deficits	than	GBS-TRF	patients	(13%
vs.	69%,	p	=	0.03).	A-CIDP	patients	more	often	showed	CIDP-like	electrophysiologic	abnormalities	and
none	of	 the	A-CIDP	patients	needed	artificial	ventilation.	GBS	patients	with	TRFs	were	more	severely
affected	 and	more	 often	 had	 sensory	 disturbances	 compared	 to	GBS	patients	without	 a	TRF.	The	CSF
protein	level	did	not	differ	between	A-CIDP	and	GBS-TRF	patients.	Most	A-CIDP	patients	did	not	fulfil
the	electrophysiological	criteria	for	CIDP	[14].	Signs	of	axonal	damage	are	rare	 in	A-CIDP	but	can	be
seen	in	more	than	half	of	GBS-TRF	patients.	Patients	without	cranial	nerve	dysfunction	that	remain	able	to
walk	independently	and	that	show	CIDP-like	abnormalities	at	electrodiagnostic	studies	are	more	likely	to
have	A-CIDP.	 This	 paper	 showed	 that	 the	 diagnosis	 of	 A-CIDP	 should	 be	 considered	when	 a	 ‘GBS’
patient	deteriorates	beyond	8	weeks	from	onset	or	when	an	exacerbation	occurs	3	times	or	more.
Dionne	A,	et	al.	Clinical	and	electrophysiological	parameters	distinguishing	acute-onset
chronic	inflammatory	demyelinating	polyneuropathy	from	acute	inflammatory	demyelinating
polyneuropathy.	Muscle	&	Nerve,	2010
Clinical	and	electrodiagnostic	records	were	reviewed	to	look	for	early	predictors	to	distinguish	A-CIDP
from	GBS.	Electrodiagnostic	studies	were	 included	when	 these	had	been	performed	within	4	weeks	of
onset.	The	authors	compared	15	A-CIDP	patients	with	30	GBS	patients	[15].	Although	sensory	symptoms
were	reported	equally	in	both	groups,	A-CIDP	patients	more	often	had	prominent	sensory	signs.	Sensory
ataxia	 was	 more	 likely	 in	 A-CIDP	 patients	 as	 compared	 to	 GBS	 patients	 (53%	 vs.	 3%,	 P	<	 0.001).
Marked	 impairment	 of	 vibration	 sense	 as	 well	 as	 abnormal	 pinprick	 sensation	 were	 both	 statistical
significantly	more	likely	in	A-CIDP	patients.	Autonomic	disturbances,	facial	weakness	and	the	need	for
artificial	ventilation	are	unlikely	in	A-CIDP.	A	sural-sparing	pattern	in	electrophysiology	was	not	helpful
in	differentiating	between	A-CIDP	and	GBS.	Although	none	of	clinical	parameters	are	pathognomonic	for
either	GBS	or	A-CIDP,	when	prominent	sensory	signs	are	found	early	one	should	be	aware	of	A-CIDP,
and	close	follow-up	is	needed	to	check	whether	long-term	treatment	is	required.
Figure	18.1		The	spectrum	of	GBS	and	CIDP.	Reproduced	with	permission	from	Elsevier.
IVIg	=	treatment	with	a	course	of	IVIg	(2	g/kg	bodyweight)	over	2–5	days
TRF	=	treatment-related	fluctuation;	A-CIDP	=	acute	onset	CIDP
Conclusions
Most	patients	clearly	fit	either	the	diagnostic	criteria	for	GBS	or	CIDP,	but	some	individual	patients	may
have	separate	episodes	of	both	GBS	and	CIDP.	CIDP	can	have	an	acute	or	subacute	onset,	and	some	GBS
patients	have	recurrent	episodes	of	GBS	or	experience	TRFs	(Figure	18.1).	On	the	other	hand	there	are
CIDP	patients	with	a	single	monophasic	course	requiring	only	one	IVIg	course.	These	cases	indicate	that
they	 can	 be	 considered	 as	 part	 of	 the	whole	 spectrum	of	 inflammatory	 demyelinating	 polyneuropathies
instead	of	separate	entities.	The	fact	 that	some	patients	may	have	recurrences	of	GBS	or	both	GBS	and
CIDP	 also	 suggests	 that	 some	 individuals	 are	 more	 susceptible	 to	 developing	 these	 inflammatory
demyelinating	 disorders.	 Distinguishing	 between	 GBS-TRF	 and	 A-CIDP	 can	 be	 important	 from	 a
treatment	perspective,	because	once	it	is	clear	that	a	patient	does	not	have	GBS,	but	A-CIDP,	regular	IVIg
treatment	or	a	switch	to	steroid	treatment	has	to	be	considered.	We	personally	know	A-CIDP	patients	who
were	initially	diagnosed	as	GBS-TRF	and	treated	with	IVIg	without	an	effect	who	showed	a	spectacular
improvement	after	steroids	when	the	diagnosis	of	A-CIDP	was	made.
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Guillain-Barré	Syndrome	in	Children
Joyce	Roodbol,	Marie-Claire	Y.	de	Wit	and	Bart	C.	Jacobs
First	Presentation
In	1924,	8	years	after	the	name-giving	publication	of	Guillain,	Barré	and	Strohl,	a	study	of	the	first	child
with	the	clinical	presentation	of	GBS	was	published	by	Mettel,	a	paediatrician	from	Michigan	(USA)	[1].
In	the	following	years	more	cases	of	children	with	GBS	were	reported,	most	notably	in	1937	by	Hecht,	a
paediatrician	from	Baltimore	[2].	Hecht	described	7	children	with	a	flaccid	paralysis	attributed	to	“acute
infective	polyneuritis”	in	detail	[2],	of	which	6	children	showed	a	clinical	course	typical	for	GBS.	Hecht
concluded	that	this	illness	is	often	preceded	by	a	respiratory	tract	infection	and	that	the	overall	prognosis
in	children	is	good	without	permanent	paralysis,	although	some	children	may	develop	respiratory	failure
or	die	in	the	acute	stage	of	disease.
Incidence
The	 reported	 incidence	 of	 GBS	 in	 children	 is	 variable,	 and	 may	 differ	 between	 age	 categories	 and
countries	 of	 residence.	 Some	 of	 these	 studies	 are	 based	 on	 the	WHO	 surveillance	 of	 poliomyelitis	 in
children	<15	years	old.	Probably	one	of	the	best	estimates	of	the	incidence	rate	of	GBS	in	children	in	a
Western	country	is	the	surveillance	made	in	Finland	based	on	nationwide	discharge	data	from	1980	until
1986.	The	reported	mean	annual	incidence	rate	was	0.38	per	100,000	children	under	15	years	old	(95%
confidence	 interval	 0.25–0.56	 per	 100,000	 per	 year,	 mean	 population	 at	 risk	 during	 this	 period	 1.02
million).	Remarkably,	 in	a	similar	study	conducted	of	children	from	Bangladesh	under	15	years	old	 the
incidence	ranged	between	1.5	and	2.5	per	100,000	children	[3].	This	much	higher	frequency	of	GBS	in
Bangladesh	may	be	related	to	the	higher	rate	of	exposure	to	infections	compared	to	the	rate	in	high-income
countries.	Most	reports	indicate	that	the	frequency	of	GBS	in	children	is	lower	than	that	in	adults,	and	that
the	frequency	may	vary	between	high-	and	 low-income	countries.	This	difference	may	be	related	 to	 the
rate	of	infections	between	these	countries.
Clinical	Presentation
Probably	the	best	prospectively	collected	cohort	of	paediatric	GBS	comes	from	the	Korinthenberg	group
in	Freiburg,	Germany	[4].	They	included	all	children	with	GBS	from	the	age	of	independent	walking	to	18
years,	from	3	German-speaking	countries	during	a	40-month	period	and	described	them	in	detail.	A	total
of	95	children	fulfilled	 the	diagnostic	 criteria	of	GBS	 (53	boys,	42	girls),	 and	 the	age	 ranged	 from	12
months	 to	 16.5	 years	 (median	 6.2	 years).	Disease	 incidence	 peaked	 during	 the	 cold	months	 (October–
April).	The	most	 frequent	 first-presenting	symptoms	were	unsteadiness	of	gait	 (45%),	neuropathic	pain
(34%)	and	inability	to	walk	(24%).	At	diagnosis,	all	patients	showed	symmetrical	weakness	and	hypo-	or
areflexia;	27%	presented	with	cranial	nerve	dysfunction	and	33%	with	autonomic	dysfunction.	At	nadir,
40%	were	still	able	 to	walk	 independently,	22%	could	walk	with	support,	38%	were	bed-bound,	20%
showed	signs	of	respiratory	failure	and	4	had	to	be	intubated.	In	30%	pain	was	rated	as	severe	or	very
severe.	In	80%	of	all	children	the	CSF	findings	were	typical	for	GBS.	In	most	children,	CSF	protein	was
found	to	be	significantly	elevated	during	the	first	days	of	the	disease.
This	Korinthenberg	study	describes	the	clinical	presentation	of	GBS	in	children	in	detail,	highlighting
the	most	common	complaints	and	the	prognosis,	and	advises	on	the	necessary	care.	This	advice	includes
closely	monitoring	autonomic	involvement	and	emphasizes	 that	neuropathic	pain	is	a	frequent	and	early
diagnostic	 feature,	 occurring	 in	 one-third	 of	 these	 patients.	The	 study	 also	 describes	minor	 differences
between	GBS	in	children	and	adults	which	should	be	considered	when	treating	a	child	with	GBS.
Natural	History
The	clinical	 course	of	GBS	varies	 between	 countries,	 partly	due	 to	 the	 availability	 of	 treatment.	Most
high-income	 countries	 treat	 adult	 and	 children	 with	 GBS	with	 IVIg	 or	 plasma	 exchange	 and	 have	 the
opportunity	to	provide	ICU	care	and	mechanical	ventilation	if	required.	In	low-income	countries	specific
treatments	and	mechanical	ventilation	may	be	available	only	for	a	minority	of	cases.	Before	the	time	of
plasma	 exchange	 and	 IVIg,	 the	 natural	 history	 of	 Guillain-Barré	 syndrome	 in	 adults	 and	 children	was
documented	in	a	Dutch	cohort	of	68	patients	admitted	between	1975	and	1987	[5]	with	GBS	according	to
the	generally	 accepted	 criteria	 [6].	Of	 these	patients,	 18	were	under	15	years	old.	Time	 from	onset	of
weakness	until	reaching	nadir	was	similar	in	children	and	adults.	There	was	also	no	difference	between
children	and	adult	patients	 in	disease	severity,	need	for	mechanical	ventilation,	and	median	duration	of
mechanical	ventilation	and	duration	of	hospitalization.	At	a	2-year	follow-up,	3	children	(17%)	had	not
made	a	complete	recovery.	Of	these	3	children	2	children	died	from	cardiac	arrest,	1	in	the	acute	phase,	1
early	in	the	plateau	phase.	In	both	cases	death	had	been	preceded	by	severe	fluctuations	in	heart	rate	and
blood	pressure.	One	child	had	a	GBS	disability	score	of	2.	Four	adults	made	an	incomplete	recovery	after
2	years	(8%).	This	study	showed	a	very	similar	disease	progression	in	both	adult	and	paediatric	patients,
but	the	groups	were	small.	In	later	published	studies	a	trend	towards	a	milder	disease	course	and	better
outcome	in	children	has	been	described.
Preceding	Infections
The	cohort	study	conducted	by	the	Korinthenberg	group	showed	that	preceding	events	were	reported	in
82%	 (78	 children)	 of	 patients	 [8].	 The	 predominant	 antecedent	 event	was	 a	 respiratory	 tract	 infection
preceding	 GBS	 in	 37%	 (33)	 of	 all	 children,	 followed	 by	 gastrointestinal	 infections	 in	 15%	 (14)	 of
children.	The	infectious	agents	responsible	for	these	infections	in	children	are	unknown.	In	some	cases	the
preceding	infection	may	be	caused	by	Campylobacter	jejuni,	but	the	frequency	seems	to	be	lower	than	in
adult	patients,	where	C.	 jejuni	 is	 the	predominant	cause	of	preceding	 infection.	Multiple	other	 types	of
preceding	 infections	 have	 been	 reported	 in	 children	 with	 GBS,	 most	 frequently	 with	 coxsackievirus,
followed	 by	Chlamydophila	 pneumoniae,	 cytomegalovirus	 and	Mycoplasma	 pneumoniae.	 In	 general,
these	studies	were	conducted	only	in	small	and	potentially	biased	cohorts	of	patients.
Problems	with	Diagnosing	GBS	in	Children
The	diagnosis	of	GBS	is	still	largely	based	on	the	findings	in	the	history	and	neurologic	exam,	since	there
are	no	specific	biomarkers	and	 the	nerve	conduction	studies	and	cerebrospinal	 fluid	examination	 in	 the
early	stage	of	GBS	may	be	normal.	The	history	and	neurological	exam,	however,	may	be	problematic	in
children,	especially	 in	 those	of	 the	preschool	age	(<6	years	old).	We	performed	a	 retrospective	cohort
study	focusing	on	the	clinical	presentation	and	the	delay	in	the	diagnosis	in	preschool	children	and	older
children	[9].	In	this	study	of	55	children,	23	(42%)	were	under	the	age	of	6	years	old.	At	the	first	contact
of	the	patients	with	a	doctor,	in	the	preschool	group	15	patients	(68%)	were	misdiagnosed	initially,	while
in	the	older	group,	6	patients	(21%)	had	another	initial	diagnosis.	The	delay	in	diagnosis,	indicated	by	the
number	of	days	between	the	moment	a	patient	was	first	seen	by	a	physician	and	the	moment	 the	patient
was	 diagnosed	with	GBS	 is	 presented	 in	 Figure	19.1.	 The	 doctors’	 delay	 in	 the	 preschool	 group	was
significantly	longer	than	for	the	older	group	[median	3	(IQR	0–8)	vs.	0	(IQR	0)	days].	The	most	common
other	 initial	diagnoses	were	meningitis	and	coxitis,	mostly	because	of	 the	presence	of	severe	pain	as	a
prominent	presenting	symptom	frequently	leading	to	misdiagnosis.	This	shows	that	for	preschool	children
presenting	with	subacute	pain	in	the	legs	and	difficulty	walking	the	diagnosis	GBS	should	be	considered
even	though	other	diagnosis	are	probably	more	common.
Figure	19.1		Kaplan-Meier	curve	showing	time	to	diagnosis	separated	by	age	groups.	Reproduced	with	permission	from	[9].
The	Role	of	Additional	Testing	in	Diagnosing	Childhood	GBS
GBS	is	a	diagnosis	made	based	on	clinical	presentation	and	neurological	examination.	The	diagnosis	can
be	supported	with	CSF	and	nerve	conduction	studies.	More	recently	there	has	been	interest	in	the	possible
role	MRI	can	have	in	diagnosing	GBS.	Smith	and	colleagues	looked	at	the	role	of	gadolinium-enhanced
MRI	of	the	spine	in	diagnosing	GBS	in	children	and	comparing	it	with	cerebrospinal	fluid	analysis	and
nerve	 conduction	 studies	 [10].	 Twenty-five	 children	 with	 the	 mean	 age	 of	 4	 years	 and	 8	 months,
diagnosed	with	GBS	between	1997	and	2007,	were	retrospectively	reviewed.	Gadolinium-enhanced	MRI
was	 performed	 in	 8	 children	 at	 a	mean	of	 8	 days	 (range	 2–16	days)	 from	 symptom	onset.	 In	 7	 (88%)
children	 there	was	 nerve	 root	 enhancement	 present	 and	 all	 had	 abnormal	CSF	 findings.	 In	 24	 children
NCS	was	performed	and	in	21	children	(88%)	it	was	consistent	with	a	demyelinating	polyneuropathy.	In
20	 children	 a	 lumbar	 puncture	 was	 performed	 and	 in	 16	 children	 (80%)	 cyto-albuminological
dissociation	was	present.	CSF	protein	concentration	was	normal	in	3	children,	at	a	mean	of	3	days	from
onset.	 One	 child	 had	 supportive	 NCS	 when	 the	 gadolinium-enhanced	 spinal	 MRI	 was	 normal.	 Two
children	displayed	positive	nerve-root	enhancement	when	NCS	was	normal,	although	F	waves	were	not
performed.
This	article	concludes	that	GBS	is	often	diagnosed	correctly	but	that	the	consequences	of	missing	other
potential	diagnoses	(cord	compression,	transverse	myelitis)	can	be	catastrophic.	They	believe	that	NCS	is
the	 gold	 standard	 for	 confirming	 the	 diagnosis	 of	GBS	 in	 children,	 but	 that	 gadolinium-enhanced	MRI
provides	a	valuable	addition	to	NCS	in	the	evaluation	of	children	with	suspected	GBS,	especially	when
the	 presentation	 is	 atypical	 and	 if	 the	 child	 is	 presenting	 to	 a	 peripheral	 centre	 were	 paediatric
neurological	and	paediatric	neurophysiological	expertise	is	unavailable.	After	the	MRI	a	lumbar	puncture
can	 be	 performed	 safely	 to	 exclude	 other	 infectious	 diagnosis.	 A	 disadvantage	 of	MRI	 to	 support	 the
diagnosis	 of	GBS	 is	 that	 young	 children	 often	 need	 to	 be	 sedated,	 a	 procedure	 that	 cannot	 always	 be
provided	in	the	acute	setting.
Pain
The	delay	in	diagnosis	and	type	of	initial	diagnosis	indicates	that	pain	may	be	a	frequent	and	predominant
presenting	 feature	of	GBS	 in	children.	Several	 studies	on	 the	occurrence	of	pain	 in	children	with	GBS
have	 been	 published.	 In	 a	 retrospective	 case	 study	 of	 29	 children	 (16	 boys	 and	 13	 girls)	 with	 GBS
younger	than	6	years	old	published	by	Nguyen	and	colleagues,	pain	was	evident	in	23	patients	(79%)	on
admission	and	often	the	most	prominent	symptom	[11].	This	led	to	a	misdiagnosis	in	20	patients	(69%).
The	 prominent	 pain	 syndrome	was	 bilateral	 deep	 lower	 limb	 pain,	 exacerbated	 by	 straight	 leg	 raising
(radicular	pain).	Moreover,	11	patients	(38%)	with	leg	pain	on	examination	were	also	found	to	have	neck
stiffness.	 Also	 headache	 (24%)	was	 often	 described.	Most	 children	 were	 treated	 with	 acetaminophen
(38%);	sometimes	this	was	insufficient	and	additional	pain	medication	was	prescribed.	Very	few	studies
have	reported	on	the	treatment	of	pain	in	children	and	an	evidence-based	and	standardized	protocol	for
daily	practice	is	still	lacking.
Autonomic	Dysfunction
Autonomic	dysfunction,	largely	of	cardiovascular	problems,	in	paediatric	GBS	patients	has	been	carefully
documented.	Watson	and	colleagues	focused	on	hypertension	as	well	as	bladder	dysfunction	in	relation	to
muscle	weakness	in	children	with	GBS	[12].	Twenty-seven	patients	with	GBS	presenting	between	2002
and	 2012	were	 retrospectively	 reviewed.	 Fifty-two	 percent	 of	 the	 patients	 (14)	 developed	 autonomic
dysfunction.	On	average,	autonomic	dysfunction	had	its	onset	at	the	same	time	the	disease	activity	reached
its	 plateau	 phase.	 Twenty-six	 percent	 (7)	 of	 the	 patients	 already	 had	 bladder	 or	 bowel	 sphincter
disturbance	at	 the	 time	of	presentation.	An	additional	3	patients	developed	urinary	 retention	during	 the
course	of	the	disease.	The	development	of	urinary	retention	correlated	significantly	with	weakness	of	all
4	 limbs	 and	 severity	 of	 upper-limb	 weakness.	 Hypertension	 was	 the	 most	 common	 manifestation	 of
autonomic	dysfunction	and	was	seen	in	12	(44%)	patients.	Resolution	or	control	of	the	hypertension	was
statistically	significantly	correlated	with	the	length	of	the	hospital	stay.	Nine	(33%)	patients	required	anti-
hypertensive	 treatment.	 The	 number	 of	 anti-hypertensive	 medications	 required	 correlated	 significantly
with	the	extent	of	muscle	weakness	in	both	upper	and	lower	limbs.	There	was	no	correlation	between	the
presence	of	persistent	hypertension	and	the	severity	of	neuropathic	pain	or	the	number	of	medicines	used
to	control	paresthesia.
This	 article	 confirmed	 previously	 presented	 data	 that	 50%	 of	 children	 with	 GBS	may	 suffer	 from
autonomic	 involvement.	But	 this	article	describes	 in	greater	detail	 the	 time	of	occurrence	of	autonomic
dysfunction	during	the	disease	course.	The	relation	between	neuropathic	pain	and	hypertension	is	always
considered	in	patients	with	severe	neuropathic	pain,	but	this	article	shows	that	this	is	not	always	correct.
Possibly	the	occurrence	of	hypertension	is	underestimated	in	children	with	GBS.
Treatment
There	are	only	a	few	randomized	trials	performed	regarding	treatment	of	GBS	in	children.	The	trial	of	El-
Bayoumi	 and	 colleagues	 compared	 PE	with	 IVIg	 in	mechanically	 ventilated	 children	with	GBS.	 They
concluded	that	children	with	GBS	requiring	mechanical	ventilation	respond	favourably	to	both	IVIg	and
PE	[7].	A	trial	looking	at	the	treatment	effect	of	different	regiments	of	IVIg	and	the	time	to	start	treatment
has	 been	 conducted	 by	 Korinthenberg	 and	 colleagues	 [13].	 In	 their	 multicentre	 study,	 63	 hospitals
participated	 and	 95	 children	 were	 included	 over	 a	 period	 of	 40	 months.	 They	 were	 divided	 in	 to	 2
groups:	the	early	and	late	treatment	study.	The	children	still	able	to	walk	unaided	(early	treatment	study)
were	randomized	for	1g/kg	IVIg	over	2	days	versus	no	immune	treatment.	The	children	who	were	unable
to	walk	unaided	(late	treatment	study)	were	randomized	for	2g/kg	IVIg	over	2	days	versus	2g/kg	IVIg	over
5	days.	Treatment	was	 to	be	 initiated	as	soon	as	possible	after	 the	randomization.	Twenty-one	children
were	included	in	the	early	treatment	study	and	51	children	in	the	late	treatment	study.	The	study	concluded
that	treatment	with	IVIg	before	loss	of	unaided	walking	ability	did	not	give	rise	to	a	less	severe	course,
but	 recovery	 occurred	 somewhat	 faster.	 For	 treatment	 after	 loss	 of	 unaided	 walking,	 there	 was	 no
significant	difference	in	the	effectiveness	of	2g/kg	IVIg	administered	over	2	days	versus	5	days,	but	early
relapses	occurred	more	 frequently	after	 the	 shorter	 treatment	 regimen.	Before	 this	 study,	 children	were
treated	the	same	as	adults	without	the	knowledge	whether	or	not	this	was	also	effective	in	children.	This
study	indicated	that	IVIg	was	also	effective	in	children	and	that	the	currently	used	method	of	starting	with
treatment	 only	 if	 the	 patient	 is	 unable	 to	 walk	 unaided	 is	 also	 sufficient	 in	 children.	 An	 important
remaining	 question,	 however,	 is	whether	 the	 dosage	 regimen	used	 in	 adults	 and	 tested	 in	 this	 paper	 is
optimal	 in	 children	 of	 all	 ages,	 or	 whether	 the	 amount	 of	 IVIg	 should	 be	 adjusted	 based	 on	 body
composition	of	the	growing	child.
The	Future
In	 the	 last	 few	 years	 a	 rise	 in	 the	 number	 of	 publications	 regarding	 childhood	 GBS	 has	 been	 seen,
especially	 from	 low-income	countries.	For	 further	 reading	we	 recommend	a	 review	of	paediatric	GBS
published	 in	 2013	 by	 M.	 Ryan	 that	 describes	 the	 variable	 clinical	 and	 neurophysiologic	 subtypes	 of
paediatric	GBS,	 including	 the	 increased	use	of	MRI	 in	diagnosing	GBS	and	 the	various	 aspects	of	 the
natural	history	and	treatment	response	that	are	still	poorly	understood	[14].	Several	important	aspects	of
paediatric	need	to	be	further	investigated,	including	the	following	topics:
While	the	overall	prognosis	of	children	is	good,	the	mental	impact	of	GBS	on	a	child	should	also	be
considered	during	follow-up.	There	 is	no	guideline	available	at	present	on	how	children	with	GBS
can	be	best	supported.
Most	outcome	measures	were	developed	for	adult	patients	with	GBS,	and	there	is	a	need	to	develop
such	outcome	measures	for	children	with	GBS.
There	are	no	models	 to	predict	 the	chance	of	respiratory	failure	or	 long-term	outcome	in	individual
children	with	GBS.
The	 optimal	 plasma	 exchange	 and	 IVIg	 treatment	 regiments	 are	 unknown	 for	 children	 with	 GBS.
Children	are	currently	treated	with	the	same	regiments	evaluated	in	adult	patients,	but	these	regimens
are	likely	less	than	optimal	in	children	with	GBS.
Pain	is	a	major	problem	for	children	with	GBS	but	there	is	very	little	information	available	on	how
children	can	best	be	treated.
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The	Differential	Diagnosis	of	GBS
Robert	D.M.	Hadden
Introduction
When	 a	 previously	 healthy	 person	 develops	 a	 mysterious	 illness	 and	 collapses,	 many	 suspicions	 are
aroused.	Who	better	to	investigate	than	James	Bond,	the	fictional	British	(Scottish)	secret	agent	007?	As	I
attended	the	same	school	as	Bond,	I	suggest	the	Bond	film	titles	may	help	to	classify	and	enliven	the	long
list	of	diagnostic	possibilities.	The	following	is	my	personal	selection	of	the	most	common	or	interesting
conditions	which	may	be	confused	with	Guillain-Barré	syndrome	(GBS),	although	 it	 is	not	meant	 to	be
comprehensive.
Diagnosis	can	be	difficult,	particularly	in	the	early	stages.	Even	in	formal,	randomised	clinical	trials
of	GBS	where	one	would	expect	a	greater	degree	of	certainty,	around	1%	of	enrolled	patients	turn	out	to
have	 a	 diagnosis	 other	 than	 GBS	 or	 acute-onset	 chronic	 inflammatory	 demyelinating
polyradiculoneuropathy	 (CIDP).	My	 informal	 survey	 of	 1,192	 patients	 in	 6	 published	 trials	 and	 series
showed	14	 (1.2%)	were	 later	diagnosed	as	 another	 condition,	 such	as	myelitis,	 botulism,	vasculitis	or
spinal	disc	herniation	[1,2,3].
Casino	Royale
Wakerley	BR,	Yuki	N.	Mimics	and	chameleons	in	Guillain-Barré	and	Miller	Fisher
syndromes.	Practical	Neurology,	2015
The	answer	to	‘why	did	it	happen	to	me?’	is	usually	just	bad	luck.	The	roulette	wheel	of	life	may	provoke
a	wide	range	of	different	conditions.	Bond	is	familiar	with	disguise	and	deceit,	and	Waverley	and	Yuki’s
article	[4]	is	a	clear	and	practical	clinical	guide	to	conditions	that	may	mimic	GBS	and	its	variants,	and
‘chameleons’	 in	which	GBS	mimics	 other	 conditions.	The	 same	 authors	 also	 recently	 proposed	 a	 new
diagnostic	 classification	 for	 the	 generalised	 and	 incomplete	 variants	 of	 GBS	 and	 (Miller)	 Fisher
syndrome	(MFS)	[5].	The	distinction	between	GBS	and	acute-onset	CIDP	is	covered	in	another	chapter.
The	Man	with	the	Golden	Gun:	Reflexes	and	Basic	Clinical	Skills
Yuki	N,	et	al.	Guillain-Barré	syndrome	associated	with	normal	or	exaggerated	tendon
reflexes.	The	Journal	of	Neurology,	2012
Although	Bond	is	supplied	with	the	latest	technical	gadgets	by	Q,	he	mainly	relies	on	his	quick	reflexes
and	 one	 core	 item	 of	 equipment	 to	 back	 up	 his	 personal	 skills.	 Advances	 in	 ultrasound	 [6],	 contrast-
enhanced	MRI	of	nerve	roots	 [7]	and	other	supportive	 tests	have	not	substantially	changed	 the	fact	 that
diagnosis	 of	 GBS	 is	 primarily	 based	 on	 clinical	 history	 and	 examination	 by	 the	 ‘neurologist	 with	 the
black	 tendon	 hammer’.	 The	 iPhone’s	 inbuilt	 accelerometer	 and	 gyroscope	 have	 been	 used	 to	 record
electronically	and	analyse	the	time	characteristics	of	the	tendon	reflex	[8].
Unfortunately	even	the	reflexes	are	diagnostically	unreliable:	23	(11%)	of	213	Japanese	patients	had
normal	or	brisk	reflexes	throughout	the	entire	disease	course	[9].	These	patients	were	more	likely	to	have
acute	motor	 axonal	 neuropathy	 (AMAN),	milder	 disease	 and	 anti-ganglioside	GM1,	GM1b,	GD1a,	 or
GalNAc-GD1a	antibodies.	In	a	European	population,	as	expected	from	the	lower	prevalence	of	AMAN,
this	proportion	was	lower:	9%	of	patients	had	normal	reflexes	in	weak	limbs	at	onset,	of	which	2%	had
persistently	normal	reflexes	[3].
Skyfall:	Spinal	Syndromes
Cakir	E,	et	al.	Clinical	course	of	spontaneous	spinal	epidural	haematoma	mimicking
Guillain-Barré	syndrome	in	a	child:	a	case	report	and	literature	review.	Developmental
Medicine	&	Child	Neurology,	2004
Falls	are	a	common	cause	of	traumatic	spinal	injury,	especially	in	the	elderly	where	a	minor	fall	(from	a
lesser	 height	 than	 the	 sky)	 may	 exacerbate	 pre-existing	 subclinical	 spondylotic	 cervical	 myelopathy.
Acute	cord	injury	may	cause	reduced	reflexes,	and	the	time	course	of	transverse	myelitis	is	identical	to
GBS	[10].	Cauda	equina	compression	may	simulate	paraparetic	GBS,	and	radicular	pain	 is	common	in
GBS.	 The	 textbook	 distinguishing	 factors	 (sphincter	 disturbance,	 sensory	 level,	 perineal	 sensory
disturbance)	may	be	hard	to	identify	in	milder	cases.
Quantum	of	Solace:	Pain
Ruts	L,	et	al.	Pain	in	Guillain-Barré	syndrome:	a	long-term	follow-up	study.	Neurology,
2010
Solace	(meaning	comfort	or	consolation	in	a	time	of	great	distress	or	sadness)	is	in	short	supply	for	the
sufferer	of	GBS.	The	Dutch	GBS	Study	Group	described	how	very	common	pain	 is	 in	GBS	 [11].	 In	 a
cohort	of	156	patients,	36%	had	pain	before	the	onset	of	weakness,	66%	had	pain	within	the	first	month
after	onset	and	38%	still	had	pain	after	one	year.	Pain	at	the	time	of	onset	was	often	severe,	typically	in
the	 extremities,	 especially	 radicular	 pain,	 painful	 paraesthesiae	 and	 muscle	 pain.	 Neuropathic	 pain
medication	may	give	a	small	quantum	of	solace.
However	a	patient	who	 is	weak	and	 in	pain	may	not	have	GBS,	but	 instead	pain-related	 functional
weakness.	A	non-neural	cause	of	back	pain	is	a	common	cause	of	apparent	weakness	in	the	lower	limbs
and	gait	disturbance,	 theoretically	distinguishable	by	 the	preserved	 reflexes,	except	when	 the	patient	 is
unable	to	relax.	The	knowledge	that	they	don’t	have	a	serious	neural	disease	may	be	little	solace.
Dry	Martini,	Shaken	Not	Stirred:	Metabolic	Causes
Wöhrle	JC,	et	al.	Alcohol-related	acute	axonal	polyneuropathy:	a	differential	diagnosis	of
Guillain-Barré	syndrome.	Archives	of	Neurology,	1998
Chronic	 alcoholism	 often	 causes	 axonal	 neuropathy,	 of	 which	 occasional	 cases	 may	 have	 acute	 onset
flaccid	tetra-paresis	within	2	weeks	[12].	Typically	these	patients	are	very	heavy	drinkers	and	have	lost
substantial	weight	due	to	poor	nutrition	and	likely	thiamine	deficiency.	CSF	protein	is	typically	normal.
Malnutrition	neuropathy	may	alternatively	be	due	to	bariatric	surgery	or	hyperemesis	of	pregnancy.	The
clue	is	the	history	of	severe	weight	loss	and	often	liver	abnormalities.	I	am	not	aware	of	any	randomised
trials	comparing	the	toxicity	of	cocktails	shaken	versus	stirred.
Hypokalaemia	with	acute	flaccid	weakness	may	be	due	to	various	underlying	causes	leading	to	a	final
common	pathway	of	myopathy	[13].	Apart	from	familial	hypokalaemic	periodic	paralysis,	causes	include
thyrotoxicosis,	 prolonged	 vomiting	 or	 diarrhoea,	 renal	 tubular	 acidosis,	 hyperaldosteronism,	 and
liquorice	 or	 barium	 toxicity.	 Many	 other	 metabolic	 disturbances	 may	 cause	 acute	 weakness:	 severe
hypophosphataemia	 or	 hypermagnesemia	 may	 cause	 acute	 neuropathy;	 diabetic	 lumbosacral
radiculoplexus	neuropathy	causes	weight	loss,	malaise	and	pain;	and	of	course	the	bedbound	patient	with
sepsis	or	an	acute	general	medical	condition	is	weak,	albeit	not	in	the	conventional	neural	sense.
Porphyria	 should	 be	 suspected	 when	 a	 GBS-like	 syndrome	 is	 accompanied	 by	 encephalopathy
(confusion	and	sometimes	 seizures)	and	abdominal	pain.	There	may	be	proximal	asymmetric	weakness
and	 numbness	 due	 to	 polyradiculopathy	 or	 neuronopathy	 [14].	 Screening	 for	 urine	 porphobilinogen
identified	a	remarkably	high	12	patients	(11%)	with	previously	undiagnosed	acute	porphyria	in	a	Russian
cohort	 of	 108	 patients	 with	 acute	 polyneuropathy	 or	 encephalopathy,	 together	 with	 pain	 (in	 back	 or
abdomen)	and/or	dysautonomia,	 though	another	11	 (10%)	were	 false	positives	due	 to	 liver	dysfunction
[15].
The	Spy	Who	Loved	Me:	Infections
Brannagan	TH	3rd,	Zhou	Y.	HIV-associated	Guillain-Barré	syndrome.	The	Journal	of	the
Neurological	Sciences,	2003
Bond’s	sexual	promiscuity	increases	his	risk	of	infection.	HIV-associated	GBS	may	occur	at	any	stage	of
infection	 from	 seroconversion	 to	AIDS,	with	CD4	 counts	 ranging	 from	55	 to	 800/µl	 in	 a	 series	 of	 10
patients	 [16].	 Cerebrospinal	 fluid	 (CSF)	 leukocyte	 count	 may	 be	 normal	 or	 mildly	 raised	 (0–17
leukocytes/µl).	Immunosuppressed	patients	may	develop	myelo-radiculo-neuropathy	due	to	opportunistic
infection	with	various	herpes	viruses.
Several	neurotropic	viruses	may	cause	acute	pure	motor	asymmetric	flaccid	paralysis	due	to	myelitis
affecting	the	anterior	horn	cells	(anterior	poliomyelitis	syndromes).	These	include	West	Nile	virus	[17],
enterovirus	71	or	coxsackievirus,	as	well	as	the	near-eliminated	poliomyelitis	virus.	There	is	typically	a
prodromal	 febrile	 meningitis	 illness	 with	 myalgia	 or	 diarrhoea,	 with	 CSF	 pleocytosis,	 and	MRI	 may
show	necrotising	myelopathy.	Other	viral	myelitis	 syndromes	 include	herpes	 simplex	and	 rabies.	Lyme
borreliosis	may	cause	a	meningoradiculitis	with	facial	palsy.
Although	CSF	pleocytosis	is	one	of	the	usual	pointers	towards	an	infectious	cause,	CSF	pleocytosis	of
up	to	230	leucocytes/µl	(sometimes	polymorphonuclear)	has	been	reported	in	idiopathic	GBS,	especially
early	or	in	severe	fulminant	cases	[18].
Licence	to	Kill:	Toxins
McCormack	J,	McKinney	W.	Thallium	poisoning	in	group	assassination	attempt.	The
Postgraduate	Medical	Journal,	1983
Thallium	may	be	considered	 the	perfect	poison	due	 to	being	 tasteless,	odourless	and	colourless.	 It	has
been	used	in	many	notorious	cases	of	murder,	by	Saddam	Hussein	against	dissidents	and	in	the	Bond	film
Spectre.	 Thallium	 poisoning	 causes	 acute	 progressive	 sensory-motor	 polyneuropathy	 with	 prominent
painful	 paraesthesiae,	 as	 well	 as	 gastrointestinal	 disturbance,	 ophthalmoplegia,	 and	 cerebellar	 and
extrapyramidal	features,	but	is	often	not	considered	until	the	development	of	alopecia	2	or	3	weeks	later
[19].	Prussian	blue	and	haemodialysis	may	be	beneficial.	Arsenic	toxicity	may	cause	acute	demyelinating
neuropathy	with	diarrhoea	and	vomiting,	confirmed	by	urine	analysis	[20].
Organophosphate	poisoning	has	occurred	due	 to	high-dose	exposure	 to	 agricultural	 insecticide	 crop
sprays	(especially	tri-ortho-cresylphosphate),	antiparasitic	sheep	dip,	or	historical	contamination	of	food
products.	Two	terrorist	attacks	with	sarin	in	Japan	in	the	1990s	killed	19	and	injured	6,000	people	[21].
Acute	poisoning	causes	an	acute	muscarinic	syndrome	with	diarrhoea,	salivation	and	miosis.	Weakness
due	to	neuromuscular	blockade	(and	encephalopathy)	occurs	after	hours	to	days,	and	typically	recovers	in
a	 week	 or	 two.	 A	 few	 weeks	 after	 initial	 exposure	 and	 recovery,	 some	 patients	 develop	 subacute
‘organophosphate-induced	delayed	polyneuropathy’,	a	distal	predominantly	motor	axonal	neuropathy	with
ataxia	 [22].	 Chronic	 low-dose	 exposure	 to	 organophosphates	 (at	 doses	 insufficient	 to	 cause	 acute
symptoms)	does	not	cause	neuropathy.
Pharmaceutical	 drugs	 occasionally	 cause	 acute	 severe	 axonal	 neuropathy,	 including	 nitrofurantoin,
colchicine,	 chloroquine	 and	 chemotherapy	 drugs	 (vincristine,	 taxols,	 platinum	 compounds	 and
bortezomib).	Acute	demyelinating	neuropathy	is	sometimes	caused	by	suramin	or	gold.
During	his	many	travels	abroad,	Bond	may	have	encountered	various	animal	and	fish	toxins	that	can
mimic	AMAN.	Tick	bite	paralysis	(not	to	be	confused	with	Lyme	borreliosis)	causes	rapidly	worsening
tetra-paresis	 in	 endemic	 regions	 (United	 States	 and	 Australia)	 due	 to	 a	 sodium	 channel	 toxin	 which
recovers	rapidly	on	removal	of	the	tick	[23].	Ingested	neurotoxins	after	eating	pufferfish	(tetrodotoxin)	or
bivalve	shellfish	(saxitoxin)	may	cause	vomiting	and	paralysis.
Golden	Eye	CU:	Critical	Illness	Polyneuropathy
Zhou	C,	et	al.	Critical	illness	polyneuropathy	and	myopathy:	a	systematic	review.	Neural
Regeneration	Research,	2014
In	 patients	 on	 an	 intensive	 care	 unit	 (ICU)	 who	 are	 too	 weak	 to	 be	 weaned	 from	 the	 ventilator,	 it	 is
sometimes	 uncertain	whether	 they	 have	GBS	 or	 critical	 illness	 polyneuropathy	 (CIP)	 [24].	 The	 neural
examination	is	similar,	though	CIP	is	distally	predominant	and	only	rarely	affects	cranial	nerves.
Usually	 the	 distinction	 is	 obvious	 from	 the	 history:	 a	 diagnosis	 of	 GBS	 is	 supported	 by	 onset	 of
weakness	before	 ICU	admission,	or	 recovery	of	 any	preceding	 infection	before	 the	onset	of	weakness.
CIP	affects	over	a	 third	of	severely	 ill	patients	 in	 ICU,	especially	 those	with	acute	 respiratory	distress
syndrome,	 sepsis,	or	 systemic	 inflammatory	 response	 syndrome,	 and	almost	100%	of	 those	with	multi-
organ	failure.	Additional	risk	factors	for	CIP	include	hyperglycaemia	and	gram	negative	bacteraemia.	The
pathogenesis	 of	 CIP	 is	 likely	 a	 combination	 of	microcirculatory	 abnormality,	metabolic	 derangements,
reversible	channelopathy,	and	bioenergetic	dysfunction.	Many	patients	also	have	critical	illness	myopathy,
which	is	more	common	following	corticosteroids	and	usually	gives	a	raised	creatine	kinase.	Prolonged
use	 of	 neuromuscular	 blocking	 agents	 (especially	 vecuronium	 bromide)	 also	 may	 lead	 to	 persistent
weakness.	 Where	 the	 distinction	 is	 difficult,	 GBS	 is	 supported	 by	 (usually)	 demyelinating
neurophysiology	 or	 raised	 CSF	 protein,	 whereas	 CIP	 has	 axonal	 neurophysiology	 and	 normal	 CSF
protein.
You	Only	Live	Twice
Zhang	L,	et	al.	Guillain-Barré	syndrome	after	transplantation.	Leukemia	&	Lymphoma,
2008
After	 death,	 many	 of	 our	 organs	 can	 live	 on	 through	 transplantation.	 Demyelinating	 neuropathies
resembling	 GBS	 or	 CIDP	may	 occur	 in	 0.3–0.7%	 of	 patients	 following	 solid	 organ	 or	 bone	 marrow
transplant	[25],	or	indeed	following	chemotherapy	or	biological	drugs	affecting	the	immune	system.	The
time	delay	from	transplant	to	GBS	onset	is	typically	a	few	months,	but	may	range	from	days	to	years.	The
pathogenesis	 is	 unclear	 but	 may	 be	 related	 to	 an	 immune	 reconstitution	 syndrome,	 graft-versus-host
disease	or	opportunistic	infection.	Such	neuropathies	usually	respond	well	to	intravenous	immunoglobulin
or	plasma	exchange.
For	Your	Eyes	Only:	Cranial	Nerve	Syndromes
Cherington	M.	Clinical	spectrum	of	botulism.	Muscle	&	Nerve,	1998
Variants	of	GBS	predominantly	affecting	the	extraocular	muscles	and	cranial	nerves	have	an	alternative
differential	 diagnosis.	 The	 following	 may	 mimic	 MFS,	 Bickerstaff’s	 brainstem	 encephalitis	 or	 the
pharyngo-cervico-brachial	variant	of	GBS.
Botulism	is	an	acute,	toxic,	pure	motor	and	autonomic	syndrome,	with	ophthalmoplegia,	ptosis,	dilated
pupils	 and	 faciobulbar	 weakness,	 and	 later	 descending	 limb	 weakness,	 preceded	 by	 diarrhoea	 and
vomiting	if	the	source	is	foodborne	[26].	Diagnosis	is	by	neurophysiological	demonstration	of	presynaptic
block	 or	 culture	 of	 the	 organism.	 Treatment	 is	 by	 antitoxin.	 Myasthenia	 gravis	 may	 also	 cause	 acute
ophthalmoplegia.
Wernicke’s	 encephalopathy	 is	 characterised	 by	 acute	 confusion,	 ataxia	 and	 nystagmus	 or
ophthalmoparesis,	 due	 to	 thiamine	 deficiency,	 typically	 occurring	 in	 alcoholics	 or	 following	 gastric
surgery	or	chronic	vomiting.	Diagnosis	may	be	confirmed	by	typical	MRI	changes	in	the	medial	thalami,
mamillary	bodies,	midbrain	and	sometimes	cerebellum.
Diphtheria	 causes	 bulbar-onset	 demyelinating	 neuropathy	 [27].	 A	 few	 weeks	 after	 pharyngitis
(typically	with	a	visible	grey	pseudomembrane),	patients	may	develop	bulbar	palsy	with	facial	numbness
and	often	respiratory	failure.	This	may	be	improving	before	limb	weakness	and	numbness	worsens	slowly
over	weeks.	Neuropathy	is	due	to	an	exotoxin	not	direct	infection,	but	antitoxin	is	beneficial	only	within
the	first	few	days.	Diagnosis	is	by	throat	swab	and	CSF	leukocyte	count	is	sometimes	raised.
Die	Another	Day
Rigamonti	A,	et	al.	Guillain-Barré	syndrome	mimicking	brain	death.	Journal	of	the
Peripheral	Nervous	System,	2009
The	ultimate	differential	diagnosis	is	between	life	and	death.	The	British	television	hospital	drama	series
Holby	City	once	asked	my	advice	on	how	to	fake	the	brainstem	reflexes	in	an	actor	playing	brain-dead	on
intensive	 care,	 which	 we	 arranged	 using	 plastic	 ice	 cubes	 and	 a	 misplaced	 ‘endotracheal’	 tube.
Fortunately	this	doesn’t	happen	in	real	life	…	or	does	it?	Occasional	cases	of	severe	GBS	mimic	brain
death	by	losing	all	motor	function	including	brainstem	reflexes,	resulting	in	‘locked-in	syndrome’	[28].
Dr	No?	Conclusion
Although	the	amateur	diagnostician	may	rely	on	Google	or	myriad	tests,	the	correct	diagnosis	is	still	most
likely	to	be	reached	by	a	well-read	neurologist	[29]	with	enough	time	to	take	a	history.
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GBS	Reflections:	What	GBS	Patients	Have	Taught
Me	Over	My	Career:	10	Lessons	from	Experience!
John	Winer
Introduction
I	have	 spent	25	years	working	as	 a	 consultant	neurologist	 in	 a	busy	 regional	 centre	 in	England.	 I	have
researched	GBS	and	looked	after	many	sick	patients	with	 the	disease.	I	 first	became	interested	in	GBS
while	working	with	Richard	Hughes	and	attending	his	district	neurology	clinics	in	Ashford	as	a	medical
registrar.	Subsequently	we	worked	together	on	an	epidemiological	and	immunological	study	in	the	south
of	England.	This	was	a	sort	of	mini	IGOS,	but	we	spent	almost	all	of	our	time	looking	for	conventional
protein	 antibodies	 since	 anti-ganglioside	 antibodies	 were	 only	 just	 being	 recognised	 in	 neuropathies.
Timing	was	never	my	best	point!	We	were	able	to	show	that	Campylobacter	was	clearly	linked	to	some
patients	with	GBS.
No	matter	how	well	trained	you	are	there	are	many	things	that	patients	can	teach	you.	Sometimes	these
lessons	 can	 be	 painful,	 sometimes	 thought	 provoking	 but	 always	 helpful.	 This	 contribution	 tries	 to
condense	my	experience	into	10	learning	points.	Not	everyone	will	agree	and	this	represents	a	personal
reflection	so	please	read	with	a	health	warning!
Lesson	1:	Predicting	Outcome
Winer	JB,	et	al.	A	prospective	study	of	acute	idiopathic	neuropathy.	Journal	of	Neurology,
Neurosurgery	&	Psychiatry,	1988;	van	Koningsveld	R,	et	al.	A	clinical	prognostic	scoring
system	for	Guillain-Barré	syndrome.	The	Lancet	Neurology,	2007
I	wrote	a	thesis	on	how	to	predict	outcome	in	GBS	[1],	but	after	a	few	years	of	becoming	a	consultant	I
realised	that	this	information	was	of	limited	use	in	managing	patients.	I	can	see	that	for	clinical	trials	it	is
useful	 to	 identify	groups	 that	 respond	poorly	 to	current	 therapies	 [2].	There	are	also	some	patients	 that
need	 to	 know	 their	 statistical	 chance	 of	 making	 a	 full	 recovery.	 Many	 others	 need	 encouragement	 to
improve	with	physiotherapy	and	do	not	need	 their	hope	 for	 recovery	dashed.	Our	models	 for	 recovery
have	wide	error	bars	and	this	is	a	concept	difficult	for	patients	to	grasp.	I	have	seen	patients	with	severe
deficit	 following	C.	 jejuni	with	 rapid	onset	of	weakness	and	worrying	electrics	who	have	made	a	 full
recovery	 despite	 everything.	 These	 are	 probably	 the	 ones	with	 reversible	 conduction	 block	 and	 early
electrical	studies	often	miss	them.	Perhaps	they	are	in	a	minority	but	for	those	individual	patients	that	is
irrelevant.	There	are	some	patients	that	react	to	being	told	they	are	in	a	poor	prognostic	group	by	vowing
to	 prove	 their	medical	 attendants	wrong	 but	 I	 suspect	 that	more	 are	 discouraged.	When	we	 have	 new
treatments	to	offer	this	group	things	may	be	different.
Lesson	2:	Treatment-Related	Fluctuations
Visser	LH,	et	al.	Risk	factors	for	treatment	related	clinical	fluctuations	in	Guillain-Barré
syndrome.	Journal	of	Neurology,	Neurosurgery	&	Psychiatry,	1998;	Ruts	L,	et	al.
Distinguishing	acute-onset	CIDP	from	Guillain-Barré	syndrome	with	treatment	related
fluctuations.	Neurology,	2005
Studies	on	the	effectiveness	of	both	plasma	exchange	and	IVIg	have	shown	that	they	both	reduce	the	time
taken	 to	 improve	 in	 functional	grades	as	well	 as	 time	 in	an	 intensive	care	unit	 and	other	outcomes.	Of
course	this	does	not	mean	that	all	patients	that	are	treated	will	stop	deteriorating	and	start	to	improve.	In
fact,	 quite	 a	 few	 patients	 do	 show	 some	 deterioration	 after	 treatment	 [3,4]	 and	 still	 end	 up	 having	 a
shorter	 disease	 course	 than	 might	 have	 occurred	 if	 they	 had	 not	 received	 treatment.	 We	 are	 just	 not
comfortable	 if	 any	 patients	 continue	 to	 get	 worse	 after	 we	 have	 treated	 them.	 Hopefully	 we	 will
eventually	know	more	 about	 the	benefit	 of	 repeating	 treatment	 in	 these	patients	 and	we	all	 await	 these
studies	with	expectation.	For	the	moment	we	have	to	balance	the	side	effects	of	a	second	course	IVIg	or
PE	 against	 an	 unproven	 benefit.	 Neurologists	 are	 divided	 on	 what	 to	 do,	 and	 I	 favour	 holding	 off
retreatment	unless	the	deterioration	is	significant.	Perhaps	less	difficult	is	the	patient	who	has	a	treatment-
related	fluctuation	6	weeks	after	IVIg	who	seems	to	recover	spontaneously	after	a	couple	of	weeks.
Lesson	3:	Recognising	GBS	Common	Mistakes
Hughes	RA,	Guillain-Barré	Syndrome	(Clinical	Medicine	and	the	Nervous	System).
Springer-Verlag.	London,1990;	Wakerley	BR	and	Yuki	N.	Mimics	and	chameleons	in
Guillain-Barré	and	Miller	Fisher	syndromes.	Practical	Neurology,	2015
I	would	consider	myself	an	expert	on	GBS,	but	I	have	made	lots	of	mistakes	in	making	the	diagnosis	over
the	years.	One	of	the	first	patients	I	studied	for	my	MD	was	an	inpatient	with	a	rapidly	progressive	flaccid
areflexic	quadriparesis	who	turned	out	to	have	neuromyelitis	optica	at	autopsy.	The	patient	did	develop
optic	 atrophy	 some	weeks	 into	 the	 illness	but	otherwise	 looked	 just	 like	GBS.	All	 trials	 of	GBS	have
included	the	occasional	patients	with	MS	presenting	as	an	apparently	lower	motor	neurone	disorder	that
only	later	shows	on	scan	or	clinically	as	a	CNS	disorder.	In	the	emergency	department	I	have	been	caught
out	with	acute	polymyositis	and	hypokalemia,	although	both	became	clear	with	 later	blood	 tests.	Brain
stem	strokes	can	mimic	Miller	Fisher	or	vice	versa.	An	infamous	case	on	the	ITU	of	my	district	hospital
just	before	I	started	as	a	consultant	was	thought	to	be	brain	stem	dead	with	no	brain	stem	reflexes	and	an
internal	ophthalmoplegia	but	 turned	out	 to	have	normal	alpha	rhythm	on	an	EEG!	I	have	seen	porphyria
mimic	 GBS	 with	 a	 subacute	 presentation.	 The	 distinction	 of	 GBS	 with	 acute	 onset	 CIDP	 is	 always
difficult	but	can	be	helped	by	an	obsessive	history	from	both	patient	and	relative	[5,6].
Lessons	4	and	5:	Recognising	Incipient	Respiratory	Failure	and	the
Dangers	of	Oxygen
Chevrolet	JC	and	Deleamont	P.	Repeated	vital	capacity	measurements	as	predictive
parameters	for	mechanical	ventilation	need	and	weaning	success	in	the	Guillain-Barré
syndrome.	American	Review	of	Respiratory	Disease,	1991;	Nunn	JF.	Applied	Respiratory
Physiology.	Oxford:	Butterworth-Heinemann,	1987
Twenty-five	 percent	 of	 GBS	 patients	 need	 respiratory	 support,	 and	 recognising	 which	 patients	 need
transfer	 to	 the	 ITU	 is	 critically	 important	 [7,8].	 In	our	unit	we	 try	 to	monitor	 all	patients	who	are	 still
deteriorating	with	a	full	vital	capacity	(FVC)	but	others	use	alternative	measures	of	respiratory	reserve
such	as	 sniff	 pressures.	Getting	 the	message	 across	 to	our	 juniors	 that	 peak-flow	measurements	 can	be
unreliable	is	hard,	and	it	often	just	takes	experience	to	see	when	a	patient	is	struggling	for	breath	when
speaking.	Strangely,	some	patients	with	GBS	have	very	low	vital	capacities	but	do	not	appear	to	be	short
of	 breath	 or	 in	 apparent	 distress.	 I	 have	 always	 wondered	 if	 this	 was	 because	 of	 their	 autonomic
neuropathy	masking	 some	 of	 the	 lung	 receptors	 that	 normally	 create	 dyspnoea.	 Not	 being	 comfortable
lying	flat	is	always	a	worrying	sign.	If	a	GBS	patient	tells	you	they	are	short	of	breath	even	when	they	do
not	look	like	it	I	always	take	it	very	seriously.	Our	juniors	are	tempted	to	give	such	patient	oxygen	but	we
have	 made	 it	 a	 rule	 that	 oxygen	 cannot	 be	 prescribed	 for	 a	 neuromuscular	 patient	 without	 consultant
approval.	 If	 the	 problem	 is	 a	 ventilation	 issue	 with	 healthy	 lungs,	 oxygen	 will	 not	 influence	 the	 CO2
levels,	and	although	it	might	increase	alveolar	oxygen	a	little	it	stands	a	chance	of	making	the	hypercapnia
worse.	At	the	very	least	its	prescription	is	a	distraction	from	getting	the	patient	into	ITU	as	an	emergency.
Lesson	6:	Late	Complications
Darweesh	SK,	et	al.	Health-related	quality	of	life	in	Guillain-Barré	syndrome	patients:	a
systematic	review.	Journal	of	the	Peripheral	Nervous	System,	2014
Neurologists	are	very	involved	in	the	acute	side	of	GBS	but	our	skills	and	experience	are	less	suited	to
late	 complications	 of	 the	 disease	 [9].	 Severe	 muscle	 atrophy	 can	 lead	 to	 contractures,	 persistent
hypoventilation,	pain	and	weakness.	A	colleague	with	a	good	knowledge	of	rehabilitation	techniques	and
access	to	innovative	aids	and	supports	can	transform	the	life	of	a	patient	with	residual	deficit.	Hopefully,
the	move	 from	 intensive	 physiotherapy	 to	 rehabilitation	 and	 support	will	 be	 seamless,	 but	 I	 have	 seen
cases	where	the	patient	feels	abandoned	when	the	active	treatment	phase	of	the	disease	is	over	and	this
transition	is	poor.	Pain	is	a	common	problem	in	GBS,	both	in	the	acute	phase	and	during	rehabilitation.
This	 has	 received	 less	 attention	 in	 the	 literature	 over	 the	 years	 and	 we	 have	 all	 developed	 our	 own
strategies	for	trying	to	help.	I	favour	asking	the	advice	of	a	pain	expert,	especially	later	on	in	the	course	of
the	disease.
Lesson	7:	Autonomic	Problems	and	Bradycardia	in	the	ITU
Winer	JB	and	Hughes	RA.	Identification	of	patients	at	risk	of	arrhythmia	in	the	Guillain-
Barré	syndrome.	Quartely	Journal	of	Medicine,	1988
I	 remember	 a	 patient	 from	 the	 early	 1980s	with	 a	 severe	 neuropathy	who	 stayed	 for	 6	months	 in	 ITU
before	making	 it	 back	 on	 to	 the	ward.	 She	 had	 a	 severe	 autonomic	 neuropathy.	 She	 died	 from	cardiac
arrest	without	warning	on	the	anniversary	of	her	first	symptoms	of	GBS.	While	I	was	a	research	registrar
I	saw	2	patients	in	ITU	with	autonomic	problems	who	developed	a	resistant	sudden	cardiac	arrest	after
tracheal	suction.	There	were	comments	in	both	of	these	cases	about	mild	bradycardia	on	tracheal	suction
24	hours	before	their	terminal	event,	so	I	always	take	any	sign	of	bradycardia	on	suction	very	seriously.	I
discuss	such	patients	with	my	cardiology	colleagues	and	err	on	the	side	of	prophylactic	pacing	to	try	to
prevent	intractable	asystole	[10].
Lesson	8:	Anaesthetists	and	Hope!
One	of	the	nice	things	about	being	a	clinical	neurologist	is	seeing	patients	progress	over	a	period	of	time.
The	feedback	you	get	from	seeing	patients	with	severe	GBS	get	better	is	rewarding	and	reminds	one	never
to	give	up	hope.	ITU	doctors	never	usually	see	patients	when	they	are	well,	but	I	make	a	point	of	asking
my	GBS	patients	 to	visit	 ITU	when	 they	have	 recovered.	This	gives	 ITU	doctors	an	opportunity	 to	see
how	much	better	recovery	can	occur	in	patients	with	profound	deficit	and	encourages	them	to	still	have
hope	 for	 the	 future.	Otherwise,	 there	 is	 a	 tendency	 for	 doctors	 to	 give	up	on	patients	who	 still	 have	 a
chance	 to	 go	 on	 and	 lead	 useful	 lives.	 The	 role	 of	 a	 neurologist	 is	 often	 to	 champion	 the	 interests	 of
patients	when	it	comes	to	rationing	expensive	and	in-demand	ITU	resources!
Lesson	9:	Improvement	over	Years
I	have	been	a	member	of	the	GBS	support	group	in	the	UK	(now	known	as	GAIN	[11])	for	many	years	and
have	attended	countless	AGMs	of	the	group.	Although	we	traditionally	consider	that	nerve	regrowth	and
repair	largely	stops	after	about	18	months	and	up	to	2	years,	patients	have	told	me	that	they	have	noticed
continued	improvement	for	many	years	after	the	acute	illness.	Mostly	this	is	in	sensory	perception	but	it	is
clear	 that	 this	 translates	 into	useful	 improvement	 in	quality	 of	 life.	 I	 am	now	very	 cautious	 about	 ever
saying	that	no	further	improvement	will	occur	in	the	deficit	from	GBS.
Lesson	10:	The	Unselfishness	of	Patients
GBS	is	a	rare	disease	and	I	would	understand	if	any	patient	just	wanted	to	forget	about	the	illness	after
recovery.	Surprisingly,	many	are	still	happy	to	contribute	to	teaching	about	the	disease.	They	want	doctors
to	 recognise	 the	 illness	more	 promptly	 and	 above	 all	 not	 give	 up	 on	 them	 if	 recovery	 is	 slow.	 In	my
experience	 they	have	been	delighted	 to	contribute	 to	 research	even	when	 it	 is	 invasive	and	unpleasant.
Support	group	members	will	come	and	 talk	 to	patients	 in	 the	acute	phase	of	 the	disease	and	give	 them
some	hope	for	 the	future.	They	fund	considerable	research	into	GBS	and	work	hard	 to	raise	awareness
about	the	disease.	My	gratitude	and	admiration	goes	out	to	all	of	them.
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Introduction
Guillain-Barré	 syndrome	 (GBS)	 is	 considered	 the	 prototype	 of	 a	 post-infectious	 immune-mediated
disorder.	One	of	the	first	descriptions	of	the	association	between	an	infectious	trigger	and	GBS	dates	back
to	1957,	when	Campbell	reported	that	60%	of	polyneuritis	cases	had	preceding	respiratory	symptoms	like
cough,	 sore	 throat	 and	 fever,	 and	 about	 10%	 to	 20%	had	 recent	 diarrhoea	 [1].	At	 this	 time,	GBS	was
believed	 to	 be	 caused	 by	 a	 virus	 infection	 of	 unknown	 aetiology,	 and	was	 linked	 to	 an	 illness	 in	 cats
(‘feline	enteritis’).
To	 date,	 it	 is	 well	 known	 that	 about	 two-thirds	 of	 GBS	 patients	 experience	 respiratory	 or
gastrointestinal	 symptoms	 days	 to	 weeks	 before	 the	 onset	 of	 neurologic	 symptoms	 [2].	 A	 specific
pathogen	 can	 be	 identified	 in	 about	 half	 of	 patients	 with	 GBS	 (Figure	 22.1).	Campylobacter	 jejuni
accounts	for	around	one-third	of	these	infections	[3,4].
Over	the	last	10	years,	evidence	on	the	role	of	preceding	infections	and	cross-reactive	anti-glycolipid
antibodies	in	the	immunopathology	of	GBS	has	been	accumulating.	Most	notably,	there	is	now	convincing
evidence	 that	C.	 jejuni	 is	 a	 potential	 trigger	 of	 GBS	 and	 is	 associated	 with	 the	 acute	 motor	 axonal
neuropathy	 (AMAN)	 subtype	 and	 IgG	 antibodies	 against	 GM1,	 GM1b,	 GD1a	 or	 GalNAc-GD1a	 [5].
Much	less	is	known	about	the	role	of	preceding	infections	and	the	pathogenesis	in	the	patients	with	GBS
who	did	not	have	a	preceding	C.	jejuni	infection.
Many	 other	 identified	 pathogens	 have	 also	 been	 reported	 in	 association	 with	 GBS,	 including
Mycoplasma	pneumoniae,	Haemophilus	influenzae,	cytomegalovirus	(CMV),	Epstein-Barr	virus	(EBV)
and	influenza	virus	[3].	There	are	even	more	pathogens	reported	in	single	GBS	case	reports	or	series.	The
involvement	 of	 these	 pathogens	 in	GBS	 is	 less	 clear	 and	has	 not	 been	determined	 in	 controlled	 larger
studies.	Here,	we	 focus	 on	 the	 spectrum	of	 these	 preceding	 infections	 in	GBS	beyond	Campylobacter
(Table	22.1).
Detecting	a	Pathogen	in	GBS:	What	Does	It	Mean?
The	demonstration	of	a	causative	pathogen	 in	GBS	 is	 rather	complex.	First,	 there	 is	usually	a	delay	of
days	to	weeks	between	the	infection	and	the	diagnosis	of	GBS.	The	detection	rate	of	a	pathogen	by	culture
and/or	 polymerase	 chain	 reaction	 (PCR)	 at	GBS	onset	 is	 low	 [2].	 It	 is	 possible	 that	 the	 pathogen	 has
already	been	cleared	at	the	infectious	site	by	the	immune	reaction	that	may	have	also	caused	GBS.
Figure	22.1		Incidence	of	positive	infection	serology	in	154	adult	GBS	patients.
Abbreviations:	CJ	=	Campylobacter	jejuni;	CMV	=	cytomegalovirus;	EBV	=	Epstein-Barr	virus;	MP	=	Mycoplasma	pneumoniae.
Other	pathogens	were	Haemophilus	influenzae,	 influenza	virus	A/B,	parainfluenza	virus,	adenovirus,	herpes	simplex	virus	and
varicella-zoster	virus.	Most	of	GBS	patients	with	>	1	pathogen	detected	had	positive	EBV	and/or	CMV	serology	in	addition	to	other
pathogens.	Adapted	 from	Jacobs	et	al.	 [3];	 rates	vary	 to	 those	 in	 the	original	publication	because	only	single	positive	 infection
serologies	are	indicated	for	CJ,	CMV,	EBV	and	MP.
Second,	demonstrating	the	presence	of	a	pathogen	in	a	GBS	patient	does	not	necessarily	implicate	that
there	 is	 an	 infection	 that	 triggered	 an	 immune	 response	 to	 the	 nerves.	Many	 pathogens,	 apart	 from	C.
jejuni,	 persist	 or	 are	 carried	 in	 healthy	 asymptomatic	 individuals	 without	 any	 symptoms.	 Multiple,
coexisting	bacterial	and	viral	pathogens	can	be	detected	in	respiratory	samples	of	healthy	asymptomatic
individuals,	particularly	children	 [6].	This	asymptomatic	carriage	of	pathogens	may	also	elicit	 immune
responses	 [6,7].	 It	 is	 unclear	 whether	 these	 immune	 responses	 reflect	 unrecognized	 damage	 by	 the
pathogen	 to	 the	host.	Thus,	 a	positive,	 single-sample	 serological	 result,	 either	 IgM	or	 IgG,	may	simply
reflect	one	or	more	previous	encounters	with	 the	pathogen	and	are	not	necessarily	 related	 to	GBS	 [8].
This	also	applies	to	human	herpes	viruses	that	persist	in	the	host	and	where	the	seroprevalence	in	adults
is	 considerably	high.	Caution	 should	be	 taken	 in	 the	 interpretation	of	 these	diagnostic	 test	 results,	 also
because	some	serological	assays	may	lack	sensitivity	and	specificity.
Third,	GBS	 is	 a	 highly	 heterogeneous	 disorder	with	 respect	 to	 the	 type	 of	 preceding	 infection,	 and
some	infections	may	have	triggered	the	onset	of	disease	only	in	a	small	minority	of	the	cases.
Fourth,	 some	patients	may	 have	 already	 received	 intravenous	 immunoglobulins	 (IVIg)	 before	 blood
samples	were	obtained	to	investigate	infection	serology,	and	such	serology	may	then	be	false	positive.
Infectious	Diagnosis	in	GBS:	What	Is	the	‘Gold	Standard’?
In	GBS,	it	may	be	of	lesser	importance	to	know	whether	or	not	the	detected	pathogen	is	the	cause	of	the
infection.	It	is	all	about	the	presence	of	cross-reactive	antibodies,	induced	by	either	infection	or	carriage
of	a	pathogen,	that	are	associated	with	GBS.
What	is	more	important	is	to	know	whether	the	encounter	with	a	pathogen	leading	to	the	production	of
(cross-reactive)	 antibodies	was	 a	 recent	 event.	 This	may	 be	 achieved	 by	 using	 paired	 patient	 sera	 in
order	 to	detect	seroconversion	and/or	a	≥4-fold	 increase	 in	antibody	 titres,	which	still	 serves	as	 ‘gold
standard’	for	many	infectious	diseases	[9].
Interestingly,	we	recently	established	the	aetiological	diagnosis	in	2	GBS	patients	by	the	detection	of	a
specific	intrathecal	antibody	synthesis	against	M.	pneumonia	[10].	The	detection	of	a	specific	intrathecal
antibody	 response	 is	 an	 established	 diagnostic	 method	 to	 prove	 an	 intrathecal	 infection	 with	 M.
pneumoniae,	 CMV,	 EBV,	 influenza	 viruses,	 etc.	 in	 encephalitis	 patients	 [9].	 An	 intrathecal	 antibody
synthesis	can	be	established	either	by	calculation	of	an	antibody	index	or	through	parallel	immunoblotting
of	 simultaneously	 collected	 cerebrospinal	 fluid	 (CSF)	 and	 serum	 samples	 [11,12].	 The	 autoimmune
response	 in	 GBS	 results	 in	 nerve	 inflammation	 at	 peripheral	 nerves	 and	 nerve	 roots,	 which	 are
surrounded	by	CSF.	The	detection	of	a	specific	intrathecal	antibody	response	may	therefore	be	useful	as
an	additional	diagnostic	tool	to	further	establish	the	infectious	diagnosis.
Infectious	Association	or	Cause?
When	an	infectious	diagnosis	can	be	made,	how	sure	are	we	that	there	is	a	causal	relationship	between
the	identified	pathogen	and	GBS?
Despite	the	association	between	many	infections	and	GBS,	the	overall	risk	of	developing	GBS	is	very
small.	For	example,	only	one	 in	1,000–5,000	patients	with	C.	 jejuni	 enteritis	will	develop	GBS	 in	 the
subsequent	 2	months	 [13],	 a	 fact	which	 certainly	 also	 applies	 to	 other	 infectious	 pathogens,	where	 the
acute	disease	is	much	more	frequent	than	this	severe	post-infectious	complication.
One	 of	 the	 critical	 steps	 in	GBS	 pathogenesis	 is	 the	 generation	 of	 antibodies	 that	 cross-react	with
specific	gangliosides.	It	has	been	shown	for	C.	jejuni	that	such	cross-reactive	antibodies	are	not	produced
during	uncomplicated	C.	jejuni	enteritis	[5].	The	variety	in	types	of	preceding	infection	is	related	to	the
diversity	 in	 clinical	 presentation	 [14],	 outcome	 [15],	 and	 specificity	 of	 antibodies	 to	 glycolipids	 [3].
Therefore,	 the	 detection	 of	 a	 distinct	 anti-glycolipid	 antibody	 type	 could	 give	 an	 indication	 on	 the
preceding	 infectious	 agent	 that	 triggered	 the	 antibody	 response	 through	 microbial	 mimic	 of	 the	 target
glycolipid	 antigen	 [16].	 It	 is	 not	 excluded	 that	 for	 other	 GBS	 patients	 cross-reactive	 T-cells	 or	 very
different	mechanisms	than	cross-reaction	may	play	a	role	in	the	pathogenesis.
Specific	Infections
An	overview	of	reported	infectious	triggers	associated	with	GBS	is	shown	in	Table	22.1.
Table	22.1		The	spectrum	of	preceding	infections	in	GBS	(beyond	Campylobacter	jejuni)
Mycoplasma	Pneumoniae
Mycoplasmas	were	first	described	as	infectious	agents	in	humans	in	the	1940s	[17].	They	are	the	smallest
self-replicating	life	forms.	Today,	we	know	that	M.	pneumoniae	 is	a	frequent	cause	of	respiratory	tract
infections	(e.g.	‘walking	pneumonia’)	and	colonizes	the	upper	respiratory	tract	of	healthy	children	[6,18].
The	incidence	of	M.	pneumoniae	infections	is	higher	in	children	than	in	adults	[19].	Interestingly,	a	wide
spectrum	 of	 extrapulmonary	 complications	 has	 been	 described	 in	 association	 with	 M.	 pneumoniae
infection,	including	encephalitis	and	GBS	[18].	Preceding	M.	pneumoniae	infection	has	been	reported	in
3–21%	of	GBS	in	adults	[3,20–22],	and	in	GBS	variants	[23–25]	and	related	neuropathies	[26].	These
patients	are	younger	and	report	respiratory	prodromes	more	often	than	M.	pneumoniae	seronegative	GBS
patients.	 There	 is	 no	 distinct	 clinical	 picture	 and	 the	 outcome	 is	 generally	 good,	 although	we	 recently
presented	 a	 case	 series	 of	 children	who	 developed	 severe	 and	 complicated	 disorders	within	 the	GBS
spectrum	after	infection	with	M.	pneumoniae	[10].
In	patients	with	GBS,	 serum	antibodies	 to	M.	pneumoniae	 have	 been	 found	 to	 cross-react	with	 the
myelin	 glycolipid	 galactocerebroside	 (GalC)	 [27,28].	 Interestingly,	 we	 recently	 detected	 anti-GalC
antibodies	 in	 the	CSF	of	a	patient	diagnosed	as	Bickerstaff	brainstem	encephalitis	(BBE)	following	M.
pneumoniae	infection	[29].	Anti-GalC	antibodies	have	been	shown	to	cause	demyelinating	neuropathy	in
rabbits	 that	 were	 immunized	 with	 GalC	 [30],	 and	 have	 been	 associated	 with	 demyelination	 in	 GBS
[28,31],	 encephalitis	 [32]	 and	 acute	 disseminated	 encephalomyelitis	 [33].	 However,	 anti-GalC
antibodies	 could	 also	 be	 detected	 in	 patients	 with	M.	 pneumoniae	 infections	 but	 without	 neurologic
symptoms	 [28,34].	The	 observation	 that	 the	 isotype	 IgG	of	 anti-GalC	 antibodies	was	more	 frequent	 in
GBS	patients	than	in	patients	without	neurologic	symptoms	[28]	suggests	that	a	subclass	switching	of	anti-
GalC	antibodies	may	pose	a	risk	for	GBS	after	M.	pneumoniae	infection.
Haemophilus	Influenzae
H.	influenzae	 is	also	frequently	carried	in	the	upper	respiratory	tract	of	humans.	The	bacteria	was	first
isolated	by	Pfeiffer	 in	1893	during	an	 influenza	outbreak	 (‘influenza	bacillus’)	 [35].	H.	 influenzae	 has
encapsulated	 (type	 a–f)	 and	 unencapsulated	 (nontypeable)	 strains,	 and	 can	 cause	 respiratory	 infections
and	severe	invasive	diseases,	particularly	in	children.	In	the	pre-vaccine	era,	H.	influenzae	type	b	(Hib)
accounted	for	95%	of	all	strains	 that	caused	 invasive	disease.	 It	 is	 this	strain	 that	has	been	reported	 in
association	with	GBS.	The	rates	of	preceding	H.	influenzae	infection	in	GBS	vary	between	1%	and	9%
[3,36,37],	 without	 significant	 differences	 to	 control	 subjects.	 Patients	 with	 GBS	 associated	 with	 H.
influenzae	 presented	with	 respiratory	prodromes,	 less	 frequent	 cranial	 and	 sensory	nerve	 involvement,
pure	motor	 axonal	 dysfunction	 and	 positivity	 for	 anti-GM1	 IgG	 antibodies	 [36].	A	GM1-like	 structure
could	be	identified	in	an	H.	influenzae	isolate	of	a	patient	with	axonal	GBS	[38].
In	 fact,	 the	 rate	 of	 positive	 IgM	 antibodies	 against	 H.	 influenzae	 was	 more	 frequent	 in	 Fisher
syndrome	(FS)	patients	(11%)	and	differed	significantly	compared	with	controls	[37].	Interestingly,	in	his
original	description	Charles	Miller	Fisher	reported	the	isolation	of	H.	influenzae	in	the	sputum	of	a	63-
year-old	man	with	pneumonia	who	developed	FS	[39].	Patients	with	both	FS	or	GBS	who	had	serologic
evidence	 of	 a	 recent	H.	 influenzae	 infection	 were	 positive	 for	 serum	 anti-GQ1b	 and	 anti-GT1a	 IgG
antibodies	 [37].	 It	 could	 be	 demonstrated	 that	H.	 influenzae	 isolates	 from	 FS	 patients	 bear	 an	 anti-
GT1a/GQ1b	epitope	[37,40].	Serological	evidence	for	a	recent	H.	influenzae	infection	was	also	found	in
6%	of	BBE	patients	 [41].	Thus,	H.	 influenzae	may	be	 involved	 specifically	 in	 the	development	of	 the
anti-GQ1b	 antibody	 syndrome	 (FS	 and	 BBE)	 [42]	 because	 of	 its	 suggested	 molecular	 mimicry	 with
GQ1b.
Salmonella	Enterica	Species
In	contrast	 to	the	bacterial	and	viral	pathogens	detected	in	the	respiratory	tract,	 the	diagnosis	of	enteric
fever	caused	by	Salmonella	typhi	(typhoid	fever)	or	Salmonella	paratyphi	(paratyphoid	fever)	is	clear-
cut	because	of	the	detection	of	the	bacteria	in	the	blood	stream.	Enteric	fever	can	cause	a	wide	range	of
neurologic	symptoms,	with	the	most	common	being	a	toxic	confusional	state	or	delirium	(‘nervous	fever’)
[43].	GBS	has	rarely	been	described	in	association	with	Salmonella	[43,44].	Single	case	reports	exist	on
different	GBS	variants	 [45–48].	The	only	 analysis	 of	 anti-glycolipid	 antibodies	 in	 a	BBE	patient	with
detection	of	S.	paratyphi	A	in	blood	cultures	revealed	anti-GQ1b	IgM	and	IgG	antibodies	[48].	However,
a	GQ1b	epitope	was	not	tested	in	this	specific	case.
Cytomegalovirus
The	 most	 frequent	 virus	 associated	 with	 GBS	 is	 cytomegalovirus	 (CMV),	 which	 emphasizes	 that
molecular	mimicry	may	be	not	restricted	to	bacterial	infections.	CMV	is	the	largest	known	human	herpes
virus	 and	 can	 be	 transmitted	 via	 saliva,	 sexual	 contact,	 placental	 transfer,	 breastfeeding,	 blood
transfusion,	 and	 solid-organ	 or	 haematopoietic	 stem-cell	 transplantation.	 The	 most	 important	 clinical
manifestations	of	CMV	are	congenital	and	neonatal	 infections	and	a	mononucleosis-like	syndrome	[49].
CMV	 establishes	 lifelong	 latency	 after	 primary	 infection	 in	 cells	 of	 the	 myeloid	 lineage.	 The	 overall
seroprevalence	 for	 CMV	 is	 30–70%	 [50].	 Long-term	 immunosuppression	 can	 lead	 to	 uncontrolled
replication	and	serious	disease	[49].	GBS	was	first	associated	with	CMV	in	1967	[51].	Since	then	rates
of	 preceding	 CMV	 infections	 are	 reported	 in	 6–15%	 of	 GBS	 cases	 [3,20,21,52–55].	 GBS	 patients
associated	 with	 CMV	 showed	 distinct	 clinical	 features:	 younger	 age,	 more	 severe	 disease	 course
indicated	 by	 a	 high	 frequency	 of	 respiratory	 insufficiency	 and	 delayed	 recovery,	 cranial	 nerve
involvement	(facial	palsy)	and	severe	sensory	loss	[53].	A	positive	IgM	serology	against	CMV	was	also
found	 in	6%	of	FS	patients	 [52].	The	electrophysiological	subtype	 is	acute	 inflammatory	demyelinating
polyneuropathy	(AIDP)	[21].
CMV	has	been	associated	with	the	occurrence	of	anti-GM2	antibodies	in	GBS	patients,	particularly	of
the	 isotype	 IgM	 [54,56].	 It	 could	 be	 demonstrated	 that	 CMV-infected	 fibroblasts	 express	 a	 GM2-like
epitope	 that	 was	 specifically	 recognized	 by	 anti-GM2	 IgM	 antibodies	 [57].	 However,	 anti-GM2	 IgM
antibodies	could	also	be	found	in	patients	with	positive	CMV	serology	but	without	neurologic	diseases
[21,52].	 Interestingly,	 CMV	 DNA	 was	 detected	 in	 the	 blood	 of	 62%	 GBS	 patients	 with	 a	 positive
serology	[54].	Although	the	presence	of	CMV	DNA	in	blood	did	not	appear	to	be	a	significant	predictive
factor	for	the	outcome,	these	findings	suggested	a	role	of	viral	replication	in	the	development	of	GBS.	In
fact,	CMV	DNA	could	 also	be	detected	 in	 the	CSF	 in	31%	 (13	out	of	42)	of	GBS	patients	 [58].	This
observation,	however,	could	not	be	reproduced	in	another	large	GBS	cohort	(n	=	170),	where	CMV	DNA
was	detected	in	only	one	single	case	(0.6%)	[59].	While	there	may	be	a	role	for	anti-GM2	IgM	antibodies
in	 the	 development	 of	 GBS	 after	 CMV	 infection,	 the	 involvement	 of	 viral	 replication	 has	 yet	 to	 be
established.
Epstein-Barr	Virus
Epstein-Barr	virus	(EBV)	is	the	causative	agent	of	infectious	mononucleosis	(‘kissing	disease’).	The	rate
of	 positive	 IgM	 against	 EBV	 viral	 capsid	 antigen	 in	 GBS	 patients	 has	 been	 reported	 with	 1–10%
[3,20,21,55].	GBS	has	also	been	described	after	EBV	reactivation	in	the	immunocompromised	host	[60].
However,	 since	over	90%	of	adults	are	 infected	with	EBV	[61]	and	because	no	known	anti-glycolipid
antibodies	 could	 be	 detected	 in	 EBV-positive	 GBS	 cases	 [3,21]	 the	 relation	 of	 EBV	 with	 GBS	 is
controversial.
Herpes	Simplex	Virus	and	Varicella-Zoster	Virus
In	contrast	to	CMV	and	EBV	that	establish	latency	in	myeloid	and	B	cells,	respectively,	the	human	herpes
simplex	 virus	 (HSV)	 and	 the	 varicella-zoster	 virus	 (VZV)	 persist	 in	 the	 ganglia	 of	 cranial	 nerves	 and
dorsal	 roots,	 and	 are	 present	 in	 virtually	 every	 elderly	 adult	 [62].	 There	 are	 case	 reports	 that	 suggest
these	viruses	as	triggers	of	GBS.	However,	the	association	is	weak	[3].
The	 infection	 with	 VZV	 usually	 occurs	 during	 childhood	 and	 may	 manifest	 as	 chickenpox.	 A
spontaneous	reactivation	of	VZV	can	lead	to	herpes	zoster.	The	pathomechanisms	leading	to	reactivation
of	the	virus	may	be	associated	with	a	derangement	of	the	immunological	status	of	the	host.	Interestingly,	a
recent	 study	 found	 an	18-times	 increased	 risk	 for	 the	 development	 of	GBS	 in	Taiwanese	 patients	with
herpes	zoster	during	a	2-month	 follow-up,	compared	 to	a	matched	control	population	 [63].	Thus,	 these
findings	first	suggest	that	factors	that	are	important	for	the	reactivation	of	VZV	may	be	also	involved	in
the	development	in	GBS.	Anti-glycolipid	antibodies	have	not	been	described	in	these	cases.
Influenza	Virus	and	the	Flu	Vaccine
In	 1967,	 the	 U.S.	 national	 influenza	 immunization	 campaign	 against	 influenza	 A	 (H1N1)	 estimated	 an
attributable	risk	of	vaccine-related	GBS	of	about	one	in	100,000	[64].	These	events	caused	considerable
public	concern.	A	similar	association	was	suggested	for	the	immunization	campaign	against	influenza	A
(H1N1)	 in	2009,	but	extensive	national	and	 international	 studies	 found	 that	vaccination	was	associated
with	 only	 a	 very	 small	 attributable	 risk	 of	 GBS	 (1.6	 excess	 cases	 of	 GBS	 per	 1,000,000	 vaccine
recipients)	[65].	In	fact,	vaccination	might	even	reduce	the	risk	of	acquiring	GBS,	as	this	condition	may
be	caused	by	influenza	[66].	Serologic	evidence	for	an	influenza	infection	has	been	reported	in	2–3%	of
GBS	cases	[3,67],	but	the	influenza	virus	does	not	share	structural	homologies	with	known	gangliosides
[68].	However,	the	risk	of	developing	GBS	after	influenza	infection	is	estimated	to	be	4	to	7	times	higher
than	after	influenza	vaccination	[69].	No	relapses	of	GBS	in	patients	with	a	history	of	this	disease	have
been	observed	after	influenza	vaccination	[69].
Human	Immunodeficiency	Virus
The	association	of	GBS	with	human	immunodeficiency	virus	(HIV)	was	reported	soon	after	the	beginning
of	the	HIV	infection	epidemic	in	the	1980s.	Peripheral	neuropathies	in	general	are	common	and	occur	in
all	stages	of	HIV	infection	[70].	The	neuropathic	complications	in	HIV	infection	may	result	from	a	variety
of	 pathologic	 processes,	 such	 as	 immune	 dysregulation	 during	 early	 stages,	 opportunistic	 infections
(CMV,	VZV,	etc.)	in	late	stages,	and	treatment-related	effects	by	antiretroviral	therapy	(ART)	(toxicity	or
aberrant	manifestation	of	immune	reconstitution	after	initiation,	re-initiation,	or	change	of	ART)	[71,72].
GBS	 in	 association	with	HIV	may	 occur	 in	 the	 early	 stage	 of	 infection	 or	 at	 seroconversion	 and	may
present	with	more	frequent	recurrent	episodes	or	the	development	of	chronic	inflammatory	demyelinating
polyneuropathy	(CIDP)	[73].	Although	HIV	infection	was	found	in	55%	of	32	consecutive	GBS	cases	in
Zimbabwe	 [74],	GBS	 has	 not	 been	 observed	 in	 a	 prospective	 study	 of	 1,500	HIV-infected	 patients	 in
Britain	[75].
Hepatitis	E	Virus
The	 latest	discovery	of	 a	preceding	 infection	 in	GBS	 is	hepatitis	E	virus	 (HEV).	HEV	 infection	 is	 the
most	 common	 cause	 of	 acute	 hepatitis	worldwide	 [76].	 In	 developed	 countries,	HEV	 infection	 usually
presents	as	a	self-limiting	disease	caused	by	genotype	3.	Notably,	a	Dutch	case-control	study	showed	that
5%	of	GBS	patients	had	serologic	evidence	for	HEV	infection,	compared	with	0.5%	of	matched	healthy
controls	[77].	HEV	RNA	was	found	in	the	serum	of	one-third	of	these	HEV	seropositive	GBS	cases	and
was	also	 found	 in	 faeces	 in	one	case	 (all	genotype	3).	Antibodies	 against	known	glycolipids	were	not
detected.	Similarly,	10%	of	patients	with	GBS	from	Bangladesh	had	an	antecedent	HEV	infection	[78],
indicating	that	HEV	may	be	a	worldwide	trigger	of	GBS.	Of	note,	hepatitis	A	and	B	virus	infections	were
not	found	in	GBS	patients	[3].
Conclusion
GBS	 is	 a	 very	 rare	 complication	 of	 common	 infections.	 The	 demonstration	 of	 a	 causative	 pathogen	 in
GBS	is	rather	complex.	The	presence	of	a	pathogen	in	a	GBS	patient	does	not	necessarily	implicate	that
there	is	an	infection	that	triggered	an	immune	response	to	the	nerves.	Almost	any	pathogen	at	least	once
has	been	reported	in	a	patient	with	GBS.	This	questions	whether	there	is	a	causal	relationship	between
the	infectious	agent	and	GBS.	In	fact,	larger,	prospective,	standardized	and	controlled	studies	are	lacking
for	most	specific	types	of	infection	associated	with	GBS.	More	stringent	criteria	are	therefore	required	to
establish	 the	 involvement	 of	 a	 pathogen	 in	 GBS	 and	 to	 direct	 the	 search	 for	 the	 target	 antigen	 in	 the
triggering	infectious	agent.
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Landry	JBO.	Note	sur	la	paralysie	ascendante	aiguë.	Gazette
Hebdomadaire	de	Médecine	et	de	Chirurgie,	1859
One	 of	 the	 first	 descriptions	 of	 the	 Guillain-Barré	 Syndrome	 (GBS)	 appears	 in	 the	 Gazette
Hebdomadaire	de	Médecine	et	de	Chirurgie,	where	Octave	Landry	describes	a	study	of	5	patients	with
an	acute	ascending	paralysis.
«	La	sensibilité	et	la	motilité	peuvent	être	également	compromises.	Cependant,	les	troubles	fonctionnels	portent	surtout	sur
le	mouvement	et	sont	alors	caractérisés	par	la	diminution	graduelle	de	la	force	musculaire,	avec	flaccidité	des	membres
sans	tremblement,	sans	contracture,	sans	convulsion.	Dans	la	presque	totalité	des	cas	la	défécation	et	la	miction	restent
normales.	On	n’observe	aucun	symptome	immédiat	du	côté	des	centres	nerveux,	pas	de	céphalalgie	ni	de	délire.	Jusqu’	à
la	fin,	 les	facultés	 intellectuelles	sont	complêtement	conservées.	Le	début	des	accidents	paralytiques	peut	être	précédé
d’un	sentiment	de	faiblesse	et	de	crampes	abdominales	passagères	».
To	the	best	of	our	knowledge,	this	is	the	first	description	of	preceding	gastrointestinal	complaints	in	GBS
patients	[1].
Escherich	T.	Beitrage	zur	Kenntniss	der	Darmbacterien.	Ueber	das
Vorkommen	von	Vibrionen	im	Darmcanal	und	den	Stuhlgangen	ser
Sauglinge.	Münchener	Medizinische	Wochenschrift,	1886
Although	Campylobacters	 were	 identified	 as	 human	 pathogens	 only	 in	 the	 1970s,	 they	 have	 probably
caused	illness	in	man	for	centuries.	In	1886,	Escherich	published	a	series	of	articles	in	the	Münchener
Medizinische	Wochenschrift	in	which	he	reports	on	spiral	bacteria	in	the	colon	of	children	who	had	died
of	an	intestinal	disease	that	he	describes	as	‘cholera	infantum’.	Attempts	to	culture	the	bacteria	on	solid
medium	were	not	successful.	He	also	saw	spiral	organisms	through	a	microscope	in	the	stools	of	35	out	of
72	 infants	 suffering	 from	other	 enteric	 diseases.	Unfortunately,	 his	 report	 remained	unreferenced	 in	 the
English	literature	as	it	was	published	in	German	[2].
McFadyean	J,	Stockman	S.	Report	of	the	Departmental	Committee
appointed	by	the	Board	of	Agriculture	and	Fisheries	to	Inquire	into
Epizootic	Abortion.	London:	His	Majesty’s	Stationery	Office,	1913
Campylobacters	were	described	for	the	first	time	in	association	with	veterinary	disease	before	they	were
identified	as	an	important	pathogen	in	human	medicine.	In	1909,	2	veterinarians	reported	the	isolation	of
vibrio-like	bacteria	from	aborted	foetuses	in	ewes.	Similar	bacteria	were	later	also	isolated	in	infectious
abortions	of	bovines	and	dysentery	in	calves	and	swine.	Vibrio	fetus	and	Vibrio	 jejuni	were	 the	names
proposed	to	these	newly	identified	veterinary	pathogens	[3].
Guillain	G,	et	al.	Sur	un	syndrome	de	radiculonévrite	avec
hyperalbuminose	du	liquide	céphalo-rachidien	sans	réaction
cellulaire.	Remarques	sur	les	caractères	cliniques	et	graphiques	des
réflexes	tendineux.	Bulletins	et	mémoires	de	la	Société	médicale	des
hôpitaux	de	Paris,	1916
During	 the	 First	 World	War,	 2	 French	 military	 doctors,	 Georges	 Guillain	 and	 Jean-Alexandre	 Barré,
together	with	André	Strohl,	all	enlisted	in	the	6th	French	Army,	described	the	case	history	of	2	paralysed
soldiers	 with	 areflexia	 associated	 with	 raised	 protein	 values	 but	 with	 normal	 cell	 counts	 in	 the
cerebrospinal	fluid.	The	three	published	their	findings	in	Bulletins	et	mémoires	de	la	Société	médicale
des	hôpitaux	de	Paris	 in	1916.	The	name	of	Strohl	was	dropped	for	unknown	reasons	and	 the	disease
became	known	as	Guillain-Barré	syndrome.	André	Strohl	became	a	medical	physiologist	and	professor	in
physiological	 medicine	 in	 Algiers	 and	 Paris.	 Georges	 Guillain	 became	 professor	 and	 chair	 of	 the
department	of	neurology	at	the	famous	Salpétriere	Hospital	in	Paris.	Jean-Alexandre	Barré	was	appointed
as	professor	of	neurology	in	Strasbourg	[4].
Levy	AJ.	A	gastro-enteritis	outbreak	probably	due	to	a	bovine	strain	of
vibrio.	Yale	Journal	of	Biology	and	Medicine	1946
The	 first	well-documented	description	of	a	Campylobacter	 outbreak	 in	humans	was	published	 in	1946
and	describes	a	milk-born	outbreak	of	diarrhoea	in	2	state	institutions	involving	355	patients.	Organisms
resembling	‘V.	jejuni’	were	grown	in	broth	cultures	of	the	blood	of	13	victims	[5].
Vinzent	R,	et	al.	Septicémie	grave	au	cours	de	la	grossesse	due	à	un
vibrion.	Avortement	consécutif.	Bulletin	de	Academie	Nationale	de
Medecine,	1947
Vinzent	and	colleagues	reported	on	the	case	histories	of	3	pregnant	women	with	fever	of	unknown	origin.
Vibrio	fetus	was	isolated	from	the	blood	specimens	taken	from	the	3	women.	Two	out	of	 the	3	aborted
within	4	weeks	and	a	necrotizing	inflammation	was	observed	on	the	placenta.	In	1957,	King	described	11
additional	 bloodstream	 infections	 with	 Vibrio	 fetus	 and	 related	 species,	 and	 a	 full	 bacteriological,
biochemical	and	serological	description	of	the	strains	[6,7].
Cambell	AMG.	The	etiology	of	polyneuritis.	Proceedings	of	the	Royal
Society	of	Medicine,	1958
Campbell	published	the	case	histories	of	his	own	GBS	patients	and	patients	from	the	literature.	He	found
that	in	about	60%	of	cases	there	is	a	respiratory	infection	with	cough,	sore	throat	and	pyrexia	before	the
onset	 of	 the	 polyneuritis.	 In	 another	 10–20%	 of	 the	 cases	 the	 onset	 is	 preceded	 by	 an	 episode	 of
diarrhoea.	He	reports	that	“recent	work	has	tended	to	emphasize	that	the	Landry-Guillain-Barré	syndrome
is	a	non-specific	reaction	to	several	infective	agents	and	is	possibly	due	to	an	abnormal	antigen-antibody
response”.	 In	 addition,	 he	 also	 reports	 that	 the	 polyneuritis	 is	 preceded	 by	 diarrhoea	 by	 3–10	 days.
However,	we	have	to	wait	until	the	late	1970s	and	the	isolation	of	Campylobacter	to	truly	understand	the
far-reaching	implications	of	his	observations	[8].
Dekeyser	P,	et	al.	Acute	enteritis	due	to	a	related	vibrio:	first	positive
stool	cultures.	Journal	of	Infectious	Diseases,	1972
Until	1968,	 the	 isolation	of	Campylobacter	 from	human	stools	was	difficult.	A	breakthrough	discovery
was	made	by	Dekeyser	and	Butzler	and	their	team	in	Brussels,	Belgium.	They	isolated	a	‘related	vibrio’
from	blood	samples	of	a	20-year-old	female	who	was	admitted	to	the	hospital	with	severe	diarrhoea	and
fever.	Using	 a	 newly	 developed	mechanical	 filtration	 technique,	 they	 also	 isolated	 the	 ‘related	 vibrio’
from	the	stools	of	diarrhoeal	patients.	This	first	faecal	isolation	of	‘related	vibrio’	from	human	stools	was
followed	by	the	observation	that	C.	jejuni/C.	coli	were	isolated	from	5.3%	of	3,800	stools	from	children.
By	 the	 mid-1980s,	Campylobacter	 species	 were	 recognized	 as	 the	 most	 common	 cause	 of	 bacterial
enterocolitis	[9].
Skirrow	MB.	Campylobacter	enteritis:	a	‘new’	disease.	BMJ,	1977
The	 filtration	 technique	 was,	 however,	 very	 cumbersome,	 time-consuming	 and	 less	 adapted	 to	 high-
throughput	 diagnostic	 microbiology	 laboratories.	 The	 development	 of	 selective	 media	 containing
antibiotics	 to	 inhibit	 the	 residential	 enteric	 flora	 proved	 to	 be	 a	 real	 breakthrough.	 In	 1977,	 Martin
Skirrow	published	 a	 selective	media	 containing	vancomycin,	 polymyxin	 and	 trimethoprim	and	 isolated
Campylobacter	 spp.	 in	 57	 stool	 samples	 out	 of	 803	 (7.1%)	 patients	 with	 diarrhoea.	 New	 isolation
protocols	 and	 selective	 media	 using	 various	 combinations	 of	 selective	 antibiotics	 were	 rapidly
introduced	 in	 diagnostic	 laboratories	 and	 Campylobacter	 diarrhoea	 emerged	 as	 a	 frequent	 cause	 of
bacterial	diarrhoea	[10].
Rhodes	KM	and	Tattersfield	AE.	Guillain-Barré	syndrome	associated
with	Campylobacter	infections.	BMJ,	1982
These	 newly	 developed	 methods	 drew	 the	 attention	 of	 scientists	 trying	 to	 decipher	 the	 aetiology	 of
preceding	infections	in	patients	with	GBS.	However,	no	Campylobacter	spp.	could	be	cultured	from	the
stools	collected	from	these	patients	at	the	onset	of	the	muscular	weakness.	The	first	report	of	a	possible
link	 between	 Campylobacter	 infections	 and	 GBS	 was	 published	 in	 1982.	 Rhodes	 and	 Tattersfield
described	the	case	history	of	a	45-year-old	man	admitted	to	the	hospital	with	severe	diarrhoea,	who,	on
the	10th	day	of	hospitalisation,	developed	a	rapidly	progressive	paresis	with	areflexia	and	was	diagnosed
with	 the	 Guillain-Barré	 syndrome.	 Campylobacter	 was	 isolated	 from	 his	 stools	 on	 the	 7th	 day	 of
admission.
Two	years	later	Kaldor	and	Speed	published	a	serological	study	of	the	association	of	Campylobacter
infections	and	GBS.	In	a	retrospective	cohort	of	56	GBS	patients,	21	(38%)	had	serological	evidence	of	a
recent	Campylobacter	 infection.	 The	Campylobacter-associated	 GBS	 cases	 manifested	 a	 significantly
more	 severe	 form	 of	 the	 disease.	 They	 also	 stated	 that	 “antigenic	 similarities	 between	 neural
glycopeptides	 and	 bacterial	 capsules	 may	 be	 the	 possible	 immunological	 link	 in	 the	 case	 of
Campylobacter”.	 These	 observations	were	 followed	 by	 to	 a	 tsunami	 of	 scientific	 communications	 and
evidence	of	the	role	of	Campylobacter	infections	preceding	the	development	of	GBS	[11,12].
Yuki	N	et	al.	A	bacterium	lipopolysaccharide	that	elicits	Guillain-Barré
syndrome	has	a	GM1	ganglioside-like	structure.	Journal	of
Experimental	Medicine,	1993
The	next	flagship	discovery	came	from	Aspinall	and	Yuki	for	what	would	become	an	excellent	paradigm
and	 attractive	 model	 for	 the	 elucidation	 of	 host	 and	 microbial	 determinants	 in	 GBS:	 the	 molecular
mimicry	hypothesis.	The	groundwork	was	led	by	Aspinall,	who	conducted	extensive	structural	studies	of
lipooligosaccharide	(LOS)	of	various	Campylobacter	serotypes	and	found	that	 the	type	strain	of	HS:19
serotype	showed	structural	similarity	with	both	GM1	and	GD1a	gangliosides.	In	addition,	the	structure	of
2	 HS:19	Campylobacter	 strains	 isolated	 from	 GBS	 patients	 showed	 structural	 similarity	 with	 GM1,
GT1a	and	GD3.
In	 1993,	 Yuki	 and	 colleagues	 published	 data	 showing	 striking	 homology	 between	 the	 core
oligosaccharides	of	Campylobacter	LOS	and	a	number	of	different	glycosphingolipids	of	the	ganglioside
groups	present	on	neural	membranes.	These	were	the	first	reports	of	molecular	mimicry	between	human
nerve	tissue	and	Campylobacter	strains	isolated	from	patients	with	GBS	[13,14].
Rees	JH,	et	al.	Campylobacter	jejuni	infections	and	the	Guillain-Barré
syndrome.	New	England	Journal	of	Medicine,	1995
To	confirm	the	association	of	Campylobacter	as	an	 important	preceding	 infection	among	GBS	patients,
Rees	and	colleagues	conducted	a	case-control	study	involving	96	GBS	patients.	They	found	evidence	of	a
recent	Campylobacter	 infection	in	26%	of	them	as	opposed	to	1–2%	in	2	different	control	groups.	The
authors	 confirmed	 that	 the	Campylobacter-associated	 cases	 were	 more	 likely	 to	 present	 with	 severe
axonal	forms	of	GBS	[15].
Jacobs	BC,	et	al.	The	spectrum	of	antecedent	infections	in	Guillain-
Barré	syndrome:	a	case-control	study.	Neurology,	1998
A	few	years	later,	a	second	state-of-the-art	case-control	study	was	published	by	Jacobs	and	colleagues.
They	conducted	a	 serological	 study	among	154	GBS	patients	 and	154	 sex-matched	controls	with	other
neurological	diseases.	Serological	evidence	of	a	recent	Campylobacter	 infection	was	observed	in	32%
of	 the	 GBS	 patients.	 They	 also	 suggested	 that	 the	 clinical	 heterogeneity	 of	 the	 syndrome	 might	 be	 a
reflection	of	the	great	variety	of	preceding	infectious	aetiologies.
A	very	similar	study	design	was	used	10	years	later	in	Bangladesh.	In	a	case-control	study	involving
97	GBS	patients	and	194	controls,	Islam	and	colleagues	found	serological	and	microbiological	evidence
of	 a	 recent	 Campylobacter	 infection	 in	 57%	 of	 the	 GBS	 cases	 and	 3%	 of	 the	 controls	 with	 other
neurological	diseases.	The	mean	age	was	21	years	and	the	majority	of	the	cases	(67%)	were	severe	and
axonal	forms	of	GBS	and	associated	with	a	high	case	fatality	(14%)	and	severe	disability	at	6	months	of
29%	[16,17].
van	Belkum	A,	et	al.	A	Campylobacter	gene	associated	with	immune-
mediated	neuropathy.	Nature	Medicine,	2001
As	 the	 molecular	 mimicry	 hypothesis	 was	 considered	 an	 excellent	 paradigm,	 the	 elucidation	 of	 the
biosynthesis	pathways	of	bacterial	ganglioside-like	structures	became	an	area	of	great	interest.	Godschalk
and	van	Belkum	demonstrated	for	the	first	time	that	specific	bacterial	genes	involved	in	the	biosynthesis
and	transfer	of	sialic	acid	were	crucial	 in	determining	specific	LOS	loci	 that	subsequently	 induce	anti-
ganglioside	 antibodies	 and	 trigger	 the	 onset	 of	 GBS.	 Knockout	mutants	 of	C.	 jejuni	 that	 lacked	 these
genes,	unlike	the	wild	types,	showed	reduced	or	no	reactivity	with	sera	from	GBS	patients.	Thus,	a	new
and	putative	GBS	marker	gene	was	identified	in	C.	jejuni	[18,19].
Yuki	N,	et	al.	Carbohydrate	mimicry	between	human	ganglioside	GM1
and	Campylobacter	jejuni	lipooligosaccharide	causes	Guillain-Barré
syndrome.	Proceedings	of	the	National	Academy	of	Sciences	of	the
United	States	of	America,	2004
For	a	long	time,	the	reproduction	of	the	disease	in	an	animal	model	remained	the	‘missing	link’	that	would
help	fulfil	Koch’s	and	Witebsky’s	postulates.	Prior	animal	studies	had	already	shown	that	 immunization
and	infection	with	C.	jejuni	or	purified	LOS	results	in	a	cross-reactive	anti-ganglioside	immune	response.
In	 2004,	 Yuki	 and	 colleagues	 demonstrated	 that	 the	 sensitization	 of	 rabbits	 with	 a	 brain	 ganglioside
mixture	 containing	GM1,	GD1a,	GD1b	 and	GT1b	 leads	 to	 high	 anti-GM1	antibody	 titres	 and	 an	 acute
flaccid	 paralysis	 with	 clinical,	 electrophysiological	 and	 histopathological	 features	 resembling	 GBS.
Experiments	with	purified	Campylobacter	LOS	 led	 to	 similar	 results.	Campylobacter-induced	GBS	 is
currently	the	best-studied	autoimmune	disease	implicating	molecular	mimicry	as	mechanisms	of	disease.
GBS	 is	 therefore	 a	 perfect	 model	 to	 study	 the	 intriguing	 aspects	 of	 post-infectious	 immune-mediated
diseases	[20,21].
References
		1.	Landry	O	(1859)	Note	sur	la	paralysie	ascendante	aiguë.	Gaz	Hebd	Med	Chir	6:	472,	486–88.
		2.	Escherich	T	(1886)	Beitrage	zur	Kenntniss	der	Darmbacterien.	Ueber	das	Vorkommen	von	vibrionen	im	Darmcanal	und	den	Stuhlgangen
ser	Sauglinge.	Münch	Med	Wochenschr	33:	815–17.
		3.	McFadyean	J,	Stockman	S	(1913)	Report	of	the	Departmental	Committee	appointed	by	the	Board	of	Agriculture	and	Fisheries	to
inquire	into	epizootic	abortion.	III.	Abortion	in	sheep.	London:	His	Majesty’s	Stationery	Office.
		4.	Guillain	G,	Barré	JA,	Strohl	A	(1916)	Sur	un	syndrome	de	radiculonévrite	avec	hyperalbuminose	du	liquide	céphalo-rachidien	sans	réaction
cellulaire.	Remarques	sur	les	caractères	cliniques	et	graphiques	des	réflexes	tendineux.	Bull	Mém	Soc	Méd	Hôp	Paris	40:	1462–70.
		5.	Levy	AJ	(1946)	A	gastro-enteritis	outbreak	probably	due	to	a	bovine	strain	of	vibrio.	Yale	J	Biol	Med	18(4):	243–58.
		6.	Vinzent	R,	Dumas	J,	Picard	N	(1947)	Septicémie	grave	au	cours	de	la	grossesse	due	à	un	vibrion.	Avortement	consécutif.	Bull	Acad	Nat
Med	Paris	131:	90–92.
		7.	King	EO	(1957)	Human	infections	with	Vibrio	fetus	and	a	closely	related	vibrio.	J	Infect	Dis	101(2):	119–28.
		8.	Cambell	AM	(1958)	The	etiology	of	polyneuritis.	Proc	R	Soc	Med	51(3):	157–59.
		9.	Dekeyser	P,	Gossuin-Detrain	M,	Butzler	JP,	Sternon	J	(1972)	Acute	enteritis	due	to	a	related	vibrio:	first	positive	stool	cultures.	J	Infect
Dis	125(4):	390–92.
10.	Skirrow	MB	(1977)	Campylobacter	enteritis:	a	‘new’	disease.	Br	Med	J	2(6078):	9–11.
11.	Rhodes	KM,	Tattersfield	AE	(1982)	Guillain-Barré	syndrome	associated	with	Campylobacter	infections.	Br	Med	J	(Clin	Res	Ed)
285(6336):	173–74.
12.	Kaldor	J,	Speed	BR	(1984)	Guillain-Barré	syndrome	and	Campylobacter	jejuni:	a	serological	study.	Br	Med	J	(Clin	Res	Ed)	288(6434):
1867–70.
13.	Yuki	N,	Taki	T,	Inagaki	F,	Kasama	T,	Takahashi	M,	Saito	K,	Handa	S,	Miyatake	T	(1993)	A	bacterium	lipopolysaccharide	that	elicits
Guillain-Barré	syndrome	has	a	GM1	ganglioside-like	structure.	J	Exp	Med	178(5):	1771–75.
14.	Aspinall	GO,	McDonald	AG,	Pang	H	(1994)	Lipopolysaccharides	of	Campylobacter	jejuni	serotype	O:19:	structures	of	O-antigen	chains
from	the	serostrain	and	two	bacterial	isolates	from	patients	with	Guillain-Barré	syndrome.	Biochemistry	33(1):	250–55.
15.	Rees	JH,	Soudain	SE,	Gregson	NA,	Hughes	RA	(1995)	Campylobacter	jejuni	infections	and	the	Guillain-Barré	syndrome.	N	Engl	J	Med
333(21):	1374–79.
16.	Jacobs	BC,	Rothbarth	PH,	van	der	Meché	FG,	Herbrink	P,	Schmitz	PI,	de	Klerk	MA,	van	Doorn	PA	(1998)	The	spectrum	of	antecedent
infections	in	Guillain-Barré	syndrome:	a	case-control	study.	Neurology	51(4):	1100–15.
17.	Islam	Z,	Jacobs	BC,	van	Belkum	A,	Mohammad	QD,	Islam	MB,	Herbrink	P,	Diorditsa	S,	Luby	SP,	Talukder	KA,	Endtz	HP	(2010)	Axonal
variant	of	Guillain-Barré	syndrome	associated	with	Campylobacter	infection	in	Bangladesh.	Neurology	74(7):	581–87.
18.	van	Belkum	A,	van	den	Braak	N,	Godschalk	P,	Ang	W,	Jacobs	BC,	Gilbert	M,	Wakarchuk	W,	Verbrugh	H,	Endtz	H	(2001)	A
Campylobacter	gene	associated	with	immune-mediated	neuropathy.	Nat	Med	7(7):	752–53.
19.	Godschalk	PC,	Heikema	AP,	Gilbert	M,	Komagamine	T,	Ang	CW,	Glerum	J,	Brochu	D,	Li	J,	Yuki	N,	Jacobs	BC,	et	al.	(2004)	The	crucial
role	of	Campylobacter	jejuni	genes	in	anti-ganglioside	antibody	induction	in	Guillain-Barré	syndrome.	J	Clin	Invest	114(11):	1659–65.
20.	Ang	CW,	Jacobs	BC,	Laman	JD	(2004)	The	Guillain-Barré	syndrome:	a	true	case	of	molecular	mimicry.	Trends	Immunol	25(2):	61–66.
21.	Yuki	N,	Susuki	K,	Koga	M,	Nishimoto	Y,	Odaka	M,	Hirata	K,	Taguchi	K,	Miyatake	T,	Furukawa	K,	Kobata	T,	et	al.	(2004)	Carbohydrate
mimicry	between	human	ganglioside	GM1	and	Campylobacter	jejuni	lipooligosaccharide	causes	Guillain-Barré	syndrome.	Proc	Natl
Acad	Sci	U	S	A	101(31):	11404–409.
	24
The	Genetic	Basis	of	Guillain-Barré	Syndrome:
Susceptibility	and	Outcome
Karin	Geleijns
Introduction
In	 the	 last	 100	 years	 many	 great	 scientific	 papers	 have	 been	 written	 about	 the	 progress	 made	 in
understanding	the	pathogenesis	of	Guillain-Barré	syndrome.	The	roles	of	antecedent	infection,	molecular
mimicry	and	anti-ganglioside	antibodies	have	been	extensively	described	elsewhere	in	this	monograph.	In
this	chapter	 I	 focus	on	 the	contribution	of	genetic	host	 factors	 in	 the	pathogenesis	of	GBS.	Why	do	we
think	that	host	factors	are	involved?	What	are	ways	to	assess	their	contribution	to	disease	susceptibility	or
severity?	What	are	the	results	of	these	studies?	What	would	be	a	direction	for	further	studies?
Why	Do	We	Think	That	Genetic	Host	Factors	Are	Involved?
In	GBS	 the	variety	 in	preceding	 infections,	 clinical	 signs	and	symptoms,	and	 severity	of	 the	disease	 is
large.	 Even	 in	 subgroups	 of	 patients	 who	 had	 the	 same	 antecedent	 infection	 the	 clinical	 signs	 and
symptoms	 are	 heterogeneous,	 suggesting	 a	 contribution	 of	 host	 factors.	Other	 reasons	 to	 think	 that	 host
factors	are	involved	are	reports	of	GBS	within	families,	the	increased	recurrence	risk	of	GBS	or	the	low
incidence	of	GBS	after	a	common	infection,	which	I	discuss	in	the	next	part	of	this	chapter.
Familial	Guillain-Barré	Syndrome
Saunders	M,	Rake	M.	Familial	Guillain-Barré	syndrome.	The	Lancet,	1965;	Geleijns	K,	et	al.
The	occurrence	of	Guillain-Barré	syndrome	within	families.	Neurology,	2004
In	1965	M.	Saunders	and	M.	Rake	reported	a	brother	and	sister	who	had	both	developed	GBS	with	a	time
interval	of	4	years	[1].	They	both	were	70+	years	old	and	had	the	same	preceding	symptoms.	Since	then	a
few	similar	family	reports	have	been	published.	In	the	largest	report,	published	in	2004,	20	families	in	the
Netherlands,	each	with	at	least	2	members	who	had	GBS,	were	contacted.	As	some	refused	to	participate
or	had	uncertain	diagnoses,	12	of	those	families	where	included	in	the	study	[2].The	patients	were	first-,
second-	 or	 third-degree	 relatives.	 The	 prodromal	 illness,	 clinical	 features	 and	 severity	 of	 the	 disease
varied	between	the	affected	members	within	 the	families.	Although	this	 is	 the	 largest	report	of	families
with	GBS,	it	is	not	sufficient	to	prove	the	occurrence	of	GBS	within	families.	Factors	that	may	suggest	a
genetic	 susceptibility	 were	 the	 slightly	 more	 frequent	 occurrence	 of	 GBS	 within	 siblings	 (2.6	 fold
increase	 compared	 to	 the	 expected	 incidence),	 the	 observed	 earlier	 onset	 of	 GBS	 in	 successive
generations	and	patients	who	had	4	episodes	of	GBS.
Recurrent	Guillain-Barré	Syndrome
Kuitwaard	et	al.	Recurrent	Guillain-Barré	syndrome.	Journal	of	Neurology,	Neurosurgery	&
Psychiatry,	2009
Although	GBS	is	a	monophasic	disease,	some	patients,	as	mentioned	above,	have	more	than	one	episode
of	Guillain-Barré	syndrome.	Previous	studies	estimated	a	recurrence	rate	of	2–5%	[3,4].	Kuitwaard	and
colleagues	reported	the	largest	cohort	of	patients	with	recurrent	GBS	[5].	They	investigated	whether	the
neurological	 symptoms	 or	 antecedent	 infections	were	 similar	 in	 each	 patient	 episode	 and	whether	 the
patients	 with	 subsequent	 episodes	 could	 be	 distinguished	 from	 those	 with	 nonrecurrent	 GBS.	 They
identified	32	patients	who	had,	in	total,	81	episodes	of	GBS:	7	patients	had	3	episodes,	2	had	4	episodes,
2	had	5	episodes,	and	 the	other	21	had	2	episodes	each.	Although	 the	patients	with	recurrent	GBS	had
different	types	of	antecedent	infections,	the	signs	and	symptoms	during	every	episode	were	similar.	Other
observations	were	 (A)	 a	 trend	 towards	 shorter	 intervals	 between	 subsequent	 recurrences,	 (B)	 a	more
severe	 deficit	with	 each	 recurrence,	 (C)	 all	 patients	with	 3	 or	more	 episodes	were	 female,	 and	 (D)	 3
patients	 with	 GBS	 had	 an	 autoimmune	 disease,	 further	 indicating	 that	 immunological	 and	 genetic	 host
factors	are	involved	in	the	pathogenesis.	In	comparison	with	the	patients	who	had	nonrecurrent	GBS,	the
patients	who	had	one	of	more	recurrences	were	younger	at	first	episode,	had	milder	symptoms,	and	more
often	had	the	GBS	variant,	Miller	Fisher	syndrome.
Guillain-Barré	Syndrome	after	Outbreaks	Part	I
Sliman	NA.	Outbreak	of	Guillain-Barre	syndrome	associated	with	water	pollution.	British
Medical	Journal,	1978
The	first	article	that	was	available	for	me	in	English	about	the	incidence	of	Guillain-Barré	syndrome	after
an	 epidemic	outbreak	was	 the	paper	 by	N.A.	Sliman.	 In	 1976	 in	 a	 rural	 town	 in	 Jordan	with	~30,000
inhabitants,	drinking	water	seemed	to	be	polluted	with	Escherichia	coli	during	a	regular	check.	A	least
5,000	inhabitants	developed	acute	diarrhoea.	Only	a	few	stool	cultures	were	positive	for	shigella	and	a
few	blood	samples	were	positive	for	Salmonella	typhi.	During	the	 third	week,	patients	with	peripheral
neuropathy	were	presented	at	the	El-Sult	Hospital.	Sixteen	patients	were	identified	with	GBS,	of	whom
13	had	mild	symptoms	of	diarrhoea	as	a	preceding	symptom	[6].	The	outbreak	of	acute	diarrhoea	didn’t
result	in	a	GBS	epidemic,	suggesting	that	host	factors	were	involved.
Guillain-Barré	Syndrome	after	Outbreaks	Part	II
Ang	CW,	et	al.	A	case	of	Guillain-Barré	syndrome	following	a	family	outbreak	of
Campylobacter	jejuni	enteritis.	The	Journal	of	Neuroimmunology,	2000
Since	Campylobacter	jejuni	is	the	most	common	antecedent	infection	in	GBS	patients	it	is	interesting	to
look	in	more	detail	about	the	incidence	of	GBS	after	an	outbreak	with	this	bacterium.	Although	there	have
been	 reports	 of	 epidemics	 of	 Campylobacter	 that	 did	 not	 result	 in	 an	 outbreak	 of	 Guillain-Barré
syndrome	[7],	the	estimation	is	that	1	out	of	1,000	will	develop	GBS	after	such	a	Campylobacter	 jejuni
infection	 [8].	 Ang	 and	 colleagues	 reported	 an	 outbreak	 of	 Campylobacter	 jejuni	 within	 a	 family
consisting	of	parents	and	2	sons	[9].	The	father	and	his	sons	had	diarrhoea	and	 the	serology	of	 these	3
family	members	 indicated	 a	 recent	 infection	with	C.	 jejuni.	 Only	 one	 son	 developed	 GBS.	 The	 stool
cultures	of	father	and	the	son	without	GBS	were	positive	for	C.	jejuni.	Only	the	serum	of	the	GBS	patient
strongly	reacted	with	the	LPS	fractions	of	the	cultured	C.	jejuni	from	his	father	and	brother.	Furthermore,
only	the	GBS	patient	had	high	titres	of	IgM	and	IgG	anti-glycolipid	antibodies,	compared	with	his	father
and	 brother,	 who	 had	 low	 titres	 of	 IgM	 anti-glycolipid	 antibodies.	 HLA-genotyping	 revealed	 that	 the
father	 and	 unaffected	 son	 had	 HLA-A2/DR4/DQ8	 haplotype,	 which	 the	 patient	 did	 not	 have,	 which
suggests	that	this	haplotype	might	be	protective	for	neurological	sequelae.
Genetic	Susceptibility	Factors
The	 paper	 of	 Ang	 and	 colleagues	 suggests	 that	 a	 certain	 HLA	 haplotype	 might	 be	 protective	 for
neurological	sequelae	after	an	infection	with	agents	associated	with	GBS.	The	highly	polymorphic	human
leucocyte	antigen	(HLA)	system	plays	a	central	role	in	the	immune	responses	by	presenting	antigens	to	the
immune	 system.	 In	 infectious	 or	 autoimmune	 disorders,	 as	 well	 as	 in	 GBS,	 many	 studies	 have	 been
performed	to	assess	whether	a	certain	HLA	haplotype	is	associated	with	disease	susceptibility.
Human-Leucocyte	Antigen	Class	II	in	GBS
Geleijns	K,	et	al.	HLA	class	II	alleles	are	not	a	general	susceptibility	factor	in	Guillain-Barré
syndrome.	Neurology,	2005
Since	disease	susceptibility	of	autoimmune	disease	is	most	closely	linked	to	HLA-DRB1	and	HLA-DQB1
alleles,	 we	 investigated	 whether	 these	 alleles	 confer	 susceptibility	 to	 GBS	 or	 are	 related	 to	 specific
clinical	and	serological	subgroups	[10].	One	hundred	and	sixty-four	patients	clinically	and	serologically
well	 characterized	 were	 genotyped.	 We	 found	 no	 association	 between	 HLA-DRB1	 and	 HLA-DQB1
alleles	 and	 GBS.	 We	 also	 reviewed	 17	 case-control	 studies	 which	 had	 previously	 investigated	 an
association	 between	 HLA-class	 I	 or	 II	 antigens	 and	 GBS	 susceptibility	 and	 subgroups	 [11–27].	 (See
Table	24.1).	With	regard	to	disease	susceptibility,	most	of	the	studies	did	not	find	any	association	or	at
most	 only	 a	 weak	 association	 that	 could	 not	 be	 confirmed	 by	 other	 studies.	 The	 same	 held	 true	 for
subgroup	 analyses.	 We	 concluded	 that	 the	 HLA-system	 probably	 does	 not	 play	 a	 general	 role	 in
susceptibility	 to	 GBS.	 Maybe	 this	 is	 not	 so	 remarkable	 in	 that	 GBS	 seems	 not	 to	 be	 a	 classical
autoimmune	disorder	given	that	women	are	not	more	frequently	affected,	incidence	is	not	highest	during
the	fertile	period	and	GBS	is	more	often	a	post-infectious	disorder	with,	most	of	the	time,	a	monophasic
course	of	disease.
Table	24.1		Overview	of	case-control	studies	of	HLA-distribution	in	Guillain-Barré	syndrome
Single	Nucleotide	Polymorphisms
Another	way	 to	 assess	 a	 genetic	 contribution	 to	 the	 pathogenesis	 of	GBS	 is	 to	 study	 single	 nucleotide
polymorphisms	 (SNPs)	 in	 relation	 to	 disease	 susceptibility	 or	 severity.	 These	 SNPs	 are	 widely
distributed	throughout	the	genome	and	are	by	definition	present	in	at	least	1%	of	the	general	population.
Within	a	protein-coding	gene	these	SNPs	can	be	located	in	(A)	the	promoter	region,	which	is	involved	in
the	 transcriptional	 regulation	 of	 the	 gene	 expression,	 (B)	 the	 coding	 region,	 which	 is	 translated	 to	 a
protein,	 (C)	 the	 intron,	 which	 is	 not	 translated	 to	 a	 protein	 but	 is	 involved	 in	 splicing,	 and	 (D)	 the
untranslated	 region	 (UTR),	which	 affects	 the	 stability	 of	RNA.	 In	 this	manner	 an	SNP	 can	 account	 for
differences	in	protein	levels,	altered	function	of	a	protein	or	the	absence	of	a	protein.
Immunogenetic	Polymorphisms	in	Guillain-Barré	Syndrome
Blum	S,	McCombe	PA.	Genetics	of	Guillain-Barré	syndrome	(GBS)	and	chronic	inflammatory
demyelinating	polyradiculoneuropathy	(CIDP):	current	knowledge	and	future	directions.
Journal	of	the	Peripheral	Nervous	System,	2014
Since	1985	several	papers	have	been	published	that	assessed	whether	immunogenetic	polymorphisms	are
a	 susceptibility	 factor	 for	GBS	or	 are	 associated	with	disease	 severity	or	other	 clinical	of	 serological
characteristics	of	GBS.	In	2014	Blum	and	McCombe	published	a	beautiful	overview	paper	in	which	they
listed	all	performed	studies	[28].	(See	Table	24.2).	The	single	nucleotide	polymorphisms	studied	were
located	in	genes	encoding	for	cytokines,	pattern	recognition	receptors,	proteins	involved	in	complement
system,	enzymes	 involved	 in	breakdown	of	blood-brain	barrier,	etc.	The	studies	were	most	of	 the	 time
single	 studies	 performed	 in	 small	 numbers	 and	 if	 studies	were	 repeated	 the	 results	were	 different.	No
clear	conclusions	can	be	drawn.	In	the	next	part	I	highlight	2	of	these	performed	studies.
Geleijns	K,	et	al.	Mannose-Binding	Lectin	Contributes	to	the	Severity	of	Guillain-Barré
Syndrome.	The	Journal	of	Immunology,	2006
The	 main	 question	 with	 all	 the	 associations	 between	 SNPs	 and	 disease	 susceptibility	 or	 severity	 is
whether	 it	 leads	 to	 a	 functional	 difference	 in	 vivo.	 In	 this	 study	we	 assessed	 the	 association	 between
polymorphisms	 in	 the	 gene	 encoding	 for	 mannose-binding	 lectin	 (MBL)	 and	 disease	 susceptibility	 or
severity	[29].	MBL	is	a	protein	involved	in	the	activation	of	complement	systems	via	the	lectin	pathway.
An	 association	 was	 found	 between	 the	 haplotypes	 associated	 with	 high-MBL	 activity	 and	 GBS
susceptibility,	and	particularly	with	disease	severity.	There	was	also	a	correlation	between	high	serum
levels	of	MBL	and	MBL	activity	in	patients	with	severe	weakness,	supporting	a	functional	effect	of	the
genetic	association	in	the	pathogenesis	of	GBS.
Table	24.2		List	of	genetic	association	studies	in	Guillain-Barré	syndrome	other	than	HLA

Wu	et	al.	The	effect	of	TNF-alpha,	FcγR	and	CD1	polymorphisms	on	Guillain-Barre
syndrome	risk:	evidences	from	a	meta-analysis.	The	Journal	of	Immunology,	2012
Since	 the	small	sample	size,	heterogeneity	of	GBS	and	 the	expected	small	effect	of	 individual	SNPs,	a
meta-analysis	 can	 improve	 the	 power	 of	 genetic	 association	 studies.	 In	 this	meta-analysis	Wu	 and	 his
colleagues	 included	 genetic	 association	 studies	 if	 a	 polymorphism	was	 assessed	 in	more	 than	 2	 case-
control	studies	[30].	The	largest	sample	size	was	for	TNF-alpha	308A/G	polymorphism:	713	cases	and
729	 controls,	 consisting	 of	 4	 Asian	 cohorts	 and	 1	 Caucasian.	 This	 polymorphism	 was	 significantly
associated	with	 disease	 susceptibility	 in	 this	 analysis.	 In	 a	 previously	 performed	 study	 by	 Prasad	 and
colleagues,	the	A-allele	of	this	polymorphism	was	associated	with	higher	circulating	TNF-alpha	levels	in
blood	 in	 GBS	 patients	 with	 the	 AMAN	 variant,	 suggesting	 a	 possible	 contributing	 factor	 to	 the
pathogenesis	of	GBS	[31].	In	their	meta-analysis	Wu	and	colleagues	did	not	find	an	association	between
CD1	genes	or	FcγR	polymorphisms	and	a	risk	of	developing	GBS.
Future	Directions
At	the	start	of	my	PhD	project	there	were	no	high-throughput	techniques	to	detect	SNPs.	In	the	last	decade
genome-wide	assays	studies	 (GWAS)	have	been	performed	 in	 infectious	and	autoimmune	diseases,	and
nowadays	 whole-exome	 sequencing	 is	 used	 to	 discover	 genetic	 causes	 of	 diseases.	 Because	 of	 the
complex	 genetic	 traits	 of	GBS	 and	 the	 expected	 small	 effects	 of	 individual	 genes,	 genetic	 association
studies	will	 require	 large	 sample	 sizes	 of	 clearly	 defined	 subgroups	 of	GBS	patients.	Another	way	 to
search	for	the	genes	or	gene	networks	involved	is	to	perform	functional	studies	like	that	done	by	Chang
and	colleagues	[32].
Identification	of	Gene	Networks	and	Pathways	in	Guillain-Barré
Syndrome
Chang	KH,	et	al.	Identification	of	gene	networks	and	pathways	associated	with	Guillain-
Barré	syndrome.	PLoS	ONE,	2012
To	 identify	 gene	 networks	 and	 pathways	 in	Guillain-Barré	 patients,	Chang	 and	 colleagues	 drew	blood
from	Taiwanese	GBS	patients	within	1–2	weeks	after	disease	onset	and	from	7	healthy	volunteers	[32].
They	 performed	 a	 genome-wide	mRNA	 expression	 data	 of	 peripheral	 blood	 leukocytes	 by	Affymetrix
Human	Genome	U133	plus	2.0	Array.	Two	hundred	and	fifty-six	genes	reached	the	minimum	fold	change
(>	2),	of	which	246	genes	were	upregulated	and	10	downregulated.	These	256	genes	were	subjected	to	a
network	 analysis	 clustered	 in	 the	 networks	 by	 (A)	 disease	 and	 disorder,	 (B)	 molecular	 and	 cellular
functions	 or	 (C)	 physiological	 system	 development	 and	 function.	 In	 these	 networks	 they	 found	 several
interesting	genes,	a	few	of	which	I	highlight	with	potential	therapeutic	options.	Matrix	metalloproteinase-
9,	detected	in	damaged	nerves	and	associated	with	disease	severity	and	electrophysiological	changes	in
GBS	patients,	 could	be	 a	potential	 target	molecule	 for	 therapy	 since	 in	 the	 animal	model	 experimental
autoimmune	neuritis	(EAN)	administration	of	a	MMP-9	inhibitor	decreased	the	disease	severity	[33–36].
The	 expression	 of	 a	member	 of	 the	 cyclooxygenase	 family	 encoded	 by	 PTGS2	was	 also	 upregulated.
Since	administration	of	COX	inhibitor	decreased	disease	parameters	at	several	levels	in	EAN	this	could
also	 be	 an	 interesting	 therapeutic	 target	 [37–39].	 With	 regard	 to	 canonical	 pathways,	 I	 highlight	 the
ERK/MAPK	 pathway	 that	 is	 involved	 in	 production	 of	 proinflammatory	 cytokines	 and	 demyelination
[40].	 Blocking	 this	 pathway	may	 be	 also	 a	 therapeutic	 target.	 In	my	 opinion	 this	 study	 shows	 another
possibility	to	further	dissect	the	genetic	contribution	in	the	pathogenesis	of	GBS.
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Guillain-Barré	Syndrome—Pathology
Claudia	Sommer	and	Klaus	Toyka
Introduction
What	is	the	essence	of	GBS,	and	can	any	part	of	it	be	understood	by	looking	at	pathology?	Which	parts	of
the	 nervous	 system	 have	 been	 studied,	 and	 are	 these	 the	 ones	 that	 give	 us	 insight	 into	 the	 formal
pathogenesis	and	pathophysiology	of	GBS?
The	early	reports	starting	some	60	years	ago	include	mostly	postmortem	evaluations	with	very	limited
clinical	 and	 electrophysiological	 data.	With	 the	 advent	 of	 artificial	 ventilation	 and	 other	 advances	 in
intensive	 care	 medicine,	 fortunately,	 fewer	 patients	 run	 a	 lethal	 course	 nowadays	 in	 optimal	 clinical
settings.	 The	 remaining	 lethal	 cases	 are	 autopsied	 very	 rarely.	 This	 causes	 a	 fundamental	 bias	 when
analyzing	older	studies.	Over	the	last	20	years,	patients	fulfilling	contemporary	diagnostic	criteria	do	not
have	sural	biopsies	done	except	with	a	clear	research	protocol.	Hence	few	studies	have	reported	on	the
sural	nerve	 and	only	occasionally	on	motor	nerves.	Technically,	 electron	microscopy	 (EM)	and	 teased
fibre	 preparations	 dominated	 the	 field	 later,	 followed	 by	 light	 microscopic	 immunopathology.	 Most
recently,	skin	biopsies	entered	the	field,	and	findings	were	correlated	to	sural	nerve	pathology.	We	here
describe	 the	 pivotal	 reports	 delineating	 the	 inflammatory	 nature	 of	 GBS	 published	 between	 1948	 and
1996	and	discuss	some	of	the	later	studies	elucidating	disease	mechanisms	in	GBS,	in	comparison	to	its
animal	model	experimental	autoimmune	(‘allergic’)	neuritis	(EAN),	where	applicable.
Sural	nerve	biopsy	limits	information	to	a	very	short	moment	in	time,	to	a	rather	small	area	of	nerve
and	to	a	less	affected	part	of	the	peripheral	nervous	system	(PNS).	The	very	few	reports	on	motor	nerves
underscore	 this	 dilemma.	 Despite	 these	 limits,	 our	 current	 hypotheses	 on	 the	 immunopathology	 have
become	more	precise	based	on	data	gained	from	(A)	numerous	diligent	EAN	studies,	(B)	data	from	ex-
vivo	studies	on	the	functional	role	of	autoantibodies	and	proinflammatory	factors	(cytokines,	chemokines,
complement)	and	(C)	data	on	other	biomarkers.	Now	we	may	be	able	to	place	these	findings	from	human
GBS	neuropathology	collectively	into	a	telling	context.
Early	Autopsy	Studies	Find	a	Polyradiculoneuropathy
Haymaker	WE	and	Kernohan	JW.	The	Landry	Guillain-Barré	syndrome;	a	clinicopathologic
study	of	50	fatal	cases.	Transactions	of	the	American	Neurological	Association,	1948;
Haymaker	WE	and	Kernohan	JW.	The	Landry-Guillain-Barré	syndrome;	a	clinicopathologic
report	of	50	fatal	cases	and	a	critique	of	the	literature.	Medicine,	1949
Haymaker	 and	 Kernohan’s	 1948	 report	 was	 the	 first	 on	 a	 large	 and	 quite	 heterogeneous	 group	 of	 50
patients	with	an	acute	and	ultimately	lethal	PNS	disease	[1].	More	than	a	quarter	of	the	group	had	findings
that	would	not	be	compatible	with	later	definitions	of	GBS.	These	included	CSF	cell	counts	of	up	to	110
cells	 per	 microlitre	 and	 perivascular	 CNS	 infiltrates;	 some	 had	 meningeal	 lymphocytic	 infiltrates.
Haymaker	 and	 Kernohan	 in	 their	 50	 autopsy	 cases,	 most	 of	 whom	 had	 died	 of	 respiratory	 failure,
described	 perivascular	 lymphocytes	 in	 the	white	matter	 in	 25%	 of	 their	 cases	 [1,2].	 They	 found	mild
cellular	 infiltration	 in	 the	 meninges	 in	 some	 cases.	 Anterior	 horn	 cells	 were	 affected	 by	 mild
chromatolysis	in	about	the	same	percentage.	In	the	PNS	spinal	root,	infiltration	was	predominant,	which
they	considered	a	secondary	feature	and	which	led	them	to	the	assumption	that	the	patients	did	not	have	an
inflammatory	type	of	neuropathy.
Since	 their	 patients	 had	died	between	2	 and	46	days	 after	 the	onset	 of	 disease,	 the	 authors	 had	 the
chance	 to	 look	at	early	and	 late	pathology	and	 to	speculate	on	 the	sequence	of	events	 in	 the	peripheral
nervous	system.	They	describe	nerve	oedema	during	the	first	3	to	4	days,	focal	swelling	of	myelin	sheaths
and	 irregularity	 of	 axon	 cylinders	 on	 day	 5,	 lymphocyte	 infiltration	 on	 day	 9	 and	 the	 presence	 of
macrophages	on	day	11.	Schwann	cell	proliferation	was	observed	on	day	13.	In	their	patients	with	a	pure
motor	phenotype,	only	the	anterior	roots	were	affected;	in	those	with	sensorimotor	deficits,	they	found	the
same	pathology	 in	 anterior	 and	posterior	 roots.	 Interestingly,	 the	 authors	 interpreted	 the	 late	 and	 rather
scarce	 presence	 of	 inflammatory	 cells	 in	 peripheral	 and	 cranial	 nerves	 as	 related	 to	 regeneration,	 not
inflammation,	and	named	the	disorder	a	polyradiculoneuropathy—not	a	neuritis.
What	then	had	these	patients	suffered	from	in	terms	of	our	contemporary	nomenclature?	Obviously,	a
selection	of	cases	by	time	of	death	imposes	a	massive	bias	and	conclusions	need	to	be	drawn	with	care.
This	was	 recognized	early	 and	 led	 to	 the	 landmark	experiments	on	 actively	 immunized	 rabbit	EAN	by
Waksman	and	Adams	in	the	early	1950s,	which	produced	enormous	momentum	to	the	field	[3].
GBS:	A	Polyneuritis	After	All?
Krücke	W.	Die	primär-entzündliche	Polyneuritis	unbekannter	Ursache.	In	Lubarsch	O,
Henke	F,	Rössle	G,	Hrsg.	Handbuch	der	speziellen	pathologischen	Anatomie	und
Histologie;	Erkrankungen	des	peripheren	Nervensystems.	Berlin:	Springer,1955;	Asbury
AK,	et	al.	The	inflammatory	lesion	in	idiopathic	polyneuritis.	Its	role	in	pathogenesis.
Medicine,	1969
The	 first	 comprehensive	 review	 of	 the	 histopathology	 GBS	 and	 other	 types	 of	 acute	 inflammatory
polyneuropathies	was	published	by	Wilhelm	Krücke	in	1955	[4],	with	the	inclusion	of	several	personal
cases.	The	 author	 discusses	 in	 detail	 the	 paper	 by	Haymaker	 and	Kernohan	 but	 also	 elaborates	 on	 the
extensive	 pathology	 literature	 from	France,	Germany,	England	 and	 the	United	States	 on	 reported	 cases
back	to	1898.	In	his	treatise	he	favours	an	‘allergic’	hypothesis	because	of	the	type	of	lesions,	but	points
out	 that	 only	 experimental	 work	 on	 animals	 models	 would	 tell.	 He	 also	 makes	 the	 point	 that	 acute
inflammatory	polyneuritis	and	parainfectious	and	postinfectious	polyneuritis	have	the	same	pathological
features	and	may	therefore	be	the	same	disease.	Of	note,	the	landmark	study	by	Waksman	and	Adams	had
not	yet	appeared	at	the	time	of	Krücke’s	writing.	In	later	years	he	extensively	studied	the	neuropathology
of	EAN	with	J.M.	Schröder	in	comparison	to	‘allergic’	polyneuritis	in	humans.
From	their	19	autopsy	cases	in	Boston,	Asbury,	Arnason	and	Adams	first	make	the	point	that	GBS	is	a
‘neuritis’	after	all	 [5].	The	authors	 find	 that	both	 the	 temporal	course	and	 the	basic	pathology	are	well
modelled	by	EAN	as	described	in	the	same	institution	[3].	They	show	massive	lymphocyte	infiltration	in
the	radial	and	femoral	nerve	of	1	patient,	 lymphocytic	and	polymorphonuclear	 infiltrates	 in	 the	anterior
roots	of	another,	and	lymphocytic	and	polymorphonuclear	infiltrates	in	the	cranial	and	peripheral	nerves
of	others.	Even	 in	muscle	sections,	 they	 found	 inflammatory	 infiltrates	around	 the	 terminal	motor	nerve
branches.	Myelin	 breakdown	 was	 observed	 in	 motor	 and	 sensory	 nerves.	 Retraction	 of	 myelin	 at	 the
nodes	 of	 Ranvier	 led	 to	 nodal	 gaps,	 indicating	 focal	 demyelination.	 In	 a	 patient	 with	 severe	 root
inflammation,	anterior	and	posterior	horn	cells	were	pathologic,	and	there	was	astroglial	proliferation	in
the	 spinal	 cord.	 Inflammatory	 infiltrates	 had	 a	 perivascular	 preference	 in	 several	 cases.	 Of	 interest,
several	patients	 survived	 the	GBS	and	died	of	other	causes	 later.	Denervation	atrophy	of	muscles	was
seen	 in	 those	 that	 survived	 the	 longest.	One	 lady	had	 recovered	 from	GBS	and	was	able	 to	walk	with
crutches.	 She	 had	 lived	 5	 more	 years	 before	 dying	 from	 a	 stroke.	 Her	 autopsy	 showed	 segmental
demyelination	 with	 insufficient	 remyelination,	 and	 there	 were	 still	 focal	 inflammatory	 infiltrates
surrounding	endoneurial	vessels.	These	consisted	of	lymphocytes	and	occasional	plasma	cells.	A	similar
pathological	 picture	was	observed	 in	 a	 patient	 surviving	 for	 6	years.	The	 authors	 conclude	 from	 these
observations	 that	 low-grade	 inflammatory	 activity	may	 persist,	 and	 that	 a	 hypothetical	 flare-up	 of	 this
process	might	underlie	recurrent	polyneuritis.	The	authors	also	conclude	that	GBS,	like	EAN,	is	a	“cell-
mediated	 immunologic	 disorder,	 in	 which	 peripheral	 myelin	 is	 attacked	 by	 specifically-sensitized
lymphocytes”.	Of	note,	macrophages	were	not	specifically	addressed	in	these	light-microscopic	analyses
nor	were	they	the	focus	in	early	EAN	pathology.
Are	Macrophages	the	Culprit?
Wiśniewski	H,	et	al.	Landry-Guillain-Barré	syndrome.	A	primary	demyelinating	disease.
Archives	of	Neurology,	1969;	Prineas	JW.	Acute	idiopathic	polyneuritis.	An	electron
microscope	study.	Laboratory	Investigation,	1972;	Matsuyama	H	and	Haymaker
W.Distribution	of	lesions	in	the	Landry-Guillain-Barré	syndrome,	with	emphasis	on
involvement	of	the	sympathetic	system.	Acta	Neuropathologica,	1967
Wiśniewski	 and	 colleagues	 reported	 on	 a	 young	 female	 patient	 who	 had	 progressive	 tetraparesis	 and
eventually	respiratory	failure	[6].	She	died	from	acute	cardiac	arrest	and	had	a	postmortem	examination
only	 4	 hours	 after	 her	 death.	No	 pathology	was	 seen	 in	 the	CNS	 (vide	 supra,	 report	 by	Haymaker	&
Kernohan	 [1]).	 In	 the	PNS	 intermodal	demyelination	was	 found,	with	macrophages	 entering	 the	myelin
sheath,	 phagozytosing	 myelin	 debris,	 and	 presumably	 activated	 lymphocytes	 were	 identified	 near	 the
lesions.	 In	 addition,	 net-like	 and	 vesicular	 myelin	 changes	 were	 noted.	 These	 authors	 cite	 the	 earlier
observations	 by	 Krücke	 [4].	 Shortly	 thereafter,	 the	 sural	 biopsy	 from	 a	 Japanese	 boy	 with	 GBS	 was
reported	by	Miyakawa	[7],	including	EM	presenting	all	the	features	described	by	Wiśniewski’s	group.
In	the	single-author	study	by	Professor	John	Prineas	of	Sydney,	sural	nerves	obtained	by	biopsy	were
studied,	allowing	better	tissue	preservation	and	excluding	terminal	disease	pathology	at	autopsy	[8].	Of
note,	6	out	of	10	patients	had	received	corticosteroids	before	the	biopsy,	which	may	have	downscaled	any
inflammatory	signs.	Perivascular	lymphocytic	infiltrates	were	seen	but	were	considered	minor.	Two	types
of	myelin	degeneration	could	be	observed:	one	resembling	Wallerian	degeneration,	the	other	one	showing
myelin	 debris	 as	 small	 and	 aligned	 along	 the	 nerve	 fibre,	 with	 myelin	 phagocytosed	 by	 an	 invading
mononuclear	cell	leaving	the	axon	intact.	Prineas	named	this	‘active	primary	demyelination’.	On	EM	the
pivotal	findings	were	macrophages	penetrating	the	myelin	sheaths	through	gaps	in	the	basement	membrane
and	 leading	 to	 lysis	 of	 major	 dense	 lines	 while	 stripping	 away	 the	 outermost	 laminae	 of	 the	 myelin
sheaths.	The	same	cells	then	phagocytosed	this	myelin,	such	that	debris	could	be	seen	in	their	cytoplasm.
Macrophage	 processes	 were	 found	 particularly	 to	 be	 burrowing	 their	 way	 along	 minor	 dense	 lines
(intraperiod	lines).	The	less	commonly	observed	vesicular	dissolution	of	myelin	appeared	to	be	mediated
by	 macrophages	 in	 the	 presence	 of	 lymphocytes.	 Demyelinated	 axons	 were	 then	 surrounded	 by
polymorphic	 mononuclear	 cells.	 Prineas	 concludes	 that	 amongst	 the	 possible	 pathomechanisms,	 an
antibody-mediated	 process	 and	 a	 direct	 cytotoxic	 attack	 by	 lymphocytes	were	 both	 unlikely,	while	 the
‘chief	 effector	 agents’	were	 supposed	 to	 be	macrophages	 ‘with	 a	 specific	 affinity	 for	myelin’.	 Prineas
also	showed	the	preferential	location	of	macrophage	attack	at	internodes	near	the	paranode	(Figure	25.1).
In	a	second	large	series	from	Bordeaux,	France	[9],	the	main	findings	of	Prineas	were	confirmed	on	65
patients	while	in	some	patients	mononuclear	cells	had	invaded	the	fibre	between	the	myelin	and	axon	and
occasionally	 inside	 the	 axon.	 This	 was	 later	 shown	 to	 be	 a	 typical	 feature	 for	 the	 Chinese	 GBS-like
syndrome	named	acute	motor	axonal	neuropathy	(AMAN)	[10].	A	variant	of	an	axonal	type	of	GBS	was
first	described	by	Feasby	and	colleagues	in	5	Canadian	patients	with	clinically	quadriplegic	acute	GBS
and	completely	 inexcitable	peripheral	nerves	on	electrophysiological	examination	[11].	Nerve	biopsies
showed	predominant	axonal	damage.	One	patient	died	and	on	autopsy	was	found	to	have	massive	axonal
degeneration	without	inflammation	or	demyelination	[11].
Figure	25.1		Simple	cartoon	proposing	how	in	GBS	a	focal	attack	of	mononuclear	cells	at	the	internode	may	widen	the	node	of
Ranvier	and	amputate	part	of	 the	Schwann	cell	 (bottom)	as	compared	 to	a	primary	Schwann	cell	disease	 (top).Modified	with
permission	from	[8].
Figure	25.2		Simplified	scheme	showing	some	major	putative	mechanisms	in	immune-inflammatory	polyneuropathies.	APC,	=
antigen	presenting	cell;	TH	=	T-helper	 lymphocyte;	B	=	B-lymphocyte	coated	with	antibodies	and	once	 transformed	 to	plasma
cells	 secrete	 antibodies	 directed	 at	 myelin	 antigens	 (AG),	 e.g.	 protein	 P2.	 Macrophages	may	 directly	 attack	 nerve	 fibres	 by
producing	proinflammatory	factors:	OH-=	hydroxyl	radicals;	PGE	=	prostaglandin	E	and	other	eicosanoids;	c	=	complement;	TNF
=	tumor	necrosis	factor	family;	IFNγ	=	Interferon	gamma;	LTC4leucotriene	C4.	Macrophages	may	also	act	by	binding	antibodies
(arming)	through	their	Fc	receptor;	granules	secreted	from	the	macrophage	cytoplasm	indicate	potentially	myelinotoxic	lysosomal
enzymes;	Schwann	cells	could	also	be	attacked	by	cytotoxic	T	cells	since	they	express	major	histocompatibility	complex	II	(MHC)
and	myelin	antigens.	Note	that	rare	mast	cells	are	not	depicted.	Modified	with	permission	from	[27].
The	 question	 as	 to	 whether	 the	 autonomic	 nervous	 system	 is	 also	 part	 of	 GBS	 was	 addressed	 by
several	authors.	In	the	study	by	Asbury,	Adams	and	Arnason	(vide	supra)	and	in	a	report	by	Matsuyama
and	Haymaker,	inflammatory	cell	infiltrates	were	described	in	sympathetic	ganglia	[12].
Much	 later,	 pathological	 studies	 on	 GBS	 sural	 nerves	 and	 numerous	 rat	 EAN	 experiments	 led	 to
several	 new	 observations	 which	 allowed	 putative	 immune	 mechanisms	 to	 be	 proposed	 including
activation	 of	 macrophages	 armed	 by	 myelin-specific	 antibodies	 (Figure	 25.2).	 More	 recently,	 using
modern	MRI	technology	and	specific	 labelling	techniques,	Stoll	and	colleagues	followed	hematogenous
macrophages	dynamically	while	they	were	infiltrating	their	nerve	target	(‘caught	in	the	act’)[13].
Evidence	from	Sural	Nerve	Biopsies:	Inflammatory	Infiltrates
Schmidt	B,	et	al.	Inflammatory	infiltrates	in	sural	nerve	biopsies	in	Guillain-Barré	syndrome
and	chronic	inflammatory	demyelinating	neuropathy.	Muscle	Nerve,	1996
With	 the	 advent	 of	 immunohistochemistry,	 inflammatory	 infiltrates	 in	 nerve	 biopsies	 could	 be	 more
precisely	differentiated.	In	a	1996	studyin	Würzburg,	Germany,	Schmidt	and	colleagues	took	sural	nerve
biopsies	from	22	GBS	patients	with	moderate	to	very	severe	disability.	All	but	2	had	a	full	course	of	IVIg
or	plasmapheresis	treatment	before	the	biopsy	was	taken	and	5	had	no	overt	sensory	deficit.	Schmidt	and
colleagues	identified	and	quantified	endo-	and	epineurial	perivascular	T-lymphocytes	in	most	specimens
(Figure	25.3)[14].	Most	of	these	were	of	the	CD4	type.	Macrophages	(CD	68)	were	abundant	and	often
appeared	 in	 large	clusters,	mostly	associated	with	endoneurial	blood	vessels.	Other	macrophages	were
diffusely	scattered	throughout	the	endoneurium.	The	number	of	T	cells	was	correlated	with	clinical	data.
Patients	with	 clinical	 sensory	 involvement	 or	with	 a	 later	 time	 point	 of	 biopsy	 had	 higher	 lymphocyte
numbers	 in	 the	 sural	 nerve	 than	 their	 counterparts.	Also,	macrophage	numbers	were	higher	 in	biopsies
taken	 later	 in	 the	 disease.	 Surprisingly,	 the	 numbers	 of	macrophages	 were	 not	 higher	 in	 patients	 with
hyperacute	 courses.	 On	 the	 contrary,	 those	 cases	 had	 fewer	 macrophages	 than	 patients	 with	 acute	 to
subacute	 GBS.	 Thus,	 the	 old	 idea	 of	 inflammatory	 cells	 being	 involved	 first	 in	 degeneration	 and
subsequently	in	regeneration	[1,2]	might	be	supported	by	these	findings.	One	permanently	disabled	patient
slowly	 deteriorated	 after	 10	 years	 at	 which	 time	 the	 other	 sural	 nerve	 was	 biopsied.	 Numbers	 and
patterns	of	inflammatory	cells	were	in	about	the	same	order	as	during	the	acute	stage.
Infiltrating	macrophage	clusters	as	observed	here	were	also	seen	in	sural	nerves	from	the	13	patients
with	CIDP	 [14],	which	was	 later	 confirmed	by	 a	 larger	 study,	 and	 this	 finding	 turned	out	 to	become	a
useful	diagnostic	marker	[15].
Are	Motor	Nerves	More	Informative	in	GBS?
Hall	et	al.	Motor	nerve	biopsy	in	severe	Guillain-Barré	syndrome.	Annals	of	Neurology,
1992
Given	 that	 GBS	 is	 clinically	 more	 a	 motor	 than	 a	 sensory	 neuropathy,	 a	 motor	 nerve	 might	 be	 more
informative	 as	 to	 the	 pathophysiology	 than	 a	 sensory	 nerve.	 Along	 these	 lines,	 Hall	 and	 colleagues
describe	 the	biopsy	findings	of	a	 terminal	branch	of	 the	musculocutaneous	nerve	 in	a	55-year-old	GBS
patient	with	hyperacute	GBS	after	a	respiratory	infection,	needing	artificial	ventilation	arising	already	on
day	2	[16].	The	patient	had	a	very	severe	course	and	responded	poorly	to	therapeutic	plasmapheresis.	He
even	further	deteriorated,	ultimately	showing	near	quadriplegia,	external	ophthalmoplegia	and	facial	and
bulbar	palsy.	In	order	not	to	miss	a	diagnosis,	a	musculocutaneous	nerve	biopsy	was	performed	on	day
16.	 Demyelination	 was	 patchy,	 with	 one	 fascicle	 much	 more	 affected	 than	 the	 second	 one.	 Some
lymphocytes	 could	 be	 detected,	 but	 the	 majority	 of	 inflammatory	 cells	 in	 the	 endoneurium	 and	 in	 the
epineurium	 were	 macrophages.	 These	 were	 laden	 with	 myelin	 debris.	 Direct	 myelin	 stripping	 by
macrophages	could	be	detected,	but	was	 rare.	 In	 the	demyelinated	axons,	 the	density	of	neurofilaments
was	increased.	In	spite	of	the	massive	demyelination,	there	was	no	indication	of	axonal	degeneration.	The
authors	concluded	that	some	of	their	findings	might	be	due	to	the	late	time	point,	and	because	the	patient
had	already	been	treated.	This	might	explain	the	low	number	of	lymphocytes	and	the	few	myelin	stripping
macrophages.
Figure	25.3		Sural	nerve	from	a	markedly	affected	GBS	patient.	Left:	Spur	medium	embedded	nerve	stained	with	toluidine	blue
showing	mild	demyelination	and	mild	endoneurial	oedema.	Right:	CD	68+	macrophages	were	scattered	(arrowheads)	or	in	large
clusters.	 Many	 slim	 macrophage	 processes	 are	 seen	 (small	 arrow)	 which	 were	 not	 quantified	 avoiding	 overestimating
macrophage	numbers.	Bar	=	20	µm.	Modified	with	permission	from	[14].
Can	We	Understand	the	Immunopathogenesis	from	Sural	Nerve
Biopsies?
Hafer-Macko	CE,	et	al.	Immune	attack	on	the	Schwann	cell	surface	in	acute	inflammatory
demyelinating	polyneuropathy.	Annals	of	Neurology,	1996;	Kiefer	R,	et	al.	Enhanced	B7
costimulatory	molecule	expression	in	inflammatory	human	sural	nerve	biopsies.	Journal	of
Neurology,	Neurosurgery	and	Psychiatry,	2000
In	 the	series	by	Schmidt	and	colleagues	([14],	vide	supra)	 immunohistochemistry	 techniques	were	 first
included	in	a	large	series	of	biopsies.	This	was	within	a	period	when	researchers	searched	for	relevant
cofactors	in	the	immunopathogenesis	of	GBS.
The	 direct	 demonstration	 of	 the	 role	 of	 circulating	 ganglioside	 antibodies	 and	 of	 complement	 is
covered	in	the	chapters	by	Plomp	and	Willison,	by	Yuki	and	by	Uncini	and	Kuwabara.	This	field	started
with	2	 independent	observations	 in	 the	Miller	Fisher	variant	 in	1995	[17,18]	 later	 followed	by	similar
experiments	in	GBS	(AIDP).	Here,	active	complement	had	a	neurotoxic	effect	on	top	of	and	separate	from
the	immunopharmacological	blockade	by	ganglioside	antibodies	alone.
Activated	complement	C3a	and	C5a	had	first	been	shown	in	the	cerebrospinal	fluid	of	GBS	patients	by
Hartung	and	colleagues	[19],	which	prompted	a	formal	study	in	EAN	by	Stoll	and	colleagues	into	its	role
as	an	important	pathogenic	cofactor	[20].	Stimulated	by	these	investigations,	Hafer-Macko	and	colleagues
investigated	 the	presence	of	complement	 in	GBS	by	 light	and	electron	microscopy	[21].	Three	subjects
with	GBS	 (AIDP)	 and	 early	 death	 (3	 to	 6	 days	 after	 onset)	were	 autopsied	 and	 showed	 a	 rim	 of	 the
complement	 activation	marker	 C3d	 and	 the	 terminal	 complement	 complex	 neoantigen	 C5b-9	 along	 the
outer	surface	of	the	Schwann	cells.	On	EM	of	the	positive	fibres	showed	mild	vesicular	changes	of	the
outermost	 myelin	 lamellae.	 Of	 note,	 in	 the	 hyperacute	 patient	 this	 was	 seen	 in	 some	 fibres	 with	 no
macrophages	as	yet.	Vesicular	degeneration	was	 seen	before	 the	 invasion	of	macrophages.	The	authors
proposed	complement	activation	as	a	definite	mechanism	in	GBS.
Kieseier	 and	 colleagues	 examined	 5	 sural	 nerves	 from	 the	Würzburg	 sural	 nerve	 collection	 for	 the
presence	of	novel	proinflammatory	mediators,	namely	metalloproteinases	MMP	7	and	MMP	9	that	could
be	produced	by	macrophages	and	endothelial	cells	candidates	for	causing	breakdown	of	the	blood-nerve
barrier	[22].	The	authors	showed	ring-shaped	immunoreactivity	around	epineurial	blood	vessels	(Figure
25.4).	Similar	findings	were	obtained	in	the	sciatic	nerve	of	adoptive	transfer	EAN	rats.	Moreover,	the
expression	of	MMP-9	and	of	its	proteinase	activity	was	highest	at	the	peak	of	the	model	disease	(Figure
25.5).
There	were	also	attempts	 to	 further	elucidate	 the	 role	of	macrophages	as	antigen	presenting	cells	 in
nerve	tissue	in	GBS	and	other	inflammatory	neuropathies.	By	PCR	and	immunocytochemistry	upregulation
and	increased	expression	of	costimulatory	molecules,	B7-1	and	B-2	appeared	in	GBS	biopsies	but	not	in
control	biopsies	from	hereditary	neuropathies,	indicating	that	TH-1-lymphcytes	may	have	been	activated
in	situ	by	this	mechanism	[23].
Figure	25.4		in	4A	MMP-9	and	in	4B	MMP-7	show	epineurial	perivascular	immunoreactivity.
Reproduced	with	permission	from	[22].
Figure	25.5		Qualitative	PCR	blots	are	shown	in	a	sural	nerve	extract	from	a	patient	with	GBS	and	a	control	with	a	hereditary
neuropathy.
Reproduced	with	permission	from	[22].
GBS	Pathology:	Skin	Innervation
Ruts	L,	et	al.	Unmyelinated	and	myelinated	skin	nerve	damage	in	Guillain-Barré	syndrome:
correlation	with	pain	and	recovery.	Pain,	2012
Given	 that	GBS	 is	a	primary	demyelinating	disease,	 involvement	of	 the	unmyelinated	axons	 in	 the	 skin
would	only	be	expected	in	cases	with	secondary	axonal	damage,	or	in	cases	that	are	clinically	diagnosed
as	GBS	but	that	may	in	fact	belong	to	the	AMAN	spectrum.	However,	as	always,	one	does	not	know	for
sure	until	the	question	is	properly	examined.	Ruts	and	colleagues	investigated	skin	biopsies	from	32	GBS
patients	[24].	Biopsies	were	taken	from	the	distal	leg	and	from	the	lumbar	region	at	2	time	points,	the	first
in	 the	 acute	 phase	 of	 the	 disease	 and	 the	 second	 at	 a	 6-month	 visit.	 Patients	 in	 the	 acute	 phase	were
biopsied	 between	 week	 1	 and	 week	 3	 after	 disease	 onset.	 Twenty-four	 patients	 were	 available	 for
follow-up.	Assessing	 the	density	of	 intraepidermal	nerve	 fibres,	 that	are	generally	considered	 to	be	C-
fibres,	 the	 authors	 found	 a	 reduction	 of	 intraepidermal	 nerve	 fibre	 density	 (IENFD)	 in	 41%	 of	 their
patients	 in	 the	distal	 leg,	and	even	 in	 the	 lumbar	 region,	 the	average	 IENFD	was	 reduced	compared	 to
normal	controls.	IENFD	was	lower	in	those	patients	who	were	biopsied	in	the	third	week	compared	to
those	biopsied	in	the	first	week,	indicating	a	decline	over	time.	Interestingly,	even	3	patients	with	‘pure
motor’	GBS	(who,	however,	had	a	complaint	of	pain)	had	reduced	IENFD	values.	Overall,	pain	intensity
was	higher	in	patients	with	lower	IENFD.
At	follow-up,	patients	still	had	a	lower	median	IENFD	than	in	controls,	both	at	 the	distal	and	at	 the
lumbar	 biopsy	 site.	 In	 some	 patients,	 IENFD	 even	 had	 decreased	 further	 at	 6	months.	Only	 4	 patients
recovered	to	normal	values	at	the	distal	leg.	In	those	patients	who	had	normal	IENFD	in	the	acute	phase,
values	mostly	remained	normal	at	follow-up.	Looking	at	the	clinical	data,	low	IENFD	in	the	acute	phase
correlated	with	a	poorer	GBS	disability	score	at	6	months	and	with	overt	dysautonomia.
Since	 the	 dermis,	 particularly	 from	 proximal	 regions,	 contains	myelinated	 nerve	 fibres,	 the	 authors
were	 also	 able	 to	 assess	 myelination	 and	 the	 morphology	 of	 Ranvier	 nodes.	 As	 expected	 in	 a
demyelinating	disease,	the	stain	for	myelin	basic	protein	was	weaker	than	in	control	nerves.	Intriguingly,
T	 lymphocytes	and	macrophages	were	seen	surrounding	dermal	nerve	bundles	with	degenerated	myelin
sheets,	 and	 there	 seemed	 to	 be	 tight	 contact	 between	 some	 of	 these	 inflammatory	 cells	 and	 the	 nerve
fibres.	Thus,	the	minimally	invasive	skin	biopsy	may	be	another	method	to	catch	macrophages	‘in	the	act’
in	GBS	and	related	diseases.
Does	Every	Acute	Auto-Immune	Polyradiculoneuritis	Qualify	as	GBS?
Doppler	K,	et	al.	Destruction	of	paranodal	architecture	in	inflammatory	neuropathy	with
anti-contactin-1	autoantibodies.	Journal	of	Neurology,	Neurosurgery	and	Psychiatry,2015
Some	 patients	 experience	 an	 acute	 polyradiculoneuropathy	 fulfilling	 all	 features	 of	 GBS;	 they	 even
improve	upon	the	standard	treatments,	but	they	later	have	relapses	or	a	chronic	progressive	neuropathy.
This	course	of	events	has	been	named	 ‘CIDP	with	acute	onset’,	or,	 formerly,	 ‘chronic	GBS’.	Recently,
different	types	of	autoantibodies	have	been	found	to	be	associated	with	acute	onset	CIDP	(aCIDP),	among
them	antibodies	to	paranodal	proteins	(for	a	review	of	this,	see	[25]).
Doppler	and	colleagues	studied	4	patients	with	a	GBS-like	onset	of	a	disease	that	later	appeared	like
CIDP,	in	whom	they	found	high-titre	antibodies	to	the	paranodal	protein	contactin-1	[26].	These	patients
responded	 to	 IVIg	 as	 primary	 treatment	 for	 their	 assumed	GBS,	 but	 then	 relapsed,	 and	 later	 had	 good
responses	mainly	to	plasmapheresis	and	Rituximab,	that	is,	treatments	which	reduce	the	autoantibody	load
from	the	system.	Skin	biopsies	were	available	from	2	and	sural	nerve	biopsies	from	3	of	the	patients.	The
sural	nerve	biopsies	 showed	 signs	of	 axonal	degeneration	and	numerous	endoneurial	macrophages,	but
not	 the	 typical	 signs	 of	 demyelination	 like	 thinly	myelinated	 nerve	 fibres	 or	 onion	 bulbs,	 although	 the
patients	had	clear	demyelinating	features	in	nerve	conduction	studies.	In	contrast,	skin	biopsies	revealed
elongated	Ranvier	nodes	as	a	sign	of	primary	demyelination,	whereas	21	concomitantly	examined	patients
with	GBS	did	not	show	this	finding.	In	1	patient,	a	follow-up	skin	biopsy	available	6	years	later	showed
complete	 depletion	 of	 myelinated	 fibres.	 Furthermore,	 in	 the	 patients	 with	 contactin-1	 antibodies,	 the
nodal	 and	paranodal	 architecture	was	profoundly	altered.	These	patients	had	 loss	or	destruction	of	 the
immunoreactivity	for	caspr	and	neurofascin,	which	was	found	neither	in	the	21	patients	with	GBS	nor	in
49	patients	with	CIDP.	Sodium	channels	were	no	 longer	clustered	at	 the	node.	 In	summary,	 in	a	patient
with	 a	GBS-like	 disease	 that	 later	 turns	 out	 to	 have	 a	CIDP-like	 course,	 paranodal	 antibodies	may	be
involved	in	the	underlying	pathology.	Sural	nerve	biopsy	may	show	a	misleading	‘axonal’	pattern.
Summary	and	Conclusions
There	 is	abundant	evidence	 that	GBS	is	an	 immune-mediated,	acute	or	subacute	PNS	disorder.	Several
immunological	markers	have	been	identified,	some	of	which	are	strong	candidates	as	pathogenic	factors.
At	various	meetings,	the	indication	for	nerve	biopsy	has	been	discussed	between	experts	in	the	field.
With	 our	 present	 armamentarium	 of	 clinical	 and	 electrophysiological	 testing,	 and	 new	 diagnostic
procedures	such	as	PNS-magnetic	resonance	imaging	and	high-resolution	ultrasound,	the	indication	can	be
questioned.	Only	in	the	context	of	new	research	hypotheses	may	nerve	biopsies	be	justified.	Unfortunately,
postmortem	examinations	have	become	so	rare	that	clinical-neuropathological	correlations	have	become
an	exception.
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The	CSF	in	GBS,	from	Historical	Origins	to	Future
Perspectives
Axel	Petzold
Introduction
At	the	time	of	writing	this	centenary	chapter,	the	diagnostic	value	of	cerebrospinal	fluid	(CSF)	testing	in
Guillain-Barré	 syndrome	 (GBS)	 has,	 ironically,	 declined,	 whilst	 the	 diagnostic	 value	 of
electrophysiological	tests	have	been	on	the	rise.	The	irony	here	is	that	the	CSF	examination	was	the	test
Guillain	 himself	 brought	 to	 the	 historical	 arena	 whilst	 electrophysiology	 was	 used	 by	 the	 historically
neglected	Strohl.	One	hundred	years	later,	data	from	electrophysiological	studies	have	profoundly	shaped
our	concept	of	GBS	and	what	little	the	CSF	has	contributed	to	the	story	my	personal	‘Top	10’	will	tell.
Quincke,	Germany,	23rd	July	1891
The	first	lumbar	punctures	(LP)	were	performed	by	Heinrich	Quincke	at	the	University	of	Kiel,	Germany
[1].	He	used	the	technique	for	treatment	of	hydrocephalus	in	children.	The	idea	stood	the	test	of	time.	To
treat	hydrocephalus	there	are	at	present	routine	neurosurgical	 techniques	to	insert	a	range	of	shunts	 into
the	ventricles	or	lumbar	canal	which	enable	controlled	CSF	outflow	by	means	of	reservoirs	and	pressure-
sensitive	valves.	Another	observation	Quincke	made	was	that	of	a	traumatic	tap.	His	fourth	attempt	of	an
LP	in	a	7-year-old	girl	on	the	23rd	of	July	1891	resulted	in	documented	blood	contamination	[1].	Again
his	observation	stood	the	test	of	time.	Presently,	we	can	distinguish	a	traumatic	tap	from	any	intracranial
bleed,	and	those	who	believe	that	a	small	yellow	drop	cannot	readily	be	seen	in	a	large	red	puddle	make
use	of	calibrated	spectrophotometry	to	this	purpose	[2].
Quincke	himself	gave	credit	 to	Essex	Wynter	 for	publishing	 the	 first	description	of	 the	 technique	of
lumbar	 puncture	 [1].	 Heinrich	Quincke	was	 present	 at	 the	 ninth	 Jubilee	 of	 the	University	 of	 Glasgow
(1901)	as	a	German	delegate	and	received	an	honorary	degree.
Essex	Wynter,	United	Kingdom,	February	1889
The	first	publication	on	the	LP	technique	was	by	Walter	Essex	Wynter	at	the	now-demolished	Middlesex
Hospital	 in	London	 [3].	The	 first	 time	Essex	Wynter	 tried	 the	 technique	was	 in	 a	 3-year-old	 boy	with
tubercular	meningitis	 in	February	1889.	Four	drachms	of	 liquor	were	collected,	besides	what	was	 lost
due	 to	 leakage.	 Following	 the	 procedure	 the	 boy	 transiently	 improved	 before	 passing	 away.	 Autopsy
showed	an	intact	spinal	equina,	but	no	trace	of	the	LP	in	the	theca.	Such	traces	were	found	in	the	next	3
cases,	 none	 of	 whom	 survived	 due	 to	 the	 primary	 disease,	 tuberculosis.	 Based	 on	 the	 results	 of	 the
meticulous	 post-mortem	 examinations,	 Essex	 Wynter	 summarises	 “though	 none	 of	 these	 cases	 were
ultimately	successful,	no	harm	in	any	one	resulted	from	interference.”
Intriguingly,	Essex	Wynter	documents	that	there	was	no	trace	of	albumin	or	sugar	in	2	of	his	4	cases.
Retrospectively,	this	was	most	likely	related	to	the	analytical	sensitivity	of	the	tests	used	at	the	time,	but
his	observation	is	a	good	reminder	that	absence	of	evidence	is	not	evidence	for	absence.
La	VIeArmée,	France	20th	September	1916:	la	dissociation	albumino-
cytologique
On	the	20th	of	August	1916	a	25-year-old	soldier	presented	with	weakness	of	his	upper	and	lower	limbs.
He	came	from	the	famous	French	Sixth	Armée,	a	corps	composed	of	various	disparate	French	armies.	The
summer	is	sorely	remembered	by	the	Battles	of	the	Somme	with	more	than	one	million	soldiers	killed	on
both	sides	between	the	1st	of	July	and	18th	of	September	1916.	The	Sixth	Armée	was	under	the	command
of	 General	 Fayolle,	 who	 was	 joined	 by	 the	 British	 forces.	 The	 walking	 distance	 of	 this	 solder	 was
reduced	to	only	200–300	meters	[4].	The	LP	revealed	a	clear	CSF	with	an	albumin	concentration	of	2.5
g/L	and	2–4	lymphocytes.	The	LP	was	repeated	on	19th	September	and	an	increase	of	albumin	was	noted
without	an	increase	of	the	white	cell	count	(WCC).	Fifty-nine	days	after	his	first	symptoms	he	was	able	to
walk	again	and	was	sent	home	as	a	convalescent	soldier	on	the	30th	of	September.
About	a	week	later,	28th	August,	another	soldier	felt	unusually	tired	and	weak	after	a	15-km	march.	He
was	aged	33	years	and	seen	by	the	neurologist	on	5th	September,	at	which	time	there	was	clear	weakness
of	the	lower	limbs.	Again	the	LP	revealed	a	clear	CSF	with	an	albumin	concentration	of	0.85	g/L	and	3–4
lymphocytes.	Again	a	repeat	LP	on	20th	September	showed	an	increase	of	albumin	without	a	change	of	the
WCC.	He	started	to	improve	31	days	after	his	first	symptoms	and	was	evacuated	behind	the	battle	lines
on	1st	October.
Surely,	whilst	the	British	attacked	Flers-Courcelette	(15–22	September),	whilst	the	Canadian	and	New
Zealand	 divisions	made	 their	 debut,	whilst	 the	 French	 attacked	Frégicourt	 and	Rancourt,	 there	were	 3
French	 neurologists	 discussing	 CSF	 results	 from	 2	 LPs	 taken	within	 24	 hours	 with	 results	 which	 had
never	been	observed	before.	The	term	‘dissociation	albumino–cytologique’	was	coined.
Later,	Guillain	refers	 to	the	“hyperalbuminosis	of	 the	CSF	in	the	absence	of	cytologic	reaction”	[5].
He	 believes	 this	 to	 be	 such	 a	 consistent	 feature	 of	 the	 disease	 that	 he	 states,	 “I	 refuse	 to	 recognize
radioculoneuritis	 with	 hyperlymphocytosis	 or	 hypernucleosis	 as	 belonging	 to	 the	 syndrome”	 [5].	 He
concludes	 that	 “because	 the	virus	of	polyradiculoneuritis	with	albuminocytologic	dissociation	does	not
destroy	nerve	paths,	progressive	improvement	and	eventual	recovery	of	the	patient	will	be	observed”	[5].
Guillain	 also	 recognised	 that	 there	 was	 no	 value	 in	 analysing	 CSF	 obtained	 by	 the	 more	 risky
suboccipital	puncture	as	opposed	to	a	LP	[6].
The	perceived	relevance	of	all	the	‘Top	10’	described	in	this	monograph	will	change	over	time.	Some
observations	will	slowly	fade	into	oblivion;	others	will	be	rediscovered	as	being	of	core	relevance.	The
‘dissociation	 albumino–cytologique’	 deserves	 to	 remain	 in	 the	 Top	 10	 because	 it	 was	 the	 first
reproducible	biomarker	discovery	of	its	kind,	made	by	3	neurologists	under	exceptional	circumstances	on
the	20th	of	September	1916.
Timeless:	Rochester	and	Rotterdam
Not	 everyone	 found	 the	CSF	 total	 protein	 to	 be	 elevated	 consistently.	But	 already	 the	 detailed	 French
observations	on	the	first	2	patients	permitted	to	hypothesise	that	the	sensitivity	of	this	test	was	less	in	a
very	early	LP	compared	to	a	later	LP	[4],	an	observation	shared	by	a	retrospective	study	from	the	Mayo
Clinic	 in	Rochester	 [7].	Extending	on	 these	observations,	 a	prospective	Dutch	 trial	 found	an	 increased
CSF	total	protein	only	in	50%	of	patients	with	GBS	if	the	LP	was	taken	in	the	first	week	after	symptom
onset	[8].	The	sensitivity	increased	to	80%	if	the	LP	was	taken	after	2–3	weeks	[8].
Some	authors	suggested	a	prognostic	value	of	high	CSF	total	protein	[9,10]	or	CSF	pleocytosis	[11],
findings	which	were	 not	 generally	 confirmed	 [12–18].	Most	 authors	 agree	 that,	 taken	 together,	 routine
CSF	findings	are	of	no	prognostic	value	in	GBS	(reviewed	in	[19]).	Notably	all	of	these	studies	relied	on
essentially	cross-sectional	CSF	data	and	indirect	correlative	evidence.
One	conclusion	from	these	studies	is	that	the	main	limitations	of	CSF	research	remains	that	serial	LPs
are	 neither	 feasible	 nor	 ethical.	 Therefore,	 and	 in	 contrast	 to	 blood	 sampling	 and	 electrophysiological
tests,	it	will	remain	extremely	difficult	to	obtain	valuable	longitudinal	data.
Another	conclusion	is	that	the	CSF	composition	from	an	early	LP	will	be	very	different	from	the	CSF
composition	of	a	later	LP.	There	might	be	other	advantages	and	disadvantages	to	both	time	points	we	are
not	necessarily	aware	of	yet.
Sendai,	Japan	2006:	CSF	Tau	Protein
A	fascinating	observation	on	the	CSF	comes	from	the	Tohoku	University	Graduate	School	of	Medicine	in
Sendai,	Japan	[20].	The	authors	had	access	to	CSF	samples	taken	at	an	average	of	about	7	days	after	onset
of	 GBS	 with	 quantitative	 clinical	 follow-up	 data	 over	 6	 months.	 Some	 did	 not	 make	 as	 excellent	 a
recovery	as	Guillain	would	have	 insisted	 to	be	 the	case	 in	GBS.	These	patients	were	not	able	 to	walk
without	 problems	 and	were	 classified	 as	 having	 a	 poor	 outcome.	The	 authors	 compared	 the	CSF	 data
from	those	with	good	outcome	(n	=	20)	with	those	with	poor	outcome	(n	=	6).	The	first	interesting	finding
was	 that	 the	 CSF	 total	 protein	 was	 about	 half	 in	 the	 latter.	 The	 second	was	 that	 the	 CSF	 tau	 protein
concentration	was	significantly	higher	in	patients	with	poor	outcome	(341.7	ng/mL)	if	compared	to	those
with	good	outcome	(159.6	ng/mL,	p	=	0.00026)	[20].
Statistically,	ordinal	 logistic	regression	analysis	showed	the	CSF	tau	protein	concentration	to	be	the
only	significant	predictor	for	poor	outcome.	The	other	factors	included	into	the	statistical	model	were	age
at	onset,	time	to	nadir,	need	for	ventilatory	support,	axonal	pattern	on	electrophysiology	and	timing	of	LP
[20].
The	data	 extends	on	earlier	work	on	CSF	 tau	protein	 in	GBS	by	 taking	a	prognostic	 as	opposed	 to
diagnostic	perspective	[21].	For	independent	interpretation	of	these	data	one	needs	to	remember	that	tau
protein	is	expressed	not	only	in	neurons	and	their	axons,	but	also	in	glial	cells.	Therefore	an	increase	of
CSF	tau	protein	can	be	caused	by	release	from	a	number	of	cells.	Consequently,	an	increase	of	CSF	tau
concentration	 will	 not	 permit	 one	 to	 be	 absolutely	 certain	 about	 the	 cellular	 origin	 [22].	 It	 will	 be
interesting	 to	 learn	 if	 future	 studies	 will	 investigate	 post-translational	 modifications	 and	 proteolytic
breakdown	products	of	this	fascinating	protein.
London,	UK,	20th	December	2001:	CSF	Neurofilament	Proteins
Personally,	 I	 find	 it	 paradoxical	 to	 write	 now	 about	 neurofilaments	 in	 the	 Top	 10	 of	 GBS	 because	 it
relates	 to	 a	 moment	 of	 complete	 despair	 just	 before	 Christmas	 2001.	 After	 4	 years	 of	 work	 with
neurofilament	 proteins	 I	 finally	 had	 completed	 collecting	 the	 reference	 population	 data	 for	 the
neurofilament	heavy	chain	(NfH).	After	analysing	the	data	I	was	disappointed	(Figure	26.1).	There	was	a
large	 scatter	 of	 CSF	NfH	 data	 [23].	 The	 reason	 for	my	 disappointment	was	 that	 I	 had	 hoped	 to	 have
chosen	an	excellent	control	group,	a	well-defined	demyelinating	peripheral	nervous	disease,	 to	 test	 the
hypothesis	 that	CSF	NfH	 levels	were	 a	biomarker	 for	neuroaxonal	degeneration	of	 the	 central	nervous
system.	In	GBS	I	had	expected	normal	CSF	NfH	levels.	Did	I	have	to	accept	the	null	hypothesis	and	did
this	mean	that	the	test	I	had	spent	the	last	4	years	on	developing	was	of	little	value?
Neurofilament	 (Nf)	 proteins	 are	 highly	 specific	 to	 the	 neuroaxonal	 compartment.	 Neurons	 of	 the
central	nervous	system	(CNS)	express	at	least	4	types	of	Nf	proteins,	α-internexin,	a	light	chain	(NfL),	a
medium	chain	(NfM)	and	a	heavy	chain	(NfH)	[24].	In	addition,	peripherin	is	expressed	in	the	peripheral
nervous	system	(PNS).	Therefore	the	hypothesis	was	that	an	increase	of	the	CSF	concentration	of	either
NfL,	 NfM,	 NfH	 or	 α-internexin	 would	 provide	 indirect	 evidence	 for	 neurodegeneration	 in	 the	 CNS.
Likewise,	an	increase	of	blood	peripherin	levels	would	indicate	axonal	degeneration	affecting	the	PNS.
So	the	choice	of	a	disease	known	to	represent	a	demyelinating	condition	of	the	PNS	seemed	ideally	suited
for	testing	my	hypothesis	on	CSF	NfH.
Figure	26.1		Scatterplot	of	CSF	levels	in	patients	with	cluster	headache	(HD),	space-occupying	lesions	(SO),	amyotrophic	lateral
sclerosis	 (ALS),	 disc	 prolapse	 (DP),	 demyelinating	 disease	 (DM),	 Guillain-Barré	 syndrome	 (GBS)	 and	 subarachnoid
haemorrhage	 (SAH).	 The	 horizontal	 reference	 line	 (dotted)	 represents	 the	 cut-off	 (0.73	 ng/mL)	 derived	 from	 the	 reference
population;	the	y-axis	is	split	at	2	ng/mL.	Figure	reproduced	with	permission	from	reference	[23].
Figure	26.2		Hypothetical	relationships	of	body	fluid	Nf	levels	prognosis	and	disease	course	in	GBS.	(A)	A	good	prognosis	for	a
patient	with	a	monophasic	disease	course	who	suffers	 from	demyelination	alone	and/or	distal	axonotemesis	and	makes	a	 full
recovery.	(B)	A	poor	prognosis	may	follow	extensive	distal	axonotemesis	leading	to	retrograde	axonal	degeneration	and	loss	or	be
caused	by	proximal	axonotemesis.	In	those	cases	where	the	motor	neuron	is	lost,	trans-synaptic	retrograde	axonal	degeneration
might	follow	and	should	be	demonstrable	by	longitudinal	structural	imaging	evidence	of	localised	atrophy	in	the	pyramidal	tracts
and	corresponding	area	of	the	primary	motor	cortex.
In	retrospect,	it	appeared	that	patients	with	high	CSF	NfH	levels	(red	dots	in	Figure	26.1)	had	a	poor
outcome	[25].	In	contrast,	patients	with	normal	CSF	NfH	levels	(green	dots	in	Figure	26.1)	made	a	good
recovery.	But,	it	took	over	a	decade	to	better	understand	the	bimodal	distribution	of	the	data	[22,26–28].
A	similar	bimodal	observation	was	made	for	CSF	NfL	levels	[29].	Figure	26.2	summarises	my	current
hypotheses	on	the	relationship	of	various	CSF	Nf	proteins	and	GBS.
Japan	and	Europe	(1983–2013):	CSF	Glial	Protein	Biomarkers
Glial	 fibrillary	 acidic	 protein	 (GFAP)	 and	S100B	 are	 2	 biomarkers	which	 have	 been	 used	 to	 provide
indirect	evidence	for	glial	pathology	in	GBS	[22,28,30].	Both	proteins	are	elevated	in	the	CSF	in	GBS.	It
is	 likely	 that	 this	 is	 not	 a	 specific	 phenomenon	 for	 GBS,	 but	 part	 of	 the	 general	 glial	 response	 to
inflammation.	As	with	all	measurements,	there	is	a	need	to	be	careful	that	good	laboratory	standards	are
followed	[31,32].	Potential	future	studies	will	need	to	relate	the	longitudinal	profile	of	GFAP	and	S100B
to	the	clinical	course.	These	data	will	decide	if	CSF	glial	protein	biomarkers	will	move	from	the	bottom
to	the	top	of	the	Top	10	list	on	CSF	in	GBS.
Never	Ending:	CSF	Anti-myelin	Protein	Auto-antibodies
One	key	pathological	feature	of	GBS	is	damage	to	the	myelin	sheath.	Conceptually,	this	has	been	related
to	presence	of	anti-myelin	protein	antibodies.	 In	fact,	over	half	of	 the	GBS	patients	 from	one	study	did
have	CSF	anti-myelin	basic	protein	(MBP)	IgG	and	IgM	auto-antibodies	[33].	Findings	of	auto-antibodies
directed	against	myelin	proteins	have	been	regarded	as	nonspecific,	because	they	are	also	found	in	many
other	 diseases.	Accepting	 that	 some	 auto-antibodies	 (anti-MBP)	 are	 of	 little	 diagnostic	 value	 in	GBS,
there	 are	 others	 which	 are	 of	 high	 diagnostic	 value	 [34].	 It	 will	 be	 interesting	 learning	 about	 the
longitudinal	 pattern	 of	 such	 auto-antibodies	 in,	 for	 example,	 patients	who	do	not	 follow	 a	monophasic
disease	course.
Forever:	Intrathecal	IgG
One	pertinent	question	for	CSF	research	is	why	there	are	so	few	high	affinity	antibodies	detected	in	the
CSF.	With	 the	 exception	 of	 IgG	 specific	 to	 neuroinvasive	 infections	 and	 their	 complications,	 such	 as
subacute	sclerosing	panencephalitis	(SSPE),	the	yield	is	generally	low	in	autoimmune	disease.
It	almost	seems	a	paradox	that	even	in	a	specific	CNS	disease	such	as	neuromyelitis	optica,	the	use	of
a	 highly	 sensitive	 cell-based	 immunoassay	 for	 aquaporin	 4	 auto-antibodies	 now	 reaches	 over	 90%
diagnostic	sensitivity	for	blood	samples	yet	remains	much	lower	for	CSF.	Over	half	a	century	of	research
for	a	diagnostic	auto-antibody	in	multiple	sclerosis	has	not	yet	brought	a	result	[35].	Why	does	the	lumbar
CSF	seem	to	be	dominated	with	intrathecally	produced	IgG	which	seems	to	act	more	as	a	smokescreen
than	to	deliver	the	holy	grail?	Could	it	be	that	high	affinity	auto-antibodies	directed	at	CNS	tissue	bind	so
strongly	 to	 the	 parenchyma	 that	 chances	 are	 minute	 for	 them	 to	 be	 detected	 with	 current	 analytical
techniques?	This	is	reminiscent	of	the	absence	of	albumin	and	sugar	in	the	CSF	of	2	of	the	patients	from
Essex	Wynter	at	the	end	of	the	19th	century.
Presently,	intrathecal	IgG	trails	my	table	of	the	CSF	Top	10	in	GBS.
The	Future:	A	Cocktail	from	Glasgow
Post-translational	modifications	 govern	 the	 interface	 between	 protein	 transcription	 and	 translation.	 For
neurofilaments,	undoubtedly	phosphorylation	 is	of	key	 relevance	 [24],	but	 I	would	be	hesitant	 to	place
this	among	the	Top	10	for	GBS.	A	much	more	promising	mechanism	for	GBS	is	glycosylation	[36].
Glycosylation	mainly	targets	Asp→Asp-glycan,	Ser→Ser-glycan,	Thr→Thr-glycan,	Hyl→Hyl-glycan,
Hyp→Hyp-glycan.	 Of	 the	 3	 types,	 only	 N-	 and	O-glycosylation	 occur	 in	 humans.	 Importantly,	 protein
glycosylation	 is	 a	 hallmark	 in	 autoimmune	 disease.	 A	 change	 of	 protein	 glycosylation	 may	 trigger	 an
autoimmune	 attack	 [37].	 Interestingly,	 glycolysation	 can	 differ	 between	 tissues	with	 evidence	 for	CNS
specific	 glycosylation	 patterns.	 Would	 it	 not	 be	 wonderful	 if	 there	 were	 an	 anatomical	 map	 of
glycosylation	patterns	of	the	PNS	and	CNS	for	those	protein	biomarkers	thought	to	be	of	relevance	in	the
disease?	 Therefore	 post-translational	 modifications	 which	 only	 occur	 in	 vivo,	 such	 as	 glycosylation,
phosphorylation,	citrullination,	N-	and	C-terminal	modifications	will	be	in	my	future	Top	10.
The	 interpretation	 of	 body	 fluid	 Nf	 levels	 will	 need	 to	 consider	 at	 least	 5	 proteins	 (α-internexin
(blue),	 NfL	 (light	 red),	 NfM	 (bright	 red),	 NfH	 (dark	 red)	 and	 peripherin	 (yellow)	 in	 2	 body	 fluid
compartments	(CSF,	blood).	In	the	acute	phase,	proximal	axonotmesis	within	the	CSF	compartment	leads
to	 high	 CSF	 NfL,	 NfM	 and	 NfH	 levels	 indicate	 early	 axonal	 loss.	 In	 cases	 of	 where	 trans-synaptic
retrograde	axonal	degeneration	follows,	one	should	also	test	for	CSF	α-internexin	levels.	A	rise	of	CSF
α-internexin	level	should	precede	visible	atrophy	on	structural	imaging	modalities.	In	contrast,	high	blood
peripherin	 levels	 in	 the	 absence	 of	 high	 CSF	 Nfl,	 NfM	 and	 NfH	 levels	 are	 indicative	 of	 distal
axonotemesis	 only.	 In	 those	 cases	 where	 axonal	 sprouting	 does	 not	 occur,	 distal	 axonotemesis	 may
continue	to	develop	to	retrograde	axonal	degeneration.	This	should	result	in	a	late	increase	of	CSF	levels.
Once	the	motor	neuron	is	lost,	trans-synaptic	retrograde	axonal	degeneration	may	follow.	There	is	also	the
possibility	 for	 a	 relapsing	 or	 chronic	 disease	 course	 to	 develop,	 which	 should	 be	 paralleled	 by	 a
persistent	or	 intermittent	 rise	of	blood	peripherin	 levels.	One	may	also	expect	 that	 the	stoichiometry	of
CSF	NfL:NfH	levels	will	change	towards	NfL,	the	smaller	and	therefore	less	resource-demanding	protein
to	be	expressed	by	the	neuron.
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The	Electrophysiology	of	Guillain-Barré	Syndrome:
Our	Shared	Journeys
Richard	A.	Lewis,	David	R.	Cornblath	and	Austin	J.	Sumner
Introduction
This	 chapter	 is	 reflections	 on	 the	 Guillain-Barré	 syndrome	 (GBS)	 with	 an	 emphasis	 on	 the
electrophysiologic	 aspects	 and	 comes	 from	 the	 exciting	 time	 when	 we	 were	 all	 at	 the	 University	 of
Pennsylvania	 under	 the	 chairmanship	 of	 Professor	Arthur	K.	Asbury.	This	was	 a	 time	 and	 place	when
investigations	 of	 GBS	 flourished,	 and	 electrophysiology	 was	 a	 major	 component	 of	 this	 exploration.
Although	we	 each	 subsequently	moved	 to	 different	 institutions,	 we	 continue	 to	 share	 an	 excitement	 in
investigating	and	thinking	about	the	physiologic	aspects	of	GBS	and	other	inflammatory	neuropathies.
The	physiologic	hallmark	of	GBS	is	conduction	block.	The	rapid	onset	of	symptoms	and	the	frequently
observed	 early	 recovery	 of	weakness	 can	 be	 attributed	 to	 the	 development	 and	 reversal	 of	 conduction
block.	For	 the	 3	 of	 us,	 understanding	 the	 clinical	 and	pathophysiologic	 nature	 of	 conduction	block	has
played	a	prominent	role	in	our	careers.
McDonald	WI.	The	effects	of	experimental	demyelination	on
conduction	in	peripheral	nerve:	a	histological	and
electrophysiological	study.	II.	Electrophysiological	observations.	Brain,
1963.
The	McDonald	paper	was	particularly	important	in	the	understanding	of	the	electrophysiology	of	acquired
demyelinative	 polyneuropathies	 [1].	 The	 extreme	 dispersion	 of	 dorsal	 root	 responses	 illustrated	 that
individual	axons	conducted	at	a	wide	range	of	velocities	indicative	of	the	heterogeneity	of	demyelination
across	the	population	of	axons.	It	also	demonstrated	that	demyelination	was	distributed	multifocally	along
the	 length	of	peripheral	nerves,	 thought	 to	be	a	consequence	of	variations	 in	blood-nerve	permeability,
particularly	in	nerve	roots	and	nerve	terminals.	Differential	effects	on	motor	versus	sensory	axons	were
also	 recognized.	These	concepts	proved	 to	be	particularly	applicable	 to	 the	electrophysiology	of	acute
demyelinating	polyradiculoneuropathy.	(Please	note	the	reference	to	the	M.	Med.	Sci.	thesis	of	one	A.J.
Sumner.)
Asbury	AK,	et	al.	The	inflammatory	lesion	in	idiopathic	polyneuritis:	its
role	in	pathogenesis.	Medicine,	1969.
This	careful	pathologic	investigation	of	19	fatal	cases	of	GBS—including	both	early	death	and	those	who
initially	survived	but	died	later—emphasized	the	importance	of	T	cells	in	the	development	of	the	disease
[2].	The	paper	was	seminal	 in	 its	 impact.	 It	 fit	nicely	with	studies	of	experimental	allergic	neuritis	 [3]
which	also	emphasized	the	role	of	T	cells.	Figure	13	from	the	paper	has	been	shown	at	many	meetings	and
is	a	standard	at	GBS	talks	worldwide.	This	paper	countered	the	hypothesis	of	Haymaker	and	Kernohan,
who	considered	humoral	immunity	as	an	initiating	event	[4].
Wiederholt	WC,	et	al.	The	Landry-Guillain-Barré-Strohl	syndrome	or
polyradiculoneuropathy:	historical	review,	report	on	97	patients,	and
present	concepts.	Mayo	Clinic	Proceedings,	1964.
This	early	electrodiagnostic	paper	was	one	of	many	which	emphasized	the	notion	that	the	primary	lesion
in	 GBS	 was	 demyelinating	 with	 secondary	 axonal	 degeneration	 [5].	 It	 showed	 the	 power	 of
electrodiagnosis	in	being	able	to	study	individuals	over	time	and	at	many	sites	in	order	to	best	understand
the	evolution	of	disease.	Wiederholt	and	colleagues’	concepts	are	still	relevant	today.
Experimentally-induced	conduction	block—several	publications
In	 the	 early	 1980s,	 a	 series	 of	 papers	 appeared	 which	 changed	 the	 field	 [6,7,8,13,14,15].	 Using	 the
intraneural	injection	technique,	it	was	possible	to	show	first	that	sera	from	various	animal	models	(EAN,
EAE	and	anti-GalC)	and	second	that	sera	from	GBS	patients	produced	an	acute	lesion	characterized	by
conduction	 block	 associated	 with	 minor	 pathological	 features,	 which	 evolved	 to	 complete	 conduction
block	and	a	demyelinative	lesion	with	recovery	over	time.	This	experimental	approach	provided	crucial
insights	into	the	pathophysiology	of	GBS.	It	was	a	remarkable	experience	to	observe	the	development	of
conduction	 block	 as	 the	 earliest	 electrophysiologic	 consequence	 of	 the	 intraneural	 injection	 of	 these
antibodies	(Figure	27.1)	as	well	as	the	restoration	of	conduction	which	corresponded	at	around	8	to	14
days	(Figure	27.2),	 to	 the	 appearance	 of	 2	 to	 8	myelin	 lamellae	 around	 each	 previously	 demyelinated
axon.	LaFontaine	and	co-workers	[8],	using	the	elegant	biophysical	techniques	pioneered	by	Rasminsky,
Bostock	and	Sears	demonstrated	 that	conduction	block	could	develop	solely	 from	paranodal	disruption
without	(or	prior	to)	segmental	demyelination	[9,10].	These	experiments	demonstrated	that	serum	factors
from	experimental	animals	or	GBS	patients	could	produce	demyelination	and,	along	with	the	concurrent
evidence	that	plasma	exchange	had	a	beneficial	effect	in	patients	with	GBS	[11,12],	rekindled	the	concept
that	humoral	immunity	was	an	important	component	in	the	pathophysiology	of	the	disease.
As	 the	 pathophysiology	 of	 GBS	 was	 being	 investigated,	 clinical	 electrodiagnosis	 of	 GBS	 was
evolving	with	 recognition	 of	 the	 importance	 of	 conduction	 block,	 that	 early	 changes	were	 particularly
found	in	the	most	distal	(low	compound	motor	action	potential	[CMAP]	amplitudes	and	prolonged	distal
motor	latencies	[DML])	and	most	proximal	segments	(absent	or	prolonged	F-wave	responses).
Figure	 27.1	 	 Development	 of	 acute	 conduction	 block	 induced	 by	 intraneural	 injection	 of	 anti-Gal-Cer	 serum	 (Modified	 with
permission	from	Figure	1	of	[6].	Serial	recordings	of	rat	hind	foot	with	stimulation	at	the	ankle	and	hip	after	injection	on	anti-Gal-
Cer	in	mid-thigh	region	of	sciatic	nerve.	Note	the	progressive	drop	in	amplitude	from	~1	hour	to	3	hours	post-injection
Figure	27.2		Recovery	of	conduction	block	after	intraneural	anti-Gal-Cer	serum.	(Modified	with	permission	from	Figure	6	of	[6].)
Serial	 recordings	 of	 recovery	 from	complete	 conduction	 block	 induced	by	 anti-Gal-Cer	 serum.	The	 first	 evidence	of	 recovery
occurred	on	day	6	with	near	full	recovery	by	day	21.
Albers	JW,	Donofrio	PD,	McGonable	TK.	Sequential	electrodiagnostic
abnormalities	in	acute	inflammatory	demyelinating	polyradiculopathy.
Muscle	&	Nerve,	1985.
This	series	of	180	electrodiagnostic	studies	of	70	patients	with	GBS	[16]	expanded	on	previous	studies
by	Lambert	 and	Mulder	 [17]	 and	McLeod	 [18],	 and	 showed	 that	 in	 the	 first	 2	weeks	motor	 amplitude
reductions	 were	 the	 most	 conspicuous	 early	 change	 but	 by	 week	 5,	 87%	 of	 patients	 had	 conduction
slowing	 suggestive	of	 segmental	 demyelination.	They	 also	 recognized	 the	 sural	 sparing	phenomenon	 in
sensory	conduction	studies.	They	noted	that	3%	of	patients	had	only	axonal	degeneration,	and	they	raised
the	question	of	a	pure	axonal	GBS.
Feasby	TE,	et	al.	An	acute	axonal	form	of	Guillain-Barré
polyneuropathy.	Brain,	1986.
Soon	after	publication	by	Albers	and	colleagues,	Feasby	and	co-workers	reported	5	patients	with	axonal
GBS	[19].	Many	in	the	field	were	sceptical	that	this	represented	a	true	axonal	form	of	GBS,	although	both
physiologically	 and	pathologically	 there	was	no	 evidence	of	 segmental	 demyelination	or	 inflammation.
Many	considered	that	this	may	have	been	the	result	of	severe,	aggressive	demyelinating	GBS	and	that	the
findings	represented	the	sequel	of	this	rapidly	progressive	disease.	However,	the	dramatic	findings	from
northern	 China	 made	 it	 clear	 that	 there	 was	 clearly	 an	 axonal	 form	 of	 Guillain-Barré	 syndrome	 (see
below).	 In	support	of	 the	axonal	 form,	Hahn	and	colleagues	showed	 that	 in	experimental	animals	EAN
could	be	a	continuum	from	pure	demyelinating	forms	with	low	amounts	of	antigen	to	pure	axonal	forms
from	high	amounts	of	antigen	[20].
Identifying	AMAN	and	AMSAN—several	publications
In	 the	1990s	a	series	of	reports	[21–25]	 identified	 the	acute	motor	axonal	neuropathy	(AMAN)	and	the
acute	motor	and	sensory	axonal	neuropathy	(AMSAM)	forms	of	GBS,	differentiated	these	from	AIDP	and
identified	the	nodal	changes	seen	in	those	disorders.	The	physiologic	consequences	of	the	immune	attack
on	the	node	of	Ranvier	has	brought	to	light	the	importance	of	conduction	block	and	how	nodal	pathology
and	demyelination	can	have	overlapping	physiologic	findings.	This	concept	has	been	extended	to	include
more	 chronic	 disorders	 such	 as	 multifocal	 motor	 neuropathy	 and	 forms	 of	 chronic	 inflammatory
demyelinating	 poly	 neuropathy	 with	 antibodies	 directed	 against	 paranodal	 constituents	 contactin	 and
neurofascin-155	(see	below).
Uncini	A,	Kuwabara	S.	Nodopathies	of	the	peripheral	nerve:	an
emerging	concept.	Journal	of	Neurology,	Neurosurgery	and	Psychiatry,
2015.	Querol	L,	et	al.	Antibodies	to	contactin-1	in	chronic	inflammatory
demyelinating	polyneuropathy.	Annals	of	Neurology,	2013.	Querol	L,	et
al.	Neurofascin	IgG4	antibodies	in	CIDP	associate	with	disabling
tremor	and	poor	response	to	IVIg.	Neurology,	2014.
The	demonstration	of	different	forms	of	GBS,	from	AIDP	to	AMAN,	AMSAN,	and	Fisher	syndrome	[26–
28]	has	 forced	us	 to	 reconsider	electrodiagnostic	criteria	 for	GBS	from	the	days	when	GBS	and	AIDP
were	synonymous	 [29,30]	 to	 those	 that	attempt	 to	differentiate	 the	axonal	 forms	 from	 the	demyelinating
forms	 [31,32].	 This	 issue	 was	 thoroughly	 reviewed	 by	 Uncini	 and	 Kuwabara,	 with	 a	 call	 for	 more
reliable	electrodiagnostic	criteria.
Uncini	A,	Kuwabara	S.	Electrodiagnostic	criteria	for	Guillain-Barré
syndrome:	A	critical	revision	and	the	need	for	an	update.	Clinical
Neurophysiology,	2012.
Criteria	have	been	proposed	that	attempt	to	come	to	grips	with	the	problem	of	differentiating	acute	axonal
forms	of	GBS	from	 the	AIDP	form	of	GBS	 in	 the	 first	week	after	disease	onset	 [33].	Some	propose	2
studies,	one	within	2	weeks	and	one	after	3	weeks	 [34].	Others	propose	 that	only	one	study	 is	needed
[35].	It	 is	anticipated	that	the	international	GBS	Outcome	Study	will	provide	important	information	that
will	lead	to	an	optimal	electrodiagnostic	approach.
Conclusion
Electrodiagnostic	 studies	 remain	 a	 crucial	 investigation	 of	 patients	 with	 suspected	 GBS.	 They	 have
diagnostic	 and	 prognostic	 value.	 In	 addition,	 the	 neurophysiologic	 changes	 in	 GBS	 have	 led	 to	 an
important	understanding	of	the	disease	process.	As	we	recognize	the	complexity	of	GBS,	our	approach	to
electrodiagnostic	studies	and	interpretation	is	becoming	increasingly	sophisticated.
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The	Emerging	Concept	of	Nodo-Paranodopathies
in	Guillain-Barré	Syndrome	and	Related	Disorders
Antonino	Uncini	and	Satoshi	Kuwabara
Introduction
The	 term	 ‘nodo-paranodopathy’	was	 originally	 proposed	 to	 better	 characterize	 neuropathies	with	 anti-
gangliosides	antibodies	and	overcame	some	inadequacies	of	the	classical	dichotomous	classification	into
demyelinating	and	axonal	[1].	More	recently	this	categorization	has	been	extended	to	include	neuropathies
of	 different	 aetiology	 (dysimmune,	 inflammatory,	 ischaemic,	 nutritional	 and	 toxic)	 in	 which	 the
involvement	of	 the	nodal	 region	 is	central	 in	 the	pathogenesis	 [2].	The	 following	studies	epitomize	 the
research	 journey	 that	 has	 led,	 over	 the	 past	 20	 years,	 to	 the	 conceptualization	 of	 dysimmune	 nodo-
paranodopathies.	Figure	28.1	 illustrates	 the	 organization	 of	 the	 nodal	 region	with	 reference	 to	 the	 key
molecular	players	of	this	concept.
Hafer-Macko	C,	et	al.	Acute	motor	axonal	neuropathy:	an	antibody-
mediated	attack	on	axolemma.	Annals	of	Neurology,	1996
By	the	middle	of	 the	1990s	 the	connections	between	an	acute,	motor,	primarily	axonal	subtype	of	GBS
(acute	 motor	 axonal	 neuropathy	 [AMAN]),	 preceding	 Campylobacter	 jejuni	 infection	 and	 anti-
ganglioside	 antibodies	were	becoming	 clearer.	The	 Johns	Hopkins	University	group	produced	detailed
pathological	studies	of	fatal	GBS	cases	from	the	Hebei	Province	in	China	providing	remarkable	insights
into	 the	 pathogenesis.	 In	 3	 seminal	 papers	 the	 authors	 described	 extensive	Wallerian-like	 degeneration
(with	only	minimal	demyelination	and	inflammation),	almost	exclusively	of	motor	fibres,	and	showed	that
the	earliest	and	mildest	changes	consisted	of	lengthening	of	the	node	of	Ranvier	with,	in	some	instances,
involvement	 of	 paranodal	 myelin	 [3,4].	 Most	 importantly,	 they	 demonstrated	 IgG	 and	 complement
deposition	 along	 the	 axolemma	 of	 motor	 fibres,	 particularly	 at	 the	 nodes	 of	 Ranvier,	 prior	 to	 the
development	of	Wallerian-like	degeneration	[5].	It	was	suggested	that	“simple	binding	of	antibody,	alone
or	with	 subsequent	 activation	 of	 complement	 at	 the	 nodes	 of	motor	 fibres,	 can	 be	 sufficient	 to	 impair
conduction”.	These	findings	could	well	explain	the	puzzling	observations	of	fatal	AMAN	cases	showing
only	minimal	pathologic	changes	and	why	some	patients	 rapidly	 recovered	 in	 spite	of	an	 initial	 severe
paralysis.	The	foundation	for	the	concept	of	nodo-paranodopathy	was	laid.
Figure	28.1		(A)	Anatomical	organisation	of	myelinated	nerve	fibre	and	its	subdomains.	(B)	Simplified	molecular	organisation	at
nodes,	 paranodes,	 and	 juxtaparanodes.	 NF,	 neurofascin,	 CNTN-1,	 contactin-1,	 Caspr,	 Contactin-associated	 protein.TAG-1,
transient	axonal	glycoprotein	1.	GM1	ganglioside	 is	enriched	at	nodal	and	paranodal	axolemma.	Modified	with	permission	from
Uncini	and	Kuwabara	2015	[2].
Kuwabara	S,	et	al.	Acute	motor	axonal	neuropathy	is	not	only
characterized	by	axonal	degeneration.	Annals	of	Neurology,	1998
AMAN	was	initially	thought	to	be	characterized	pathophysiologically	by	simple	axonal	degeneration,	and
its	electrodiagnosis	was	based	on	the	absence	of	demyelinating	features	and	reduced	compound	muscle
action	 potential	 (CMAP)	 amplitudes	 (Figure	 28.2A)	 [6].	 In	 1998	 Kuwabara	 and	 colleagues	 reported
AMAN	patients	with	antibodies	against	ganglioside	GM1	who	had	conduction	block	(CB)	in	distal	and
intermediate	nerve	segments	and	conduction	slowing	which	promptly	resolved	without	 the	development
of	 excessive	 temporal	 dispersion	 (TD)	 (Figure	 28.2C,	 28.2D)	 [7].	 This	 feature,	 named	 ‘reversible
conduction	 failure’	 (RCF)	 to	 distinguish	 it	 from	 demyelinating	 CB,	 mimics	 demyelination	 on	 early
electrophysiological	 studies,	 but	 sequential	 recordings	 did	 not	 demonstrate	 the	 development	 of	 slow
components	characteristic	of	demyelination	(Figure	28.2E).	The	authors	suggested	that	conduction	failure
was	caused	by	“impaired	physiological	conduction	at	the	node	of	Ranvier”	and	that	AMAN	patients	are
not	only	characterized	by	axonal	degeneration	but	also	by	RCF	[7].	These	important	electrophysiological
observations	 well	 correlated	 with	 the	 pathological	 findings	 showed	 by	 the	 Johns	 Hopkins	 group	 but
remained	somewhat	disregarded	by	the	neurological	community	in	Western	countries.
Capasso	M,	et	al.	Acute	motor	conduction	block	neuropathy.
Neurology,	2003
Capasso	and	colleagues	reported	2	patients	with	antecedent	diarrhoea	and	high	titres	of	IgG	antibodies	to
GM1,	 GD1a	 and	 GD1b	 who	 acutely	 developed	 symmetric	 weakness	 without	 sensory	 symptoms.
Electrophysiology	showed	a	reduction	of	distal	CMAP	amplitudes	and	early	partial	motor	CB	with	focal
conduction	slowing	in	intermediate	nerve	segments	[8].	In	these	patients	distal	CMAPs	normalized,	and
CB	 and	 conduction	 slowly	 resolved	 in	 2	 to	 5	 weeks	 in	 parallel	 with	 strength	 recovery	 without	 the
development	 of	 excessive	 TD	 or	 denervation	 at	 electromyography.	 These	 patients	 were	 initially
considered	a	rare	GBS	subtype	named	acute	motor	conduction	block	neuropathy	(AMCBN).	AMAN	and
AMCBN	have	 in	 common	 antecedent	C.	 jejuni	 enteritis	 and	 anti-ganglioside	 IgG	 antibodies.	AMCBN
patients	 show	 the	 RCF	 pattern	 in	 most	 nerves.	 Therefore,	 it	 was	 hypothesized	 that	 AMCBN	 was	 an
‘arrested	AMAN’,	in	which	anti-ganglioside	antibodies	bind	to	the	nodal	axolemma	and	induce	RCF	not
progressing	to	axonal	degeneration	[8].	Similar	patients	were	reported	under	different	names	(reviewed
in	 Uncini	 and	 Kuwabara,	 2012)	 [9].	 The	 description	 of	 patients	 with	 conduction	 failure	 evolving	 to
axonal	degeneration	(Figure	28.2B)	or	showing	RCF	and	axonal	degeneration	co-occurring	in	the	same	or
different	nerves	 confirms	 that	AMCBN,	AMAN	with	RCF	and	AMAN	with	 axonal	 degeneration	 are	 a
pathophysiological	continuum	[10–12].	This	explains	why	 recovery	 in	AMAN	may	be	either	 rapid	and
complete	or	prolonged	with	poor	outcome	in	a	dichotomous	pattern	according	to	the	relative	amount	of
axonal	degeneration	and	RCF	in	each	patient	[13].
At	 this	 point	AMAN	was	 electrophysiologically	 characterized	 not	 only	 by	 axonal	 degeneration	 but
also	by	a	reversible	failure	of	conduction,	and	that	both	processes	could	be	due	to	an	immune	mediated
attack	to	the	nodal	axolemma	became	quite	certain.
Figure	28.2	 	 Spectrum	of	motor	 nerve	 conduction	 abnormalities	 in	GBS.	Superimposed	 compound	muscle	 action	 potentials
(CMAPs)	recorded	from	the	abductor	digiti	minimi	after	ulnar	nerve	stimulation	at	wrist,	below-elbow	and	above-elbow,	and	from
the	abductor	pollicis	brevis	after	median	nerve	stimulation	at	wrist	and	elbow.	(A)	AMAN	with	axonal	degeneration.	Ulnar	nerve.
Distal	CMAP	amplitude	was	already	decreased	(4	mV)	on	day	4	and	further	decreased	(2	mV)	on	day	11.	The	patient	had	IgG
anti-GM1	 and	 anti-GD1a.	 (B)	 AMAN	with	 conduction	 failure	 followed	 by	 axonal	 degeneration.	 Ulnar	 nerve.	 Note	 on	 day	 3	 the
gradual	reduction	of	CMAP	amplitudes	from	elbow	and	axilla	stimulation	followed	on	day	7	by	reduced	amplitudes	of	all	CMAPs.
The	 patient	 had	 IgG	 anti-GM1.	 (C)	AMAN	with	 reversible	 distal	 conduction	 failure	 pattern.	Median	 nerve.	On	 day	 6	 distal	 and
proximal	CMAP	amplitudes	were	 reduced	 (2.6	mV).	On	day	12	distal	CMAP	was	142%	 increased	 returning	within	 the	normal
range.	There	was	no	excessive	temporal	dispersion	of	proximal	or	distal	CMAP	in	all	recordings.	The	patient	had	IgG	anti-GD1b.
(D)	AMAN	with	reversible	conduction	failure	pattern	in	intermediate	nerve	segments.	Ulnar	nerve.	On	day	10	there	was	a	partial
CB	 across	 the	 elbow	 which	 improved	 on	 day	 20	 and	 resolved	 at	 day	 27	 without	 the	 development	 of	 excessive	 temporal
dispersion.	The	patient	had	IgG	anti-GM1,	anti-GD1a	and	anti-GD1b.	(E)	Acute	inflammatory	demyelinating	polyneuropathy.	Ulnar
nerve.	On	day	2	all	 conduction	parameters	were	normal.	On	day	14	all	CMAPs	were	dispersed,	distal	CMAP	amplitude	was
greatly	reduced	(1	mV),	distal	motor	latency	was	increased	(5.7	ms),	the	CMAP	amplitude	ratio	between	below-elbow	and	wrist
stimulation	was	0.2	and	conduction	velocities	were	reduced	(20	m/s	in	the	below-elbow	wrist	segment	and	26	m/s	across	the
elbow).	On	day	40	the	CMAP	amplitude	ratio	between	below-elbow	and	wrist	stimulation	was	0.5	but	all	CMAPs	were	still	reduced
in	amplitude	and	dispersed,	DML	was	further	increased	(7.2	ms)	and	conduction	velocities	reduced	(19	m/s	in	the	below-elbow
wrist	segment	and	16	m/s	across	the	elbow).	The	patient	did	not	have	anti-ganglioside	antibodies.	Used	with	permission	from
Uncini	et	al.	2010	[15].
Uncini	A,	et	al.	Pitfalls	in	electrodiagnosis	of	Guillain-Barré	syndrome
subtypes.	Journal	of	Neurology	Neurosurgery	&	Psychiatry,	2010
The	recognition	that	RCF	was	a	characteristic	of	AMAN	led	to	a	reconsideration	of	 the	sensitivity	and
specificity	of	the	2	most	commonly	used	criteria	sets	in	the	electrodiagnosis	of	GBS	[6,14].	In	an	Italian
population,	 at	 first	 test,	 the	 electrodiagnosis	 was	 almost	 identical	 with	 both	 criteria	 sets:	 65–67%	 of
patients	were	classifiable	as	acute	inflammatory	demyelinating	polyradiculoneuropathy	(AIDP)	and	18%
as	 axonal	 GBS;	 14–16%	were	 equivocal	 [15].	 At	 follow-up,	 24%	 of	 patients	 changed	 classification:
AIDP	decreased	 to	58%,	axonal	GBS	 increased	 to	38%,	and	equivocal	patients	decreased	 to	4%.	The
majority	of	 shifts	were	 from	AIDP	and	equivocal	groups	 to	 axonal	GBS,	 and	 the	main	 reason	was	 the
recognition	by	serial	recordings	of	the	RCF	as	expression	of	axonal	pathology.	All	patients	who	shifted	to
the	axonal	group	had	antibodies	to	gangliosides.	Similar	results	were	reported	in	Japanese	series	[11,16].
These	 studies	 demonstrate	 that	 in	 early	 GBS	 it	 may	 be	 impossible	 to	 distinguish	 between	 AIDP	 and
axonal	GBS	in	some	patients	and	indicate	that	the	lack	of	distinction	between	demyelinating	CB	and	RCF
by	 serial	 conduction	 studies	 may	 fallaciously	 classify	 patients	 with	 axonal	 GBS	 as	 having	 AIDP.
Moreover,	 these	 observations	 explain	why,	 especially	 in	Western	 countries,	 antibodies	 to	 gangliosides
were	thought	to	be	associated	with	AIDP.
Currently	employed	electrophysiological	criteria	for	diagnosis	of	GBS	subtypes	do	not	require	serial
studies	and	do	not	include	RCF	as	expression	of	axonal	pathology,	and	therefore	are	inadequate	for	the
correct	diagnosis	of	GBS	subtypes.	This	highlights	the	necessity	of	developing	more	reliable	criteria	or	a
different	categorization	of	axonal	GBS	with	anti-ganglioside	antibodies	[9].
Susuki	K,	et	al.	Anti-GM1	antibodies	cause	complement-mediated
disruption	of	sodium	channel	clusters	in	peripheral	motor	nerve
fibres.	The	Journal	of	Neuroscience,	2007;	McGonigal	R,	et	al.	Anti-
GD1a	antibodies	activate	complement	and	calpain	to	injure	distal
motor	nodes	of	Ranvier	in	mice.	Brain,	2010
The	most	clinically	 relevant	animal	model	of	AMAN	was	developed	by	a	Japanese	group	 led	by	Yuki
[17].	The	sensitization	of	rabbits	with	purified	GM1	induced	flaccid	monophasic	weakness,	high	titres	of
anti-GM1	or	anti-GD1b	IgG	antibodies,	IgG	deposition	on	motor	axons	and	Wallerian-like	degeneration
without	 prominent	 demyelination	 or	 inflammation.	 In	 a	 further	 study	 the	 same	 group	 showed	 that	 IgG
antibodies	bound	to	GM1,	which	is	strongly	expressed	at	the	nodes	of	Ranvier,	and	activated	complement
resulting	in	the	formation	of	the	membrane	attack	complex	at	the	nodal	axolemma	and	destruction	of	nodal
molecular	complexes	including	Nav	channels	[18].	The	autoimmune	processes	caused	lengthening	of	the
nodes	 and	 paranodal	 detachment	 of	 myelin	 sheath	 identical	 to	 the	 early	 pathology	 found	 in	 AMAN
patients.	 Anti-GD1a	 antibodies	 disrupt	 the	 nodes	 by	 the	 same	 mechanisms.	 In	 an	 ex	 vivo	 mouse
preparation	 it	 was	 shown	 that	 the	 nodes	 of	 Ranvier	 were	 targeted	 by	 anti-GD1a	 antibody	 [19].
Complement	deposition	was	associated	with	complete	loss	of	nodal	protein	staining,	including	voltage-
gated	sodium	channels,	and	nerve-conduction	failure.	Both	morphological	and	conduction	abnormalities
were	prevented	by	eculizumab	(a	humanised	mouse	monoclonal	antibody	which	prevents	the	formation	of
the	 terminal	 complement	 complex),	 whereas	 inhibition	 of	 the	 protease	 calpain	 preserved	 the
immunostaining	profiles	of	nodes	of	Ranvier	without	protecting	nerve	conduction.
The	above	findings	 indicate	 that	 the	early	 immunopathologic	stage	of	AMAN	is	characterized	by	an
attack	 to	 the	nodal	region	and	failure	of	nerve	conduction	which	may	still	be	promptly	reversible	as	 in
AMAN	with	 RCF	 or	 AMCBN.	 If	 the	 immune	 reaction	 progresses,	 calcium	 entry	 in	 the	 axon	 triggers
protease	 activation	 and	 consequent	 axonal	 damage	 and	 Wallerian-like	 degeneration.	 Macrophages
subsequently	move	from	the	nodes	into	the	periaxonal	space,	scavenging	the	injured	axons	(Figure	28.3).
Experimental	models	 have	 thus	 confirmed	 that	 in	AMAN	 the	major	 injury	 site	 of	 the	 antibodies	 is	 the
nodal	 region,	 clarified	 the	 immunopathologic	 cascade	 and	 furnished	 an	 explanation	 for	 the
electrophysiologic	and	clinical	correlates.
Susuki,	et	al.	Dysfunction	of	nodes	of	Ranvier:	a	mechanism	for	anti-
ganglioside	antibody-mediated	neuropathies.	Experimental	Neurology,
2012
The	careful	reconsideration	of	different	experimental	models	of	neuropathies	associated	with	antibodies
to	GM1,	GD1a	and	GD1b	indicated	a	common	pathophysiologic	mechanism	characterized	by	complement
mediated	 dysfunction	 and	 disruption	 of	 the	 nodes	 of	 Ranvier	 [20].	 In	 recent	 years	 evidence	 has
accumulated	that	dysfunction/disruption	of	the	nodal	region	is	a	pathogenic	mechanism	not	only	in	AMAN
but	also	in	other	acute	neuropathies	with	antibodies	to	gangliosides.	RCF	has	been	described	in	motor	and
sensory	 fibres	of	patients	with	acute	motor	 and	 sensory	axonal	neuropathy	 (AMSAN)	and,	 similarly	 to
AMAN,	abnormally	 elongated	nodes	were	 found	 in	 the	dorsal	 roots	of	patients	with	AMSAN	[21,22].
RCF	in	motor	and	sensory	fibres	has	also	been	reported	in	patients	with	the	pharyngeal-cervical	brachial
subtype	 of	 GBS	 [23].	 RCF	 restricted	 to	 sensory	 fibres	 has	 been	 reported	 in	 patients	 with	 promptly
reversible	 acute	 sensory	 ataxic	 neuropathy	 and	 IgG	 anti-GD1b	 or	 -GQ1b	 antibodies	 and	 in	 the	Miller
Fisher	 syndrome	which	 is	 also	known	 to	have	 a	good	prognosis	 [24,25].	Moreover,	 the	 sensory	nerve
biopsy	of	an	anti-GQ1b	positive	patient	with	the	Miller	Fisher	syndrome	showed	lengthening	of	nodes	of
Ranvier,	 myelin	 splitting	 and	 macrophage	 invasion	 of	 the	 internodal	 axon	 without	 any	 features	 of
demyelination	strikingly	similar	to	the	pathological	features	found	in	motor	fibres	of	AMAN	patients	[26].
The	experimental	and	clinical	electrophysiological	observations	indicated	that	RCF	can	be	found	also
in	sensory	fibres	and	that	in	different	acute	anti-ganglioside	antibody	mediated	neuropathies	the	main	site
of	injury	is	the	same:	the	excitable	axolemma	of	the	nodal	region.
Uncini	A,	et	al.	Nodo-paranodopathy:	beyond	the	demyelinating	and
axonal	classification	in	anti-ganglioside	antibody-mediated
neuropathies.	Clinical	Neurophysiology,	2013
The	 traditional	 classification	 of	 neuropathies	 into	 axonal	 or	 demyelinating	might	 generate	 confusion	 in
diagnosing	GBS	 subtypes.	AMAN	 is	 classified	 as	 an	 axonal	 neuropathy	 because	 the	 primary	 attack	 is
directed	 towards	 the	 nodal	 axolemma,	 leading	 ultimately	 to	 axonal	 degeneration.	 However,	 the	 term
‘axonal’	 may	 be	 misleading	 as	 in	 common	 neurological	 knowledge	 it	 is	 linked	 to	 Wallerian-like
degeneration	and	evokes	poor	prognosis,	and	not	everybody	agrees	on	an	axonal	scenario	characterized
by	transitory	dysfunction	and	prompt	recovery	as	in	AMAN	with	RCF	or	AMCBN.	On	the	other	hand,	in
GBS	patients	with	 anti-ganglioside	 antibodies	 and	 in	 the	 experimental	models,	 although	 the	pathogenic
mechanism	is	mainly	focused	on	the	node,	some	demyelinating-like	features	such	as	detachment	of	myelin
terminal	loops	and	lengthening	of	the	nodes	(but	never	true	segmental	demyelination)	have	been	reported.
Moreover,	RCF,	on	the	basis	of	a	single	electrophysiological	test,	can	be	misdiagnosed	as	demyelinating
CB,	leading	to	a	diagnosis	of	AIDP.
Figure	28.3	 	The	 immunopathologic	cascade,	 the	electrophysiologic	and	clinical	correlates	 in	acute	motor	axonal	neuropathy
(AMAN).	 (A–D)	Acute	nodal	disruption.	 (A)	Cartoon	showing	 the	normal	node	 (top),	 the	early	 (middle)	and	advanced	 (bottom)
phase	of	nodal	disruption.	Caspr,	contactin-associated	protein;	Nav,	voltage-gated	sodium	channel.	(B)	Immunostaining	of	ventral
roots	 from	normal	 (top)	or	AMAN	 rabbits	with	 IgG	anti-GM1	antibodies.	Autoimmune	attack	 (blue,	membrane	attack	 complex)
occurs	at	 the	nodes	first	 then	extends	to	the	paranodes.	Clusters	of	nodal	Nav	channels	(red)	or	paranodal	Caspr	(green)	are
destroyed	and	eventually	disappear.	(C)	Toluidine	blue	staining	of	ventral	roots	from	AMAN	rabbits.	The	arrow	indicates	a	normal
node	 (top).	 The	 bracket	 indicates	 an	 abnormally	 elongated	 node	 (bottom).	 (D)	 Electron	 microscopy	 showing	 abnormally
lengthened	node	and	paranodal	myelin	detachment	 in	ventral	 roots	 from	AMAN	rabbit.	At	 this	point	 the	cascade	may	 follow	2
paths.	(1)	Left.	Rapid	repair	of	disrupted	nodes	as	in	AMAN	with	reversible	conduction	failure	(RCF)	or	acute	motor	conduction
block	neuropathy	(AMCBN)	associated	with	prompt,	favourable	recovery	(E–G).	(E)	Cartoon	schematizing	the	recovery	pattern	of
affected	nodes.	(F)	Immunostaining	of	ventral	roots	from	AMAN	rabbits	during	recovery	phase.	Deposition	of	membrane	attack
complex	is	reduced.	Clusters	of	Nav	channels	(red)	and	Caspr	(green)	are	formed	on	both	sides	of	affected	nodes,	and	appear	to
fuse	together	to	form	a	new	node	of	Ranvier.	(G)	Serial	motor	conductions	of	the	ulnar	nerve	from	an	AMAN	patient	with	high	titre
of	 IgG	anti-GM1	antibodies.	On	Day	8	conduction	block	 (CB)	 is	present	across	 the	elbow:	proximal	compound	muscle	action
potential	(CMAP)	amplitude	is	48%	reduced	with	slow	(27	m/s)	conduction	velocity	(CV).	CB	improves	on	day	12	and	disappears
by	day	25	with	normalization	of	CV	and	without	development	of	CMAP	temporal	dispersion.	(2)	Right.	Progression	to	typical	AMAN
with	axonal	degeneration	associated	with	poor	outcome	(H–K).	 (H)	Cartoon	schematizing	 the	nodal	disruption	with	abnormally
elongated	 nodal	 gaps	 progressing	 to	 axonal	 degeneration.	 (I)	 Electron	 microscopy	 of	 ventral	 root	 from	 AMAN	 rabbit.	 A
macrophage	(M)	is	in	the	periaxonal	space	with	an	injured	axon	(A)	in	presence	of	intact	myelin	sheath.	(J)	Toluidine	blue	staining
of	sciatic	nerve	from	AMAN	rabbit.	Arrowheads	indicate	the	degenerated	nerve	fibres.	(K)	Serial	motor	conductions	of	the	ulnar
nerve	 from	an	AMAN	patient	with	high	 titre	of	 IgG	anti-GM1	and	-GD1a	antibodies.	On	day	3	 there	 is	only	a	slight	 reduction	of
proximal	 CMAP	 amplitude	 across	 the	 elbow	 segment.	 On	 day	 6	 CB	 is	 present	 across	 the	 elbow	 segment	 (proximal	 CMAP
amplitude	 is	 78%	 reduced).	 At	 day	 22	 a	 reduction	 of	 all	 CMAP	 amplitudes	 is	 evident,	 indicating	 the	 evolution	 to	 axonal
degeneration.	The	cartoon	on	the	right	details	the	possible	events	leading	to	axonal	degeneration.	Antibodies	bind	to	gangliosides
in	 the	axolemma	(1),	 the	classical	pathway	of	complement	 is	activated	(2),	 the	 terminal	components	of	complement	 form	the
membrane	attack	complex	(MAC)	pore	(3),	Ca2+	enters	through	the	MAC	pores	and	accumulates	in	the	axoplasma	(4),	activation
of	Ca2+-dependent	calpain	(5)	causing	proteolytic	cleavage	of	neurofilaments	(NF),	damage	of	mitochondria	(Mit)	and	Wallerian
degeneration.	Finally	macrophages	move	from	nodal	gaps	into	the	periaxonal	space	to	remove	degenerating	axons	(H).	Figures
A,	C,	E,	H	and	J	used	with	permission	from	Uncini	et	al.	2013	[1].	Figure	C	was	originally	from	Dr	Koujiro	Tohama	(The	Centre	for
Electron	Microscopy	and	Bio-Imaging	Research,	Laboratory	of	Nano-Neuroanatomy,	 Iwate	Medical	University,	Morioka,	Japan).
Figures	 B,	 D	 and	 F	 used	 with	 permission	 from	 [18].	 Figures	 G	 and	 K	 used	 with	 permission	 from	 [10].	 Figure	 I	 used	 with
permission	from	[42].
To	 overcome	 these	 nosologic	 difficulties	 and	 avoid	 misclassification	 the	 new	 category	 of	 nodo-
paranodopathies	was	proposed	[1].	Figure	28.4	summarizes	 the	association	of	dysimmune	neuropathies
with	 antibodies	 to	 gangliosides	 and	 to	 axo-glial	 proteins	 and	 the	 evidence	 supporting	 the	 nodal	 and
paranodal	involvement.
Acute	neuropathies	with	anti-ganglioside	antibodies	can	be	classified	as	nodopathies	because	of	 the
common	 pathophysiologic	 mechanism	 and	 continuum.	 In	 the	 appropriate	 clinical	 setting	 the
electrodiagnosis	of	an	acute	dysimmune	nodopathy	can	be	made	by	serial	conduction	studies	documenting
a	promptly	reversible	CB	or	conduction	slowing	without	development	of	excessive	temporal	dispersion,
which	is	therefore	defined	RCF,	or	a	progression	from	CB	to	axonal	degeneration.
Regarding	chronic	neuropathies	it	has	been	debated	whether	multifocal	motor	neuropathy	(MMN)	is	a
demyelinating	or	an	axonal	disorder.	MMN	is	characterized	by	persistent	motor	CB	(with	or	without	TD),
presence	of	IgM	to	GM1	in	about	50%	of	patients	and	response	to	intravenous	immunoglobulin	(IVIg)	in
up	 to	 90%	 of	 patients	 [27].	 In	 addition	 to	 CB,	 MMN	 is	 characterized	 by	 axonal	 degeneration	 [28].
Pathology	studies	in	MMN	are	scarce	and	contradictory,	with	evidence	of	mild	demyelination	as	well	as
of	primary	axonal	degeneration	[29,30].	Injection	of	human	sera	containing	IgM	anti-GM1	antibodies	into
the	rat	sciatic	nerve	induced	CB,	immunoglobulin	deposition	at	the	nodes	of	Ranvier,	nodal	widening	and
some	 paranodal	 demyelination	 [31].	 Application	 of	 high-concentration	 anti-GM1	 sera	 to	 rat	 single-
myelinated	axons	after	addition	of	complement	reduced	Na+	currents	sufficient	 to	block	action	potential
electrogenesis	[32].	Results	of	nerve	excitability	studies	suggest	the	Na+/K+	pump	was	blocked	at	the	site
of	CB,	causing	permanent	depolarization	and	continuous	Na+	influx	[33].	Permanent	axonal	depolarization
may	 induce	 increased	Na+	 influx,	 intra-axonal	Na+	 accumulation,	 reversal	 of	 the	 axolemmal	Na+/Ca2+
exchanger,	 intra-axonal	 Ca2+	 accumulation,	 and	 Ca2+-mediated	 axonal	 degeneration.	 All	 of	 the	 above
findings	 suggest	 that	 MMN	 could	 be	 better	 classified	 as	 a	 chronic	 dysimmune	 nodo-paranodopathy
(Figure	28.4).
Figure	28.4	 	Dysimmune	nodo-paranodopathies.	The	association	of	neuropathies	with	antibodies	to	gangliosides	and	axo-glial
proteins	and	 the	evidences	supporting	 the	nodal	and	paranodal	 involvement	are	shown.	Strength	 in	association	and	evidence:
black,	 strong;	 dark	 grey,	medium;	 light	 grey,	weak;	 blank,	 none.	NCS	 indicates	 evidence	of	 rapid	 reversible	 nerve	 conduction
failure	or	persistent	nerve	conduction	block.	Pathology	indicates	evidence	of	lengthened	nodes	in	human	autopsy.	Model	indicates
evidence	of	disruption	of	nodes	in	animal	models	by	active	immunization	or	by	passive	transfer	of	antibodies.	AMAN,	acute	motor
axonal	neuropathy;	AMSAN,	acute	motor-sensory	axonal	neuropathy;	ASAN,	acute	sensory	ataxic	neuropathy;	PCB,	pharyngeal-
cervical-brachial	 subtype	 of	 Guillain-Barré	 syndrome;	MFS,	Miller	 Fisher	 syndrome;	MMN,	multifocal	motor	 neuropathy,	 CIDP
chronic	inflammatory	demyelinating	polyneuropathy.	Modified	from	Uncini	et	al.	2013	[1].
Devaux	JJ,	et	al.	Nodal	proteins	are	target	antigens	in	Guillain-Barré
syndrome.	Journal	of	the	Peripheral	Nervous	System,	2012;	Querol	L,	et
al.	Antibodies	to	contactin-1	in	chronic	inflammatory	demyelinating
polyneuropathy.	Annals	of	Neurology,	2013
Chronic	 inflammatory	 demyelinating	 polyradiculoneuropathy	 (CIDP)	 is	 thought	 to	 be	 an	 autoimmune
disorder	 with	 heterogeneous	 clinical	 phenotypes.	 The	 proteins	 of	 the	 compact	 myelin	 have	 long	 been
thought	 to	be	 likely	 autoantigens	because	of	 segmental	 demyelination	 seen	on	pathological	 examination
and	because	of	 the	similarity	with	experimental	allergic	neuritis	 induced	in	rats	by	purified	P0,	P2	and
PMP	22.	Nonetheless,	after	many	years	of	investigation	there	is	little	evidence	for	a	pathogenic	role	of	an
autoantibody	response	to	these	proteins	in	the	majority	of	CIDP	patients	[34].
An	innovative	research	path	was	opened	by	Devaux	and	colleagues	 in	2012	reporting	that	IgG	from
30%	 of	 CIDP	 patients	 bound	 at	 the	 nodal	 region	 of	 rat	 sciatic	 nerve	 recognizing,	 in	 some	 instances,
contactin-1	 (CNTN-1),	 neurofascin-186,	 gliomedin	 [35].	 The	 following	 year	 Querol	 and	 colleagues
showed	that	6.5%	of	45	CIDP	patients	had	IgG	to	CNTN-1	or	CNTN-1	and	contactin-	associated	protein
(Caspr)	[36].	These	patients	shared	a	phenotype	characterized	by	aggressive	onset,	motor	predominance
and	poor	 response	 to	 IVIg.	The	 same	Spanish	group	 reported	4	patients	with	antibodies	 to	neurofascin
155,	 predominantly	 of	 the	 IgG4	 isotype,	 presenting	with	 severe	distal	weakness,	 disabling	 tremor	 in	 3
patients	 and	poor	 response	 to	 IVIg	 [37].	Anti-CNTN-1	antibodies,	 exclusively	or	predominantly	of	 the
IgG4	 isotype,	were	 found	 in	 2.4%	 of	 500	 Japanese	CIDP	 patients	 presenting	with	 subacute	 onset	 and
sensory	ataxia,	and	in	8%	of	53	German	patients	showing	acute	onset,	prevalently	motor	neuropathy	and	a
high	occurrence	of	tremor	[38,39].	The	axonal	cell	adhesion	molecules	CNTN-1	and	Caspr,	and	the	glial
neurofascin-155	 form	 a	 ternary	 complex	 located	 in	 the	 paranode	 and	 is	 essential	 in	 the	 formation	 and
stability	of	septate-like	junctions	and	contributes	to	the	impulse	propagation	in	myelinated	fibres	(Figure
28.1).	Interestingly	IgG4	antibodies	have	a	reduced	capacity	to	activate	complement	and	have	been	shown
to	be	pathogenic	via	an	‘antigen	blocking’	mechanism	in	which	the	antibody	blocks	critical	functions	of
the	target	antigen.	Studies	of	dermal	myelinated	fibres	and	sural	biopsies	of	patients	with	anti-CNTN-1
antibody	 showed	 loss/destruction	 of	 paranodal	 Caspr	 and/or	 neurofascin	 immunoreactivity,	 elongated
nodes	and	axonal	damage	but	not	demyelination	[39].	The	authors	concluded	that	anti-CNTNI	antibody-
associated	neuropathy	“does	not	meet	morphological	criteria	of	demyelinating	neuropathy	and	therefore
might	 rather	 be	 termed	 a	 paranodopathy”.	 Electrophysiological	 studies	 of	 patients	 with	 antibodies	 to
CNTN-1,	Caspr,	and	neurofascin	155,	show	prolonged	distal	motor	latencies	and	slowing	of	conduction
in	the	‘demyelinating’	range,	CB	and	TD	but	also	low	amplitude	distal	CMAPs	and	spontaneous	activity
at	electromyography	 indicative	of	significant	coexistent	axonal	degeneration.	Proofs	of	pathogenicity	of
these	antibodies	are	still	circumstantial.	In	an	in	vitro	myelinated	model,	IgG4	anti-CNTN-1	from	patients
of	the	Spanish	cohort	prevent	adhesive	interaction	between	CNTN-1/Caspr	and	neurofascin-155	and	lead
to	alteration	of	paranodes	[40].	Antibodies	against	neurofascin	exacerbate	and	prolong	adoptive	transfer
experimental	autoimmune	neuritis	and	caused	conduction	defects	when	injected	intraneurally	[41].	So	in
summary,	antibodies	to	CNTN-1,	Caspr,	or	neurofascin155,	are	present	in	up	to	12%	of	CIDP	patients	and
seems	to	be	associated	with	acute/subacute	onset	and	poor	response	to	IVIg.	Because	of	the	localization
and	 function	 of	 the	 axo-glial	 protein	 and	 the	 lack	 of	 true	 segmental	 demyelination	 at	 pathology,	 the
neuropathy	with	antibodies	to	CNTN-1,	Caspr,	or	neurofascin	155	could	be	better	classified	as	a	chronic
paranodopathy.	 Compared	 to	 acute	 nodopathy	 associated	 with	 anti-ganglioside	 antibodies	 this	 chronic
paranodopathy	 seems	 to	 show	 the	 electrophysiological	 features	 of	 de-remyelination,	 even	 though
segmental	 demyelination	 was	 not	 demonstrated,	 possibly	 because	 of	 the	 major	 involvement	 of	 the
paranodes.	Accurate	sequential	neurophysiological	studies	are	necessary	to	investigate	whether	it	will	be
possible	to	distinguish	patients	with	antibodies	to	paranodal	axo-glial	proteins	from	other	CIDP	patients.
Conclusions
The	nosological	entity	of	nodo-paranodopathy	we	propose	has	the	advantage	of	focussing	on	the	site	of
primary	 nerve	 injury	 and	 avoids	 the	 confusing	 situation,	 as	 in	 neuropathies	 associated	 with	 anti-
ganglioside	 antibodies,	 that	 in	 spite	 of	 the	 common	 site	 of	 nerve	 damage	 and	 pathophysiological
mechanism,	some	patients	might	be	classified	as	having	a	demyelinating	and	others	as	having	an	axonal
neuropathy.	 In	 our	 opinion	 the	 nodo-paranodopathy	 category	 seems	 appropriate	 for	 various	 dysimmune
acute	 and	 chronic	 neuropathies	 associated	 with	 antibodies	 to	 gangliosides	 and	 to	 paranodal	 axo-glial
proteins,	better	systematizes	 the	neuropathies	characterized	by	an	autoimmune	attack	 targeting	 the	nodal
region,	and	integrates	the	classical	classification	into	demyelinating	and	axonal.
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Nonconventional	Electrophysiological	Techniques
Judith	Drenthen
Introduction
The	 development	 of	 electrophysiology	 started	 in	 the	 18th	 century	 with	 Galvani’s	 discovery	 of	 animal
electricity.	 He	 showed	 that	 electrical	 stimulation	 of	 muscular	 tissue	 produces	 contraction	 and	 force.
Although	brilliant,	his	findings	came	too	early	for	his	time.	His	concept	was	received	with	considerable
scepticism	and	it	was	not	until	the	19th	century	that	his	theory	gained	new	enthusiasm.	Then	these	findings
were	reproduced	and	various	stimulation	procedures	were	developed.	In	1852,	Hemlholtz	was	the	first	to
measure	nerve	conduction	in	human	subjects.	In	the	next	century	the	development	of	electrophysiological
techniques	gained	momentum.	During	the	first	half	of	the	20th	century	the	recording	equipment	improved.
The	 first	 modern	 electromyography	 (EMG)	 machine	 was	 constructed	 by	 Jasper	 in	 1942	 at	 McGill
University,	Montreal,	Canada,	and	in	1950	the	first	commercially	available	EMG	system	was	introduced.
This	 technical	 progress	 and	 a	 better	 understanding	 of	 disease	 processes	 led	 to	 an	 increased	 use	 of
electrical	investigations	and	has	led	to	our	extensive	knowledge	of	the	human	peripheral	nervous	system.
Even	in	this	day	and	age	new	techniques	are	being	developed	and	old	techniques	are	being	rediscovered
and	 adjusted	 for	 new	 purposes	 to	 study	 the	 various	 aspects	 of	 the	 human	 nerve	 and	 muscle.	 In	 this
GBS100	 monograph	 I	 try	 to	 give	 an	 impression	 of	 current	 and	 promising	 nonconventional
electrophysiological	techniques.	It	is	not	meant	as	a	complete	overview	of	all	promising	techniques.
Threshold	Tracking	Techniques	in	the	Human	Peripheral	Nerve
One	of	the	most	important	neurophysiologists	of	our	time	(of	my	time	anyway)	is	Professor	Hugh	Bostock.
His	 pioneering	 techniques	 have	 improved	 our	 understanding	 of	 the	 electrical	 properties	 of	 nerve
membranes	and	their	alterations	in	various	diseases.	One	paragraph	about	his	work	is	not	doing	justice	to
the	 enormous	 impact	 he	 has	 had	 on	 the	 neurophysiological	 world,	 and	 is	 not	 sufficient	 to	 explain	 his
brilliant,	albeit	complex	threshold	tracking	technique.	However,	in	this	short	overview	I	will	try	to	give
an	impression	of	the	basic	principles	of	this	sophisticated	technique.
In	 the	 1990s,	 Professor	Bostock	 developed	 a	 semiautomatic	 program	 called	QTRAC	 [1].	With	 this
program	various	nerve	excitability	tests	assessing	nerve	membrane	properties	in	vivo	can	be	performed.
It	 provides	 information	 about	 motor	 or	 sensory	 axons	 complementary	 to	 the	 information	 provided	 by
conventional	 nerve	 conduction	 studies	 (NCS).	 Nerve	 excitability	 testing	 provides	 information	 on	 ion
channels	and	 the	 functions	of	energy-dependent	pumps	 in	 the	nodal	and	 internodal	membrane,	and	 their
changes	during	disease.	In	threshold	tracking	a	resting	threshold	is	compared	to	a	threshold	produced	by
changes	in	the	nerve	environment.	First,	the	resting	threshold	has	to	be	established.	This	is	the	threshold
that	 produces	 a	 predefined	 compound	 muscle	 action	 potential	 (CMAP)	 size	 (often	 40%	 of	 maximum
CMAP	 amplitude).	 Then	 nerve	 excitability	 is	 changed	 by	 different	 manoeuvres	 (by	 altering	 the	 nerve
environment	or	by	applying	additional	currents).	The	current	that	is	then	required	to	elicit	the	predefined
CMAP	amplitude	will	be	determined	automatically.	For	example,	when	axons	are	hyperpolarized,	the	test
potential	 becomes	 smaller	 and	 the	 computer	will	 increase	 stimulus	 intensity	 until	 the	 test	 potential	 has
returned	to	its	target	size.	In	clinical	practice,	the	nerve	is	stimulated	using	a	computerized	protocol	and
takes	 approximately	 15	 minutes.	 With	 this	 protocol	 several	 indices	 of	 axonal	 excitability,	 such	 as
refractoriness,	strength–duration	properties,	threshold	electrotonus,	supernormality	and	late	subnormality
can	 be	 measured.	 Multiple	 studies	 have	 been	 performed	 with	 this	 technique	 in	 a	 wide	 subset	 of
neuromuscular	disorders,	providing	a	whole	new	insight	into	the	physiology	of	those	diseases.
Differences	in	Membrane	Properties	of	Axonal	and	Demyelinating
Guillain-Barré	Syndromes
Although	the	threshold	tracking	technique	is	used	in	various	neuromuscular	disorders,	so	far	only	1	study
has	been	performed	in	Guillain-Barré	syndrome	(GBS)	patients.	In	this	study	threshold	tracking	was	used
to	 measure	 axonal	 excitability	 in	 acute	 motor	 axonal	 neuropathy	 (AMAN)	 and	 acute	 inflammatory
demyelinating	polyneuropathy	 (AIDP)	patients.	Axonal	excitability	properties	were	different	 in	AMAN
patients	than	in	those	with	AIDP.	AMAN	patients	had	a	greater	refractoriness	during	the	acute	phase	of	the
disease	 that	 normalised	 during	 follow-up.	 The	 recovery	 cycle	 data	 suggest	 a	 critically	 reduced	 safety
factor	for	impulse	conduction	in	distal	nerve	terminals	of	AMAN	patients	[2].
The	Electrophysiological	Muscle	Scan
In	 2007,	 2	 publications	 were	 published	 more	 or	 less	 simultaneously	 about	 the	 clinical	 potential	 of	 a
detailed	 stimulus	 response	 curve	 [3,4].	 The	 stimulus	 response	 curve	was	 originally	 developed	 for	 the
excitability	testing	technique.	Up	until	these	2	publications,	the	diagnostic	value	of	this	stimulus	response
curve	itself	was	rare.	When	recorded	with	a	sufficient	stimulus	number,	this	detailed	curve	has	much	to
reveal	that	is	of	clinical	interest.	The	2	research	groups	joined	together	and	explored	the	possibilities	and
optimal	settings	to	record	this	technique.	The	technique	was	soon	labelled	the	CMAP	scan.	The	CMAP
scan	is	noninvasive	and	is	based	on	the	successive	activation	of	motor	units	(MUs)	through	transcutaneous
electrical	 stimulation.	Each	MU	has	 a	 different	 stimulus	 intensity	 (SI)	 at	which	 it	will	 be	 activated.	A
gradual	increase	in	SI	from	threshold	(the	SI	at	which	the	MU	with	the	lowest	threshold	is	activated)	to
supramaximal	values	 (the	SI	 that	 elicits	 a	maximum	CMAP)	will	 result	 in	 successive	 activation	 of	 all
MUs	 in	 the	 muscle.	 Plotting	 the	 elicited	 CMAP	 amplitudes	 versus	 the	 corresponding	 SIs	 results	 in	 a
curve.
If	made	with	many	stimuli	and,	hence,	a	high	resolution,	the	CMAP	scan	provides	information	that	is
not	(easily)	available	through	conventional	EMG	methods.	For	example,	it	allows	the	identification	and
quantification	 of	 steps.	 Steps	 are	 clearly	 visible	 size	 differences	 in	 the	 CMAP	 amplitude	 between
consecutive	stimuli.	They	appear	as	abrupt	jumps	in	the	usually	sigmoid	curve	and	result	from	the	firing	of
large,	newly	recruited	MU	potentials.	They	are	a	sign	of	reinnervation	and/or	MU	loss.	The	presence	and
properties	 of	 steps	 differ	 significantly	 between	 normal	 subjects	 and	 patients	 with	 amyotrophic	 lateral
sclerosis	(ALS).	Furthermore,	this	curve	can	be	used	to	study	basic	excitability	properties	of	peripheral
nerves.	 In	Miller	 Fisher	 patients,	 subclinical	 limb	motor	 nerve	 dysfunction	 can	 be	 identified	with	 this
technique	 [5].	 Also,	 the	 CMAP	 scan	 displays	 great	 differences	 in	 excitability	 between	 axonal	 and
demyelinating	GBS	patients,	very	early	in	its	disease	course.
Estimating	Motor	Unit	Numbers	from	the	CMAP	Scan
The	exact	amount	of	MUs	within	the	human	muscles	is	unknown.	With	histopathological	studies	it	is	not
possible	to	count	the	number	of	MUs.	To	evaluate	changes	of	MU	number	during	disease	and	recovery,	the
number	 of	MUs	 have	 to	 be	 estimated.	 Various	MU	 number	 estimation	 (MUNE)	 techniques	 have	 been
proposed.	Each	method	has	its	own	shortcomings	regarding	reliability	and	reproducibility.	Most	methods
are	 also	 very	 time	 consuming.	 The	 paper	 of	 Bostock	 [6]	 describes	 a	 new	 technique,	 based	 upon	 the
CMAP	 scan.	 It	 is	 a	 very	 quick	method	 and	 consists	 of	 fitting	 a	 recorded	CMAP	 scan	 into	 a	 simulated
CMAP	 scan.	 The	 model	 of	 the	 simulated	 CMAP	 scans	 consists	 of	 a	 wide	 range	 of	 MUs.	 Each	 MU
contributing	to	the	scan	is	described	by	3	basic	parameters:	threshold,	amplitude	and	spread	of	threshold.
With	this	new	method,	MUNE	values	had	a	mean	absolute	error	of	7%.
As	with	all	modelling	techniques,	 this	 technique	is	based	on	simplification	of	reality.	Real	scans	do
not	necessarily	behave	like	the	idealized	simulated	scans.	An	important	simplification	of	the	model	is	the
assumption	 that	 the	 contribution	 of	 each	 MU	 to	 the	 maximum	 CMAP	 amplitude	 is	 constant.	 Another
simplification	 is	 that	 the	 spread	 of	 thresholds	 is	 assumed	 equal	 for	 all	MUs	 and	 based	 on	 findings	 in
healthy	human	MUs.	For	diseases	such	as	ALS	and	GBS,	these	spread	in	thresholds	are	unknown.	Despite
these	 simplifications,	 this	 technique	 is	very	pragmatic.	 It	 is	very	easy	 to	perform,	produces	 reasonably
accurate	MUNE	values	and	takes	only	a	few	minutes.
Motor	Unit	Number	Estimation	Using	High-Density	Surface
Electromyography
A	 more	 time-consuming,	 but	 elegant	 method	 to	 estimate	 the	 number	 of	 MUs	 is	 the	 multiple	 point
stimulation	technique	with	high-density	surface	EMG	(HDsEMG)	[7].	MUNE	is	based	upon	the	division
of	 the	maximal	CMAP	amplitude	by	 an	 estimate	of	 the	mean	MU	potential	 (MUP)	 size	 [8].	This	mean
MUP	 is	 calculated	 by	 averaging	 a	 number	 of	 individual	MUPs	 that	 have	 been	 sampled	 using	 one	 of	 a
variety	 of	 approaches.	 In	 MUNE	 with	 HDsEMG,	 the	 nerve	 is	 stimulated	 and	 the	 MU	 responses	 are
recorded	with	an	array	of	126	densely	spaced	electrodes	positioned	over	the	muscle.	Using	such	an	array
provides	spatiotemporal	profiles	(‘fingerprints’)	of	individual	MUs,	which	facilitates	the	detection	of	MU
potentials	 and	 increases	 the	 number	 of	 MUs	 that	 can	 be	 sampled	 compared	 to	 conventional	 single-
electrode	recordings	[7,9].	Hence,	this	increases	the	accuracy	of	the	MUNE.	MUNE	can	be	used	to	detect
axonal	loss,	ranging	from	mild	to	severe.	The	more	conventional	electrophysiological	methods	are	often
not	sensitive	enough	to	detect	mild	to	moderate	axonal	loss,	especially	when	reinnervation	has	occurred.
With	 this	 technique	 it	 has	 been	 demonstrated	 that	 residual	 fatigue	 after	 GBS	 is	 related	 to	 axonal	 loss
(lower	MUNEs),	while	conventional	techniques	have	failed	to	show	objective	abnormalities	[10].
Motor	Unit	Tracking	with	High-Density	Surface	EMG
Most	neuromuscular	disorders	affect	MUs.	This	explains	the	diagnostic	relevance	of	electrophysiological
tests	such	as	needle	EMG	and	NCS.	A	disadvantage	of	these	conventional	electrophysiological	techniques
is	that	for	the	most	part	they	rely	on	samples	of	MUs.	Comparison	of	properties	of	MU	samples	obtained
in	 various	 stages	 of	 a	 disease	 yield	 only	 indirect	 evidence	 of	 changes	 occurring	 in	 individual	 MUs.
Following	individual	MUs	over	time	(tracking)	can	overcome	this	problem	and	provides	insight	into	the
functional	 and	morphological	 properties	 of	 these	MUs.	 It	 allows	 investigation	 of	 how	 these	MUs	 are
influenced	over	time	by	neuromuscular	disorders	or	treatment.
Similar	to	the	MUNE	technique	described	in	the	paragraph	above,	MU	tracking	uses	an	array	of	126
densely	spaced	electrodes	positioned	over	 the	muscle	 [11].	Since	each	MU	has	a	distinct	 ‘fingerprint’,
this	allows	for	detection	of	these	individual	MUs	in	different	sessions,	which	are	months	or	even	years
apart.	To	‘track’	MUs	and	identify	the	same	MU	in	different	sessions,	it	is	essential	that	the	high-density
electrodes	 are	 placed	 in	 the	 same	 position.	 To	 adjust	 for	 potential	 translational	 and	 rotational
displacements,	 automated	 corrections	 are	 possible	 and	 are	 described	 in	 a	 paper	 by	 Gligorijević	 and
colleagues	[12].	The	development	of	this	technique	is	an	example	of	how	collaboration	between	various
fields	(doctors,	physiologists	and	engineers)	can	lead	to	new	techniques.
Electrophysiological	Signs	of	Permanent	Axonal	Loss	in	a	Follow-Up
Study	of	Patients	with	Guillain-Barré	Syndrome
Permanent	 axonal	 loss	 is	 possibly	 responsible	 for	 long-term	motor	 impairment	 in	 various	GBS	 forms
[13].	Motor	axonal	loss	is	often	compensated	by	reinnervation	and	is	hard	to	identify	with	conventional
electrophysiological	 techniques.	 The	 macroelectromyography	 (macro-EMG)	 signal	 can,	 in	 contrast	 to
conventional	EMG,	be	used	as	a	measure	of	the	MU	size	including	the	number	of	fibres	[14].	Thus,	it	can
evaluate	reinnervation.	In	macro-EMG,	the	recording	electrode	is	the	cannula	of	a	modified	single	fibre
electromyography	 electrode.	 By	 means	 of	 spike-triggered	 averaging,	 the	 contribution	 from	 all	 muscle
fibres	in	a	MU	is	extracted.	The	resulting	signal	reflects	the	number	and	size	of	muscle	fibres	in	one	MU
and	is	called	macro	MU	potential	(macro-MUP).	In	the	current	paper,	[13]	it	was	shown	that	the	macro-
MUP	 amplitudes	 of	 GBS	 patients	 were	 clearly	 larger	 compared	 to	 healthy	 controls.	 Furthermore,	 the
macro-MUP	 amplitudes	were	 also	more	 increased	 in	GBS	 patients	with	 a	 residual	 neuropathy	 than	 in
those	without.	With	this	technique,	reinnervation	can	be	objectified	and	quantified.
Triple-Stimulation	Technique	Improves	the	Diagnosis	of	Chronic
Inflammatory	Demyelinating	Polyradiculoneuropathy
In	demyelinating	neuropathies,	conventional	NCS	can	be	consistent	with	axonal	neuropathies	and	can	lead
to	 the	 misdiagnosis	 of	 a	 potentially	 treatable	 neuropathy.	 The	 electrodiagnostic	 features	 of	 acquired
demyelination,	such	as	the	presence	of	conduction	blocks	and	focal	temporal	dispersion,	are	sometimes
not	detected	due	to	the	occasionally	very	proximal	location	of	these	features.	The	transcranial	magnetic
stimulation	 (TMS)	 technique,	 using	 collision	 (the	 triple	 stimulation	 technique	 (TST))	 is	 a	 quantitative
method	 for	measuring	 the	 fraction	 of	 spinal	motor	 neurons	 that	 can	 be	 brought	 to	 discharge.	 In	 healthy
persons	this	approaches	100%.	The	presence	of	very	proximal	conduction	blocks,	between	root	entry	and
Erb’s	point,	can	be	assessed	with	 the	TST.	Attarian	and	colleagues	demonstrate	 the	additional	value	of
using	TST	in	the	diagnosis	of	chronic	inflammatory	demyelinating	polyradiculoneuropathy	(CIDP)	[15].
In	 4	 of	 the	 14	 CIDP	 patients	 they	 studied,	 conventional	 NCS	 showed	 an	 ‘axonal-like’	 CIDP,	 without
evidence	of	demyelination.	Sural	nerve	biopsy	in	these	4	patients	showed	demyelination.	With	TST,	very
proximal	conduction	blocks	 in	all	4	patients	were	detected.	Also,	 in	studies	of	patients	with	multifocal
motor	neuropathy,	one-third	of	the	conduction	blocks	were	located	in	the	very	proximal	nerve	segments,
which	cannot	be	accessed	by	conventional	NCS.	GBS	is	sometimes	difficult	to	diagnose,	especially	the
paraparetic	 form.	 In	 these	cases	 finding	demyelination	might	 aid	 the	diagnosis.	TST	might	be	useful	 to
detect	proximal	demyelination.
Cauda	Equina	Conduction	Time	in	Guillain-Barré	Syndrome
As	 described	 in	 the	 paragraph	 above,	 proximal	 nerve	 segments	 are	 not	 easily	 accessible	 with
conventional	 electrophysiological	 techniques.	 This	 is	 especially	 the	 case	 for	 the	 nerves	 in	 the	 lower
extremities.	The	most	proximal	stimulation	site	for	the	most	common	investigated	nerves	in	the	legs,	i.e.
the	peroneal	and	tibial	nerve,	is	the	knee	pit.	In	the	early	phase	of	GBS,	the	disappearance	of	f-waves	is
frequently	the	only	abnormal	finding	with	conventional	NCS.	However,	the	f-wave	technique	has	no	clear
localizing	value.	Matsumoto	and	colleagues	describe	a	method	to	measure	 the	cauda	equina	conduction
time	 (CECT)	 [16].	With	magnetic	 stimulation,	 both	 the	distal	 and	proximal	 cauda	 could	be	 stimulated.
Reproducible	CMAPs	were	recorded.	By	subtracting	the	CMAP	latency	to	S1-level	stimulation	from	that
to	L1-level	stimulation,	the	CECT	could	be	obtained.	Sixteen	GBS	patients	(9	AIDP	and	7	AMAN)	were
examined	with	conventional	NCS	and	CECT.	All	axonal	patients	had	a	normal	CECT.	Ninety	percent	of
the	 demyelinating	patients	 had	 abnormal	CECT,	 even	when	 the	 distal	 conduction	velocity	was	 normal.
When	there	is	a	difficulty	in	diagnosing	GBS,	especially	in	patients	with	predominantly	leg	symptoms	(the
paraparetic	form),	this	technique	may	be	useful.
Contact	Heat	Evoked	Potentials	as	a	Useful	Means	in	Patients	with
Guillain-Barré	Syndrome
Most	conventional	and	nonconventional	electrophysiological	techniques	investigate	the	large	myelinated
nerve	fibres.	Zhang	and	colleagues	describe	a	technique	that	detects	impairment	of	the	small	myelinated
fibres	[17].	With	contact	heat	evoked	potentials	(CHEPs)	they	studied	the	nociceptive	pathway	in	GBS.
Short,	painful	heat	stimuli	were	applied	on	the	leg	and	waist,	and	cortical	responses	were	recorded.	The
cortical	 responses	 in	 GBS	 patients	 had	 longer	 latencies	 and	 lower	 amplitudes	 than	 those	 in	 healthy
control	subjects,	 indicating	 that	 the	acute	neuropathy	not	only	 involves	 the	 larger	myelinated	fibres,	but
also	small	nociceptive	fibres.
Discussion
Our	understanding	of	nerve	physiology	has	greatly	expanded	since	Galvani’s	time,	especially	in	the	last
30	 years.	 New	 neurophysiological	 techniques	 have	 been	 developed	 and	 are	 now	 being	 used	 in	 daily
practice.	 Yet,	 despite	 this	 progress,	 the	 underlying	 pathology	 in	 GBS	 is	 still	 not	 fully	 known.	 More
advanced	electrophysiological	techniques,	focussing	on	other	properties	of	the	peripheral	nerve	than	with
conventional	techniques,	might	help	elucidate	the	continuing	enigma.
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The	Development	of	Nerve	Imaging	in	GBS	and
Inflammatory	Neuropathies
Guido	Stoll
Introduction
The	Guillain-Barré	(-Strohl)	syndrome	(GBS)	represents	an	acute	inflammatory	polyradiculoneuropathy.
It	is	widely	held	that	immune	cells	such	as	T-cells	and	macrophages	as	well	as	autoantibodies,	activated
or	 produced	 during	 host	 defence	 against	 infections,	 erroneously	 attack	 peripheral	 myelin	 or	 axonal
components	with	 ensuing	 demyelination	 and/or	 axonal	 injury.	GBS	 encompasses	 a	 number	 of	 different
clinical	manifestations	with	 a	predominant	demyelinating	or	 axonal	phenotype.	Electroneurography	and
electromyography	 are	 the	 classical	means	 of	 assessing	 peripheral	 nerve	 function	 and	 allow	distinction
between	demyelinating	and	axonal	nerve	damage	in	GBS.	By	electrophysiology,	however,	one	can	only
assess	nerve	dysfunction	and	grossly	define	 lesion	patterns,	because	morphological	details	are	 lacking.
The	diagnostic	workup	of	disorders	of	the	central	nervous	system	regularly	employs	imaging	techniques,
in	particular	magnetic	 resonance	 imaging	(MRI),	while	 in	peripheral	nerve	disorders	 imaging	has	been
restricted	 to	 conditions	 in	which	 a	mass	 lesion	 compressing	 nerves	 or	 roots	was	 expected	 on	 clinical
grounds.	This	 restraint	approach	has	changed.	 In	1993,	Filler	and	colleagues	presented	 the	 first	 ‘image
neurogram’	 showing	 a	 human	 nerve	 graft	 by	 commercial	 MRI	 [1].	 They	 coined	 the	 term	 ‘magnetic
resonance	 neurography’	 (MRN).	During	 the	 last	 20	 years	 peripheral	 nerve	 imaging	 developed	 into	 an
innovative	 scientific	 subspecialty	 with	 growing	 clinical	 impact.	 In	 this	 chapter	 I	 review	 advances	 in
depicting	nerve	damage	using	MRI	with	 focus	on	 inflammatory	neuropathies,	 and	provide	 insights	 into
current	experimental	approaches	to	directly	visualize	nerve	inflammation.
Magnetic	Resonance	Neurography:	Clinical	Applications
MRN	can	be	performed	with	routine	1.5	or	3T	MR	machines.	It	relies	on	the	application	of	special	MR
pulse	sequences	 to	distinguish	peripheral	nerves	 from	 the	surrounding	soft	 tissue.	Technical	details	are
described	 elsewhere	 [1,2].	 Briefly,	 fat-saturated,	 heavily	 T2-w	 (T2*-w)	 sequences	 are	 applied	 for
detection	of	pathological	signal	alterations	in	nerves.	In	addition,	unenhanced	T1-w	MRI	scans	are	taken
for	 anatomical	 orientation,	 and,	 finally,	 gadolinium	 (Gd)-DTPA-enhanced	 and	 fat-suppressed	 T1-w
images	are	required	 to	distinguish	pathological	nerve	signals	from	vessels	which	also	appear	bright	on
T2-w	sequences.	For	correct	interpretation	of	the	imaging	data	it	is	mandatory	to	apply	these	sequences
with	 the	 same	 slice	 thickness	 and	 anatomical	 orientation.	MRN	mainly	 exploits	 alterations	 of	 the	 T2-
signal	of	peripheral	nerves	upon	injury.	Intact	nerves	cannot	be	discriminated	on	T2-w	MRI	because	they
are	 isointense	 to	 the	 surrounding	 tissue.	 The	 intrinsic	 nerve	 signal,	 however,	 profoundly	 changes	 upon
nerve	injury	[1,2]:	nerve	segments	with	axonal	damage	undergoing	Wallerian	degeneration	(WD)	become
hyperintense	 on	 T2-W	 MRI,	 and	 this	 hyperintensity	 disappears	 after	 nerve	 regeneration.	 T2-
hyperintensities,	 however,	 are	 not	 specific	 for	 axonal	 injury.	 Nerves	 undergoing	 demyelination	 also
display	 T2-signal	 increases	 which,	 in	 contrast	 to	 nerves	 undergoing	WD,	 are	 patchy	 and	 focal.	 Thus,
MRN	 can	 disclose	 areas	 of	 axonal	 damage	 as	well	 as	 demyelination.	As	 a	 note	 of	 caution,	 the	 nerve
signal	 depends	 on	 the	 orientation	 of	 the	 nerve	 within	 the	 magnetic	 field,	 which	 may	 also	 lead	 to	 a
hyperintense	signal	of	normal	nerves	at	a	critical	orientation	of	55°,	called	the	‘magic	angle	effect’.	This
is	relevant	when	assessing	the	integrity	of	the	cervicobrachial	and	lumbosacral	plexus	often	involved	in
inflammatory	neuropathies.
The	 diagnosis	 of	 inflammatory	 neuropathies	 such	 as	 GBS	 and	 chronic	 inflammatory	 demyelinating
polyneuropathy	 (CIDP)	 is	 usually	 based	 on	 the	 history	 of	 onset	 and	 course,	 clinical	 evaluation	 of
neurological	 signs	 and	 characteristic	 electrophysiological	 findings	 which	 in	 typical	 cases	 reveal
conduction	block	and/or	slowing	of	nerve	conduction.	Thus,	imaging	is	not	required	for	the	diagnosis,	but
may	 be	 extremely	 useful	 in	 the	 diagnostic	 workup	 of	 patients	 with	 suspected	 focal	 mononeuritis	 (see
below).	MRI	in	GBS	patients	revealed	thickening	and	Gd-DTPA-enhancement	of	spinal	nerve	roots	and
the	 cauda	 equine.	 Gorson	 and	 colleagues	 [3]	 prospectively	 obtained	 Gd-DTPA-enhanced	 lumbosacral
spine	MRIs	in	24	consecutive	patients	with	acute	GBS	at	an	average	of	13	days	after	onset.	Twenty	of	24
patients	had	some	degree	of	cauda	equine	nerve	root	enhancement,	indicating	a	disturbance	of	the	blood-
nerve	barrier.	Patients	with	prominent	nerve-root	enhancement	had	greater	proximal	weakness	and	were
more	 likely	 to	have	back	or	 leg	pain	and	 lower	functional	GBS	scores	 than	 those	with	mild	or	no	root
enhancement	 [3].	Other	 studies	 showed	 that	mostly	 anterior	 spinal	 nerve	 roots	were	 affected,	 and	 that
imaging	abnormalities	regressed	upon	clinical	recovery.	Similarly	to	GBS	patients,	CIDP	patients	show
symmetrical	 nerve-root	 abnormalities	 on	 MRI,	 such	 as	 enlargement,	 T2-hyperintensities	 and	 contrast
enhancement	(Figure	30.1a).	An	MRI	is	sometimes	required	in	GBS	patients	to	exclude	a	spinal	cord	or
lumbar-spinal	mass	lesion,	especially	in	cases	with	the	rare	paraplegic	variant	(Figure	30.1b).
In	contrast,	focal	nerve	lesions	often	cause	difficulties	in	the	diagnostic	workup	and	may	lead	to	the
suspicion	of	a	peripheral	nerve	tumour	[4].	An	MRN	may	disclose	additional	lesions	within	other	nerves
and	thereby	support	the	diagnosis	of	a	multifocal	inflammatory	neuropathy.	In	2000,	Van	den	Berg-Vos	and
colleagues	coined	the	term	‘multifocal	inflammatory	demyelinating	neuropathy’	based	on	MRN	studies	in
patients	suffering	from	a	focal	neuropathy	of	unknown	cause	[5].	Areas	with	a	pathological	MRI	signal	in
these	 patients	 underwent	 a	 fascicular	 biopsy	 which	 revealed	 focal	 inflammation	 and	 nerve	 lesions
responded	 to	 anti-inflammatory	 treatments.	 Thus,	 from	 a	 clinical	 standpoint	 MRI	 could	 dramatically
improve	the	diagnostic	yield	if	we	were	able	to	(A)	specifically	identify	inflammatory	foci	(see	below),
and	 (B)	 cover	 larger	 parts	 of	 the	 PNS	 than	 with	 conventional	 MRI.	 In	 2009,	 a	 technique	 termed
‘diffusion-weighted	 whole	 body	 imaging	 with	 suppression	 of	 body	 signal’	 (DWIBS)	 was	 introduced,
which	 allows	 selective	 visualization	 of	 peripheral	 nerves	 over	 long	 trajectories.	 This	 reconstruction
magnetic	neurography	was	recently	applied	to	CIDP	patients	in	a	proof-of-concept	study,	and	disclosed
widespread	symmetric	and	root-dominant	nerve	hypertrophy	[6].	Interestingly,	patients	with	the	multifocal
acquired	 demyelinating	 sensory	 and	motor	 (MADSAM)	 variant	 of	CIDP	 displayed	multifocal	 fusiform
hypertrophy	 only	 in	 some	 nerve	 trunks.	 This	 novel	 imaging	 technique	 may	 dramatically	 improve	 our
diagnostic	yield	in	inflammatory	neuropathies,	similar	to	another	emerging	technology,	nerve	ultrasound.
Figure	 30.1	 	 (A)	 MRI	 abnormalities	 in	 a	 CIDP	 patient.	 Note	 hyperintense	 (white),	 swollen	 nerve	 roots	 and	 plexus	 cervico-
brachialis	 fibres	 (arrows)	 on	 T2*-w	 MRI.	 (B)	 Differential	 diagnosis	 of	 GBS:	 T2-w	 spinal	 MRI	 scan	 of	 a	 bacterial	 abscess
compressing	lumbar	spinal	nerve	fibres	(arrows)	mimicking	“paraplegic”	GBS.	The	patient	had	an	increased	CSF	cell	count	of
around	900,	predominantly	neutrophils.
Visualization	of	Nerve	Inflammation	and	Breakdown	of	the	Blood-
Nerve	Barrier
Nerve	 signal	 alterations	 as	 revealed	 by	 conventional	 MRN	 are	 nonspecific,	 and	 the	 extractable
information	is	limited	to	the	distribution	of	nerve	lesions.	In	both	GBS	and	CIDP,	the	pathophysiological
hallmark	is	macrophage-mediated	demyelination	or,	less	frequently,	axonal	injury,	but	inflammation	itself
is	 not	 visible	 on	 conventional	 MRI.	 There	 is	 good	 evidence	 in	 inflammatory	 neuropathies	 that
macrophages	are	attracted	from	the	circulation	to	peripheral	nerves	and	nerve	roots	by	locally	released
chemokines,	and	upon	nerve	infiltration	attack	their	targets	by	binding	to	the	Fc-receptors	of	pathological
autoantibodies	deposited	at	myelin	sheaths	or	paranodal	axonal	sites	[7].
Over	the	last	15	years	there	have	been	intensive	attempts	to	directly	visualize	inflammation	in	living
organisms.	 This	was	made	 possible	 by	 the	 availability	 of	 novel,	 at	 present	 mainly	 experimental	MR-
contrast	agents	[2,8].	Currently,	there	are	2	MR-based	approaches	that	hold	promise	for	clinical	use	in	the
future,	 iron	oxide	particle-enhanced	T1-and	T2-w	MRI,	and	perfluorocarbon	(PFC)	emulsion-enhanced
1H/19F	MR	spectroscopy	(MRS).	Iron	oxide	particles	used	for	MRI	as	contrast	agents	consist	of	an	iron
oxide	core	of	4–8nm	 in	 superparamagnetic	 iron	oxide	 (SPIO)	particles	or	 a	 smaller	 core	 in	ultrasmall
superparamagnetic	 iron	 oxide	 (USPIO)	 particles,	 both	 of	 which	 are	 surrounded	 by	 a	 variable	 coating
affecting	biological	properties	such	as	half-life	within	the	blood.	In	tissues,	iron	oxide	particles	shorten
both	 the	 T1	 and	 T2	 relaxation	 time.	Mostly,	 SPIO	 particles	 have	 been	 used	 to	 study	 inflammation	 in
experimental	animals	 in	 the	PNS.	When	SPIO	particles	are	 injected	systemically	 into	 the	circulation	of
mice	 or	 rats,	 they	 are	 avidly	 phagocytosed	 by	monocytes/macrophages,	 before	 free	SPIO	particles	 are
cleared	 by	 the	 reticuloendothelial	 system.	 Since	 this	 occurs	 rapidly,	 within	 30	 to	 60	 minutes,	 most
remaining	 SPIO	 particles	 in	 the	 circulation	 are	 cell-	 (macrophage)	 bound	 thereafter,	 and	 blood	 pool
effects	can	be	neglected.	This	is	in	contrast	to	free	USPIO	particles	which	have	an	extended	half-life	of
around	 24	 hours.	 When	 SPIO-laden	 macrophages	 are	 attracted	 to	 tissues	 during	 inflammation,	 they
become	visible	due	to	a	signal	loss,	appearing	as	hypointensity	on	T2	and	T2*-w	MR	images.
In	a	 seminal	MRI	study,	Bendszus	and	Stoll	 injected	SPIO	particles	 into	 rats	 at	various	 time	points
after	 sciatic	 nerve	 crush	 and	 could	 follow	 macrophage	 infiltration	 in	 vivo	 [9].	 Blood-derived
macrophages	first	 infiltrated	 the	 lesion	site	 (figure	30.2).	Thereafter,	 the	entire	distal	 stump	undergoing
WD	 became	 hypointense	 due	 to	 continuous	 accumulation	 of	 SPIO-laden	 macrophages.	 This	 process
abruptly	ceased	around	day	10	after	nerve	crush.	Importantly,	macrophage	recruitment	as	shown	by	SPIO-
enhanced	MRI	strongly	corresponded	to	the	well-known	expression	pattern	of	the	chemokine	macrophage
chemoattractant	protein-1	(MCP-1)	produced	by	Schwann	cells	during	WD.	Delayed	application	of	SPIO
particles	beyond	day	10	after	nerve	crush	no	longer	led	to	signal	loss	despite	the	persistence	of	numerous
ED-1	positive	macrophages	in	the	degenerating	nerve	segment	(see	below).	In	the	next	step,	we	applied
this	technology	to	rats	in	adoptive	transfer	experimental	autoimmune	neuritis	(AT-EAN),	an	animal	model
for	 human	 GBS.	 SPIO-enhanced	 MRI	 revealed	 focal	 signal	 loss	 of	 the	 cauda	 equine	 indicating
macrophage	infiltration	already	at	day	3	after	T-cell	transfer,	which	was	at	a	preclinical	stage.	Signal	loss
had	already	peaked	at	day	4	when	first	clinical	signs	had	developed,	but	rapidly	ceased	thereafter	at	the
peak	of	clinical	EAN.	Similar	to	the	behaviour	of	‘nerve-based’	macrophages	in	late	WD,	spinal	nerves
at	a	more	advanced	stage	of	AT-EAN,	at	days	6	and	beyond,	displayed	no	more	signal	loss	upon	systemic
application	of	SPIO	particles	despite	histological	evidence	of	dense	macrophage	infiltrates.
Two	major	conclusions	emerged	from	these	studies:	(A)	SPIO-enhanced	peripheral	nerve	MRI	covers
active	phases	of	macrophage	infiltration,	but	does	not	depict	the	proportion	of	the	already	‘nerve-bound’
macrophages	that	entered	from	the	circulation	prior	to	contrast	application,	and	(B)	macrophage	invasion
in	both	WD	and	EAN	occurs	during	a	narrow	time	window.	Thus,	it	is	feasible	to	selectively	visualize	the
recruitment	 of	 immune	 cells,	 mainly	 macrophages,	 to	 the	 PNS	 by	 SPIO-enhanced	MRI.	 In	 contrast	 to
monocytes/macrophages,	spontaneous	uptake	of	SPIO	or	USPIO	particles	by	other	immune	cells	such	as
T-cells	is	limited,	but	they	can	be	preloaded	in	vitro	with	the	aid	of	transfection	agents,	re-injected	into
the	circulation,	and	then	followed	in	vivo	even	in	small	numbers	by	T2-w	and	T2*-w	MRI	when	entering
tissues	during	inflammation.	Iron-contrast-based	‘inflammation	imaging’	is	very	sensitive,	but	hampered
by	 some	 specificity	 issues:	 (A)	 small	 local	 haemorrhages	 can	 also	 cause	 signal	 loss	 and	 erroneously
indicate	 ‘inflammation’,	and	(B)	postphagocytic	macrophages	naturally	contain	significant	 intrinsic	 iron
deposits	which	have	to	be	taken	into	account	at	ultra-high	field	strengths.
Figure	30.2		Imaging	of	macrophage	infiltration	in	rats	during	adoptive	transfer	experimental	autoimmune	neuritis	(AT-EAN),	an
animal	model	of	GBS,	by	SPIO-enhanced	MRI	(technique	see	text).	(A-C).	Axial	T2*-w	MRI	scans	of	the	cauda	equine	in	a	normal
rat	(A),	at	3	days	(B),	and	4	days	(C)	after	T-cell	transfer.	All	animals	received	SPIO-particles	intravenously	24	hours	before	MRI.
While	the	cauda	equine	still	appears	isointense	in	normal	rats	(A),	signal	loss	due	to	infiltration	of	iron	(SPIO)-laden	macrophages
into	spinal	nerves	occurs	focally	in	at	day	3	prior	to	clinical	disease	(B)	(Fe	=	iron,	arrow),	and	culminates	in	complete	signal	loss
at	day	4	(C,	arrow).	(D)	Histological	examination	of	spinal	nerves	stained	by	Prussian	blue	confirms	presence	of	iron-laden	cells
(black	 dots)	 representing	 infiltrating	 blood-derived	 macrophages.	 Adapted	 with	 permission	 from	 Stoll	 et	 al.,	 Journal	 of
Neuroimmunology	149	(2004)	142–146.
Recently,	19F-MRI	 emerged	 as	 a	 novel	 imaging	modality	 for	 inflammation	 [8].	 19F	markers	 such	 as
PFC	compounds	provide	a	unique	signal	in	vivo	due	to	the	negligible	19F	background	signal	of	the	body.
Similar	 to	 SPIO/USPIO	 particles,	 PFC	 nanoparticles	 are	 preferentially	 phagocytosed	 by
monocytes/macrophages	in	the	circulation	and,	thus,	the	fluorine	signal	in	inflamed	organs	is	mainly	due
to	macrophage	infiltration	carrying	intracellular	PFC	nanoparticles.	In	addition	to	19F	images,	1H	images
are	 acquired	 by	 MRS,	 which	 aid	 in	 placing	 the	 PFC-labelled	 cells	 into	 their	 anatomical	 context.
Currently,	 there	 is	 only	 one	 study	 on	 1H/19F	 MRS	 in	 the	 PNS.	 In	 a	 pilot	 study,	 we	 induced	 focal
demyelination	in	sciatic	nerves	of	rats	by	the	chemical	lysolecithin.	At	a	certain	concentration	lysolecithin
dissolves	 myelin	 sheaths	 while	 sparing	 the	 axons,	 and	 thereby	 induces	 a	 robust	 local	 inflammatory
reaction	 with	 recruitment	 of	 hematogenous	 macrophages.	 We	 were	 able	 to	 visualize	 this	 macrophage
infiltration	by	1H/19F	MRS	in	the	rat,	but	compared	to	other	organ	systems	like	the	heart	and	lung	19F–MRI
of	neuroinflammation	is	still	challenging,	mainly	because	of	sensitivity	issues.
The	central	nervous	system	and	peripheral	nerves	are	secluded	from	the	circulation	by	the	blood-brain
barrier	(BBB)	or	blood	nerve	barrier	(BNB),	respectively.	Gadolinium-DTPA	is	a	approved	MR	contrast
agent	clinically	used	for	detection	of	disturbances	of	the	BBB	and	BNB	since	it	does	not	pass	the	intact
barriers.	 Although	 the	 BNB	 becomes	 leaky	 during	WD,	 patients	 and	 experimental	 animals	 with	 acute
axonal	nerve	 lesions	often	do	not	 show	Gd-DTPA-enhancement.	 In	contrast,	 as	described	above,	nerve
roots	from	GBS	and	CIDP	patients	often	show	Gd-DTPA-enhancement.	Thus,	it	appears	that	Gd-DTPA-
enhancement	 can	 be	 taken	 as	 a	 biomarker	 for	 inflammatory	 activity	 in	 the	 nervous	 system	 as	 widely
anticipated	 in	multiple	sclerosis	 (MS)	patients.	However,	 there	 is	strong	evidence	against	 this	common
assumption.	Experimental	studies	in	experimental	autoimmune	encephalomyelitis,	an	animal	model	of	MS,
and	patients	with	MS	which	combined	Gd-DTPA-	or	Gadofluorine-	(Gf,	an	experimental	agent)	enhanced
MRI	with	SPIO/USPIO-enhanced	MRI	revealed	that	areas	with	breakdown	of	the	BBB	(leakage	of	Gd-
DTPA	or	Gf)	and	areas	with	acute	macrophage	 infiltration	 (iron-particle	 induced	hypointensities)	often
did	not	correspond.	It	appeared	that	leakage	of	the	BBB/BNB	for	soluble	factors	such	as	contrast	agents,
and	leukocyte	infiltration	were	timely	and	locally	discordant	[10].	This	notion	is	supported	by	numerous
histological	 studies	 showing	 that	 immune	 cells	 mainly	 enter	 the	 nervous	 system	 by	 trans-endothelial
migration,	 and	 not	 through	 the	 extracellular	 space	 due	 to	 destruction	 of	 tight	 junctions.	 Taken	 together,
these	studies	emphasize	the	necessity	to	develop	specific	cellular	MR	contrast	agents	for	clinical	use	that
allow	us	to	monitor	inflammatory	activity	directly.	A	breakthrough	in	this	field	could	help	to	improve	the
prognosis	 of	 GBS	 and	 CIDP	 patients	 by	 tailoring	 and	 monitoring	 stage-specific	 anti-inflammatory
treatment	strategies	based	on	cellular	MRI.
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The	Schwann	Cell	Biology	Underlying	GBS
P.J.	Armati	and	E.K.	Mathey
Introduction
Schwann	 cells,	 like	 the	 Guillain-Barré	 syndrome,	 have	 been	 victims	 of	 the	 lumpers	 and	 splitters
phenomenon—the	 lumpers	proclaim	 ‘A	Schwann	 cell	 is	 a	Schwann	 cell	 is	 a	Schwann	 cell’,	while	 the
enlightened	such	as	Emily,	myself	and	all	the	other	Schwann	cell	aficionados,	consider	it	to	be	a	wonder
of	 the	cellular	world,	complex,	multifunctional	and	multiphenotypic.	And	so	 this	cell	has	had	an	 image
problem,	 apart	 from	 the	wonderful	moment	 in	 1838,	when	 Schwann	 one	 evening	 after	 dinner	with	 the
botanist	Schleiden	went	to	Schwann’s	laboratory,	where	he	realised	and	described	for	the	first	time	that
animals	were	composed	of	cells—just	as	Schleiden	had	described	for	plants.	He	went	on	in	the	1840s	to
define	and	describe	cells	aligned	along	the	nerve	fibres	which	bear	his	name	to	this	day.	However,	it	was
Ranvier	who	was	one	of	the	first	to	acknowledge	that	Schwann	cells	are	masters	of	multitasking	and	can
do	 more	 than	 merely	 myelinate.	 In	 1878	 Ranvier	 mooted	 that	 the	 perisynaptic	 cells	 at	 the
neuromuscular/tripartite	synapse	were	in	fact	Schwann	cells	and	not	part	of	the	muscle	fibres	[1].
So	now	to	the	next	century	and	the	defining	of	GBS	in	its	many	subtypes	via	a	long	and	winding	road	to
the	 ‘Rise	 of	 the	 Schwannopathies’.	 The	 light	 and	 electron	 microscope	 study	 by	 Wiśniewski,	 Terry,
Whitaker,	Cook	and	Dowling	in	1969	of	the	‘spinal	nerve	roots,	spinal	ganglia	and	sciatic	nerve’	from	a
patient	 with	 GBS	 (then	 called	 Landry-Guillain-Barré	 syndrome	 but	 now,	 like	 Strohl,	 Landry	 has
disappeared)	 [2]	 was	 pivotal.	While	 the	 light	 microscopy	 showed	 no	 CNS	 abnormalities,	 in	 the	 EM
~15%	 of	 the	 sciatic	 nerve	 showed	 no	 evidence	 of	 axonal	 degeneration	 and	 for	 the	 first	 time	 clearly
demonstrated	severely	damaged	myelin	lamellae,	sometimes	with	adjacent	normal	myelin	lamellae.	They
go	on	to	describe	macrophage	infiltration	through	the	Schwann	cell	basal	lamina	and	invasion	of	the	outer
mesaxon	 of	 the	 damaged	 Schwann	 cell.	 So	 now,	 for	 maybe	 the	 first	 time,	 comes	 recognition	 that	 the
compact	 myelin-forming	 Schwann	 cells	 are	 more	 than	 their	 compacted	 spiralling	 lamellae;	 that	 the
Schwann	cell	itself	can	be	the	primary	target	pre-empting	the	rise	of	the	Schwannopathies.
It	is	interesting	that	John	Prineas	in	his	perspicacious	GBS	paper	of	1981	acknowledges	that	of	GBS
“the	 precise	 mechanism	 that	 leads	 macrophages	 to	 seek	 out	 and	 amputate	 a	 specialized	 region	 of	 the
Schwann	 cell	 plasma	membrane	 remains	 unexplained”	 [3].	 It’s	 rather	 scary	 to	 think	 about	 ‘amputated’
Schwann	 cells	when	we	 now	 recognise	 their	 pivotal	 role	 in	maintaining	 normal	 neural	 function	 of	 the
peripheral	nerve.	They	are	no	longer	considered	‘insulation’	for	the	neuron	but	complex	multifaceted	cells
that	contribute	to	the	functioning	of	the	peripheral	nervous	system	(PNS)	in	a	variety	of	ways.
The	Rise	of	Schwannopathies
The	complexity	of	the	Schwann	cell	was	unveiled	in	the	riveting	lecture	by	Steve	Scherer	in	2001	at	the
Innsbruck	 Peripheral	 Nerve	 Society	 meeting,	 where	 he	 presented	 the	 drawing	 of	 the	 myelin-forming
Schwann	cell	in	all	its	architectural	wonder,	at	the	nodes	of	Ranvier,	the	uncompacted	paranodal	swirls
with	 their	 microvilli	 stretching	 out	 to	 the	 axolemma,	 the	 Nav	 channels	 clustering	 together,	 the
juxtaparanode	 harbouring	 the	K	 channels.	 These	 show	 so	 clearly	 the	 importance	 of	 the	 organisational
basis	of	the	Schwann	cell/axonal	relationship	and	the	importance	of	maintaining	this	channel	organisation
for	salutatory	conduction	(see	Figure	31.1)	[4].	This	really	nailed	the	concept	that	diseases	such	as	GBS
and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 (CIDP)	 are	 diverse	 syndromes,	 subsets	 of
specific	effects	on	not	only	 the	neurons	but	 the	conversation	between	 the	axon,	cell	body	and	Schwann
cell	 compartments.	 Although	 the	 focus	 of	 neuropathologists	 and	 electrophysiologists	 has	 been	 on	 the
damaged	 compact	 myelin	 regions	 of	 the	 Schwann	 cell	 and	 the	 associated	 significant	 slowing	 of
conduction,	 it	 is	 also	 crucial	 to	 consider	 how	 maintenance	 of	 the	 axon/Schwann	 cell	 relationship
underpins	 normal	 conduction.	 Because	 of	 the	 complex	 organisation	 of	 the	 node	 of	 Ranvier	 with	 its
Schwann	cell	microvilli	and	tightly	organised	suites	of	molecules	associated	with	the	node,	paranode	and
juxtaparanode,	the	role	of	the	Schwann	cell	in	all	its	forms	and	architecture	is	being	examined	for	clues	as
to	 subtypes	 of	 GBS;	 especially	 the	 demyelinating	 subtype,	 acute	 inflammatory	 demyelinating
polyneuropathy	(AIDP).
That	 said,	 although	AIDP	may	 be	 considered	 to	 be	 a	 demyelinating	 disease,	 it	 also	 affects	 the	 so-
called	unmyelinated	fibres	such	as	the	autonomic	postganglionic	axons.	As	Jack	Griffin	has	pointed	out,
approximately	80%	of	peripheral	nerve	is	made	up	of	unmyelinated	axons	[5].	However,	even	these	axons
have	 a	 complex	 relationship	 with	 their	 ensheathing	 nonmyelinating	 Schwann	 cells,	 a	 fact	 that	 is	 often
overlooked	in	many	GBS-related	publications.	But	this	is	still	not	their	full	story,	as	there	are	a	diversity
of	Schwann	cell	phenotypes—satellite	cells,	nonmyelin-forming	Schwann	cells,	myelin-forming	Schwann
cells	and	perisynaptic	Schwann	cells—all	with	the	potential	to	contribute	to	the	pathogenesis	of	GBS.
The	Schwann	Cell	as	a	Target	in	AIDP/GBS
Due	to	the	prominent	demyelination	observed	in	nerve	biopsies	of	patients	with	AIDP,	myelin	proteins	of
the	compact	myelin	region	have	long	been	regarded	as	the	most	likely	targets	of	an	autoimmune	attack	in
the	demyelinating	 form	of	GBS.	However,	 the	major	myelin	proteins	have	not	proven	 to	be	 significant
targets.	Hafer-Macko	and	colleagues	[6]	examined	3	autopsies	taken	3,	8	and	9	days	after	disease	onset	in
order	 to	 determine	 the	 role	 of	 complement	 in	 the	 pathogenesis	 of	 demyelination	 in	 these	 patients.
Components	of	the	complement	pathway,	including	the	activation	marker	C3d	and	the	terminal	activation
complex	C5b-9,	were	found	deposited	in	the	outer	surface	of	the	abaxonal	Schwann	cell	plasmolemma.
This	finding	led	the	authors	to	speculate	that	the	target	of	the	immune	attack	was	an	antigen	located	in	this
region	of	the	Schwann	cell	and	not	in	the	compact	myelin.	These	AIDP	autopsies	were	part	of	a	series	of
14;	the	other	11	autopsies	had	an	axonal	subtype	of	GBS	[7],	where	there	was	evidence	of	an	antibody-
mediated	attack	on	the	axolemma	rather	than	on	the	Schwann	cells.
Figure	31.1		The	organization	of	a	myelinated	axon.
(A)	An	‘unrolled’	myelinating	Schwann	cell,	revealing	the	regions	that	form	compact	and	noncompact	myelin.	Tight	junctions	are
depicted	 as	 2	 continuous	 (green)	 lines;	 these	 form	 a	 circumferential	 belt	 and	 are	 also	 found	 in	 incisures.	Gap	 junctions	 are
depicted	as	orange	ovals;	these	are	found	between	the	rows	of	tight	junctions	and	are	more	numerous	in	the	inner	aspects	of
incisures	and	paranodes.	Adherens	 junctions	are	depicted	as	purple	ovals;	 these	are	more	numerous	 in	 the	outer	aspects	of
incisures	and	paranodes.	The	nodal,	paranodal	and	juxtaparanodal	regions	of	the	axonal	membrane	are	coloured	blue,	red	and
green,	 respectively.	 (B)	 The	 proteins	 of	 compact	 and	 noncompact	 myelin.	 Compact	 myelin	 contains	 P0,	 PMP22	 and	 MBP;
noncompact	myelin	contains	E-cadherin,	MAG,	Cx32,	Cx29	and	claudins	1	and	5.	Schwann	cells	can	make	as	many	as	100
spiral	turns	around	an	axonal	 length	so	that	their	 longitudinal	 length	far	exceeds	that	of	the	axon	they	ensheathe.	To	put	this	 in
perspective,	 an	 unwrapped	 Schwann	 cell	 from	 an	 axon	 with	 a	 hypothetical	 diameter	 of	 6mm	 would	 be	 39m	 in	 length	 if
unwrapped.	Used	with	permission	from	Scherer	and	Arroyo	[4].
Whereas	 the	 identities	 of	 the	 target	 antigens	 in	 the	 axonal	 form	 of	 GBS	 have	 been	 identified	 and
rigorously	 described,	 the	 target	 of	 attack	 in	 AIDP	 is	 still	 unknown.	 However,	 further	 evidence	 of	 an
autoantibody	response	directed	towards	the	surface	of	the	Schwann	cell	plasmolemma	comes	from	a	study
using	primary	human	Schwann	cell	cultures	to	screen	GBS	sera	for	IgG	binding	[8].	In	this	study,	24%	of
GBS	sera	bound	to	the	distal	tips	of	proliferating,	nonmyelinating	Schwann	cells,	indicating	that	there	is	a
significant	 response	 against	 antigens	not	 present	 in	 the	 compact	myelin.	The	 reason	 the	 target(s)	 of	 the
immune	response	remain	elusive	in	AIDP	is	unclear,	but	it	may	be	that	for	decades	we	have	been	barking
up	the	wrong	tree	 in	 looking	for	 targets	 in	 the	compact	myelin.	The	fact	 that	compact	myelin	 is	but	one
component	of	the	complex	cellular	arrangement	of	the	Schwann	cell	has	often	been	overlooked.	In	reality,
the	 perinodal	 loops,	 Schmidt	 Lanterman	 incisures	 and	 transverse	 processes	 interdigitated	 between	 the
compact	myelin	 lamellae	and	 the	outer	and	 inner	mesaxon	are	all	 in	continuity	with	each	other	and	 the
compact	myelin	spiral.	Immune-mediated	injury	to	any	of	these	areas	has	the	potential	to	cause	problems
with	maintenance	of	myelin	integrity	and	possibly	signal	transduction.
This	 can	 be	 demonstrated	 by	Willison’s	 finding	 that	 in	 the	 Miller	 Fisher	 variant	 of	 GBS	 the	 non
myelin-forming	membranes	 of	 the	 perisynaptic	 Schwann	 cells	 [9]	 as	well	 as	 the	motor	 nerve	 terminal
membranes	 are	 targeted.	 This	 shows	 that	 the	 pathophysiology	 is	 antibody-mediated,	 with	 both	 the
Schwann	 cells	 and	 the	 terminals	 specifically	 targeted	 and	 damaged	 by	 the	 binding	 of	 the	 anti	 GQ1b
gangliosides	 and	 complement-mediated	 membrane	 attack	 complex	 formation.	 The	 dual	 targeting	 is	 a
unique	GBS	neuropathology.	This	raises	yet	again	the	importance	of	the	Schwann	cell	beyond	its	compact
myelin-forming	capacity.	Thus	the	perisynaptic	Schwann	cells,	in	concert	with	the	motor	nerve	terminals
and	the	muscle	fibres	with	their	acetylcholine	receptors,	are	now	recognised	as	essential	elements	of	the
triumvirate	forming	tripartite	synapse,	formerly	the	neuromuscular	junction.
More	Than	a	Myelinator:	Schwann	Cells	Provide	Metabolic	Support	to
the	Longest	Cells	in	History
Although	 Schwann	 cells	 are	 conspicuous	 for	 making	 myelin,	 they	 also	 support	 axons	 independent	 of
myelination,	and	any	perturbations	in	Schwann	cell	physiology	has	the	potential	to	impact	axonal	function.
In	the	PNS,	axonal	projections	can	extend	up	to	1.5m	in	a	human,	over	30m	in	a	blue	whale	and	as	long	as
40m	in	a	supersaurus.	Many	soluble	proteins	vital	for	axonal	form	and	function	are	synthesised	in	the	cell
body	of	the	neuron	and	carried	through	the	axon	by	slow	axonal	transport	at	the	rate	of	~	0.2–10	mm/day.
Some	of	these	proteins	could	take	years	to	reach	the	terminal	of	very	long	axons,	making	the	supply	lines
for	essential	metabolites	exceedingly	slow.	While	it	has	long	been	postulated	that	Schwann	cells	provide
essential	metabolites	for	axons	we	are	only	now	beginning	to	understand	how.	Beirowski	and	colleagues
studied	the	impact	of	ablating	the	serine/threonine	kinase	LKB1,	a	pathway	that	has	been	associated	with
neurodegeneration	only	 in	Schwann	cells	 [10].	Knocking	out	 the	LKB1	pathway	in	Schwann	cells	 from
birth	 led	 to	 progressive	 degeneration	 of	 both	 myelinated	 and	 unmyelinated	 axons,	 where	 small
unmyelinated	sensory	fibres	were	amongst	the	worst	affected.	Deleting	LKB1	from	mature	Schwann	cells
after	 they	 had	 completed	 myelination	 also	 led	 to	 axonal	 loss,	 while	 the	 myelin	 remained	 ostensibly
normal.	This	 study	provides	 strong	 evidence	 that	 Schwann	 cells	 are	 essential	 to	 axonal	wellbeing	 and
provide	metabolic	support	independent	of	myelination.
Schwann	Cells	Turn	Up	in	the	Most	Unexpected	Places:	Overlook
Them	at	Your	Peril;	Or	Alternatively,	a	Saga	of	Bad	Table	Manners
While	 the	 following	 paragraph	 has	 little	 or	 nothing	 to	 do	 with	 GBS,	 the	 tale	 of	 the	 Tasmanian	 devil
(Sarcophilus	harrisii)	is	a	bizarre	story	that	is	worth	telling,	and	who	knows	it	may	have	relevance	in	the
future.	The	Tasmanian	devil,	the	world’s	largest	marsupial	carnivore,	has	the	strongest	bite	per	unit	body
mass	of	any	extant	mammal	land	predator.	It	survived	as	an	apex	predator	for	thousands	of	years	without
challenge,	until	it	encountered	an	extremely	rare,	aggressive	and	transmissible	cancer	[11].	Now	known
as	 the	 devil	 facial	 tumour	 disease	 (DFTD),	 its	 origin	 appears	 to	 have	 arisen	when	 a	 single	 cell	 in	 a
female	 devil	 transformed	 into	 a	 cancerous	 clonal	 cell	 line.	 This	was	 then	 transmitted	 to	 another	 devil
during	 a	 facial	 biting	 session	 (the	 bad	 dining	 manners	 of	 Tasmanian	 devils	 are	 legendary—see
https://www.youtube.com/watch?v=SU44KwIfBXM).
DFTD	 is	 one	of	 only	 2	 currently	 known	 transmissible	 tumours	 and	 the	 only	 one	 that	 is	 fatal.	 It	 has
almost	forced	the	Tasmanian	devil	population	into	extinction.	Because	the	disease	spread	geographically
over	time,	epidemiologists	assumed	that	the	cause	was	an	infectious	agent,	but	they	could	not	identify	a
virus	 or	 bacterium.	Karyotypic	 studies	 suggested	 that	 the	 infectious	 agent	was	 in	 fact	 the	 tumour	 cells
themselves,	as	tumour	cells	isolated	from	different	devils	had	similar	karyotypic	rearrangements.	In	2010
Murchison	and	colleagues	used	large-scale	genetic	analysis	to	confirm	that	the	disease	was	caused	by	a
clonally	transmissible	cancer	of	Schwann	cell	origin	[11].
While	not	directly	related	to	GBS,	the	tale	of	the	Tasmanian	devil	and	the	Schwann	cell	emphasises
the	 point	 that	 abnormal	 or	 damaged	 Schwann	 cells	 can	 have	 unexpected	 effects	 and	 should	 not	 be
overlooked	as	a	cause	of	neurological	dysfunction	in	GBS.
“If	you	do	not	expect	the	unexpected,	you	will	not	find	it;	for	it	is	hard	to	be	sought	out,	and	difficult”.
—HERACLITES	(CA	535	BC–475	BC)
Or	alternatively:
“To	expect	the	unexpected	shows	a	thoroughly	modern	intellect”.
—OSCAR	WILDE,	AN	IDEAL	HUSBAND
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The	Node	of	Ranvier
Steven	Scherer
Introduction
The	 node	 of	Ranvier	 is	 the	 anatomical	 substrate	 for	 saltatory	 conduction.	 Just	 as	 interactions	 between
myelinating	 glial	 cells	 and	 axons	 are	 required	 for	 the	 development	 of	 myelin	 sheaths,	 the	 molecular
anatomy	of	nodes	is	based	on	specific	molecular	interactions	between	these	2	cell	types.
1:	Ranvier,	Paris,	1876–1878
In	 1878,	Louis-Antoine	Ranvier	 published	 “Leçons	 sur	 l’Histologie	 du	 Systeme	Nerveux”	which	was
based	on	a	series	of	lectures	he	had	given	between	1876	and	1877	[1].	In	that	book,	he	reported	the	thin
(~1	micron)	periodic	interruptions	between	adjacent	myelin	internodes	in	the	peripheral	nerves	of	frogs
and	mammals.	He	 called	 these	 structures	 ‘étranglement	 annulaire’	 (Figure	32.1),	 but	 subsequently	 they
have	 been	 linked	 to	 his	 name.	 Whereas	 Ranvier	 had	 the	 prescient	 insight	 that	 myelin	 was	 a	 liquid
covering	of	axons	that	serves	protective,	insulating	and	nutritive	functions,	his	idea	that	nodes	prevented
the	effects	of	gravity	on	the	myelin	sheaths	has	not	been	confirmed.
2:	Ramón	y	Cajal,	Madrid,	1899–1904
The	greatest	neuro-anatomist	of	all,	Ramón	y	Cajal,	used	a	 repertoire	of	 staining	 techniques	 to	discern
many	features	of	the	nodal	region	and	masterfully	illustrated	them	as	shown	in	Figure	32.2.	He	wrote	of
the	peripheral	nervous	system,	“The	myelin	sheath	is	interrupted	at	the	nodes	of	Ranvier,	where	a	short
length	of	axon	always	appears	to	be	exposed,	covered	only	by	the	Schwann	membrane”	[2].	This	space	is
filled	with	a	material	 that	could	be	stained	with	silver	nitrate	 that	 is	 then	reduced	by	exposure	 to	 light,
revealing	 the	 ‘discs	of	Ranvier’	 (Figure	32.2A).	The	paranodes	 illustrated	 in	Figure	32.2B	 showed	 “a
double	 axonic	 bracelet	 …	 the	 constitutive	 laminae	 of	 the	 medullary	 sheath	 end	 perpendicularly”,
anticipating	what	would	be	revealed	by	electron	microscopy	50	years	later	(Figure	32.4).	Ramón	y	Cajal
also	recognized	nodes	of	Ranvier	in	the	central	nervous	system,	a	topic	that	would	remain	controversial
for	decades.
Figure	32.1		Plate	I,	from	“Leçons	sur	l’Histologie	du	Systeme	Nerveux”[1].
Figures	X.5–9	were	made	from	sciatic	nerves	that	were	teased	after	fixation	in	osmic	acid,	which	hardens	the	myelin	sheaths	and
turns	them	black.	Figures	4,	7	and	9	are	from	rabbits;	Figures	X.5,	X.6	and	X.8	are	from	frogs.
Figure	32.2		Ramón	y	Cajal’s	depiction	of	the	nodal	region.
AB:	 “Node	of	nerve	fibres.	A,	axonic	 impregnation	often	found	 in	diluted	and	quick-acting	silver	solutions;	B,	 impregnation	with
silver,	after	 fixation	 in	 formol-pyridine-manganese;	a,	spinous	bracelets	of	Nageotte;	b,	disc	of	Ranvier;	d,	axon;	e,	Schwann’s
membrane.”	C:	“Schematic	drawing	of	the	nerve	fibre	at	the	level	of	the	node.	a,	fine	oblique	neurofibrils;	b,	cementing	discs;	c,
longitudinal	stout	neurofibril;	d,	neurilemma;	e,	 region	of	 the	axon	which	corresponds	 to	 the	node.”	Figures	and	quotations	are
from	[17]	with	permission	of	Oxford	University	Press.
3:	Lillie,	Chicago,	1925
In	1925	Ralph	Stayner	Lillie	demonstrated	that	interrupted	glass	segments	increase	conduction	of	an	iron
wire	 immersed	 in	 nitric	 acid	 [3].	 He	 introduced	 the	 term	 ‘saltatory’	 conduction,	 and	 emphasized	 the
analogy	to	myelinated	axons:	“Whether	conditions	analogous	to	those	just	described	enter	in	the	case	of
nerve	 and	 other	 transmitting	 structures	 in	 living	 organisms	 is	 difficult	 to	 determine	 experimentally,	 but
seems	not	improbable.	We	observe,	for	example,	that	in	the	most	rapidly	conducting	protoplasmic	tracts
known,	 the	medullated	 nerves	 of	 vertebrates,	 the	 conducting	 element	 (axone)	 is	 enclosed	 by	 a	 tubular
sheath	of	apparently	high	electrical	resistance,	the	medullary	sheath,	which	is	constricted	or	interrupted	at
regular	 intervals.	 The	 medullated	 nerve	 transmits	 impulses	 at	 about	 10	 times	 the	 velocity	 of	 the
nonmedullated	nerve,	in	which,	except	for	the	absence	of	the	segmented	sheath,	the	structure	is	similar.”
4:	Huxley	and	Stämpfli,	Cambridge	and	Berne,	1949
Erlanger	 and	Gasser,	 pioneers	of	peripheral	nerve	 electrophysiology	 (for	which	 they	 shared	 the	Nobel
Prize	 in	 1944),	 appreciated	 that	 nodes	 likely	 “regenerated”	 action	 potentials	 [4]	 “It	 seem	much	more
reasonable	to	suppose	that	a	nerve	fiber	conducts	by	means	of	a	self-contained	mechanism	…”	This	was
directly	demonstrated	by	Huxley	 and	Stämpfli	 in	1949	 [5],	who	 isolated	 single	myelinated	 axons	 from
frog	sciatic	nerves	and	measured	the	amplitude	of	the	current	as	a	function	of	position	along	the	internode
(Figure	32.3).	They	 found	 that	 the	 amplitude	was	 highest	 at	 nodes,	 and	 that	 “positive	 current	 began	 to
enter	the	axis	cylinder	before	the	potential	change	had	reached	its	maximum.	This	relation	is	impossible
in	a	system	of	resistances	and	capacities	and	is	shown	to	be	a	necessary	characteristic	of	the	points	which
maintain	decrementless	conduction	in	a	cable-like	structure.	It	is	concluded	that	the	process	which	gives
rise	 to	 the	 action	 potential	 takes	 place	 at	 the	 nodes	 of	 Ranvier,	 confirming	 the	 theory	 of	 saltatory
conduction.”
Figure	32.3		Membrane	currents	of	a	myelinated	fibre.
“Each	curve	shows	the	difference	between	the	longitudinal	currents	at	2	points	0.75	mm.	apart	on	the	fibre.	The	positions	of	those
2	points	relative	to	the	nodes	is	indicated	on	the	diagrammatic	fibre	on	the	right.	The	vertical	mark	above	each	graph	shows	the
time	when	the	change	in	membrane	potential	reached	its	peak	at	that	position	on	the	fibre.”	Outward	current	is	plotted	leftwards.
Reproduced	with	permission	from	[5].
5:	Electron	microscopists,	from	around	the	world,	1955–1990
The	resolution	of	the	electron	microscope	was	required	to	reveal	the	relationships	of	glial	cells	to	axons,
including	the	structure	of	the	nodal	region.	From	humble	beginnings	in	the	1950s,	and	through	the	efforts
of	many	workers	who	refined	the	preparation	of	specimens	and	the	microscopes	 themselves,	a	detailed
ultrastructure	of	the	nodal	region	was	developed	over	30	years.	Figure	32.4	is	a	beautiful	depiction	of	this
work.	The	structure	of	CNS	nodes	are	quite	similar	to	that	of	PNS	nodes,	with	the	major	exception	that
glial	processes	do	not	contact	the	nodal	axolemma	nearly	as	extensively	as	do	Schwann	cell	microvilli.
6:	Levinson	lab,	Denver,	2000
Beginning	 in	 the	 1980s,	 the	 molecular	 architecture	 of	 nodes	 of	 Ranvier	 has	 been	 built,	 molecule-by-
molecule,	 with	 antibodies	 that	 recognized	 its	 molecular	 constituents.	 The	 intramembranous	 particles
(1200/m2)	 in	 the	 nodal	 axolemma	 shown	 in	 Figure	 32.4	 are	 mostly	 voltage-gated	 Na+	 channels	 (Nav
channels),	which	are	essential	for	the	propagation	of	action	potentials.	Mature	channels	are	composed	of
one	α	and	2	β	subunits;	a	single	α	subunit	forms	the	actual	channel.	Of	the	Nav1.1-Nav1.9	a	subunits	gene
family,	Nav1.6	is	the	main	one	expressed	in	mature	CNS	and	PNS	nodes	[6].	Recessive	mutations	in	the
gene	encoding	Nav1.6	lead	to	paralysis	and	death	in	mice,	demonstrating	that	motor	axons	require	this	Nav
channel.
Figure	32.4		Depiction	of	the	ultrastructure	of	the	node	and	paranode.
Note	that	the	nodal	axolemma	has	many	large	particles,	some	of	which	are	voltage-gated	Na+	channels,	and	transcellular	bridges
connect	the	Schwann	cell	microvilli	the	nodal	axolemma.	Rows	of	particles	in	axolemma	are	in	register	with	the	rows	of	particles
in	the	paranodal	loops,	forming	septate-like	junctions.	From	[16],	with	permission	of	Kluwer	Academic	Press.
7:	Bennett	lab,	Durham,	1990s
In	 the	 1990s,	 Bennett	 and	 colleagues	 identified	 isoforms	 (270	 and	 480	 kDa)	 of	 ankyrinG,	 that	 were
localized	 to	 nodes	 of	Ranvier	 and	 axon	 initial	 segments	 [7].	This	 group	 also	 discovered	 that	 two	 cell
adhesion	molecules,	NF186	 and	Nr-CAM,	were	 localized	 to	 nodes	 and	 axon	 initial	 segments	 by	 their
intracellular	interactions	with	ankyrinG	an	adaptor	protein	that	links	these	intrinsic	membrane	proteins	to
the	spectrin	cytoskeleton.	Specific	interactions	with	ankyrinG	have	been	subsequently	identified	for	other
molecules	that	are	localized	to	nodes	(Figure	32.5).
Figure	32.5		Molecular	organization	of	the	nodal	region.
This	schematic	drawing	depicts	the	molecular	organization	of	nodes,	paranodes,	and	juxtaparanodes.	At	nodes,	ankyrinG	binds	to
KCNQ23	 channels	 and	Nav	 channels	 β	 subunits,	 as	well	 as	Nav	 channels	 α	 subunits,	 tenascin-R,	 and	 tenascin-C,	 and	 the
spectrin	 cytoskeleton.	 Nr-CAM,	 NF186,	 and	 β	 subunits	 may	 interact	 in	 trans	 with	 CAMs	 on	 the	 Schwann	 cell	 microvilli.	 At
paranodes,	 Caspr	 and	 contactin	 heterodimers	 interact	 in	 trans	 with	 NF155.	 At	 juxtaparanodes,	 TAG-1	 dimers	 interact
homophilically	in	trans.	Axonal	TAG-1	forms	a	complex	with	Caspr2,	tetramers	of	Kv1.1/Kv1.2	channels,	and	PSD-93,	PSD-95.
Protein	4.1B	 links	 the	cytoplasmic	 tail	of	Caspr	and	Caspr2	 to	 the	spectrin	cytoskeleton.	Homotypic	gap	 junctions	comprised
Cx32	link	the	paranodal	membranes	of	the	myelin	sheath.
8:	Peles	lab,	Tel	Aviv,	2005–2010
The	 Peles	 lab	 [8]	 identified	 gliomedin	 as	 a	 binding	 partner	 for	 NF186	 and	 Nr-CAM,	 showed	 that
gliomedin	is	expressed	by	myelinating	Schwann	cells	and	is	localized	to	nodes,	and	is	required	to	form
nodes	 of	 Ranvier	 in	myelinating	 co-cultures.	 Subsequently,	 this	 group	 showed	 that	 gliomedin	 and	Nr-
CAM	are	required	to	cluster	voltage-gated	Na+	channels	at	hemi-nodes,	which	then	fuse	to	form	mature
nodes	of	Ranvier	[9].	Because	gliomedin	is	scarcely	expressed	in	the	CNS,	other	mechanisms	must	form
nodes	of	Ranvier	in	the	CNS.
9:	Brophy	lab	and	Peles,	Edinburgh	and	Redwood	City,	1997–2000
At	paranodes,	the	lateral	edge	of	the	myelin	sheath	spirals	around	the	axon,	forming	the	axoglial	junctions
that	 contain	 septate-like	 junctions	 (Figure	 32.5).	 Septate-like	 junctions	 limit	 the	 diffusion	 of	 large
molecules	 and	 separate	 the	 juxtaparanodal	 Kv1.1/Kv1.2	 K+	 channels	 from	 the	 node	 of	 Ranvier.	 The
molecular	composition	of	paranodes	began	with	the	discovery	that	Caspr	interacts	with	contactin,	a	GPI-
linked	protein	[10],	that	Caspr	was	localized	to	paranodes	[11],	and	that	contactin/Caspr	heteromers	bind
in	trans	to	NF155,	a	glial	isoform	of	neurofascin	that	is	located	at	the	paranodal	loops	[12].	The	genetic
deletion	 of	 contactin,	 Caspr,	 or	 NF155	 results	 in	 the	 failure	 to	 form	 septate-like	 junctions,	 and	 is
associated	with	neurological	deficits.
10:	Scherer	and	Paul,	Philadelphia	and	Boston,	1995
There	 are	 “reflexive”/“autotypic”	 junctions	 between	 the	 paranodal	 loops	 themselves—	 including	 tight
junctions,	gap	junctions,	and	adherens	junctions	(Figure	32.5).	Tight	 junctions	(formed	by	claudin-11	 in
the	CNS	and	claudin-19	in	the	PNS)	join	the	layers	of	the	myelin	sheath	together.	Gap	junctions	formed	by
Cx32	appear	to	be	crucial	in	allowing	the	diffusion	of	ions	and	small	molecules	through	the	layers	of	the
myelin	 sheath	 [13];	 loss	 of	 these	 channels	 may	 be	 the	 reasons	 that	 mutations	 in	GJB1,	 the	 gene	 that
encodes	Cx32,	cause	an	inherited	neuropathy.
Next	up	at	the	nodes
Nodal	antigens	are	the	likely	targets	for	a	variety	of	acquired	peripheral	neuropathies.	Gangliosides	have
been	long	implicated	as	immunological	targets	of	antibodies	in	multi-focal	motor	neuropathy	and	various
form	of	Guillain-Barré	 syndrome	 [14].	More	 recently,	 antibodies	 against	nodal	 (NF186,	Nr-CAM,	and
gliomedin),	 paranodal	 (contactin,	 NF155),	 and	 juxtaparanodal	 (TAG-1/contactin-2	 and	 Caspr2)	 have
been	found	in	small	subsets	of	patients	with	chronic	inflammatory	demyelinating	neuropathy	and	Guillain-
Barré	 syndrome	 [15],	 and	 Caspr2	 is	 the	 main	 target	 antigen	 in	 acquired	 neuromyotonia.	 It	 will	 be
interesting	to	determine	how	these	antibodies	cause	their	associated	diseases,	and	whether	there	are	more
specific	therapies.
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Pain	and	GBS:	The	Basic	and	Clinical	Science
David	L.H.	Bennett
Introduction
Given	the	grievous	consequences	of	motor	dysfunction,	this	has	understandably	taken	precedence	in	GBS
research	over	and	above	the	understanding	of	sensory	loss	and	pain.	It	has	however	been	long	understood
that	persistent	pain	is	an	important	and	common	sequel	of	GBS	with	major	deleterious	impact	on	quality
of	life.	In	the	initial	sequence	of	papers	I	will	review	clinical	progress	in	defining	the	nature	of	pain	in
GBS	 and	 its	 pathological	 correlates,	 and	 subsequently	 focus	 on	 progress	 in	 understanding	 the
pathophysiology	 of	 this	 pain.	 There	 has	 been	 a	 recent	 convergence	 between	 the	 pain	 and	 immunology
fields	 in	 recognising	 that	 immune	mechanisms	 have	 an	 important	 part	 to	 play	 in	 the	 development	 and
persistence	of	neuropathic	pain	whatever	 the	cause.	These	 innate	and	adaptive	 immune	mechanisms	not
only	 impinge	on	neurons	but	 also	have	 a	major	 impact	 on	myelinating	 and	non-myelinating	glia.	 I	will
discuss	not	only	what	we	have	learnt	about	the	specifics	of	pain	aetiology	in	GBS	but	also	how	this	has
gone	 hand	 in	 hand	 with	 our	 wider	 understanding	 of	 the	 many	 factors	 which	 drive	 neuropathic	 pain
following	nerve	injury.
The	Recognition	and	Description	of	Pain	in	GBS
Haymaker	WE	and	Kernohan	JW.	The	Landry-Guillain-Barré	syndrome;	a	clinicopathologic
report	of	50	fatal	cases	and	a	critique	of	the	literature.	Medicine,	1949
Of	 course	 the	 first	 question	 in	 relation	 to	 pain	 and	 GBS	 is	 how	 common	 is	 it	 and	 what	 are	 the
characteristics	of	 the	pain?	In	fact	pain	was	noted	 in	 the	 initial	cases	described	by	Guillain,	Barré	and
Strohl	and	in	subsequent	case	reports/series.	However,	 it	was	not	until	 the	publication	of	 this	paper	by
Haymaker	 and	 Kernohan	 that	 a	 more	 systematic	 approach	 was	 employed	 in	 elucidating	 sensory
dysfunction	 in	GBS	 [1].	Many	 of	 their	 comments	 chime	with	 our	 experience	 of	 pain	 suffered	 by	GBS
patients	 in	 the	21st	century.	They	reviewed	a	clinicopathological	series	of	50	cases	from	the	American
Army	 Institute	 of	 Pathology.	 In	 50%	 of	 cases,	 sensory	 symptoms,	 pain,	 paraesthesia	 and	 numbness	 in
various	combinations	were	 the	presenting	 symptoms	preceding	weakness.	Paraesthesia	usually	affected
the	hands	and	feet.	Overall	pain	was	reported	in	56%	of	cases,	which	is	a	lower	frequency	than	in	modern
series	perhaps	due	to	fact	that	this	was	a	retrospective	case	review.	Pain	was	often	described	as	initially
affecting	the	lower	trunk	and	legs	but	was	also	described	in	a	minority	of	patients	as	affecting	the	joints
and	muscles.	Usually	pain	developed	early	in	the	course	of	the	illness	and,	although	pain	improved	in	the
majority	of	 cases,	 in	 a	 significant	group	 it	 persisted.	The	authors	note	 that	 the	majority	of	patients	had
demonstrable	evidence	of	sensory	loss,	usually	in	a	‘glove	and	stocking’	distribution	but	 in	some	cases
also	affecting	the	trunk.	Not	only	is	impaired	sensibility	described	on	examination	(to	touch,	pinprick	and
vibration	 sense),	 but	we	 also	 see	 descriptions	 of	 sensory	 abnormalities	which	we	 now	 associate	with
neuropathic	 pain,	 such	 as	 hyperalgesia	 and	 allodynia	 [2].	 There	 is	 some	 comparison	 of	 sensory
dysfunction	with	pathology	in	that	those	patients	with	prominent	sensory	loss	had	a	greater	inflammatory
change	within	the	dorsal	roots.	The	authors	also	noted	variable	changes	within	dorsal	root	ganglia	(DRG)
with	injury	to	DRG	cells	clearly	present	in	some	cases,	as	demonstrated	by	the	presence	of	chromatolysis.
This	paper	therefore	firmly	established	sensory	dysfunction	and	pain	as	key	features	of	GBS.
Ropper	AH	and	Shahani	BT.	Pain	in	Guillain-Barré	syndrome.	Archives	of	Neurology,	1984
Ropper	and	Shahani	published	the	first	GBS	cohort	specifically	focussing	on	pain	and	its	characteristics
[3].	They	reported	29	patients	with	GBS	who	were	assessed	in	the	acute	phase	of	the	illness	(within	15
days	 of	 onset	 of	 weakness)	 making	 comparison	 with	 clinical,	 electrophysiological	 and	 pathological
features.	The	cohort	was	described	as	being	mainly	typical	GBS	with	2	of	the	29	having	the	Miller	Fisher
syndrome	(MFS).	Fifty-five	percent	of	patients	had	pain	early	in	the	course	of	GBS	and	72%	of	patients
reported	significant	pain	(which	in	the	vast	majority	was	described	as	moderate	or	severe)	at	some	point
during	the	course	of	their	illness.	The	most	common	locations	were	the	upper	legs;	back	pain	was	often
transient;	other	affected	areas	were	 flanks	and	shoulders,	with	 the	hands	and	 feet	being	 less	commonly
affected.	 There	was	 very	 little	 correlation	 between	 clinical	 signs,	 electrophysiological	 findings	 or	 the
presence	of	inflammation	within	the	DRG	and	the	presence	of	pain.	The	lack	of	correlation	between	the
presence	 of	 pain	 and	 sensory	 loss	 make	 the	 authors	 conclude	 that	 is	 unlikely	 to	 be	 arising	 as	 a
consequence	of	nerve	injury,	suggesting	that	it	is	more	likely	to	be	muscular	in	nature.	However,	it	should
be	noted	that	subsequent	studies	will	show	that	although	there	is	likely	to	be	a	musculoskeletal	component
pain	in	GBS	there	is	clearly	also	a	neuropathic	component.
Moulin	DE,	et	al.	Pain	in	Guillain-Barré	syndrome.	Neurology,	1997
Moulin	prospectively	followed	a	cohort	of	59	GBS	patients	between	admission	and	24	weeks	[4].	There
was	a	high	rate	of	pain	which	was	reported	in	89%	of	patients	during	the	course	of	their	illness.	The	pain
was	moderate	to	severe	in	intensity	(mean	pain	rating	on	visual	analogue	scale	at	admission	of	4.7).	The
severity	of	the	pain	is	borne	out	by	the	fact	that	three-quarters	of	patients	required	opioid	analgesics.	The
most	 common	 pain	 distribution,	 consistent	with	 the	 findings	 of	Ropper	 and	 colleagues,	was	 the	 lower
back	 and	 upper	 legs,	 although	 a	 significant	 group	 reported	 pain	 in	 the	 extremities.	 One	 means	 of
explaining	 such	 a	 distribution	 would	 be	 dorsal	 root	 inflammation,	 which	 is	 commonly	 reported	 in
pathological	series	of	GBS	(see	Haymaker	and	Kernohan	above)	resulting	in	lumbar	back	pain	and	pain
in	 the	upper	 thighs.	 In	addition,	 inflammation	may	ultimately	 lead	 to	 secondary	axon	 injury	 resulting	 in
sensory	loss	and	pain	in	the	extremities.	Subsequently,	Ruts	and	colleagues	described	a	large	longitudinal
cohort	of	156	GBS	patients	with	follow-up	to	1	year,	at	which	point	38%	of	patients	reported	significant
pain	[5].	These	initial	case	series	did	not	find	a	simple	relationship	between	pain	incidence/severity	and
injury	 to	 sensory	 neurons.	However,	 the	 use	 of	 skin	 biopsy	 to	 directly	 visualise	 sensory	 fibres	would
throw	light	on	this	issue.
Pan	CL,	et	al.	Cutaneous	innervation	in	Guillain-Barré	syndrome:	pathology	and	clinical
correlations.	Brain,	2003
In	 the	1990s	 it	became	clear	 that	 the	 free	nerve	endings	of	C-fibres	and	 thin	myelinated	A-delta	 fibres
could	be	visualised	and	quantified	within	the	epidermis	by	immunostaining	for	the	pan-neuronal	marker
PGP-9.5.	 These	 represent	 the	 terminals	 of	 nociceptors	 and	 thermoceptors,	 and	 this	 technique	 is	 now
widely	used	in	both	research	and	clinical	practice.	This	has	been	a	major	advance	given	that	the	function
of	 these	 fibres	 is	 not	 interrogated	 with	 standard	 electrophysiological	 testing.	 Pan	 and	 colleagues	 [6]
applied	 this	 technique	 to	 a	 group	 of	 GBS	 patients,	 showing	 that	 there	 was	 a	 significant	 reduction	 in
intraepidermal	nerve	fibre	density	(IENFD)	in	the	distal	leg	as	compared	to	matched	controls.	There	was
a	correlation	between	the	reduction	in	IENFD	and	raised	thermal	thresholds	in	GBS	patients.	There	was	a
correlation	between	 IENFD	and	disability;	however,	 the	 authors	 reported	 that	 IENFD	was	 the	 same	 in
those	patients	with	and	without	neuropathic	pain.	It	was	not	clear,	however,	exactly	what	tool	was	used
for	the	assessment	of	neuropathic	pain	in	this	study,	and	there	was	no	assessment	of	pain	intensity	reported
which	would	have	enabled	a	direct	correlation	with	IENFD.	These	issues	were	dealt	with	at	a	functional
level	by	Martinez	and	colleagues	[7],	who	demonstrated	that	there	was	a	significant	relationship	between
the	 degree	 of	 small	 fibre	 dysfunction	 as	 assessed	 by	 quantitative	 sensory	 testing	 to	 measure	 thermal
thresholds	and	the	presence	of	neuropathic	pain.	The	subsequent	paper	went	on	to	thoroughly	assess	the
relationship	between	neuropathic	pain	and	cutaneous	innervation.
Ruts	L,	et	al.	Unmyelinated	and	myelinated	skin	nerve	damage	in	Guillain-Barré	syndrome:
correlation	with	pain	and	recovery.	Pain,	2012
In	 a	 cohort	 of	 32	GBS	 patients	 these	 authors	 showed	 a	 significant	 reduction	 in	 IENFD	 in	 the	 lumbar
region	 in	 61%	of	 patients,	 and	 at	 the	 distal	 leg	 in	 60%	of	 patients	 in	 the	 acute	 phase	 of	GBS	 (first	 3
weeks)	 [8].	 One	 important	 implication	 is	 that	 injury	 to	 small	 fibres	 is	 not	 length	 dependent	 given	 the
significant	 reduction	 in	 IENFD	 in	 the	 lumbar	 region.	Additionally,	 even	some	patients	with	pure	motor
forms	of	GBS	or	MFS	had	a	significant	reduction	in	IENFD.	Patients	were	followed	for	up	to	6	months
and	IENFD	remained	low;	only	a	minority	showed	recovery	of	IENFD.	In	the	acute	phase	those	patients
with	neuropathic	pain	were	more	likely	to	have	a	reduction	in	IENFD	at	the	distal	leg	and	there	was	an
inverse	 correlation	 between	 IENFD	and	pain	 intensity.	Lumbar	 IENFD	during	 the	 acute	 phase	 of	GBS
also	correlated	with	poorer	GBS	disability	at	6	months.	The	authors	also	studied	myelinated	cutaneous
dermal	fibres	and	demonstrated	that	GBS	is	associated	with	fragmentation	of	myelin	and	disorganisation
of	the	nodal	complex.	This	was	only	performed	in	a	subset	of	patients	and	so	statements	on	the	degree	of
myelin/nodal	injury	and	pain	or	functional	status	could	not	be	made.
This	series	of	papers	have	provided	important	insight	into	the	clinical	characteristics	of	pain	in	GBS.
It	 is	 common,	 severe	 and	 in	 a	 significant	 group	 of	 patients	 persistent	 even	 at	 1	 year	 and	 affects	 both
proximal	 regions	such	as	 lower	back	as	well	as	 the	extremities.	With	pathological	correlations	we	can
even	make	 some	broad	hypotheses	on	 causation—severity	 is	 related	 to	degree	of	 injury	 to	 the	 sensory
nervous	system,	there	is	prominent	inflammation	in	GBS	and	myelin	loss	which	is	one	potential	factor	in
pain	aetiology,	and	there	is	direct	evidence	that	the	loss	of	C-fibre	terminals	inversely	correlates	to	pain
severity.	Subsequently	I	will	go	on	to	consider	which	studies	have	provided	mechanistic	insight	into	the
pathogenesis	of	neuropathic	pain	in	GBS	at	both	the	molecular	and	cellular	level.
The	Aetiology	of	Pain	in	GBS
Wall	PD	and	Gutnick	M.	Properties	of	afferent	nerve	impulses	originating	from	a	neuroma.
Nature,	1974
This	paper	relates	to	a	model	of	painful	traumatic	neuropathy;	however,	it	was	seminal	in	moving	forward
our	 understanding	 of	 peripheral	 neuropathic	 pain	 [9].	 We	 now	 take	 for	 granted	 the	 fact	 that	 sensory
neurons	develop	ectopic	or	 spontaneous	activity	 following	nerve	 injury;	 this	paper	was	 the	 first	direct
demonstration	of	these	phenomena.	Prior	to	this	report	it	had	been	shown	that	cutting	a	nerve	would	lead
to	 an	 acute	 ‘injury	 discharge’	 within	 seconds,	 which	 would	 then	 subside;	 however,	 there	 was	 no
knowledge	 as	 to	what	would	 happen	 to	 the	 electrophysiological	 properties	 of	 primary	 afferents	 in	 the
subsequent	days	and	weeks,	which	was	the	topic	of	this	paper.
The	authors	 ligated	 the	sciatic	nerve	 to	generate	a	neuroma	and	 then	 recorded	 from	 individual	units
within	 fine	 filaments	 of	 the	 teased	 dorsal	 root	 at	 up	 to	 40	 days	 post-injury.	 They	 noted	 ongoing
spontaneous	 activity	 in	 myelinated	 afferents	 terminating	 in	 the	 neuroma.	 The	 fact	 that	 application	 of
lidocaine	 to	 the	neuroma	could	block	 this	ongoing	activity	was	provided	as	evidence	 that	 the	 impulses
arose	from	the	neuroma	itself;	subsequent	studies	have	shown	that	ectopic	activity	can	also	arise	at	 the
level	of	the	cell	body	within	the	DRG	[10].	The	sensory	neurons	also	adopted	a	novel	mechanosensitivity.
In	 the	 conclusion	 the	 authors	 presciently	 argue	 that	 this	 ongoing	 activity	 would	 be	 an	 important
pharmacological	target	for	novel	analgesics.	A	recent	study	using	peripheral	nerve	blocks	in	man	suggests
that	 such	 ongoing	 spontaneous	 activity	 is	 required	 for	 the	 maintenance	 of	 neuropathic	 pain,	 and
spontaneous	activity	in	myelinated	and	unmyelinated	afferents	has	been	noted	in	many	different	types	of
neuropathy,	including	following	demyelination	(see	below).
Wallace	VC,	et	al.	Focal	lysolecithin-induced	demyelination	of	peripheral	afferents	results
in	neuropathic	pain	behavior	that	is	attenuated	by	cannabinoids.	J	Neurosci,	2003
Historically	in	preclinical	models	of	neuropathic	pain	the	major	emphasis	has	been	on	traumatic	injury	to
axons	in	the	rodent	(usually	involving	partial	axotomy	of	the	sciatic	nerve	or	its	branches).	An	important
question	 for	 the	 demyelinating	 variants	 of	GBS	 is	whether	 primary	 demyelination	 in	which	 the	myelin
sheath	is	removed	while	the	axon	remains	intact	can	result	 in	neuropathic	pain.	Wallace	and	colleagues
showed	 clearly	 in	 their	 work	 that	 this	 is	 in	 fact	 the	 case;	 they	 also	 went	 on	 to	 provide	 mechanistic
understanding	 of	 pain	 aetiology	 [11].	They	 used	 topical	 application	 of	 the	 chemical	 lysolecithin	 to	 the
mouse	sciatic	or	saphenous	nerve	in	order	to	induce	primary	demyelination.	On	behavioural	testing	within
a	week,	this	resulted	in	the	development	of	both	thermal	and	mechanical	hypersensitivity,	which	lasted	for
the	subsequent	2	weeks,	a	time	course	which	would	parallel	the	period	of	remyelination.
Electrophysiological	recordings	at	the	peak	of	these	behavioural	changes	demonstrated	the	presence	of
ectopic	ongoing	activity.	Such	ectopic	activity	 is	 a	virtually	 invariant	 feature	of	peripheral	neuropathic
pain	and	is	a	major	 target	for	drug	discovery.	Following	primary	demyelination	this	ongoing	activity	 is
likely	to	be	a	consequence	of	altered	expression/trafficking	of	voltage-gated	ion	channels	in	the	axolemma
of	sensory	axons	as	a	consequence	of	the	altered	interaction	with	Schwann	cells.
The	 authors	 show	 that	 primary	 demyelination	 results	 in	 increased	 expression	 of	 the	 voltage-gated
sodium	 channel	 NaV1.3,	 which	 is	 normally	 only	 expressed	 during	 development	 and	 is	 absent	 in
adulthood.	Others	had	previously	demonstrated	 that	demyelination	of	axons	 leads	 to	 radical	 changes	 in
ion	channel	distribution:	for	instance,	voltage-gated	sodium	channels,	which	would	normally	be	confined
to	the	node	of	Ranvier,	now	spread	along	the	axolemma	and	could	act	as	ectopic	‘generators’.	This	study
was	 significantly	 extended	when	 it	 was	 shown	 that	 pain-related	 hypersensitivity	 was	 not	 restricted	 to
demyelination	produced	by	chemical	means	but	was	also	observed	in	an	animal	model	of	 inflammatory
neuropathy	‘experimental	auto-immune	neuritis’	[12].
Xiao	WH,	et	al.	Electrophysiological	characteristics	of	primary	afferent	fibers	after
systemic	administration	of	anti-GD2	ganglioside	antibody.	Pain,	1997
Gangliosides	either	individually	or	in	complexes	have	been	implicated	as	targets	for	autoantibodies.	This
paper	 provides	 a	 mechanistic	 link	 between	 ganglioside	 autoantibodies	 and	 the	 development	 of
neuropathic	pain	[13].	The	‘B’	series	gangliosides	(such	as	GD2)	in	particular	are	known	to	be	expressed
by	 sensory	 neurons	 at	 the	 surface	 of	 the	 cell	 body	 and	 along	 the	 axolemma.	An	 example	 of	 the	 direct
effects	 of	 antiganglioside	 antibodies	 is	 that	 a	 monoclonal	 antibody	 directed	 against	 GD2	 used
therapeutically	 in	 the	 treatment	of	neuroblastoma	was	noted	 to	cause	pain	and	mechanical	 allodynia	as
side	effects.
To	 understand	 the	 pathogenic	 effects	 of	 anti-GD2	 antibodies,	 Xiao	 and	 colleagues	 systemically
administered	anti-GD2	antibody	to	rats.	These	antibodies	resulted	in	the	rapid	development	of	mechanical
hypersensitivity	 in	 the	 rat	 which	 mirrored	 the	 development	 of	 mechanical	 allodynia	 in	 patients
administered	 these	 antibodies.	 On	 electrophysiological	 recording	 (performed	 on	 the	 same	 day	 as	 the
behavioural	 assessment)	 both	 C-fibres	 and	 A-delta	 sensory	 fibres	 developed	 spontaneous	 activity.	 In
addition,	 their	 threshold	 to	mechanical	stimuli	dropped.	In	summary,	antibodies	 to	 the	GD2	ganglioside
known	 to	 be	 expressed	 by	 sensory	 neurons	 could	 acutely	 sensitise	 primary	 afferents	 leading	 to
spontaneous	 activity,	 reduced	 mechanical	 thresholds	 and	 the	 development	 of	 spontaneous	 pain	 and
mechanical	 allodynia.	 This	 is	 therefore	 proof	 of	 concept	 of	 the	 potential	 effects	 of	 antiganglioside
antibodies	in	GBS.
Zhang	ZY,	et	al.	Improved	outcome	of	EAN,	an	animal	model	of	GBS,	through	amelioration
of	peripheral	and	central	inflammation	by	minocycline.	J	Cell	Mol	Med,	2009
Experimental	 allergic	 neuritis	 is	 an	 animal	 model	 in	 which	 an	 acute,	 inflammatory	 demyelinating
neuropathy	develops	and	is	used	as	a	model	of	the	AIDP	variant	of	GBS.	A	number	of	groups	(including
Moalem-Taylor	and	colleagues	[12]),	have	recently	shown	that	the	development	of	experimental	allergic
neuritis	 (EAN)	 is	associated	with	 the	development	of	pain-related	hypersensitivity.	 In	 this	paper	Zhang
and	colleagues	study	the	effects	of	minocycline—a	second-generation	tetracycline	with	anti-inflammatory
properties—in	 this	model	 [14].	EAN	was	 induced	by	a	neuritogenic	peptide	of	P2.	EAN	results	 in	 the
recruitment	 of	 inflammatory	 infiltrate	 to	 peripheral	 nerve	 and	 increased	 inflammatory	 cytokine	 (TNF-
alpha)	 expression.	 This	 inflammatory	 environment	 is	 likely	 to	 sensitise	 primary	 afferents,	 and	 indeed
individual	 cytokines	 such	 as	 TNF	 can	 produce	 spontaneous	 activity	 and	 sensitise	 primary	 afferent
nociceptors.	Although	EAN	results	 in	peripheral	nerve	 injury,	maladaptive	plasticity	within	 the	CNS	is
also	 likely	 to	 have	 a	 role	 in	 neuropathic	 pain	 development.	 Indeed,	 as	 has	 also	 been	 noted	 following
traumatic	nerve	injury,	microglia	within	the	spinal	cord	transform	to	a	pro-inflammatory	phenotype	[15]
and	express	the	purinoceptor	P2Rx4.	These	pro-inflammatory	(P2RX4	+ve)	microglia	within	the	dorsal
horn	 release	 brain-derived	 neurotrophic	 factor	 (BDNF),	 which	 sensitises	 nociceptive	 signalling.
Minocycline	treatment	reduces	the	severity	of	EAN	as	assessed	by	motor	function	and	ameliorates	all	of
the	 inflammatory	 changes	 described	 above,	 resulting	 in	 reduced	 pain-related	 hypersensitivity.	 This
produces	an	important	illustration	of	how	pro-inflammatory	process	engaged	by	EAN	(and,	by	inference,
in	GBS)	can	act	to	sensitise	the	nociceptive	system.	Disease-modifying	therapy	in	GBS	is	likely	to	reduce
the	 incidence/persistence	 of	 neuropathic	 pain	 associated	 with	 GBS	 but	 how	 should	 we	 approach
analgesic	therapy?
Finnerup	N,	et	al.	Pharmacotherapy	for	neuropathic	pain	in	adults:	a	systematic	review
and	meta-analysis.	The	Lancet	Neurology,	2015
This	recent	paper	on	behalf	of	the	Neuropathic	Pain	Special	Interest	Group	(NeuPSIG)	of	the	International
Association	 for	 the	 Study	 of	 Pain	 (IASP)	 is	 a	 comprehensive,	 systematic	 review	 and	meta-analysis	 of
pharmacotherapy	 for	 neuropathic	 pain	 [16].	 There	 have	 been	 a	 number	 of	 small	 studies	 of	 analgesic
therapy	in	GBS;	however,	a	recent	Cochrane	review	pointed	out	that	the	quality	of	the	evidence	was	poor
and	it	was	not	possible	to	draw	definitive	conclusions	[17].	One	of	the	emerging	themes	in	neuropathic
pain	 is	 that	 pathophysiological	 mechanisms	 (for	 instance	 ectopic	 activity	 in	 primary	 afferents	 or
sensitisation	 within	 the	 CNS)	 are	 not	 aetiology	 specific	 and	 in	 general	 pharmacological	 agents	 show
efficacy	across	a	range	of	causes	of	neuropathic	pain.	In	fact,	an	aspiration	for	the	future	is	that	we	should
use	somatosensory	phenotyping	rather	than	aetiology	to	stratify	patients	and	target	treatment.	The	authors
of	 this	 paper	 point	 out	 that	 their	 analysis	 and	 guidance	 should	 be	 applicable	 to	 a	 wide	 range	 of
neuropathic	causes	(and	we	hope	this	includes	GBS).	One	caveat	is	that	most	large	randomised	controlled
trials	 for	 neuropathic	 pain	 are	 performed	on	patients	with	 painful	 diabetic	 neuropathy	or	 post-herpetic
neuralgia.	Based	on	efficacy	and	tolerability,	recommended	first-line	agents	for	neuropathic	pain	are	the
gabapentinoids,	 tricyclic	 antidepressants	 (TCAs)	 or	 serotonin/noradrenaline	 reuptake	 inhibitors.	 In	 the
acute	phase,	care	would	need	to	be	taken	with	the	use	of	TCAs	if	there	were	autonomic	involvement.	The
second-line	 agents	 which	 were	 recommended	 included	 lidocaine	 plasters	 and	 high-dose	 capsaicin
patches;	however,	the	regions	of	neuropathic	pain	may	well	be	too	extensive	for	topical	therapy	in	GBS.
Third-line	 agents	 include	 strong	 opiates.	 This	 systematic	 review	 also	 emphasises	 that,	 although
combination	analgesic	therapy	is	intellectually	appealing,	the	trial	results	have	been	mixed.	The	hope	for
the	future	is	further	well-powered	studies	of	combination	therapy	and	a	more	stratified	approach	to	see	if
this	can	predict	treatment	response.
Summary	and	Conclusions
It	is	now	well	recognised	that	pain	is	an	important	and	disabling	consequence	of	GBS.	There	may	be	a
musculoskeletal	component,	but	a	key	element	is	neuropathic	pain	due	to	damage	to	sensory	afferents,	and
a	number	of	studies	have	shown	a	relationship	between	the	degree	of	injury	to	small	nerve	fibres	within
the	epidermis	and	pain	severity.	The	aetiology	of	neuropathic	pain	is	likely	to	be	multifactorial,	including
inflammation	triggered	by	humoral	and	cell-mediated	immunity	as	well	as	the	consequences	of	injury	to
sensory	 axons	 and	dysfunction	of	 ion	 channels	 resulting	 in	 ectopic	 activity.	 Interestingly,	 there	 is	 some
experimental	 evidence	 that	 antiganglioside	 antibodies	 (anti-GD2)	 can	 trigger	 spontaneous	 activity	 in
sensory	neurons.	Currently	the	best	treatment	algorithms	will	use	generic	guidelines	on	the	management	of
neuropathic	pain	such	as	those	recently	developed	by	NeuPSIG;	however,	future	trials	are	needed	to	test
analgesic	efficacy	specifically	 in	GBS.	A	key	aspiration	of	 the	neuropathic	pain	field	 is	 to	use	sensory
profiling	 in	 order	 to	 stratify	 patients,	 with	 the	 hope	 that	 such	 stratification	 will	 reveal	 particular
underlying	 pathophysiology	 and	 hence	 predict	 treatment	 response.	 Given	 the	 pain	 drivers	 which	 are
proposed	in	GBS,	it	would	be	advised	that	analgesic	trials	in	GBS	employ	such	an	approach.
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Complement	in	Guillain-Barré	Syndrome:	From
Bench	to	Bedside
Amy	Davidson	and	Susan	K.	Halstead
Introduction
Having	previously	joined	Professor	Hugh	Willison’s	group	at	different	times,	we	were	jointly	approached
to	write	 a	 chapter	 based	 on	 complement	 and	 its	 role	 in	Guillain-Barré	 syndrome.	Given	 our	 different
backgrounds,	 we	 aim	 take	 you	 through	 scientific	 research	 (Sue	Halstead)	 into	 a	 clinical	 setting	 (Amy
Davidson),	reflecting	the	translational	nature	of	our	work.
Due	to	the	personal	journeys	this	chapter	represents	it	is	not	intended	to	be	a	comprehensive	review	of
the	literature	in	this	field.	First,	Susan	highlights	5	papers	which	influenced	her	as	a	PhD	student,	and	later
as	a	postdoctoral	scientist	aiming	to	glean	new	insights	and	strategies	for	complement	therapeutics,	with
the	hope	that	these	could	prove	influential	in	the	clinic.	This	is	followed	by	5	papers	selected	by	Amy,	a
clinical	 fellow	 who	 took	 up	 the	 gauntlet	 and	 is	 now	 recruiting	 GBS	 patients	 for	 a	 clinical	 trial	 of
eculizumab,	the	world’s	first	clinically	approved,	antibody-derived	complement	therapeutic.
The	Science	of	Complement
Having	graduated	with	a	B.Sc.	(Hons)	in	neuroscience,	I	joined	the	Willison	group	in	2000	to	embark	on
3-year	journey	to	gain	my	Ph.D.,	funded	by	the	Guillain-Barré	support	group	in	the	UK.	With	only	a	very
basic	appreciation	of	the	various	branches	of	immunology,	I	found	this	to	be	a	steep	learning	curve,	as	my
remit	was	 firmly	 focused	 on	 dissecting	 out	 the	 role	 of	 the	 complement	 cascade	 in	 the	 pathogenesis	 of
GBS.	At	the	time	of	joining	the	group,	we	worked	very	closely	with	our	friends	in	Leiden	(Jaap	Plomp
and	group).	This	collaboration	had	proved	very	successful,	having	already	established	an	ex	vivo	mouse
model	of	GBS	which	was	described	as	producing	an	‘alpha-latrotoxin-like	effect’,	resulting	in	extensive
destruction	of	the	presynaptic	neuromuscular	membrane.	As	this	model	was	complement-dependent,	I	was
initially	set	the	task	of	determining	the	critical	components	of	complement	resulting	in	damage,	with	the
long	term	goal	of	developing	an	in	vivo	mouse	model.
Over	the	last	15	years,	I’ve	read	many	papers	that	greatly	assisted	me	in	my	quest,	and	in	the	following
section	I	would	like	to	highlight	5	papers	that	I’ve	found	both	helpful	and	encouraging.
Morgan	BP.	The	role	of	complement	in	neurological	and	neuropsychiatric	diseases.	Expert
Review	of	Clinical	Immunology,	2015
When	 first	 approached	 to	 contribute	 to	 this	 publication,	 I	 knew	 without	 doubt	 that	 one	 of	 Professor
Morgan’s	publications	had	to	be	featured	in	my	list	of	notable	papers.	The	only	problem	was	which	one	to
select.	As	a	prolific	author	of	numerous	high	 impact	 journals	and	publications,	Morgan	 is	a	 true	world
expert	in	complement,	who	has	always	been	extremely	generous	with	both	his	time	and	reagents.	Amongst
his	many	publications	I	have	selected	his	recent	review	regarding	the	evidence	for	a	pathogenic	role	for
complement	in	a	host	of	neurological	and	neuropsychiatric	diseases	[1].	The	reason	I	picked	this	over	one
of	his	original	research	papers	is	that	I	find	whenever	I’m	presented	with	new	subject	matter,	it	is	vitally
important	to	place	it	in	context.	In	this	article	both	PNS	and	CNS	diseases	are	discussed	and	evidence	is
presented	implicating	complement	as	driving	key	pathological	events.	Disease	types	include	autoimmune
(including	GBS),	 infections,	 neurodegenerative,	 acute	 injuries	 and	neuropsychiatric.	The	 importance	of
understanding	 the	 disease	 process	 in	 these	 diseases	 has	 become	 increasingly	 important	 of	 the	 last	 few
years,	 as	new	 regulators	of	 complement	have	 emerged	which	 target	 different	points	 of	 the	 complement
cascade,	making	it	feasible	in	the	future	to	attenuate	complement-driven	pathology.
Ong	GL	and	Mattes	MJ.	Mouse	strains	with	typical	mammalian	levels	of	complement
activity.	Journal	of	Immunological	Methods,	1989
For	research	scientists,	it	is	fundamental	to	have	an	accurate	and	reproducible	model	system	in	which	to
study	 disease	 pathology.	Despite	 the	 existence	 of	 several	 valuable	 animal	models	 of	GBS,	 to	 date	 no
model	fully	encompasses	all	the	pathological	events	seen	in	humans.	But	why	is	this?	Although	there	are
numerous	explanations	for	the	differences	seen,	my	personal	research	focus	has	been	on	complement	and
why	I	was	unable	to	detect	endogenous	complement	at	the	mouse	neuromuscular	junction,	when	abundant
mouse	 antibody	 deposits	 were	 present	 on	 the	 presynaptic	 membranes	 after	 passive	 immunisation.	My
naive	understanding	of	the	mouse	immune	system	led	me	in	search	of	an	explanation,	and	I	came	across
this	publication	which	shed	light	on	this	conundrum.
In	 this	 article	Ong	 and	Mattes	 acknowledge	 that	 “common	 laboratory	mouse	 strains	 have	 very	 low
complement	 levels	 relative	 to	 humans,	 rats,	 guinea	 pigs,	 rabbits	 and	 other	mammals,	 which	 limits	 the
value	of	the	mouse	as	an	experimental	model”	[2].	To	address	this	issue,	this	paper	sought	to	measure	the
complement	activity	of	43	strains	of	mice,	using	both	antibody-coated	erythrocytes	and	human	tumour	cell
targets,	thereby	measuring	classical	pathway	activation.	Only	8	of	the	43	mouse	strains	tested	had	levels
of	complement	comparable	to	other	mammals,	and	it	was	interesting	to	learn	that	4	of	these	had	only	very
recently	been	derived	from	a	wild	mouse	population.	Of	course,	the	mice	I	had	been	using	in	my	research
didn’t	make	this	short	 list	of	strains	with	effective	complement	activity!	In	search	of	an	explanation	for
this	phenomenon,	the	authors	measured	the	individual	components	of	the	classical	pathway	and	reported
elevated	levels	of	C3,	C5,	C6	and	C7	(with	no	difference	in	other	component	levels)	in	mice	with	greater
complement	activity.
Because	 this	 article	 provided	 a	 valuable	 insight	 into	 the	 issue	 of	 mouse	 complement,	 we	 were
confident	 that	 this	 relatively	weak	 performance	 of	 complement	 in	 our	mice	 could	 be	 circumvented	 by
utilising	complement-regulator	knockout	mice,	and	this	takes	me	nicely	on	to	my	next	paper.
Lin	F,	et	al.	Markedly	enhanced	susceptibility	to	experimental	autoimmune	myasthenia
gravis	in	the	absence	of	decay-accelerating	factor	protection.	Journal	of	Clinical
Investigation,	2002
In	2003	I	was	very	fortunate	to	spend	a	week	in	the	laboratory	of	Professor	M.	Edward	Medof	and	Dr
Feng	Lin	at	Case	Western	Reserve	University	in	Ohio.	This	visit	resulted	from	reading	this	article,	which
drew	many	similarities	with	my	own	model	system,	and	I	was	keen	to	see	if	the	impressive	results	that
they	had	documented	in	their	decay	accelerating	factor	knockout	(DAF	KO)	mouse	model	of	myasthenia
gravis	could	be	replicated	for	GBS	[3].
In	their	model	of	myasthenia	gravis,	Lin	and	colleagues	passively	induced	mice	with	rat	monoclonal
antibodies	targeting	nicotinic	acetylcholine	receptors	on	the	post-synaptic	neuromuscular	membrane.	They
reported	 that,	 compared	 to	 wild	 type	mice,	 knocking	 out	 the	 gene	 for	 the	 complement	 regulator	 DAF,
which	 accelerates	 the	 breakdown	 of	 both	 the	 classical	 and	 alternative	 pathway	 derived	 C3	 and	 C5
convertases,	 resulted	 in	 mice	 with	 exacerbated	 disease	 pathology.	 This	 was	 measured	 both
physiologically	 and	 at	 the	 ultrastructural	 level,	 in	 addition	 to	 detecting	 a	 greater	 frequency	 of	 NMJ
colocalising	with	the	intermediate	complement	component	C3b.	This	clearly	demonstrated	a	key	role	for
this	complement	regulator	at	the	post-synaptic	membrane,	but	I	wanted	to	see	if	the	presynaptic	membrane
would	be	equally	governed	by	this	regulator	in	our	disease	paradigm.	Disappointingly,	preliminary	results
didn’t	 reveal	 an	 acute	model	 of	GBS	 in	 these	mice.	 However,	 this	 presented	 us	with	 a	 new	 tactic	 to
bypass	 the	 inherent	 issues	 of	 low	 complement	 activity	 in	mice	 and	 site-specific	 complement	 regulator
activity	in	mice.
Pangburn	MK	and	Müller-Eberhard	HJ.	Complement	C3	convertase:	cell	surface
restriction	of	β1H	control	and	generation	of	restriction	on	neuraminidase-treated	cells.
Proceedings	of	the	National	Academy	of	Sciences	of	the	United	States	of	America,	1978
Following	on	the	theme	of	complement	regulators,	I	have	selected	another	paper	highlighting	the	dominant
activity	of	the	complement	regulator	β1H	(Factor	H)	in	a	sialic	acid	rich-membrane	environment.
In	this	paper	the	authors	identify	a	role	for	sialic	acid	in	influencing	alternative	pathway	activation	of
complement	[4].	While	the	alternative	pathway	is	not	directly	triggered	by	antibody	fixation,	it	can	serve
to	 amplify	 the	 complement	 cascade	 subsequent	 to	 classical	 pathway	 activation.	 In	 this	 article	 treating
cells	with	neuraminidase	(which	cleaves	sialic	acid	residues	from	cells)	converted	a	non-activator	into
an	activator	of	alternative	complement.	 It	 is	now	understood	 that	 the	 fluid	phase	complement	 regulator,
Factor	H	(β1H),	 readily	binds	 to	 sialic	 acid	 and	other	polyanionic	molecules,	 thereby	protecting	 cells
from	complement	by	decay	accelerating	activity	of	 the	alternative	pathway	C3	convertase	and	cofactor
activity	 for	 Factor	 I	 mediated	 C3b	 cleavage.	 While	 this	 principal	 suggests	 a	 relative	 protective
environment	 of	 ganglioside-rich	 neuronal	 membranes	 to	 complement	 activation,	 whereby	 alternative
pathway	amplification	is	attenuated	under	normal	conditions,	it	also	highlights	one	of	the	many	problems
associated	with	generating	a	reliable	complement-dependent	model	at	this	site.
Hillmen	P,	et	al.	Effect	of	eculizumab	on	hemolysis	and	transfusion	requirements	in	patients
with	paroxysmal	nocturnal	hemoglobinuria.	The	New	England	Journal	of	Medicine,	2004
As	discussed	in	the	Morgan	paper	above,	complement	plays	a	key	role	in	driving	inflammation	and	cell
damage	 in	 many	 neurological	 diseases.	 Pharmaceutical	 companies	 are	 aware	 of	 the	 great	 need	 to
modulate	or	inhibit	complement	activity,	yet	until	recently	there	has	been	a	void	of	clinical	complement
therapeutics.	It	was	in	2007	that	the	FDA	approved	the	use	of	eculizumab	for	the	treatment	of	patients	with
paroxysmal	 nocturnal	 hemoglobinuria	 (PNH)	 and	 to	 date	 it	 has	 been	 approved	 for	 use	 in	 50	 other
countries.	 Eculizumab	 is	 a	 recombinant	 humanised	 monoclonal	 antibody	 which	 binds	 to	 complement
component	C5,	thereby	specifically	inhibiting	progression	of	the	complement	cascade	to	the	terminal	lytic
pore,	membrane	attack	complex	and	the	release	of	the	potent	anaphylatoxin	C5a.
In	this	paper	the	authors	describe	the	trial	use	of	eculizumab	over	a	12-week	period	for	the	clinical
treatment	of	a	small	group	of	patients	with	PNH,	a	rare	genetic	disorder	arising	from	the	somatic	mutation
of	 the	 PIG-A	 gene	 in	 pluripotent	 hematopoietic	 stem	 cells,	 which	 encodes	 a	 protein	 essential	 for	 the
synthesis	of	glycosylphophatidyllinositol	(GP1,	a	lipid	component	which	anchors	a	variety	of	proteins	in
the	plasma	membrane)	[5].	Two	of	these	GPI-anchored	proteins	that	are	absent	in	PNH	patients	are	the
complement	 regulators	 DAF	 and	 CD59,	 which	 leaves	 patient	 erythrocytes	 highly	 vulnerable	 to
intravascular	hemolysis,	venous	thrombosis	and	hemoglobinuria.	Biochemical	and	clinical	monitoring	of
the	patients	in	this	trial	revealed	a	remarkable	improvement	in	haemolytic	indicators.	The	requirement	for
blood	transfusion	was	reduced,	hemoglobinuria	was	reduced	by	96%	and	quality	of	life	indicators	also
improved	significantly.
Back	in	2003	I	was	first	introduced	to	Alexion	Pharmaceuticals	at	the	European	Complement	Network
in	Trieste,	 Italy.	The	 therapeutic	power	of	eculizumab	was	very	apparent	and	we	were	delighted	when
they	agreed	to	let	me	test	its	effectiveness	in	our	humanised	mouse	model	of	GBS.	This	was	the	beginning
of	our	collaboration	with	Alexion	Pharmaceuticals	which	has	now	flourished	into	an	ongoing	clinical	trial
of	 eculizumab	 in	GBS.	 I	 am	extremely	proud	 to	have	contributed	 towards	 this	goal	of	developing	new
therapeutics,	and	I	wait	with	great	anticipation	for	the	outcome	of	this	study.
Complement	in	the	Clinic
One	of	my	favourite	quotes	of	all	time	is	from	Sir	Isaac	Newton—“If	I	have	seen	further	than	others,	it	is
by	standing	upon	the	shoulders	of	giants”—and	I	feel	it	is	a	fantastic	image	of	research	in	general,	and	of
our	progress	in	understanding	complex	conditions	such	as	GBS.	Whilst	I	have	no	pretensions	to	my	own
significance,	contributing	to	this	chapter	allows	me	to	reflect	on	the	path	that	has	shaped	my	own	role	in
GBS	research.
Selecting	papers	from	the	legion	that	have	shaped	our	understanding	of	the	role	of	complement	in	GBS
is	nearly	impossible,	so	forgive	any	perceived	folly	and	allow	me	to	indulge	in	a	rather	personal	journey,
chronicling	key	moments	in	my	understanding.
Koski	CL,	et	al.	Activation	of	terminal	components	of	complement	in	patients	with	Guillain-
Barré	syndrome	and	other	demyelinating	neuropathies.	The	Journal	of	Clinical
Investigation,	1987
This	paper	was	my	very	first	introduction	to	the	topic	of	complement	and	GBS.	Little	did	I	realise	that	I
would	go	on	to	be	intimately	familiar	with	it,	and	frequently	quote	it,	when	discussing	my	project.
Koski	and	colleagues’	use	of	ELISA,	using	antibodies	to	C9	expressed	neoantigens,	on	sera	from	both
patients	with	GBS	and	controls	showed	the	presences	of	SC5b-9,	or	the	complement-induced	membrane
attack	 complex	 (MAC),	 in	 those	with	GBS,	 but	 none	 in	 the	 normal	 control	 group	 [6].	 Their	 work	 on
kinetic	 studies	 for	 complement-fixing	 antibodies	 showed	 a	 correlation	 between	 decreasing	 levels	 of
circulating	antibody	and	SC5b-9,	and	an	improvement	in	muscular	strength.	Immunostaining	of	peripheral
nerve	 segments	 detected	 the	 presence	 of	 C9,	 which	 was	 focal	 and	 segmental	 in	 nature.	 This	 drew	 a
temporal	association	between	antibody	production	and	MAC	formation	in	patients	with	GBS.
Griffin	JW,	et	al.	Pathology	of	the	motor-sensory	axonal	Guillain	Barré	syndrome.	Annals
of	Neurology,	1996;	and	Hafer-Macko	C,	et	al.	Acute	motor	axonal	neuropathy:	an
antibody	mediated	attack	on	axolemma.	Annals	of	Neurology,	1996
With	my	appetite	whetted,	 I	delved	further	 into	 the	work	of	Griffin	 ,	Hafer-Macko	and	 their	colleagues
during	 the	 1990s,	 who	 characterised	 pathological	 findings	 in	 GBS	 and	 formed	much	 of	 the	 basis	 our
modern	understanding	of	the	AMAN	variant	[7].	These	2	papers	explore	the	immunopathology	of	axonal
GBS	 through	 autopsy	 pathological	 samples.	 The	 former	 demonstrates	 Wallerian-like	 degeneration	 in
affected	 nerves,	 showing	 macrophage	 infiltration	 in	 the	 peri-axonal	 space,	 and	 uses	 its	 discussion	 to
postulate	links	between	severity	of	nodal	damage	and	activation	of	complement	in	the	nodal	region.	The
Hafer-Macko	 paper	 describes	 nodal	 complement	 deposition,	 and	 highlights	 the	 differences	 in	 patterns
between	what	we	see	 in	AIDP	and	AMAN	[8].	Together	 these	papers	began	 to	unpick	 the	 relationship
between	 complement	 and	 AMAN,	 allowing	 me	 to	 get	 a	 further	 handle	 on	 not	 only	 the	 complex
relationships	 between	 complement	 and	 GBS,	 but	 also	 on	 the	 complex	 relationships	 between	 different
subtypes	of	GBS.
McGonigal	R,	et	al.	Anti-GD1a	antibodies	activate	complement	and	calpain	to	injure	distal
motor	nodes	of	Ranvier	in	mice.	Brain,	2010
Jumping	 forward	 somewhat,	 to	 a	 time	 when	 pathogenic	 anti-ganglioside	 antibodies	 thought	 to	 drive
axonal	GBS	were	characterised,	McGonigal	and	colleagues’	paper	not	only	demonstrated	the	deposition
of	 membrane	 attack	 complexes	 at	 nodes	 of	 Ranvier,	 but	 also	 offered	 a	 functional	 analysis,	 using
electrophysiological	assessments	to	show	lack	of	current	flow	once	the	MAC	had	bound,	and	conversely
showing	that	inhibiting	complement	activation	could	also	be	protective	to	the	nodes	of	Ranvier,	which	of
course	 was	 significant	 to	 me	 as	 I	 was	 hoping	 to	 prove	 something	 akin	 to	 this	 on	 a	 slightly	 different
population	[9]!
Halstead	SK,	et	al.	Eculizumab	prevents	anti-ganglioside	antibody	mediated	neuropathy	in
a	murine	model.	Brain,	2008
This	paper	is,	for	me,	a	cornerstone	for	the	use	of	C5	inhibitors	in	the	treatment	of	GBS.	Sue	Halstead	and
colleagues	used	a	novel	murine	model	of	Miller	Fisher	variant	GBS,	created	by	intraperitoneal	injection
of	 anti-GQ1b	 antibody	 and	 normal	 human	 serum,	 to	 show	 the	 antibody-driven,	 complement-derived
respiratory	paralysis	could	be	abrogated	by	intravenous	injections	of	C5	inhibitor	eculizumab	[10].	The
in	 vitro	 work	 performed	 in	 parallel	 showed	 application	 of	 Eculizumab	 completely	 prevented	 MAC
deposition	at	neuromuscular	 junctions,	 compared	 to	 controls	using	a	 ‘dummy’	mAb,	 and	damage	 to	 the
perisynaptic	Schwann	cells	was	abolished.	This	evidence	was	pivotal	in	the	move	to	use	eculizumab	in	a
clinical	trial	setting,	in	a	patient	cohort	with	severe	GBS.
What	I	have	touched	on	here	is	very	much	the	tip	of	the	iceberg,	but	for	me	encapsulates	the	beginnings
of	a	journey	into	understanding	some	of	the	complex	immunopathology	of	GBS.	As	a	clinician	by	trade	I
also	am	drawn	to	translational	research,	where	I	can	see	a	story	moving	from	‘bench	to	bedside’,	which	is
very	much	the	case	for	complement	and	GBS.	We	are	now	at	a	point	where,	for	the	first	time	ever,	people
have	 received	 doses	 of	 eculizumab	 for	 their	GBS,	 and	 time	will	 tell	 if	we	 can	 replicate	 the	 fantastic
responses	we	have	 seen	 in	 our	 animal	models.	What	 I	 find	most	 intriguing	 about	 this	 is	 the	 thought	 of
reading	this	chapter	again	in	10	years’	time.	Will	complement	inhibition	be	the	norm	in	treating	GBS?	Or
will	it	be	relegated	to	annals	of	history?	I	await	with	bated	breath	what	the	future	will	hold.
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The	Role	of	T	Cells	in	Guillain-Barré	Syndrome
Christopher	Linington
Introduction
Adoptive	 transfer	 studies	 demonstrate	 that	 the	 minimal	 requirement	 to	 initiate	 inflammation,
demyelination	and	axonal	 loss	 in	 the	peripheral	nervous	system	(PNS)	 is	a	 tissue-specific	CD4+	T-cell
response.	This	observation	marked	my	first	foray	into	neuroimmunology	and	prompted	speculation	that	a
similar	mechanism	contributed	 to	 the	pathogenesis	of	Guillain-Barré	 syndrome	 (GBS).	This	 concept	 is
now	 largely	discounted	with	 respect	 to	GBS,	but	 increasing	evidence	 indicates	 the	T-cell	 compartment
plays	 important	 roles	 in	 other	 diseases	 affecting	 the	 PNS,	 in	 particular	 Charcot-Marie-Tooth	 disease
(CMT)	 and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 (CIDP).	 My	 personal	 and	 somewhat
eclectic	Top	10	attempts	to	place	these	studies	in	their	historical	context,	developing	a	theme	that	T	cell-
mediated	autoaggression	synergises	with	other	effector	mechanisms	to	exacerbate	tissue	damage	across	a
broad	swath	of	PNS	disorders.
Boston	1955:	Experimental	Autoimmune	Encephalomyelitis	(EAN)
Adams	 and	 Waksman	 developed	 the	 first	 model	 of	 experimental	 allergic	 neuritis	 (EAN)	 in	 which
inflammatory	 demyelination	 was	 restricted	 to	 the	 PNS	 by	 immunising	 rabbits	 with	 sciatic	 nerve
homogenates	 emulsified	 in	 Freund’s	 complete	 adjuvant	 [1].	 They	 noted	 that	 the	 structure	 and	 cellular
composition	of	 these	 lesions	resembled	 that	seen	 in	some—but	not	all—cases	of	GBS,	 leading	 them	to
state	 these	 were	 “sufficiently	 impressive	 to	 justify	 a	 further	 exploration	 of	 the	 possibility	 that	 acute
‘infectious’	polyneuritis	may	have	an	immunologic	basis”.	Moreover,	as	similar	lesions	could	be	induced
by	 immunizing	 rabbits	 with	 CNS	 tissue	 homogenates,	 they	 concluded	 “there	 must	 clearly	 exist	 in	 the
rabbit’s	 peripheral	 nervous	 system	 an	 antigen	 which	 is	 absent	 in	 its	 central	 nervous	 system.”	 This
statement	set	the	scene	for	future	studies	on	EAN	and	its	relationship	to	GBS,	but	30	years	passed	before
the	efforts	of	researchers	across	the	globe	identified	this	‘neuritogen’	and	its	mode	of	action.
Evidence	is	lacking,	however,	that	humoral	antibody	to	nervous	tissue	antigens	is	in	any	way	related	to
the	 disease	 process;	 passive	 transfer	 of	 either	 disease	with	 serum	 from	 sensitised	 animals	 has	 proved
impossible.
Boston	1962:	EAN,	a	Cell-Mediated	Disease
The	development	of	EAN	as	a	model	replicating	several	of	the	clinical	and	pathological	features	of	GBS
in	 man	 prompted	 an	 intense	 effort	 to	 determine	 the	 nature	 of	 the	 immune	 response	 responsible	 tissue
damage	in	the	PNS.	Initial	interest	focused	on	the	possible	role	of	antibodies,	but	passive	transfer	of	EAN
with	 serum	 from	 sensitised	 animals	 was	 ineffective.	 This	 led	 Åström	 and	 Waksman	 to	 consider	 the
possibility	 it	 was	 mediated	 by	 a	 cellular,	 delayed	 hypersensitivity	 response	 within	 the	 PNS	 [2].	 The
ability	 of	 lymph	 node	 cells	 derived	 from	 a	 sensitized	 animal	 to	 induce	 hypersensitivity	 responses	 in
normal	 recipients	 had	 been	 established	 some	 40	 years	 earlier	 by	 Landsteiner	 and	 Chase,	 so	 it	 was	 a
logical	step	to	extend	this	concept	to	the	pathogenesis	of	tissue	specific	‘allergic’	diseases	such	as	EAN.
In	 this	 paper	 Åström	 and	 Waksman	 describe	 the	 ability	 of	 lymph	 node	 cells	 isolated	 from	 donors
immunised	with	bovine	sciatic	nerve	homogenate	in	adjuvant	to	induce	in	naïve	recipients	a	disease	that
was	 indistinguishable	 from	actively	 induced	EAN.	This	 study	was	performed	 in	New	Zealand	 rabbits,
and	perhaps	not	surprisingly,	in	view	of	our	current	understanding	of	immunology,	disease	penetrance	and
severity	 were	 low.	 Nonetheless,	 cells	 from	 donors	 immunised	 with	 kidney	 homogenates	 or	 adjuvant
alone,	 or	 killed	 cells	 from	 animals	 immunised	 with	 nervous	 tissue,	 were	 unable	 to	 induce	 EAN,
establishing	the	dominant	role	of	a	cellular	immune	response	in	disease	induction.
London,	1979:	P2	Protein:	The	First	Defined	Neuritogen
Beyond	the	fact	EAN	was	cell	mediated	[2]	further	progress	towards	understanding	its	pathogenesis	had
to	await	identification	of	the	‘neuritogenic’	component	of	PNS	myelin	first	posited	to	exist	by	Adams	and
Waksman	[1].	This	was	finally	achieved	in	1979	by	Kadlubowski	and	Hughes,	who	demonstrated	purified
bovine	P2	protein	was	highly	neuritogenic	in	the	Lewis	rat,	thereby	opening	the	way	towards	elucidating
the	mechanistic	basis	of	EAN	[3].	The	authors’	 success	was	dependent	 largely	on	 their	 selection	of	an
appropriate	combination	of	antigen	source	and	species,	but	they	also	note	“clinical	disease	produced	by
the	 pure	 neuritogen	 was	 slightly	 less	 severe	 than	 that	 induced	 by	 whole	 myelin”,	 an	 observation	 that
pointed	 towards	 the	 existence	 other	 neuritogens	 in	 PNS	 myelin	 [4].	 A	 complication	 that	 may	 in	 part
account	for	the	failure	of	subsequent	attempts	to	identify	a	clear	association	between	P2	protein-specific
immunity	and	disease	activity	in	human	disease.
Würzburg,	1984:	Adoptive	Transfer	of	EAN	by	P2-Specific	CD4+	T	Cells
Demonstrating	that	the	P2	protein-specific	T-cell	response	was	the	minimal	requirement	to	induce	EAN	in
the	Lewis	 rat	marked	my	 entry	 into	 the	world	 of	 neuroimmunology	 [5].	 I	was	 fortunate	 enough	 to	 join
Hartmut	Wekerle	at	 the	Max-Planck	Clinical	Research	Group	for	Multiple	Sclerosis	and	developed	 the
first	adoptive	transfer	model	of	T	cell-mediated	EAN	in	the	rat.	We	found	intravenous	transfer	of	as	few
as	5	×	104	freshly	activated	P2-specific	T	cells	was	sufficient	to	induce	mild	but	consistent	clinical	signs
of	disease	in	naïve	Lewis	rats.	Clinical	disease	in	these	animals	was	associated	with	focal	infiltrates	of
CD4+	 T	 cells	 and	 macrophages,	 breakdown	 of	 the	 blood-nerve	 barrier	 and	 primary	 demyelination.
However,	 the	 intensity	 of	 this	 inflammatory	 response	 increased	 in	 proportion	with	 the	 dose	 of	T	 cells
transferred,	 reaching	 a	 threshold	 beyond	which	 axonal	 degeneration	was	 the	 primary	 pathologic	 effect
which	 resulted	 in	 widespread	 secondary	 demyelination	 that	 in	 many	 cases	 extended	 into	 the	 dorsal
columns	of	the	spinal	cord.	This	study	established	that	the	minimal	requirement	to	initiate	EAN	in	a	naïve,
immunocompetent	 host	 was	 a	 neuritogenic	 CD4+	 T-cell	 response,	 and	 it	 initiated	 a	 number	 of	 studies
exploring	effector	mechanisms	 that	were	ultimately	 responsible	 for	 loss	of	 function	and	 tissue	damage.
These	 are	 now	 known	 to	 be	 largely	 macrophage-dependent	 and	 can	 be	 exacerbated	 by	 antibody-
dependent	mechanisms	[6],	raising	speculation	about	a	similar	combination	of	effector	mechanisms	which
might	drive	disease	progression	in	CIDP.
Chicago,	2001:	Spontaneous	Murine	Autoimmune	Peripheral
Polyneuropathy	(SAPP)
As	documented	elsewhere	in	this	volume,	the	last	decade	of	the	20th	century	saw	an	increasing	awareness
that	 autoantibody-dependent	 pathomechanisms	were	 involved	 in	many	 peripheral	 neuropathies,	 and	 not
surprisingly	this	was	paralleled	by	a	concurrent	decline	in	interest	in	T	cell-dependent	mechanisms.	That
was	until	the	serendipitous	and	completely	unexpected	finding	that	the	B7-2	blockade	in	the	NOD	mouse
initiates	 a	 spontaneous	 autoimmune	 peripheral	 polyneuropathy	 (SAPP)	 which	 reproduces	 many	 of	 the
clinical,	 electrophysiological	 and	 pathological	 features	 of	 CIDP	 [7].	 The	 mechanistic	 basis	 by	 which
ablation	of	the	CD28/B7-2	co-stimulatory	pathway	unleashed	this	previously	cryptic	neuritogenic	CD4+
T-cell	 response	 in	 the	 context	 of	 this	 particular	 genetic	 background	 remains	 unclear,	 but	 it	 rekindled
interest	 in	 the	 possibility	 that	 the	 CD4+	 T-cell	 compartment	 contributes	 to	 the	 aetiology	 of	 CIDP,	 and
possibly	even	to	some	variants	of	GBS.
San	Francisco,	2009:	P0-Specific	CD4+	Th1	Effector	T	Cells	Mediate
SAAP	in	NOD	Mice
Some	8	years	after	the	initial	description	of	SAPP	[7],	Bluestone’s	group	identified	myelin	P0	protein	as
the	major	 target	 for	 the	 neuritogenic	T-cell	 response	 [4].	Using	P0-specific	T-cell	 hybridomas	derived
from	 T	 cells	 infiltrating	 the	 PNS	 of	 affected	 mice,	 the	 authors	 then	 generated	 a	 P0	 T-cell	 receptor
transgenic	mouse	 line	(POT)	 to	explore	 the	development,	 regulation	and	pathogenicity	of	P0-specific	T
cells	 in	 vivo.	 This	 revealed	 that	 P0-specific	 T	 cells	 can	 survive	 thymic	 selection	 to	 populate	 the
periphery,	 but	 their	 neuritogenic	 potential	 in	 immunocompetent	 wild	 type	 mice	 is	 then	 held	 in	 check,
primarily	by	CD4+	Foxp3+	regulatory	T	cells.	This	regulatory	checkpoint	is	lost	when	POT	mice	are	bred
onto	 a	 recombination-activating	 gene	 (RAG)	 deficient	 background,	 resulting	 in	 a	 fulminant	 early-onset
neuropathy	mediated	by	P0-specific	CD4+	IFNγ+	Th1	effector	T	cells.	The	phenotype	of	this	effector	T-
cell	response	is	in	agreement	with	other	studies,	indicating	development	of	SAPP	is	IFNγ	dependent,	and
by	extrapolation	suggests	this	T-cell	subset	might	contribute	to	the	immunopathogenesis	of	CIDP.
London,	2009:	CIDP	Is	Associated	with	a	Functional	Defect	in
Regulatory	T	Cells
The	 low	 prevalence	 of	 CIDP	makes	 it	 difficult	 to	 obtain	 sufficiently	 large	 patient	 cohorts	 to	 identify
disease-associated	 changes	 in	 immune	 cell	 function.	 However,	 several	 research	 groups	 took	 on	 this
challenge,	 including	 Hughes	 and	 colleagues,	 who	 provide	 evidence	 that	 CIDP	 is	 associated	 with	 a
functional	defect	in	regulatory	CD4+CD25high	T	cells	[8].	However,	this	defect	does	not	occur	in	isolation
as	 immunophenotyping	 revealed	 circulating	 monocytes	 were	 increased	 whilst	 NK	 cell	 numbers	 were
decreased	 between	 patients	 and	 controls.	 In	 contrast,	 there	 were	 no	 significant	 differences	 in	 the
frequency	 of	 circulating	 B	 cells,	 CD4+	 and	 CD8+	 T-cell	 subsets	 or	 crucially	 CD4+	 Foxp3+	 or
CD4+CD25highFoxp3+	cells.	The	authors	were	cautious	in	interpreting	their	findings	and	state	that	further
studies	will	certainly	require	larger	numbers	of	patients.	Nonetheless,	their	results	clearly	indicate	CIDP
is	associated	with	a	defect	in	Treg	function,	an	observation	that	has	parallels	to	the	SAPP	in	the	mouse
[4,7].
Sydney,	2014:	Synergy	between	T-Cell	and	Antibody-Dependent
Mechanisms	in	EAN
Neuritogenic	CD4+	Th1	T	cell	responses	play	an	essential	role	in	the	pathogenesis	of	EAN	[5]	and	SAPP
[4,7],	 and	 many	 may	 be	 persuaded	 this	 is	 also	 the	 case	 in	 CIDP	 [8].	 However,	 while	 these	 studies
highlight	the	ability	of	CD4+	T	cells	to	trigger	inflammatory	disease	activity	in	the	PNS,	they	do	not	rule
out	 involvement	 of	 other	 immune	 effector	 mechanisms,	 in	 particular	 autoantibody-	 and	 CD8+	 T	 cell-
mediated	effects.	The	former	is	particularly	relevant	in	CIDP,	which	exhibits	multiple	clinical	phenotypes
and	in	some	cases	responds	to	plasma	exchange.	However,	if	antibodies	are	involved	in	these	cases,	how
do	pathologically	significant	amounts	gain	access	to	the	PNS?	In	this	report	Mathey’s	group	demonstrate
the	 inflammatory	 response	 induced	by	a	 low	dose	of	neuritogenic	CD4+	T	cells	 is	 sufficient	 to	disrupt
BNB	integrity	enough	 to	 facilitate	access	of	pathogenic	neurofascin-specific	antibody	 into	 the	PNS	and
exacerbate	 clinical	 disease	 [6].	 Extrapolating	 this	 concept	 to	 human	 neuropathies	 raises	 a	 simple	 but
rather	important	question:	what	are	the	threshold	values	for	antigen-specific	T	cells	and/or	autoantibodies
to	induce	a	clinically	relevant	effect	in	the	PNS?	This	is	important	as	progressively	more	sensitive	cell-
based	 assays	 are	being	 introduced	 to	detect	 ‘potentially’	pathogenic	 autoantibody	 responses	 in	 clinical
samples.
Montreal,	2014:	At	Last	Something	about	CD8+	T	Cells
EAN	 [5]	 and	 SAPP	 [4,7]	 established	 a	 pre-eminent	 role	 for	 CD4+	 T	 cells	 in	 the	 pathogenesis	 of
inflammatory	demyelinating	peripheral	neuropathies,	but	as	 stated	by	Salomon	 in	2001	 these	 results	do
not	 rule	out	 the	possibility	pathogenic	CD8+	T	cells	may	play	a	 role	 in	 the	aetiology	of	 these	diseases
after	longer	periods	of	time.	Thirteen	years	later	evidence	is	now	available	that	this	is	indeed	the	case,	as
demonstrated	by	the	development	of	a	spontaneous	autoimmune	peripheral	polyneuropathy	(SAPP)	in	L31
transgenic	mice	bred	onto	a	CD4-/-	 background	 [9].	These	mice	develop	a	 range	of	motor	 and	 sensory
deficits	 that	 are	 associated	with	 large	 numbers	 of	macrophages	 and	CD8+	 T	 cells	 infiltrating	 the	 PNS
accompanied	by	demyelination	and	varying	degrees	of	axonal	loss.	This	model	indicates	that	disruption	of
immune	 homeostasis	 due	 to	 constitutive	 overexpression	 of	 B7.2	 can	 trigger	 a	 profound	 CD4+	 T	 cell-
independent	 inflammatory	 response	 in	 the	 PNS.	 However,	 data	 are	 not	 yet	 available	 to	 formally
demonstrate	or	confirm	tissue	damage,	and	associated	clinical	deficits	in	this	model	are	mediated	directly
by	components	of	the	CD8+	T-cell	repertoire.
Würzburg,	2006:	T	Cells	in	Inheritable	Neuropathies
The	 rather	 eclectic	 collection	 of	 papers	 discussed	 above	 map	 the	 development	 of	 the	 concept	 that
adaptive	 T-cell	 responses	 play	 significant	 roles	 in	 the	 pathogenesis	 of	 acquired	 inflammatory
demyelinating	 diseases	 of	 the	 PNS,	 but	 it	 should	 not	 be	 forgotten	 that	 there	 is	 a	 small	 but	 parallel
literature	implicating	T-cell	immunity	in	the	pathogenesis	of	demyelination	in	mouse	models	of	Charcot-
Marie-Tooth	(CMT)	disease	[10].	In	these	genetically	determined	neuropathies,	demyelination	and	axonal
injury	are	associated	with	CD8+	T	cells	 infiltrating	the	PNS,	an	observation	that	 led	Martini’s	group	to
cross	 these	 mutants	 onto	 a	 RAG-1-deficient	 background	 to	 determine	 whether	 this	 response	 had	 any
functional	significance	[10].	This	proved	to	be	the	case	as	tissue	damage	was	significantly	ameliorated	in
the	 double	 mutants,	 demonstrating	 for	 the	 first	 time	 the	 involvement	 of	 the	 immune	 system	 in	 the
pathogenesis	of	an	inherited	neuropathy.
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Towards	Understanding	Endoneurial	Inflammation
and	Nerve	Injury	in	GBS
Kazim	A.	Sheikh
Introduction
We	begin	by	strongly	commending	Hugh	Willison	and	John	Goodfellow’s	 initiative	of	GBS100	Top	10
monographs,	particularly	its	clever,	unconventional/bohemian	format.	This	format	allows	free	association
of	one’s	own	work	with	that	of	most	influential	and	brilliant	works	in	the	field;	provides	another	chance
to	give	new	meaning	and	context	 to	one’s	works;	gives	unfettered	opportunities	 to	generate	hypotheses
(conjecture)	and	conclusions	(opinions);	and	importantly	unburdens	the	fear	of	rejection	from	the	highly
overrated	process	of	peer	review.	We	take	the	liberty	of	formulating	this	chapter	in	conformity	with	the
free-spirited	intent	of	the	editors	(Hugh	and	John).
Understanding	the	Final	Common	Pathogenetic	Pathway(s)	of
Endoneurial	Inflammation	That	Mediate	Nerve	Injury	(Myelin	and
Axonal)
Guillain-Barré	 syndrome	 (GBS)	 encompasses	 a	 group	 of	 related	 neuropathic	 disorders,	 considered
autoimmune	in	nature,	that	commonly	share	endoneurial	inflammation	(cellular	and	noncellular)	as	a	key
feature.	 That	 a	 synergism	of	 cellular	 and	 humoral	 immune	 elements	 is	 involved	 in	 the	 pathogenesis	 of
these	disorders	is	a	commonly	favoured	hypothesis	but	not	accepted	universally.	That	antigen	specificity
and	 nature	 of	 adaptive	 autoimmune	 responses,	 especially	 T-cell	 responses,	 are	 not	 well	 defined,
particularly	 for	 the	commonest	 form	of	GBS,	acute	 inflammatory	demyelinating	polyradiculoneuropathy
(AIDP);	this	is	considered	a	critical	gap	in	our	knowledge	by	some.	There	is	strong	evidence	for	the	role
of	specific	anti-glycan	or	ganglioside	antibodies	(AGAs)	in	the	pathogenesis	of	axonal	and	Fisher	forms
of	GBS.	Adaptive	autoimmunity	uses	the	powerful	effector	functions	of	cells	of	the	innate	immune	system,
including	 monocytes/macrophages	 to	 induce	 target	 tissue	 inflammation	 and	 injury	 in	 autoimmune
disorders.	 The	 pathologic	 studies	 in	 demyelinating	 and	 axonal	 GBS	 indicate	 a	 central	 role	 for
macrophage	 populations,	 which	 are	 the	 key	 components	 of	 innate	 immune	 system	 and	 endoneurial
inflammation.	 Macrophage-mediated	 myelin	 stripping	 and	 nodal	 and	 periaxonal	 macrophage-mediated
attacks	 on	 axons	 are	 pathognomonic	 features	 of	 AIDP	 and	 axonal	 GBS,	 respectively.	 Perhaps	 classic
immunology	paradigms	overemphasize	the	role	of	recognizing	the	specific	antigens	and	adaptive	immune
responses	in	autoimmune	disorders.	Studying	inflammation,	independent	of	antigen	and	adaptive	immune
response	specificity,	can	be	a	fruitful	endeavour,	as	borne	out	in	the	area	of	multiple	sclerosis.	A	major
challenge	in	the	context	of	GBS	is	to	determine	whether	shared	common	pathways	of	innate	immunity	that
constitute	 endoneurial	 inflammation	 and	 mediate	 nerve	 (myelin	 and	 axonal)	 injury	 exist	 in	 individual
inflammatory	neuropathies	grouped	under	GBS	and	what	their	key	components	are.	The	current	discussion
narrowly	 focuses	 on	 the	 role	 of	 inflammation	 and/or	 inflammatory	 milieu,	 downstream	 of	 known	 or
unknown	adaptive	nerve-specific	immune	responses,	in	mediating	nerve	injury	in	GBS,	highlighting	some
of	 our	 work	 in	 this	 context.	 The	 discussion	 is	 skewed	 towards	 macrophage	 inflammation	 in	 the
endoneurium,	as	we	anticipate	other	contributors	of	this	volume	will	cover	other	cellular	and	noncellular
(such	as	complement)	elements	of	endoneurial	 inflammation.	With	 this	background	in	mind,	our	Top	10
monographs	in	English	follow.
Waksman	BH	and	Adams	RD.	Allergic	neuritis:	Experimental	disease
in	rabbits	induced	by	the	injection	of	peripheral	nervous	tissue	and
adjuvants.	Journal	of	Experimental	Medicine,	1955
Waksman	 and	Adams’	 landmark	 paper	 is	 highly	 likely	 to	 feature	 in	 several	monographs	 in	 the	 current
collection	[1].	The	authors	provide	fundamental	and	comprehensive	experimental	animal	data	that	support
the	concept	of	 inflammatory	neuropathic	disease.	In	 this	study,	 the	experimental	allergic	neuritis	(EAN)
was	generated	in	rabbits	by	immunizing	with	homologous	and	heterologous	sciatic	nerves.	These	animals
developed	 clinical	 disease	 approximately	 2	 weeks	 after	 immunization.	 There	 was	 elevation	 of	 CSF
protein	without	pleocytosis.	Notably,	spinal	roots,	dorsal	root	ganglion,	and	peripheral	nerves	developed
endoneurial	 histiocytic/monocytic	 and	 lymphocytic	 inflammation	 and	 nerve	 fibre	 demyelination	 with
variable	secondary	axonal	injury.	Importantly,	the	authors	emphasize	the	close	relationship	of	histiocytes
with	 demyelination,	 including	 the	 presence	 of	 myelin	 debris	 in	 post-phagocytic	 monocytes.	 Based	 on
these	 clinical,	 CSF	 and	 pathologic	 findings,	 Waksman	 and	 Adams	 postulated	 that	 this	 disease	 model
resembles	 the	 clinical	 conditions	 grouped	 under	 Landry’s	 paralysis,	 GBS	 and	 acute	 infectious
polyneuritis,	and	represents	one	of	 the	earliest	models	of	 inflammatory	disease	of	peripheral	nerves.	In
the	 context	 of	 the	 current	 discussion,	 this	 is	 one	 of	 the	 earliest	 studies	 noting	 endoneurial
histiocytic/monocytic	cell	populations	as	 immune	effectors	mediating	myelin	 injury	and	clearance.	This
monumental	 study	 has	 influenced	 innumerable	 researchers	 in	 the	 area	 of	GBS	 and	 led	 to	 an	 enormous
amount	of	clinical	and	experimental	work	over	the	following	half	century.
Subsequent	studies	in	EAN	have	confirmed	the	critical	role	of	lymphocytes	in	inducing	nerve	injury	in
adoptive	EAN	models	[2].	Early	ultrastructural	studies	on	EAN	nerves	by	Lampert	emphasized	the	role	of
mononuclear	 cells	 in	demyelination	 [3].	He	 reported	 that	mononuclear	 cells	 traverse	 the	Schwann	 cell
sheath,	penetrate	the	outer	mesaxon,	push	the	Schwann	cells	aside,	contact	the	myelin	sheath,	and	strip	and
dissolve	 myelin	 sheath.	 These	 studies	 imply	 mononuclear	 cellular	 contact-dependent	 inflammatory
demyelination.	In	contemporaneous	ultrastructural	studies,	Ballin	and	Thomas	reported	early	disruption	of
contacts	 formed	 by	 myelin	 terminal	 loops	 and	 paranodal	 axolemma	 at	 the	 nodes	 of	 Ranvier	 after
inflammatory	cells	 invaded	endoneurium	 in	EAN	 [4].	These	 studies	 reported	myelin	vesicular	 changes
and	postulated	that	some	of	the	demyelination	is	‘chemical’,	implying	the	endoneurial	presence	of	contact-
independent	soluble	mediators	of	inflammation	that	induce	myelin	injury.
Asbury,	et	al.	The	inflammatory	lesion	in	idiopathic	polyneuritis:	its	role	in	pathogenesis.
Medicine,	1969
Another	hugely	influential	study	from	Ray	Adams’	group,	a	direct	extension	of	their	experimental	work	in
EAN,	reported	the	universal	presence	of	lymphocytic	inflammation,	 in	autopsied	peripheral	nerves	of	a
MGH	 cohort	 of	 19	 GBS	 patients,	 at	 all	 stages	 of	 the	 disease	 [5].	 Analogous	 to	 EAN,	 primary
demyelination,	including	early	nodal	changes,	and	secondary	axonal	injury	was	found	in	almost	all	cases.
The	 authors	 opined	 “the	 role	 of	 macrophages	 in	 EAN	 and	 in	 idiopathic	 polyneuritis	 is	 uncertain.
Macrophages	 in	 both	 diseases	 are	 particularly	 prominent	 at	 sites	 of	 extensive	 myelin	 breakdown	 and
contain	 fragments	 of	 degenerating	 myelin.	 Whether	 they	 have	 some	 primary	 role	 in	 initiating	 myelin
breakdown	or	act	purely	to	clean	up	myelin	destroyed	by	lymphocytes	is	not	known.”
Whether	 demyelination	 and	 T-cell	 inflammation	 are	 universal	 pathologic	 features	 of	 all	 patients
grouped	under	GBS	was	unclear	at	 that	 time.	Haymaker	and	colleagues,	prior	 to	 the	publication	of	 the
Asbury	study,	reported	that	T-cell	inflammation	was	not	a	constant	early	pathologic	feature	in	their	GBS
cases	with	 demyelinating	 pathology	 [6].	 In	 the	mid	 1990s,	Hafer-Macko	 and	 colleagues	 also	 reported
demyelinating	GBS	cases	with	sparse	endoneurial	T-cell	inflammation	[7].	Overall,	these	clinical	studies
suggest	heterogeneity	in	T-cell	inflammation	and	pathogenesis	of	demyelinating	GBS.
In	 a	 related	 series	 of	 experimental	 studies,	 Saida	 and	 colleagues	 showed	 that	 inflammatory
demyelinating	neuropathy	can	be	induced	in	experimental	animals	without	prominent	T-cell	inflammation
[8,9,10].	 In	 their	 studies,	 rabbits	 immunized	 with	 galactocerborside	 (GalC)	 developed	 anti-GalC
antibody-mediated	 demyelinating	 neuropathy,	 which	 was	 complement	 dependent.	 Notably,	 macrophage
recruitment	and	macrophage-mediated	myelin	phagocytosis	was	prominent	in	these	studies	as	well.
In	 sum,	 T-cell	 inflammation	 could	 significantly	 vary	 in	 demyelinating	 GBS	 and	 both	 T	 cells	 and
autoantibodies	 can	 induce	overlapping	pathological	 inflammatory	demyelinating	neuropathic	 features	 in
EAN	models.	Macrophages	fare	prominently	in	pathological	descriptions	of	demyelinating	GBS	and	EAN
models	independent	of	T-cell	inflammation.
Heininger	K,	et	al.	The	role	of	macrophages	in	experimental	autoimmune	neuritis	induced
by	a	P2-specific	T-cell	line.	Annals	of	Neurology,	1988
Heininger	 and	 colleagues’	 important	 study	 showed	 that	 macrophages	 are	 essential	 to	 endoneurial
inflammation	and	nerve	fibre	damage	in	adoptive	EAN	[11].	A	number	of	studies	prior	to	this	publication
had	 shown	 the	 effector	 role	 of	macrophages	 in	 active	 EAN	 [12].	 Active	 EAN	with	myelin	 or	myelin
protein	 immunization	 include	an	 induction	phase	of	 the	autoimmune	response	 to	myelin	antigens,	during
which	 macrophages	 play	 an	 important	 role	 as	 antigen-presenting	 cells	 to	 the	 lymphocytes	 (adaptive
immune	 arm).	 The	 AT-EAN	 paradigm	 precludes	 the	 antigen-presenting	 role	 of	 macrophages	 as	 a
mechanism	 of	 protection	 in	 this	 model.	 This	 Heininger	 study	 supports	 the	 hypothesis	 that	 adoptively
transferred	T	cells	interact	with	macrophages	at	amplification	and	effector	phases	in	this	paradigm,	and
thus	 that	macrophages	are	key	components	of	endoneurial	 inflammation	 that	mediate	myelin/nerve	 fibre
injury.	This	and	other	EAN	studies	by	the	same	group	support	the	notion	that	macrophages	induce	myelin
injury	 by	 soluble	 effectors	 and	 myelin	 phagocytosis	 (cellular	 contact-independent	 and	 -dependent,
respectively)	[13,14].
Spies	JM,	et	al.	Intraneural	activated	T	cells	cause	focal	breakdown	of	the	blood-nerve
barrier.	Brain,	1995
Spies	 and	 colleagues’	 influential	 study	 demonstrates	 that	 local	 inflammatory	 milieu	 is	 important	 in
mediating	 antibody-induced	 demyelination	 [15].	 Myelin	 protein	 P2	 reactive	 T	 cells	 were	 injected
intraneurally	and	 rabbit	EAN	serum	containing	anti-GalC	activity	was	administered	systemically	 (i.p.),
which	 led	 to	 focal	 demyelination	 detected	 by	 electrophysiology	 and	 pathology.	 Similar	 changes	 in
endoneurial	 milieu	 could	 be	 obtained	 with	 activated	 T	 cells	 specific	 for	 non-neural	 antigens,	 again
emphasizing	 the	 role	of	 local	 inflammatory	milieu,	 including	 the	breakdown	of	 the	blood-nerve	barrier
(BNB)	as	critical	determinants	of	nerve	fibre	demyelination/injury.	This	study	showed	synergism	between
cellular	and	humoral	autoimmune	responses	to	produce	inflammatory	demyelination	in	peripheral	nerves.
Feasby	TE,	et	al.	An	acute	axonal	form	of	Guillain-Barré	polyneuropathy.	Brain,	1986
Introducing	 the	 concept	 of	 axonal	 GBS	 in	 the	 absence	 of	 T-cell	 inflammation,	 Feasby	 and	 colleagues
describe	7	patients	with	acute	neuropathic	illness	with	motor	predominant	phenotype	(similar	to	Landry’s
cases)	and	axonal	electrophysiology	and	pathology	[16].	The	detailed	pathological	studies	on	autopsied
materials	 in	 one	 case	 showed	 primary	 axonal	 degeneration	 without	 significant	 demyelination	 or
lymphocytic	 inflammation.	Predominant	motor	 axonal	 involvement	was	confirmed	by	electrophysiology
(inexcitable	motor	 nerves)	 and	 anterior	 root	 and	 phrenic	 (motor)	 nerve	 pathology.	 Notably,	 this	 study
directly	 correlated	 the	 severity	 of	 axonal	 injury	 with	 poor	 recovery.	 The	 authors	 opined	 that	 one
mechanism	for	 inexcitable	motor	nerves	 is	an	 increase	 in	 the	 threshold	of	excitation	of	 the	nerve	fibres
due	 to	 undefined	 changes	 in	 Schwann	 cells	 or	 axonal	 membranes,	 particularly	 along	 the	 nodal	 and
paranodal	regions	of	 the	nerve	fibre.	Subsequent	experimental	studies	support	 this	notion	of	conduction
failure	along	the	nodal	axolemma	[17].
Yuki	N,	et	al.	Acute	axonal	polyneuropathy	associated	with	anti-GM1	antibodies	following
Campylobacter	enteritis.	Neurology,	1990
Nobuhiro	 Yuki	 and	 colleagues	 reported,	 for	 the	 first	 time,	 a	 triad	 of	 acute	 axonal	 motor	 neuropathy,
preceding	Campylobacter	 infection,	 and	 IgG	 anti-GM1	 antibodies	 [18].	 This	 small	 but	 pivotal	 study
(based	 on	 2	 cases)	 wielded	 huge	 influence	 in	 this	 area	 of	 research.	 The	 triad	 recognized	 in	 this
observational	 study	 forms	 the	 basis	 of	 the	 now	well-accepted	 hypothesis	 of	molecular	mimicry	 as	 the
pathogenetic	mechanism	for	axonal	and	Fisher	variants	of	GBS.	A	large	number	of	experimental	studies
have	 established	 that	 Campylobacter	 jejuni	 lipooligosaccharides	 carry	 ganglioside-like	 moieties
mimicking	 peripheral	 nerve	 gangliosides,	 that	 these	 lipooligosaccharides	 can	 induce	 AGAs	 in
experimental	animals,	and	that	AGAs	can	produce	axonal	injury,	mimicking	the	pathology	of	axonal	GBS,
in	preclinical	models.	Recognition	of	specific	AGAs	in	association	with	axonal	GBS	has	paved	the	way
for	the	experimental	studies	linking	these	autoantibodies	with	axonal	injury.
Griffin	JW,	et	al.	Early	nodal	changes	in	the	acute	motor	axonal	neuropathy	pattern	of	the
Guillain-Barré	syndrome.	Journal	of	Neurocytology,	1996
Jack	Griffin	and	colleagues	have	performed	a	seminal	series	of	studies	to	define	the	pathology	of	axonal
GBS	[19].	This	ultrastructural	study	examined	the	peripheral	nervous	system	(PNS)	of	7	cases	afflicted
with	the	acute	motor	axonal	neuropathy	variant	of	GBS.	The	study	focused	on	identifying	early	changes
and	establishing	the	sequence	of	those	changes.	By	electron	microscopy	the	earliest	and	mildest	changes
consisted	 of	 lengthening	 of	 the	 node	 of	 Ranvier	 with	 distortion	 of	 the	 paranodal	myelin,	 and	 in	 some
instances	 breakdown	 of	 the	 outermost	 myelin	 terminal	 loops.	 At	 this	 stage	many	 nodes	 had	 overlying
macrophages	which	extended	 their	processes	 through	 the	Schwann	cell	basal	 lamina	covering	 the	node
and	 apposed	 the	 axolemma.	 At	 later	 time	 points	 macrophage	 processes	 extended	 beneath	 the	 myelin
terminal	 loops	 and	 the	 whole	 macrophage	 entered	 the	 periaxonal	 space	 at	 the	 paranode.	Macrophage
processes	 dissected	 the	 axon	 from	 the	 adaxonal	 Schwann	 cell	 plasmalemma	 and	 the	 macrophages
advanced	 into	 the	 internodal	periaxonal	 space,	where	 they	 typically	 surrounded	a	condensed-appearing
axon.	 This	 association	 of	 macrophage	 and	 axons	 appeared	 to	 be	 stable	 for	 some	 time,	 and	 the	 axons
subsequently	 underwent	 Wallerian-like	 degeneration.	 The	 internodal	 myelin	 sheath	 and	 the	 abaxonal
Schwann	cell	cytoplasm	remained	normal.	The	pathologic	sequence	emerging	from	these	studies	 is	 that
early	in	the	course	there	are	only	mild	changes	at	the	nodes	of	Ranvier,	sufficient	to	induce	paralysis;	it	is
only	later	that	the	axons	degenerate.	This	study	suggests	that	macrophages	are	critical	to	the	pathogenesis
and	injury	and	dysfunction	of	the	nodal	axolemma	initially	and	of	the	internodal	motor	axons	subsequently.
Moreover,	the	nodal	and	axonal	injury	likely	depends	upon	macrophage	contact	with	the	axons/axolemma
(contact-dependent).
In	separate	studies,	the	same	group	has	demonstrated	the	deposition	of	IgG	and	C3d	(membrane	bound
cleaved	product	of	C3)	at	the	nodes	of	Ranvier	initially	and	at	paranodal	and	internodal	axolemma	at	later
time	 points	 after	 the	 onset	 of	 the	 disease	 [20].	 Whether	 early	 complement	 component(s)	 deposits	 at
structural	 specializations	 along	 myelinated	 axons	 originate	 from	 circulation	 or	 adjacent
microglial/macrophage	 cells	 in	 the	 endoneurium	 and/or	 perinodal	 and	 periaxonal	 spaces	 is	 not
established.	It	has	been	shown	previously	that	macrophage	populations	can	synthesize	and	secrete	various
complement	 components.	 It	 is	 believed	 that	 complement	 activation	 products	 may	 provide	 chemotactic
cues	for	macrophage	recruitment	at	the	nodes	and	periaxonal	location.	In	summary,	these	human	studies	on
pathologic	materials	from	axonal	GBS	cases	implicate	macrophages	as	effector	cells	mediating	nodal	and
axonal	injury.
Yuki	N,	et	al.	Carbohydrate	mimicry	between	human	ganglioside	GM1	and	Campylobacter
jejuni	lipooligosaccharide	causes	Guillain-Barré	syndrome.	Proceedings	of	the	National
Academy	of	Sciences,	2004
In	 this	 study	 Yuki	 and	 colleagues	 report	 an	 animal	 model	 of	 post-infectious	 autoimmune	 neuropathy
induced	by	immunization	of	rabbits	with	C.	jejuni	 lipooligosaccharide-bearing	GM1-like	moieties	[21].
These	 animals	developed	 IgG	anti-GM1	antibodies,	which	were	 associated	with	paralytic	disease	 and
peripheral	 neuropathy	 with	 overlapping	 pathological	 features	 with	 axonal	 GBS,	 including	 periaxonal
macrophages	characteristic	of	 the	human	disorder.	These	studies	provide	strong	support	for	 the	concept
that	axonal	GBS	are	post-infectious	disorders	 in	which	humoral/antibody	directed	against	carbohydrate
antigens	 shared	 by	 peripheral	 nerve	 fibres	 and	 infectious	 agents	 induce	 axonal	 neuropathy.	 Whether
autoantibodies	against	gangliosides	are	by	themselves	sufficient	to	induce	nerve	damage	or	require	other
effectors	 of	 the	 innate	 immune	 system	 was	 not	 established	 in	 this	 study.	 The	 presence	 of	 periaxonal
macrophages	 in	 this	 experimental	 model	 again	 emphasized	 that	 axonal	 injury	 may	 depend	 on	 contact
between	axons	and	macrophages.
Zhang	et	al.	Fcγ	receptor-mediated	inflammation	inhibits	axon	regeneration.	PLoS	ONE,
2014
The	 background	 for	 the	 study	 by	 Zhang	 and	 colleagues	 is	 that	 our	 translational	work	 initially	 focused
narrowly	on	establishing	reproducible	passive	transfer	animal	models	of	AGA-mediated	nerve	injury	in
the	context	of	axonal	GBS	[22].	Reproducing	human	pathology	in	mouse	models	has	been	daunting.	Early
on	we	 learned	 that	 passive	 transfer	 of	AGAs	 in	 small	 laboratory	 animals	 did	 not	 produce	neuropathic
disease.	This	 led	us	 to	 study	 the	pathogenic	 effects	 of	AGAs	 in	 a	nerve	 crush	model,	 as	nerve	 stumps
distal	 to	 the	crush	site	have	an	inflammatory	milieu	due	to	recruitment	of	macrophages	and	virtually	no
BNB	integrity.	We	showed	that	passive	transfer	of	AGAs	(experimental	and	human)	impair	nerve	repair
and	 severely	 inhibit	 axon	 regeneration	 [23,24].	 The	 primary	 intent	 of	 these	 studies	 was	 to	 show	 that
passive	transfer	of	AGAs	has	deleterious	effects	on	nerve	fibres	and	this	antibody-mediated	nerve	fibre
injury	 is	 dependent	 upon	 endoneurial	 inflammatory	 milieu	 (including	 recruited	 macrophages).	 An
implication	of	 these	findings	was	 that	 they	echo	the	clinical	association	of	AGAs	and	poor	recovery	in
GBS.
The	 goal	 of	 the	Zhang	 and	 colleagues	 study	was	 a	 careful	 dissection	 of	 a	 nerve	 crush	model	 using
various	 mutant	 and	 transgenic	 mice	 with	 an	 altered	 expression	 of	 specific	 FcγRs	 and
macrophage/microglia	 populations	 and	 nerve	 transplant	 strategy,	 to	 demonstrate	 that	 the	 presence	 of
AGAs	in	the	injured	mammalian	peripheral	nerves	switch	the	proregenerative	inflammatory	environment
to	 growth	 inhibitory	 milieu	 by	 engaging	 specific	 activating	 FcγRs	 on	 recruited	 monocyte-derived
macrophages	to	cause	severe	inhibition	of	axon	regeneration.	A	fundamental	principle	learned	from	this
series	 of	 nerve	 crush	 studies	 was	 that	 inflammatory	 milieu,	 primarily	 consisting	 of	 activated	 FcγR-
bearing	 macrophage/microglia,	 are	 critical	 mediators	 of	 Ab-mediated	 nerve	 injury.	 These	 data
demonstrate	 that	 the	 passive	 transfer	 of	 AGAs	 can	 induce	 neuropathic	 injury,	 but	 endoneurial
inflammation,	 particularly	 macrophages	 bearing	 Fcγ	 receptors,	 are	 necessary	 for	 antibody-mediated
pathogenicity.
He	et	al.	Anti-ganglioside	antibodies	induce	nodal	and	axonal	injury	via	fcgamma	receptor-
mediated	inflammation.	Journal	of	Neuroscience,	2015
The	 ‘inflammatory	milieu’	hypothesis	 stemming	 from	 the	 crush	model	discussed	 above	was	 tested	 in	 a
new	 AGA-mediated	 passive	 transfer	 mouse	 model	 induced	 by	 L5	 spinal	 nerve	 transection	 (L5SNT;
modified	 Chung’s	 model)	 to	 study	 AGAs	 effects	 on	 intact	 nerve	 fibres	 [25].	 L5SNT	 causes	 the
degeneration	of	a	small	proportion	of	 fibres	 that	constitute	 the	sciatic	nerve	and	 its	branches,	but	more
importantly	sets	up	an	 inflammatory	milieu	 in	 the	endoneurium.	Our	studies	 indicate	 that,	 in	 this	mouse
model,	AGAs	 induce	 sequential	 nodal	 (early)	 and	 then	 axonal	 (late)	 injury	 of	 intact	myelinated	 nerve
fibres,	recapitulating	pathologic	features	of	human	disease.	Notably,	macrophages	were	seen	adjacent	to
widened	 nodes	 of	Ranvier	 at	 early	 time	 points.	 Importantly,	 our	 studies	 showed	 that	 immune	 complex
formation,	macrophage/microglia	 and	 the	 activating	 FcγRs	were	 involved	 in	 the	AGA-mediated	 nodal
and	 axonal	 injury	 in	 this	 model.	 These	 studies	 provide	 further	 experimental	 evidence	 of	 the	 role	 of
macrophages	in	AGAs-mediated	nodal	and	axonal	injury	in	axonal	GBS.
Discussion
The	majority	of	clinical	and	experimental	studies	included	in	this	discussion	highlight	the	importance	of
endoneurial	inflammation	in	mediating	myelin	and	axonal	injury	in	AIDP	and	axonal	forms	of	GBS.	Many
aspects	of	endoneurial	inflammation	are	shared	between	demyelinating	and	axonal	GBS	and	their	animal
models,	and	macrophage	inflammation	appears	to	be	common	to	clinical	disease	and	disease	models.	In
sum,	inflammatory	cells	in	the	endoneurium,	particularly	macrophage	recruitment,	is	associated	with	early
injury	 to	 the	 nodes	 of	 Ranvier	 in	 both	 demyelinating	 and	 axonal	 variants	 of	 the	 disease.	 Although
macrophages	in	the	vicinity	of	the	nodes	are	well	documented	in	axonal	cases,	whether	the	nodal	injury	is
macrophage	contact-dependent	and/or	 -independent	and	 the	 the	precise	molecular	mechanisms	of	nodal
injury	in	this	situation	are	not	well	defined	for	either	axonal	or	demyelinating	cases	of	GBS.	Monocyte-
derived	macrophages	appear	to	be	important	effectors	of	nerve	injury	in	experimental	studies	of	EAN	and
anti-ganglioside	 antibody-mediated	 nerve	 injury	 models.	 T-cell	 inflammation	 orchestrates	 endoneurial
inflammation	and	macrophage	recruitment	in	EAN	and	probably	in	AIDP	cases	with	T-cell	inflammation.
How	macrophages	mediate	Schwann	cell/myelin	 injury	 is	not	 completely	understood.	The	pathological
studies	 favour	 both	 chemical	 (cell	 contact-independent)	 and	 phagocytic	 (cell	 contact-dependent)
macrophage-mediated	 injury	 to	myelin	 compartment	 in	demyelinating	variants	of	GBS,	but	mechanisms
and	 molecular	 actors	 involved	 in,	 perhaps,	 the	 dichotomous	 injury	 to	 Schwann	 cells/myelin	 are	 not
completely	understood.
How	endoneurial	 inflammation	and	macrophage	 recruitment	 is	accomplished	 in	AIDP	cases	without
prominent	 T-cell	 inflammation	 and	 axonal	 variants	 of	 GBS	 is	 a	 key	 question,	 which	 to	 a	 large	 part
remains	 unaddressed.	 Could	 endoneurial	 glia	 (including	 microglia)	 be	 activated	 by	 soluble	 signals
diffusing	from	systemic	immune	compartment	and	subsequently	set	up	endoneurial	inflammation	including
macrophage	 recruitment	 in	 these	 situations?	 Our	 studies	 in	 Chung’s	 (L5SNT)	model	 show	 that	 partial
nerve	 injury	 generates	 endoneurial	 signals	 that	 recruit	 macrophages	 from	 circulation	 and	 set	 up
inflammatory	milieu	 in	 the	nerve.	Moreover,	our	experimental	 studies	 in	 the	context	of	anti-ganglioside
antibodies	and	axonal	injury	indicate	that	activating	FcγRs	on	macrophage	populations	are	key	molecular
effectors	mediating	nerve	injury.	Whether	the	macrophage	and	activating	FcγRs	interactions	with	immune
complexes	 formed	on	nerve	 fibres	are	 random	or	other	molecular	 signals	abet	 in	 this	process	 (such	as
complement	 activation	 products)	 acting	 as	 chemoattractants	 for	 directing	 the	 macrophages	 within
endoneurium	to	specific	sites	along	the	nerve	fibres	remains	to	be	established.	Moreover,	the	kinetics	and
evolving	 phenotype(s)	 (pro-inflammatory,	 anti-inflammatory	 or	 in	 between	 these	 polarized	 states)	 of
macrophage/microglial	cells	in	the	endoneurial	compartment	of	intact	and	injured/diseased	nerves	are	not
well	defined.	The	molecular	effectors	of	nerve	fibre	injury	downstream	of	macrophage-immune	complex
interactions	are	also	not	elucidated.	 It	appears	more	 than	one	 inflammatory	pathway	at	 the	motor	nerve
terminal	 and	 in	 the	 endoneurium	can	produce	 similar	pathologic	 reactions	 (nodal	 and	axonal	 injury)	 in
experimental	models,	as	indicated	by	a	series	of	elegant	studies	with	AGAs	and	complement	[26,27,28].
It	 is	 likely	 that	 there	 is	 close	 coordination	 and	 crosstalk	 between	 noncellular	 and	 cellular	 elements	 of
endoneurial	inflammation	to	produce	specific	patterns	of	pathologic	injury	in	GBS.	Current	therapies	in
GBS,	for	the	most	part	modulate	components	of	immune	system	in	the	systemic	immune	compartment.	We
believe	understanding	the	endoneurial	inflammation	particularly	the	pathobiology	of	macrophages	within
this	nerve	compartment	is	a	promising	avenue	likely	to	identify	molecular	effector	pathways	that	could	be
targets	of	new	drug	development	for	GBS	and	beyond.	Indeed	novel	strategies	to	deliver	such	therapies
selectively	to	endoneurial	compartment	would	be	a	requisite	and	a	challenge.
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The	Motor	Nerve	Terminal	as	a	Site	of	Anti-
Ganglioside	Antibody	Attack	in	Guillain-Barré
Syndrome
J.J.	Plomp	and	H.J.	Willison
“If	I	have	seen	further	it	is	by	standing	on	the	shoulders	of	giants.”
Sir	Isaac	Newton,	letter	to	Robert	Hooke,	5th	February	1675.
Introduction
Everything	we	think	about	is	predicated	on	the	discoveries	of	those	who	thought	long	before	us.	When	we
(the	 authors)	 started	 investigating	 the	 possibility	 that	 Guillain-Barré	 syndrome	 (GBS)	 associated	 anti-
ganglioside	antibodies	could	injure	the	motor	nerve	terminal,	we	marshalled	our	thoughts	around	existing
studies	that	might	support	such	an	idea,	of	which	there	were	many.	We	gathered	techniques	and	reagents
that	had	been	previously	developed	and	used	 to	 study	neuromuscular	 synaptic	 function	 in	 experimental
mouse	preparations,	and	applied	them	to	investigate	our	hypotheses.	In	doing	so	we	quickly	realised	that
pretty	much	everything	we	thought	about	had	already	been	thought	about	by	someone	before	us,	and	we
were	 simply	 inching	 an	 old	 idea	 forward	 or	 nudging	 it	 sideways	 towards	 our	 application.	When	 Jaap
starting	quoting	that	we	should	not	aim	to	drag	“oude	koeien	uit	de	sloot”	(old	cows	out	of	the	ditch)	we
both	knew	that	truly	new	knowledge	was	a	rare	beast,	mostly	well	beyond	our	grasp.	The	purpose	of	this
memoir	is	to	highlight	some	of	the	pre-existing	ideas,	reagents	and	methods	described	within	our	‘Top	10’
papers	that	helped	us	to	investigate	this	problem,	rather	than	describe	the	findings	and	conclusions	that	we
reached;	these	can	be	accessed	in	great	detail	elsewhere	[1,2].	Choosing	these	‘Top	10’	papers	does	not
undermine	the	importance	of	many	hundreds	of	others	that	form	part	of	this	field	of	exploration,	including
the	wonderful	work	more	directly	on	GBS	 that	has	 seen	 the	 field	move	 forward	 in	extraordinary	ways
over	the	last	100	years.	In	particular	we	acknowledge	the	large	number	of	outstanding	papers	on	the	motor
nerve	terminal	in	GBS	conducted	by	other	researchers	that	lie	out	with	the	scope	of	this	memoir.
Svennerholm	L.	Chromatographic	separation	of	human	brain
gangliosides.	Journal	of	Neurochemistry,	1963
The	structural	analysis	of	gangliosides	(sialylated	glycosphingolipids	first	discovered	in	the	1930s	in	the
brain	by	the	German	biochemist,	Ernst	Klenk)	and	their	classification	has	been	a	key	resource	for	GBS
researchers	who	in	general	are	not	drawn	from	the	carbohydrate	chemistry	community.	Working	one’s	way
through	ganglioside	nomenclature	and	committing	the	structures	to	memory	in	a	clinically	meaningful	way
is	 greatly	 aided	 by	 the	 logical	 layout	 of	 the	 members	 of	 the	 complex	 and	 large	 ganglioside	 family
described	 by	 Lars	 Svennerholm,	 one	 of	 the	 founding	 fathers	 of	 ganglioside	 biochemistry	 [3].	 His
classification,	 based	 on	 the	 migration	 pattern	 seen	 on	 thin	 layer	 chromatography,	 is	 still	 widely	 used
today,	 and	 the	 underlying	 synthesizing	 enzymatic	 pathways	 leading	 to	 this	 neuronal	 ‘sialome’	 are	 now
well-known.	Svennerholm	worked	in	an	incredibly	rich	community	of	ganglioside	biologists	to	whom	our
GBS	field	owes	a	huge	debt	[4].
Fatt	P,	Katz	B.	An	analysis	of	the	end-plate	potential	recorded	with	an
intracellular	electrode,	The	Journal	of	Physiology,	1951
The	ability	to	record	and	analyse	the	synaptic	signals,	i.e.	miniature	endplate	potentials,	at	neuromuscular
junctions	is	a	cornerstone	of	synaptic	neuroscience	and	has	allowed	for	the	discovery	of	many	universal
synaptic	principles.	The	neuromuscular	junction	offers	a	perfect	ex	vivo	system,	and	Bernard	Katz	used
this	 system	 to	 work	 out	 key	 aspects	 of	 the	 quantal	 theory	 of	 neurotransmission	 [5]	 for	 which	 he	 was
awarded	 the	 Nobel	 Prize	 for	 Physiology	 or	Medicine	 in	 1970	 (jointly	 with	 Ulf	 von	 Euler	 and	 Julius
Axelrod).	Our	studies	on	the	electrophysiological	effects	of	anti-ganglioside	antibodies	at	neuromuscular
junctions,	 first	performed	with	 the	Miller	Fisher	syndrome	sera	 in	Oxford,	and	subsequently	 in	Leiden,
relied	heavily	on	the	classical	technical	and	theoretical	knowledge	of	this	process	provided	by	Katz.	The
measurements	 nowadays	 are	 obviously	 much	 more	 accurate	 and	 efficient	 due	 to	 modern	 digital
electrophysiological	equipment	and	data	acquisition	and	analysis	software.
Simpson	LL,	Rapport	MM.	Ganglioside	inactivation	of	botulinum	toxin.
Journal	of	Neurochemistry,	1971
Three	pieces	of	knowledge	have	been	crucial	for	directing	our	studies:	(A)	that	clostridial	botulinum	and
tetanus	 neurotoxins	 exert	 their	 paralytic	 effects	 by	 first	 binding	 to	 the	 presynaptic	 membrane	 at
neuromuscular	 junctions;	 (B)	 that	 these	 toxins	bind	complex	gangliosides	 [6];	and	(C)	 that	gangliosides
are	 present	 in	 high	 density	 at	 presynaptic	membranes	 of	 neuromuscular	 junctions	 to	 which	 circulating
factors	have	ready	access	because	these	synapses	are	localized	outside	the	blood-nerve	barrier.	This	led
us	to	the	hypothesis	that	autoantibodies	against	the	relevant	gangliosides,	from	the	Miller	Fisher	variant
but	also	other	GBS	cases,	should	also	bind	and	exert	effects	at	the	motor	nerve	terminal.	Proving	this	to
be	 the	 case	 was	 a	 lot	 more	 complicated	 than	 developing	 the	 idea.	 Similarly,	 the	 development	 of
knowledge	about	botulinum	neurotoxin	binding	to	cholinergic	nerve	terminals	was	a	longstanding	process
that	 has	 gradually	 evolved	 since	 the	 1960s	 and	 still	 remains	 an	 interesting	 area	 for	 research	 today,
particularly	 with	 the	 booming	 use	 of	 botulinum	 neurotoxins	 in	 medical	 and	 cosmetic	 applications.
Specific	 ganglioside	 binding	 sites	 have	 now	 been	 identified	 on	 the	 neurotoxin	molecule,	 as	well	 as	 a
mechanism	 of	 secondary	 binding	 to	 synaptic	 vesicles	 proteins	 when	 they	 become	 exposed	 to	 the
extracellular	 environment	 during	neuroexocytosis.	Contemporaneous	 studies	 on	 cholera	 toxin	B	 subunit
binding	to	GM1	ganglioside,	and	its	use	for	localisation	of	GM1	including	nerve	terminals	and	nodes	of
Ranvier,	 also	provided	us	 and	others	working	on	GBS	with	 crucial	 insights	 into	 the	predicted	 sites	of
action	of	anti-GM1	antibodies.
Chang	CC.	Looking	back	on	the	discovery	of	α-Bungarotoxin.	Journal
of	Biomedical	Science,	1999
Continuing	 on	 the	 toxin	 theme,	 the	 use	 of	 a	 wide	 range	 of	 neurotoxins	 has	 been	 germane	 to
electrophysiological	 studies	 on	 both	 neuromuscular	 synapse	 and	 nodal	 function	 over	 many	 decades.
Professor	Chang	from	National	Taiwan	University,	Taipei,	clearly	merits	 recognition	for	his	discovery,
reported	 in	 the	early	1960s	 (with	CY	Lee),	 that	 a	 fraction	 in	 the	venom	of	 the	banded	krait,	Bungarus
multicinctus,	 irreversibly	 blocked	 nicotinic	ACh	 receptors	 [7].	 The	 reference	we	 include,	 rather	 than
reverting	 to	 the	 primary	 literature	 (which	 at	 the	 time	 was	 rejected	 by	 the	 Journal	 of	 Physiology!),
comprises	a	delightfully	 insightful	and	very	 funny	 retrospective	account	of	Professor	Chang’s	 scientific
adventures	 that	 we	 recommend	 as	 a	 must-read	 for	 all	 interested	 in	 this	 area.	 The	 fraction,	 called	 α-
Bungarotoxin,	 has	 become	 perhaps	 the	 most	 applied	 pharmacological	 tool	 in	 neuromuscular	 junction
research,	and	indeed	has	been	vitally	important	for	our	work.	Rarely	has	a	day	past	in	which	fluorophore-
labelled	α-Bungarotoxin	hasn’t	been	applied	to	illuminate	ACh	receptors	to	enable	easy	identification	of
neuromuscular	junctions	in	preparations	used	for	our	immunostaining	studies.	Professor	Chang	was	also
highly	instrumental	in	understanding	the	mechanism	of	action	of	μ-Conotoxin-GIIIB	and	the	application	of
this	toxin	as	an	important	pharmacological	tool	in	the	electrophysiological	recording	of	synaptic	signals	at
neuromuscular	junctions.	Due	to	its	selective	blocking	action	on	skeletal	muscle	type	voltage-gated	Na+
channels	(NaV1.4),	μ-Conotoxin-GIIIB	prevents	muscle	fibre	action	potentials	and	thus	contraction.	This
allows	for	undisturbed	microelectrode	recording	of	endplate	potentials.
Frontali	N,	Ceccarelli	B,	Gorio	A,	Mauro	A,	Siekevitz	P,	Tzeng	MC,
Hurlbut	WP.	Purification	from	black	widow	spider	venom	of	a	protein
factor	causing	the	depletion	of	synaptic	vesicles	at	neuromuscular
junctions.	Journal	of	Cell	Biology,	1976
The	 recurring	 theme	 of	 toxins	 must	 include	 reference	 to	 the	 electrophysiological	 and	 morphological
effects	of	α-Latrotoxin,	a	neurotoxic	component	of	the	venom	of	the	black	widow	spider	venom.	Frontali
and	colleagues	[8]	purified	a	protein	fraction	from	the	venom	that	was	highly	toxic	for	mice	and	showed
that	 this	 factor	 was	 responsible	 for	 the	 depletion	 of	 synaptic	 vesicles	 from	 motor	 nerve	 terminals,
associated	with	a	tremendous	increase	in	the	frequency	of	miniature	endplate	potentials,	shown	before	by
others	with	the	whole	venom.	Later	studies	showed	that	one	of	the	toxin’s	mechanisms	of	action	is	to	form
a	 tetrameric	pore	 that	 causes	uncontrolled	presynaptic	 influx	of	Ca2+,	 stimulating	 neuroexocytosis.	 The
similarity	 between	 the	 effects	 of	 this	 α-Latrotoxin	 and	 the	 action	 of	 anti-ganglioside	 autoantibody
containing	 the	Miller	 Fisher	 syndrome	 sera	 (and	 later,	 acute	motor	 axonal	 neuropathy	 sera	 as	well	 as
corresponding	 anti-ganglioside	monoclonal	 antibodies	 generated	 by	 us)	 in	 the	 presence	 of	 complement
activation	is	remarkable.	It	allowed	us	to	build	up	a	model	of	presynaptic	membrane	injury	resulting	from
pore	 formation	 with	 aberrant	 Ca2+	 influx.	 The	 electron	 micrographs	 of	 nerve	 terminals	 are	 virtually
identical	 between	 the	 2	 conditions,	 i.e.,	 swollen	 terminals	 devoid	 of	 synaptic	 vesicles.	 Similarly,	 the
electrophysiological	phenotypes	are	identical,	i.e.	the	‘explosion’	of	miniature	endplate	potentials	for	tens
of	minutes	 (corresponding	with	 the	 release	 of	>100,000	ACh	 quanta),	 followed	 by	 complete	 block	 of
ACh	release.
Podack	ER,	Tschopp	J.	Membrane	attack	by	complement.	Molecular
Immunology,	1984
Where	antibodies	bind,	complement	follows.	This	is	a	long-held	maxim	that	applies	to	GBS	as	much	as
other	 autoantibody-mediated	 disorders.	 Clearly	 this	 especially	 refers	 to	 the	 complement-fixing
immunoglobulin	isotypes	and	subclasses,	notably	IgM	and	IgG1-3.	Elucidating	the	role	of	complement	in
humans	 and	 animal	models	 of	GBS	 has	 occupied	 researchers	 for	 over	 20	 years.	 In	 parallel,	 the	 basic
biology	of	the	complement	system	has	been	elucidated	in	great	detail	and	there	is	no	better	place	to	focus
attention	than	on	the	formation	of	membrane	attack	complex	[9].	This	is	a	self-assembling	transmembrane
complex	that	becomes	deposited	in	plasma	membranes	targeted	by	complement-fixing	autoantibodies.	In
an	autoimmune	situation,	at	nerve	membranes	 in	particular,	 it	 appears	 to	be	highly	 toxic,	disturbing	 the
ionic	 balance	 between	 intra-	 and	 extracellular	 compartments	 and	maintenance	 of	 the	 resting	membrane
potential.	 In	 this	 review	 paper,	 Podack	 and	 Tschopp	 presented	 beautiful	 ultrastructural	 images	 and	 a
model	 of	 this	 process	 that	 greatly	 helped	 us	 understand	 the	 relationship	 between	 membrane	 attack
complex	and	the	pore-forming	α-Latrotoxin.	In	our	studies,	immunostaining	clearly	showed	the	presence
of	membrane	attack	complex	at	mouse	motor	nerve	terminals	in	nerve-muscle	preparations	that	had	been
treated	with	anti-ganglioside	antibodies	and	added	human	serum	as	a	source	of	complement.
Köhler	G,	Milstein	C.	Continuous	cultures	of	fused	cells	secreting
antibody	of	predefined	specificity.	Nature,	1975
We	 are	 only	 now	beginning	 to	 understand	why	 anti-glycolipid	 antibody-containing	 sera	 collected	 from
clinically	affected	GBS	cases	may	not	be	the	best	source	of	antibodies	for	investigating	neurotoxic	effects
in	 GBS.	 Very	 early	 on	 in	 our	 joint	 studies	 we	 invested	 considerable	 time	 in	 isolating	 monoclonal
antibodies	 reactive	 with	 neural	 gangliosides,	 also	 relying	 heavily	 on	 the	 GM2/GD2	 synthase	 mice
referred	 to	below	as	 an	 excellent	 immunisation	vehicle.	Köhler	 and	Milstein’s	brilliant	 contribution	 to
medical	science	in	the	form	of	cell	fusion	for	hybridomas	ranks	alongside	PCR	as	a	fundamental	tool	of
daily	lab	activity	[10].	Along	with	Niels	Jerne,	Köhler	and	Milstein	were	awarded	a	Nobel	Prize	in	1984
for	the	discovery	of	this	principle	of	antibody	production.	We	have	learnt	a	huge	amount	about	GBS	by
trawling	 through	 panels	 of	 our	 anti-ganglioside	monoclonal	 antibodies	 trying	 to	 understand	 why	 some
have	 effects	 whereas	 others	 do	 not.	 The	 ability	 to	 accurately	 apply	 fixed	 concentrations	 of	 known
monoclonal	 antibodies	 with	 known	 ganglioside	 binding	 patterns	 in	 unlimited	 supply,	 compared	 with
scarce	human	sera	with	less	well-defined	properties,	has	been	a	cornerstone	of	our	lab	activities.	Indeed,
without	these	monoclonal	antibodies	we	would	not	have	succeeded	in	further	understanding	our	subject
area	beyond	the	simplest	of	points.	So	hats	off	to	hybridoma	technology	as	a	remarkable	game	changer	for
our	field!
Takamiya	K,	Yamamoto	A,	Furukawa	K,	et	al.	Mice	with	disrupted
GM2/GD2	synthase	gene	lack	complex	gangliosides	but	exhibit	only
subtle	defects	in	their	nervous	system.	Proceedings	of	the	National
Academy	of	Sciences	of	the	United	States	of	America,	1996
The	development	of	 transgenic	mice	 that	 lack	glycosyltransferases	 involved	 in	ganglioside	biosynthesis
has	 allowed	 researchers	 to	 uncover	 hitherto	 unknown	 functions	 of	 gangliosides.	A	 preplanned	meeting
with	Koichi	 and	Keiko	Furukawa	 at	 the	Gordon	Research	Conference	on	Glycolipid	 and	Sphingolipid
Biology	in	2000	provided	the	opportunity	for	us	 to	use	 the	GM2/GD2	synthase	knockout	mice	 they	had
recently	 developed	 that	 lacked	 complex	 gangliosides	 [11].	No	 other	 single	 animal	 tool	 has	 been	more
important	 to	 us	 than	 these	mice.	 Similar	 studies	 have	 been	 conducted	 by	 other	GBS	 researchers	 using
mice	 generated	 contemporaneously	 by	 the	 Proia	 group	 at	 NIH.	 GM2/GD2	 synthase	 knockout	 mice
develop	sensory	and	motor-coordination	deficiencies	upon	aging.	Despite	prior	suggestions	that	complex
gangliosides	 were	 key	 components	 of	 the	 presynaptic	 apparatus,	 it	 turned	 out	 that	 gangliosides	 are
remarkably	 redundant	 in	 supporting	 neurotransmitter	 release	 at	 the	 neuromuscular	 junction.	 Even	 total
ganglioside	 ablation	 (obtained	 by	 crossing	GM2/GD2	 synthase	KO	mice	with	GD3	 synthase	 knockout
mice	 and	 treating	 their	 nerve-muscle	 preparations	 with	 neuraminidase	 to	 destroy	 the	 only	 remaining
ganglioside	 GM3)	 resulted	 in	 only	mild	 changes	 in	 ACh	 release	 from	 the	motor	 nerve	 terminal.	 This
indicates	 that	 gangliosides	 are	 not	 absolutely	 required	 for	 neurotransmitter	 release.	 Nevertheless,	 the
ability	to	manipulate	ganglioside	content	and	levels	in	presynaptic	membranes	provided	key	insights	into
the	binding	and	subsequent	action	of	anti-ganglioside	antibodies.
Lloyd	KO,	Gordon	CM,	Thampoe	IJ,	DiBenedetto	C.	Cell	surface
accessibility	of	individual	gangliosides	in	malignant	melanoma	cells
to	antibodies	is	influenced	by	the	total	ganglioside	composition	of	the
cells.	Cancer	Research,	1992
Monoclonal	 antibodies	 targeted	 against	 tumour	 cell-specific	 antigens	 have	 long	 been	 considered	 to	 be
magic	 bullets	 for	 therapy	 development.	Whilst	 the	GBS	 field	 has	 been	working	 out	 how	 to	 stop	 anti-
ganglioside	 antibodies	 from	 killing	 neural	 tissue,	 cancer	 scientists	 have	 been	working	 on	 the	 opposite
problem—how	to	coax	anti-ganglioside	antibodies	into	becoming	effective	killers.	The	use	of	anti-GM3
and	GD3	antibodies	to	kill	melanoma	and	neuroblastoma	cells	(which	express	relatively	high	GM3	and
GD3	levels	at	their	membrane)	has	been	a	long-studied	problem	[12].	We	were	often	surprised	by	how
difficult	it	was	to	get	anti-GD3	antibodies	to	bind	GD3-rich	nerve	membranes,	and	the	answer	clearly	lies
in	the	similar	problem	encountered	by	Lloyd	and	colleagues	in	a	large	series	of	papers	published	in	this
area.	Reading	this	and	related	work	crystallised	our	 ideas	on	the	principle	 that	one	type	of	ganglioside
can	sterically	hinder	the	binding	of	antibodies	to	another	type	in	the	plane	of	the	plasma	membrane,	thus
limiting	nerve	injury	in	models	of	GBS.	This	is	perhaps	best	illustrated	in	the	work	we	did	on	anti-GM1
antibodies,	 showing	 that	 some	 of	 these	 can	 only	 exert	 neuropathophysiological	 effects	 at	 motor	 nerve
terminals	 if	 the	presynaptic	membrane	had	been	 treated	with	sialidase	 to	 remove	 (apparently	sterically
hindering)	neighbouring	gangliosides	such	as	GD1a.
Ritchie	TC,	Fabian	RH,	Choate	JV,	Coulter	JD.	Axonal	transport	of
monoclonal	antibodies.	The	Journal	of	Neuroscience,	1986
The	presynaptic	membrane	of	motor	nerve	terminals	is	not	static,	but	exists	in	a	highly	dynamic	state	due
to	 the	 continuous	 addition	 and	 removal	 of	membrane	 surface	 due	 to	 the	 processes	 of	 synaptic	 vesicle
exocytosis	and	endocytosis,	respectively.	One	issue	that	always	intrigued	us	has	been	the	fate	of	antibody
landing	on	this	surface.	How	long	is	it	held	there	and	does	this	provide	sufficient	time	for	activation	of	the
complement	cascade?	The	papers	by	Fabian	and	colleagues	provided	constant	 interest	whilst	we	were
studying	this	field,	making	us	realise	 that	 the	motor	nerve	 terminal	was	a	highly	dynamic	structure	with
very	rapid	rates	of	membrane	turnover	[13].	Once	a	ligand,	in	our	case	a	GBS-associated	anti-ganglioside
autoantibody,	in	another	case	perhaps	a	neurotoxin	or	virus,	has	landed	on	the	presynaptic	membrane,	how
quickly	 is	 it	 endocytosed?	 Is	 it	 then	 recycled	 to	 the	 plasma	 membrane	 or	 destined	 for	 a	 retrograde
trafficking	pathway?	This	remains	an	area	of	great	interest,	almost	30	years	after	this	beautiful	paper	was
published,	and	a	constant	 source	of	 inspiration	 that	also	undermines	any	 idle	preconceptions	one	might
hold.
Conclusions
Research	on	the	effects	of	anti-ganglioside	antibodies	at	the	mouse	motor	nerve	terminal	has	engaged	us	in
collaborative	work	for	15	years,	during	which	time	we	published	25	papers	and	reviews	in	what	for	us
has	been	a	 totally	engaging	and	 interesting	aspect	of	GBS	research.	Perhaps	most	 importantly,	we	each
also	gained	 a	highly	 trusted	 and	 lifelong	 friend.	We	are	 the	 first	 to	 acknowledge	 the	 limitations	of	 our
experiments	and	have	regularly	been	challenged,	quite	 rightly,	about	 the	clinical	 relevance	of	 the	nerve
terminal	as	a	site	of	 injury	in	GBS	patients	and	its	variants.	Now	is	not	 the	time	to	argue	a	case	for	or
against.	Perhaps	more	 simply	 it	 is	 the	 time	 to	quote	 the	 immortal	 lines	 from	 ‘The	Adventure	of	Silver
Blaze’,	penned	by	Sir	Arthur	Conan	Doyle,	one	of	 the	most	popular	 stories	 from	 the	Sherlock	Holmes
canon:
Detective	Gregory	“Is	there	any	other	point	to	which	you	would	wish	to	draw	my	attention?”
Holmes:	“To	the	curious	incident	of	the	dog	in	the	night-time.”
Detective	Gregory:	“The	dog	did	nothing	in	the	night-time.”
Holmes:	“That	was	the	curious	incident.”
Paraphrased	 for	 the	 current	 context,	 hypothesis-driven	 scientific	 enquiry	 perhaps	 provides	 more
information	when	the	results	are	negative,	than	when	they	are	positive.
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Introduction
In	 the	 100	 years	 since	GBS	was	 first	 described,	GBS	 research	 has	 advanced	 significantly	 from	 basic
electrophysiology	studies	 to	 the	 identification	of	 the	pathological	pathways	 involved	 in	 the	onset	of	 the
disease.	Arguably,	one	of	the	most	important	discoveries	in	the	history	of	GBS	was	the	association	of	the
condition	 with	 anti-ganglioside	 antibodies.	 These	 antibodies	 are	 able	 to	 elicit	 injury	 by	 targeting
gangliosides	in	the	peripheral	nerves	and	have	become	a	major	focus	of	current	research—but	what	of	the
gangliosides	themselves?
Since	their	discovery	in	the	late	1930s,	these	cell	surface	receptors	have	been	shown	to	be	essential
components	of	not	only	the	nervous	system,	but	also	of	almost	all	cells	and	tissues	of	the	body.	This	Top
10,	 therefore,	 focuses	 on	 establishing	 the	 major	 milestones	 in	 ganglioside	 research,	 with	 a	 particular
emphasis	on	their	impact	on	the	study	of	GBS.
Let’s	Start	at	the	Very	Beginning:	Ernst	Klenk	and	Gunnar	Blix
The	discovery	of	gangliosides	is	often	attributed	to	a	German	scientist	named	Ernst	Klenk,	but	their	initial
description	was	more	of	a	collaborative	process	and	took	place	over	a	number	of	years.	Klenk	was	the
first	 researcher	 to	describe	gangliosides,	which	he	 isolated	 from	 the	organs	of	patients	with	Niemann-
Pick	 and	 Tay-Sachs	 disease	 [1],	 but	 his	work	was	 reinforced	 by	 that	 of	 a	 Swedish	 researcher	 named
Gunnar	Blix,	who	was	the	first	person	to	identify	sialic	acid	[2].
Klenk	 initially	 called	 his	 unknown	 lipid	 ‘Substanz	X’and	 found	 that	 it	 formed	black	 humin	when	 it
underwent	acid	hydrolysis	and	produced	a	purple	colour	when	heated	with	Bial’s	reagent.	Blix,	following
on	 from	his	 sialic	 acid	 discovery,	 also	 isolated	 a	 compound	 from	bovine	 brain	 that	 he	 believed	 to	 be
‘Substanz	X’,	but	he	also	noted	the	similarities	between	this	compound	and	sialic	acid	[3].
As	 a	 result	Blix	 compared	 both	 compounds	 using	Bial’s	 and	Ehrlich’s	 reagents	 and	 found	 that	 they
produced	 the	 same	 colours.	 Based	 upon	 this	 observation,	 he	 postulated	 that	 sialic	 acid	 was	 a	 major
component	 of	 ‘Substanz	 X’,	 but	 Klenk	 disagreed.	 He	 had	 isolated	 a	 similar	 compound,	 termed
‘neuraminic	acid’,	which	he	believed	to	be	a	major	component	of	the	lipid	[4].
As	 such,	Klenk	 developed	 a	method	 for	 quantifying	 the	 distribution	 of	 neuraminic	 acid	 in	 different
brain	sections	using	orcinol	and	found	that	it	was	only	present	in	the	grey	matter,	where	it	was	particularly
enriched	in	the	cerebral	cortex	[5].	This	observation	led	to	the	adoption	of	the	name	‘gangliosides’	and
thus	a	new	lipid	was	founded.
The	rivalry	between	Klenk	and	Blix	persisted	for	several	years	as	 they	 investigated	 the	structure	of
gangliosides.	 Ultimately,	 both	 competitors	 were	 proven	 right,	 as	 Klenk	 demonstrated	 that	 N-acylated
neuraminic	acid	was	a	major	component	of	gangliosides,	whilst	Blix	showed	that	all	acylated	neuraminic
acids	 were	 sialic	 acids	 [6].	 Regardless	 of	 their	 competitiveness,	 both	 scientists	 made	 important
contributions	to	ganglioside	research,	which	helped	set	the	topic	on	the	right	path.
What	Is	in	a	Name?
Following	 on	 from	 the	 fiery	 beginnings	 of	 gangliosides,	 our	 focus	 shifts	 to	 one	 of	 the	 lipids’	 more
important	 aspects,	 its	 nomenclature.	As	more	 gangliosides	were	 discovered	 it	 became	 apparent	 that	 a
unified	naming	system	was	required	to	simplify	their	identification	in	the	literature.	This	task	was	taken
on	 by	 one	 of	 the	 lipids’	 earliest	 proponents,	 Lars	 Svennerholm,	who	 in	 1964	 developed	 a	 beautifully
simplistic	naming	strategy	that	is	still	in	use	today	[7].
This	simplified	system	employs	the	use	of	a	code,	where	‘G’	denotes	a	ganglioside,	whilst	the	use	of	a
prefix	represents	the	number	of	sialic	acids,	such	as	M	for	mono,	D	for	di,	T	for	tri	and	Q	for	quad.	This
is	followed	by	a	number,	which	is	determined	by	the	migration	of	the	lipids	on	TLC	and	is	related	to	the
size	 of	 the	 oligosaccharide	 chain.	 Finally,	 a	 lowercase	 letter	 denotes	 the	 isometric	 arrangement	 of	 the
sialic	acids	on	the	headgroup;	for	example	GQ1b	[8].
GM1	and	Cholera	Toxin:	A	Toxic	Relationship
Early	 researchers	 focussed	 on	 the	 biochemistry	 of	 gangliosides,	 but	 the	 1997	 paper	 by	 Hansson,
Holmgren	and	Svennerholm	was	among	the	first	to	determine	their	specific	location	in	the	ultrastructure	of
the	nerves	[9].	This	was	achieved	through	the	ingenious	use	of	cholera	toxin,	which	previous	research	by
Holmgren,	Lönnroth	and	Svennerholm	had	suggested	bound	to	the	ganglioside	GM1	[10].
By	using	this	toxin	as	a	ganglioside	marker,	Hansson,	Holmgren	and	Svennerholmwere	able	to	localise
GM1	to	the	pre-	and	postsynaptic	membranes	of	 the	synaptic	 terminals.	Furthermore,	 through	the	use	of
sialidases,	they	were	able	to	show	that	other	complex	gangliosides	were	also	enriched	in	these	locations.
This	experiment	led	to	the	widespread	adoption	of	cholera	toxin	as	a	ganglioside	marker,	which	has
proven	so	popular	that	it	is	still	in	use	today.	In	addition,	this	method	of	localising	gangliosides	formed
the	basis	for	the	electron	microscopy	and	immunofluorescence	work	that	is	currently	carried	out	in	GBS
research	laboratories.
Ganglioside	Function:	It’s	a	Bit	Complex
Despite	 the	 plethora	 of	 research	 that	 had	 been	 performed	 on	 gangliosides,	 their	 functions	 remained
obscure	and	poorly	defined	until	the	generation	of	ganglioside	knockout	mice.	It	was	only	once	these	mice
were	created	that	the	roles	of	complex	gangliosides,	particularly	within	the	context	of	a	whole	organism,
could	be	elucidated.
The	knockout	mice	were	generated	by	disrupting	the	GalNAc	T	gene,	which	prevented	the	formation	of
the	enzyme	responsible	for	the	synthesis	of	all	complex	gangliosides	[11].	Initial	histological	analysis	of
tissue	 from	 these	mice	 indicated	 that	 the	 complex	 gangliosides	 did	 not	 have	 roles	 in	 organogenesis	 or
morphogenesis.	 However,	 there	 was	 a	 reduction	 in	 neuronal	 conduction	 velocity,	 suggesting	 that
gangliosides	had	a	role	in	normal	neuronal	function.
This	was	confirmed	 in	a	subsequent	study,	which	analysed	 the	behaviour	of	 these	mice	 [12].	 It	was
found	that	the	mice	developed	tremors	and	deficits	in	balance,	strength	and	coordination	at	12	weeks	of
age.	 In	addition,	 they	experienced	Wallerian	degeneration	and	myelination	defects,	which	demonstrated
the	roles	complex	gangliosides	play	in	normal	neuronal	maintenance.
These	mice	were	the	first	example	of	the	necessity	of	gangliosides	and	indicated	how	disruption	could
lead	to	the	symptoms	experienced	by	GBS	patients.	As	a	result,	these	mice	act	as	an	essential	tool	in	many
GBS	research	laboratories.
The	Rise	of	the	Anti-Ganglioside	Antibody
The	papers	discussed	thus	far	have	focussed	on	the	structures	and	characteristics	of	gangliosides,	but	it	is
their	roles	in	disease	that	are	of	a	particular	interest	to	neuropathy	researchers.	In	GBS,	these	roles	were
first	explored	in	a	paper	from	1992	in	which	antibodies	targeting	the	ganglioside,	GQ1b,	were	discovered
in	the	serum	of	6	patients	with	Miller	Fisher	syndrome	(MFS)	[13].	The	authors	of	this	paper	postulated
that	these	antibodies	may	act	as	a	marker	for	this	disease,	which	was	confirmed	in	subsequent	research
that	explored	the	pathology	of	MFS.
It	 was	 discovered	 through	 biochemical	 analysis	 and	 immunofluorescence	 studies	 that	 GQ1b	 was
enriched	 in	 the	 oculomotor	 and	 cranial	 nerves	 in	 humans	 [14,15].	 The	 close	 association	 of	 these
antibodies	 with	 opthalmoplegia	 therefore	 led	 researchers	 to	 conclude	 that	 they	 were	 causing	 the
symptoms	by	specifically	binding	and	injuring	the	oculomotor	nerve.
This	study	was	the	first	to	demonstrate	a	cause-and-effect	mechanism	in	GBS	and	led	to	the	search	for
anti-ganglioside	antibodies	in	a	host	of	other	GBS	subtypes.	In	addition,	the	discovery	of	a	biomarker	led
to	the	adoption	of	ganglioside	enzyme-linked	immunosorbent	assays	(ELISA)	as	a	supportive	clinical	test
in	hospitals,	which	has	aided	in	the	diagnosis	of	GBS	in	thousands	of	patients	worldwide.
Keeping	Up	the	Standards
As	 the	 use	 of	 ELISAs	 increased	 as	 a	 diagnostic	 tool,	 it	 became	 apparent	 that	 discrepancies	 existed
between	 different	 laboratories.	 Although	 both	 clear	 positive	 and	 negative	 results	 tended	 to	 remain
consistent,	 intermediate	 signals	 could	 vary	 25-fold,	 which	 raised	 questions	 about	 the	 validity	 of	 the
results.
In	 an	 attempt	 to	 address	 this	 problem,	Willison	 and	 colleagues	 produced	 a	 standardised	 ELISA	 in
conjunction	with	 the	 other	 laboratories	 that	 formed	 the	 European	 Inflammatory	Neuropathy	 Cause	 and
Treatment	 (INCAT)	 group	 [16].	 Using	 this	 method,	 they	 were	 able	 to	 reduce	 the	 variation	 between
laboratories;	however,	there	was	an	internal	laboratory	error	rate	of	41%.
This	 suggested	 that	 further	 technical	 enhancements	 would	 be	 required	 to	 improve	 the	 standardised
ELISA.	It	also	suggested	that	even	with	the	upgrade	the	new	format	was	still	highly	variable.	This	was	an
important	point,	as	it	showed	that	the	technique	was	not	robust	enough	to	be	used	for	definitive	diagnosis
and	could	only	act	in	a	supportive	role.
Further	 improvements	 in	quality	 control,	 new	 techniques	 such	as	 the	combinatorial	glycoarray	 [17],
and	the	use	of	ganglioside	complexes	(see	below)	have	addressed	some	of	these	issues,	but	further	work
is	still	required	to	further	the	use	of	gangliosides	assays	in	diagnosing	autoimmune	neuropathies.
Imitation	Is	the	Sincerest	Form	of	Flattery
The	connection	between	GBS	and	antecedent	infections	has	been	noted	by	clinicianssince	the	1950s	but	it
was	 not	 until	 the	 discovery	 of	 anti-ganglioside	 antibodies	 that	 researchers	 were	 able	 to	 adequately
explain	 this	 link.	Based	upon	 the	 similarities	 between	 the	 lipooligosaccharide	 (LOS)	 coats	 of	 bacteria
and	 host	 gangliosides,	 they	 proposed	 that	 cross-reactive	 antibodies	 arose	 in	 GBS	 that	 targeted	 both
structures,	in	a	process	known	as	molecular	mimicry	[18].
It	was	not	until	2004,	however,	that	this	hypothesis	was	proven	in	an	in	vivo	model	of	GBS.	Yuki	and
colleagues	immunised	rabbits	with	LOS	from	Campylobacter	jejuni	and	found	that	the	animals	developed
anti-GM1	 IgG	 antibodies,	which	 produced	 acute	 flaccid	 paralysis	 [19].	 In	 addition,	 they	 demonstrated
that	immunising	mice	with	LOS	resulted	in	the	production	of	anti-GM1	IgG	antibodies	that	were	capable
of	binding	to	human	peripheral	nerve.
This	paper	was	the	first	to	definitively	show	a	pathological	mechanism	for	the	onset	of	paralysis	and
proved	 that	 the	 antibodies	 detected	 in	 patient	 sera	 were	 relevant	 to	 the	 induction	 of	 GBS.	 This	 also
supported	 the	 research	 being	 performed	 by	 other	 groups	 and	 substantiated	 the	 use	 of	 monoclonal
antibodies	in	GBS	models.
A	Little	More	Complication,	a	Little	More	Action
Following	 the	 discovery	 of	 anti-GQ1b	 antibodies	 in	 MFS,	 researchers	 began	 screening	 other	 GBS
patients	for	anti-ganglioside	antibodies.	Whilst	a	number	of	these	were	found	against	a	variety	of	targets,
they	were	rarely	found	in	as	high	numbers	as	in	MFS.	In	an	attempt	to	overcome	this	problem	and	improve
antibody	detection,	 a	 Japanese	 research	group	 screened	patient	 sera	 against	 complexes	 composed	of	 2
different	gangliosides	[20].
They	found	that	a	number	of	patients	had	antibodies	which	bound	to	GD1a:GT1b	complexes	without
binding	 to	 the	single-constituent	gangliosides.	The	authors	proposed	 that	 these	antibodies	differed	 from
regular	anti-ganglioside	antibodies	in	that	they	likely	bound	to	clustered	epitopes	formed	by	components
of	both	gangliosides	rather	than	to	an	epitope	expressed	by	just	one.
This	 was	 a	 completely	 novel	 concept	 that	 opened	 up	 new	 avenues	 in	 GBS	 research.	 Antibodies
specifically	 targeting	 ganglioside	 complexes	 were	 found	 in	 other	 autoimmune	 neuropathies	 and	 were
linked	to	different	clinical	outcomes	[21,22,23].	In	addition,	antibody	detection	increased	in	patient	sera
which	improved	the	performance	of	clinical	assays.
This	 discovery	 also	 changed	 researcher’s	 viewpoints	 of	 how	 gangliosides	 exist	 in	 the	 membrane.
Rather	 than	 being	 expressed	 in	 standalone	 formations,	 gangliosides	 are	 likely	 to	 form	 complexes	with
neighbouring	 lipids	and	proteins,	which	will	affect	 their	presentation	 to	 the	 immune	system.	The	use	of
ganglioside	 complexes	 therefore	 takes	 the	 complexity	 of	 the	membrane	 into	 account	 for	 the	 first	 time,
which	has	shaped	the	direction	GBS	research	has	taken	in	recent	years.
Come	Out,	Come	Out,	Wherever	You	Are
Although	anti-ganglioside	antibodies	were	thought	to	be	responsible	for	the	pathology	observed	in	GBS,
researchers	had	noted	that	their	abilities	to	bind	their	respective	target	antigens	could	be	highly	variable.
The	reason	for	this	variability	was	explored	by	Greenshields	and	colleagues,	who	found	that	the	binding
epitopes	of	GM1	could	be	shielded	from	antibody	access	by	the	presence	of	neighbouring	gangliosides
[24].
This	 was	 shown	 in	 particular	 with	 GD1a,	 which,	 due	 to	 its	 terminal	 sialic	 acid,	 prevented	 the
exposure	of	certain	epitopes	on	the	GM1	molecule.	When	the	tissue	was	treated	with	neuraminidase	this
sialic	 acid	 could	 be	 removed,	which	 liberated	 the	GM1	 binding	 epitope	 and	 allowed	 binding	 to	 take
place.
This	novel	work	demonstrated	that	a	gangliosides	local	microenvironment	affected	which	antibodies
could	bind	and	which	tissues	were	vulnerable	to	immune	mediated	injury.	This	had	huge	implications	in
assessing	 the	 sites	 of	 injury	 in	 different	 autoimmune	 neuropathies	 and	 determining	 the	 relevance	 of
clinical	data	in	disease	pathogenesis.	The	work	derived	from	this	research	is	therefore	ongoing.
Conclusion
Gangliosides	 are	 an	 essential	 component	 of	 life	 and	 have	 important	 roles	 in	 neuroregulation,	 signal
transduction,	and	maintenance	and	repair	of	the	nervous	system.	As	a	result	they	are	abundantly	expressed
throughout	 the	 body,	 but	 unfortunately	 this	 high	 expression	 makes	 them	 particularly	 vulnerable	 to	 the
immune	mediated	attackwseen	in	GBS.
Although	this	Top	10	may	only	offer	a	snapshot	of	the	importance	of	gangliosides,	it	covers	the	major
milestones	in	their	history	and	their	relevance	in	GBS.	As	our	knowledge	into	their	roles	progresses	I’m
sure	more	discoveries	will	be	added	to	this	list,	because,	as	the	old	adage	goes,	the	best	is	yet	to	come.
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IVIg	Pharmacokinetics	and	Mechanisms	of	Action
in	GBS
Willem	Jan	R.	Fokkink
Introduction
Ever	 since	 intravenous	 immunoglobulin	 (IVIg)	 proved	 to	 have	 an	 elusive	 immune	modulatory	 effect	 in
many	 inflammatory	diseases,	 there	has	been	an	ongoing	 rat	 race	 (quite	 literally,	given	 the	many	animal
studies)	to	find	the	mechanism	of	action.	IVIg	has	pleiotropic	effects	on	the	activated	immune	system,	and
every	 year	 more	 and	 more	 potential	 mechanisms	 are	 added	 to	 the	 list.	 One	 may	 wonder	 if	 all	 these
reported	effects	of	IVIg	actually	hold	true	in	all	the	numerous	disorders	it	is	prescribed	for,	and	in	every
single	 patient.	 In	 spite	 of	 this	 continuous	 quest	 to	 decipher	 the	 pharmacodynamics	 of	 IVIg,	 its
pharmacokinetics	 receive	 little	 attention.	While	we	 do	 not	 know	 how	 exactly	 IVIg	works	 in	 the	many
indications	it	is	administered	in,	the	common	denominator	is	the	need	for	a	high	dose.	The	current	dosing
strategy,	of	2	grams	per	kilogram	bodyweight	over	5	days,	is	derived	from	Imbach	and	colleagues	study	in
1981	[1],	and	has	been	given,	unaltered,	to	all	patients	ever	since.	Many	questions	regarding	the	dosing
still	remain	unanswered:	Is	a	peak	in	IgG	levels	necessary	for	its	effect?	Or	is	it	better	to	have	sustained
high	 levels?	Where	 does	 IVIg	 in	 the	 body	 go?	 Should	we	 dose	 higher	 or	 lower?	 Should	we	 base	 our
dosage	 on	 something	 other	 than	 bodyweight?	 Answering	 these	 basic	 questions	 regarding	 the	 dosing,
distribution	and	metabolism	of	 IVIg	 is	prudent	 to	 fine-tuning	 this	 therapy.	So	where	do	we	stand	 today
regarding	the	pharmacokinetics	of	IVIg?
Intravenous	Immunoglobulin
IVIg	 is	 not	 a	 typical	 pharmaceutical	 drug,	 but	 a	 preparation	of	 pooled	human	 immunoglobulin	G	 (IgG)
obtained	 from	 thousands	 of	 blood	 donors.	 Depending	 on	 the	 product,	 IVIg	 mostly	 consists	 of	 IgG	 (>
95%),	with	 the	 addition	of	 sodium	and/or	 stabilizers,	 and	 trace	 amounts	 of	 other	molecules	 [2].	 Since
treatment	 of	 GBS	 with	 IVIg	 proved	 equal	 to	 plasma	 exchange	 [3],	 the	 products	 underwent	 several
modifications.	Currently	most	products	are	in	liquid	form,	which	has	the	advantages	of	being	storable	at
room	temperature,	a	longer	shelf-life,	an	increased	infusion	rate	and	possibly	fewer	adverse	events	[4,5].
The	 latter	 is	 in	 part	 achieved	 by	 the	 reduction	 of	 the	 dimeric	 fraction	 in	 IVIg	 [6].	 Interestingly,	 this
fraction	was	also	thought	to	be	the	‘active	ingredient’	for	IVIg’s	anti-inflammatory	effects	[7].	(For	more
postulated	mechanisms	of	action,	see	Table	39.1.)
Table	39.1		Top	10	IVIg	working	mechanisms	in	GBS
In	general,	all	products	are	considered	equal	[8,9,10],	and	often	only	patient	tolerability	plays	a	role
in	 selecting	 a	 particular	 product	 [11].	 However,	 sufficient	 data	 on	 clinical	 efficacy	 of	 different	 IVIg
products	are	lacking	[12],	and	products	are	known	to	differ	from	each	other	in	various	aspects.	Regarding
IVIg	 as	 just	 a	 generic	 product	 is	 therefore	 an	 oversimplification;	 choosing	 a	 product	 that	 is	 readily
available	(or	least	expensive)	can	very	well	impact	efficacy	and/or	responsiveness	to	treatment	[13].	One
of	 the	striking	differences	between	 the	marketed	products	at	a	 first	glance	 is	 the	half-life,	 ranging	 from
~23	to	~40	days	on	average,	and	in	individual	patients	and	products	it	can	even	range	from	~10	to	~90
days.	Results	are	influenced	by	the	study	design	(dosing,	interval,	sampling	time	points	etc.),	but	they	also
indicate	the	wide	range	of	clearances	of	IVIg.	The	importance	of	this	variation	is	emphasized	in	GBS	by
the	 finding	 that	 increases	 in	 IgG	 levels	 2	weeks	 following	 the	 start	 of	 a	 5-day	 course	 impacts	 clinical
outcomes	[14].	Patients	that	seem	to	clear	the	IVIg	faster	were	worse	off;	however,	an	explanation	for	this
large	 variation	 in	 pharmacokinetics	 is	 lacking.	 Identifying	 these	 patients,	 preferably	 before	 the	 start	 of
treatment,	 could	 be	 of	 great	 benefit.	 An	 important	 limitation	 in	 these	 pharmacokinetic	 studies	 is	 the
inability	to	distinguish	exogenous	IgG	(via	IVIg)	from	endogenous	IgG,	making	it	difficult	to	do	a	proper
IVIg	pharmacokinetic	study.
The	Unique	Pharmacokinetics	of	IgG
Pioneering	 work	 on	 the	 pharmacokinetics	 (PK)	 of	 IgG	 was	 completed	 in	 the	 1960s,	 cumulating	 in	 a
hallmark	paper	by	Waldmann	and	colleagues	in	1970	[15,16].	In	this	110-plus	page	body	of	work,	iodine-
radiolabeled	IgG	was	administered	to	patients	with	a	neoplastic	cancerous	disease,	allowing	separation
of	the	administered	IgG	from	the	total	serum	pool.	After	administration	of	a	small	amount	of	radiolabeled
IgG	 subclass	 (1–4)	 in	 patients	 with	 either	 normal	 or	 increased	 serum	 IgG	 levels,	 radio	 decay	 and
immunoglobulin	 levels	were	measured	over	a	period	of	2	weeks.	Several	key	observations	were	made
during	this	study.	Firstly,	the	extraordinary	half-life	of	IgG	and	its	subclasses	(~21	days,	except	for	IgG3
~7	days)	was	observed,	which	is	still	textbook	knowledge.	Secondly,	the	observation	of	the	concentration
dependence	of	IgG	was	established:	the	higher	the	total	serum	level	the	faster	the	catabolism,	the	shorter
the	half-life	(i.e.,	first-order	kinetics).	Both	the	long	half-life	and	concentration	dependent	clearance	are
unique	and	unlike	any	other	serum	protein	(the	only	exception	is	albumin,	showing	comparable	features).
An	explanation	for	these	peculiar	observations,	and	at	the	same	time,	transfer	of	humoral	immunity	from
mother	to	neonate,	was	already	devised:	the	Brambell	receptor	[17,18].	If	not	saturated	by	high	amounts
of	IgG,	this	hypothetical	receptor	would	selectively	bind	and	protect	IgG	molecules	from	degradation.	It
took	a	further	2	decades	before	the	‘neonatal	Fc	receptor’	(FcRn)	was	unambiguously	identified	[19],	and
even	 longer	 for	 all	 concepts	 of	 IgG	 catabolism	 and	 transport	 to	 be	 unified	 and	 attributed	 to	 this	 one
receptor	[20,21,22,23].
Next	to	the	catabolism,	distribution	in	the	body	is	equally	important.	IVIg	as	a	therapy	is	far	removed
from	the	concept	of	Ehrlich’s	magic	bullet—frankly	we	just	overload	the	humeral	immune	system,	rather
than	having	a	specific	target,	without	knowing	whether	the	IVIg	actually	reaches	the	site	of	inflammation
at	all	(and	does	that	even	matter,	in	light	of	all	possible	working	mechanisms)?	Subsequent	radiolabeling
studies	found	that	the	majority	of	intravenous-administered	IgG	first	accumulates	in	the	skeletal	muscles
and	the	liver.	Thereafter,	despite	being	nonspecific,	the	radio-traceable	polyvalent	IgG	migrates	to	sites	of
inflammation	within	24	hours	 [24,25].	While	no	 inflammatory	neuropathy	patients	were	 tested	 in	 these
studies,	an	educated	guess	would	be	that	in	the	case	of	ongoing	inflammation	at	the	peripheral	nerves	or
nerve	roots	in	GBS,	IVIg	will	actually	reach	it	(and	for	instance;	interfere	with	complement	deposition).
Current	knowledge	on	IVIg	pharmacokinetics	is	mostly	derived	from	immune	deficiencies	(low	levels
of	IgG)	and	discussed	in	an	excellent	review	by	Bonilla	[26].	However,	GBS	patients	have	normal,	and
some	perhaps	even	slightly	elevated	IgG	levels	[27].	Therefore,	it	is	not	hard	to	imagine	that	introducing
truckloads	of	IgG	directly	into	the	venous	pool,	increasing	blood	viscosity	and	causing	a	high	peak	in	IgG
[28]	 alters	 pharmacokinetics	 compared	 to	 patients	 receiving	 replacement	 therapy.	 Bearing	 in	mind	 the
concentration-dependent	catabolism	of	IgG,	the	half-life	of	supraphysiologic	quantities	of	IgG	is	greatly
diminished	[29].	This	mechanism	of	accelerated	(auto)	antibody	clearance,	via	the	saturation	of	FcRn,	is
one	of	the	more	popular	mechanisms	of	action	of	IVIg	as	immune-modulator.
IVIg	as	Immune	Modulator
Concurrent	 to	 all	 the	 work	 done	 on	 the	 catabolism	 of	 IgG,	 a	 different	 revolution	 occurred	 with
immunoglobulins	as	treatment,	either	as	pooled	polyvalent	immunoglobulins	or	eventually	as	monoclonal
antibody	(mAb).	The	former	was	successfully	used	as	replacement	therapy	in	an	immune-deficient	patient
lacking	 IgG	 in	 1952	 [30].	 Next	 to	 replacement	 therapy,	 an	 additional	 beneficial	 factor	 in	 fresh-frozen
plasma	 was	 suspected	 by	 several	 authors	 studying	 immune	 thrombocytopenia	 (ITP),	 typically	 a	 post-
infectious,	 acute	 but	 self-limiting,	 predominantly	 antibody	 mediated	 disease	 against	 glycoproteins	 on
platelets.	As	early	as	1933	it	was	noted	that	blood	transfusions	could	induce	disease	remission	in	acute
ITP,	 whilst	 stressing	 the	 necessity	 of	 repeated	 transfusions	 [31].	 Almost	 20	 years	 later	 it	 was	 first
speculated	 (to	my	 knowledge)	 that	 some	 factors	 in	 the	 transfused	 blood,	 other	 than	 platelets,	might	 be
responsible	for	the	beneficial	effect	(an	increase	in	platelets)	[32].	Closing	down	on	this	elusive	factor
was	 carried	 out	 by	 work	 from	Mila	 Pierce	 and	 colleagues,	 when	 she	 contemplated	 that	 the	 transient
beneficial	 effect	 in	a	patient	 (lasting	20–23	days)	 correlates	with	blood	 infusions	and	 that	 fresh-frozen
plasma	 (FFP,	 devoid	 of	 platelets)	 could	 also	 elicit	 this	 response	 [33].	 The	 authors	 discontinued
corticosteroid	 therapy	 and	 found	 that	 FFP	 gave	 a	 dose-dependent	 beneficial	 effect,	 leading	 to	 the	 first
speculation	and	research	performed	regarding	the	mode	of	action	of	this	factor	in	FFP.	The	authors	found
and	settled	on	an	effect	on	megakaryocytes	(Note:	Thirty	years	later	Saito	and	colleagues	showed	this	to
be	at	least	partly	true,	with	IVIg	entering	the	bone	marrow	and	these	cells	[34]).
But	 IVIg’s	 current	 claim	 to	 fame	 came	 with	 successful	 treatment	 with	 intravenous	 immunoglobulin
(IVIg)	 of	 patients	 with	 ITP	 by	 Imbach	 and	 colleagues,	 causing	 a	 surge	 of	 interest	 in	 high-dose
immunomodulatory	 functions	 [1].	 Based	 on	 previous	 observations,	 the	 decision	 was	 made	 to	 treat	 a
patient	 refractory	 to	all	other	 treatments	with	a	course	of	 IVIg	 [35].	The	proposed	working	mechanism
was	the	requirement	of	a	large	amount	of	IgG	to	overload	and	block	the	reticuloendothelial	system	by	its
catabolism.	The	treatment	with	0.4	g/kg	of	bodyweight	(BW)	a	day	was	deduced	from	the	use	of	IVIg	as
replacement	 therapy	 in	 an	 ITP	 patient	 with	 hypogammaglobulinemia,	 wherein	 Imbach	 and	 colleagues
found	the	first	effects	of	an	increase	in	platelets.
In	contrast,	the	choice	to	administer	the	IVIg	over	5	days,	resulting	in	the	high-immunomodulatory-dose
of	2	gr/kg	BW	(for	GBS	considered	as	standard),	is	more	enigmatic	(and	might	very	well	have	been	just
out	of	convenience:	Monday–Friday).	Nevertheless,	this	regimen	was	subsequently	tried	in	many	different
autoimmune	 diseases.	 The	 field	 of	 neurology	 quickly	 followed	 and	 successful	 treatment	 of	 chronic
inflammatory	demyelinating	polyneuropathy	(CIDP)	with	FFP,	and	subsequently	attaining	the	same	results
with	IVIg	(identifying	IgG	as	the	crucial	factor	in	FFP)	was	reported	[36].	Later	on	the	need	for	a	high-
dose	IVIg	regimen	was	also	established	in	CIDP	[37].	Given	the	initial	findings	in	CIDP,	it	did	not	take
long	before	the	first	experiences	with	IVIg	and	GBS	were	noted	[38,39].	Unambiguous	clinical	efficacy	of
IVIg	in	GBS	was	for	the	first	time	demonstrated	by	the	Dutch	Guillain-Barré	study	group	[3],	when	it	was
found	to	be	equally	effective	to	plasmapheresis.
Rigid	Regimen
Alas,	since	that	major	breakthrough	and	despite	meticulous	efforts	to	improve	therapy	for	GBS,	we	still
treat	with	 IVIg	 in	 that	 same,	 high-dose,	 2	gr/kg	BW,	5-day	 regimen.	Dose-dependent	 anti-inflammatory
effects	were	reported	in	in	vitro	studies	early	on	[40,41],	and	also	in	animal	models	[42,43].	Yes,	good
comparative	clinical	studies	of	different	regimens	are	lacking,	but	there	is	evidence	from	other	fields	that
the	high	dose	is	indeed	necessary	for	an	immunomodulatory	effect.	Whilst	low	dosing	might	yield	some
effect	 in	 ITP,	 there	 is	 a	 correlation	with	 a	 better	 effect	 and	 higher	 response	 rate	with	 increased	 doses
[44,45].	 Furthermore,	 for	 ITP,	 IgG	 levels	 within	 the	 normal	 range	 values	 (~6	 g/L—16	 g/L)	 seem
inadequate	to	halt	the	disease	[46].
Another	 disease	 treated	 with	 IVIg	 is	 Kawasaki’s	 disease	 (KD),	 suspected	 to	 be	 post-infectious	 in
nature,	 acute	 but	 self-limiting,	 with	 an	 important	 role	 for	 mucosal	 antibodies,	 resulting	 in	 systemic
vasculitis,	and	steroids	seem	not	of	benefit,	or	even	counterproductive.	Considerable	progress	has	been
made	early	on	regarding	the	IVIg	regimen	used	in	these	patients.	Next	to	the	proven	dose	dependency	of
beneficial	effects	[47],	2gr/kg	BW	given	in	1	day	proved	superior	(with	no	increase	in	adverse	events),
rather	 than	 spreading	 the	 IVIg	 course	 over	multiple	 days.	 This	 also	 underscores	 the	 importance	 of	 the
pharmacokinetics	of	IVIg:	one	massive	boost	in	IgG	is	more	efficacious	here	than	multiple	smaller	peaks
[48].	Further	progress	 in	 this	 field	discriminates	between	patients	 requiring	either	1,	2	or	even	4	gr/kg
(for	initial	IVIg-resistant	patients)	of	IVIg	all	given	at	a	rate	of	1	gr/kg	BW	an	hour	[49].	The	‘luxury’	that
these	IVIg-treated	diseases	have	in	common	for	comparative	studies	are	relatively	easy	to	measure	and
are	 reliable	 clinical	 and	 physiological	markers	 for	 IVIg	 response,	 things	 sorely	 lacking	 in	 the	 field	 of
GBS	[50].
Nonetheless,	speculation	on	a	potentially	increased	efficacy	for	a	shorter	treatment	duration	was	made
immediately	 after	 proof	 of	 IVIg’s	 effectiveness	 in	 GBS	 [51].	 A	 small	 number	 of	 studies	 have	 been
performed	assessing	different	IVIg	regimens.	The	only	study	in	adults	compared	a	3-day	regimen	versus	a
6-day	 regimen	 of	 0.4	 gr/kg	 BW	 in	 GBS	 patients	 unsuitable	 for	 plasma	 exchange.	 Whilst	 the	 authors
mentioned	several	study	limitations,	they	found	a	tendency	for	better	efficacy	with	the	6-day	regimen	[52].
However,	the	pharmacokinetics	of	IVIg	were	not	tested	here,	since	the	authors	essentially	compared	1.2
g/kg	(3	days)	versus	2.4	g/kg	(6	days).	Later	on	this	hiatus	was	assessed	in	a	study	on	childhood	GBS.
The	authors	found,	contrary	to	what	was	expected	and	what	was	previously	published	in	smaller	studies,
no	 difference	 between	 2g/kg	 over	 2	 days	 versus	 the	 exact	 same	 amount	 over	 5	 days.	While	 the	 2-day
course	was	 safe,	 increased	 treatment-related	 fluctuations	were	 reported,	 and	 the	 authors	 speculated	 on
still	ongoing	disease,	not	sufficiently	covered	by	the	2	days	of	treatment	[53].	Yet,	this	hypothesis	could
not	be	proven	 since	 IgG	 serum	 levels	were	not	 available.	Also,	 this	 study	was	performed	 in	 children,
thought	to	have	a	relative	mild	disease	course	compared	to	adults	[54].	Children,	of	course,	also	differ
from	adults	in	their	body	composition	and	subsequently	in	a	key	pharmacokinetic	parameter:	the	volume
of	 distribution	 [55].	Dosing	 of	 IVIg	 however,	 is	 still	 based	 on	 actual	 bodyweight	 for	 all	 patients	 (NB
Imbach’s	 study	 in	 1981	 were	 all	 children).	 Peculiar,	 since	 IVIg’s	 pharmacokinetics	 (a	 relative	 small
volume	of	distribution)	imply	that	it	hardly	distributes	into	body	fat	[56].	Taking	account	for	this	fact	is
dosing	based	on	adjusted	or	ideal	bodyweight.	However,	this	is	largely	motivated	by	cost-saving	and	to
prevent	overdosing	in	case	of	obesity	[57],	rather	than	by	improving	efficacy.
Future	Perspectives
It	 seems	 that	 almost	 every	 aspect	 of	 GBS	 seems	 challenging	 to	 resolve,	 and	 this	 certainly	 applies	 to
treatment	with	IVIg.	Even	in	2016,	we	at	least	know	that	IVIg	works	and	that	a	prolonged	increment	in	IgG
levels	after	IVIg	seems	to	positively	affect	outcome	in	GBS.	Have	we	then	made	no	further	advancement
these	past	3	decades	of	 IVIg	 treatment	for	GBS?	That	 is	definitely	not	 the	case.	The	coming	years	will
allow	us	 to	clarify	 some	mysteries	concerning	 immunoglobulin	 therapy	 in	GBS.	Will	 a	 second	dose	of
IVIg	 be	 beneficial	 in	 severe	 patients?	 Will	 subcutaneous	 IgG,	 providing	 a	 more	 favourable
pharmacokinetic	profile	over	time,	offer	new	therapeutic	options?
In	addition,	improvements	and	alternatives	to	polyvalent	immunoglobulin	therapy	are	well	underway.
This	will	allow	us	 to	 finally	decrease	 the	enormous	 list	of	postulated	IVIg	working	mechanisms.	Some
promising	developments	with	 IgG-based	mAbs	 are	 eculizumab	 in	GBS,	 an	 IgG2/4	hybrid	 blocking	 the
complement	 cascade;	 a	mAb	 targeting	 the	 FcRn	 receptor,	 increasing	 the	 catabolism	 of	 auto-antibodies
[58];	and	mAbs	directed	against	FcyRIIb,	the	inhibitory	Fc-receptor	with	the	potential	to	enhance	existing
therapies	[59,60].	Alternatively	to	a	mAb	against	FcyRIIb,	a	recombinant	soluble	variant	of	this	receptor
is	 currently	 being	 tested	 for	 its	 anti-inflammatory	 effects	 [61].	 IVIg	 itself	 is	 also	 subject	 to	 potential
improvement:	 a	 highly	 sialylated	 version	 has	 been	 developed,	 aiming	 to	 exploit	 the	 anti-inflammatory
effects	described	when	this	carbohydrate	is	present	on	the	IgG	molecule	[62].	The	cationization	of	IVIg	is
also	being	explored,	which	should	increase	the	bio-distribution,	making	it	easier	for	IgG	to	enter	organs
or	cross	 the	blood-brain/nerve	barrier	 [63].	A	very	appealing	alternative	 is	an	 IVIg	biomimetic,	which
does	 not	 focus	 on	 one	mechanism	 of	 action,	 but	 rather	 is	 capable	 of	 binding	 or	 blocking	 a	 number	 of
receptors	and	complement	factors	[64].	It	is	hoped	that	one	of	these	directions	or	other	developments	not
mentioned	 here	 will	 take	 IVIg’s	 place.	 For	 now,	 IVIg	 remains	 the	 cornerstone	 of	 GBS	 treatment	 and
somehow	tailoring	the	dose	to	the	patient’s	needs	may	already	yield	benefit.
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The	Ganglioside-Based	Medications:	Cronassial	and	Sygen
Gangliosides,	 sialic	 acid-containing	 glycosphingolipids,	 are	 components	 of	 the	 external	 layer	 of	 all
plasma	membranes	and	are	particularly	abundant	in	neurons.	Their	oligosaccharide	chains	are	protruding
towards	the	extracellular	aqueous	environment,	anchored	to	the	membrane	via	the	ceramide	hydrophobic
moiety,	which	is	inserted	in	the	lipid	bilayer.
Ganglioside	 research	 developed	 at	 the	 beginning	 of	 the	 20th	 century;	 however,	 it	was	 necessary	 to
wait	until	the	1960s	to	have	their	structures	elucidated.	Then,	this	family	of	glycoconjugates	immediately
attracted	 the	 interest	 of	 several	 scientists,	 whose	 work	 convincingly	 showed	 that	 gangliosides	 are
important	physiological	regulators	of	a	variety	of	neuronal	processes,	like	neuritogenesis,	synaptogenesis
and	cell-cell	interactions	such	those	involved	in	the	migration	of	neuronal	precursors	and	the	wrapping	of
myelin	around	axons.	 In	particular,	 the	 finding	 that	 the	administration	of	ganglioside	mixtures	 to	animal
models	 of	 peripheral	 sympathetic	 regeneration	 and	 reinnervation	 was	 able	 to	 improve	 the	 recovery
processes	 of	 both	 cholinergic	 and	 adrenergic	 nerve	 fibres	 was	 extremely	 appealing,	 suggesting	 that
gangliosides	 might	 play	 a	 relevant	 role	 in	 neural	 regeneration	 after	 injuries	 that	 could	 be
pharmacologically	exploited	[1].	Subsequently,	and	up	to	today	[2],	a	great	number	of	basic,	preclinical
and	 clinical	 studies	 supported	 the	 notion	 that	 the	 administration	 of	 exogenous	 gangliosides	 could	 be
effective	in	enhancing	recovery	from	both	peripheral	and	central	nervous	system	injuries.
The	most	relevant	clinical	trials	involving	gangliosides	suggested	that	the	administration	of	exogenous
gangliosides
improved	both	electromyographic	findings	and	clinical	symptoms	in	patients	with	diabetic	peripheral
neuropathy;
had	some	success	in	patients	with	uremic	neuropathy;
had	some	neuro-protective	effectiveness	for	acute	ischemic	stroke	and	spinal	cord	injuries;	and
gave	promising	results	in	the	prevention	and	treatment	of	degenerative	diseases	of	the	central	nervous
system,	especially	Parkinson’s	and	Alzheimer’s	disease.
The	research	on	the	effects	of	gangliosides	received	a	big	impulse	from	the	availability	of	great	quantities
of	 pure	 ganglioside	molecules,	GM1	and	polysialylated	 gangliosides,	 following	 the	 introduction	 in	 the
drug	market	of	ganglioside-containing	formulations.
In	1973,	the	drug	Cronassial,	containing	the	highly	purified	ganglioside	mixture	from	calf	brains,	was
launched	 in	 Italy	 and	 prescribed	 for	 peripheral	 neuropathies	 and	 back	 pain.	 From	 1976,	 the	 drug	was
commercialized	 under	 several	 different	 names	 in	 20	 countries	 in	 Europe,	 South	 and	Central	 America,
Asia	 and	 Africa.	 Later,	 in	 1985,	 the	 drug	 Sygen,	 containing	 highly	 purified	 GM1	 and	 prescribed	 for
neurodegenerative	 diseases	 and	 cerebral	 and	 spinal	 injuries,	 flanked	 Cronassial	 in	 Italy	 and	 later	 in
Argentina,	 Brazil,	 Greece	 and	 Singapore.	 FIDIA	 S.p.A.	 prepared	 the	 gangliosides	 used	 for	 these
formulations	in	its	plants	in	the	city	of	Abano	Terme	in	Italy,	and	later	in	other	countries.
For	several	years	both	Cronassial	and	Sygen	were	extensively	prescribed	for	the	therapy	of	nervous
system	diseases	to	the	satisfaction	of	both	doctors	and	patients.
Sygen	was	 entered	 in	 new	 trials	 for	 the	 treatment	 of	 central	 nervous	 system	 diseases	 like	 cerebral
ischemia	 and	 dementia,	 stroke	 and	 spinal	 cord	 injury;	 however,	 many	 of	 these	 trials	 could	 not	 be
completed.	In	fact,	at	the	beginning	of	the	1990s,	some	scientists	claimed	that	the	presence	of	gangliosides
in	the	bloodstream	was	able	to	stimulate	the	production	of	anti-ganglioside	antibodies.	Anti-ganglioside
antibodies	raised	by	the	administration	of	ganglioside-containing	drugs	were	indicated	as	responsible	for
the	 occurrence	 of	 GBS,	 due	 to	 their	 interaction	 with	 the	 axonal	 surface	 at	 the	 node	 of	 Ranvier.	 This
opened	a	fierce	debate	on	 the	safety	of	gangliosides	as	drugs.	Some	scientists	were	against	 the	 therapy
and	others	in	favour.	The	discussion	also	involved	the	Italian	drug	committee	that,	after	over	16	million
prescriptions	 and	 a	 few	 cases	 of	 GBS	 claimed	 to	 be	 derived	 by	 the	 therapy,	 decided	 to	 withdraw
gangliosides	at	the	end	of	1993,	in	Italy.	The	same	occurred	later	in	other	countries.	However,	Brazil	and
China	 still	 prescribe	 Sygen	 and	 a	 generic	 ‘monosialotetrahexosylganglioside	 sodium’,	 respectively.	 In
some	countries,	GM1	is	still	involved	in	clinical	trials	at	different	stages.
After	over	20	years	since	 the	withdrawal	of	 the	ganglioside-containing	drugs	 in	many	countries,	 the
notion	 that	 the	 administration	of	gangliosides	 is	not	 associated	with	 the	 appearance	of	 anti-ganglioside
antibodies	in	serum,	nor	with	the	onset	of	GBS,	seems	to	be	sounder.
Immunogenicity	of	Gangliosides
Several	lines	of	evidence	show	that	oligosaccharide	chains	are	haptens,	and,	in	the	majority	of	cases,	they
do	 not	 display	 immunogenic	 properties,	 as	 do	 not	 the	 soluble	 gangliosides.	 On	 the	 other	 hand,
gangliosides	become	immunogenic	when	carried	by	an	adjuvant,	such	as	a	microorganism.
The	 production	 of	 antisera	 against	 gangliosides	 in	 experimental	 animals	 invariably	 requires	 heavy
manipulation	of	the	material	used	for	immunization.	All	procedures	reported	in	the	literature	are	based	on
the	mixing	or	coupling	of	gangliosides	with	a	variety	of	strongly	immunogenic	carrier	substances,	such	as
heterologous	whole	 serum,	methylated	 bovine	 serum	 albumin,	 heterologous	 glycoprotein,	Mycoplasma
membrane	proteins	and	Freund’s	complete	adjuvant.	To	the	best	of	our	knowledge,	there	is	only	a	single
paper	claiming	immunization	against	gangliosides	in	experimental	animals	without	use	of	carrier	proteins
or	immunologic	adjuvants	[3].
Information	on	the	onset	of	an	autoimmune	neurological	syndrome	upon	administration	of	gangliosides
is	 very	 rare.	 In	 addition,	 this	 was	 obtained	 by	 injection	 of	 liposomes	 composed	 of	 gangliosides,	 egg
lecithin	and	cholesterol,	and	methylated	bovine	serum	albumin.	In	addition,	liposomes	were	emulsified	in
complete	 Freund’s	 adjuvant	 [4].	No	 reports	 are	 available	 on	 the	 onset	 of	 an	 autoimmune	 neurological
syndrome	 following	 controlled	 ganglioside	 injections	 in	 a	 large	 cohort	 of	 humans	 that	 exceeds	 15,000
units.
On	 the	 other	 hand,	 convincing	 proof	 that	 highly	 purified	 gangliosides	 are	 not	 immunogenic	 when
injected	in	patients	comes	from	the	extensive	use	of	gangliosides	for	20	years,	and	by	the	clinical	trials
developed	 to	 understand	 some	 pharmacological	 properties	 of	 gangliosides	 on	 neurodegenerative
diseases,	as	neuro-protective	compounds	and	as	promoters	of	spinal	cord	recovery	following	injury:
Five	 Alzheimer’s	 disease	 patients	 received	 up	 to	 30	 mg/day	 of	 GM1	 ganglioside	 by	 continuous
injection	 into	 the	 brain	 lateral	 ventricles	 for	 12	 months.	 None	 of	 these	 patients	 developed	 serum
antibodies	recognizing	gangliosides	in	an	ELISA	test.	None	developed	GBS	or	any	other	neurological
autoimmune	 syndrome.	 Instead,	 these	 patients	 became	 more	 active,	 had	 improved	 reading
comprehension	 and	 were	 able	 to	 perform	 activities	 such	 as	 writing	 reports	 and	 short	 letters	 on	 a
computer	[5].
In	2	trials,	about	100	Parkinson’s	disease	patients	received	100mg	of	GM1	daily,	both	intravenously
and	 by	 subcutaneous	 injection,	 for	 up	 to	 2	 years.	 None	 developed	GBS	 or	 any	 other	 neurological
autoimmune	syndrome.	The	treatment	improved	motor	symptoms	and	lowered	the	disease	symptoms’
progression	[6].
Both	the	above	trials	were	carried	out	with	the	same	GM1	used	for	the	preparation	of	Sygen.
Oxaliplatin	is	a	very	powerful	drug	against	gastrointestinal	 tumours;	however,	 it	 is	characterized	by
severe	peripheral	neurotoxicity.	Sixty	patients	with	gastrointestinal	tumours	were	injected	daily	with
100mg	 of	 GM1	 for	 3	 days	 following	 chemotherapy	 treatment.	 The	 treatment	 showed	 some	 minor
protection	against	the	oxaliplatin	neurotoxicity,	but	no	case	of	GBS	onset	was	reported	[7].
Several	trials	were	carried	out	on	over	700	patients	to	determine	the	properties	of	GM1	in	recovering
spinal	cord	injury,	but	no	reports	on	the	onset	of	peripheral	neuropathies	are	available	[8].
These	are	a	few	examples	of	the	controlled	administration	of	gangliosides,	clearly	proving	that	continuous
administration	of	highly	purified	gangliosides	to	a	very	high	number	of	patients	do	not	lead	to	serum	anti-
ganglioside	antibody	production.
Ganglioside	Mimicry
Guillain-Barré	syndrome	and	related	neuropathies,	which	were	among	the	first	to	be	associated	with	anti-
oligosaccharide	antibodies,	are	preceded	in	two-thirds	of	cases	by	Campylobacter	jejuni,	Mycoplasma
pneumoniae	or	cytomegalovirus	infections.	Infection	with	C.	jejuni,	usually	contracted	by	consumption	of
raw	 or	 undercooked	 poultry,	 unpasteurized	milk	 or	 contaminated	water,	 is	 the	most	 common	 cause	 of
bacterial	gastroenteritis.	The	 isolation	rate	of	C.	 jejuni	 from	stool	culture	of	GBS	patients	 ranges	 from
8%	to	50%.	Some	of	these	patients	developed	serum	antibodies	recognizing	gangliosides	by	ELISA	or	by
immune-TLC	staining.
The	 above-mentioned	microorganisms	 display	 complex	 glycoconjugates	with	 terminal	 carbohydrate
sequences	 similar	 to	 those	 present	 in	 the	 cell	membrane	 glycoconjugates	 of	 humans.	 Bacteria	 isolated
from	the	stool	culture	of	GBS	patients	were	analysed	for	their	membrane	complex	lipid	composition,	and
found	to	contain	terminal	oligosaccharide	structures	overlapping	to	those	of	neuronal	gangliosides.	These
microorganism-associated	structures	are	believed	to	be	responsible	for	an	‘oligosaccharide	mimicry’	and
for	the	immunogenic	response	[9].
Epidemiological	Studies
The	 above-mentioned	 studies	 in	 our	 opinion	 convincingly	 demonstrate	 that	 there	 has	 never	 been	 any
relationship	 among	 administration	 of	 gangliosides,	 anti-ganglioside	 antibodies	 and	 GBS.	 However,	 a
further	piece	of	evidence	should	dissipate	any	possible	scepticism	with	this	regard.
At	the	time	of	the	first	case	reports,	a	retrospective	cohort	study	based	on	administrative	data	found	no
cases	of	GBS	among	13,373	subjects	prescribed	with	gangliosides	between	1988	and	1990	in	an	Italian
district	[10].	Spanish	epidemiological	data	regarding	17	patients	with	GBS	did	not	show	any	association
with	 ganglioside	 treatment	 [11].	A	 subsequent	 study	 found	 42	 cases	 of	GBS	 among	579,725	 discharge
codes	 referring	 to	 the	year	 1989	 in	3	 Italian	districts.	 In	 another	 Italian	district,	 9	 cases	of	GBS	were
reported	 in	 subjects	 receiving	 ganglioside	 treatment	 from	 1981	 to	 1993;	 among	 those	 9	 patients,	 7
received	gangliosides	after	 the	diagnosis	of	GBS;	 the	 risk	of	GBS	 in	subjects	exposed	 to	gangliosides
was	 not	 significantly	 higher	 as	 compared	with	 nonexposed	 subjects.	 A	 Spanish	 study	 showed	 that	 the
incidence	of	GBS	was	not	higher	 in	geographical	areas	where	gangliosides	were	frequently	prescribed
than	 in	 those	 in	which	 they	were	not	prescribed	 [12].	The	 local	health	district	 (LHD)	of	Ferrara,	 Italy
reported	an	epidemiological	 investigation	on	the	possible	relationship	between	ganglioside	therapy	and
GBS	by	a	systematic	comparison	of	the	incidence	of	GBS	in	the	period	between	1988	and	1993	(when
ganglioside-based	drugs	were	widely	 prescribed)	 vs.	 the	 1994–2001	period	 (following	withdrawal	 of
such	drugs)	[10].	The	study	found	that	the	incidence	of	GBS	increased	from	1981	to	1993,	especially	in
urban	areas	and	among	elderly	subjects;	however,	only	one	of	the	GBS	cases	occurred	during	treatment
with	gangliosides;	moreover,	no	decline	in	incidence	was	observed	from	1992	to	1993,	the	year	in	which
gangliosides	were	withdrawn	 from	 the	 Italian	market.	When	 extending	 case	 ascertainment	 up	 to	 2001,
only	a	small	decline	in	the	incidence	of	GBS	was	found	that	might	be	better	explained	by	fluctuations	in
GBS	incidence	than	by	the	withdrawal	of	ganglioside	treatment.
In	 the	 LHD	 of	 Ferrara	 the	 resident	 mean	 population	 was	 165,239,	 with	 77,630	 men	 and	 87,609
women,	in	the	years	1994–2001.	The	cases	of	GBS	were	24.3	in	the	years	1981–1987,	20.1	in	the	years
1988–1993	and	25.4	in	the	years	1994–2001.
In	 the	years	1981–1993	 there	was	an	 incidence	rate	of	GBS	of	1.87	per	100,000	population,	which
become	 2.30	 for	men	 and	 1.48	 for	women.	 In	 the	 years	 1994–2001,	 after	 ganglioside	withdrawal,	 the
investigation	 identified	 an	 incidence	 rate	 of	 1.97	 per	 100,000	 population,	 2.25	 for	 men	 and	 1.71	 for
women.	Recalling	that	the	onset	of	GBS	is	age	related,	the	age-adjusted	rates	became	1.65	and	1.66	per
100,000	in	the	years	1981–1993	and	1994–2001,	respectively.	Considering	the	calendar	years,	the	highest
rate	was	in	1997,	4.22	per	100,000,	while	the	lowest	one	was	in	1981,	0.54	per	100,000.
These	studies	clearly	support	no	action	of	ganglioside	treatment	in	onset	of	GBS.
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My	Top	10	Images
Rhona	McGonigal
Introduction
As	 the	 old	 adage	 goes,	 ‘A	 picture	 is	worth	 a	 thousand	words’,	 and	 I	 think	 this	 is	 particularly	 true	 in
scientific	 research.	We	might	 not	 fully	 digest	 or	 remember	 the	 exact	 text	 in	 every	 article	we	 read,	 but
incredible	 images	will	 convey	novel	 information	with	 immediate	 effect	 and	 spring	 to	mind	effortlessly
over	the	years.	Scientific	images	are	at	the	heart	of	our	belief	in	our	data	and	findings	as	we	can	see	the
results	with	our	own	eyes.
To	tackle	this	Top	10	I	had	to	decide	whether	to	pick	the	most	visually	pleasing	images,	or	figures	that
changed	the	way	we	thought	about	aspects	of	GBS.	Conveniently,	often	the	images	fit	into	both	categories!
Ten	is	really	not	enough;	there	are	countless	inspiring	high	quality	images.	Here	I	opted	to	follow	quite	a
personal	 route,	 picking	 the	 images	 and	 figures	 that	 have	 been	 the	 most	 remarkable,	 influential	 and
meaningful	to	my	own	line	of	research.
Guillain,	Barré	and	Strohl
No	book	on	GBS	would	be	complete	without	a	tribute	to	the	three	forefathers	of	Guillain-Barré	syndrome,
French	army	physicians	Georges	Guillain,	Jean	Alexandre	Barré	and	Andre	Strohl	who	reported	the	first
cases	of	what	we	now	know	as	GBS	in	1916	(Figure	41.1)	[1].
AIDP	and	AMAN	Pathology
I	could	have	chosen	every	single	incredible	image	from	both	Griffin	and	colleagues	[2]	and	Hafer-Macko
and	colleagues	[3]	but	then	thankfully	the	authors	created	these	beautiful	overview	figures	(Figures	41.2
and	 41.3)	 in	 a	 subsequent	 review	 of	 human	 immune-mediated	 neuropathies	 [4]	 so	 I	 wasn’t	 forced	 to
choose.	Animal	models	have	of	course	been	indispensable	in	furthering	our	understanding	of	GBS,	but	I
think	where	 possible	 it’s	 beneficial	 that	we	 use	 patient	 autopsy	 tissue	 as	 a	 reference	 point,	 and	 these
studies	 have	 provided	 a	wonderful	 foundation	 for	 our	 knowledge	 of	 disease	 processes.	 These	 figures
clearly	demonstrate	the	differing	patterns	of	nerve	fibre	targeting	and	mode	of	injury	in	the	demyelinating
and	axonal	variants	of	GBS.	Complement	deposition	occurs	on	the	axolemma	(primarily	at	the	nodes	of
Ranvier)	in	AMAN	and	AMSAN	patients	or	on	the	Schwann	cell	abaxonal	membrane	in	AIDP,	where	it
is	 likely	 involved	 in	 membrane	 disruption	 and	 vesiculation,	 respectively.	 Complement	 activation	 is
followed	by	subsequent	macrophage	invasion	at	each	respective	membrane	where	they	likely	participate
in	opening	of	 the	periaxonal	 space	 and	degeneration	of	 axons	 (AMAN),	 and	 removal	of	myelin	debris
(AIDP).	Thorough	 ultrastructural	 and	 immunohistochemical	 analysis	 of	 nerve	 pathology	 in	 patients	 has
highlighted	the	disease	processes	and	aspects	we	must	simulate	when	developing	animal	models.
Figure	41.1		Georges	Guillain,	Jean	Alexandre	Barré	and	Andre	Strohl.	Public	domain.
Figure	41.2		Immunopathology	of	AIDP.	(A)	Two	fibres	from	an	early	AIDP	case	ringed	by	positive	immunostaining	for	C3d	are
indicated	by	asterisks	(*).	(B)	Activation	of	complement	followed	by	calcium	entry	and	vesicular	demyelination	are	a	hypothesized
sequence	of	events	 in	AIDP.	 (C)	Macrophages	attracted	by	complement	activation	remove	myelin.	 (D)	Schematic	depiction	of
proposed	pathogenesis	 in	AIDP,	with	antibody	binding	 to	myelin	 followed	by	complement	activation	and	macrophage-mediated
demyelination.	Images	(A,	B,	C)	adapted	with	permission	from	[19].	Image	D	reproduced	with	permission	from	[4].
Figure	41.3		Immunopathology	of	AMAN.	(A)	C3d	deposition	in	a	node	of	Ranvier,	demonstrated	by	immunostaining	in	the	ventral
root	of	a	patient	with	AMAN.	(B)	Macrophages	overlying	a	lengthened	node	of	Ranvier	in	the	ventral	root	of	a	patient	with	AMAN.
(C)	Macrophage	within	the	periaxonal	space	and	(boxed	region)	extending	processes	around	the	axon	(D)	Schematic	depiction	of
proposed	 pathogenesis	 in	 AMAN,	 showing	 antibody	 binding	 to	 the	 axonal	 targets	 followed	 by	 complement	 activation	 and
macrophage	 invasion	 through	 the	 node	 of	 Ranvier.	 Images	 A	 and	 D	 adapted	 with	 permission	 from	 [4].	 Images	 B	 and	 C
reproduced	with	permission	from	[2].
Complexities	of	Ganglioside	Distribution	and	Membrane	Interactions
The	 blots	 in	 Figure	 41.4	 are	 wonderfully	 simple	 images,	 but	 the	 information	 that	 they	 convey	 both
individually	 and	 together	 fundamentally	 changes	 the	 way	 ganglioside-antibody	 interactions	 are
understood.	 Anti-ganglioside	 antibodies	 are	 found	 in	 approximately	 60%	 of	 patient	 sera	 and	 are
associated	 with	 pathogenesis	 through	 binding	 gangliosides	 on	 peripheral	 nerve.	 The	 following	 is	 a
description	of	just	two	complexities	that	we	are	currently	aware	of.
Figure	41.4a	Ganglioside	patterns.	Ganglioside	fractions	corresponding	to	4.0	mg	wet	weight	of	tissue	were	chromatographed	on
an	HPTLC	plate,	then	stained	with	resorcinol.	The	oculomotor	nerve	(OM)	has	more	GQ	than	do	the	ventral	root	(VR)	and	dorsal
root	(DR)	of	the	lumbar	spinal	cord	for	the	same	wet	weight	(arrowhead).	ST	=	mixture	of	known	standard	gangliosides	(500	ng
each).	Reproduced	with	permission	from	[5].
Figure	41.4b	Thin-layer	chromatogram	(TLC)	immunostaining	of	sera	from	Patients	1	and	3.	TLC	results	in	plates	A	and	C	are
made	visible	by	the	orcinol	reagent.	Bovine	brain	gangliosides	extracted	by	0.1M	ammonium	acetate	are	in	lane	(1),	GD1a	(3µg)
in	lane	(2),	GD1b	(3	µg)	in	lane	(3),	and	both	GD1a	and	GD1b	(3	µg	each)	in	lane	(4).	Plate	B	shows	the	TLC	immunostaining	of
the	serum	from	Patient	1,	and	plate	D	that	of	the	serum	from	Patient	3.	Compared	with	the	slight	immunostaining	present	in	lanes
(2)	and	(3),	the	overlapping	portion	of	GD1a	and	GD1b	in	lane	(4)	is	strongly	immunostained.	Reproduced	with	permission	from
[6].
Figure	41.5		Immunoelectron	microscopy	of	mouse	spinal	roots.	(A)	CT	binding	to	nodal	axolemma;	(B)	CT	binding	extending	to
paranodal	axolemma;	(C)	CT	binding	to	intermodal	axolemma	in	an	area	where	myelin	is	thinned	and	retracted;	(D)	CT	binding	to
axolemma	of	amyelinated	axons	in	a	dystrophic	spinal	root;	(E)	PNA	binding	to	nodal	axolemma,	the	outside	of	Schwann	cells,
and	microvilli	of	 the	terminal	myelin	 loops;	 inset	shows	PNA	binding	to	amyelinated	axons	 in	a	dystrophic	spinal	root;	 (F)	TTC
binding	to	nodal	axolemma;	inset	shows	TTC	binding	to	amyelinated	axons	in	a	dystrophic	spinal	root.	Scale	bar	represents	5
μm.	Reproduced	with	permission	from	[7].
In	a	series	of	experiments,	Chiba	and	colleagues	demonstrated	for	the	first	time	a	relationship	between
anti-GQ1b	antibody	serum	levels	and	patients	with	ophthalmoplegia	in	MFS	and	GBS	and	the	underlying
cause	[5].	The	landmark	finding	is	illustrated	in	the	blot	where	GQ1b	content	is	significantly	greater	in	the
human	occulomotor	nerve	compared	to	ventral	and	dorsal	roots.	This	study	demonstrates	that	ganglioside
expression	occurred	at	different	densities	 in	various	nerve	membranes	throughout	 the	body,	and	thereby
could	uniquely	influence	site-specific	pathogenesis	and	clinical	manifestation.
A	 decade	 later,	 Kaida	 and	 colleagues	 observed	 another	 new	 feature	 of	 patient	 anti-ganglioside
antibodies	[6].	 It	 is	possible	 to	find	antibodies	 in	patient	sera	 that	bind	to	gangliosides	 in	complex	and
their	 newly	 formed	 glycoepitopes,	 rather	 than	 single	 ganglioside	 epitopes.	 In	 the	 TLC	 blot	 from	 this
article,	 lanes	 2	 (single	 GD1a)	 and	 3	 (single	 GD1b)	 show	 no	 or	 weak	 bands	 when	 patient	 serum	 is
overlaid,	while	lane	4	(GD1a	+	GD1b)	shows	prominent	binding.	Gangliosides	can	form	clusters	in	the
plasma	membrane,	but	until	 this	 study	 it	had	never	been	shown	 that	antibodies	could	exclusively	 target
these	clusters	instead	of	individual	lipids.	Antibody	binding	to	complexes	may	correlate	with	a	specific
GBS	phenotype	just	as	GQ1b	binding	is	associated	with	ophthalmoplegia.	Additionally,	currently	not	all
GBS	patients	have	identifiable	serum	antibodies;	assessing	patient	sera	for	complexes	as	well	as	single
gangliosides	may	account	for	this	gap.
Figure	41.6	 	Fresh-frozen	cross-sections	of	 rat	cauda	equina	 triple-labelled	with	anti-ganglioside	mAbs	(green),	neurofilament
(red)	and	IB-4	(blue).	Co-localization	of	three	labels	is	also	shown	(merged).	The	mAbs	included	in	this	figure	are	shown	on	the
left.	Bar	=	20	mm.	Reproduced	with	permission	from	[8].
Localisation	of	Gangliosides	in	the	PNS
Figures	41.5	and	41.6,	from	the	work	of	Sheikh	and	colleagues	[7]	and	Gong	and	colleagues	[8],	are	as
meaningful	and	interesting	now	as	when	they	were	first	published.	It	is	highly	relevant	to	the	above	ideas
that	 gangliosides	 are	 not	 homogenously	 expressed	 and	 that	 not	 all	 characteristics	 of	 anti-ganglioside
antibody	binding	can	be	revealed	by	array.	Indeed,	it	is	now	known	that	antibodies	binding	similarly	on
array	can	bind	differently	in	processed	or	living	tissue	[9].
It	has	been	known	 for	many	years	 that	 anti-ganglioside	antibodies	 are	 found	at	high	 titres	 in	patient
serum,	and	that	some	of	these	antibodies	are	associated	with	clinical	symptoms	implying	specific	nerves
or	 sites	 are	 targeted	 (e.g.	 anti-GD1a	 Ab	 in	 AMAN).	 Why	 are	 some	 membranes	 (e.g.	 motor	 axons)
preferentially	targeted	when	gangliosides	are	comparably	expressed	in	myelin	and	axon	fractions?	Does
localisation	 of	 gangliosides	 differ,	 just	 as	 the	 density	 of	 GQ1b	 differs	 among	 nerves?	 Detailed	 and
thorough	 ganglioside	 localisation	 is	 essential	 to	 answering	 these	 questions,	 and	 as	 such	 ganglioside
localisation	was	first	probed	using	indirect	markers	(e.g.	cholera	toxin	is	a	known	receptor	for	GM1)	but
high-affinity	monoclonal	antibodies	now	prevail	as	a	more	precise	tool.
Figure	41.5	shows	immunoelectron	microscopy	of	cholera	toxin	binding	in	mouse	spinal	roots.	In	these
striking	ultrastructural	images,	cholera	toxin	binds	specifically	to	the	nodal	axolemma	and	paranodes	in
normal	 nerve.	 However,	 binding	 is	 not	 so	 restricted	 in	 transverse	 cryosections	 where	 Schwann	 cell
membrane	and	compact	myelin	are	also	positive.	Tissue	was	processed	differently	 for	 immunoelectron
microscopy	and	cryosectioning	and	that	likely	underlies	these	slightly	different	results.	Additional	binding
is	 found	along	 the	 internode	 in	areas	of	 thinned	myelin	and	all	 the	way	along	unmyelinated	 fibres	 from
amyelinated	 dystrophic	mice	 indicating	 that	GM1	 is	 present	 on	 the	 entire	 axon	 but	 its	 accessibility	 is
restricted	 under	 normal	 conditions.	 Taken	 together,	 these	 results	 raised	 awareness	 that	 there	 are	many
technical	considerations	to	be	made	when	interpreting	binding	and	localisation	data.	And	unfortunately	a
beautiful	image	does	not	reflect	the	whole	story!
In	 Figure	 41.6,	 the	 authors	 used	 high-affinity	 mouse	 monoclonal	 antibodies	 raised	 against	 the	 four
major	brain	complex	gangliosides	 to	probe	 the	peripheral	nerve	and	produce	 these	memorable	 images.
The	 immunohistochemical	 results	 clearly	 demonstrate	 that	 antibodies	 can	 differentially	 bind	motor	 and
sensory	fibres,	and	in	this	scenario	axonal	but	not	myelin	membranes.	This	indicated	that	gangliosides	can
be	inaccessible	to	circulating	antibody	binding	(e.g.	in	compact	myelin),	displayed	within	the	membrane
in	 an	unfavourable	manner	 for	 binding,	 and	 that	 individual	 antibodies	 can	 exhibit	 fine	 specificity.	This
finding	has	 further	highlighted	 the	causal	 relationship	between	certain	anti-ganglioside	antibodies,	 their
preferential	fibre	system/cell	type	binding,	and	the	ultimate	clinical	manifestation.
Complement-Mediated	Nodal	Injury	in	a	Rabbit	Model	of	GBS
The	active	immunisation	rabbit	GBS	model	has	provided	great	insight	into	the	pathomechanisms	of	axonal
GBS	 [10,11].	 It	 has	 also	 helped	 to	 establish	 the	 node	 of	Ranvier	 as	 a	 primary	 site	 for	 immune	 attack
associated	with	dysfunction.	Figure	41.7,	from	Susuki	and	colleagues	[12],	clearly	indicates	Na	channel
disruption	 at	 the	 node	 of	Ranvier	 associated	with	 complement	 deposition	 and	 nodal	 lengthening	 in	 the
acute	disease	phase.	Disruption	to	Na	channel	clustering	critically	impairs	saltatory	conduction	and	aligns
with	the	motor	nerve	conduction	block	observed	in	rabbits	and	humans.	This	finding	forms	the	foundation
for	 the	 fascinating	 new	 concept	 of	 nodo-paranodopathy,	 whereby	 antibody	 binding	 and	 complement
activation	at	the	NoR	can	cause	a	continuum	of	dysfunction	ranging	from	reversible	conduction	block	and
recovery	to	axonal	degeneration	and	poor	outcome	[13].
Figure	41.7		Lesions	at	the	nodes	of	Ranvier	with	complement	deposition	and	disrupted	NaV	channel	clusters.	(A)	Disruption	of
NaV	channel	clusters	at	the	acute	progressive	phase.	Both	C3	(green)	and	MAC	(blue)	staining	is	present	at	nodes.	Clusters	of
NaV	 channels	 (red)	are	preserved	at	 lesions	 restricted	 to	 the	node	 (left	 column),	whereas	NaV	 channels	 almost	 disappear	 at
lengthened	nodes	with	extended	C3	and	MAC	staining	(right	column).	Nerve	fibres	run	horizontally	in	both	columns.	Scale	bars,
10μm.	Reproduced	with	permission	from	[12].
Complement	Inhibition	as	a	Therapeutic	for	Attenuating	Peripheral
Nerve	Degeneration	in	a	Mouse	Model	of	GBS
The	powerful	potential	of	using	an	antibody	that	binds	and	inhibits	complement	component	C5	to	attenuate
pathology	in	a	GBS	disease	scenario	is	outlined	by	Figure	41.8.	Mice	that	are	transgenically	engineered
to	endogenously	express	cyan	fluorescent	protein	(CFP)	in	the	cytoplasm	of	their	axons	are	a	useful	tool
for	 live-imaging	 experiments	…	 and	 also	 produce	 rather	 eye-catching	 images!	 Here,	 the	 authors	 used
these	mice	to	show	the	effect	of	blocking	the	formation	of	the	complement	cascade’s	terminal	MAC	pore
on	 peripheral	 intramuscular	 nerve	 bundles	 subjected	 to	 anti-ganglioside	 antibody	 and	 a	 source	 of
complement	 [14].	 The	 fluorescent	 signal	 (white)	 is	 absent	 from	 the	 most	 terminal	 branches	 of	 the
intramuscular	 nerve	 bundles	 and	 weak	 more	 proximally,	 indicating	 a	 severe	 disruption	 to	 the	 nerve
membrane	 that	 coincided	with	 loss	of	 function.	This	 is	 completely	prevented	by	 the	blockade	of	MAC
pore	formation	by	anti-C5	antibody,	eculizumab	(Alexion	Pharmaceuticals	Ltd).
Figure	 41.8	 	 Complement	 inhibition	 with	 eculizumab	 attenuates	 nerve	 injury	 in	 an	 animal	 model	 of	 GBS.	 Antiganglioside
antibodies	and	complement	injure	distal	nerves	resulting	in	axonal	injury	and	loss	of	fluorescent	signal	(bottom	panel;	NMJs	are
labelled	 with	 bungarotoxin	 in	 red;	 fluorescent	 axonal	 signal	 in	 white).	 The	 addition	 of	 the	 complement	 inhibitor	 eculizumab
preserves	axonal	integrity	(top	panel).	Reproduced	with	permission	from	[14].
Serum	IgG	from	Guillain-Barré	Syndrome	AMAN	and	AIDP	Variants,
and	Chronic	Inflammatory	Demyelinating	Polyneuropathy	(CIDP)
Patients	Bind	the	Nodes	of	Ranvier	and	Paranodes,	Respectively,	and
This	Binding	Is	Blocked	by	Soluble	Antigens	to	Nodal	Proteins
Figure	41.9	elegantly	adds	to	the	evidence	corroborating	the	recent	theory	that	antibodies	targeting	nodal
proteins	can	be	found	in	patients	[15].	It	is	unclear	whether	these	antibodies	to	nodal	proteins	exist	either
as	part	of	the	initial	disease	pathogenesis	or	are	produced	subsequently	due	to	the	unveiling	of	epitopes
leading	 to	 disease	 augmentation.	 Evidence	 from	 animal	 models	 [16],	 points	 towards	 the	 targeting	 of
peripheral	myelin	protein	 in	 the	demyelinating	phenotype.	The	number	of	patients	who	have	anti-nodal
protein	antibodies	is	very	small,	but	the	summation	of	antibodies	to	each	individual	protein	could	account
for	many	patients.	The	fact	that	the	node	is	the	general	target	regardless	of	specific	epitope	could	underlie
a	similar	pathogenesis	among	patients	with	differing	preceding	infections.
Figure	41.9	 	 The	 binding	 of	 Guillain-Barré	 syndrome	 (GBS)	 and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 (CIDP)
patients’	IgG	to	nodes	of	Ranvier	is	blocked	by	soluble	antigens.	Mouse	sciatic	nerve	fibres	were	incubated	with	sera	(red)	from
(A,	B)	acute	 inflammatory	demyelinating	polyneuropathy	(AIDP)	or	 (C,	D)	acute	motor	axonal	neuropathy	(AMAN)	patients	and
were	stained	 for	Caspr	 (green)	 to	 label	paranodes.	Pre-incubation	of	AIDP	serum	with	soluble	contactin-Fc	 (B)	abolished	 the
binding	of	IgG	to	contactin	at	paranodes	(arrowheads).	Also,	pre-incubation	of	AMAN	serum	with	soluble	NF186-Fc	(D)	abolished
the	binding	of	IgG	to	neurofascin	at	nodes	(arrows)	and	paranodes	(arrowheads).	Scale	bar:	10μm.	Reproduced	with	permission
from	[15].
Figure	41.10a		Molecular	components	at	the	node	of	Ranvier
Schematic	drawing	shows	some	of	 the	molecular	 components	of	 the	peripheral	 nervous	system	nodal	 region,	which	 can	be
divided	into	the	node,	paranode,	and	juxtaparanode.	At	the	node,	gliomedin,	Nr-CAM,	and	neurofascin	(NF)	186	link	the	Schwann
cell	microvilli	to	the	nodal	axolemma.	In	the	paranode,	NF155	interacts	with	Caspr	and	contactin	heterodimers	to	link	the	glial	and
axonal	 membranes.	 In	 the	 juxtaparanode,	 TAG-1	 homodimers	 link	 the	 adaxonal	 Schwann	 cell	 membrane	 to	 the	 axonal
membrane.	In	the	internodal	region,	Necl4	interacts	with	Necl1,	and	myelin-associated	glycoprotein	(MAG)	has	several	potential
axonal	ligands.	Reproduced	with	permission	from	[17].
Molecular	Components	of	the	Nodes	of	Ranvier
Schematics	 themselves	 have	 become	 more	 sophisticated	 over	 the	 years	 and	 form	 a	 really	 important
reference	 point	 for	 our	 understanding.	As	we	 add	more	 pieces	 to	 the	 puzzle	 through	 our	 research,	 the
schematics	can	be	revised	and	edited,	but	I	think	they	form	a	neat	starting	point	for	new	researchers	and	a
helpful	quick	reminder	for	those	already	immersed	in	the	field.	I	have	chosen	the	particular	schematic	in
Figure	41.10a	[17]	because	at	first	glance	it	looks	complex	and	daunting,	but	what	I	think	it	also	reveals	is
that	we	 need	 to	 look	 at	 the	whole	 picture	 and	 not	 isolated	 elements.	 The	 node	 of	Ranvier	 is	 a	 highly
specialised	 structure	 with	 a	 critical	 role	 in	 nerve	 conduction.	 It	 is	 a	 known	 site	 of	 antibody	 binding,
disruption	 and	 injury	 in	 GBS,	 but	 the	 specific	 mechanisms	 are	 yet	 to	 be	 revealed.	 With	 the	 recent
emergence	of	antibodies	that	bind	nodal	proteins	in	GBS	patient	sera,	the	interest	in	this	structure	is	even
greater.	Therefore,	this	figure	can	be	used	to	guide	us	when	we	study	antibody-nodal	protein	interactions
and	remind	us	that	changes	to	one	component	will	influence	many	other	parts.
Figure	41.10b		Possible	immunopathogenesis	of	the	Guillain-Barré	syndrome
Panel	A	shows	the	immunopathogenesis	of	acute	inflammatory	demyelinating	polyneuropathy.	Although	autoantigens	have	yet	to
be	 unequivocally	 identified,	 autoantibodies	 may	 bind	 to	 myelin	 antigens	 and	 activate	 complement.	 This	 is	 followed	 by	 the
formation	of	membrane-attack	complex	(MAC)	on	the	outer	surface	of	Schwann	cells	and	the	initiation	of	vesicular	degeneration.
Macrophages	 subsequently	 invade	 myelin	 and	 act	 as	 scavengers	 to	 remove	 myelin	 debris.	 Panel	 B	 shows	 the
immunopathogenesis	of	acute	motor	axonal	neuropathy.	Myelinated	axons	are	divided	into	four	functional	regions:	the	nodes	of
Ranvier,	 paranodes,	 juxtaparanodes,	 and	 internodes.	 Gangliosides	 GM1	 and	 GD1a	 are	 strongly	 expressed	 at	 the	 nodes	 of
Ranvier,	where	the	voltage-gated	sodium	(NaV)	channels	are	localized.	Contactin	associated	protein	(Caspr)	and	voltage-gated
potassium	 (KV)	 channels	 are	 respectively	 present	 at	 the	 paranodes	 and	 juxtaparanodes.	 IgG	 anti-GM1	 or	 anti-GD1a
autoantibodies	bind	to	the	nodal	axolemma,	leading	to	MAC	formation.	This	results	in	the	disappearance	of	NaV	clusters	and	the
detachment	of	paranodal	myelin,	which	can	 lead	 to	nerve-conduction	 failure	and	muscle	weakness.	Axonal	degeneration	may
follow	at	a	later	stage.	Macrophages	subsequently	invade	from	the	nodes	into	the	periaxonal	space,	scavenging	the	injured	axons.
Reproduced	with	permission	from	[18].
Possible	Pathogenesis	of	the	Guillain-Barré	Syndrome
Schematics	 themselves	 have	 become	 more	 and	 more	 sophisticated	 over	 the	 years,	 but	 the	 general
principles	hold	true.	I	wanted	to	include	Figure	41.10b	[18]	as	I	think	the	image	is	a	neat	point	to	work
from	and	also	to	refer	back	to	whenever	new	discoveries	emerge.
Conclusion
These	10	images	are	just	the	tip	of	the	iceberg	of	influential	images	in	the	GBS	field.	There	has	been	such
a	diverse	array	of	incredible	images	in	just	100	years.	With	all	of	the	advances	in	imaging	and	labelling
technology,	what	will	the	next	centenary	of	GBS	research	generate?
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Animal	Models:	Anti-Ganglioside	Antibodies	as
Causative	Factor	for	GBS
Susumu	Kusunoki
Introduction
Guillain-Barré	 syndrome	 (GBS)	 is	 an	 acute,	 self-limited	 peripheral	 neuropathy	 often	 preceded	 by	 an
infection.	 The	 pathogenetic	 mechanism	 of	 GBS	 is	 considered	 to	 be	 autoimmunity.	 Antibodies	 against
glycolipids,	including	gangliosides,	have	been	reported	to	be	present	in	around	60%	of	the	sera	from	GBS
patients	 in	 the	 acute	phase.	They	 are	 actually	useful	 diagnostic	markers	 of	GBS.	 In	 contrast,	 it	was	 an
issue	of	debate	whether	anti-ganglioside	antibodies	were	directly	involved	in	the	pathogenesis	of	GBS.
Now,	the	pathogenetic	roles	are	recognised,	at	least	for	some	of	the	anti-ganglioside	antibodies,	because
the	neuropathic	effects	of	those	antibodies	have	been	shown	in	in	vivo	animal	models.	In	this	chapter,	10
papers	 regarding	 the	 animal	models	of	 anti-ganglioside	 antibody-mediated	neuropathy	are	 selected	and
briefly	introduced	(Table	42.1).
Nagai	Y,	et	al.	Ganglioside	syndrome,	a	new	autoimmune	neurologic
disorder,	experimentally	induced	with	brain	gangliosides.
Neuroscience	Letters,	1976
Nagai	and	colleagues	 investigated	 the	modulation	of	 the	 immunologic	 response	 to	myelin	basic	protein
(MBP)	by	the	formation	of	a	conjugate	of	MBP	and	acidic	sphingoglycolipids	[1].	During	the	course	of
their	 investigations,	 they	 noticed	 that	 rabbits	 intensively	 immunised	 with	 total	 brain	 gangliosides
sometimes	 developed	 neurologic	 symptoms	 and	 signs.	 They	 then	 immunised	 rabbits	 with	 purified
gangliosides.	As	a	result,	4	of	the	8	rabbits	which	had	been	injected	with	GD1a	ganglioside	developed
neurological	symptoms	and	signs.	When	they	immunised	rabbits	with	GM1	ganglioside,	the	rabbits	were
also	 affected	 with	 neurological	 disease,	 although	 the	 rate	 of	 induction	 of	 neurological	 problems	 was
lower	than	it	had	been	with	GD1a.	The	rabbits	injected	with	GM1	had	high	titres	of	antibody	activities	to
GM1,	but	 those	 injected	with	GD1a	produced	a	small	or	negligible	amount	of	antibody	activities.	This
paper	 is	 the	 first	 to	 describe	 the	 animal	model	with	 robust	 neurological	 symptoms	 and	 signs	with	 the
sensitisation	 with	 ganglioside.	 However,	 descriptions	 of	 the	 neurological	 symptoms	 and	 signs,	 the
serological	examinations,	and	pathological	investigations	were	not	sufficient	enough	to	evaluate	in	detail.
They	 described	 that	 the	 rabbits	 injected	with	 GD1a	 ganglioside	 developed	 a	 state	 of	 rigid	 or	 spastic
paralysis	whereas	 those	 injected	with	GM1	ganglioside	 developed	 flaccid	 paralysis.	 If	 so,	 the	 rabbits
injected	with	GD1a	ganglioside	might	develop	a	central	nervous	system	disease.	But,	in	any	case,	it	can
be	 said	 that	 this	 work	 paved	 the	 way	 to	 the	 later	 research	 of	 autoimmune	 neuropathies	 with	 anti-
ganglioside	antibodies.
Table	42.1		Animal	model	of	autoimmune	neuropathy	mediated	by	anti-glycolipid	antibodies
Saida	T,	et	al.	Experimental	allergic	neuritis	induced	by	sensitization
with	galactocerebroside.	Science,	1979
Saida	and	colleagues	 immunised	 rabbits	with	galactocerebroside	 (GalC),	 a	major	glycolipid	 in	central
and	peripheral	nervous	systems	[2].	They	reported	that	13	of	31	sensitised	rabbits	showed	flaccid	paresis
and	 hypesthesia	 of	 4	 limbs.	 Some	 of	 the	 rabbits	 showed	 respiratory	 paresis.	 Electrophysiologically,
multifocal	 conduction	 block	 and	 reduction	 of	motor	 conduction	 velocities	were	 revealed.	 Pathological
findings	showed	multifocal	demyelinative	lesions	with	macrophage	infiltration	in	the	peripheral	nervous
system,	primarily	in	spinal	ganglia,	roots,	and	cauda	equina.	This	is	the	first	established	animal	model	of
autoimmune	neuropathy	in	which	glycolipid	is	the	target	molecule.
Saida	K,	et	al.	In	vivo	demyelination	induced	by	intraneural	injection	of
anti-galactocerebroside	serum:	a	morphologic	study.	American	Journal
of	Pathology,	1979
Saida	and	colleagues	performed	intraneural	injection	of	rats	with	rabbit	anti-GalC	serum	and	found	that
there	were	demyelinating	changes	followed	by	macrophage	infiltration	[3].	Demyelinating	activity	of	the
antiserum	was	 removed	by	preincubation	with	GalC	 and	was	 lost	when	 the	 serums	were	 heated	 at	 56
degrees	centigrade	 for	30	minutes,	 indicating	 that	 the	pathogenetic	mechanism	was	anti-GalC	antibody-
dependent	 and	 complement-mediated.	 Although	 the	 pathogenetic	 roles	 of	 anti-GalC	 antibodies	 were
shown	 in	 this	 work,	 clinical	 relevance	 was	 not	 fully	 recognised	 at	 that	 time	 because	 a	 significant
association	between	anti-GalC	antibody	and	human	diseases	had	not	been	reported.	It	was	not	until	1995
that	the	presence	of	anti-GalC	antibodies	in	GBS	subsequent	to	mycoplasma	infection	was	first	reported
[4].
Kusunoki	S,	et	al.	Experimental	sensory	neuropathy	induced	by
sensitization	with	ganglioside	GD1b.	Annals	of	Neurology,	1996
Even	after	the	publication	of	the	animal	model	of	demyelinating	neuropathy	caused	by	anti-GalC	antibody,
the	role	of	anti-ganglioside	antibodies	in	the	pathogenesis	was	still	a	matter	of	controversy	because	there
was	no	established	animal	model	induced	by	gangliosides.	One	reason	for	the	difficulty	of	development
of	 the	 animal	model	was	 the	 differences	 in	 the	 distribution	 of	 individual	 gangliosides	 from	 species	 to
species.	It	was	reported	that	antibody	activities	to	gangliosides	with	disialosyl	residue,	including	GD1b,
were	associated	with	sensory	ataxic	neuropathy.	Kusunoki	and	colleagues	found	that	GD1b	was	densely
localised	 in	 the	 large	 neurons	 in	 human	 dorsal	 root	 ganglia.	 Because	 such	 localisation	 of	 GD1b
ganglioside	was	 also	 seen	 in	 rabbits,	 they	 hit	 upon	 an	 idea	 that	 the	 effective	 animal	model	would	 be
developed	by	the	sensitisation	of	the	rabbits	with	GD1b	ganglioside.	They	then	immunised	rabbits	with
GD1b	 ganglioside	 and	 succeeded	 in	 developing	 the	 animal	model	 with	 robust	 neurological	 signs	 [5].
Muscle	power	 in	 these	 rabbits	was	 intact	but	 the	 rabbits	 showed	awkward	movements.	Pathologically,
axonal	degeneration	was	observed	in	the	dorsal	root	and	dorsal	column	of	the	spinal	cord,	whereas	the
ventral	root	was	completely	intact.	Therefore,	the	rabbits	were	diagnosed	with	sensory	ataxic	neuropathy
both	clinically	and	pathologically.	This	rabbit	model,	GD1b-induced	sensory	ataxic	neuropathy	(GD1b-
induced	SAN),	was	 the	 first	established	animal	model	of	autoimmune	neuropathy	 targeting	ganglioside.
The	 titres	 of	 the	 anti-GD1b	 antibodies	 were	 increased.	 In	 contrast,	 no	 lymphocytic	 infiltration	 was
observed	 in	 the	 affected	 areas,	 indicating	 that	 the	 autoantibodies	 play	 the	 crucial	 roles	 in	 this	 animal
model.
Kusunoki	S,	et	al.	Monospecific	anti-GD1b	IgG	is	required	to	induce
rabbit	ataxic	neuropathy.	Annals	of	Neurology,	1999
In	Kusunoki	and	colleagues’	1999	study,	the	incidence	of	GD1b-induced	SAN	was	about	50%	[6].	One
reason	for	that,	they	reasoned,	might	be	differences	in	the	fine	specificity	of	the	antibodies.	Injection	with
GD1b	ganglioside	could	cause	the	production	of	the	antibodies	to	GM1	as	well	as	GD1b	because	those	2
gangliosides	share	Gal-GalNAc	residue.	Using	the	GM1-affinity	column,	the	antibodies	specific	to	GD1b
gangliosides	could	be	separated	from	those	binding	to	both	GD1b	and	GM1.	The	authors	then	examined
the	 titres	 of	 the	 antibodies	 specific	 to	 GD1b	 and	 found	 that	 the	 titres	 were	 significantly	 higher	 in	 the
affected	rabbits	than	in	the	unaffected	ones.	This	shows	that	the	antibodies	specific	to	GD1b	are	required
to	induce	sensory	ataxic	neuropathy	in	rabbits.	It	was	reported	in	another	paper	that	passive	transfer	of	the
antiserum	caused	neuropathological	changes	similar	 to	 the	GD1b-induced	SAN	[7].	Taken	 together,	 the
antibodies	specific	 to	GD1b	ganglioside	should	be	 the	main	causative	factor	 in	 this	animal	model.	The
association	between	the	antibody	activities	highly	specific	to	GD1b	and	the	ataxia	in	GBS	has	later	been
shown	by	the	investigation	of	the	acute-phase	sera	from	GBS	patients	[8].
Yuki	N,	et	al.	Animal	model	of	axonal	Guillain-Barré	syndrome	induced
by	sensitization	with	GM1	ganglioside.	Annals	of	Neurology,	2001
Anti-GM1	IgG	antibody	is	frequently	detected	in	GBS	subsequent	to	Campylobacter	jejuni	infection	[9].
GBS	subtypes	of	those	cases	are	predominantly	acute	motor	axonal	neuropathy	(AMAN)	type.	There	was
a	 controversy	 over	 whether	 or	 not	 immunisation	 of	 the	 animals	 with	 GM1	 ganglioside	 would	 cause
neurological	 problems.	 Yuki	 and	 colleagues	 sensitised	 rabbits	 with	 bovine	 brain	 ganglioside	 mixture
(BBG)	containing	GM1	or	purified	GM1	according	to	the	procedure	of	GD1b-induced	SAN	model	[10].
Results	 showed	 that	all	of	 the	13	 rabbits	 inoculated	with	BBG	and	9	of	 the	11	 rabbits	 inoculated	with
purified	 GM1	 developed	 acute	 motor	 neuropathy.	 The	 rabbits	 inoculated	 with	 BBG	 had	 anti-GM1
antibodies.	 Pathological	 findings	 showed	 axonal	 degeneration	with	 neither	 lymphocytic	 infiltration	 nor
demyelination.	This	study	indicated	that	anti-GM1	antibody	is	a	causative	factor	and	this	model	should	be
a	 useful	 animal	 model	 for	 investigation	 of	 AMAN.	 The	 authors	 used	 functional	 grades	 (FG)	 from	 0
(normal)	 to	 5	 (dead).	 In	 BBG-inoculated	 rabbits,	 9	 of	 13	 rabbits	 showed	 FG	 of	 4	 (showing	 severe
weakness	of	the	4	limbs,	which	were	spread	out)	at	the	nadir	and	one	rabbit	showed	FG	of	3	(showing
moderate	weakness	of	 the	4	 limbs	and	unable	 to	walk).	Therefore	10	of	 the	13	 rabbits	were	unable	 to
walk	at	the	nadir.	In	contrast,	in	GM1-inoculated	rabbits,	only	3	of	11	rabbits	were	FG	of	3	or	more	(2
were	FG	of	5).	This	 suggests	 that	BBG	may	be	a	more	effective	agent	 for	 the	 induction	of	 this	 animal
model	than	purified	GM1.
Susuki	K,	et	al.	Anti-GM1	antibodies	cause	complement-mediated
disruption	of	sodium	channel	clusters	in	peripheral	motor	nerve
fibers.	The	Journal	of	Neuroscience,	2007
In	 this	 study,	 Susuki	 and	 colleagues	 investigated	 the	 molecular	 organisation	 at	 the	 nodes	 of	 Ranvier
immunohistochemically,	using	the	BBG-induced	motor	axonal	neuropathy	model	described	above	[11].	In
the	acute	phase,	voltage-gated	sodium	channel	clusters	were	disrupted	or	disappeared	at	the	nodes.	The
deposition	of	IgG	and	complement	products	were	observed.	Pathological	changes	were	also	detected	in
paranodal	 axo-glial	 junctions.	 This	 paper	 revealed	 the	 precise	molecular	 pathogenetic	mechanisms	 of
BBG-induced	motor	axonal	neuropathy	and	clearly	showed	that	 it	was	a	complement-mediated	disease.
The	 results	 shown	 in	 this	 report	 should	 give	 us	 very	 important	 clues	 to	 elaborating	 novel	 therapeutic
methods	for	AMAN.
Takada	K,	et	al.	Apoptosis	of	primary	sensory	neurons	in	GD1b-
induced	sensory	ataxic	neuropathy.	Experimental	Neurology,	2008
In	a	GD1b-induced	SAN	model,	axonal	degeneration	with	macrophage	 infiltration	was	observed	 in	 the
dorsal	root	and	in	the	dorsal	column	of	the	spinal	cord.	However,	in	spite	of	the	looseness	of	the	blood-
nerve	 barrier	 in	 DRG,	 there	 were	 no	 significant	 pathological	 changes	 in	 DRG.	 It	 was	 possible	 that
apoptosis	of	 the	 large	 sensory	neurons	occur	 in	 this	animal	model.	To	 find	out,	Takada	and	colleagues
performed	a	TUNEL	assay	of	the	DRG	from	the	affected	rabbits	and	discovered	that	a	subset	of	neurons
were	 TUNEL	 positive	 [12].	 Anti-caspase	 3	 antibody	 also	 immunostained	 some	 of	 the	 DRG	 neurons.
TUNEL	positivity	was	found	in	the	neurons	with	large	diameter.	Therefore,	apoptosis	of	the	large	primary
sensory	 neurons	 subsequent	 to	 the	 binding	 of	 the	 GD1b-specific	 antibodies	 should	 be	 one	 important
pathogenetic	mechanism	of	GD1b-induced	SAN.	 In	addition	 to	complement-mediated	membrane	attack,
apoptotic	mechanisms	after	the	binding	of	the	antibodies	should	be	considered	for	the	possible	mechanism
of	the	anti-ganglioside	antibody-mediated	neuropathies	or	neuronopathies.
Sheikh	KA,	et	al.	An	anti-ganglioside	antibody-secreting	hybridoma
induces	neuropathy	in	mice.	Annals	of	Neurology,	2004
In	order	 to	develop	passive	 transfer	model	 of	 anti-ganglioside	 antibody-mediated	neuropathies,	Sheikh
and	 colleagues	 performed	 intraperitoneal	 implantation	 of	 hybridoma-secreting	 anti-ganglioside
antibodies,	 reacting	with	GD1a	 ganglioside,	 in	mice	 [13].	As	 a	 result,	 approximately	 half	 the	 animals
implanted	with	the	hybridoma	developed	a	patchy,	predominantly	axonal	neuropathy	in	a	small	proportion
of	 nerve	 fibres.	 Passive	 transfer	 with	 systemically	 administered	 antibodies	 did	 not	 cause	 such
pathological	changes.	The	authors	discussed	whether	hybridoma	implantation	might	make	the	blood-nerve
barrier	leaky.	Even	in	the	mice	implanted	with	the	hybridoma,	neuropathological	changes	were	mild.	This
study	 showed	 that,	 in	 addition	 to	 the	 antibodies,	 other	 factors	 such	 as	 antibody	 accessibility	 were
important.	 It	 also	 indicated	 that	mouse	 nerves	might	 be	 resistant	 to	 anti-ganglioside	 antibody-mediated
injury.
Halstead	SK,	et	al.	Eculizumab	prevents	anti-ganglioside	antibody-
mediated	neuropathy	in	a	murine	model.	Brain,	2008
Dr	Hugh	Willison’s	group	reported	that	anti-GQ1b	antibodies	were	able	to	bind	and	disrupt	presynaptic
motor	 nerve	 terminals	 at	 the	 neuromuscular	 junction	 (NMJ)	 using	mouse	 hemi-diaphragm	model	 [14].
Based	 on	 this	 finding,	Halstead	 and	 colleagues	 injected	 balb/c	mice	 intraperitoneally	with	 anti-GQ1b
antibody,	 followed	 by	 an	 intraperitoneal	 injection	 of	 normal	 human	 serum.	Mice	 treated	 as	 described
above	showed	breathing	difficulties	 [15].	Anti-GQ1b	antibodies	are	detected	 in	about	90%	of	 the	sera
from	patients	with	Miller	Fisher	syndrome	(MFS)	in	the	acute	phase.	Breathing	difficulty	is	not	observed
in	MFS.	However,	when	anti-GQ1b	antibody	is	positive	in	patients	with	GBS	with	ophthalmoplegia,	the
patients	more	 frequently	need	mechanical	ventilation	 than	 anti-GQ1b-negative	patients	 [16].	Therefore,
this	 mouse	 model	 is	 a	 nice	 model	 of	 GBS	 with	 respiratory	 insufficiency.	 Halstead	 and	 colleagues
reported	 that	 eculizumab,	 which	 blocks	 the	 formation	 of	 human	 C5a	 and	 C5b-9,	 protected	 mice	 from
respiratory	paralysis	 in	 this	model	by	preventing	complement-mediated	damage	at	 the	NMJ.	This	work
provides	 us	 with	 the	 rationale	 for	 the	 clinical	 trials	 of	 eculizumab	 for	 GBS.	 The	 clinical	 trials	 of
eculizumab	are	currently	underway	at	time	of	writing.	If	 they	show	good	results,	we	can	obtain	a	novel
therapeutic	method	for	GBS,	especially	intractable	cases.
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Experimental	Autoimmune	Neuritis	and
Spontaneous	Autoimmune	Polyneuropathy
Betty	Soliven
Introduction
Animal	 models,	 in	 spite	 of	 their	 limitations,	 are	 essential	 research	 tools	 for	 deciphering	 disease
mechanisms	 in	 autoimmune	 diseases.	 The	 use	 of	 animal	 models	 has	 facilitated	 the	 discovery	 of	 new
susceptibility	 genes,	 detailed	 immunologic,	 and	 morphologic	 and	 functional	 studies	 as	 well	 as	 the
development	 of	 novel	 therapeutic	 strategies.	Within	 the	 context	 of	 Guillain-Barré	 syndrome	 and	 other
autoimmune	neuropathies,	these	models	include	experimental	autoimmune	neuritis	(EAN),	antibody	(Ab)-
mediated	experimental	 autoimmune	neuropathy	and	 spontaneous	autoimmune	polyneuropathy	 (SAP).	As
the	 crucial	 role	 of	 antibodies	 (Abs)	 against	 glycolipids	 in	GBS	will	 be	 discussed	 elsewhere,	we	will
focus	on	lessons	learnt	from	EAN	and	SAP	in	this	chapter.
Experimental	Autoimmune	Neuritis	(EAN)
Waksman	BH	and	Adams	RD.	Allergic	neuritis:	an	experimental	disease	of	rabbits	induced
by	the	injection	of	peripheral	nervous	tissue	and	adjuvants.	Journal	of	Experimental
Medicine,	1955;	Aström	KE,	Webster	HD	and	Arnason	BG.	The	initial	lesion	in
experimental	allergic	neuritis.	A	phase	and	electron	microscopic	study.	Journal	of
Experimental	Medicine,	1968;	Asbury	AK,	Arnason	BG	and	Adams	RD.	The	inflammatory
lesion	in	idiopathic	polyneuritis.	Its	role	in	pathogenesis.	Medicine,	1969
The	Discovery	of	EAN	and	the	Role	of	Cell-Mediated	Immunity
EAN	was	 first	 induced	 in	 rabbits	by	Waksman	and	Adams	 in	1955	by	 immunization	with	sciatic-nerve
homogenates	 with	 Freund’s	 adjuvants	 [1].	 After	 a	 latent	 period	 of	 about	 2	weeks,	 animals	 developed
weakness	and	ataxia	that	reached	their	maximum	in	3	days,	with	most	of	them	recovering	within	the	next	6
days.	Aside	from	the	typical	albumino-cytologic	dissociation	in	the	CSF,	these	animals	exhibited	lesions
in	nerve	roots,	spinal	ganglia	and	peripheral	nerves	 that	were	characterized	by	perivascular	 infiltration
with	mononuclear	cells,	segmental	demyelination	and	varying	degrees	of	axonal	degeneration.	Subsequent
successful	transfer	of	disease	with	lymphocytes	from	immunized	animals	and	reports	on	similar	autopsy
findings	 of	 19	 fatal	 cases	 of	 human	 GBS	 had	 led	 to	 conclusions	 that	 cellular	 immunity	 to	 myelin
components	is	the	underlying	culprit	in	GBS	[2–4].	Of	note,	Dr	Waksman	has	also	been	recognized	for	his
pioneering	work	 on	 circulating	 T	 lymphocytes	 as	well	 as	 the	 role	 of	 thymus	 in	 immune	 response	 and
tolerance.
Brostoff	SW,	Levit	S	and	Powers	JM.	Induction	of	experimental	allergic	neuritis	with	a
peptide	from	myelin	P2	basic	protein.	Nature,	1977
Although	myelin	 P0	 is	 the	most	 abundant	 myelin	 protein	 in	 the	 PNS,	 the	 first	 myelin	 peptide	 used	 to
induce	EAN	was	a	21	amino	acid	P2	peptide	from	the	NH2	terminal	[5].	This	was	followed	by	studies	on
EAN	induced	by	other	myelin	proteins	such	as	myelin	P0	and	PMP22.	In	spite	of	a	failure	to	translate	to
successful	identification	of	antigenic	targets	of	autoreactive	T	cells	in	GBS,	EAN	has	provided	valuable
information	such	as	the	role	of	costimulatory	signals,	adhesion	molecules	and	various	cytokines,	as	well
as	 mechanisms	 of	 injury.	 We	 have	 learnt	 that	 EAN	 is	 alleviated	 in	 CD28-deficient	 C57BL/6	 mice
immunized	with	P0	peptide	180–199	[6].	Recovery	from	EAN	is	associated	with	M2	milieu	promoted	by
IL-10	and	IL-4	[7].	The	crucial	role	of	macrophages	in	EAN	is	also	demonstrated	by	altering	the	balance
of	M1/M2	macrophages	in	TNF-α	knockout	(KO)	mice	[8].	B	cells	contribute	to	the	pathogenesis	of	EAN
via	 CD40L-CD40	 interactions,	 regulatory	 mechanisms	 and	 production	 of	 auto-Abs.	 B	 cells	 play	 a
suppressive	 role	 during	 the	 induction	 of	 EAN,	 but	 enhance	 the	 severity	 of	 EAN	 during	 peak	 disease
[9,10].	The	latter	may	be	due	to	auto-Abs	to	multiple	myelin	proteins	and/or	gangliosides	in	EAN	induced
by	peripheral	nerve	myelin,	which	could	contribute	significantly	 to	demyelination	or	conduction	failure
after	disruption	of	the	blood	nerve	barrier	by	myelin-reactive	T	cells.
Novakovic	SD,	et	al.	Disruption	and	reorganization	of	sodium	channels	in	experimental
allergic	neuritis.	Muscle	Nerve,	1998;	Lonigro	A	and	Devaux	JJ.	Disruption	of	neurofascin
and	gliomedin	at	nodes	of	Ranvier	precedes	demyelination	in	experimental	allergic	neuritis.
Brain,	2009
Mechanisms	of	Conduction	Failure	in	EAN:	Demyelination	vs	Nodal-Paranodal	Dysfunction
Weakness	 in	GBS	and	EAN	arises	 from	either	axonal	 loss	or	conduction	 failure.	Conduction	 failure	 in
demyelinated	fibres	occurs	as	a	consequence	of	capacitance	impedance	mismatch,	leakage	of	currents	and
exposure	 of	 internodal	K+	 channels.	However,	 conduction	 failure	 in	 EAN	 and	GBS	 often	 precede	 the
onset	 of	 demyelination,	 and	 is	 attributed	 to	 paranodal	 retraction	 and	 disruption	 of	 nodal	Na+	 channels
[11,12].
Whether	axonal	or	demyelinating	 features	predominate	 in	EAN	depends	on	 the	disease	severity	and
method	of	disease	 induction.	Adoptive	 transfer	 of	P2-reactive	T	 cell	 lines	 in	Lewis	 rats	 led	 to	 axonal
dysfunction	or	degeneration	with	minimal	demyelination,	whereas	adoptive	transfer	of	myelin-sensitized
lymph	 node	 cells	 (T	 cells	 and	 B	 cells)	 led	 to	 prominent	 demyelinating	 features	 [13].	 Interestingly,
disappearance	 of	 adhesion	 molecules	 neurofascin	 186	 and	 gliomedin,	 thought	 to	 be	 mediated	 by	 Abs
against	these	proteins,	was	observed	in	EAN	induced	by	peripheral	myelin,	but	not	in	EAN	induced	by	P2
[12].	These	 findings	 indicate	 that	 the	 antigenic	 targets	of	 immune	attack	extend	 to	nodal	 and	paranodal
proteins	 and	 is	 not	 restricted	 to	 myelin	 proteins.	 Indeed,	 immunization	 with	 gliomedin	 induces	 a
progressive	 neuropathy	 that	 is	 characterized	 by	 nodal	 disruption	 and	 demyelination	 [14].	 In	 addition,
antibodies	 to	 neurofascin	 cause	 exacerbation	 and	 prolongation	 of	 adoptive	 transfer	 EAN	 [15].	 Taken
together,	 these	 results	 suggest	 that	early	conduction	 failure	 in	EAN	and	GBS	 is	due	 to	nodal/paranodal
dysfunction,	 which	 can	 be	 reversed	 by	 plasmapheresis	 or	 intravenous	 immunoglobulin	 (IVIg)	 before
demyelination	and	axonal	degeneration	develop.
EAN:	Development	of	Therapies
Although	T	cells	dominated	the	fields	of	EAN	and	GBS	research	for	 three	decades,	anti-myelin	Abs	in
sera	 from	EAN	 and	GBS	 had	 been	 demonstrated,	 albeit	 not	 correlating	well	with	 clinical	 severity.	A
possible	 role	 of	Abs	 or	 other	 serum	 factors	 in	 the	 pathogenesis	 of	 EAN	 is	 supported	 by	 the	work	 of
Antony	and	colleagues	demonstrating	the	beneficial	effect	of	plasma	exchange	in	rabbits	when	given	prior
to	 the	 establishment	 of	 clinical	 disease	 [16].	 The	 effectiveness	 of	 IVIg	 as	 a	 treatment	 of	 EAN	 was
published	 in	 1997,	 the	 same	 year	 that	 results	 of	 the	 Plasma	 Exchange/Sandoglobulin	 Guillain-Barré
Syndrome	 Trial	 were	 published	 in	 The	 Lancet	 [17,18].	 The	 study	 by	 Gabriel	 and	 colleagues
demonstrated	 that	 the	 Ig	 treatment	 from	 disease	 onset	 was	 more	 beneficial	 than	 treatment	 from
immunization	 and	was	 associated	with	 a	 decrease	 in	 rat	 anti-myelin	Abs	 [17].	Miyagi	 and	 colleagues
found	that	the	intact	IVIg,	but	not	F(ab′)2	ameliorated	the	clinical	course	of	EAN	induced	by	P2	[18].
Because	 of	 the	 natural	 history	 of	 GBS	 and	 the	 favourable	 response	 to	 intravenous	 Ig	 and	 plasma
exchange,	many	studies	on	experimental	therapeutics	in	EAN	were	not	translated	to	clinical	trials	or	use
for	 this	 disorder.	 I	 was	 involved	 in	 a	 study	 demonstrating	 the	 suppressive	 effect	 of	 a	 β2	 adrenergic
agonist	 terbutaline	 on	 EAN	 in	 Lewis	 rats	 even	 when	 given	 after	 disease	 onset	 [19].	 The
immunomodulatory	 effect	 of	 cAMP-elevating	 agents	 in	 EAN	 was	 demonstrated	 by	 another	 agent,
Rolipram,	 a	 phosphodiesterase-4	 inhibitor,	 which	 induced	 downregulation	 of	 interferon-γ	 and	 pro-
inflammatory	 chemokines,	 and	 upregulation	 of	 interleukin	 4	 [20].	 But	 no	 clinical	 trials	 on	 cAMP-
elevating	agents	ensued	from	these	investigations.	On	the	other	hand,	studies	on	the	role	of	complement
activation	in	EAN	and	related	animal	models	have	led	to	an	ongoing	clinical	trial	of	eculizumab	in	GBS
[21,22].	Fingolimod,	an	S1P	receptor	modulator	studied	in	EAN	and	B7-2	knockout	non-obese	diabetic
(NOD)	mice,	 is	 currently	 being	 investigated	 in	 a	 clinical	 trial	 of	 chronic	 inflammatory	 demyelinating
polyradiculoneuropathy	(CIDP)	[23,	24].
Spontaneous	Autoimmune	Polyneuropathy	(SAP)	in	the	NOD	Mouse
Model
Salomon	B,	et	al.	Development	of	spontaneous	autoimmune	peripheral	polyneuropathy	in
B7-2-deficient	NOD	mice.	Journal	of	Experimental	Medicine,	2001;	Kim	HJ,	et	al.
Targeting	of	myelin	protein	zero	in	a	spontaneous	autoimmune	polyneuropathy.	Journal	of
Immunology,	2008;	Su	MA,	et	al.	Defective	autoimmune	regulator-dependent	central
tolerance	to	myelin	protein	zero	is	linked	to	autoimmune	peripheral	neuropathy.	Journal	of
Immunology,	2012;	Meyer	zu	Horste	G,	et	al.	Thymic	epithelium	determines	a
spontaneous	chronic	neuritis	in	Icam1(tm1Jcgr)NOD	mice.	Journal	of	Immunology,	2014
Most	human	autoimmune	diseases	occur	spontaneously	in	genetically	susceptible	Individuals,	albeit	with
some	exogenous	triggers	that	are	often	unknown	or	not	easily	identified.	In	animals,	a	naturally	occurring
model	 of	 spontaneous,	 organ-specific	 autoimmunity	 is	 the	 NOD	 mouse,	 which	 exhibits	 increased
susceptibility	 to	 multiple	 autoimmune	 diseases,	 including	 type	 1	 diabetes,	 thyroiditis,	 sialadenitis,
gastritis,	and	inflammatory	neuropathy.
Disease	manifestations	 in	NOD	mice	can	vary,	depending	on	 the	cytokine	and	costimulatory	milieu.
The	B7-1/B7-2:CD28/CTLA4	costimulatory	pathway	is	critical	to	the	regulation	of	lymphocyte	activation
and	homeostasis	of	 regulatory	T	cells	 (Tregs)	 [25,26].	The	B7-2	knockout	NOD	mouse	was	originally
generated	in	Dr	Bluestone’s	laboratory	to	study	the	role	of	costimulatory	molecules	in	type	1	diabetes.	He
was	 still	 at	 the	 University	 of	 Chicago	 at	 that	 time.	 One	 of	 his	 postdocs,	 Dr	 Salomon,	 observed	 that
elimination	 of	 B7-2	 (CD86)	 in	 NOD	mice	 led	 to	 protection	 against	 type	 1	 diabetes	 but	 triggered	 the
development	of	progressive	weakness	at	6	to	7	months	of	age.	I	was	asked	to	help	with	the	analysis	of	the
clinical	phenotype.	Electrophysiological	and	histological	studies	revealed	features	of	demyelination	and
axonal	 loss,	 and	 inflammatory	 infiltrates	 in	 sciatic	 nerves	 and	 dorsal	 root	 ganglia,	 as	 can	 be	 seen	 in
progressive	form	of	CIDP	[24,27].	 I	was	 intrigued	by	 the	concept	 that	elimination	of	one	molecule	can
alter	the	manifestation	of	autoimmune	disease	in	susceptible	animals.	Because	my	main	research	interest
at	 that	 time	was	 in	 oligodendrocyte	 and	 Schwann	 cell	 biology	 rather	 than	 neuroimmunology,	 I	 did	 not
pursue	 further	 investigations	 until	 6	 years	 later.	Using	 different	 approaches,	 both	Bluestone’s	 group,	 at
University	of	California	San	Francisco,	and	my	group,	at	the	University	of	Chicago,	found	that	myelin	P0
is	 the	 antigenic	 target	 in	 SAP	 in	 NOD	mice.	 SAP	 is	 mediated	 by	 IFN-γ-secreting	 Th1	 cells	 that	 are
reactive	against	myelin	P0,	and	at	least	2	pathogenic	P0	epitopes	are	involved,	P0	(1–25)	and	P0	(180–
199)	 [28–30].	Myelin	 P0	 is	 an	Aire-regulated,	 tissue-specific	 self-Ag	 in	 the	 thymus.	Maureen	 Su	 and
colleagues	 found	 that	 Aire-deficient	 mice	 have	 increased	 autoreactivity	 against	 P0	 and	 develop
autoimmune	neuropathy	that	is	mediated	by	IFN-γ	similar	to	that	observed	in	B7-2	knockout	NOD	mice
[31].
Aside	from	T	cells,	sera	from	SAP	mice	contain	Abs	to	P0,	which	may	contribute	to	peripheral	nerve
injury	[29].	We	found	that	depletion	of	B	cells	and	plasmablasts	with	anti-CD19	Ab	led	to	the	attenuation
of	SAP	[32].	SAP	is	also	attenuated	by	S1P	receptor	modulators	such	as	Fingolimod	and	SEW2871	[24].
More	recently,	we	have	demonstrated	that	B7-2-deficient	dendritic	cells	(DCs)	exhibit	impaired	capacity
to	 induce	 tolerance	 to	 P0,	which	 can	 be	 rescued	 by	 preconditioning	with	 IL-10	 [33].	Another	way	 to
overcome	impaired	DC	function	is	by	transduction	with	lentiviral	vectors	expressing	vasoactive	intestinal
peptide	(LV-VIP-BCD11b+	DCs),	which	delays	 the	onset	 of	 disease	 and	 attenuates	 clinical	 severity	 in
SAP	[34].
Of	note,	P0	is	expressed	not	only	in	the	PNS	myelin	but	also	by	peri-islet	Schwann	cells,	suggesting	a
potential	 mechanism	 linking	 the	 islet	 and	 PNS	 autoimmunity	 [29].	 The	 shift	 from	 islet	 to	 PNS
autoimmunity	is	also	observed	in	intercellular	adhesion	molecule1	(ICAM-1)	deficient	NOD	mice,	and	is
due	to	altered	thymic	selection	rather	than	loss	of	adhesive	activity	of	ICAM-1.	In	contrast	to	B7-2	KO
NOD	mice,	ICAM-1	deficient	NOD	mice	exhibit	Th17	bias	instead	of	Th1	bias	[35].
Overall,	these	studies	demonstrate	that	a	progressive	autoimmune	neuropathy	mimicking	CIDP	can	be
triggered	 by	 changes	 in	 costimulatory	 molecules/pathways.	 It	 is	 tempting	 to	 speculate	 that	 similar
mechanisms	occur	in	humans	in	that	GBS	is	monophasic	in	most	patients	but	can	switch	to	relapsing	and
remitting	 CIDP	 or	 progressive	 CIDP	 when	 regulatory	 mechanisms	 are	 impaired	 due	 to	 altered
costimulatory	or	cytokine	milieu.
Conclusions
Based	 on	 time	 course,	 EAN	would	 be	 considered	 more	 relevant	 to	 GBS	 while	 SAP	 would	 be	 more
pertinent	to	CIDP.	The	popularity	of	EAN	induced	by	PNS	myelin	or	myelin	protein	has	been	challenged
to	some	extent	by	the	discovery	of	anti-glycolipid	Abs	in	GBS	variants,	and	by	successful	establishment
of	animal	models	of	AMAN	and	ataxic	neuropathy	in	rabbits	and	mice.	Nonetheless,	EAN	and	SAP	have
facilitated	investigations	on	the	pathogenicity	of	PNS-reactive	T	cells	and	auto-Abs	against	PNS	antigens,
as	well	as	regulatory	mechanisms	pertinent	to	disease	development.	In	addition,	these	models	have	been
used	for	the	development	of	novel	therapeutic	strategies.
There	 are	 many	 investigators	 who	 have	 contributed	 significantly	 to	 the	 advancement	 of	 our
understanding	of	pathogenesis	of	GBS.	Within	the	context	of	EAN	and	SAP,	my	top	10	publications	were
chosen	based	on	 their	 impact	or	 implications	on	 the	field	of	neuroimmunology	of	PNS.	The	 three	early
publications	 by	 investigators	 at	Harvard	 (Waksman,	Adams,	Arnason,	Asbury	 and	Webster)	 led	 to	 the
decades	of	emphasis	on	the	role	of	PNS-reactive	T	cells	and	other	effector	mechanisms	in	GBS.	Brostoff
and	 colleagues	were	 the	 first	 to	 show	 that	 EAN	 can	 be	 induced	 by	 a	 peripheral	myelin	 peptide.	 The
pathology	 of	 EAN	 consists	 of	 inflammatory	 infiltrates,	 demyelination	 and	 varying	 degrees	 of	 axonal
degeneration.	 The	 realization	 that	 nodal	 and	 paranodal	 dysfunction	 plays	 an	 important	 role	 in	 the
pathophysiology	of	EAN	is	highlighted	by	the	work	of	Shrager’s	group,	and	Lonigro	and	Devaux.	Last	but
not	 the	 least,	 studies	 on	 SAP	 by	 different	 groups	 of	 investigators	 (Bluestone’s,	 Soliven’s,	 Su’s,
Keiseier’s)	have	illustrated	the	complexity	of	regulatory	mechanisms	(thymic	selection,	Tregs,	DCs),	and
how	elimination	of	a	single	molecule	could	shift	the	manifestations	from	one	disease	phenotype	to	another
in	susceptible	animals	or	individuals.	No	doubt,	we	have	come	a	long	way	in	our	understanding	of	GBS,
CIDP	and	other	inflammatory	neuropathies,	though	some	mysteries	remain	to	be	unravelled	in	the	future.
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Spontaneous	Models	of	Guillain-Barré	Syndrome	in
Animals
Angie	Rupp
Introduction
Spontaneous	conditions	similar	 to	 those	of	Guillain-Barré	syndrome	(GBS),	 leading	 to	acute	ascending
paralysis	 and	 associated	 with	 polyradiculoneuropathies	 of	 unknown	 origin,	 have	 been	 reported	 in	 a
number	of	different	animal	species.	Unfortunately,	in	many	cases,	comparison	and	interpretation	of	these
reports	 is	 challenging,	 since	 depending	 on	 when	 these	 examinations	 were	 conducted	 and	 whether	 the
animals	survived,	the	extent	and	modality	of	investigations	carried	out	often	varies.
The	majority	 of	 descriptions	 focus	 on	 dogs,	 cats	 and	 chickens.	 Individual	 case	 reports	 include	 the
description	 of	 a	 chimpanzee	with	 acute	 onset	 of	 ascending,	 symmetrical,	monophasic	 flaccid	 paralysis
and	 high	 protein	 in	 the	 CSF,	 possibly	 associated	 with	 a	 preceding	 rabies	 vaccination	 [1],	 and
polyradiculoneuritis	with	mononuclear	cell	infiltrates,	demyelination	and	Schwann	cell	proliferation	in	a
6-week-old	goat	[2].
Dogs:	The	Early	Investigations	into	Coonhound	Paralysis
In	1954	a	disease	resembling	GBS	in	dogs	was	described	by	Kingma	and	Catcott	and	termed	‘coonhound
paralysis’,	since	for	induction	of	the	disease	the	bite	(or	even	only	a	scratch)	of	a	racoon	was	considered
to	be	necessary.	However,	it	was	not	until	the	late	1960s	to	1980s,	that	coonhound	paralysis	underwent
extensive	 further	 examinations	 on	 both	 the	 clinical	 and	 experimental	 level	 and	 was	 discussed	 as	 a
potential	canine	equivalent	to	GBS	[3].
Initially	this	condition	was	predominantly	seen	as	an	occupational	hazard	in	‘coonhounds’—dogs	that
hunt	racoons,	such	as	Redbone	hounds,	Walker	hounds	and	Black	and	Tan	hounds	and	other	large-breed
dogs—which	had	experienced	a	close	encounter	with	a	racoon	resulting	in	a	bite	(Figure	44.1).	Within	7–
14	 days	 of	 being	 bitten	 by	 a	 racoon,	 these	 dogs	 exhibited	 an	 acute,	 symmetrical,	 ascending	 paralysis,
occasionally	also	involving	the	tail,	neck	and	trunk.	Hyperaesthesia,	involvement	of	cranial	nerves,	death
(presumed	 to	 be	 caused	 by	 respiratory	 failure)	 and	 multiple	 episodes	 after	 repeated	 bites	 were	 also
observed.	It	does,	however,	need	to	be	noted,	 that	only	a	few	dogs	bitten	by	raccoons	actually	develop
coonhound	paralysis.
The	 detailed	 histological	 investigations	 conducted	 in	 dogs	 succumbing	 to	 the	 disease	 revealed	 the
most	striking	changes	to	be	in	the	ventral	roots	(Figure	44.2)	with	lumbosacral	areas	more	involved	than
thoracic	or	 cervical	 areas,	 and	 the	myelin	 sheaths	 affected	more	 than	 the	 axons.	The	 extent	 of	 changes
varied	in	peripheral	nerves;	however,	both	in	nerves	and	nerve	roots	predominantly	large-diameter	nerve
fibres	were	affected.	The	myelin	damage	exhibited	a	segmental	pattern	with	the	myelin	appearing	either
swollen	or	pale,	or	 fragmented	 into	globules.	Complete	 loss	of	myelin	 resulted	 in	empty	Schwann	cell
sheaths.	Associated	axons	ranged	from	appearing	quite	normal	to	undergoing	degeneration.	In	other	cases,
the	 axons	 were	 more	 frequently	 involved	 when	 compared	 to	 the	 myelin	 sheaths	 [4].	 The	 intraneural
inflammatory	 infiltrates	 varied	 both	 in	 intensity	 and	 quality	 between	 the	 different	 dogs	 assessed	 and
consisted	of	macrophages,	plasma	cells,	lymphocytes	and	variable	numbers	of	neutrophils,	with	severity
of	the	infiltrates	reflecting	the	extent	of	the	damage.	Prominent	infiltrates	invariably	were	associated	with
myelin	and	axonal	damage;	however,	swelling	and	breakdown	of	myelin	also	could	be	observed	in	areas
of	 sparse	 or	 absent	 inflammation.	 Similar	 to	 reports	 in	 GBS,	 macrophages	 were	 present	 within	 the
periaxonal	spaces.
Figure	44.1		Redbone	coonhound	in	the	recovery	phase	of	coonhound	paralysis
Note	 the	 marked	 muscle	 atrophy	 and	 decubital	 ulcers	 acquired	 during	 the	 paralytic	 phase	 of	 disease.	 Reproduced	 with
permission	from	[21].
Figure	44.2	 	 Transverse	 section	 of	 a	 lumbar	 spinal	 nerve	 from	a	 dog	with	 coonhound	 paralysis	 stained	with	 Luxol	 fast	 blue
(myelin	stain).
The	ventral	root	(lower	half)	exhibits	marked	demyelination,	whilst	the	upper	half	(dorsal	root)	is	considered	within	normal	limits.
Reproduced	with	permission	from	[21].
The	cerebrospinal	fluid	exhibited	variable	protein	levels,	with	elevations	more	consistently	observed
following	lumbar	puncture	when	compared	to	cisternal	puncture	[4].
Roughly	the	same	time	as	these	very	detailed	examinations	into	coonhound	paralysis	were	carried	out,
further	 investigations	 by	 other	 groups	 examining	 dogs	 with	 similar	 clinical	 presentation	 in	 which,
however,	 a	 preceding	 raccoon	 bite	 was	 not	 reported	 or	 could	 be	 excluded,	 indicated	 that	 a	 raccoon
encounter	did	not	appear	to	be	necessary	to	induce	a	disease	of	great	similarity	with	coonhound	paralysis
[5].
Dogs:	Current	Perspectives	and	Clinical	Implications
Currently,	acute	canine	polyradiculoneuritis	(ACP)	is	subclassified	into	coonhound	paralysis,	idiopathic
polyradiculoneuritis	and	post-vaccination	polyradiculoneuritis,	the	latter	of	which	is	very	rare.	Most	dog
breeds,	ranging	from	toy	to	large	breeds	and	including	cross-breeds,	may	be	affected.	However,	despite
representing	the	most	common	acute	canine	polyneuropathy,	ACP	is	only	observed	sporadically.
Clinically,	ACP	dogs	show	a	short-strided	and	stiff	gait,	which	within	2	to	4	days	progresses	to	lower
motor	 neuron	 tetraparesis	 or	 flaccid	 paralysis	 [6].	 Symptoms	 usually	 start	 in	 the	 hind	 limbs	 and	 then
progress	 to	 the	 forelimbs;	 the	 progressive	 phase	 tends	 to	 last	 for	 roughly	 5	 days,	 occasionally	 longer.
Some	dogs	continue	 to	exhibit	voluntary	movement	of	all	4	 limbs	 throughout	 the	disease,	whilst	others
suffer	 complete	 paralysis	 of	 limbs	 and	 neck,	 and	 may	 experience	 respiratory	 compromise,	 requiring
mechanical	ventilation.	Muscle	atrophy	develops	within	7	to	10	days	and	hypo-	or	areflexia,	a	decrease
or	 loss	of	muscle	 tone	and	 in	many	cases	hyperesthesia	of	 the	 limbs	and	 trunk	are	noted.	Owners	often
recognize	a	change	or	loss	in	bark	and	some	dogs	develop	bilateral	facial	paralysis	and	tongue	weakness.
Generally,	however,	dogs	remain	alert	and	responsive	 throughout	 the	disease,	continue	 to	eat	and	drink
normally	and	 in	 the	vast	majority	of	cases	 remain	 in	control	of	 their	urination	and	defecation	and	even
continue	to	wag	their	tail.
In	 electrophysiological	 investigations,	 ACP	 dogs	 exhibit	 signs	 both	 for	 demyelinating	 and	 axonal
neuropathies,	 combined	with	 evidence	 of	muscle	 denervation	 (Figure	 44.3).	 Some	 investigations	 have
revealed	 demyelinating	 and	 axonal	 changes	 in	 the	 ventral	 roots,	 with	 a	 prominent	 axonopathy
overshadowing	 the	 demyelination	 in	 the	 peripheral	 nerves	 [7].	 Prolonged	 F-wave	 latencies	 or
unrecordable	F	waves	are	seen	as	early	as	4	days	from	disease	onset.
Figure	44.3		Electrophysiological	examinations	of	two	ACP	dogs,	both	of	which	exhibited	anti-GM2	Abs
A1/B1	spontaneous	activity	in	electromyographic	assessments	of	the	tibial	cranial	muscle;	A2/B2	motor	nerve	conduction	studies
of	ulnar	(A2)	and	sciatic/tibial	(B2)	nerve.	Note	the	reduction	of	CMAP	amplitude	and	CMAP	dispersion	in	the	2nd	trace	of	dog	A.
This	dog	also	exhibited	a	reduced	MNCV	(28.7	m/s).	Dog	B	exhibited	a	vast	reduction	of	its	CMAP	amplitude	in	both	traces	(<	1
mV)	with	a	MNCV	(49.1	m/s)	at	the	lower	end	of	the	physiological	reference	range.
Divisions	on	the	abscissa	are	2	ms	(A2)	and	5	ms	(B2).	Divisions	on	the	ordinate	are	1	mV	(A2)	and	200	μV	(B2).	Reproduced
with	permission	from	[9].
Nerve	 biopsies	 exhibit	 no	 changes	 or	 mildly	 reduced	 myelinated	 fibre	 density,	 occasional	 myelin
ovoids	 and	 mild	 inflammatory	 infiltrates,	 whilst	 muscles	 exhibit	 changes	 consistent	 with	 denervation
atrophy	[5,8].
Routinely,	 ACP	 patients	 receive	 no	 treatment	 and	 all	 efforts	 are	 put	 into	 supportive	 care	 and
rehabilitation.	Dogs	need	to	be	turned	every	few	hours	to	prevent	pressure	sores,	and	ventilated	and	hand
fed	 if	 necessary.	 Intensive	 physiotherapy	 in	 the	 form	 of	 passive	 range-of-motion	 exercises,	 massages,
encouraging	the	dog	to	ambulate	with	support	(in	a	sling	or	cart),	hydrotherapy	(swimming)	and	walking
on	a	treadmill	aim	to	minimize	muscle	atrophy,	help	rebuild	muscle	and	keep	the	joints	mobile.	Most	dogs
make	a	complete	recovery,	which	can	take	between	3	weeks	and	a	half	a	year	[6].	However,	depending	on
the	disease	severity	and	the	degree	of	muscle	atrophy,	some	dogs	may	retain	residual	deficits.	Death	due
to	respiratory	paralysis	or	concurring	pneumonia	occurs	in	roughly	10%	of	ACP	patients	[8,9].	Similar	to
GBS	 patients	 and	 the	 early	 reports	 of	 coonhound	 paralysis,	 multiple	 episodes	 of	 ACP	 are	 possible
[3,5,8].
Considering	the	clinical,	electrophysiological	and	pathological	findings,	the	latter	obtained	in	the	early
investigations	into	coonhound	paralysis,	ACP	indeed	in	many	respects	needs	to	be	considered	strikingly
comparable	to	GBS.
Dogs:	Possible	Pathophysiology	and	Aetiological	Link	to	GBS
Potential	antecedent	events	in	ACP	include	a	recent	upper	respiratory	or	gastrointestinal	 tract	 infection,
vaccination	or	the	bite	of	a	raccoon.	However,	host	factors	also	are	considered	to	contribute	to	disease
susceptibility	since	in	a	number	of	cases	related	animals	have	been	affected	and	early	investigations	into
coonhound	paralysis	revealed	that	the	induction	of	lesions	and	early	clinical	signs	following	inoculation
of	dogs	with	canine	sciatic	nerve	emulsified	in	Freud’s	complete	adjuvant	(experimental	allergic	neuritis)
could	 only	 be	 induced	 in	 offspring	 from	 coonhound-type	 dogs	 who	 had	 recovered	 from	 coonhound
paralysis	 [10].	 Similarly,	 the	 reproduction	 of	 coonhound	 paralysis	with	 raccoon	 saliva	 had	 only	 been
possibly	in	dogs	who	had	previously	experienced	naturally	occurring	coonhound	paralysis	[11].
More	recent	investigations	were	able	to	provide	a	potential	aetiological	and	pathophysiological	link
to	GBS	by	examining	the	incidence	of	serum	anti-ganglioside	antibodies	(Abs)	in	a	small	Italian	cohort	of
ACP	dogs,	local	control	dogs	and	dogs	with	idiopathic	epilepsy.	Here,	15	out	of	25	ACP	dogs,	1	of	19
control	dogs	and	0	of	15	dogs	with	 idiopathic	epilepsy	exhibited	such	Abs,	 the	vast	majority	of	which
were	reactive	with	ganglioside	GM2	[9].	These	findings	were	confirmed	in	a	larger,	ongoing,	multicentre
extension	 of	 the	 pilot	 study,	 at	 this	 stage	 incorporating	 10	 institutions	 from	 4	 European	 countries	 and
including	 dogs	 with	 other	 cranial	 and	 peripheral	 neuropathies	 of	 unknown	 origin,	 myopathies	 and
neuromuscular	disorders	(OMN	group),	which	altogether	are	examining	162	canine	sera.	Here,	32	of	73
ACP	dogs	exhibited	anti-GM2	Abs,	4	of	73	exhibited	anti-GA1	Abs	and	13	of	73	exhibited	both	(overall
67%),	whilst	 only	 3	 of	 40	 (7.5%)	OMN	 dogs	 and	 5	 of	 49	 (10%)	with	 non-neurological	 control	 sera
exhibited	such	Abs	(Figure	44.4).
The	concurrent	staining	investigations	carried	out	with	anti-GM2	Ab-containing	canine	sera	on	murine
sciatic	nerves	and	murine	monoclonal	anti-GM2	Abs	on	canine	 sciatic	nerves	 indicated	 that	GM2	was
localized	to	the	abaxonal	Schwann	cell	surface	and	multifocally	in	the	axonal	areas.	Experimental	support
for	potential	demyelinating	properties	of	ACP	serum	is	lent	by	the	observation	that	intraneural	injection	of
canine	 ACP	 serum	 into	 rat	 sciatic	 nerves	 in	 conjunction	 with	 a	 source	 of	 complement	 induces
demyelination	at	a	higher	frequency	when	compared	to	control	serum	[12].	Also	the	observation	that	the
application	 of	 IVIg	 in	ACP	 dogs	 has	 shown	 a	 clear	 trend	 towards	 treated	 dogs	 recovering	 faster	 than
nontreated	dogs	[8]	provides	a	further	potential	pathophysiological	link	between	ACP	and	GBS.
Chickens:	Marek’s	Disease
Roughly	around	 the	 same	 time	as	 the	extensive	 investigations	 into	coonhound	paralysis	began,	Marek’s
disease	in	chickens	was	reported	to	represent	a	model	for	GBS	[13],	since	its	histological	features	in	the
early	course	of	the	disease	were	considered	to	be	indistinguishable	from	those	of	the	demyelinating	form
of	GBS,	AIDP.
The	 infection	 of	 chickens	with	Marek’s	 disease	 virus,	 a	 cell-associated	 lymphotropic	 herpes	 virus,
results—in	its	classic	form—in	a	paralytic,	demyelinating	peripheral	neuropathy,	with	affected	chickens
exhibiting	asymmetrical,	partial	paresis	of	the	wings	and	legs,	progressing	to	complete	paralysis	of	one	or
more	 extremities,	 torticollis,	 paralysis	or	 dilation	of	 the	 crop	 and	 respiratory	distress.	Grossly,	 one	or
more	peripheral	nerves	are	enlarged,	usually	involving	the	brachial	and	sciatic	plexus	and	nerve	trunks,
the	 coeliac	 plexus,	 abdominal	 vagus	 and	 intercostal	 nerves.	Histologically,	 a	 spectrum	of	 proliferative
(neoplastic),	inflammatory	(lymphoplasmacytic	infiltrates	with	small	numbers	of	macrophages)	or	minor
inflammatory	changes	(termed	A-,	B-	and	C-type	lesions,	respectively)	are	observed,	some	of	which	are
combined	with	demyelination	(A	and	B	types)	or	Schwann	cell	proliferation	(B	types).	 In	experimental
disease,	the	proliferative	A	type	precedes	the	inflammatory	infiltrates	of	the	B	type	[14].
Figure	44.4		Heat	map	depicting	the	examination	of	162	canine	sera	for	anti-ganglioside	Abs.
Overall	49/73	ACP	sera	contained	either	anti-GM2,	anti-GA1	Abs	or	both,	whilst	only	3/40	ONM	dogs	and	5/49	of	non-neurological
control	 sera	exhibited	such	Abs.	Black	corresponds	 to	Ab-negative	signals.	The	 intensity	of	Ab	 reactivity	 increases	of	blue	 to
green	and	red,	with	red	indicating	the	strongest	signals.
Closer	 research	 into	 the	 pathophysiological	 events	 associated	 with	 the	 severe	 polyneuritis	 and
associated	demyelination	in	Marek’s	disease	revealed	an	underlying	latent	viral	infection	of	the	satellite
cells,	nonmyelinating	Schwann	cells	and	lymphocytes.	Whilst	thymectomy	apparently	resulted	in	reducing
the	incidence	of	disease	and	the	predominant	population	of	cells	associated	with	the	nerve	lesions	were	T
cells,	IgG	antibodies	against	peripheral	nerve	myelin	were	seen,	the	quantity	of	which,	however,	did	not
appear	to	correlate	with	the	intensity	of	the	nerve	lesions.	These	anti-myelin	antibodies	were	considered
a	possible	consequence	of	a	latent	viral	infection	resulting	in	expression	of	a	viral-induced	antigen	on	the
cell	surface,	which	in	turn	was	detected	by	reactive	lymphocytes	and	resulted	in	neural	injury	including
disruption	of	myelin	sheaths	via	‘bystander	demyelination’	[13].
Chickens:	Acute	Paretic	Syndrome	in	Juvenile	White	Leghorn
Chickens
More	recently,	very	 thorough	investigations	[15]	have	described	a	sporadic,	acute,	paretic	syndrome	in
juvenile	 White	 Leghorn	 chickens	 apparently	 not	 associated	 with	 Marek’s	 disease	 virus	 (MDV)	 and
characterised	by	cell-mediated,	inflammatory	demyelination	present	in	cranial	nerves,	spinal	nerves	and
nerve	 roots.	Clinically,	 these	 animals	 exhibit	 progressive	 asymmetric	 paresis	with	 intermittent	 relative
extensor	hypertonicity.	Grossly,	cranial	nerves	and	spinal	nerve	roots	are	 thickened,	whilst	histological
examinations	 reveal	multifocal	 lymphohistiocytic	 infiltrates	within	 the	proximal	 aspects	of	 some	of	 the
cranial	 nerves	 as	 well	 as	 the	 dorsal	 and	 ventral	 roots,	 which	 colocalise	 with	 demyelinated	 and
hypomyelinated	 axons.	 Similar	 to	 findings	 in	 GBS,	 electron	 microscopical	 investigations	 reveal
macrophages	 invading	 the	 myelin	 sheaths	 (Figure	 44.5).	 Additionally,	 a	 genetic	 susceptibility	 factor
confined	to	the	avian	major	histocompatibility	complex	was	found.	Whether	this	syndrome	corresponds	to
a	 previously	 described	 syndrome	 of	 spastic	 paralysis	 in	 young	 White	 Leghorn	 pullets,	 which	 is	 not
associated	with	MDV	and	appears	to	have	a	genetic	disposition	[16]	is	not	clear;	however,	the	findings	in
these	chickens	combined	with	the	fact	that	between	1%	and	4%	of	chickens	are	reported	to	spontaneously
be	affected,	indicate	that	this	disorder	may	present	a	valuable	future	model	for	AIDP.
Figure	44.5		Macrophage-mediated	myelin	stripping	in	Acute	Paretic	syndrome	in	juvenile	White	Leghorn	chickens
Macrophage	processes	(arrows)	are	seen	splitting	the	outer	mesaxon	(A)	and	invading	the	myelin	along	the	intraperiod	line	(arrow
in	B).	MS	=	myelin	sheath.	Scale	bar	=	2	μm.	Reproduced	with	permission	from	[15].
Cats
Cats	 are	 only	 rarely	 affected	 by	 acute	 idiopathic	 poly(radiculo)neuropathies	 and	 in	 this	 species	 the
comparison	to	GBS	is	hindered	most	by	the	inconsistency	of	the	examinations	carried	out	in	each	report.
The	 largest	 case	 series	 describes	 9	 young	 (4-month-old	 to	 4-year-old)	 cats	 with	 acute	 ascending
tetraparesis	or	tetraplegia,	a	loss	of	spinal	reflexes,	and	variable	dyspnoea	and	involvement	of	the	cranial
nerves	 [17].	 The	 nadir	 of	 clinical	 signs	 was	 reached	 3	 days	 after	 onset	 and	 7	 out	 of	 9	 cats	 made	 a
complete	recovery	with	supportive	treatment	over	the	following	4–6	weeks,	whilst	the	remaining	2	cats
were	 euthanized	 following	 progressive	 respiratory	 distress.	 Histologically,	 the	 ventral	 roots	 and
multisegmentally	the	peripheral	nerves,	including	the	phrenic	and	intercostal	nerves,	exhibited	moderate
to	severe	axonal	degeneration,	demyelination	and	histiocytic	infiltrates.	Considering	that	the	cause	of	the
clinical	and	pathological	changes	could	not	be	elucidated,	these	cases	were	classified	as	idiopathic	with
an	immune-mediated	aetiology	discussed.
Similar	conclusions	were	reached	in	a	report	describing	a	young	adult	Bengal	cat	[18],	who	presented
with	rapidly	progressive,	symmetrical	and	flaccid	tetraparesis	and	upon	electrophysiological	examination
of	muscles	 and	 nerves	 revealed	 changes	 consistent	 with	 generalised	 axonal	 neuropathy	 predominantly
affecting	the	ventral	nerve	roots,	and	in	an	adult	domestic	shorthair	cat	who	presented	with	acute	pelvic
limb	weakness	 progressing	 to	 nonambulatory	 tetraparesis	 over	 3	 days,	 proprioceptive	 deficits,	 cranial
nerve	involvement,	absent	spinal	reflexes	and	absent	superficial	pain	perception	[19].	Whilst	the	latter	of
these	 cats—euthanized	 following	 progressive	 respiratory	 compromise—exhibited	 an	 acute	 motor	 and
sensory	 polyradiculoneuritis	 combined	 with	 demyelination	 and	 axonal	 degeneration	 in	 histological
examinations,	the	young	Bengal	survived	and—similar	to	reports	of	GBS	patients—was	reported	to	have
experienced	multiple	episodes	of	varying	intensity.	The	cat	recovered	from	each	of	these	with	supportive
care.
Horses
Originally,	equine	cauda	equina	neuritis	also	had	been	considered	a	possible	equine	equivalent	to	GBS
due	to	the	lymphoplasmacytic	and	histiocytic	infiltrates	combined	with	demyelination	present	in	the	sacral
and	caudal	spinal	nerve	roots	and	occasionally	other	(including	sciatic	and	facial)	nerves	[20].	However,
the	 chronic	 course	 of	 this	 disease,	 the	 aetiology	 of	which	 remains	 unknown,	 is	 considered	 to	 possibly
represent	an	immunogenic	response	to	a	persisting	herpes	virus	infection,	an	infection	of	other	aetiology
or	 antigens	 released	 by	 trauma	 or	 infection.	 This	 contrasts	 with	 GBS,	 making	 this	 disease	 a	 less
compatible	model.
Conclusion
Spontaneous	 animal	models	 of	GBS	 are	 present	 in	 numerous	 animal	 species,	with	 the	most	 promising
models	 at	 this	 stage	 represented	 by	 chickens	 and	 dogs,	 the	 former	 of	 which	 (chickens)	 recommend
themselves	due	to	the	numerical	availability	of	subjects	for	examination,	whilst	the	latter	of	which	(dogs)
are	 more	 amenable	 to	 more	 detailed	 and	 advanced	 investigations,	 including	 neurological,
electrophysiological	and	CSF	examinations,	which	combined	with	the	heterogeneity	of	the	canine	strains
involved	is	likely	to	mimic	the	situation	in	human	GBS	patients	better.
Following	 a	 relatively	 long	 period	 of	 paucity	 of	 reports	 on	 the	 subject	 of	 acute
polyradiculoneuropathies	 in	 animals,	 this	 fascinating	 field	 currently	 is	 experiencing	 a	 revival	 and	 the
results	of	these	investigations	are	likely	to	be	of	interest	for	human	and	animal	patients	alike.
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Anti-Ganglioside	Antibodies	in	Guillain-Barré
Syndrome	and	Variants
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Introduction
Since	1988	antibodies	to	glycolipids	and	in	particular	to	gangliosides	have	become	a	major	actor	in	the
diagnosis	 and	 pathogenesis	 of	Guillain-Barré	 syndrome	 and	 of	 its	 variants.	A	 large	 number	 of	 studies
progressively	 showed	 an	 increased	 prevalence	 of	 these	 antibodies	 in	 GBS	 and	 its	 variants,	 their
association	with	specific	clinical	forms,	the	antecedent	infective	agents	leading	to	their	production,	their
effect	in	vitro	and	the	animal	models	of	GBS	induced	by	immunization	with	these	gangliosides.	Even	if
the	results	of	this	data	point	to	a	direct	role	of	these	antibodies	in	the	pathogenesis	of	GBS,	there	are	still
some	aspects	that	need	to	be	clarified	to	definitely	confirm	this	hypothesis.	I	will	here	review	the	most
brilliant	studies	that	in	my	opinion	opened	the	way	to	a	better	comprehension	of	the	immune	pathogenesis
of	GBS.
Before	the	Beginning:	Are	there	anti-ganglioside	antibodies?	Ilyas	et
al.	1984,
The	story	of	the	association	of	anti-ganglioside	antibodies	with	neuropathy	started	with	the	description	of
a	 reactivity	 to	 a	 ganglioside	 that	 ultimately	 proved	 not	 to	 be	 a	 ganglioside.	 Ilyas	 and	 colleagues	 first
reported	in	1984	[1]	that	sera	from	3	patients	with	neuropathy	and	IgM	monoclonal	gammopathy	reacted
with	 the	 nerve	 antigen	myelin-associated	 glycoprotein	 (MAG)	bound	 to	 an	 antigen	 in	 the	 carbohydrate
moiety	of	this	molecule,	which	was	also	present	in	a	glycolipid	of	peripheral	nerve	that	was	deemed	to	be
a	 ganglioside.	 This	 cross-reacting	 glycolipid	 was	 later	 found	 not	 to	 be	 a	 ganglioside	 but	 2
glycosphingolipids	 named	 sulfoglucuronylparagloboside	 (SGPG)	 and
sulfoglucuronyllactosaminylparagloboside	(SGLPG)	[2].	The	same	or	a	closely	related	reactive	epitope
was	 reported	 the	 previous	 year	 to	 react	 with	 the	 mouse	 IgM	monoclonal	 antibodies	 H-NK1	 directed
against	 a	 surface	 epitope	 expressed	 by	 human	 natural	 killer	 cell	 and	 by	 several	 neural	 cell	 adhesion
molecules	 [3].	This	 study	opened	 the	way	 to	 the	 search	 for	 antibodies	 to	gangliosides	 in	patients	with
different	 forms	 of	 neuropathy,	 leading	 in	 the	 following	 years	 to	 the	 association	 of	 IgG	 antibodies	 to
different	gangliosides	in	patients	with	Guillain-Barré	syndrome	and	its	variants	and	of	IgM	antibodies	to
GM1	and	other	gangliosides	in	patients	with	multifocal	motor	neuropathy	[4,5].
A	New	Entry:	Anti-GM1	Antibodies	in	Guillain-Barré	Syndrome:	Yuki	et
al.	1990
The	 real	 start	 of	 the	 association	 of	 anti-gangliosides	 antibodies	 and	Guillain-Barré	 syndrome	was	 the
fundamental	1990	study	by	Yuki	and	colleagues	[6]	that	reported	on	2	patients	who	developed	an	acute
axonal	polyneuropathy	after	Campylobacter	 jejuni	 enteritis.	Both	patients	 had	high	 titres	 of	 serum	 IgG
antibodies	to	the	gangliosides	GM1	that	progressively	decreased	during	recovery.	Despite	its	relevance,
this	 manuscript	 was	 accepted	 at	 Neurology	 only	 as	 a	 brief	 communication,	 and	 there	 were	 many
discussions	 about	 this	 study.	 I	 remember	 that	 in	 those	 days	 there	was	 some	 scepticism	 among	 experts
about	the	existence	of	an	axonal	form	of	GBS	that	was	considered	to	be	only	a	demyelinating	neuropathy,
and	 indeed	 the	 term	 ‘GBS’	 did	 not	 appear	 in	 the	 title.	 Even	 though	 a	 previous	 study	 by	 Feasby	 and
colleagues	in	1986	[7]	had	already	described	5	patients	with	an	acute	axonal	form	of	GBS,	I	remember	an
expert	at	a	meeting	saying	that	“there	is	no	such	thing	as	an	axonal	Guillain-Barré”.	This	may	also	explain
why	 the	 concomitant	 report	 of	 an	 epidemic	 among	 people	 living	 in	 the	 country	 in	 northern	China	 of	 a
disease	 that	 is	 now	 considered	 to	 be	 axonal	GBS	was	 originally	 postulated	 to	 be	 a	 different	 disease,
termed	 ‘acute	 motor	 axonal	 neuropathy’	 (AMAN)	 [8,9]	 which	 was	 only	 later	 included	 under	 GBS
[10,11].
To	make	 things	more	 complicated,	 during	 those	years	 an	 influential	 Italian	pharmaceutical	 company
was	 producing	 therapeutic	 agents	 for	 neuropathy	 containing	 a	 mixture	 of	 gangliosides	 (GM1,	 GD1a,
GD1b	and	GT1b;	Cronassial)	or	GM1	alone	(Sygen)	so	that	the	association	of	antibodies	to	gangliosides
and	GBS	was	quite	disturbing,	considering	that	some	reports	of	GBS	after	treatment	with	this	therapy	had
started	 to	 appear	 [12].	 It	 is	 now	 accepted	 by	 the	 neurological	 community	 that	 the	 paper	 by	 Yuki	 and
colleagues	 included	most	 of	 the	 current	 knowledge	 that	 a	 predominantly	 axonal	 form	 of	 GBS	may	 be
induced	by	an	antecedent	infection	by	Campylobacter	jejuni	 that	by	a	mechanism	of	molecular	mimicry
may	 induce	 the	production	of	 IgG	antibodies	 to	GM1	in	some	patients.	Subsequent	studies	showed	 that
anti-GM1	IgG	antibodies	occur	 in	30–40%	of	patients	with	GBS,	are	more	common	 in	patients	with	a
predominantly	motor	and	axonal	form	of	GBS,	may	be	also	found	in	those	with	demyelinating	GBS	and
are	mostly	associated	with	an	antecedent	Campylobacter	jejuni	enteritis.	Studies	also	showed	that	either
this	infection	or	the	associated	antibodies	or	both	are	associated	with	a	less	favourable	prognosis.	Not	all
studies	were	concordant	on	each	of	these	aspects	[13–17].
A	Second	New	Entry:	Anti-GQ1b	Antibodies	in	Miller	Fisher	Syndrome.
Chiba	et	al.	1992
In	1992	Chiba	and	colleagues	[18]	made	another	fundamental	discovery,	 reporting	 the	presence	of	high
titres	of	anti-GQ1b	IgG	antibodies	in	6	patients	with	the	Miller	Fisher	syndrome	(MFS),	a	variant	of	GBS
characterized	 by	 the	 concomitant	 presence	 of	 ophthalmoplegia,	 ataxia	 and	 areflexia.	 Since	 then	 this
reactivity	has	been	 reported	 in	 approximately	90%	of	patients	with	MFS	 [19,20],	 and	 in	patients	with
Bickerstaff’s	brain-stem	encephalitis	[21]	which	differs	from	MFS	in	the	presence	of	concomitant	signs	of
central	nervous	system	(CNS)	involvement,	including	impairment	of	consciousness	or	pyramidal	signs,	in
some	patients	with	GBS	and	ophthalmoplegia	 [22]	or	with	acute	ophthalmoparesis	 (reviewed	 in	 [23]).
This	has	also	led	to	the	proposal	of	the	term	‘anti-GQ1b	syndrome’	for	patients	with	these	antibodies	and
a	number	of	 acute	 clinical	 syndromes	characterized	by	 the	presence	of	oculomotor	 impairment	with	or
without	ataxia.	I	have	to	say	that	the	close	association	of	these	antibodies	with	this	syndrome	has	led	to	an
amazing	 increase	 in	 the	 diagnosis	 of	 MFS,	 at	 least	 in	 Italy,	 where	 a	 number	 of	 patients	 with
ophthalmoparesis	 and	 these	 antibodies	where	 diagnosed	 to	 have	MFS	 even	when	 tetraplegic	 and	with
assisted	 respiratory	 ventilation.	 The	 selective	 impairment	 of	 the	 oculomotor	 nerve	 was	 related	 to	 the
abundant	expression	of	GQ1b	in	these	nerves	[22].	Also,	in	these	cases	the	presence	of	these	antibodies
was	associated	with	an	antecedent	Campylobacter	jejuni	 infection	[24],	even	if	 the	pathogenic	bacteria
were	later	reported	to	differ	from	those	associated	with	anti-GM1	antibodies	(see	below).
Other	Anti-Ganglioside	Antibodies	in	Axonal	GBS.	Mostly	a	Japanese
story.
Several	antibodies	to	different	gangliosides	appeared	in	the	following	years	and	were	variably	associated
with	 different	 clinical	 and	 electrophysiological	 presentations	 of	 GBS,	 different	 antecedent	 events	 and
possibly	 pathogenetic	mechanisms,	 and	 to	 the	 definition	 of	 a	 number	 of	 new	 functional	 or	 topographic
variants	of	GBS.	In	1992	Yuki	and	colleagues	reported	2	patients	with	an	explosive,	motor	GBS	rapidly
evolving	 into	 respiratory	 insufficiency	and	mainly	axonal	 impairment	who	had	high	 titres	of	anti-GD1a
IgG	 antibodies	 [25].	 Subsequent	 studies	 showed	 that	 these	 antibodies	 are	 present	 in	 approximately	 5–
20%	of	patients	with	GBS,	most	of	whom	have	a	severe	axonal	form	[26–28].	Studies	also	reported	an
association	 of	 this	 reactivity	 with	 an	 antecedent	 infection	 by	 Campylobacter	 jejuni	 [29].	 A	 closely
related	 reactivity	 against	N-acetylgalactosaminyl	GD1a	 (GalNAcGD1a)	 [30]	 and	often	with	 the	 cross-
reacting	GM1b	ganglioside	[31]	was	subsequently	reported	in	approximately	20%	of	patients	with	GBS
and	was	 initially	 associated	with	 an	 axonal	motor	 form	of	GBS	 and	 antecedent	Campylobacter	 jejuni
infection	 [32]	 and	 occasionally	 with	 Mycoplasma	 pneumoniae	 infection	 [33].	 More	 heterogeneous
clinical	 presentations	 were,	 however,	 later	 associated	 with	 these	 reactivities,	 indicating	 that	 these
antibody	reactivities	are	not	always	strictly	associated	with	a	definite	clinical	presentation.
Anti-Ganglioside	Antibodies	in	Other	Forms	of	GBS.	Willison	et	al,
1994;	Irie	et	al,	1996
New	 antibody	 reactivities	were	 also	 associated	with	 demyelinating	 forms	 of	GBS.	 In	 1996	 Irie	 et	 al.
reported	3	patients	with	GBS	and	an	acute	cytomegalovirus	(CMV)	infection	revealed	by	increased	anti-
CMV	IgM	antibodies	who	had	high	 titres	of	anti-GM2	IgG	and	IgM	antibodies	 [34].	Subsequent	series
reported	 this	 reactivity	 in	up	 to	10%	of	patients.	These	antibodies	were	 later	 found	to	cross-react	with
CMV-infected	 fibroblasts,	 supporting	 the	 hypothesis	 of	 a	 possible	 mechanism	 of	 molecular	 mimicry
between	 the	 pathogen	 and	 the	 ganglioside	 [35].	 These	 studies	 opened	 the	 way	 to	 the	 possible
understanding	 of	 the	 pathogenesis	 of	 demyelinating	 GBS	 since	 most	 patients	 with	 GBS	 after	 CMV
infection	appeared	to	have	a	demyelinating	GBS	with	more	prominent	sensory	impairment	 than	patients
with	 an	 antecedent	 Campylobacter	 jejuni	 infection	 or	 without	 a	 known	 infection	 [36].	 The	 relation
between	 anti-GM2	 antibodies	 and	 CMV-associated	 GBS	 was	 not,	 however,	 always	 confirmed	 in
subsequent	studies	[37,38].
Another	 infrequent	 reactivity	 with	 ganglioside	was	 described	 in	 1994	 by	Willison	 and	 colleagues,
who	reported	a	patient	with	an	acute	sensory	neuropathy	without	ophthalmoplegia	with	IgG	antibodies	to
GD1b	 and	GD3	 but	 not	 to	GQ1b,	 distinguishing	 him	 from	MFS	 [39].	A	 few	 other	 patients	with	 acute
ataxic	neuropathy	and	a	selective	reactivity	to	GD1b	were	later	reported	[40,41].	A	more	extensive	study
[42]	 reported	 that	 9	 out	 445	 patients	 (2%)	with	GBS	had	 a	 selective	 reactivity	with	GD1b.	All	 these
patients	had	sensory	motor	GBS,	with	electrophysiological	signs	of	demyelination	in	the	majority,	while
none	had	signs	of	primary	axonal	degeneration.	These	findings	led	to	the	very	interesting	animal	model	of
GBS	induced	immunization	with	GD1b	(see	below).
Another	 peculiar	 association	 is	 that	 of	 a	 selective	 IgG	 reactivity	 with	 GT1a	 with	 or	 without
concomitant	 reactivity	 with	 GQ1b	 in	 a	 form	 of	 GBS	 with	 prominent	 or	 exclusive	 cervico-brachial-
oropharyngeal	 impairment.	This	was	 initially	 reported	 in	 a	patient	with	 a	pharyngeal-cervical	 brachial
variant	 of	 GBS	 with	 a	 separate,	 concomitant	 lower	 reactivity	 with	 GD1a	 [43].	 A	 similar	 selective
reactivity	with	GT1a	was	subsequently	reported	in	a	few	other	patients	with	oropharyngeal	palsy,	neck
weakness	or	polyneuritis	cranialis	[44,45],	while	in	the	majority	of	positive	patients	the	correlation	was
difficult	 to	ascertain	considering	the	frequent	concomitant	reactivity	 to	GQ1b.	The	difficulty	 in	defining
the	 clinical	 correlate	 of	 this	 reactivity	 also	 derives	 from	 another	 study	 confirming	 the	 frequent
concomitant	reactivity	with	GQ1b	[46].	Other	reactivities	were	subsequently	reported	in	a	small	number
of	 patients	 against	 the	 gangliosides	GM1α,	GM1	 (NeuGC),	GD1α,	 GalNAcGM1b,	GD3,	GT3,	GT1b,
GQ1β,	9-O-acetyl	GD1b	and	others.	I	have	to	say	that	some	of	these	studies	are	complicated	by	the	fact
that	a	number	of	patients	have	concomitant	reactivities	to	other	gangliosides	making	it	difficult	to	interpret
the	clinical	correlation	reported	for	each	of	these	reactivities.
Anti-Ganglioside	Antibodies	and	Campylobacter	Jejuni	Serotypes.
Mostly	Yuki
As	mentioned	before,	anti-ganglioside	antibodies	in	both	GBS	and	MFS	were	frequently	associated	with
an	 antecedent	 Campylobacter	 jejuni	 infection	 but	 it	 was	 unclear	 how	 the	 same	 pathogen	 could	 be
associated	with	different	clinical	conditions.	Kuroki	and	colleagues	were	the	first	to	relate	the	presence
anti-GM1	IgG	antibodies	in	GBS	with	an	antecedent	infection	by	Campylobacter	jejuni	of	the	Penner	19
serogroup	 [47,48].	 Yuki	 and	 colleagues	 subsequently	 reported	 that	 the	Campylobacter	 jejuni	 isolates
from	stool	cultures	of	most	patients	with	GBS	(51%)	was	of	the	serotype	Penner	19	while	the	majority	of
the	isolates	from	patients	with	MFS	(71%)	was	of	Penner	2	serotype	[49].	In	addition,	most	patients	with
Penner	19	isolates	had	anti-GM1	IgG	antibodies	while	the	majority	of	those	with	Penner	2	serotype	had
anti-GQ1b	antibodies.
This	 study	 supported	 the	 hypothesis	 that	molecular	mimicry	 between	 the	 epitopes	 expressed	 on	 the
surface	of	the	infectious	agent	and	certain	a	ganglioside	was	responsible	for	inducing	an	immune	response
that	also	affected	the	nerve.	A	further	support	to	this	theory	derives	from	a	study	by	the	same	group	that
showed	that	the	polymorphism	of	the	genes	of	Campylobacter	jejuni	affecting	the	patients	resulted	in	the
expression	on	the	surface	of	the	bacteria	of	the	lipooligosaccharide	(LOS)	bearing	a	GQ1b	or	GM1	and
GD1a	epitope	[50].	In	addition,	most	patients	infected	by	GQ1b-Campylobacter	 jejuni	developed	anti-
GQ1b	antibodies	and	MFS,	while	those	infected	by	a	GM1-GD1a-Campylobacter	jejuni	most	frequently
developed	anti-GM1	and	anti-GD1	antibodies	and	had	limb	weakness.	This	might	also	explain	while	only
a	minority	of	patients	with	Campylobacter	 jejuni	 infection	 develop	GBS	 (1.17/1000,	 77	 times	 greater
risk	than	in	the	general	population)	and	that	the	probability	of	developing	GBS	in	the	2	months	following
Campylobacter	jejuni	is	less	than	2/10,000	[51].	The	hypothesis	that	the	immunologic	predisposition	of
the	 host	may	 also	 contribute	 to	 this	 susceptibility	 has	 also	 been	 investigated	with	 inconclusive	 results
[52,53].
The	In	Vitro	Effect	of	Anti-GM1	Antibodies.	Buchwald	et	al.	1998
The	 possible	 mechanism	 by	 which	 anti-GM1	 antibodies	 may	 affect	 peripheral	 nerve	 function	 was
examined	in	an	 in	vitro	model	by	Buchwald	and	colleagues,	who	adopted	 the	same	macro-patch-clamp
system	used	to	study	neuromuscular	transmission	in	myasthenia	gravis	[54].	Using	this	model	the	authors
found	 that	 serum	and	purified	 IgG	from	patients	with	GBS	containing	anti-GM1	antibodies	consistently
reduced	the	evoked	quantal	release	at	the	neuromuscular	junction	in	the	mouse	hemidiaphragm.	A	similar
effect	was,	however,	obtained	with	sera	from	GBS	patients	not	containing	anti-GM1	antibodies,	leaving	it
unclear	whether	this	effect	was	caused	by	undetectable	levels	of	these	antibodies	or	other	factors	in	the
sera	 of	 the	 patients.	 The	 same	 authors	 later	 reported	 that	 this	 blocking	 effect	was	 reduced	 in	 a	 dose-
dependent	way	by	the	addition	of	the	intravenous	immunoglobulin	used	for	therapy	[55].
The	In	Vitro	Effect	of	Anti-GQ1b	Antibodies:	α-Latrotoxin	Comes	to
Neurology.	Willison	et	al,	1994
The	mechanism	by	which	anti	GQ1b	IgG	antibodies	can	affect	peripheral	nerves	were	mainly	examined
by	Willison	and	colleagues.	They	first	examined	the	in	vitro	effect	on	a	mouse	phrenic	nerve/diaphragm
preparation	of	the	sera	from	3	patients	with	MFS	and	high	anti-GQ1b	antibodies	[56].	Contrary	to	what
one	would	theoretically	expect,	soon	after	addition	of	the	sera,	there	was	a	markedly	increased	frequency
of	 miniature	 endplate	 potentials	 followed	 by	 a	 complete	 block	 of	 neuromuscular	 transmission.	 In	 a
subsequent	 study	 [57]	 they	 showed	 that	 anti-GQ1b	 antibodies	 bind	 at	 the	 neuromuscular	 junctions,
inducing	 a	 massive	 quantal	 release	 of	 acetylcholine	 from	 nerve	 terminals	 followed	 by	 a	 block	 of
neuromuscular	 transmission.	 This	 effect	 resembled	 that	 of	 the	 neurotoxin	α-latrotoxin,	 a	 component	 of
black	 widow	 spider	 venom,	 raising	 the	 possibility	 that	 the	 antibodies	 bound	 to	 the	 same	 receptor	 as
bound	 by	 this	 toxin.	 The	 effect	 of	 anti-GQ1b	 antibodies	 was	 strictly	 dependent	 on	 the	 activation	 of
complement	components	but	neither	the	classical	pathway	activation	nor	the	formation	of	membrane	attack
complexes	was	required,	supporting	the	possibility	of	the	activation	of	the	alternative	pathway.
In	 a	 subsequent	 study	 the	 authors	 found	 that	 these	 antibodies	 mediated	 complement-dependent
destruction	of	the	motor	nerve	terminal	[58].	Somehow,	contrasting	results	were	reported	at	the	same	time
by	Buchwald	and	colleagues,	who	examined	the	in	vitro	effect	on	the	neuromuscular	transmission	of	anti-
GQ1b	containing	IgG	from	patients	with	MFS	using	the	same	model	used	to	study	the	effect	of	anti-GM1
antibodies	 (see	above)	 [59,60].	They	 found	 that	 IgG	from	patients	with	MFS	had	a	combined	pre-	and
postsynaptic	action	blocking	the	neuromuscular	transmission	sera.	In	this	case,	however,	a	similar	effect
was	 obtained	with	 sera	 from	 patients	 in	whom	 anti-GQ1b	 antibodies	were	 not	 found.	 In	 general	 both
groups	 showed	 that	 sera	 from	patients	with	MFS	 impaired	 neuromuscular	 transmission	 even	 if	 in	 both
studies	it	remains	unclear	how	these	impairments	can	be	related	to	a	disease	where	weakness	is	mainly	of
the	oculomotor	nerve	while	limb	weakness	is	by	definition	mild	or	absent.
Animal	Models	of	Anti-Ganglioside	Neuropathy.	Kusunoki	et	al,	1996
The	first	animal	model	of	anti-ganglioside	neuropathy	was	reported	in	1996	by	Kusunoki	and	colleagues,
who	induced	an	ataxic	sensory	axonal	neuropathy	in	rabbits	by	immunization	with	ganglioside	GD1b	[61].
Three	of	 the	6	 immunized	 rabbits	developed	a	 sensory	neuropathy	without	motor	 involvement	 that	was
associated	with	axonal	 loss	 in	 the	dorsal	 roots	and	sciatic	nerve	and	with	 loss	of	nerve	cell	bodies	 in
dorsal	 root	ganglia.	All	animals	developed	antibodies	 to	GD1b.	This	presentation	was	similar	 to	what
had	been	observed	 in	some	patients	with	anti-GD1b	antibodies	and	an	acute	sensory	ataxic	neuropathy
(see	above).	A	similar	model	of	anti-ganglioside	neuropathy	was	later	induced	in	rabbits	by	immunization
with	 a	 mixture	 of	 ganglioside	 containing	 GM1	 or	 with	 GM1	 alone	 [62].	 In	 this	 case	 the	 animals
developed	high	 titres	of	 anti-GM1	antibodies	 associated	with	 the	 acute	onset	of	 flaccid	paresis	with	a
monophasic	illness	course.	Pathological	studies	revealed	axonal	degeneration	with	deposits	of	IgG	on	the
axons	of	anterior	roots.	This	animal	model	strictly	resembled	human	axonal	GBS.	In	addition,	similar	to
what	 had	 been	 observed	 in	 human	 GBS,	 treatment	 of	 the	 immunized	 rabbits	 with	 intravenous
immunoglobulin	induced	a	faster	recovery	of	GBS	compared	to	untreated	animals	[63].	A	similar	axonal
neuropathy	was	induced	in	mice	by	intraperitoneal	implantation	of	hybridoma-secreting	antibodies	to	the
gangliosides	 GD1a/GT1b-2b	 [64].	 This	 experimental	 model	 may	 explain	 the	 already	 mentioned
neuropathy	induced	in	humans	by	treatment	with	gangliosides;	subsequent	studies	revealed	the	ability	to
induce	 an	 acute	 axonal	 GBS	 by	 sensitization	 with	 the	 lipooligosaccharide	 of	 Campylobacter	 jejuni
isolated	 from	patients	with	GBS	 [65,66].	 Immunized	animals	developed	high	 titres	of	 serum	anti-GM1
antibodies,	 followed	 by	 an	 acute	 flaccid	 paresis.	 Pathological	 studies	 revealed	 signs	 of	 Wallerian
degeneration	 in	 some	 animals	 with	 deposits	 of	 IgG	 in	 the	 nerve.	 In	 addition,	 the	 same	 pathological
features	 observed	 in	 some	patients	with	 acute	GBS	of	macrophage	 infiltrating	 between	 the	myelin	 and
axon	were	found	in	some	animals	[65].	I	think	that	these	experiments	clearly	showed	how	exposure	of	the
animals	 to	Campylobacter	 jejuni	 may	 induce	 the	 development	 of	 anti-GM1	 antibodies	 and	 an	 acute
axonal	GBS.
A	Personal	View
I	 think	 that	 there	 is	 considerable	 evidence	 from	 the	 above-mentioned	 studies	 that	 anti-ganglioside
antibodies	play	an	important	role	in	the	pathogenesis	of	GBS	and	MFS.	As	neurologists,	however,	we	are
a	little	bit	spoiled	by	what	we	observed	in	myasthenia	gravis,	where	80–90%	of	patients	have	antibodies
to	 an	 acetylcholine	 receptor,	while	 a	 consistent	 proportion	 of	 the	 negative	 patients	 have	 antibodies	 to
other	components	at	the	neuromuscular	junction,	including	MUSK	and	LRP4.	This	is	what	we	observe	in
MFS,	where	approximately	the	same	proportion	of	patients	have	anti-GQ1b	antibodies.	In	patients	with
GBS,	however,	no	more	than	50%	have	antibodies	to	one	or	more	gangliosides,	suggesting	that	what	we
observe	is	probably	only	part	of	the	story.	It	is	true	that	more	recent	studies	have	shown	that	some	patients
with	 GBS	 or	 MFS	 have	 antibodies	 to	 a	 complex	 of	 gangliosides	 [67,68]	 even	 if	 these	 patients	 only
represent	a	minority.	It	remains	unclear	why	a	difference	in	the	prevalence	of	antecedent	infection	from
country	 to	country	does	not	 result	 in	consistent	differences	 in	 the	 incidence	of	GBS	[69]	nor	 is	 it	clear
why	 a	 similar	 proportion	 of	 patients	 in	 different	 countries	 eventually	 develop	 the	 same	 disease	 from
different	triggering	events.	Even	if	we	now	have	fantastic	evidence	on	how	the	mechanism	of	molecular
mimicry	between	external	pathogens	and	our	molecules	may	explain	 the	disease,	 in	 almost	50%	of	 the
patients	the	triggering	events	and	the	mechanism	by	which	they	can	induce	GBS	remain	to	be	clarified.
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Antibodies	to	Ganglioside	Complexes
Kenichi	Kaida
Introduction
In	 Guillain-Barré	 syndrome	 (GBS)	 and	 its	 variants,	 antibodies	 to	 glycolipids,	 especially	 N-
acetylneuraminic	 acid-	 (sialic-acid)	 bearing	glycosphingolipids,	which	 are	 referred	 to	 as	 gangliosides,
have	been	 tested	 in	acute	phase	sera	as	diagnostic	markers.	Generally,	 to	detect	pathogenic	antibodies,
purified	single	substances	have	been	used	as	test	antigens.	Thorough	purification	of	natural	substances	and
avoidance	 of	 antigen	 contamination	 provide	 accurate	 and	 reliable	 results.	 It	 has	 been	 the	 same	 in
measurement	of	anti-ganglioside	antibodies.	Over	10	years	ago,	we	detected	IgG	antibodies	specifically
reacting	 with	 a	 mixture	 of	 2	 different	 gangliosides	 in	 sera	 from	 patients	 with	 GBS,	 and	 named	 such
mixture	as	ganglioside	complex	(GSC).	In	thin-layer	chromatogram	(TLC)	immunostaining	assay,	the	anti-
GSC	 antibodies	 do	 not	 bind	 to	 each	 constituent	 ganglioside,	 but	 bind	 to	 overlapping	 portions	 of	 2
gangliosides.	 Currently,	 antibodies	 to	GSCs	 as	well	 as	 single	 glycolipid	 antigens	 have	 been	 routinely
tested	in	serum	samples	from	patients	with	GBS	or	other	immune-mediated	neuropathy.
Kaida	K,	et	al.	Ganglioside	complexes	as	new	target	antigens	in
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In	the	late	1990s,	Dr	Susumu	Kusunoki	found	that	serum	IgG	from	a	patient	with	severe	GBS	distinctly
reacted	with	 unknown	 antigens	 just	 below	 a	 level	 of	GD1a	 in	TLC	 immunostaining	 assay	 using	 crude
bovine	 brain	 ganglioside	 fraction	 which	 was	 obtained	 through	 DEAE	 Sephadex	 A-25	 column	 by
extraction	 with	 0.1M	 ammonium	 acetate.	 Conventional	 ELISA	 screening	 for	 serum	 anti-ganglioside
antibodies	showed	negative	results	for	GD1a,	GalNAc-GD1a,	and	GD1b.	Identification	of	the	invisible
targets	 for	 the	 immunoreaction	on	a	TLC	plate	was	one	of	 tasks	 the	visionary	 supervisor	Dr	Kusunoki
assigned	to	a	graduate	student.	In	spite	of	considerable	laboratory	work	with	use	of	various	purification
methods,	 we	 could	 not	 purify	 and	 confirm	 the	 unknown	 target	 glycolipids.	 Antibody	 activities	 to
ganglioside	mix	were	negative.	Three	years	passed	before	we	confirmed	that	the	immunostaining	revealed
a	specific	reaction	against	a	GSC,	GD1a/GD1b	complex	(Figure	46.1).	A	study	of	a	mixture	of	GM1	and
a	phospholipid	[1]	gave	us	a	clue.	In	2004,	the	mission	‘invisible’	was	accomplished	with	publication	in
Annals	of	Neurology	[2].
Considering	 that	 glycosphingolipids	 form	 a	 cluster	 with	 other	 glycolipids	 in	 lipid	 rafts,
glycosphingolipid-enriched	membranes,	 it	 is	 no	 wonder	 that	 clustered	 glycol-epitopes	 in	 the	 rafts	 are
targeted	 by	 anti-ganglioside	 antibodies.	 Ligands	 of	 adhesion	 molecules	 such	 as	 selectins	 and	 siglecs
(sialic	 acid-recognizing	 immunoglobulin-superfamily	 lectins)	 are	 assumed	 to	 comprise	 complex
glycoconjugates,	which	 are	 packed	 closely	 in	 the	 cell	membrane	 to	 form	 rigid,	 rod-like	 configurations
with	multiple	valency	and	strict	binding	specificity	[3].	Anti-GSC	antibodies	are	real	examples	of	such	a
concept.
Figure	46.1		Carbohydrate	structures	of	ganglioside	complexes	(GSCs)	and	thin-layer	chromatogram	(TLC)	immunostaining	of
the	serum	of	patient	with	GBS.
Pattern	diagrams	of	GSCs	are	shown:	GM1/GD1a,	GD1a/GD1b,	GM1/GT1b,	and	GD1b/GT1b.	Squares	with	dotted	lines	illustrate
putative	 antigenic	 epitopes	 for	 anti-GSC	 antibodies.	 In	 TLC	 immunostaining,	 the	 developing	 solvent	 consisted	 of	 chloroform,
methanol	and	0.2%	CaCl2·2H2O	(50:45:10,	v/v).	Lower	 left	panel:	TLC	results	visualised	by	orcinol	 reagent;	 lower	 right	panel:
TLC	 immunostaining.	 Positive	 immunostaining	 on	 the	 right	 panel	 indicates	 an	 antibody	 reaction	 to	 the	GD1a-GD1b	 complex
(GD1a/GD1b)	(reproduced	with	permission	from	[2]).
Kaida	K,	et	al.	Anti-ganglioside	complex	antibodies	in	Miller	Fisher
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We	conducted	a	survey	of	antibodies	to	GSC	containing	GQ1b	or	GT1a	in	Miller	Fisher	syndrome	(MFS)
because	they	are	key	molecules	in	MFS,	and	we	found	IgG	antibodies	to	GSC	containing	GQ1b	or	GT1a
in	half	of	MFS	patients	[4].	Binding	reactivity	of	the	MFS-associated	anti-GSC	antibodies	is	classified
into	 2	 patterns:	 reactivity	 against	 a	 combination	 of	 [Galβ1-3GalNAc]	 and	 [NeuAcα2-8	 NeuAc	 α	 2-
3Galβ1-3GalNAc]	 in	 terminal	 residues	 of	 ganglio-N-tetraose	 structures,	 or	 reactivity	 against	 a
combination	 of	 [NeuAcα2-3Galβ1-3GalNAc]	 and	 [NeuAcα2-8	 NeuAcα	 2-3Galβ1-3GalNAc]	 in
terminal	residues	(Figure	46.2).	Such	antibodies	to	GSC	containing	GQ1b	or	GT1a	are	also	found	in	half
of	GBS	patients	with	ophthalmoplegia	[5].	Regarding	anti-GSC	antibodies,	MFS	is	different	from	GBS	in
that	 there	 are	 no	 IgG	 antibodies	 to	 GSCs	 consisting	 of	 2	 of	 GM1,	 GD1a,	 GD1b	 and	 GT1b	 in	MFS.
Colocalization	of	GQ1b,	GM1	and	GD1a	remains	to	be	proved	in	nerve	membranes	of	oculomotor	nerves
and	dorsal	root	ganglion	neurons.
Glycolipid	 complexes,	GA1/GQ1b	or	GA1/GT1a,	 are	 targeted	 in	 some	patients	with	MFS	or	GBS
with	ophthalmoplegia.	Seventy	percent	of	antibodies	to	GA1/GQ1b	or	GA1/GT1a,	however,	did	not	bind
to	GM1/GQ1b	or	GD1b/GQ1b,	which	are	similar	to	GA1/GQ1b	regarding	terminal	residues	in	the	GSC
[6].	Factors	such	as	conformational	epitopes	or	electric	charges	of	sialic	acids	in	GSC	may	influence	the
immune	response	to	GSC	in	the	nerve	membrane.
Figure	46.2		Carbohydrate	structures	of	ganglioside	complexes	containing	GQ1b	or	GT1a	and	TLC	immunostaining	of	the	serum
of	patient	with	Fisher	syndrome.
Pattern	diagrams	of	GSCs	are	shown:	GM1/GQ1b,	GM1/GT1a,	GD1a/GQ1b,	and	GD1a/GT1a.	Squares	with	dotted	lines	illustrate
putative	antigenic	epitopes	for	anti-GSC	antibodies.	Lower	left	panel:	TLC	results	visualised	by	orcinol	reagent;	lower	right	panel:
TLC	 immunostaining.	 Positive	 immunostaining	 on	 the	 right	 panel	 indicates	 antibody	 reactions	 to	GT1a/GM1	 and	GQ1b/GM1.
Antibody	reactions	to	GT1a,	GD1b,	GM1,	GT1a	and	GQ1b	were	negative	(reproduced	with	permission	from	[4]).
Kaida	K,	et	al.	Anti-ganglioside	complex	antibodies	associated	with
severe	disability	in	GBS.	Journal	of	Neuroimmunology,	2007
At	first	we	conducted	a	survey	of	IgG	antibodies	to	GSCs	consisting	of	2	of	4	major	gangliosides,	GM1,
GD1a,	GD1b	and	GT1b,	in	consecutive	Japanese	patients	with	GBS,	revealing	that	the	frequency	of	anti-
GSC	 antibodies	 was	 17%	 in	 GBS	 [7].	 In	 target	 GSC,	 the	 combination	 of	 gangliosides	 appears	 to	 be
governed	 by	 a	 principle	 that	 a	 target	 molecule	 is	 an	 epitope	 formed	 by	 a	 combination	 of	 [Galβ1-
3GalNAc]	 and	 [NeuAcα2-3Galβ1-3GalNAc]	 in	 terminal	 moieties	 of	 ganglio-N-tetraose	 structures
(Figure	 46.1).	 GBS	 patients	 with	 such	 anti-GSC	 antibodies	 were	 characterized	 by	 having	 had	 an
antecedent	gastrointestinal	infection,	lower	cranial	nerve	deficits	and	severe	disability.	The	association	of
anti-GSC	 antibodies	 with	 severe	 disability	 should	 be	 confirmed	 in	 future	 prospective	 studies.	 The
severity	may	be	explained	by	tighter	interactions	between	anti-GSC	antibodies	and	GSC	with	multivalent
glycol	 epitopes.	 Whether	 the	 tighter	 interactions	 induce	 stronger	 antibody-mediated	 immunoreactions
remains	to	be	confirmed.
Todeschini	AR,	et	al.	Ganglioside	GM2/GM3	complex	affixed	on	silica
nanospheres	strongly	inhibits	cell	motility	through	CD82/cMet-
mediated	pathway.	Proceedings	of	the	National	Academy	of	Sciences	of
the	United	States	of	America,	2008
Cell	adhesion	processes	in	the	plasma	membrane	are	regulated	by	carbohydrate-binding	proteins	such	as
selectins	 and	 Siglecs	 (sialic-acid-recognizing	 immunoglobulin-superfamily	 lectins),	 based	 on	 a	 cis-	 or
trans-carbohydrate-to-carbohydrate	 interaction	 [8,9].	 Ganglioside	 complexes	 providing	 clustered
carbohydrate	epitopes	are,	 therefore,	 likely	 to	be	 influential	on	 the	cell	 adhesion	process.	Research	by
Todeschini	 and	 colleagues	 exhibited	 that	 a	 GM2/GM3	 complex	 more	 efficiently	 inhibits	 cell	 motility
through	blocking	of	c-Met	activation	than	GM2	or	GM3	alone	[10].	This	was	the	first	report	showing	that
GSCs	play	a	functional	role	in	the	cell	function.	One	future	task	is	to	amass	convincing	evidence	proving
the	hypothesis	 that	GSCs	or	multivalent	glycol	epitopes	 in	 the	cell	membrane	have	a	 functional	 role	 in
cell-to-cell	recognition	rather	than	isolated	gangliosides	or	monovalent	glycol	epitopes.
Kaida	K,	et	al.	GM1/GalNAc-GD1a	complex:	a	target	for	pure	motor
Guillain-Barré	syndrome.	Neurology,	2008
An	antibody	to	a	complex	consisting	of	GM1	and	GalNAc-GD1a	(GM1/GalNAc-GD1a)	is	found	in	5%
of	 GBS	 patients.	 Anti-GM1/GalNAc-GD1a-positive	 patients	 usually	 develop	 a	 pure	 motor	 variant	 of
GBS	 with	 preserved	 cranial	 and	 sensory	 nerves	 and,	 contrary	 to	 expectations,	 are	 characterized	 by
experiencing	a	preceding	respiratory	infection	and	early	conduction	block	(CB)	in	motor	nerves.	The	CB
arises	at	intermediate	nerve	segments	of	motor	nerves,	but	not	at	common	compression	sites	such	as	the
wrists	 and	elbows.	 In	view	of	 the	 rapid	 recovery	of	CB	and	no	evidence	of	 remyelination	 and	axonal
degeneration	 in	 subsequent	 electrophysiological	 studies,	 the	 CB	 is	 likely	 to	 result	 from	 reversible
conduction	failure	caused	by	temporary	blockade	of	voltage-gated	sodium	channels	(NaV)	at	the	nodes	of
Ranvier.	GM1	and	GalNAc-GD1a	may	assemble	and	form	a	GM1/GalNAc-GD1a	complex	in	the	vicinity
of	NaV	 clusters	 at	 nodal	membranes	 in	motor	 nerves,	where	 antibody-antigen	 interactions	may	 disturb
regulatory	functions	of	NaV	[11].
Kaida	K,	et	al.	GD1b-specific	antibody	induces	ataxia	in	Guillain-Barré
syndrome.	Neurology,	2008
In	 the	 routine	 measurement	 of	 anti-GSC	 antibodies	 in	 sera	 from	 GBS	 patients,	 some	 IgG	 anti-GD1b
antibodies	revealed	prominent	decrease	of	anti-GD1b	activities	by	the	addition	of	gangliosides	with	2	or
more	sialic	acids	to	GD1b.	In	a	larger	number	of	GBS	patients,	we	confirmed	that	such	GD1b-specific
antibodies	 were	 significantly	 associated	 with	 development	 of	 ataxia,	 whereas	 GBS	 patients	 without
ataxia	had	anti-GD1b	antibodies	which	equally	reacted	against	a	mixture	of	GD1b	and	other	gangliosides,
and	 often	 had	 antibodies	 to	GSCs	 containing	GD1b	 [12].	These	 findings	 suggest	 that	 colocalization	 of
another	ganglioside	with	GD1b	in	the	cell	membrane	forms	novel	glycol	epitopes,	different	from	GD1b,
and	influences	the	accessibility	of	the	anti-GD1b	antibodies.	That	is,	cis-interaction	of	the	sugar	chain	of
gangliosides	in	lipid	rafts	may	modify	the	steric	structure	of	the	glycol	epitopes	in	the	cell	membrane.
Greenshields	KN,	et	al.	The	neuropathic	potential	of	anti-GM1
autoantibodies	is	regulated	by	the	local	glycolipid	environment	in
mice.	The	Journal	of	Clinical	Investigation,	2009
In	 a	 sophisticated	 ex	 vivo	 study	 using	GalNAc	 transferase-deficient	 and	GD3	 synthase-deficient	mice,
Greenshields	and	colleagues	clearly	showed	that	the	glycolipid	environment	governs	the	accessibility	and
the	avidity	of	anti-ganglioside	antibodies	[13].	A	monoclonal	anti-GM1	antibody	(DG2)	with	activity	not
attenuated	 by	 GSC	 was	 found	 to	 bind	 to	 motor	 nerve	 terminals.	 In	 contrast,	 a	 monoclonal	 anti-GM1
antibody	 (DG1)	 with	 activity	 that	 was	 attenuated	 by	 GSC	 could	 not	 bind	 to	 motor	 nerve	 terminals.
Conversion	of	GD1a	to	GM1	by	neuraminidase	treatment	made	it	possible	for	DG1	to	access	to	GM1	in
the	 motor	 terminal	 axons.	 These	 study	 results	 clearly	 indicate	 that	 the	 glycolipid	 environment	 and
antibody	 specificity	 are	 influential	 factors	 in	 antibody-antigen	 interactions.	 Based	 on	 the	 binding
specificity,	finally,	the	anti-ganglioside	antibodies	are	classified	into	3	types:	complex-attenuated	(DG1),
complex-independent	(DG2),	and	complex-enhanced.	Neighbour	glycolipids	as	well	as	anti-ganglioside
antibody	 specificity	 play	 a	 crucial	 role	 in	 antibody	 binding	 and	 subsequent	 immunoreaction	 such	 as
complement	activation.
Zitman	FM,	et	al.	Neuropathophysiological	potential	of	Guillain-Barré
syndrome	anti-ganglioside	complex	antibodies	at	mouse	motor	nerve
terminals.	Clinical	and	Experimental	Neuroimmunology,	2011
Complement	 activation	 is	 considered	 to	 play	 a	 key	 role	 in	 anti-ganglioside	 antibody-mediated	 nerve
injury	 in	GBS	 and	 its	 variants,	 as	 shown	 in	 vitro	 and	 ex	 vivo.	 Zitman	 and	 colleagues	 showed,	 in	 the
nerve-muscle	co-culture	ex	vivo	model,	that	anti-GSC	antibodies	from	patients	with	GBS	and	its	variants
had	a	neurophysiological	blocking	effect	at	motor	nerve	terminals	and	induce	complement-mediated	nerve
damage	 through	an	antigen-antibody	 interaction	 [14].	 In	addition,	 the	authors	 showed	 that	GSC	such	as
GM1/GD1a	actually	exists	as	an	available	antigen	 in	 living	neuronal	membranes.	Their	 study	provides
direct	experimental	evidence	for	the	neuropathogenicity	of	anti-GSC	antibodies	in	GBS.
Rinaldi	S,	et	al.	Combinatorial	glycoarray.	Methods	in	Molecular
Biology,	2012
ELISA	is	an	easy	and	universal	method	for	screening	antibodies.	However,	96	wells	 in	a	conventional
ELISA	 plate	 are	 not	 enough	 to	 test	 antibody	 reactivity	 against	 a	 multitude	 of	 glycolipid	 complexes.
Rinaldi,	Brennan	and	Willison	(2012)	developed	a	new	screening	method—combinatorial	glycoarray—
which	is	appropriate	for	testing	antibody	activities	to	many	heteromeric	complexes	consisting	of	various
lipids	 as	 well	 as	 glycolipid	 complexes	 [15].	 Their	 method	 can	 test	 antibodies	 to	 many	 glycolipid
complexes	simultaneously,	discover	new	anti-glycolipid	antibodies	and	save	scarce	reagents.
As	 reported	 elsewhere	 [16],	 in	 multifocal	 motor	 neuropathy,	 IgM	 anti-GM1	 antibodies	 revealed	 a
stronger	binding	ability	to	GM1	ganglioside-containing	lipid	mixture	than	to	GM1	alone.	A	recent	study
using	 the	 combinatorial	 glycoarrays	with	 polyvinylidene	 difluoride	 (PVDF)	membrane	 has	 pointed	 out
that	 glycol	 epitopes	 newly	 formed	 in	 a	mixture	 of	 glycolipid	 and	 lipid	 can	 be	 novel	 targets	 [17].	We
should	 note	 that	 the	 sensitivity	 and	 the	 specificity	 of	 antibodies	 to	 such	 heteromeric	 complexes	 may
depend	 upon	 the	 weight	 proportions	 of	 their	 constituents	 [17,18].	 Mixture	 in	 equal	 amounts	 of	 the
constituents	does	not	necessarily	provide	the	optimal	sensitivity	of	the	antibodies	to	the	lipid	complexes.
Mauri	L,	et	al.	Anti-GM1/GD1a	complex	antibodies	in	GBS	sera
specifically	recognize	the	hybrid	dimer	GM1-GD1a.	Glycobiology,	2012
There	is	little	evidence	to	elucidate	the	details	of	a	real	glycolipid	environment	in	the	nerve	membrane.
Reconstructing	 biological	 membrane	 models	 faithfully	 is	 an	 urgent	 issue.	 It	 is,	 however,	 difficult	 at
present	to	artificially	reproduce	the	same	lipid	environment	as	lipid	rafts	of	the	plasma	membrane.	It	is
unclear	how	GSCs	are	 formed,	 are	distributed	and	 function	 in	 the	nervous	 system.	 In	2012,	Mauri	 and
colleagues	provided	a	dimeric	GM1-GD1a	hybrid	ganglioside	derivative,	which	contains	2	structurally
different	 oligosaccharide	 chains	 [19].	 Such	 synthetic	 dimeric	 hybrids	 mimic	 GSCs	 and	 are	 useful	 for
studies	 on	 anti-GSC	 antibody-mediated	 immunoreaction	 to	 carbohydrates.	 The	 combinatory	 glycoarray
systems	 are	 important	 tools	 for	 extensively	 investigating	 anti-ganglioside	 antibody-mediated
glycoconjugate	 recognition,	 as	well	 as	 for	 detecting	 novel	 anti-GSC	 antibodies.	 It	 is,	 however,	 nearly
impossible	 to	 adjust	 the	 condition	 of	 the	 glycoarray	 systems	 regarding	 their	 glycolipid	 density	 and	 the
clustering	of	sugar	ligands.	Antibody-mediated	carbohydrate	recognition	on	the	cell	surface	is	regulated
by	 the	chemical	property	of	 the	constituents	of	glycoconjugates	 in	 the	cell	membrane.	Additionally,	 the
nature	 of	 the	 glycoconjugates	 is	 governed	 by	 parameters	 consisting	 mainly	 of	 multivalency	 of	 sugar
epitopes,	 their	 orientation	 and	 conformational	 flexibility	 of	 their	 presentation,	 and	 ligand	 density	 and
spacing	of	 interaction	partners	 [20]	 (figure	46.3).	Synthetic	 clustered	glycolipids	of	different	valencies
vary	 in	 carbohydrate	density	on	 a	PVDF	or	 a	 polystyrene	 surface	 and	 are	useful	 to	 adjust	 some	of	 the
above	parameters	and	to	make	efficient	use	of	the	present	glycoarray	systems.
Perspectives
In	 addition	 to	 the	GM1-GD1a	hybrid,	 a	dimeric	GM1	hybrid	 (GM1-GM1	dimer)	 and	a	dimeric	GD1a
hybrid	(GD1a-GD1a	dimer)	are	also	important	tools	for	analysing	anti-ganglioside	antibody-carbohydrate
interaction	 on	 the	 cell	 surface	 [21].	 We	 should	 equip	 a	 series	 of	 synthetic	 mono-,	 di-,	 and	 trivalent
gangliosides	 to	 improve	 our	 understanding	 of	 anti-ganglioside	 antibody-mediated	 carbohydrate
recognition.
Figure	46.3		Structures	of	GM1	dimer	and	natural	GM1	in	the	cell	membrane.
Clusters	of	synthetic	GM1	dimers	are	assumed	to	be	more	multivalent	and	denser	than	those	of	natural	(bovine)	GM1	at	nerve
membranes.
A	 recent	 study	 has	 shown	 that	 GM1-like	 and	 GD1a-like	 lipooligosaccharides	 may	 form	 a	 GM1b
epitope,	inducing	the	development	of	anti-GM1b	antibodies	[22].	This	result	indicates	that	the	complex	of
2	 different	 structures	 may	 form	 a	 new	 molecular	 mimicry,	 although	 it	 is	 unclear	 whether	 the	 anti-
GM1/GD1a	 antibodies	 and	 the	 anti-GM1b	 antibodies	 bind	 to	 the	 same	 carbohydrates	 in	 living	 nerve
membrane.	We	should	carefully	interpret	the	configuration	of	clustered	glycol	epitopes	in	GSCs.
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Antibody	and	B	Cell	Immunology	in	GBS:	From
Evolution	to	Current	Concepts
Ruth	Huizinga
Introduction
Serum	anti-glycolipid	 antibodies	 are	 a	 hallmark	of	 the	Guillain-Barré	 syndrome	 (GBS)	 and	have	been
demonstrated	to	induce	complement-mediated	nerve	damage	[1].	The	pathogenic	antibodies	are	produced
by	plasma	cells,	which	differentiate	from	B	cells.	Here	I	discuss	my	10	favourite	papers	that	have	shed
important	light	on	the	immunological	mechanisms	of	the	induction	of	anti-glycolipid	antibodies	in	GBS.
Cook	SD,	et	al.	The	Guillain-Barré	syndrome.	Relationship	of
circulating	immunocytes	to	disease	activity.	Archives	of
Neurology,1970
One	of	the	earliest	studies	that	I	could	find	on	PubMed,	suggesting	that	a	systemic	immune	response	plays
a	role	 in	 the	pathogenesis	of	GBS,	 is	from	Cook	and	colleagues	[2].	The	paper	reports	 the	presence	of
atypical	basophilic	mononuclear	cells	in	the	blood	of	patients	with	GBS,	so-called	atypical	leukocytes	or
circulating	 immunocytes.	 They	 found	 many	 of	 these	 cells	 proliferating,	 as	 indicated	 by	 the	 uptake	 of
tritiated	 thymidine,	 demonstrating	 DNA	 synthesis.	 This	 was	 analysed	 cell-by-cell	 (imagine	 all	 the
counting	that	it	required!).	Sixty-four	percent	of	the	GBS	patients,	mostly	in	the	acute	stage	of	the	disease,
had	 increased	 numbers	 of	 these	 DNA-synthesizing	 cells.	 The	 numbers	 subsequently	 declined	 to	 basal
levels.	Importantly,	there	was	a	correlation	between	the	number	of	DNA-synthesizing	cells	and	the	onset
of	 clinical	 recovery.	The	 responses	 in	peripheral	blood	were	 reminiscent	of	 the	 responses	 seen	during
immune	 reactions	 in	 man	 and	 animals	 immunised	 with	 peripheral	 nervous	 system	 tissue	 in	 complete
Freund’s	adjuvant	 (CFA)	[3].	Building	further	onto	 the	 landmark	histopathology	study	[4],	showing	 that
mononuclear	 infiltrates	 are	 present	 in	 demyelinating	 areas	 of	 peripheral	 nerves	 of	 GBS	 patients,	 the
authors	 proposed	 the	 concept	 that	 “antigenic	 stimulation	 occurs	 in	 patients	 with	GBS,	 resulting	 in	 the
presence	of	circulating	DNA	synthesizing	cells	which	may	play	an	important	role	in	the	development	of
peripheral	nerve	injury”	[2].	The	sequence	of	events	turned	out	to	be	correct	as	we	now	consider	GBS	to
be	a	post-infectious	disease.
Willison	HJ,	et	al.	Immunoglobulin	subclass	distribution	and	binding
characteristics	of	anti-GQ1b	antibodies	in	Miller	Fisher	syndrome.
Journal	of	Neuroimmunology,	1994
After	 the	 discovery	 that	 antibodies	 in	 GBS	 patients	 were	 recognising	 glycolipids	 [5],	 an	 important
question	arose	as	to	what	subclasses	were	produced.	Since	antibodies	to	lipopolysaccharides	(LPS)	and
bacterial	capsular	polysaccharides	are	predominantly	of	the	IgG2	subclass	[6,7],	Hugh	Willison	and	co-
workers	 must	 have	 been	 surprised	 to	 find	 that	 the	 antibodies	 were	 actually	 of	 the	 IgG1	 and	 IgG3
subclasses	 [8].	 Interestingly,	 some	patients	with	MFS,	but	not	GBS,	did	have	 low	 levels	of	 IgG2	anti-
GQ1b,	 suggesting	 that	 a	 typical	 carbohydrate	 antibody	 response	 to	 glycolipids	 can	 occur	 in	 some
instances.	 The	 ‘atypical	 immune	 response’,	 as	mentioned	 in	 the	 discussion	 of	 the	 paper	 [8],	 has	 been
confirmed	 by	 many	 other	 groups	 and	 was	 found	 to	 be	 related	 to	 preceding	 infections,	 where
gastrointestinal	 infections	 were	 linked	 to	 IgG1	 and	 respiratory	 infections	 to	 both	 IgG1	 and	 IgG3	 [9].
Immunisation	 of	 humans	 with	 GM2	 combined	 with	 Bacillus	 Calmette-Guérin	 also	 resulted	 in	 the
induction	 of	 IgG1	 and	 IgG3	 antibodies	 to	GM2	 [10],	 indicating	 that	 the	 IgG	 1/3	 antibody	 response	 to
glycolipids	is	not	a	unique	feature	of	patients	with	GBS.	The	finding	of	IgG1	and	IgG3	preference	has	led
to	the	assumption	that	T	cells	are	required	for	 the	development	of	anti-glycolipid	antibodies.	However,
the	exact	phenotype	of	the	cells	that	induce	class	switch	recombination	in	GBS	remains	unknown.
HeidenreichF,	et	al.	T	cell-dependent	activity	of	ganglioside	GM1-
specific	B	cells	in	Guillain-Barré	syndrome	and	multifocal	motor
neuropathy	in	vitro.	Journal	of	Neuroimmunology,1994
The	paper	by	Heidenreich	and	colleagues	is	of	particular	interest	because	it	provides	evidence	that	GM1-
reactive	B	cells	are	present	in	the	peripheral	blood	of	patients	with	GBS	[11].	Although	the	study	mainly
focussed	on	 the	 in	vitro	production	of	anti-GM1	IgM,	and	 this	was	also	 found	 in	some	disease	control
patients,	 in	 2	 GBS	 cases	 evidence	 was	 found	 for	 the	 production	 of	 anti-GM1	 IgG.	 In	 addition,	 in	 2
patients	 in	 vitro	 IgM	 anti-GM1	 production	was	 found	 early	 in	 the	 disease	 course	 and	 in	 unstimulated
cultures,	 suggesting	 that	 plasmablasts	 were	 present	 in	 the	 cell	 preparation.	 The	 mitogen	 used	 for
stimulating	the	cells	was	derived	from	pokeweed.	Recently,	these	preparations	were	further	examined	and
were	found	to	contain	several	Toll-like	receptor	(TLR)	ligands	[12].	These	ligands	may	cause	production
of	cytokines	that	cause	activation	and	differentiation	of	B	cells.	In	conclusion,	the	data	suggests	that	GBS
patients	have	circulating	B	cells	or	plasmablasts	that	can	secrete	anti-glycolipid	antibodies	in	vitro.	This
implies	that	the	cloning	and	detailed	characterisation	of	these	B	cells	should	in	principle	be	possible.
Freimer	ML,	et	al.	Gangliosides	elicit	a	T-cell	independent	antibody
response.	Journal	of	Autoimmunity,	1993
So	what	are	the	real	requirements	for	the	activation	of	anti-glycolipid	reactive	B	cells?	An	elegant	animal
study	performed	by	Freimer	and	colleagues	demonstrates	that,	at	least	in	mice,	B	cells	can	be	activated	to
produce	anti-GM1	IgM	using	GM1-containing	liposomes,	with	lipid	A	as	an	adjuvant	[13].	The	response
was	also	present	 in	nude	mice,	 lacking	a	thymus.	Upon	each	booster,	 there	was	an	increase	in	antibody
levels,	 suggesting	a	 step-wise	expansion	of	GM1-specific	B	cells.	Hence	 the	data	nicely	 indicates	 that
activation	 of	B	 cells	 is	 possible	 in	 a	 thymus-independent	manner,	without	 the	 help	 of	T	 cells	 and	NK
cells,	which	also	develop	in	the	thymus.	In	a	control	experiment	using	the	protein	antigen	albumin,	no	IgM
or	IgG	responses	could	be	induced,	as	expected.	In	the	study,	absolutely	no	anti-GM1	IgG	response	could
be	measured,	not	even	IgG3,	which	is	the	mouse	equivalent	of	the	thymus-independent	antibody	response.
This	finding	may	be	explained	by	later	studies	using	ganglioside-deficient	mice	(see	below).	In	principle,
this	study	shows	that	a	thymus-independent	response	to	glycolipids	can	occur	and,	possibly,	that	this	is	the
reason	for	the	presence	of	low	levels	of	IgM	antibodies	against	glycolipids	in	healthy	humans	[14],	which
are	most	likely	induced	because	of	cross-reactivity	with	bacterial	antigens.
Wirguin	I,	et	al.	Induction	of	anti-GM1	ganglioside	antibodies	by
Campylobacter	jejuni	lipopolysaccharides.	Journal	of
Neuroimmunology,1997
The	 ‘antigenic	stimulation’	 in	GBS	patients,	as	observed	by	Cook	and	colleagues,	 is	now	known	 to	be
caused	by	various	pathogens,	most	frequently	Campylobacter	jejuni	[15].	Therefore	the	Norman	Latov’s
group	wondered	whether	 immunisation	with	 lipooligosaccharides	 (LOS)	derived	 from	C.	 jejuni	 would
give	rise	to	anti-glycolipids	[16].	They	were	able	to	induce	high	titres	of	anti-GM1	IgM	antibodies	in	rats
that	were	immunised	with	keyhole	limpet	hemocyanin	(KLH)	prior	to	injection	with	C.	jejuni	LOS.	The
specificity	 of	 the	 antibodies	 indicated	 that	 stimulation	 though	 the	 B-cell	 receptor	 is	 required.	 KLH	 is
glycosylated	and	immunisation	induces	antibodies	to	the	Gal-GalNAc	epitope	[17].	The	findings	suggest
that	the	subsequent	challenge	with	C.	jejuni	LOS	is	further	stimulating	the	Gal-GalNAc-specific	B	cells
induced	by	KLH	to	produce	antibodies	that	are	also	cross-reactive	with	GM1.	As	many	individuals	have
antibodies	to	asialo-GM1,	which	also	contains	the	Gal-GalNAcepitope,	it	will	be	interesting	to	compare
the	sequences	of	asialo-GM1	and	GM1-reactive	B	cells.
Bowes	T,	et	al.	Tolerance	to	self	gangliosides	is	the	major	factor
restricting	the	antibody	response	to	lipopolysaccharide	core
oligosaccharides	in	Campylobacter	jejuni	strains	associated	with
Guillain-Barré	syndrome.	Infection	and	Immunity,	2002
Major	progress	was	made	in	determining	some	of	the	mechanisms	of	anti-glycolipid	antibody	induction
using	mice	that	lack	glycosyltransferases	and	are	hence	deficient	in	certain	types	of	gangliosides.	Using
these	mice,	anti-glycolipid	IgG	could	be	induced	not	only	in	response	to	ganglioside	liposomes,	but	also
following	 immunisation	 with	 C.	 jejuni	 LOS	 [18].	 In	 this	 model,	 ‘intermolecular’	 T-cell	 help	 was
provided	by	the	addition	of	ovalbumin	to	the	ganglioside	liposomes,	or	by	the	use	of	CFA.	This	resulted
in	class	switching	to	IgG1	and	IgG2a/b.	In	the	same	paper	it	was	shown	that	in	ganglioside-sufficient,	but
TLR4	 hyporesponsive	 mice,	 no	 anti-glycolipid	 antibodies	 could	 be	 induced.	 This	 experiment	 clearly
demonstrates	the	important	role	of	TLR4	activation.	Mice	immunised	with	LOS	devoid	of	a	ganglioside
mimic	 did	 not	 produce	 cross-reactive	 antibodies,	 indicating	 that	 the	 exact	mimic	must	 be	 present.	The
mouse	model	was	 later	 used	 to	 demonstrate	 that	 the	 induction	 of	 anti-glycolipid	 antibodies	 can	 occur
independent	of	CD1d	[19].
Lee	et	al.	Induction	of	human	IgM	and	IgG	anti-GM1	antibodies	in
transgenic	mice	in	response	to	lipopolysaccharides	from
Campylobacter	jejuni.	Journal	of	Neuroimmunology,	2004
In	 the	quest	 for	 a	mouse	model	 for	 anti-GM1	antibody-mediated	neuropathy,	 the	 laboratory	of	Norman
Latov	generated	a	transgenic	mouse	with	a	population	of	B	cells	expressing	an	anti-GM1	B-cell	receptor
[20].	The	 sequence	of	 the	antibody	was	derived	 from	a	patient	with	multifocal	motor	neuropathy	 [21].
One	of	the	most	striking	observations	to	me	is	that	the	B	cells	with	anti-GM1	reactivity	were	not	deleted
due	 to	 negative	 selection	during	development,	which	 is	 observed	 in	 other	models	 of	 anti-carbohydrate
antibodies,	such	as	in	transgenic	anti-αGal	mice	[22].	This	was	elegantly	demonstrated	using	an	idiotype
antibody	that	recognises	the	anti-GM1	antibody.	Apparently,	the	presence	of	GM1	epitopes	is	sufficiently
low	to	allow	normal	development	of	these	B	cells.	During	steady	state,	the	transgenic	mice	produced	low
levels	of	anti-GM1	IgM,	as	can	be	observed	in	some	humans.	Injection	with	only	C.	jejuni	LOS,	without
proteins	or	other	adjuvants,	resulted	in	high	titres	of	anti-GM1	IgM,	and	after	18	days,	IgG	responses	also
occurred	 (mainly	 IgG3	and	 IgG2b).	 Immunisation	with	GM1	alone	or	E.	coli	 LPS	did	 not	 induce	 anti-
GM1	 IgG	 antibodies,	 indicating	 that	 both	 the	 carbohydrate	mimic	 and	 an	 innate	 trigger	 is	 required	 to
overcome	peripheral	tolerance	mechanisms.	Although	the	antibodies	were	able	to	bind	to	mouse	nerves
and	activate	complement,	 the	mice	did	not	develop	neuropathy	and	hence	a	complete	animal	model	 for
GBS	was	still	lacking.
Borsellino	G,	et	al.	Phenotypic	and	functional	properties	of	gamma
delta	T	cells	from	patients	with	Guillain-Barré	syndrome.	Journal	of
Neuroimmunology,	2000
The	 studies	 in	 rodents,	 discussed	 above,	 in	 which	 glycolipids	 predominantly	 induce	 antibodies	 with
thymus-independent	 characteristics,	 suggest	 that	 T	 cells	 are	 required	 for	 switching	 to	 the	 isotypes
associated	with	GBS.	So	what	is	known	about	T-cell	responses	in	GBS?	Evidence	for	involvement	of	γδ
T	cells	in	GBS	is	provided	by	the	2000	study	by	Borsellino	and	colleagues	[23].	Most	importantly,	the
percentage	 of	 Vδ1	 cells	 was	 significantly	 increased	 in	 the	 peripheral	 blood	 of	 GBS	 patients,	 and
approximately	half	of	the	cells	also	expressed	the	NK	cell	marker	NKRP1A.	T-cell	clones	derived	from
these	cells	secreted	high	levels	of	IL-4.	This	study	is	 in	 line	with	 the	observation	that	γδ	T	cells	were
present	in	the	peripheral	nerves	of	a	GBS	patient	with	a	preceding	C.jejuni	infection	[24].	Together	the
data	may	suggest	that	a	population	of	NK	T	cells	may	be	increased	in	acute	GBS.	However,	whether	these
cells	are	able	to	induce	isotype	switching	of	human	glycolipid-reactive	B	cells	remains	to	be	determined.
Yuki	N,	et	al.	Carbohydrate	mimicry	between	human	ganglioside	GM1
and	Campylobacter	jejuni	lipooligosaccharide	causes	Guillain-Barré
syndrome.	Proceedings	of	the	National	Academy	of	Sciences	of	the
United	States	of	America,	2004
The	 final	 ‘missing	 link’	 experiment,	 to	 prove	 that	 cross-reactive	 antibodies	 are	 generated	 through	 a
process	of	molecular	mimicry	and	cause	neuropathy,	was	reported	by	Yuki	and	colleagues	in	2004	[25].
Rabbits	were	 immunised	 at	 3-week	 intervals	with	C.	 jejuni	 LOS	 dissolved	 in	KLH	 and	 emulsified	 in
CFA.	In	the	high-dose	group,	all	animals	developed	antibodies	to	GM1	and	flaccid	paralysis	occurred	at
various	time	points.	The	rabbit	model	pathologically	resembles	human	acute	motor	axonal	neuropathy.	Of
note,	 the	 anti-GM1	 titres	 gradually	 increased	 following	booster	 immunisations,	 and	 the	majority	 of	 the
animals	 developed	 paralysis	 within	 3	 weeks	 after	 the	 anti-GM1	 titre	 peak	 was	 reached.	 One	 animal
started	 to	 recover	 16	 days	 after	 the	 onset	 of	 symptoms,	 hence	 mimicking	 the	 disease	 in	 humans.
Importantly,	the	study	demonstrates	that	the	induction	of	GM1	antibodies	is	not	the	result	of	a	polyclonal	B
cell	response	due	to	TLR	triggering,	since	immunisation	of	rabbits	with	LPS	from	E.	coli	or	S.	minnesota
did	not	lead	to	the	generation	of	cross-reactive	antibodies.	This	proves	again	that	the	exact	carbohydrate
structure,	mimicking	gangliosides,	needs	to	be	present	for	the	development	of	cross-reactive	antibodies.
What	then	makes	the	rabbit	so	successful?	Although	differences	in	B-cell	development	and	mechanisms	of
affinity	maturation	may	account	for	the	ability	of	rabbits	to	produce	high	affinity	antibodies	to	a	diverse
set	of	molecules	[26],	it	is	also	intriguing	that	rabbits	have	high	numbers	of	γδ	T	cells	and	that	the	T	cell
receptor	gamma	loci	have	more	sequence	identity	to	humans	than	mice	[27].	Finally,	rabbits	have	more
CD1	molecules	compared	to	mice,	which	only	express	CD1d.
Kuijf	MI,	et	al.	LR4-mediated	sensing	of	Campylobacter	jejuni	by
dendritic	cells	is	determined	by	sialylation.	Journal	of	Immunology,
2010
I	would	like	to	end	this	monograph	by	briefly	discussing	the	project	that	took	me	into	the	GBS	field	when
I	 joined	 the	 laboratory	of	Bart	 Jacobs.	The	project	underscores	 the	 long-standing	 fruitful	 collaboration
between	 microbiologists,	 immunologists	 and	 neurologists	 at	 Erasmus	MC.	 By	 using	 mutant	C.	 jejuni,
unable	to	sialylate	LOS	[28],	the	first	author	of	the	paper,	Mark	Kuijf,	found	that	sialic	acid	on	C.	jejuni
LOS,	leading	to	mimicry	with	gangliosides,	also	resulted	in	a	potent	activation	of	human	dendritic	cells
[29].	Thus	the	addition	of	only	one	sialic	acid	carbohydrate	made	LOS	more	potent	by	a	factor	of	100.	So
unlike	 the	general	notion	that	only	 lipid	A	is	 important	for	TLR4	signalling,	 this	study	clearly	 indicates
that	 the	carbohydrate	composition	also	plays	an	important	role.	How	can	this	strong	innate	response	be
linked	to	the	development	of	anti-glycolipid	antibodies?	The	activation	of	dendritic	cells	resulted	in	the
production	of	cytokines	that	enhanced	the	proliferation	of	B	cells.	Hence	the	cytokine	milieu	produced	by
innate	 immune	cells	 is	 facilitating	 the	 initiation	of	 subsequent	 adaptive	 immune	 responses.	Recent	data
further	 indicates	 that	 dendritic	 cells	 of	 almost	 all	GBS	patients	 showed	a	 strong	 response	 to	C.	 jejuni
LOS	by	producing	type	I	interferon,	in	contrast	to	control	subjects	[30].	This	indicates	that	a	strong	innate
immune	response	to	C.	jejuni	may	be	a	critical	host	condition	for	the	development	of	GBS.
Conclusions	and	Future	Perspectives
A	hundred	years	of	GBS	research	has	resulted	in	the	general	elucidation	of	the	pathogenesis	of	GBS.	It	is
clear	 now	 that	 GBS	 is	 a	 post-infectious	 disease,	 mediated	 by	 B	 cells	 and	 antibodies	 that	 are	 cross-
reactive	 with	 glycolipids	 in	 the	 peripheral	 nerve.	 Although	 B	 cells	 can	 be	 activated	 to	 produce	 anti-
glycolipid	 antibodies	 in	 a	 thymus-independent	manner	 in	 rodents,	 and	most	 likely	 also	 in	 humans,	 for
class	 switching	 to	 IgG1	 and	 IgG3	 additional	 B-cell	 help	 seems	 to	 be	 required.	 The	 exact	 cellular
mechanism,	 however,	 remains	 to	 be	 determined.	 Both	 the	 presence	 of	 a	 carbohydrate	 mimic,	 which
activates	 the	B-cell	 receptor,	and	signalling	 through	innate	antigen	receptors	appears	 to	be	required	for
the	development	of	cross-reactive	antibodies.	A	great	challenge	for	the	future	will	be	to	reveal	the	factors
that	determine	the	magnitude	and	persistence	of	the	anti-glycolipid	antibody	response	in	GBS.	This	may
open	up	new	ways	for	interfering	with	these	responses	early	during	disease.
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Myelin	Antigens	in	Guillain-Barré	Syndrome:	EAN,
the	Pied	Piper	of	Myelin
Emily	K.	Mathey	and	John	Pollard
Myelin	Becomes	the	Prime	Suspect
The	possibility	that	myelin	antigens	may	play	a	pathogenic	role	in	GBS	was	not	seriously	considered	until
the	description	of	experimental	autoimmune	neuritis	(EAN)	by	Waksman	and	Adams	in	1955	[1].	Indeed,
it	was	 that	 discovery	which	provided	 the	 first	 indication	 that	myelin	might	 be	 selectively	destroyed	 in
GBS.	 Prior	 to	 that	 date,	 pathological	 studies,	 even	 the	 landmark	 report	 of	Haymaker	 and	Kernohan	 in
1949,	 which	 examined	 50	 fatal	 cases,	 did	 not	 mention	 demyelination,	 although	 the	 extent	 of	 nerve
devastation	was	thoroughly	documented	[2].	The	first	major	study	to	recognise	specific	myelin	destruction
in	 GBS	 was	 the	 postmortem	 analysis	 of	 19	 fatal	 cases	 by	 Asbury,	 Arnason	 and	 Adams	 from
Massachusetts	General	Hospital	in	1969	[3].	That	study	noted	the	association	between	demyelination	and
infiltrating	inflammatory	cells,	thus	suggesting	some	homology	with	EAN.
In	the	same	year	(1969)	a	number	of	publications	appeared	which	examined	the	mechanism	by	which
myelin	was	 targeted	 in	 these	 disorders.	Wisniewski,	Terry,	Whitaker,	Cook	 and	Dowling	published	 an
autopsy	 study	 which	 showed	 that	 myelin	 dissolution	 occurred	 in	 immediate	 proximity	 to	 invading
macrophages	and	that	lymphocytes	were	not	present	within	the	basal	lamina	of	affected	fibres	[4].	Similar
macrophage-mediated	 demyelination	 in	 EAN	 was	 reported	 by	 Lampert	 in	 1969	 [5].	 In	 1972	 Prineas
described	changes	 in	GBS	of	 stripping	and	phagocytosis	of	compact	myelin	by	macrophages	 following
displacement	of	normal	appearing	Schwann	cell	cytoplasm	away	from	the	sheath	[6].	(See	Figure	48.1.)
These	dramatic	illustrations	suggested	that	if	GBS	and	EAN	were	homologous	autoimmune	disorders
then	 the	 target	 of	 immune	 attack	 did	 indeed	 appear	 to	 reside	 within	 compact	 myelin.	 Moreover	 the
pathological	changes	in	GBS	and	EAN	were	so	similar	that	investigations	into	the	pathogenesis	of	GBS
were	for	some	years	dominated	by	studies	in	EAN.	Studies	of	immune	targets	in	myelin	in	the	EAN	model
may,	in	retrospect,	have	retarded	progress	in	understanding	the	pathogenesis	of	the	human	disease.
Wherefore	Art	Thou	P0?
Although	EAN	has	informed	many	areas	of	GBS	pathogenesis	with	respect	to	identifying	target	antigens,
the	model	has	been	akin	to	a	reverse	Pied	Piper	where	the	rats	have	lead	us	all	on	a	merry	dance	towards
the	major	myelin	proteins.	In	1979	Kadlubowski	and	Hughes	identified	P2	as	the	neuritogen	responsible
for	induction	of	EAN	after	immunisation	with	whole	peripheral	nerve	and	was	also	shown	to	induce	EAN
by	active	immunisation	in	its	purified	form	[7].	P2	is	expressed	in	the	compact	myelin	and	is	thought	to
play	a	role	in	the	stacking	and	stabilisation	of	apposing	Schwann	cell	membranes	as	they	come	together	to
form	 myelin.	 Kadlubowski	 and	 Hughes	 finished	 their	 paper	 by	 stating,	 “Now	 that	 we	 have	 clearly
identified	the	neuritogen	involved	in	the	animal	model	of	Guillain-Barré	Syndrome,	we	intend	to	extend
our	study	to	look	for	evidence	of	sensitisation	to	P2	in	the	human	disease”.	And	so	began	the	merry	dance.
Figure	48.1		Myelin	stripping	and	phagocytosis	of	compact	myelin.	Reproduced	with	permission	from	[6].
Over	 the	 next	 few	 decades	 researchers	 screened	 patient	 sera	 for	 antibodies	 to	 the	 major	 myelin
proteins—particularly	for	those	that	could	induce	EAN,	including	P2,	P0	and	PMP-22.	There	have	been
numerous	studies	screening	sera	for	antibody	reactivity	to	these	major	myelin	proteins,	but	thus	far	they
have	 not	 proven	 to	 be	 key	 targets	 and	 there	 is	 no	 consensus	 as	 to	 their	 pathogenic	 relevance	 in	 those
patients	in	whom	antibodies	have	been	detected.
P0	Protein
P0	is	 the	most	abundant	protein	 in	PNS	myelin.	 It	 forms	 tetramers	 that	 interact	 in	cis	and	 transform	the
molecular	glue	that	holds	together	the	extracellular	space	of	compact	myelin.	Immunisation	with	bovine
P0	produces	EAN	in	the	Lewis	rat	and	P0-specific	T	cells	transfer	EAN	to	naïve	rats.	In	1992	Khalili-
Shirazi	and	colleagues	reported	T-cell	responsiveness	to	purified	P0	protein	in	6	of	19	GBS	cases,	and
IgG	and	IgM	antibodies	to	P0	in	about	one-third	of	cases	[8].	However,	there	is	no	convincing	evidence
from	passive	transfer	studies	for	pathogenicity	of	these	autoimmune	responses	to	P0	in	GBS.
PMP-22	Protein
Duplications	or	deletions	in	the	gene	for	PMP-22	protein	account	for	the	majority	of	cases	of	hereditary
neuropathy.	 PMP-22	 is	 also	 neuritogenic	 in	 the	 Lewis	 rat,	 and	 antibodies	 to	 synthetic	 peptides
representing	either	the	first	or	second	extracellular	domains	of	PMP-22	have	been	reported	in	58%	of	19
GBS	 patients	 and	 4%	 of	 51	 normal	 subjects	 [9].	 Other	 groups	 have	 failed	 to	 detect	 such	 a	 clear
relationship	 between	GBS	or	CIDP	 and	 antibodies	 to	 this	 protein.	 Interestingly,	 antibodies	 to	 PMP-22
appear	in	70%	of	patients	with	CMT1a	and	60%	of	those	with	CMT2	and	in	23%	of	normal	people	[10].
It	has	been	suggested	that	such	antibodies	may	play	a	role	in	patients	with	CMT1a	who	experience	sudden
deterioration.
Galactocerebroside
In	1978	and	over	the	next	few	years	the	husband-and-wife	team	of	Takahiko	and	Kyoko	Saida,	working	in
Philadelphia,	published	reports	in	Nature	and	Science	which	aroused	considerable	international	interest
[12,13].	These	reports	described	a	powerful	demyelinating	effect	of	rabbit	EAN	serum	when	injected	into
rat	sciatic	nerve.	This	effect	was	shown	to	be	due	to	antibodies	 to	galactocerebroside	(GalC),	and	this
glycolipid	was	shown	to	be	neuritogenic	in	the	rabbit.	The	Philadelphia	group	subsequently	reported	that
sera	from	patients	with	GBS	caused	demyelination	when	injected	into	rat	nerve	[14],	a	finding	confirmed
by	some	but	not	by	others,	but	none	of	the	positive	findings	showed	the	potency	of	rabbit	EAN	serum	and
the	technique	of	intraneural	injection	was	felt	to	be	unphysiological.	Although	GalC	is	highly	enriched	in
compact	myelin,	it	is	also	present	in	Schwann	cells	and	the	Saidas’	group	described	extensive	Schwann
cell	 damage	 in	 their	 original	 description	 of	 anti-GalC-induced	 EAN.	 Samukawa	 and	 colleagues	 have
reported	antibodies	to	GalC	in	patients	with	GBS,	some	following	CMV	infection	[15].	Passive	transfer
studies	of	these	antibodies	would	be	of	great	interest.
Molecular	Mimicry	in	AIDP?
Thus	 far,	 the	major	 advances	 in	 pathogenesis	 and	 defining	 pathogenic	 antigens,	 at	 least	 in	 the	AMAN
subtype,	occurred	in	the	1990s	in	studies	of	human	serum	particularly	by	Nobuhiro	Yuki	in	Japan.	Due	to
the	success	of	identifying	the	relationship	between	antecedent	Campylobacter	jejuni	infection	in	AMAN
and	the	generation	of	pathogenic	anti-ganglioside	antibodies,	attempts	have	been	made	to	identify	similar
mechanisms	of	molecular	mimicry	 in	AIDP.	Recently	Sawai	and	colleagues	 identified	antibodies	 to	 the
protein	 moesin	 in	 5	 out	 of	 6	 AIDP	 patients	 who	 had	 antecedent	 CMV	 infections	 [16].	 Moesin	 was
identified	as	a	 target	 in	 this	case	by	using	a	proteomic	approach	 to	screen	sera	with	proteins	extracted
from	schwannoma	cells	and	identify	proteins	that	bound	IgG	using	mass	spectrometry.	Moesin	is	part	of
the	ERM	(ezrin,	 radixin,	moesin)	 family	expressed	on	Schwann	cell	microvilli	at	 the	nodes	of	Ranvier
and	is	among	a	growing	group	of	proteins	that	may	be	relevant	to	demyelinating	neuropathies	but	are	not
located	 in	 the	compact	myelin.	However,	nothing	 is	ever	 simple	 in	 the	complicated	world	of	GBS	and
another	group	were	unable	to	detect	an	autoantibody	response	to	any	of	the	ERM	proteins	in	AIDP	with
antecedent	CMV	nor	in	CIDP	cases	[11].
Searching	for	a	Needle	in	a	Haystack
Studies	such	as	that	by	Sawai	and	colleagues	[16]	have	come	full	circle	compared	with	the	approach	of
finding	a	protein	that	induces	EAN	and	then	searching	for	its	relevance	in	the	human	disease.	In	the	1970s
and	1980s	the	diversity	of	myelin	proteins	was	severely	underestimated	due	to	the	rudimentary	methods
available.	At	the	time,	separation	of	myelin	proteins	by	gel	electrophoresis	and	Coomassie	staining	could
identify	the	3	major	bands	of	P0,	P1	and	P2	and	little	else.	Novel	proteins	were	gradually	added	to	the
cache	 as	 new	methods	 of	 detection	 became	 available,	 and	 by	 2010	 there	 were	 about	 40	 known	 PNS
myelin	proteins.
In	 2011	 the	 first	 proteomic	 analysis	 of	 PNS	myelin	 identified	 545	 proteins	 in	mouse	 sciatic	 nerve,
including	36	previously	 identified	myelin	proteins	 [17].	This	study	confirmed	 that	PNS	myelin	 is	much
more	complex	than	previously	thought	and	that	in	terms	of	identifying	auto-antibodies	to	myelin	antigens
in	GBS	we	have	really	only	considered	the	tip	of	the	iceberg.	With	this	increase	in	the	number	of	myelin
proteins	it	is	not	in	the	least	way	feasible	to	test	candidate	antigens	for	their	ability	to	induce	EAN	and
then	correlate	this	immune	response	with	clinical	serological	analyses.	Further	advances	will	come	from
unbiased	screening	of	patient	sera	and	identification	of	novel	targets	in	patients	first,	a	strategy	that	has
been	recently	successful	in	identifying	novel	autoantibody	responses	to	the	nodal	regions	in	CIDP.
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Molecular	Mimicry
Nobuhiro	Yuki
From	the	time	autoimmune	diseases	were	first	discovered,	molecular	mimicry	between	human	tissue	and
micro-organisms	had	been	proposed	 to	be	a	pathogenic	mechanism.	However,	until	 recently,	no	studies
had	convincingly	demonstrated	this	[1]	because	4	criteria	had	to	be	satisfied	to	conclude	that	a	disease	is
triggered	 by	 molecular	 mimicry	 [2]:	 (A)	 establishment	 of	 an	 epidemiological	 association	 between	 an
infectious	 disease	 and	 immune-mediated	 diseases;	 (B)	 identification	 of	 T	 cells	 or	 antibodies	 directed
against	 human	 target	 antigens;	 (C)	 identification	 of	 microbial	 mimics	 of	 the	 target	 antigen;	 and	 (D)
reproduction	of	the	disease	in	an	animal	model.
Guillain–Barré	syndrome	(GBS)	is	the	first	disease	to	fulfil	all	the	4	criteria:	(A)	an	epidemiological
association	 between	 GBS	 and	 Campylobacter	 jejuni	 infection	 [3]	 has	 been	 established;	 (B)	 auto-
antibodies	against	GM1	or	GD1a	in	patients	with	GBS	subsequent	to	C.	jejuni	enteritis	[4,5]	have	been
identified;	(C)	Molecular	mimicry	between	GM1	or	GD1a	and	lipooligosaccharides	(LOSs)	of	C.	jejuni
isolated	 from	 GBS	 [6,7]	 has	 been	 demonstrated;	 and	 (D)	 a	 disease	 replica	 has	 been	 produced	 by
sensitizing	 rabbits	with	GM1	or	GM1-like	LOS	of	C.	 jejuni	 and	passive	 transfer	of	 anti-GM1	or	anti-
GD1a	 antibodies	 in	 mice	 [8–11].	 Here	 I	 describe	 how	 we	 and	 other	 investigators	 have	 shown	 that
molecular	mimicry	is	a	cause	of	GBS.
Identification	of	Autoantibodies
Yuki	N,	et	al.	Acute	axonal	polyneuropathy	associated	with	anti-GM1	antibodies	following
Campylobacter	enteritis.	Neurology,	1990;	Chiba	A,	et	al.	Serum	IgG	antibody	to
ganglioside	GQ1b	is	a	possible	marker	of	Miller	Fisher	syndrome.	Annals	of	Neurology,
1992
My	first	encounter	with	a	GBS	patient	was	in	1989	when	the	individual	was	admitted	to	our	hospital	due
to	bilateral	 leg	weakness	followed	by	arm	weakness	developing	over	several	days.	He	had	had	watery
diarrhoea	1	week	before	the	onset.	He	presented	with	tetraplegia	and	areflexia	without	any	sensory	signs,
in	contrast	to	the	typical	patient	with	GBS	who	usually	describes	a	glove-and-stocking	pattern	of	sensory
impairment.	 Feasby	 and	 colleagues	 had	 reported	 “an	 acute	 axonal	 form	 of	 Guillain-Barré
polyneuropathy”	 in	 1986	 [12],	 but	 at	 that	 time	 most	 clinicians	 believed	 GBS	 to	 be	 a	 demyelinating
peripheral	nerve	disease.	Repeated	nerve	conduction	study	results	in	our	patient	supported	a	diagnosis	of
axonal	 degeneration,	 and	 not	 demyelination.	 Although	 our	 patient	 complained	 of	 subjective	 distal
paresthesia,	his	clinical	and	electrophysiological	 features	were	similar	 to	amyotrophic	 lateral	sclerosis
(ALS).	I	recalled	a	paper	I	had	read	by	Latov’s	group	published	in	1986	in	which	his	group	reported	a
patient	 with	 ALS-like	 disorder	 who	 had	 IgM	 M-protein	 against	 GM1	 and	 who	 improved	 after
immunotherapy	 [13],	 suggesting	 what	 we	 know	 now	 as	 multifocal	 motor	 neuropathy.	 Their	 report
prompted	 me	 to	 consider	 the	 possibility	 that	 our	 patient	 might	 also	 have	 anti-GM1	 antibodies.	 Our
investigations	 revealed	 IgG,	 not	 IgM,	 antibodies	 reacting	with	GM1	 [4].	The	 titres	 decreased	with	 the
course	 of	 the	 illness.	 A	 second	 patient	 with	 GBS	 who	 carried	 anti-GM1	 IgG	 antibodies	 was	 later
identified.	This	patient	also	had	antecedent	diarrhoea	and	pure	motor	weakness.	Nerve	conduction	studies
suggested	axonal	degeneration	in	motor	nerves,	but	no	demyelination.
The	 presence	 of	 watery	 diarrhoea	 prior	 to	 the	 illness	 in	 both	 patients	 provided	 the	 clue	 that	 a
microbial	 agent	 might	 be	 the	 trigger	 for	 the	 development	 of	 GBS.	 There	 had	 been	 a	 few	 reports	 of
association	of	GBS	with	diarrhoea	or	C.	jejuni	enteritis	[14,15].	Although	C.	jejuni	had	not	been	widely
recognized	 as	 an	 antecedent	 infectious	 agent	 of	GBS	 at	 that	 time,	 both	 our	 patients	were	 serologically
confirmed	 as	 having	had	 an	 antecedent	C.	 jejuni	 infection	 [4].	We	 reported	 the	 2	 patients	with	 axonal
GBS	following	C.	jejuni	enteritis	and	positive	anti-GM1	antibodies.	In	1999	the	Hopkins	group	extended
the	concept	by	showing	anti-GD1a	antibodies	and	axonal	GBS	associated	with	C.	jejuni	infection	[16].
The	Miller	Fisher	syndrome	(MFS)	is	characterized	by	ophthalmoplegia,	ataxia	and	areflexia	[17].	Its
link	to	GBS	is	strengthened	by	the	observation	that	some	MFS	patients	develop	profound	limb	weakness
typical	of	GBS	during	the	clinical	course	of	their	illness	[18].	Chiba	and	colleagues	identified	anti-GQ1b
IgG	antibodies	in	patients	with	MFS	[19],	thereby	linking	not	only	its	clinical	features	to	GBS	but	also	the
proposed	immune	mechanism.
Molecular	Mimicry
Yuki	N,	et	al.	A	bacterium	lipopolysaccharide	that	elicits	Guillain-Barré	syndrome	has	a
GM1	ganglioside-like	structure.	The	Journal	of	Experimental	Medicine,	1993;	Yuki	N,	et
al.	Molecular	mimicry	between	GQ1b	ganglioside	and	lipopolysaccharides	of
Campylobacter	jejuni	isolated	from	patients	with	Fisher’s	syndrome.	Annals	of	Neurology,
(1994)
Administration	 of	 bovine	 brain	 gangliosides	 (BBG)	 was	 widely	 used	 in	 Western	 Europe	 and	 South
America	 in	 the	 early	 1990s.	 Since	 our	 case	 report	 of	 an	 ALS-like	 disorder	 after	 ganglioside	 therapy
[20,21],	there	have	been	other	reports	of	patients	who	developed	GBS	after	ganglioside	administration	in
Italy	and	Spain	[22,23].	A	causal	association	between	ganglioside	injection	and	the	precipitation	of	GBS
was	inferred,	and	gangliosides	were	eventually	withdrawn	in	Italy	in	1993.
The	occurrence	of	GBS	in	association	with	ganglioside	administration	suggested	that	C.	jejuni	might
carry	ganglioside-like	structures.	LOS	constitutes	the	outer	membrane	of	C.	jejuni.	I	cultured	a	C.	 jejuni
strain	isolated	from	a	patient	with	GBS	who	was	positive	for	anti-GM1	IgG	antibodies.	I	extracted	LOS
using	 the	 hot	 phenol-water	 technique	 and	 discovered	 that	 rabbit	 anti-GM1	 antibodies	 and	 the	 cholera
toxin	B-subunit,	a	specific	ligand	for	GM1-oligosaccharide,	reacted	with	the	LOS,	as	well	as	GM1,	on
thin-layer	chromatogram	plates,	which	consisted	of	silica	beads	[24].	This	suggested	that	the	LOS	carried
a	GM1	epitope,	and	that	silica	bead	column	chromatography	might	be	helpful	in	the	purification	of	LOS
with	a	GM1	epitope.	The	LOS	was	 separated	by	column	chromatography,	 and	 fractions	were	obtained
that	 showed	 reactivity	 to	 rabbit	 anti-GM1	 antibodies	 and	 cholera	 toxin	 B-subunit.	 By	 gas-liquid
chromatography	mass	spectroscopy,	I	found	that	 the	purified	LOS	contained	D-galactose,	D-glucose,	N-
acetyl-D-galactosamine,	 N-acetyl-D-glucosamine	 and	 N-acetyl	 neuraminic	 acid,	 which	 are	 sugar
components	of	GM1	ganglioside.	1H	nuclear	magnetic	resonance	showed	that	the	terminal	tetrasaccharide
of	 the	purified	LOS	was	 identical	 to	 that	of	GM1	(Figure	49.1)	 [7].	The	bacterial	strain	also	carried	a
GD1a-like	LOS	[25].
As	 there	were	 reported	 cases	 of	MFS	 subsequent	 to	C.	 jejuni	 enteritis	 [26],	 I	 postulated	 that	 there
were	some	strains	of	C.	jejuni	that	had	the	GQ1b	epitope.	In	1993,	when	I	investigated	the	presence	of	the
GQ1b	epitope	 in	C.	 jejuni	 strains	 isolated	 from	patients	with	 enteritis,	 clinicians	 requested	me	 to	 test
anti-GQ1b	 antibodies	 in	 2	 patients	 with	 MFS	 from	 whom	 C.	 jejuni	 was	 isolated	 [27].	 I	 therefore
performed	 thin-layer	 chromatography	 immunostaining	 to	 show	 the	 presence	 of	 GQ1b-like	 LOS	 of	C.
jejuni	 from	 the	 patients	 using	 monoclonal	 anti-GQ1b	 antibody.	 In	 1994,	 we	 reported	 the	 results,
suggesting	 the	 existence	 of	 molecular	 mimicry	 between	 GQ1b	 and	 the	C.	 jejuni	 LOS	 [28].	 In	 1997,
Aspinall’s	group	demonstrated	 that	LOS	of	C.	 jejuni	 isolated	 from	 a	 patient	with	MFS	 carried	GD1c-
oligosacharride	(Figure	49.2)	[29].	In	collaboration	with	Gilbert,	we	were	also	able	to	demonstrate	that
C.	jejuni	isolated	from	patients	with	MFS	bore	GD1c-like	or	GT1a-like	LOS	mimicking	GQ1b	[6,30].
Epidemiological	Association
Rees	JH,	et	al.	Campylobacter	jejuni	infection	and	Guillain-Barré	syndrome.	The	New
England	Journal	of	Medicine,	1993
Hughes’	group	established	an	epidemiological	association	between	C.	jejuni	 infection	and	GBS	through
their	 prospective	 case-control	 study	 of	 96	 patients	 with	 GBS	 [3].	 Patients	 and	 controls	 were
systematically	examined	for	evidence	of	C.	jejuni	infection	and	a	recent	C.	jejuni	infection	was	noted	in
26%	of	the	patients	with	GBS,	compared	with	2%	of	the	household	controls	(a	member	of	the	patient’s
household)	and	1%	of	the	age-matched	hospital	controls.
Serological	evidence	of	C.	jejuni	infection	was	found	in	31%	of	201	patients	with	GBS	and	18%	of
65	patients	with	MFS	[31].	Between	2000	and	2003,	we	received	367	serum	samples	from	patients	with
MFS,	of	which	73	samples	with	paired	hospital	controls	were	available	for	further	analysis.	During	the
same	period,	we	received	1,814	serum	samples	from	patients	with	GBS,	and	73	samples	were	randomly
selected	as	disease	controls.	From	these	samples,	we	demonstrated	that	the	serologic	evidence	of	recent
C.	jejuni	(21%)	infection	was	more	common	in	patients	with	MFS	than	in	the	hospital	controls	[6].
Figure	49.1		Molecular	mimicry	as	a	cause	of	Guillain-Barré	syndrome
(A)	Molecular	mimicry	 exists	 between	 gangliosides	 (GM1	 and	GD1a)	 and	Campylobacter	 jejuni	 lipooligosaccharides	 (LOSs).
Infection	by	C.	jejuni	bearing	GM1-like	or	GD1a-like	LOSs	may	induce	the	production	of	anti-GM1	or	anti-GD1a	IgG	antibodies	in
certain	patients.	Modified	from	44	with	permission.
(B)	Myelinated	 axons	 are	 divided	 into	 4	 functional	 regions:	 the	 nodes	 of	 Ranvier,	 paranodes,	 juxtaparanodes	 and	 internodes.
Gangliosides	GM1	and	GD1a	are	strongly	expressed	at	the	nodes	of	Ranvier,	where	the	voltage-gated	sodium	(NaV)	channels	are
localized.	Contactin-associated	protein	 (Caspr)	and	voltage-gated	potassium	(KV)	 channels	are	present	at	 the	paranodes	and
juxtaparanodes,	 respectively.	Anti-GM1	or	anti-GD1a	 IgG	antibodies	bind	 to	 the	nodal	 axolemma,	 leading	 to	membrane	attack
complex	(MAC)	formation.	This	results	in	the	disappearance	of	NaV	clusters	at	the	nodes,	mislocalization	of	KV	clusters	at	 the
paranodes	and	the	detachment	of	paranodal	myelin,	which	can	lead	to	nerve-conduction	failure	and	muscle	weakness.	Axonal
degeneration	 may	 follow	 at	 a	 later	 stage.	 Macrophages	 subsequently	 invade	 from	 the	 nodes	 into	 the	 periaxonal	 space,
scavenging	the	injured	axons.	Modified	from	43	with	permission.
Figure	49.2		Bacterial	gene	polymorphism	to	determine	clinical	features	of	autoimmune	diseases
Campylobacter	sialyltransferase	cst-II,	N-acetylgalactosaminyltransferase	cgtA	and	galactosyltransferase	cgtB	are	instrumental
in	the	biosynthesis	of	LOS.	The	51st	amino	acid	of	cst-II	determines	its	enzymatic	activity.	cst-II	(Thr51)	produces	GM1-like	and
GD1a-like	LOSs,	whereas	cst-II	(Asn51)	synthesizes	GT1a-like,	GD1c-like	or	GD3-like	LOS,	which	mimics	GQ1b.	The	C.	jejuni
carrying	cst-II	(Thr51)	can	express	GM1-like	or	GD1a-like	LOS.	Infection	by	such	a	strain	may	induce	anti-GM1	or	anti-GD1a	IgG
antibodies.	The	auto-antibodies	bind	to	GM1	or	GD1a	expressed	on	the	motor	nerves	of	the	4	limbs,	causing	acute	motor	axonal
neuropathy.	In	contrast,	C.	jejuni	that	carries	cst-II	(Asn51)	expresses	GQ1b-mimicking	LOS.	Infection	by	these	C.	jejuni	strains
may	induce	anti-GQ1b	IgG	antibody	production.	The	anti-GQ1b	antibodies	bind	to	GQ1b	expressed	on	oculomotor	nerves	and
muscle	spindles	in	the	limbs,	leading	to	Miller	Fisher	syndrome.	Modified	from	43	with	permission.
Animal	Models
Yuki	N,	et	al.	Animal	model	of	axonal	Guillain-Barré	syndrome	induced	by	sensitization	with
GM1	ganglioside.	Annals	of	Neurology,	2001;	Yuki	N,	et	al.	Carbohydrate	mimicry
between	human	ganglioside	GM1	and	Campylobacter	jejuni	lipooligosaccharide	causes
Guillain-Barré	syndrome.	Proceedings	of	the	National	Academy	of	Sciences	of	the	United
States	of	America,	2004;	Goodfellow	JA,	et	al.	Overexpression	of	GD1a	ganglioside
sensitizes	motor	nerve	terminals	to	anti-GD1a	antibody-mediated	injury	in	a	model	of
acute	motor	axonal	neuropathy.	The	Journal	of	Neuroscience,	2005;	Susuki	K,	et	al.	Anti-
GM1	antibodies	cause	complement-mediated	disruption	of	sodium	channel	clusters	in
peripheral	motor	nerve	fibers.	The	Journal	of	Neuroscience,	2007
Kusunoki	and	colleagues	induced	acute	sensory	ataxic	neuropathy	by	repeated	sensitization	of	Japanese
white	 rabbits	 with	 0.5	 mg	 of	 GD1b	 together	 with	 keyhole	 limpet	 hemocyanin	 and	 complete	 Freund’s
adjuvant	[32].	I	postulated	that	when	we	inoculated	Japanese	white	rabbits	with	2.5	mg	of	a	BBG	mixture
(GM1	21%,	GD1a	40%,	GD1b	16%,	GT1b	19%;	Cronassial®)	according	to	their	protocol	[32],	at	least
some	 rabbits	 might	 develop	 flaccid	 paralysis	 or	 ataxia	 associated	 with	 anti-GD1a	 or	 anti-GD1b
antibodies	because	the	mixture	contained	0.5	mg	of	GM1,	1	mg	of	GD1a	or	0.4	mg	of	GD1b.
When	we	started	our	animal	experiments	in	1998,	I	was	very	sceptical	as	to	whether	the	rabbits	would
develop	 muscle	 weakness.	 Surprisingly,	 all	 13	 rabbits	 inoculated	 with	 the	 ganglioside	 mixture
(Cronassial®)	developed	 flaccid	paralysis	 [9].	Limb	weakness	progressed	 for	4	 to	13	days	 (median,	5
days)	after	onset,	indicating	acute	onset.	Some	of	the	rabbits	began	to	recover	spontaneously,	suggesting	a
monophasic	course	of	the	illness	as	shown	in	patients	with	GBS.	Unexpectedly,	all	the	diseased	rabbits
developed	high	titres	of	anti-GM1	IgG	antibodies,	but	not	anti-GD1a	antibodies.	The	antibody	titres	did
not	differ	before	and	after	the	disease	onset,	but	high	affinity	antibodies	were	detected	only	at	the	disease
onset	[33].	This	suggested	that	a	high	affinity	of	anti-GM1	antibodies	was	essential	for	the	development	of
the	disease.	We	started	 inoculating	rabbits	with	Sygen®	 (isolated	GM1)	when	a	 few	rabbits	developed
anti-GM1	 IgG	antibodies	 and	 acute	 flaccid	 paralysis	 [9].	Nine	 of	 11	 rabbits	 developed	 anti-GM1	 IgG
antibodies	 and	 acute	 flaccid	 paralysis.	 Pathological	 findings	 in	 the	 rabbit	 peripheral	 nerves	 were
predominantly	Wallerian-like	 degeneration	with	 neither	 lymphocytic	 infiltration	nor	 demyelination.	 IgG
was	deposited	at	 the	nodal	or	 intranodal	 axolemma	 in	 the	 spinal	 anterior	 roots.	Anterior	 spinal	nerves
showed	macrophage	 infiltration	 in	 the	 periaxonal	 space,	 but	 the	 surrounding	 myelin	 sheaths	 remained
almost	 intact	 [34].	 In	 addition	 to	 these	 pathological	 findings,	 neurophysiological	 findings	 also
corresponded	well	with	those	in	human	acute	motor	axonal	neuropathy	(AMAN),	an	axonal	form	of	GBS.
We	 repeatedly	 injected	 Japanese	 white	 rabbits	 with	 C.	 jejuni	 LOS	 isolated	 from	 a	 patient	 with
AMAN,	which	 consisted	 of	GM1-like	 and	GD1a-like	LOSs	 [6,8].	We	 started	 this	 experiment	 in	 1999
when	a	few	rabbits	developed	the	disease	by	sensitization	with	the	BBG	mixture.	First,	we	used	2.5	mg	of
C.	jejuni	LOS,	as	well	as	the	BBG	mixture	experiment.	Only	4	of	10	rabbits	developed	flaccid	paralysis,
suggesting	 that	 sensitization	had	 to	be	more	 frequent.	Next,	we	 sensitized	10	 rabbits	with	10	mg	of	C.
jejuni	 LOS,	 and	 all	 the	 rabbits	 developed	 flaccid	 paralysis.	 The	 diseased	 rabbits	 had	 anti-GM1	 IgG
antibodies,	 but	 not	 anti-GD1a	 antibodies.	 The	 pathological	 findings,	 compatible	 with	 the	 features	 of
human	 AMAN,	 were	 evidence	 that	 rabbits	 inoculated	 with	C.	 jejuni	 LOS	 constitute	 a	 valid	 AMAN
model.
I	postulated	that	anti-GM1	IgG	antibodies	block	voltage-gated	sodium	(NaV)	channels	at	the	nodes	of
Ranvier	 [35].	 Susuki	 and	 I	 began	 these	 series	 of	 experiments	 in	 2004.	We	 showed	 that	 in	 the	 spinal
anterior	 roots	 of	 AMAN	 rabbits,	 IgG	 antibodies	 bound	 to	 nodes	 of	 Ranvier,	 where	 GM1	was	 highly
expressed,	and	activated	complement,	resulting	in	the	formation	of	membrane	attack	complex	at	the	nodal
axolemma	 [36].	 NaV	 channel	 clusters	 disappeared	 at	 lengthened	 nodes	 with	 complement	 deposition.
There	 was	 paranodal	 detachment	 along	with	 nodal	 lengthening,	 which	was	 seen	 at	 the	 early	 phase	 in
patients	 with	 AMAN	 [37].	 These	 pathological	 changes	 are	 able	 to	 produce	 muscle	 weakness.
Complement	 deposition	was	 prominent	 at	 the	 acute	 progressive	 phase,	 but	 decreased	with	 the	 clinical
course	of	the	disease.
Willison’s	group	was	successful	in	producing	murine	models	of	axonal	GBS	by	the	passive	transfer	of
human	or	mice	anti-GM1	or	anti-GD1a	antibodies	 in	 the	presence	of	human	complement	[10,11].	Their
excellent	studies	provided	conclusive	evidence	of	the	pathogenic	roles	of	anti-ganglioside	antibodies	and
complement	in	the	development	of	axonal	GBS.
The	possible	pathogenesis	of	AMAN	subsequent	to	C.	jejuni	enteritis	are	shown	in	Figure	49.1:	 (A)
infection	by	C.	jejuni	bearing	GM1-like	or	GD1a-like	LOS	induces	the	production	of	anti-GM1	or	anti-
GD1a	IgG	antibodies	 [6,8];	 (B)	 these	autoantibodies	bind	 to	GM1	or	GD1a	at	 the	nodes	of	Ranvier	 in
peripheral	motor	nerves	[36];	(C)	bound	anti-GM1	or	anti-GD1a	IgG	antibodies	induce	local	complement
activation,	 resulting	 in	 the	 formation	 of	membrane	 attack	 complex;	 (D)	 the	 autoimmune	 attack	 disrupts
NaV	 channel	 clusters,	 producing	 muscle	 weakness	 at	 the	 early	 phase	 of	 illness.	 Axonal	 degeneration
subsequently	occurs.
Bacterial	Gene	Polymorphism	to	Determine	Clinical	Features	of
Autoimmune	Diseases
Koga	M,	et	al.	Campylobacter	gene	polymorphism	as	a	determinant	of	clinical	features	of
Guillain-Barré	syndrome.	Neurology,	2005
Ganglioside-like	LOSs	are	synthesized	by	sialyltransferase	cst-II,	N-acetylgalactosaminyltransferase	cgtA
and	galactosyltransferase	cgtB	[38].	LOS	biosynthesis	loci	have	been	divided	into	several	classes	based
on	gene	organization,	and	classes	A,	B	and	C	carry	cgtA,	cgtB,	and	cst-II,	and	 the	strains	belonging	 to
these	classes	could	express	ganglioside-like	LOSs	[39].	In	2003,	Gilbert	and	I	began	our	collaborative
work.	Most	isolates	from	GBS	and	MFS	patients	belonged	to	classes	A,	B	or	C,	and	the	frequency	was
significantly	higher	 than	 isolates	 from	patients	with	uncomplicated	enteritis	 [25].	 In	other	words,	 cgtA,
cgtB	and	cst-II	are	the	genes	responsible	for	the	development	of	peripheral	neuropathies.	In	contrast,	two-
thirds	of	enteritis	strains	belonged	to	the	classes,	and	they	did	not	always	induce	the	development	of	GBS.
This	suggested	that	host	factors	are	also	important	for	the	development	of	neuropathies	after	the	bacterial
infection.
In	2002,	Gilbert	and	colleagues	reported	that	cst-II	sialyltransferase	consists	of	291	amino	acids,	with
the	51st	determining	 its	enzymatic	activity	 [38].	Cst-II	 (Thr51)	has	only	α-2,3-sialyltransferase	 activity
(mono-functional)	and	produces	GM1-like	and	GD1a-like	LOSs	(Figure	49.2).	In	contrast,	cst-II	(Asn51)
has	 both	 α-2,3-	 and	 α-2,8-sialyltransferase	 activities	 (bi-functional),	 and	 synthesizes	 GT1a-like	 or
GD1c-like	LOSs,	mimicking	GQ1b.	When	I	read	their	paper,	I	postulated	that	C.	jejuni	isolates	from	GBS
had	cst-II	(Thr51)	and	that	the	isolates	from	MFS	had	cst-II	(Asn51).	Koga	and	I	began	experiments	using
the	 relevant	 isolates.	We	 found	 that	 neuropathic	 strains	 were	 more	 frequently	 found	 to	 have	 cst-II,	 in
particular	 cst-II	 (Thr51),	 than	 did	 enteritic	 ones	 (82%	 versus	 52%)	 [40],	 whereas	 strains	 with	 cst-II
(Thr51)	 had	 the	 GM1	 and	 GD1a	 epitopes,	 strains	 with	 cst-II	 (Asn51)	 regularly	 expressed	 the	 GQ1b
epitope.	The	presence	of	 these	bacterial	 epitopes	 in	neuropathic	patients	corresponded	 to	autoantibody
reactivity.	Patients	 infected	with	C.	 jejuni	 (cst-II	Asn51)	more	 often	were	 positive	 for	 anti-GQ1b	 IgG
antibodies	 and	had	ophthalmoparesis	 and	 ataxia.	 In	 contrast,	 patients	who	 had	C.	 jejuni	 (cst-II	 Thr51)
were	more	frequently	positive	for	anti-GM1	and	anti-GD1a	IgG	antibodies	and	had	limb	weakness.
Why	a	microbial	 infection	 leads	 to	 the	development	of	different	 autoimmune	diseases	has	yet	 to	be
clarified.	For	example,	 the	mechanism	of	how	group	A	streptococcal	 infection	 induces	acute	 rheumatic
fever	 in	 some	 patients	 and	 acute	 glomerulonephritis	 in	 others	 is	 unknown.	 The	mechanism	 of	 how	C.
jejuni	induces	GBS	in	some	patients	and	MFS	in	others,	however,	was	made	clear	by	our	findings.
The	molecular	pathogenesis	of	GBS	or	MFS	subsequent	to	C.	jejuni	enteritis	is	as	follows	(see	Figure
49.2):	C.	jejuni	strains	that	carry	cst-II	(Thr51)	express	GM1-like	or	GD1a-like	LOS	on	its	cell	surface
and	may	induce	anti-GM1	or	anti-GD1a	IgG	antibodies	in	some	infected	patients.	The	autoantibodies	bind
to	GM1	or	GD1a	expressed	on	 the	motor	nerves	of	 the	 limbs,	producing	AMAN.	In	contrast,	C.	 jejuni
strains	that	carry	cst-II	(Asn51)	expresses	GT1a-like	or	GD1c-like	LOS	on	its	cell	surface,	and	infection
by	 such	 a	 strain	may	 induce	 anti-GQ1b	 antibodies	 in	 some	patients.	The	 autoantibodies	 bind	 to	GQ1b
expressed	in	the	oculomotor	nerves	and	muscle	spindles	[41,42],	resulting	in	MFS.
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Predicting	Outcome	in	GBS
Christa	Walgaard
Introduction
A	neuromuscular	professor	in	Rotterdam	has	a	Mark	Twain	quote	pinned	to	the	wall	of	his	room,	which
states	 “It	 is	 difficult	 to	make	 predictions,	 especially	 about	 the	 future.”	The	 relevance	 of	 this	 statement
became	apparent	when	the	professor	and	I	were	trying	to	make	predictions	about	the	future	of	individual
patients	with	the	Guillain-Barré	syndrome	(GBS).	And	we	are	not	the	first	to	do	so;	in	the	last	100	years
much	hard	work	was	done	to	make	the	best	possible	prognostication	to	guide	patients	and	their	families.
And	 nowadays	 also	 their	 doctors	 to	 give	 the	 best	 suitable	 therapies,	 ultimately	 accomplishing
personalized	medicine.
Top	10
Guillain	G,	Barré	JA,	Strohl	A.	Sur	un	syndrome	de	radiculonévrite	avec	hyperalbuminose
du	liquide	céphalo-rachidien	sans	réaction	cellulaire.	Remarques	sur	les	caractères
cliniques	et	graphiques	des	réflexes	tendineux.	Bulletins	et	Mémoires	de	la	Société
médicale	des	Hôpitaux	de	Paris,	1916.
In	1916	the	3	founders	and	name-givers	of	the	Guillain-Barré	syndrome	described	a	flaccid	paralysis	in	2
formerly	healthy	soldiers	[1].	This	disease	entity	was	different	from	the	then	much-more-prevalent	cause
of	flaccid	paralysis,	polio	myelitis,	in	2	ways:	the	‘dissociation	albumin-cytologique’	and	the	much	better
prognosis.	The	authors	stated,	‘The	prognosis	does	not	appear	to	be	extremely	serious,	if	we	may	judge
from	 the	 course	 of	 the	 disease	 in	 our	 two	patients;	 the	 first	 had	 almost	 recovered	 and	 the	 second	was
improving	when	they	were	discharged	from	the	army’.	In	1936	Guillain	described	10	more	cases,	all	with
a	favourable	outcome	[2].	The	medical	journals	in	those	days	must	not	have	had	as	strict	regulations	on
maximum	word	counts	as	we	enjoy	nowadays,	as	Guillain	meticulously	describes	those	10	cases.	In	one
of	 those	 cases	 he	 makes	 probably	 the	 first	 of	 many	 predictions	 of	 outcome	 in	 a	 patient	 with	 GBS:
‘Although	physicians	who	had	examined	 the	patient	had	given	an	unfavourable	prognosis,	 I	predicted	a
favourable	outcome.’	In	those	first	decades	after	the	first	description	of	the	disease	the	outcome	looked
good	just	because	the	diagnosis	was	GBS	instead	of	polio	myelitis.
Pleasure	DE,	et	al.	The	prognosis	of	acute	polyradiculoneuritis.	Neurology,	1968.
At	that	time	they	were	in	such	a	way	convinced	that	the	prognosis	of	GBS	was	good,	that	patients	with	a
poor	prognosis	were	labelled	as	having	‘atypical	polyneuritis’.	Osler	and	Sidell	suggested	in	1960	that
the	 eponym	Guillain-Barré	 syndrome	 should	be	 applied	only	 to	patients	without	 atypical	 signs	 such	 as
incomplete	recovery	[3].	However,	in	1968,	Pleasure,	Lovelace	and	Duvoisin	described	a	cohort	of	49
patients	 and	 found	 no	 differences	 in	 the	 clinical	 picture	 between	 patients	 with	 GBS	 and	 ‘atypical
polyneuritis’	 as	 suggested	by	Osler	 and	Sidell	 [4].	They	 concluded	 that	 patients	with	GBS	can	 indeed
have	an	unfavourable	clinical	course	and	outcome,	probably	due	to	severe	demyelination	and	Wallerian
degeneration.
Eberle	E,	et	al.	Early	predictors	of	incomplete	recovery	in	children	with	Guillain-Barré
polyneuritis.	Journal	of	Pediatrics,	1975.
Surprisingly,	one	of	the	first	large	cohorts	analysed	to	find	predictors	of	outcome	included	only	children.
This	was	a	retrospective	study	of	47	children	admitted	to	a	rehabilitation	centre	between	1959	and	1972
[5].	 The	 children	were	 followed	 until	 full	 recovery	 or	 for	 at	 least	 3	 years	without	 full	 recovery.	 Full
recovery	was	defined	as	good	and	normal	strength	of	all	muscle	groups	(grading	scale:	zero,	trace,	poor,
fair,	good	and	normal)	in	the	first	3	years	after	GBS.	Thirty-six	children	(77%)	made	a	full	recovery,	but
all	 47	 children	 were	 ambulant	 after	 3	 years,	 even	 in	 the	 incomplete	 recovery	 group.	 Eberle	 and
colleagues	found	muscle	weakness	of	the	upper	and	lower	extremities,	absence	of	deep	tendon	reflexes	in
lower	extremities,	low	protein	level	in	cerebrospinal	fluid,	long	hospitalization	time	and	longer	time	from
maximal	weakness	until	beginning	of	 the	 improvement	as	significant	predictors	of	 incomplete	recovery.
This	last	predictor	was	seen	as	the	most	useful	clinical	predictor	and	plotted	in	a	graph	(Figure	50.1)	as	a
tool	for	clinicians.	They	concluded	that	prospective	studies	would	be	needed	to	further	investigate	their
findings.	In	hindsight	it	seems	likely	that	the	long	period	between	maximal	weakness	and	the	beginning	of
improvement	was	caused	by	axonal	damage.
Raman	PT,	Taori	GM.	Prognostic	significance	of	electrodiagnostic	studies	in	the	Guillain-
Barré	syndrome.	Journal	of	Neurology	Neurosurgery	and	Psychiatry,	1976.
Only	one	year	later	Raman	and	Taori	initiated	a	study	of	the	prognostic	significance	of	electrodiagnostic
studies	in	GBS,	the	first	to	suggest	that	axonal	damage	is	a	poor	prognostic	sign	[6].	They	found	striking
differences	 in	 prognosis	 between	 patients	 who	 had	 no	 fibrillation	 potentials	 (81%	 good	 prognosis),
indicating	pure	demyelinating	disease,	and	patients	with	fibrillation	potentials,	with	or	without	conduction
velocity	 abnormalities	 (32%	good	prognosis),	 indicating	 (secondary)	 axonal	damage.	Debate	 about	 the
optimal	timing	of	nerve	conduction	studies	and	the	phenomenon	of	switching	between	categories	is	still
ongoing.	However,	in	this	study	serial	nerve	conduction	studies	were	performed	biweekly	and	none	of	the
50	patients	showed	any	significant	alterations	from	the	category	originally	noted.
Figure	 50.1	 	 Probability	 of	 incomplete	 recovery	 versus	 time	 interval	 from	 maximum	 weakness	 to	 improvement	 (days).
Reproduced	with	permission	from	[5]
Winer	JB,	et	al.	Prognosis	in	Guillain-Barré	syndrome.	The	Lancet,	1985.
Winer	and	colleagues’	short	communication	of	only	2	pages	in	the	Lancet	in	1985	[7]	is	important,	as	it
was	 the	 first	 paper	 that	 analysed	 prospectively	 collected	 trial	 data	 (on	 prednisolone	 [8]	 and	 plasma
exchange	[9])	of	71	patients	to	discover	early	predictors	of	poor	prognosis.	Mechanical	ventilation,	time
to	 improvement	 of	 more	 than	 1	 month	 and	 a	 plateau	 time	 of	 more	 than	 3	 weeks	 were	 identified	 as
significant	 predictors	 of	 poor	 outcome	 (restricted	 in	manual	 activities	 at	 12	months;	 see	 Table	 50.1).
Also,	 patients	with	 a	 poor	 outcome	had	 a	 higher	mean	peak	deficit	 on	 a	 functional	 scale	 and	 a	 longer
average	time	to	onset	of	improvement.
Winer	JB,	et	al.	A	prospective	study	of	acute	idiopathic	neuropathy.	I.	Clinical	features	and
their	prognostic	value.	Journal	of	Neurology	Neurosurgery	and	Psychiatry,	1988.
After	 their	analysis	of	 trial	data,	Winer	and	colleagues	set	up	a	prospective	cohort	 study	 to	answer	all
kinds	of	questions	about	GBS,	including	identifying	predictors	of	outcome	[10].	This	study	was	published
as	 a	 triptych	 in	 May	 1988.	 One	 hundred	 patients	 with	 GBS	 in	 southeast	 England	 were	 included	 and
followed	for	12	months.	As	outcome	measures	Winer	and	colleagues	used	being	bed-bound	at	3	months
and	the	inability	to	undertake	manual	work	after	one	year.	The	4	most	discriminating	variables	are	shown
in	Table	50.2.	This	was	the	first	study	to	find	age	as	a	significant	predictor	of	poor	outcome,	which	can	be
explained	by	different	cut-offs	used	in	former	studies.	After	this	study	many	more	studies	were	published,
confirming	 the	 following	 factors	 as	 predictors	 for	 poor	 outcome:	 age,	 clinical	 severity,	 diarrhoea	 and
axonal	features	in	nerve	conduction	studies.
Table	50.1		Significance	of	possible	predictive	factors.	Reproduced	with	permission	from	[7]
Table	50.2		Relative	risks	of	poor	outcome	at	12	months	attributable	to	the	4	most	discriminating	variables.	Reproduced	with
permission	from	[7]
van	Koningsveld	R,	et	al.	A	clinical	prognostic	scoring	system	for	Guillain-Barré	syndrome.
The	Lancet	Neurology,	2007
In	 this	 landmark	study,	van	Koningsveld	and	colleagues	developed	a	simple	clinical	prognostic	scoring
system	 for	 use	 in	 clinical	 practice,	which	 combined	 different	 statistical	 significant	 predictors	 for	 poor
outcome	after	6	months	using	prospectively	collected	trial	data	(Table	50.3	and	Figure	50.2)	[11].
Kuitwaard	K,	et	al.	Pharmacokinetics	of	intravenous	immunoglobulin	and	outcome	in
Guillain-Barré	syndrome.	Annals	of	Neurology,	2009.
Immune	 therapy	 with	 IVIg	 and	 plasmapheresis	 undoubtedly	 improved	 the	 prognosis	 of	 GBS	 patients;
however,	not	all	patients	do	well	after	therapy.	Kuitwaard	and	colleagues	searched	for	an	explanation	and
found	 that	 there	 is	 a	 large	 variability	 in	 IgG	 rise	 after	 IVIg	 treatment	 [12].	 A	 multivariate	 analysis,
correcting	for	known	prognostic	factors,	indicated	that	a	low	rise	in	serum	IgG	after	IVIg	therapy	was	an
independent	 predictor	 for	 poor	 outcome.	This	may	 suggest	 that	 some	 patients	 need	 a	 higher	 dosage	 of
IVIg.	 Confirmation	 of	 this	 finding	would	 be	 a	 first	 step	 towards	 personalized	medicine	 in	 GBS;	 IVIg
dosage	 can	 be	 tailored	 individually	 according	 to	 serum	 IgG	 rise.	 In	 the	 ongoing	 randomized	 placebo-
controlled	trial	 to	 the	effect	of	a	second	IVIg	dosage	in	GBS	patients	with	a	poor	prognosis	(SID-GBS
trial)	this	will	be	tested.
Table	50.3		The	Erasmus	GBS	outcome	score.	Reproduced	with	permission	from	[11]
Figure	50.2	 	Predicted	 fraction	of	 patients	unable	 to	walk	 independently	at	 6	months	after	 randomization	on	 the	basis	of	 the
Erasmus	GBS	outcome	score	(n	=	762).	Vertical	bars	indicate	95%	CI.	Point	sizes	proportionate	to	the	number	of	patients	with	a
specific	 score.	 The	 probability	 of	 not	 walking	 independently	 at	 6	 months	 is	 given	 by	 the	 equation	 1/(1+exp[8.2-1.4xEGOS]).
Reproduced	with	permission	from	[11]
Walgaard	C,	et	al.	Prediction	of	respiratory	insufficiency	in	Guillain-Barré	syndrome.
Annals	of	Neurology,	2010.
The	previously	described	studies	all	tried	to	predict	clinical	outcome	in	terms	of	functional	outcome	after
a	 longer	 period	 of	 time.	 In	 this	 study	Walgaard	 and	 colleagues	 constructed	 a	 simple	 clinical	model	 to
predict	 respiratory	 insufficiency;	 the	model	 can	be	 applied	 at	 hospital	 admission	 and	 is	 therefore	very
useful	in	clinical	practice	[13]	(Table	50.4).	Patients	with	a	high	risk	of	respiratory	insufficiency	need	to
be	monitored	closely,	possibly	in	an	intensive	care	unit,	to	take	precautions	when	the	need	for	mechanical
ventilation	 emerges.	 By	 now	 this	 model	 is	 used	 in	 many	 countries	 and	 included	 in	 many	 clinical
guidelines	on	the	management	of	GBS	patients.
Fourrier	F,	et	al.	A	simple	functional	marker	to	predict	the	need	for	prolonged	mechanical
ventilation	in	patients	with	Guillain-Barré	syndrome.	Critical	Care,	2011
The	duration	of	mechanical	ventilation	varies	widely	in	GBS	patients,	ranging	from	a	few	days	to	months
and	 even	 years.	 When	 a	 long	 duration	 of	 mechanical	 ventilation	 is	 expected,	 tracheotomy	 should	 be
considered.	Fourrier	and	colleagues	analysed	40	mechanically	ventilated	GBS	patients	and	found	that	the
lack	 of	 foot	 flexion	 after	 immunotherapy	 combined	 with	 sciatic	 motor	 conduction	 block	 is	 strongly
predictive	of	prolonged	mechanical	ventilation	and	tracheotomy	should	be	considered	[14].
Future	Perspectives
In	the	last	100	years	a	lot	has	been	learned	about	the	prognosis	of	GBS	patients	and	it	is	now	possible	to
predict	long-term	outcome	and	other	sequelae	of	the	disease	quite	well	in	general	perspectives.	However,
much	is	not	known	or	not	confirmed	yet.	Patients	and	their	families	have	a	lot	of	questions	(Will	I	get	rid
of	this	awful	tiredness?	When	will	I	be	able	to	work	again?)	that	are	not	easy	to	answer	despite	all	the
knowledge	we	have	gathered,	nor	is	it	possible	to	tailor	treatment	personally	for	individual	patients.	So
Mark	 Twain	 is	 still	 right	 in	 his	 quote	 and	 inspires	 professors	 today	 to	 conduct	 large	 studies.	 The
International	 GBS	 Outcome	 Study	 (IGOS),	 a	 large	 international	 prospective	 study	 set	 up	 by	 the
International	Neuropathy	Consortium	included	>	1,000	GBS	patients	worldwide	(www.gbsstudies.org).
Final	goals	of	the	IGOS	are	to	be	able	to	better	inform	patients	and	relatives	about	the	prognosis	of	GBS,
to	 understand	 the	mechanism	of	 disease	 progression	 and	 recovery	 and	 to	 conduct	 selective	 therapeutic
trials	to	improve	outcome	in	patients	with	poor	prognosis.
Table	50.4		Erasmus	GBS	Respiratory	Insufficiency	Score	(EGRIS)
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Outcome	Measures	in	Guillain-Barré	Syndrome:
From	a	Plummer’s	Tool	to	Interval-Based	Metrics
Ingemar	S.J.	Merkies,	Mariëlle	H.J.	Pruppers	and	Catharina	G.	Faber
Introduction
Change	has	a	considerable	psychological	impact	on	the	human	mind
To	the	fearful	ones	it	is	threatening	because	it	means	that	things	may	get	worse	…
To	the	hopeful	it	is	encouraging	because	things	may	get	better	…
To	the	confident	it	is	inspiring	because	the	challenge	exists	to	make	things	better	…
Whitney	Young,	1921–1971
In	a	recent	paper	 it	was	stated	 that	 the	development	of	outcome	measures	 in	 inflammatory	neuropathies
has	 received	 little	 attention	when	 compared	 to	 the	 efforts	 taken	 in	 understanding	of	 the	many	 facets	 of
inflammatory	 neuropathies	 [1].	 Capturing	 the	 history	 of	 scoring	 in	 neurology	 brings	 us	 to	 Dr	 Henry
Plummer,	 who	 developed	 an	 outcome	 measure	 to	 ‘objectively	 and	 reliably’	 measure	 neuromuscular
weakness	in	patients	[2].	It	is	surprising	to	see	that	this	tool	is	still	broadly	being	used.	Plummer’s	idea
could	presumably	be	considered	as	a	strong	geological	phenomenon	resembling	a	monolith,	such	as	the
Rock	of	Gibraltar.	We	can	imagine	Dr	Plummer	being	very	proud	that	his	idea,	captured	in	its	beauty	of
simplicity,	went	‘viral’	decades	before	the	Internet	was	launched.
It	is	also	amazing	to	note	that	we	as	‘modern’	physicians	are	still	stuck	in	Plummer’s	non-algorithmic
way	of	describing	ordinal-based	observations,	despite	 the	known	constraints	of	ordinal-based	data.	We
still	consider	the	findings	at	neurological	examination	as	real	measurements,	which	in	essence	they	are	not
[3,4,5].	 ‘Quantitative’	 (e.g.	 neurological)	 observations	 are	 based	 on	 counting	 observed	 events,	 while
meaningful	measurements	 are	 based	 on	 the	 arithmetical	 properties	 of	 interval	 or	 ratio	measures	 [3,6].
Observations,	like	muscle	strength	assessment	at	bedside	using	Plummer’s	modified	tool,	provide	a	good
description	of	the	clinical	question	of	interest.	The	problem	arises	when	we	create	sum	scores	from	these
observations,	 treating	 these	 scores	 as	 linear,	 and	 make	 assumptions	 from	 the	 findings	 [4,7].	 We,	 as
physicians,	tend	to	hold	on	to	the	‘known	truth’	and	provide	information	regarding	‘the	best	way’	to	assess
clinical	changes	 in	a	particular	 illness	of	 interest,	 thereby	assuming,	often	 incorrectly,	 that	we	have	 the
proper	 knowledge	 to	 do	 so	 [8].	What	 we	 ‘know’	 often	 tends	 to	 limit	 our	 ability	 to	 look	 at	 the	 same
construct	from	a	different	perspective.	We	irrationally	apply	fixed	decision-making	to	our	use	of	outcome
measures	 in	 the	 belief	 that	 what	 we	 ‘know’	 reflects	 real	 ‘knowledge’.	 And	 yet	 that	 belief	 is	 not
necessarily	‘true’	[9].
In	the	following,	we	describe	eight	papers	that	reflect	the	evolution	of	outcome	measures	assessment
in	Guillain-Barré	syndrome	(GBS),	highlighting	briefly	their	content,	main	strengths	and	weaknesses.
Dyck	PJ,	et	al.	History	of	standard	scoring,	notation,	and	summation	of
neuromuscular	signs.	Journal	of	the	Peripheral	Nervous	System,	2005
This	is	a	must-read	‘historical	essay’	for	all	researchers	in	the	field	of	inflammatory	neuropathies	and	for
neurologists	 in	 general	 [2].	 The	 history	 of	 scoring	 neurological	 observations	 like	 muscle	 weakness,
sensory	deficit,	and	tendon	reflexes	are	being	highlighted	in	an	elegant	way	in	this	paper,	starting	from	the
19th	century	when	Mitchel	and	Lewis	initiated	the	practice	of	alphanumeric	scoring	of	neurological	signs
[10].	 The	 historical	 links	 between	 Plummer’s	 tool,	 the	 introduction	 of	 the	Medical	 Research	 Council
(MRC)	grading	system	and	the	motor	subset	of	the	neurological	impairment	scoring	(NIS)	system	are	also
addressed.	The	strength	of	this	paper	is	captured	in	the	historical	findings	which	shaped	our	neurological
observations	of	today	and	suggesting	standardisation	of	the	various	parts	to	increase	consistency,	as	was
recently	demonstrated	in	an	additional	paper	[11].
Its	weakness	 relates	 to	 the	 relatively	 ‘unknown’.	As	 an	 example,	 the	NIS,	 introduced	 in	 1991,	 is	 a
composite	 score	 of	 various	 neurological	 observations	 such	 as	 muscle	 weakness,	 sensory	 deficit	 and
changes	 in	 tendon	 reflexes,	 and	 has	 been	 the	 primary	 outcome	 measure	 in	 a	 large	 number	 of
neuromuscular	 studies	 [12,13].	Despite	 its	 broad	 use,	 the	 obtained	 scores	 from	 the	NIS	 are	 used	 as	 if
these	 observations	 represent	 a	 ruler	with	 a	 fixed	 unit,	which	 is	 highly	 unlikely.	Others	 have	 suggested
using	great	caution	when	 interpreting	changes	 in	 scores	coming	 from	ordinal-based	scales	 like	 the	NIS
[14,4,3].	 There	 is	 a	 risk	 of	 drawing	 incorrect	 inferences	 using	 ordinal-based	 composite	 measures:
positive	trials	may	be	falsely	positive	and	as	a	consequence	we	may	expose	patients	to	interventions	that
might	be	harmful,	and	negative	trials	might	be	falsely	negative,	denying	proper	therapy	to	patients	[3,14].
These	methodological	inconsistencies	as	part	of	modern	scientific	assessments	are	not	addressed	in	this
paper	and	will	be	the	focus	throughout	this	chapter.
Hughes	RA,	et	al.	Controlled	trial	prednisolone	in	acute
polyneuropathy.	The	Lancet,	1978
This	is	the	first	randomized	trial	of	prednisolone	versus	placebo	in	patients	with	GBS	[15].	A	total	of	40
patients	 entered	 the	 trial	 and	 the	 primary	 outcome	 measure,	 the	 Functional-score	 was	 introduced	 that
ranged	from	0	(healthy)	to	6	(dead).	The	authors	concluded	that	steroid	treatment	is	not	beneficial	and	can
even	 be	 detrimental	 in	 GBS.	 The	 functional	 score	 (F-score),	 a	 ranked	 ordinal-based	 scale,	 has	 been
slightly	modified	through	the	years,	introducing	the	ability	to	walk	5	or	10	meters	and	was	later	named	the
GBS-disability	 score.	 This	 score	was	 used	 in	 subsequent	 trials	 in	GBS	 as	 the	 primary	 outcome:	 only
patients	who	were	not	able	to	walk	5	to	10	meters	independently	were	eligible	for	randomization	and	the
primary	objective	was	often	addressed	as	the	proportion	of	patients	that	improved	one	grade	or	more	on
the	GBS-disability	score,	thus	reflecting	the	ability	to	walk	5	to	10	meters	independently	[16,17,18].	In
the	 1984	 trial,	 Greenwood	 and	 colleagues	 stated	 the	 F-scores	 “were	 easy	 to	 assess	 and	 not	 usually
subjected	to	observer	variability”	[16].
Simplification	of	assessment	may	indeed	enhance	consistency,	and	the	GBS-disability	score	has	also
been	incorporated	in	prognostic	models	providing	evidence	for	‘good	recovery’	at	the	six-month	follow-
up	[19].	However,	in	a	recently	presented	study	as	part	of	the	Peripheral	Neuropathy	Outcome	Measures
Standardisation	Study	(PeriNomS),	it	was	demonstrated	that	having	the	ability	to	walk	independently	did
not	adequately	reflect	the	full	scope	of	activity	limitations	and	participation	restrictions	as	perceived	by
patients	 using	 the	 inflammatory	 Rasch-built	 overall	 disability	 scale	 (I-RODS),	 an	 interval	 ruler	 that
assesses	a	larger	array	of	functionality	[20,21].	The	patients	with	GBS	may	indeed	improve	to	the	ability
of	walking	5	to	10	meters	independently,	thus	‘doing	better’,	but	they	are	not	necessarily	doing	well	[22].
This	observation	implies	that,	in	performing	randomized	trials	including	only	those	patients	who	are	not
able	to	walk	independently,	we	might	bypass	those	who	still	experience	substantial	functional	limitations
despite	their	ability	to	walk	independently.
Kleyweg	RP,	et	al.	Interobserver	agreement	in	the	assessment	of
muscle	strength	and	functional	abilities	in	Guillain-Barré	syndrome.
Muscle	&	Nerve,	1991
In	 this	 study,	 Kleyweg	 and	 colleagues	 state	 that	 the	 level	 of	 interobserver	 agreement	 using	 the	 GBS-
disability	score	“is	not	known	and	that	this	method	seems	to	be	insensitive	when	applied	to	bedridden	and
artificially	ventilated	patients”	[23].	Therefore,	they	developed	an	additional	score,	the	MRC	sum	score,
which	ranges	from	0	(total	paralysis)	to	60	(normal).	The	authors	reported	kappa	coefficients	that	were
“almost	perfect”	and	also	analysed	the	range	of	MRC	sum	score	in	relation	to	the	GBS-disability	scores.
The	results	showed	functional	groups	1–3	having	limited	variation	in	their	MRC	sum	scores,	whereas	in
functional	groups	4	and	5,	 the	MRC	sum	score	ranged	from	0	 to	55.	Deterioration	as	well	as	 recovery
was	better	monitored	by	the	MRC	sum	scores.
Since	then,	the	MRC	sum	score	has	been	used	in	several	trials	in	GBS	and	has	been	incorporated	as
part	of	the	daily	routine	examination.	However,	there	are	severe	methodological	limitations	to	the	use	of	a
composite	measure	like	the	MRC	sum	score:	the	MRC	grades,	introduced	in	1943,	are	ordinal-based	and
creating	such	a	sum	score	only	reflects	counting	observed	events	rather	than	creating	a	ruler	with	a	fixed
unit,	 thus	having	no	 intrinsic	numerical	value	[24].	Hence,	 this	brings	us	back	 to	 the	concept	of	 type	of
data	and	how	 to	deal	with	 these	 [5].	This	will	be	 thoroughly	discussed	 in	 the	 section	about	Vanhoutte,
Faber,	Merkies	and	the	PeriNomS	study	group	article,	below.
Vanhoutte	EK,	et	al.	Modifying	the	Medical	Research	Council	grading
system	through	Rasch	analyses.	Brain,	2012
The	MRC	 grading	 system	 is	 the	most	 commonly	 used	method	 of	 evaluating	muscle	 strength	 clinically
[2,24].	Despite	 the	power	of	 its	simplicity,	with	great	 reliability	scores	 reported,	 this	method	has	been
criticized	due	to	the	unequal	width	of	its	ordinal	constructed	categories.	In	particular,	the	inequality	of	the
MRC	grades	(grades	1,	2	and	3	being	too	narrow,	and	4	being	too	broad)	has	been	extensively	discussed
by	 comparison	 with	 a	 dynamometer	 (data	 at	 the	 ratio	 level)	 for	 assessing	 strength	 [25,26,27,28,29].
Attempts	to	modify	the	scale	even	further	have	been	reported	[26,30,31,32].	The	2012	study	by	Vanhoutte
and	 colleagues	 [25]	 investigated	 whether	 clinicians	 in	 the	 neuromuscular	 field	 could	 properly
differentiate	 between	 patients	 with	 various	 neuromuscular	 disorders	 and	 degrees	 of	 muscle	 weakness
using	 a	 Rasch	 method	 [33].	 The	 results	 demonstrated	 disordered	 thresholds	 in	 80%	 of	 the	 muscles
examined	according	to	the	MRC	grades	in	1,065	patients	(n	=	480	had	GBS)	[34,35].	Physicians	(whether
senior	experts	or	residents)	were	unable	to	differentiate	between	the	grades	1	through	4.	Most	thresholds
were	restored	after	rescoring	the	original	6	response	options	to	4	categories.	The	MRC	grading	system,
although	in	use	for	7	decades,	failed	to	meet	Rasch	model’s	expectations.	A	modification	to	a	4	response
categories	(0:	paralysis,	1:	severe	weakness,	2:	slight	weakness,	3:	normal	strength)	was	suggested.	This
paper	has	attracted	a	 lot	of	 arguments	and	 led	 to	quite	a	bit	of	discomfort	 among	physicians,	 since	 the
meaning	of	the	original	MRC	grading	system	has	been	blunted	through	‘Raschification’,	leading	to	a	less
significant	meaning	[1].
Merkies	IS,	Faber	CG.	Fatigue	in	immune-mediated	neuropathies.
Neuromuscular	Disorder,	2012
Examining	residual	deficits	and	improvement	in	GBS	was	generally	driven	by	a	need	to	determine	muscle
weakness	and	 sensory	deficit,	 and	hardly	any	attention	was	given	 to	being	 fatigued	 [36].	 In	 this	paper,
Merkies	and	Faber	systematically	examine	fatigue	in	113	patients	with	inflammatory	neuropathy	(n	=	83
had	GBS)	and	compare	them	to	age-	and	gender-matched	controls	[37].	‘Severe’	fatigue	was	present	in
80%	 of	 the	 patients,	 and	 these	 findings	 were	 not	 related	 to	 general	 strength,	 sensory	 deficits,	 GBS
disability	score	and	duration	of	symptoms.	This	paper	has	taught	us	that	there	is	more	to	GBS	than	looking
at	strength,	sensation	and	tendon	reflexes	alone.	Fatigue	turned	out	to	be	a	major	symptom	in	patients	with
immune-mediated	polyneuropathies	and	it	may	persist	for	years	after	apparent	recovery	[37].	Since	this
publication,	 attempts	 were	 have	 been	 made	 to	 reduce	 fatigue	 in	 GBS,	 with	 only	 marginal	 success
[38,39,40].
From	a	clinimetric	point	of	view,	the	fatigue	severity	scale	(FSS),	another	composite	measure	with	7
Likert-type	 of	 response	 options	 per	 item,	 was	 used	 for	 the	 assessment	 of	 fatigue	 [41].	 Good	 internal
consistency,	significant	 reliability	and	validity	were	 reported.	However,	 the	composite	9-item	FSS	had
the	 same	 problems	 as	 the	 MRC	 sum	 score	 and	 did	 not	 meet	 the	 Rasch	 model’s	 expectations	 [42].
Disordered	thresholds	were	particularly	seen	in	all	 items	and	were	systematically	rescored	(see	Figure
51.1)	[35].	The	final	interval	Rasch-modified	FSS	consisted	of	7	items	with	4	response	options	per	item,
which	also	reflected	the	maximum	ability	of	adults	to	discriminate	among	response	categories	[43].
Figure	 51.1	 	 Example	 illustrating	 disordered	 threshold	 in	 item	 number	 7	 of	 the	 FSS	 in	 patients	 with	 immune-mediated
polyneuropathies	and	its	response	options	being	rescored.	FSS	=	fatigue	severity	scale.	Item	number	7	=	Fatigue	interferes	with
carrying	out	certain	duties/responsibilities.	The	top	graph	shows	the	 inability	of	patients	 to	discriminate	among	the	7	response
options	 using	Rasch	 analyses.	 The	 bottom	 graph	 illustrates	 the	 rescoring	 of	 the	 response	 options,	 hereby	 creating	 an	 ideal
picture	of	an	ordered	threshold.	Reproduced	with	permission	from	[20].
van	Nes	SI,	et	al.	Rasch-built	Overall	Disability	Scale	(R-ODS)	for
immune-mediated	peripheral	neuropathies.	Neurology,	2011
The	 van	Nes	 and	 colleagues’	 E-ODS	 study	 presents	 the	 development	 of	 a	 new	 scale	 based	 on	Rasch
methodology	that	challenges	the	outcome	measurement	belief	we	have	acknowledged	for	decades	[1,33].
The	paper	also	aims	to	teach	the	basic	principles	of	types	of	data	and	their	requirements,	and	highlights
the	 steps	 needed	 to	 transform	 ordinal-obtained	 data	 into	 interval	measures	 using	 the	 Rasch	 technique,
aiming	to	simplify	its	mathematical	background	to	more	digestible	pieces.	A	comprehensive	educational
paper	 on	 Rasch’s	 background,	 specifically	 for	 neurologists,	 was	 also	 recently	 published	 [44].	 The
inflammatory	RODS	(I-RODS)	is	the	first	disease-specific	interval	measure	constructed	for	patients	with
inflammatory	neuropathies.	 I-RODS	was	built	 after	 completion	of	 its	 preliminary	 form	by	294	patients
(174	with	GBS),	hence	capturing	and	centralizing	the	voice	of	patients	and	fulfilling	all	the	Rasch	model
expectations,	including	high	validity	and	reliability	scores.	Through	comparative	responsiveness	studies,
the	PeriNomS	study	group	subsequently	succeeded	in	demonstrating	the	superiority	of	the	I-RODS	over
the	ordinal-based	outcome	measures	used	thus	far	in	inflammatory	neuropathies	[45].	Despite	these	steps
forward,	I-RODS	needs	further	evaluation,	particularly	regarding	its	cross-cultural	validity.
Vanhoutte	EK,	et	al.	196th	ENMC	international	workshop:	Outcome
measures	in	inflammatory	peripheral	neuropathies.	Neuromuscular
Disorder,	2013
At	 the	 3rd	European	Neuromuscular	Centre	 (ENMC)	workshop	 the	PeriNomS	 study	group	produced	 a
paper	on	outcome	measures	in	inflammatory	neuropathies	[46,47,48].	In	this	workshop,	20	neuromuscular
researchers	from	various	countries	and	a	patient	representative	of	the	GBS	CIDP	Foundation	International
discussed	the	longitudinally	obtained	responsiveness	results	for	selected	outcome	measures	comparison
and	strove	for	consensus	on	a	specific	core	set	of	scales	 for	 future	clinical	studies	 in	various	forms	of
inflammatory	 neuropathies.	 The	 workshop	 highlighted	 themes	 like	 the	 historical	 background	 of
assessment,	 various	 trial	 design	 aspects,	 traditional	 versus	 modern	 requirements	 for	 evaluation	 and
construction	 of	 (new)	 outcome	 measures	 and	 the	 concept	 of	 minimum	 clinically	 important	 difference
(MCID).	Finally,	all	serially	obtained	comparative	data	were	presented.
Recommendations	were	ultimately	provided:	for	future	trials	in	GBS,	the	consensus	was	to	adopt	the
I-RODS	 as	 the	 primary	 outcome,	 since	 this	 outcome	 measure	 has	 demonstrated	 significantly	 higher
(heuristic	 and	 statistical	MCID	 related	 to	 varying	 standard	 errors	 (SE)	 across	 the	 metric;	MCID-SE)
responsiveness.	In	addition,	the	following	outcome	measures	were	suggested	as	part	of	the	minimum	core
set	of	scales	for	future	GBS	studies:	grip	strength	(Martin	Vigorimeter),	the	Rasch-transformed	modified
INCAT	 sensory	 sum	 score,	 being	 ventilated	 (yes/no),	 duration	 of	 respiratory	 ventilation,	 and	 the	GBS
disability	scale	(for	historical	purposes).	Recommendations	to	also	focus	on	pain	and	fatigue	were	given.
Measuring	strength	at	bedside	needed	further	exploration,	since	there	was	no	consensus	on	how,	and	if,
strength	should	be	measured.
Vanhoutte	EK,	et	al.	Rasch-ionale	for	neurologists.	Journal	of	the
Peripheral	Nervous	System,	2015
Various	educational	papers	have	been	written	on	 the	Rasch	method	some	of	which	are	 referred	 to	here
[49,50].	We	strongly	recommend	physicians	in	the	research	field	of	GBS	read	these	papers	as	well	as	the
recently	published	 “Rasch-ionale	 for	 neurologists”	 [44].	 In	 the	 latter	 paper,	 the	PeriNomS	 study	group
aimed	to	systematically	address	the	concept	of	types	of	scales	based	on	types	of	data	(nominal,	ordinal,
interval,	 ratio)	 collected,	 discussing	 differences	 between	 classical	 versus	 modern	 test	 theories,
emphasizing	the	(dis)advantages	of	both	streams,	highlighting	and	simplifying	the	various	steps	needed	in
the	 evaluation	 and	 construction	 of	 (new)	 outcome	 measures	 using	 the	 Rasch	 method,	 and	 striving	 to
increase	the	knowledge	and	utility	of	this	technique.	The	background	of	the	Rasch	modelling	is	discussed,
providing	 simple	 graphical	 examples	 to	 improve	 its	 understanding.	 In	 addition,	 various	 steps	 are
addressed	 like	 statistical	 model	 fit	 requirements,	 having	 (or	 not)	 ordered	 thresholds,	 differential	 item
functioning,	 local	 dependency,	 uni-dimensionality,	 and	 other	 requirements	 like	 items’	 weights	 and
persons’	location	reliability,	as	well	as	various	definitions	of	being	a	responder,	emphasizing	the	use	of
MCID-SE.	All	 these	 steps	 are	graphically	 explained,	highlighting	potential	 pitfalls	 and	ways	 to	handle
and	improve	the	data.	It	is	argued	that	Rasch-built	outcome	measures	should	be	used	for	future	studies	in
neuromuscular	 disorders	 and	 their	 method	 of	 construction	 could	 easily	 be	 extrapolated	 to	 other
neurological	illnesses.
Epilogue
Future	studies	embracing	the	unmet	needs	highlighted	by	the	PeriNomS	group	should	be	imbedded	in	the
ongoing	 registries	 in	 GBS	 and	 other	 inflammatory	 neuropathies.	 Validation	 of	 new	 outcome	measures
using	 larger	 samples	 of	 collected	 data	 from	 independent	 cohorts,	 potential	 relation	 to	 biomarkers,
development	of	new	prognostic	models	to	predict	clinical	course,	and	examining	cross-cultural	validation
of	 selected	 outcome	 measures	 like	 the	 I-RODS	 are	 just	 some	 of	 the	 essentials	 that	 require	 further
investigation.	We	believe	that	the	lessons	learned,	particularly	from	the	PeriNomS	studies,	should	help	us
to	 utilize	 and	 focus	 more	 on	 outcome	 measures	 that	 are	 preferably	 at	 the	 interval	 and	 ratio	 level	 of
assessment.
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Introduction
Guillain-Barré	 Syndrome	 (GBS)	 or	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP)	 is	 a
monophasic	immune-mediated	disorder	due	to	inflammation	of	peripheral	nerves	and	nerve	roots	[1].	It
presents	 as	 an	 evolving	 sensorimotor	 polyneuropathy	 of	 varying	 severity,	 which	 leads	 to	 rapidly
developing	motor	deficits	(symmetrical	ascending	paralysis),	autonomic	dysfunction,	sensory	deficits	and
respiratory	 failure	 [2,3,4].	 The	 annual	 incidence	 is	 estimated	 to	 be	 1–2	 per	 100,000	 worldwide	 and
affects	both	sexes	equally	[5,6].	It	can	occur	at	any	age,	but	has	a	reported	preponderance	between	ages
30	 and	 50	 (approximately	 30%	 of	 cases	 are	 under	 20	 years	 old)	 [7,8].	 GBS	 can	 be	 described	 as	 a
heterogeneous	 syndrome	 with	 several	 variants	 and	 as	 a	 collection	 of	 clinical	 syndromes,	 the	 most
common	type	being	AIDP	[4].
With	 advances	 in	 medical	 management,	 the	 incidence	 of	 GBS	 has	 been	 stable	 in	 the	 majority	 of
developing	 countries	 and	mortality	 has	 been	 reduced	 to	 2–3%	 (but	 is	 higher	 in	 the	 developing	world)
[6,9].	In	general,	mean	time	to	the	clinical	function	nadir	is	12	days,	with	98%	of	patients	reaching	a	nadir
within	4	weeks	from	onset	[8].	Overall	mortality	from	GBS	is	low;	approximately	5–10%	of	patients	may
die	 of	 complications	 in	 the	 acute	 phase	 of	 GBS	 [8,9,10].	 The	 progressive	 phase	 of	 GBS	 typically	 is
limited	to	4	weeks,	and	the	majority	of	patients	make	a	good	physical	recovery	and	are	ambulant	within	6
months	from	onset	of	symptoms	[11].	However,	just	under	two-thirds	(30%)	of	patients	may	have	rapid
progression,	requiring	artificial	ventilation	within	a	couple	of	days,	due	to	involvement	of	respiratory	and
bulbar	muscles	[2].	Approximately	20%	of	patients	may	have	residual,	permanent,	severe	disability,	with
deficits	in	ambulation,	or	require	ventilator	assistance	12	months	later	[1].	Autonomic	dysfunction	(sinus
tachycardia	 or	 bradycardia,	 fluctuating	 hypertension	 or	 hypotension,	 flushing	 of	 the	 face,	 loss	 of	 or
excessive	 sweating)	 can	occur	 in	up	 to	70%	of	patients;	 this	 can	be	associated	with	 sudden	death	 [3].
Facial	weakness	 and	 cranial	 nerve	 involvement	 occurs	 in	more	 than	 half	 of	 patients	 [2].	A	 number	 of
factors,	 including	 preceding	 diarrhoea,	 older	 age,	 rapid	 progression,	 disability	 at	 nadir	 and	 specific
neurophysiological	parameters	have	been	associated	with	poor	outcome	[12,13].
Long-Term	Disabilities	in	Persons	with	GBS
There	 is	 limited	 information	 on	 longer-term	 sequelae	 of	 GBS	 and	 their	 impact	 on	 everyday	 life.	 A
longitudinal	study	(N	=	76	patients)	reported	that	despite	good	functional	recovery	up	to	14	years	post-
GBS	(median	6	years,	range	1–14),	16%	of	patients	continued	to	report	moderate	to	extreme	impact	on
work,	family	and	social	activities;	and	22%	reported	ongoing	substantial	impact	on	mood,	confidence	and
ability	to	live	independently	[14].	Other	studies	show	that	psychosocial	performance	does	not	necessarily
correlate	with	the	severity	of	impairment	in	GBS,	but	may	be	explained	by	poor	conditioning	and	fatigue
[15,16].	Approximately	40%	of	all	cases	require	intensive	inpatient	rehabilitation	[10]	and	can	present	to
rehabilitation	 settings	 with	 a	 wide	 array	 of	 physical,	 emotional,	 psychosocial	 and/or	 environmental
difficulties.	These	disabilities	can	have	a	cumulative	effect	over	time	and	cause	considerable	distress	to
GBS	survivors	(and	their	families),	and	reduce	their	quality	of	life	(QoL)	[14,17].	These	can	limit	their
function	and	participation	with	a	high	impact	on	daily	activities,	vocational	activities	and	social	activities
(work,	family	and	intimate	relationships,	and	community/social	activities).
The	 World	 Health	 Organization,	 International	 Classification	 of	 Functioning,	 Disability	 and	 Health
(ICF)	[18],	provides	a	standard	framework	for	disability	and	participation	in	various	health	conditions,
including	 contextual	 factors.	 Rehabilitative	 care	 uses	 the	 terminology	 of	 this	 classification	 system	 to
describe	the	impact	of	the	disease	at	different	levels.	A	simulated	case	example	of	the	ICF	model	related
to	GBS	is	given	in	Figure	52.1.
A	 list	 of	 ICF	 categories	 (in	 all	 domains)	 relevant	 to	 the	 care	 of	 pwGBS	was	 developed	 through	 a
rigorous,	multi-method,	scientific	process,	incorporating	patient	and	multidisciplinary	perspectives	[19].
The	GBS	‘core	set’	represents	a	selection	of	ICF	categories/items	for	a	minimal	standard	of	reporting	in
clinical	 settings	 (brief	 core	 set)	 or	 comprehensive	 assessment	 (comprehensive	 core	 set)	 [19].	 It	 is
envisaged	 that	 these	 core	 sets	 describe	 specific	 biopsychosocial	 issues;	 provide	 a	 solid	 and	 stable
reference	 point;	 test	 the	 current	 and	 future	 health	 status	measures;	 and	 can	 be	 used	 for	 defining	 ‘what
should	be	measured’	[20].
An	integrated	approach	was	used,	which	included	a	comprehensive	review	of	literature	(peer	review
and	 grey	 literature)	 documenting	 rehabilitation	 interventions	 currently	 used	 in	management	 of	 a	 person
with	 GBS	 (pwGBS).	 A	 comprehensive	 search	 of	 the	 literature	 published	 up	 to	 December	 2015	 was
undertaken	 using	 the	Medline,	 Embase,	 PubMed	 and	Cochrane	 Library	 databases.	 The	 search	 strategy
included	interventional	studies	investigating	rehabilitative	management	of	pwGBS,	using	combinations	of
multiple	 search	 terms	 for	 3	 themes:	 GBS,	 rehabilitation	 interventions	 and	 patient	 outcomes.	 Medical
subject	heading	(MeSH)	search	terms	were	used	for	all	databases,	and	a	keyword	search	was	used	if	the
MeSH	 term	 was	 not	 available.	 Bibliographies	 of	 identified	 articles	 were	 scrutinised	 for	 additional
references	 and	 a	 manual	 search	 of	 relevant	 journals	 was	 undertaken.	 A	 grey	 literature	 search	 using
different	 Internet	 search	 engines	 and	 websites	 such	 as	 System	 for	 Information	 on	 Grey	 Literature	 in
Europe,	 New	 York	 Academy	 of	 Medicine	 Grey	 Literature	 Collection,	 and	 Google	 Scholar,	 was	 also
undertaken.	 Additional	 searches	 of	 the	 websites	 of	 prominent	 national	 and	 international	 organisations
associated	 with	 GBS	 management	 were	 conducted	 to	 identify	 relevant	 reports,	 health	 technology
assessments	 or	 other	 related	 materials.	 This	 review	 excluded	 pharmacological	 agents	 and	 other
alternative/conservative	interventions,	which	do	not	typically	form	part	of	the	rehabilitation	process.
Figure	52.1		ICF	model	with	case	example	for	GBS
Systematic	 reviews,	meta-analyses	 (MA),	 and	 randomised	 controlled	 trials	 (RCT)	were	 given	 high
priority,	and	where	high-level	evidence	was	not	available	lower	levels	of	evidence	were	reviewed	(such
as	observational	studies,	narrative	reviews	etc.).
Evidence	for	GBS	Rehabilitation
The	majority	of	GBS	survivors	are	young;	hence,	 the	emphasis	should	be	on	the	provision	of	long-term
integrated	care	[17].	Rehabilitation	is	an	integral	component	in	overall	management	[17].	The	main	focus
of	rehabilitation	in	pwGBS	is	on	reducing	symptoms	and	limitations	at	the	level	of	a	person’s	activity	and
participation	 (including	 personal	 and	 environmental	 factors).	 It	 extends	 beyond	 acute	 management,	 to
restoration	of	patient’s	previous	daily	activities	and	reintegration	into	the	home	and	community	[1,17].	It
is	estimated	that	over	one-third	of	all	GBS	patients	require	inpatient	rehabilitation,	particularly	those	who
are	more	 severely	 disabled	with	 an	 extended	 period	 of	 disease	 nadir	 [1].	 Earlier	 reports	 suggest	 that
inpatient	rehabilitation	should	be	initiated	earliest	possible	and	continued	for	3–6	weeks,	followed	by	a
community	and	home-based	rehabilitation	program	for	3–4	months	[10].	Existing	GBS	clinical	guidelines
and	frameworks	recommend	comprehensive,	flexible	interdisciplinary	coordinated	care	with	appropriate
follow-up,	education	and	support	for	patients	(and	carers)	[21,22].
A	 rehabilitation	 approach	 to	 GBS	 includes	 a	 wide	 spectrum	 of	 treatments	 and	 use	 of	 diverse
interventions.	 The	 existing	 best-evidence	 synthesis	 for	 specific	 rehabilitation	 interventions	 in	GBS	 are
summarised	below,	based	on	compilation	of	most	recently	published	studies.	(See	Table	52.1.)
Multidisciplinary	Rehabilitation
Multidisciplinary	(MD)	rehabilitation	is	defined	as	the	“co-ordinated	delivery	of	intervention	by	two	or
more	disciplines	(physiotherapy,	occupational	therapy,	social	work,	psychologist	and	other	allied	health,
nursing),	 under	 medical	 supervision	 (neurologist,	 rehabilitation	 physician)”	 [23].	 It	 is	 designed	 to	 be
patient-centred,	 time-based	 and	 functionally	 oriented,	 and	 aims	 to	 maximise	 activity	 and	 participation
(social	integration)	using	a	biopsychosocial	model	[20].
Table	52.1		Summary	of	studies	evaluating	rehabilitation	intervention	in	GBS.
Khan	and	colleagues	conducted	a	 comprehensive	 systematic	 review	 to	 evaluate	 the	effectiveness	of
MD	care	in	adults	with	GBS,	especially	the	types	of	approaches	that	are	effective	(settings,	intensity)	and
the	outcomes	that	are	affected	[17].	This	review	did	not	identify	any	RCTs	or	CCTs,	and	evidence	were
summarised	 based	 on	 3	 observational	 studies,	which	 supported	 the	 effectiveness	 of	MD	 rehabilitation
programs	in	inpatient	settings	in	terms	of	improvements	in	activity	(disability)	and	participation	for	up	to
6	months	[17].	These	3	studies	[24,25,26]	included	a	total	of	128	participants	and	all	were	rated	as	‘very
low’	 quality	 using	 the	 grades	 of	 recommendation,	 assessment,	 development	 and	 evaluation	 (GRADE)
approach	[27].	All	studies	showed	a	consistent	result	with	an	improvement	in	disability	from	the	time	of
inpatient	 rehabilitation	 admission	 to	 discharge	 in	 a	 timeframe	 shorter	 than	 12	 months.	 There	 was	 no
conclusive	 evidence	 in	 regards	 to	 improvement	 in	 QoL	 during	 or	 after	 rehabilitation.	 Overall
generalisation	of	 the	 results	was	 limited,	as	 the	3	studies	 included	patients	with	severe	GBS	with	high
levels	 of	 physical	 dependency.	 This	 highlighted	 a	 need	 for	 future	 research	 using	 robust	 study	 designs,
appropriate	outcome	measures	and	optimal	intensity/modality	of	rehabilitation	therapy	[17].
Khan	 and	 colleagues	 subsequently	 conducted	 a	RCT	 (N	=	 79)	 to	 evaluate	 the	 effectiveness	 of	MD
ambulatory	rehabilitation	in	pwGBS	after	the	initial	post-acute	phase	(median	6.5	years	since	diagnosis)
[23].	The	authors	compared	a	high-intensity	MD	rehabilitation	program	with	a	low-intensity	rehabilitation
program	over	12	months.	The	intensive	rehabilitation	program	included	individualized,	functional,	goal-
oriented	 MD	 treatment	 comprising	 half-hour	 blocks	 of	 therapy	 sessions	 from	 a	 MD	 team	 (medical,
occupational,	social,	psychology,	speech	and	physiotherapist),	2	to	3	times	per	week	for	up	to	12	weeks.
The	therapeutic	model	included	physiotherapy	for	strengthening,	endurance	and	gait	training;	occupational
therapy	 to	 improve	 everyday	 function	 (domestic,	 community	 tasks),	 driving	 and	 return	 to	 work;	 and
clinical	 psychology	 for	 counselling	 and	 support,	 and	 medical	 input	 from	 rehabilitation	 consultants	 as
required.	The	findings	demonstrated	that	high-intensity	rehabilitation	programs	were	effective	in	reducing
motor	 disability	 (mobility,	 self-care,	 continence	 program)	 and	 improving	 participation	 (relationships)
[23].
Specific	Rehabilitation	Interventions
A	 variety	 of	 rehabilitative	 interventions	 have	 been	 trialled	 in	 pwGBS;	 there	 is,	 however,	 a	 dearth	 of
research	 evaluating	 these	 interventions.	Moreover,	many	 of	 these	 proposed	 interventions	 are	 yet	 to	 be
integrated	into	comprehensive	MD	rehabilitation	programs,	and	few	studies	show	its	implementation.	The
existing	evidence	for	various	specific	rehabilitation	interventions	in	GBS	are	summarised	below.
Physical	Therapeutic	Modalities
Improving	or	restoring	physical	abilities	is	a	key	issue	in	rehabilitation	of	pwGBS.	Physical	therapeutic
modalities	 may	 involve	 a	 graduated	 mobility	 program,	 which	 includes	 maintenance	 of	 posture	 and
alignment,	maintaining	joint	range	of	motion,	provision	of	orthotics,	endurance	and	muscle	strengthening,
and	 progressive	 ambulation	 program	 using	 adaptive	 gait	 aids	 [21].	 The	 literature	 investigating
effectiveness	of	physical	therapeutic	modalities	is	sparse.
Physical	Therapy/Exercise
The	review	did	not	identify	any	systematic	reviews	or	RCTs	evaluating	physical	therapy	in	persons	with
GBS.	The	best	evidence	are	summarised	below	from	a	few	observational	studies.
El	Mhandi	and	colleagues	conducted	a	prospective	cohort	 study	 (N	=	 6)	 to	 evaluate	 individualized
physical	therapy	programs	based	on	muscular	reinforcement	and	active	mobilization	(average	2–3	weekly
sessions)	 for	 pwGBS	 [28].	 The	 results	 demonstrated	 significant	 muscle	 strength	 improvement	 using
dynamometric	 measures	 and	 all	 patients	 satisfied	 the	 criteria	 for	 a	 full	 recovery	 at	 18	 months.	 At	 6
months,	 manual	 muscle	 testing	 and	 functional	 independence	 motor	 total	 scores	 were	 close	 to	 normal
levels.	Compared	with	matched	healthy	controls,	isometric	and	isokinetic	strength	increased	significantly
during	the	first	6	months,	though	muscle	strength	increased	less	rapidly	between	6	and	18	months	[28].
Garssen	 and	 colleagues,	 in	 a	 prospective	 cohort	 study,	 evaluated	 the	 effectiveness	 of	 a	 12-week
bicycle	exercise	training	in	20	patients	with	polyneuropathy	(including	16	with	GBS)	and	severe	fatigue
[29].	The	findings	showed	significant	beneficial	effect	of	bicycle	training	on	physical	fitness,	functional
outcome	 and	QoL	 of	 these	 patients.	 There	was	 also	 a	 significant	 improvement	 in	 the	 post-intervention
fatigue	 scores	 (decrease	by	20%).	Further,	 all	participants	 tolerated	 intervention	well	 and	 the	majority
(80%)	were	motivated	to	continue	with	regular	training	activities	[29].
Bussmann	and	colleagues,	in	a	case	series	report,	explored	the	effects	of	physical	exercise	in	severely
fatigued	 pwGBS	 and	 chronic	 inflammatory	 demyelinating	 polyneuropathy	 patients	 [30].	 The	 authors
reported	 that	 physical	 exercise	 did	 not	 influence	 changes	 in	 fatigue,	 actual	 mobility	 and	 perceived
functioning,	but	did	improve	fitness.	Significant	relationships	were	found	between	the	domains:	perceived
mental	functioning	and	actual	mobility,	perceived	mental	functioning	and	perceived	physical	functioning,
and	fatigue	and	perceived	physical	functioning.
Other	physical	modalities,	such	as	digital	gait	analysis	[31],	partial	body	weight	support	systems	[32],
percutaneous	 kyphoplasty	 [33]	 and	 podiatrons	 (mechanized	 rotating	 platforms)	 [34]	 were	 explored	 in
pwGBS,	but	their	effectiveness	is	yet	to	be	determined.	Earlier	reports	suggest	that	care	should	be	taken
not	 to	overwork	muscle	groups	 [35]	 as	 this	 can	 lead	 to	paradoxical	weakening	 [36].	Patients	 also	 can
develop	tightness	of	muscles,	rather	than	joint	contractures	[1,8].	It	is	advocated	that	exercise	programs
should	 initially	 be	 non-fatiguing	 and	 strengthening	 exercises	 can	 be	 applied	 as	muscles	 regain	 greater
antigravity	strength	[37].	More	evidence	is	needed	for	the	use	of	physical	therapeutic	modalities.
Transcutaneous	Electrical	Nerve	Stimulation
There	 is	 conflicting	 evidence	 in	 regards	 to	 the	 beneficial	 effect	 of	 transcutaneous	 electrical	 nerve
stimulation	(TENS)	in	pwGBS.	Evidence	from	2	case	reports	suggests	that	the	application	of	TENS	may
be	an	effective	treatment	for	pain	in	patients	with	peripheral	neuropathy	[38,39].	The	authors	concluded
that	further	research	is	needed	to	use	TENS	in	routine	management	of	pain	in	GBS.
Orthoses	and	Ambulatory	Aids
A	 high	 proportion	 of	 pwGBS	 experience	 mobility	 problems,	 muscle	 weakness,	 paralysis,	 balance
impairment	and/or	fatigue,	which	can	be	alleviated	by	using	assistive	devices	[21].	To	date	there	are	no
studies	evaluating	the	effectiveness	of	these	devices	in	persons	with	GBS.	Current	guidelines	and	reports
recommend	 that	 mobility	 assistive	 devices	 such	 as	 ankle-foot	 orthoses,	 canes,	 crutches,	 walkers	 and
wheelchairs	should	be	prescribed	for	proper	positioning	and	optimising	residual	motor	function	[1,21].
Patients	 with	 prolonged	 residual	 weakness	 of	 calf	 (for	 example	 anterior	 compartment	 musculature)
benefit	 from	 devices	 such	 as	 ankle-foot	 orthosis,	 modified	 shoes	 with	 a	 broadened	 heel	 and	 good
stabilization	around	the	ankle	joint	[21,40].
Occupational	and	Recreational	Therapy
Many	pwGBS	may	have	prolonged	neurologic	deficits,	subsequently	limiting	their	function,	 that	require
occupational	restoration	and	maintenance	of	functional	independence	skills	in	everyday	activities	[8,41].
There	is	lack	of	studies	evaluating	OT	in	persons	with	GBS.	Published	reports	recommend	OT	to	promote
activities	 in	 pwGBS	 to	 facilitate	 functional	 self-care,	 which	 may	 include	 task	 reacquisition,	 use	 of
adaptive	 equipment,	 and	 the	modification	 of	 environment	 for	 personal,	 domestic	 and	 community	 tasks
[8,21,24,41].	 The	 introduction	 of	 recreational	 therapy	 may	 also	 support	 a	 patient’s	 adjustment	 to
disability	and	improve	social	reintegration	[41].
Speech	Therapy
Severe	 cases	 of	 GBS	 can	 be	 associated	 with	 cranial	 nerve	 involvement	 leading	 to	 dysphagia	 and
dysarthria,	necessitating	a	speech	therapy	program	to	promote	communication	and	safe	swallowing	skills
[40,41].	Speech	therapy	programs	may	include	proper	positioning,	head	control,	oral	motor	coordination
and	conscious	swallowing	techniques	(thicken	fluids	progressively	depending	on	patient	response)	[41].
More	 specific	 communication	 strategy	 may	 be	 required	 for	 ventilator-dependent	 patients	 and
tracheostomies	[41].	Clinical	trials	evaluating	speech	therapy	programs	in	pwGBS	are	lacking.
Nutritional	Interventions
Malnutrition	 in	 pwGBS	 can	 be	 caused	 by	 immobility,	 decreased	 gastric	 motility,	 dysphagia	 and
psychological	symptoms	(such	as	depression)	[42].	Many	patients	tend	to	lose	weight	in	the	acute	phase;
therefore,	routine	assessment	of	nutritional	status	is	important	[43].	Those	with	malnutrition	may	require
enteric	or	parenteral	 nutrition	 and	high	protein,	 high-energy	 enteral	 diets	 [43,44].	There	 are	no	 studies
evaluating	nutritional	status	in	GBS.
Cognitive	and	Psychological	Interventions
Cognitive	 problems	 have	 been	 reported	 in	 pwGBS,	 especially	 in	 the	 acute	 phase	 and	 in	 those	 with
extended	ICU	stay	[8,17,40].	Anxiety	and	fear	are	common	due	to	the	sudden	onset	of	symptoms	and	may
accompany	with	depression	 in	many	 [40].	Psychotic	 symptoms	 (hallucinations,	 delusions,	 incoherence)
have	been	reported	in	more	severe	patients	[40].	There	is	a	lack	of	studies	addressing	psychosocial	and
vocational	outcomes	in	GBS.	Expert	opinion	recommends	early	cognitive	screening	and	implementation
of	psychological	interventions,	such	as	good	communication	with	patients	and/or	their	families	regarding
prognosis	 and	 treatment	 plan,	 involvement	 in	 decision-making	 and	 early	 counselling	 from	 experts
[8,40,42].
Interventions	for	Respiratory	Complications
Respiratory	dysfunction	is	common	in	one-third	of	pwGBS,	which	can	lead	to	serious	complications	such
as	 incomplete	 respiratory	 recovery	 including	 chronic	 obstructive	 pulmonary	 disease,	 restrictive
respiratory	disease	 (pulmonary	scarring,	pneumonia),	 tracheitis	 from	chronic	 intubation	and	 respiratory
muscle	 insufficiency	 [4,22,45].	 A	 few	 expert	 opinions	 suggest	 initiation	 of	 physical	 therapy	measures
(chest	percussion,	breathing	exercises,	resistive	inspiratory	training)	to	clear	respiratory	secretions	and,
for	 more	 severe	 patients	 with	 tracheostomy,	 a	 special	 weaning	 protocol	 to	 prevent	 over-fatigue	 of
respiratory	muscles	[1,8].
Bladder/Bowel	Intervention
Autonomic	dysfunction	in	GBS,	including	urinary	and	bowel	dysfunction,	have	been	reported	in	pwGBS
[21,46].	Bladder	 dysfunction	may	 include	 detrusor	 acontractility,	 disturbed	 bladder	 sensation	 and	 non-
relaxing	urethral	sphincter,	causing	symptoms	such	as	voiding	difficulty,	urinary	retention,	frequency	and
urge	 incontinence	 [47,48].	 There	 is	 lack	 of	 studies	 in	 GBS	 addressing	 bowel/bladder	 dysfunction	 in
pwGBS,	 expert	 opinion	 suggests	 individualised	 management	 programs	 may	 include:	 timed	 voiding,
intermittent	 catheterization	 and	 anticholinergic	 medication	 [35].	 Pelvic	 floor	 muscle	 training	 with	 or
without	biofeedback	or	electrical	stimulation,	are	also	commonly	used	in	women	with	stress	leakage	and
mixed	 urinary	 incontinence	 [35,41].	 Similarly,	 effective	 bowel	 management	 program	 includes	 an
appropriate	diet,	adequate	fluids,	scheduled	bowel	care,	and	laxatives	for	those	with	bowel	dysfunction
[4,35].
Discussion
This	 narrative	 review	 provides	 an	 evidence-based	 overview	 of	 the	 effectiveness	 of	 rehabilitation
intervention	 in	 pwGBS.	 A	 limited	 number	 of	 studies	 evaluate	 the	 effectiveness	 of	 rehabilitation
intervention,	and	‘best’	evidence	to	date	is	based	upon	expert	opinions	and	observational	studies.	Despite
recommendations	for	many	rehabilitation	interventions,	there	is	a	paucity	of	information	on	effectiveness
of	 these	 treatments.	 The	 ‘best’	 available	 evidence	 to	 date	 is	 for	 studies	 evaluating	MD	 rehabilitation
which	 provide	 some	 support	 in	 producing	 longer-term	 gains	 in	 the	 levels	 of	 activity	 (disability)	 and
participation	 of	 pwGBS.	 The	 evidence	 for	 most	 uni-disciplinary	 rehabilitation	 interventions	 remains
limited	 and/or	 poor	 and	 is	 based	 upon	 ‘low	 quality’	 observational	 studies	 (using	 the	 GRADE
methodology	 for	 bias)	 or	 inferred	 from	 other	 neurological	 conditions.	 Adequate	 descriptions	 of	 what
comprises	a	‘black	box	of	rehabilitation’	(therapy	intensity,	duration,	modalities)	in	GBS	are	lacking.
GBS	 is	 a	 complex	 condition	 with	 marked	 clinical	 heterogeneity	 and	 a	 varied	 level	 of	 disability,
requiring	 an	 individualised	 approach	 to	 rehabilitation.	 The	 clinical	 decision-making	 process	 can	 be
subjective	and	biased,	and	clinicians	may	not	always	agree	with	one	another	[49].	GBS	survivors	need
regular	 evaluation	 for	 persisting	 disability	 and	 psychological	 sequelae	 (especially	 over	 time),	 and
clinicians	should	incorporate	the	patient	perspective	on	functioning	and	health	[19].	The	ICF,	a	useful	tool
in	 the	rehabilitation	context,	can	describe	 the	patients’	experience	by	emphasizing	 the	complex	ways	 in
which	 the	 ‘condition’	 and	 contextual	 (environmental	 or	 personal)	 factors	 (Figure	 52.1)	 may	 modify
outcomes	 [17].	 It	 lists	 information	 for	 clinicians	 about	 domains	 that	 are	 considered	 important	 by	 the
pwGBS	and	provides	a	common	language	for	more	effective	communication	and	agreement	amongst	the
treating	MD	clinicians	[19].
Difficulties	 in	 assimilation	 of	 data	 are	 further	 compounded	 by	 a	 wide	 range	 of	 rehabilitation
interventions	 proposed	 for	 the	 pwGBS	 and	 diverse	 outcomes	 used	 [17].	 Integrated	 GBS	 services	 are
needed	 to	 address	 issues	not	 only	 in	 acute	 settings,	 but	 also	over	 the	 longer-term	care	 [17].	Further,	 a
national	 registry	 and	 or	 formal	 data	 collection	 process	 (nationally	 and	 internationally)	 are	 needed	 to
gather	information	on	variability	in	the	types	of	rehabilitation	programs	available	and	their	outcomes	in
GBS	 survivors.	 An	 analysis	 of	 the	 National	 Rehabilitation	 Dataset	 reviewed	 outcomes	 of	 inpatient
rehabilitation	 for	pwGBS	(N	=	 572)	 from	162	accredited	 rehabilitation	 facilities	 across	Australia	 and
New	Zealand,	and	showed	improved	clinical	efficiency	of	inpatient	rehabilitation,	reductions	in	hospital
length	of	stay	and	increased	discharge	of	these	persons	back	to	community	[50].	Such	analyses	assist	in
reviewing	rehabilitation	outcomes	to	identify	future	clinical	needs	for	planning	health	service	provision
[50].
Conclusions
GBS	is	a	complex	and	challenging	condition,	with	many	survivors	experience	residual	neurological	and
neuropsychological	 sequelae	 over	 the	 long	 term.	This	 paper	 highlights	 the	 current	 gap	 in	 evidence	 for
rehabilitation	 intervention	 in	 persons	 with	 GBS.	 However,	 a	 gap	 in	 current	 research	 should	 not	 be
interpreted	 as	 an	 ineffectiveness	 of	 rehabilitative	 intervention.	 Integrated,	 holistic,	 multidisciplinary
rehabilitative	 care	with	 integrated	 long-term	care	of	 these	persons	 is	 recommended	 to	 address	various
medical	and	physical	problems	and	issues	of	participatory	restriction.	Education	and	support	for	pwGBS
(and	their	carers),	and	the	treating	multidisciplinary	teams	should	be	incorporated	into	future	management
models.	More	research	is	needed	to	support	specific	rehabilitative	interventions	in	GBS.
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Physiotherapy	in	Guillain-Barré	Syndrome:
Developing	the	Evidence	over	the	Years
Claire	White
Introduction
It	 is	not	easy	to	show	the	value	of	physiotherapy	in	 the	management	of	GBS;	the	condition	is	relatively
rare	 and	 there	 is	 limited	 previous	 research.	 There	 are	 currently	 no	 comprehensive,	 evidence-based
guidelines	 for	 physiotherapy,	 and	 practice	 has	 been	 based	 on	 experience	 from	 other	 neurological
conditions.
The	following	compilation	of	my	Top	10	is	a	reflection	on	the	history	of	physiotherapy	in	the	United
Kingdom,	the	role	of	physiotherapy	within	the	multidisciplinary	management	of	GBS	and	the	potential	for
a	better	understanding	of	any	unique,	effective	contribution	of	physiotherapy	to	patient	outcomes.
The	History	of	Physiotherapy	in	the	United	Kingdom
Nicholls	DA,	Cheek	J.	Physiotherapy	and	the	shadow	of	prostitution:	the	Society	of
Trained	Masseuses	and	the	massage	scandals	of	1894.	Social	Science	and	Medicine,
2006;	Øvretveit	J.	Medical	dominance	and	the	development	of	professional	autonomy	in
physiotherapy.	Sociology	of	Health	&	Illness,	1985
Nicholls	 and	 Cheek	 provide	 a	 commentary	 on	 the	 emergence	 of	 new	 forms	 of	 physiotherapy	 practice
against	the	social	and	political	background	of	the	late	Victorian	era	[1].	The	period	was	influenced	by	the
industrial	 revolution,	 urban	 overcrowding	 as	 the	 population	 moved	 from	 the	 country	 to	 the	 cities,
associated	public	health	developments	and	 the	greater	emancipation	of	women.	The	authors	note	 that	 it
was	 becoming	more	 acceptable	 for	 educated	women	 to	 take	 up	 professional	 roles	 not	 only	within	 the
previously	 accepted	 female	 professions	 of	 nursing	 and	 teaching	 but	 also	 in	 new	 areas.	 One	 area	 that
burgeoned	 during	 this	 period	was	 the	 use	 of	massage	 and	 the	movement	 to	 complement	 nursing.	 This
became	 so	 popular	 that	 soon	 the	 market	 for	 masseurs	 and	 masseuses	 was	 overstocked	 with	 variably
trained	individuals	and	an	editorial	in	the	British	Medical	Journal	(1894)	described	concerns	regarding
the	practices	of	less	reputable	massage	establishments.	This	led	to	the	birth	of	physiotherapy,	when	in	the
same	year	the	Society	of	Trained	Masseuses	(STM)	was	formed	by	4	nurses	and	midwives	in	a	response
to	 the	 massage	 scandals.	 They	 sought	 to	 regulate	 the	 education,	 training,	 registration	 and	 practice	 of
massage	by	establishing	one	of	their	founding	rules	of	the	society	that	“no	massage	be	undertaken	except
under	 medical	 direction”.	Whilst	 this	 achieved	 the	 aim	 of	 distancing	 therapeutic	 massage	 from	moral
outrage,	 it	 was	 a	 rule	 that	 the	 profession	 subsequently	 fought	 long	 and	 hard	 to	 remove	 to	 establish
professional	independence.
Health	 services	 organisational	 research	 in	 the	 1980s	 [2]	 further	 documents	 the	 development	 of	 the
profession	 as	 the	 STM	 became	 chartered	 in	 1920	 and	 was	 renamed	 the	 Chartered	 Society	 of
Physiotherapy	 (CSP)	 in	 1944.	 Later,	 following	 the	 creation	 of	 the	 Council	 for	 the	 Professions
Supplementary	to	Medicine	in	1960,	where	membership	of	the	board	was	still	one-third	medical,	the	CSP
was	 awarded	 the	 right	 to	monitor	 its	 own	 standards	 and	 quality	 of	 education	 before	 finally	 achieving
autonomous	 practitioner	 status	 in	 1977.	 Since	 that	 time	 physiotherapists	 have	 furthered	 their	 clinical
autonomy	 by	 advancing	 methods	 of	 clinical	 reasoning,	 increasing	 specialisation	 and	 becoming	 more
theoretically	oriented	with	greater	involvement	in	research	activity.
Learning	from	Poliomyelitis:	A	role	for	Physiotherapy	in	the
Management	of	GBS
Cooksey	FS.	The	role	of	physiotherapy	in	the	treatment	of	poliomyelitis.	Proceedings	of
the	Royal	Society	of	Medicine,	1948
Guillain-Barré	syndrome	(GBS)	and	poliomyelitis	(polio)	share	some	characteristics	of	both	presentation
and	clinical	course	with	initial	acute	flaccid	paralysis	followed	by	a	period	of	neurological	recovery	and
later	 adaptation	 to	 long-term	 problems.	 In	 1916,	 the	 same	 year	 as	 Guillain,	 Barré	 and	 Strohl	 first
described	the	symptoms	of	acute	ascending	motor	weakness	and	showed	how	signs	from	lumbar	puncture
could	differentiate	between	the	2	conditions,	there	was	also	a	major	polio	epidemic.	During	the	epidemic
physical	remedies	and	therapeutic	massage	were	already	being	used	to	treat	polio	sufferers.	A	description
of	 physiotherapy	 as	 an	 important	 therapeutic	 approach	 for	 the	management	 of	 polio	 was	 subsequently
published	in	1948	by	Dr	Frank	Cooksey	and	his	description	compares	well	with	current	recommendations
for	the	management	of	patients	with	GBS:
First	 the	 inflammatory	 phase	…	when	 treatment	 is	 directed	…	 to	 relieve	pain,	 and	 to	 prevent	 stiffness	or	 deformity	 by
prophylactic	movements.…	Treatment	involving	some	disturbance	of	the	patient	is	necessary	to	mitigate	these	secondary
effects.
Secondly	 the	stage	of	potential	 recovery	…	when	 the	purpose	of	 treatment	 is	 to	assist	 the	 recovery	of	paralysed	or
weak	muscles	within	the	limits	determined	by	the	permanent	damage	in	the	CNS.
Thirdly	 the	 stage	of	 chronic	disability	when	…	appliances,	 vocational	 training	and	 the	development	of	 compensatory
function	in	surviving	muscles	are	re-employed	…	suited	to	the	residual	capacity	of	the	individual.	[3]
Cooksey	 also	 identifies	 potential	 dangers	 of	 physiotherapy	 and	 highlights	 the	 need	 to	 evaluate
interventions	for	fidelity,	safety	and	efficacy.
The	 obvious	 danger	 is	 that	 physiotherapy	 will	 be	 too	 vigorous	 and	 meddlesome	 in	 the	 beginning	 when	 hope	 and
enthusiasm	run	high,	and	ineffective	at	the	end	of	a	long	period	of	treatment	just	when	it	might	make	all	the	difference	in	the
final	accommodation	to	a	permanent	disability.
Understanding	Disablement	and	Functioning	in	GBS
Lennon	SM,	et	al.	Reasons	for	persistent	disability	in	Guillain-Barré	syndrome.	Clinical
Rehabilitation,	1993;	World	Health	Organization.	International	Classification	of
Functioning,	Disability	and	Health	(ICF).	Geneva:	WHO,	2001
Several	 previous	 reports	 identified	 persistent	 motor	 weakness	 as	 the	 primary	 cause	 of	 long-term
disability	in	people	after	GBS.	However,	Lennon	and	colleagues	demonstrated	that,	rather	than	presuming
a	 hierarchical	 relationship	 between	 impairment,	 disability	 and	 handicap,	 clinicians	 should	 undertake
objective	measurements	of	all	3	outcomes	to	evaluate	the	true	impact	of	the	condition	after	neurological
recovery	 [4].	 Indeed,	 the	 INCAT	group	 later	 showed	 that	 significant	 and	meaningful	 associations	 exist
between	impairment,	disability	and	handicap	[5].	They	recommended	wider	consideration	of	the	factors
contributing	to	disablement,	since	only	just	over	half	of	the	variance	in	handicap	could	be	explained	by
impairment	scores.
This	disconnect	between	impairment,	 function	and	societal	 impact	 is	something	that	physiotherapists
repeatedly	 encounter	 when	 working	 with	 clients,	 and	 physiotherapy	 education	 was	 a	 relatively	 early
adopter	 of	 the	 International	 Classification	 of	 Functioning	 that	 was	 published	 by	 the	 World	 Health
Organisation	 in	2001	[6].	The	ICF	superseded	 the	previous	classification	of	 impairment,	disability	and
handicap	(ICIDH)	[7]	for	use	as	the	scientific	standardization	of	data	on	health	and	disability	worldwide.
It	 incorporates	 both	 the	 medical	 and	 social	 models	 of	 disability	 and	 a	 role	 for	 contextual	 personal
(psychological)	and	environmental	(physical	and	social)	factors	in	describing	functioning	that	recognises
reductions	in	the	incidence	and	severity	of	disability	in	a	population	can	be	brought	about	both	by	enhancing	the	functional
capacity	of	the	person	and	by	improving	performance	by	modifying	features	of	the	social	and	physical	environment.
This	acknowledges	different	perspectives	of	functioning	and	disablement	and	supports	a	multidisciplinary
approach	to	management	of	disablement	in	GBS.
Multidisciplinary	Care	in	GBS
Khan	F,	et	al.	Outcomes	of	high-	and	low-intensity	rehabilitation	programme	for	persons
with	chronic	phase	after	Guillain-Barré	syndrome:	a	randomized	controlled	trial.	Journal	of
Rehabilitation	Medicine,	2011
The	first	randomised	controlled	trial	of	a	multidisciplinary	intervention	for	people	at	least	one	year	after
recovery	from	GBS	illustrates	the	challenges	of	implementing	the	MRC	guidelines	for	evaluating	complex
interventions	[8].	The	meticulously	described	and	comprehensive	study	evaluated	outcome	at	the	level	of
activity	and	participation,	and	reported	both	on	intention	to	treat	and	on	treatment	analyses	of	all	complete
cases.	 The	 moderate	 to	 small	 effects	 of	 reduction	 in	 activity	 limitations	 of	 mobility,	 self-care	 and
continence	 as	 well	 as	 a	 similar	 improvement	 in	 participation	 for	 ‘personal	 relationships’	 suggests	 an
important	 role	 for	 MDT	 rehabilitation	 but	 highlights	 the	 challenges	 associated	 with	 interpreting	 the
findings	 for	 specific	 active	 components	of	 the	 intervention.	The	 intervention	 comprised	 individualised,
goal-oriented	 treatment	 incorporating	 therapy	 sessions	 with	 relevant	 disciplines	 based	 on	 participant
need.	The	clinical	rationale	for	this	form	of	tailored	approach	to	MDT	intervention	is	clear	but	in	RCTs
the	 impact	 of	 such	 an	 individualised	 approach	 means	 the	 role	 of	 specific	 therapeutic	 components
including	physiotherapy	is	hard	to	determine.
One	 uncontrolled	 prospective	 study	 [9]	 evaluated	 the	 feasibility	 and	 likely	 effect	 of	 unsupervised
physiotherapist-prescribed	exercise	on	disability	 for	people	 following	recovery	 from	GBS	and	chronic
inflammatory	demyelinating	polyradiculoneuropathy	 (CIDP).	 Improvements	 in	 the	majority	of	 outcomes
were	 observed	 after	 the	 intervention,	 suggesting	 that	 exercise	may	 be	 beneficial	 in	 ameliorating	 these
persistent	 problems.	 However,	 the	 study	 design	 means	 it	 is	 not	 possible	 to	 attribute	 observed
improvements	 directly	 to	 the	 intervention.	 Therefore,	 as	Khan	 recommends	 [8],	 future	 research	 should
address	 the	 paucity	 of	 evidence	 with	 well-designed	 RCTs	 of	 rehabilitation	 for	 GBS	 that	 include
quantifying	the	specific	components	of	rehabilitation	interventions.
What	Research	Questions	Are	Important	to	People	with	GBS?
Forsberg	A,	et	al.	Balancing	everyday	life	two	years	after	falling	ill	with	Guillain-Barré
Syndrome:	a	qualitative	study.	Clinical	Rehabilitation,	2015
In	 order	 to	 ensure	 that	 research	 addresses	 important	 outcomes	 for	 patients,	 evidence	 from	 qualitative
studies	 is	 essential.	 A	 recent	 qualitative	 interview	 study	 is	 one	 of	 only	 a	 few	 aimed	 at	 exploring	 the
experience	of	people	living	with	GBS	[10].	Interviews	were	conducted	with	people	at	least	2	years	after
onset	 of	GBS	 and	 reiterate	 the	 variability	 in	 recovery	 of	 impairment,	 activities	 and	 participation	 from
observational	 studies.	 The	 study’s	main	 theme	 of	 ‘Striving	 for	 balance	 in	 everyday	 life’	 highlights	 the
impact	of	symptoms	and	psychological	adaptation	on	how	patients	manage	the	recovery	process.	What	is
particularly	 interesting	is	not	only	 the	varied	 lived	experience	but	 that	 the	extent	 to	which	interviewees
were	able	to	cope	with	or	accept	their	situation	was	crucially	important.	Where	people	had	felt	able	to
cope	with	long-term	limitations,	they	also	expressed	greater	satisfaction	with	health	care.	Conversely,	and
more	importantly,	where	people	felt	they	had	not	been	listened	to	by	health	care	professionals,	they	felt
vulnerable	 and	had	difficulty	 accepting	 the	 consequences	of	 their	 illness.	The	 fact	 that	 all	 participants,
irrespective	of	 their	 impairments,	 including	fatigue,	described	prioritizing	 time	 to	exercise	as	a	way	of
feeling	 better	 suggests	 that	 listening	 to	 patients’	 needs	 and	 preferences	 to	 enable	 them	 to	 engage
effectively	in	exercise	or	physical	activity	is	likely	to	be	important	in	promoting	well-being.
Fatigue	in	GBS
Merkies	IS,	et	al.	Fatigue	in	immune	mediated	polyneuropathies.	Neurology,	1999
Fatigue	 is	 a	 highly	 prevalent	 problem	 for	 people	 with	 GBS.	 Experienced	 fatigue	 is	 the	 subjective
sensation	of	persistent	feelings	of	overwhelming	tiredness	or	fatigue	unrelated	to	physical	activity.	This	is
in	contrast	to	fatigability	which	is	the	observable	change	in	physical	performance	or	muscle	fatigue	that	is
associated	with	 physical	 activity.	Whilst	 both	 are	 likely	 to	 exist	 for	 some	 people	with	GBS,	 Ingemar
Merkies	and	colleagues	demonstrated	that	experienced	fatigue	was	reported	by	80%	of	people	with	GBS
[11].	This	fatigue	was	not	associated	with	physical	symptoms	of	strength,	sensory	disturbance	or	physical
function	but	 rather	with	 social	 and	emotional	 functioning.	Severe	 fatigue,	defined	as	 a	 score	of	greater
than	5	on	the	fatigue	severity	scale,	reportedly	occurs	for	between	35%	and	80%	of	people	with	GBS	in
observational	 studies,	 although	 the	 relationship	 between	 fatigue	 and	 health	 status	 is	 somewhat	 unclear.
However,	one	uncontrolled	study	of	supervised	exercise	for	people	with	severe	fatigue	as	a	result	of	GBS
showed	improvements	in	fatigue	and	quality	of	life	associated	with	participation	in	regular	exercise	[12],
but	this	remains	to	be	confirmed	in	future	RCTs.
Evaluating	Complexity	and	Behaviour	Change	in	Interventions	for
GBS
Campbell	M,	et	al.	Framework	for	design	and	evaluation	of	complex	interventions	to
improve	health.	BMJ,	2000;	Michie	S,	et	al.	The	behavior	change	technique	taxonomy	(v1)
of	93	hierarchically	clustered	techniques:	building	an	international	consensus	for	the
reporting	of	behavior	change	interventions.	Annals	of	Behavioral	Medicine,	2013
In	the	BMJ,	Campbell	and	colleagues	describe	 the	 important	contribution	 to	health	care	research	of	 the
MRC	guidelines	for	designing	and	evaluating	complex	interventions	[13].	Multidisciplinary	care	for	the
management	 of	 GBS	 constitutes	 significant	 complexity	 at	 both	 disciplinary	 and	 organisational	 levels.
Research	into	only	a	single	MDT	discipline	can	also	present	substantial	complexity	since	a	typical	home
exercise	programme	prescribed	by	a	physiotherapist	includes	individualised	assessment,	prescription	of
exercise	tailored	to	client	clinical	presentation,	needs	and	preferences,	compliance	with	and	adherence	to
a	programme	of	 exercise,	 self-monitoring	 and	progression	of	 activity.	This	often	 requires	 considerable
and	sustained	behaviour	change	on	the	part	of	the	patient	and	it	is	therefore	important	to	propose	a	clear
mechanism	for	how	an	exercise	intervention	is	likely	to	work	at	the	outset.
If	behaviour	change	is	a	desired	outcome	then	one	tool	for	achieving	this	is	a	recent	classification	of
93	behaviour	change	 techniques	 (BCT)	by	Michie	and	colleagues	 [14].	The	BCT	 taxonomy	may	aid	 in
identifying	 components	 of	 physiotherapy	 or	 exercise	 prescription	 and	 progression	 alongside	 more
conventional	descriptions.	The	 taxonomy	includes	groupings	of	 techniques	such	as	‘goals	and	planning’
(problem	solving)	and	‘shaping	knowledge’	(behavioural	experiments).	These	could	be	used	to	explore
whether	 exercise	 interventions	 may	 be	 more	 effective	 if	 patients	 are	 involved	 in	 problem-solving	 by
identifying	any	potential	barriers	to	exercise	prior	to	setting	specific	exercise	goals.	In	addition,	exercise
adherence	may	be	enhanced	if	patients	are	able	to	self-monitor	the	outcomes	of	exercise,	including	in	the
form	of	behavioural	experiments	where	they	can	be	encouraged	to	test	out	any	negative	beliefs	they	may
hold	about	exercise	(e.g.	 ‘all	exercise	will	 increase	my	fatigue’,	 ‘people	will	stare	at	me	 if	 I	go	 to	 the
gym’).	Behavioural	experiments	and	graded	activity	permit	patients	to	try	out	new	behaviours	and	use	the
results	 to	 inform	 their	 ongoing	 exercise.	 Thus	 physiotherapists	 can	 use	 BCT	 to	 ensure	 that	 they	 listen
effectively	 to	 patients’	 experiences	 and	 incorporate	 them	 in	 a	 genuinely	 client-centred	 approach	 to
prescribing	exercise	 that	 is	meaningful	 to	patients	with	a	 fair	chance	of	successful	uptake.	Our	ongoing
Home	Exercise	for	Inflammatory	Neuropathy	Trial	(HINT)	includes	the	use	of	BCT	as	part	of	a	theory-
driven	exercise	intervention	[15].
Conclusion
The	patient-focussed	 approach	of	 physiotherapy	offers	 great	 possibilities	 in	 the	management	 of	 people
with	GBS.	I	hope	that	this	brief	history	of	physiotherapy	in	relation	to	the	condition	shows	that	in	order	to
improve	outcomes	for	patients	we	need	to	conduct	qualitative	research	in	true	collaboration	with	patients
to	 identify	 meaningful	 questions.	 This	 will	 allow	 us	 develop	 rigorous	 randomised	 controlled	 trials,
paying	 meticulous	 attention	 to	 components	 of	 both	 physiotherapy	 and	 wider	 multidisciplinary
interventions.
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Fatal	Guillain-Barré	Syndrome
Bianca	van	den	Berg	and	Bart	C.	Jacobs
When	the	paralysis	reaches	its	maximum	intensity	the	danger	of	asphyxia	is	always	imminent.	However	in	eight	out	of	ten
cases	death	was	avoided	either	by	skillful	professional	intervention	or	a	spontaneous	remission	of	this	phase	of	the	illness.
In	two	cases	death	occurred	at	this	stage.
Jean	Baptiste	Octave	Landry,	1859	[translated,	original	version	in	French]	[1]
Introduction
Landry	already	 reported	 in	1859	 that	 the	disorder,	 later	known	as	 the	Guillain-Barré	syndrome	(GBS),
can	be	fatal	[1].	Guillain,	Barré	and	Strohl	instead	emphasized	the	spontaneous	recovery	and	relatively
good	outcome	of	this	syndrome,	but	GBS	has	been	a	life-threatening	disorder	ever	since	[2].
As	a	reference	centre	for	GBS	in	the	Netherlands,	we	are	frequently	consulted	about	the	most	severe
cases	of	GBS.	We	would	 like	 to	present	2	 impressive	cases	 that	we	have	encountered	 in	 the	 last	years
showing	that	GBS	still	can	be	fatal	and	that	the	influence	of	medical	care	is	substantial.
The	first	case	was	a	child	of	4	years	old	who	was	transferred	to	our	centre	from	another	hospital	after
a	 resuscitation	and	an	emergency	 intubation.	According	 to	 the	 treating	paediatrician	of	 that	hospital	 the
patient	was	admitted	with	pain	in	the	neck,	swallowing	difficulty,	drooling	and	frequent	falling	in	the	last
days.	The	working	diagnosis	of	 the	paediatrician	was	a	 tonsillitis/tonsillar	 tumour,	and	 the	patient	was
admitted	to	the	children’s	ward	and	treated	with	antibiotics.	The	day	after	admission	he	became	abruptly
respiratory	 insufficient	and	 just	before	 intubation	 the	patient	had	an	asystole	and	required	resuscitation.
After	 transferal	 to	 our	 hospital	 we	 saw	 the	 child	 for	 the	 first	 time,	 who	 had	 a	 severe	 post-anoxic
encephalopathy	without	showing	any	sign	of	neurological	improvement	in	the	next	days.	When	we	talked
with	the	parents	about	the	grave	situation	and	the	poor	prognosis,	they	explained	to	us	that	in	the	last	week
the	patient	already	had	difficulty	walking	and	 the	day	before	admission	he	was	unable	 to	 lift	his	arms.
Considering	the	diagnosis	of	GBS,	nerve	conduction	studies	showed	a	severe	motor	polyneuropathy,	CSF
an	elevated	protein	level,	with	normal	leukocyte	count,	and	in	serum	high	titres	of	IgG	antibodies	to	the
ganglioside	GM1were	 found.	Patient	died	 some	days	 later.	All	 findings	were	consistent	with	a	 rapidly
progressive	GBS	followed	by	respiratory	failure.[3]
A	second	case	was	in	another	hospital	 in	one	of	the	clinical	studies	coordinated	by	our	centre.	This
patient	was	84	years	old	and	developed	a	severe	form	of	GBS	with	 tetraplegia,	 facial	diplegia,	bulbar
weakness,	ventilator	dependency	and	many	complications	with	autonomic	dysfunction	and	even	a	 short
asystole.	 In	 addition	 there	were	 severe	 decubital	wounds	 for	which	 necrotectomy	was	 necessary.	 The
patient	had	already	been	ventilated	for	more	than	3	months	without	any	signs	of	recovery	and	had	suffered
from	persistent	 and	 progressive	 pain.	 The	 treating	 neurologists	 asked	 for	 our	 advice,	 and	 although	we
indicated	 that	 even	 severe	 cases	 of	 GBS	 may	 recover,	 the	 patient,	 his	 family	 and	 the	 local	 treating
multidisciplinary	 team	made	a	decision	not	 to	perform	any	 life-prolonging	 treatments.	The	patient	died
one	week	later.
These	2	cases	of	 fatal	GBS	not	only	 illustrate	 the	 rapidity	and	severity	of	GBS,	 they	also	show	 the
problems	 in	 clinical	 decision-making	 for	 the	 physicians.	 Although	mortality	 from	GBS	 is	 rare,	 it	 still
exists	in	both	developing	and	developed	countries.	For	this	chapter	we	have	selected	10	studies	that	we
found	important	for	understanding	the	background	of	the	mortality	of	GBS.	In	this	chapter	we	describe	the
history	of	mortality	and	GBS,	the	mortality	rate,	the	causes	of	death	and	risk	factors	of	mortality	in	GBS,
and	give	our	personal	view	on	how	mortality	may	be	reduced.
Mortality	Rate	of	GBS
GBS	has	a	variable	mortality	rate	worldwide.	Already	many	clinical	cohort	studies	have	been	performed
studying	 the	mortality	 rate	 in	GBS.	 Table	 54.1	 gives	 a	 short	 overview	 of	 the	mortality	 rate	 of	 the	 10
articles	included	in	this	chapter.	In	1991	Ropper,	Wijdicks	and	Truax	wrote	a	monumental	book	for	the
Contemporary	Neurology	Series	[4].	In	this	book	only	a	small	section	was	dedicated	to	the	mortality	in
GBS.	An	overview	was	given	about	 the	mortality	 in	different	series	 ranging	from	1966	 to	1988	with	a
mortality	rate	from	1%	to	20%.	The	authors	state	that,	due	to	improvements	in	respiratory	and	 intensive
care,	the	overall	mortality	from	GBS	decreased,	although	they	show	no	data	to	illustrate	this.
Table	54.1		Mortality	in	GBS
In	1988	Winer,	Hughes	and	Osmond	published	an	 influential	prospective	 study	of	100	patients	with
acute	idiopathic	neuropathy,	compatible	with	a	diagnosis	of	GBS	[5].	After	a	12-month	follow-up,	 they
found	that	13	%	of	the	patients	had	died.	Ten	of	the	13	(77%)	deaths	probably	could	be	attributed	to	GBS,
indicating	a	GBS-related	mortality	 rate	of	10%.	The	 Italian	GBS	study	group	found	a	similar	mortality
rate	of	11%	[6].
Lawn	and	Wijdicks	were	 among	 the	 first	 to	 dedicate	 a	whole	 article	 to	mortality	 in	GBS	 [7].	This
study	provides	a	nice	overview	of	the	studies	investigating	the	mortality	of	GBS	conducted	between	1962
and	1995,	with	mortality	rates	ranging	from	1%	to	10%.	They	also	reviewed	the	medical	records	of	320
patients	with	GBS	admitted	to	Mayo	Clinic-affiliated	hospitals	and	reported	a	mortality	rate	of	4%.
More	 recent	 studies	 show	 a	 somewhat	 lower	 mortality	 rate.	 Alshekhlee	 and	 colleagues	 used	 a
Nationwide	Inpatient	Sample	database	(2000–2004)	and	searched	for	patients	diagnosed	with	GBS	using
the	 ICD-9-CM	 to	 determine	 the	 in-hospital	 mortality	 rate	 and	 predictors	 of	 death	 of	 GBS	 in	 U.S.
hospitals.	The	mortality	rate	was	2.58%.	This	study	had,	however,	some	important	limitations,	including	a
lack	of	case	ascertainment	[8].
In	2008	Dhar,	Stitt	and	Hahn	studied	the	morbidity	and	outcome	of	GBS	patients	admitted	to	the	ICU
and	included	76	GBS	patients.	They	found	that	the	majority	of	GBS	patients	admitted	to	the	ICU,	although
suffering	 from	high	morbidity,	have	a	good	outcome	(ability	 to	walk	 independently).	The	mortality	 rate
they	found	of	6.5%	is	probably	higher	than	in	other	recent	studies	due	to	the	selection	of	severely	affected
GBS	patients	[9].
In	our	own	 study,	 published	 in	2013,	we	 reviewed	prospectively	 collected	data	of	 a	 cohort	 of	 527
GBS	patients	 from	1986	 to	2008.	We	found	a	 low	mortality	 rate	of	2.8%	[10].	A	reason	 for	 the	 lower
mortality	 rate	 could	 be	 the	 improvements	 in	 standard	 and	 intensive	 care	 and	 the	 high	 proportion	 of
patients	receiving	treatment	with	plasma	exchange	and	intravenous	immunoglobulins,	2	proven	effective
treatments	for	GBS.
Although	these	studies	show	a	lower	mortality	rate	in	high-income	countries,	a	much	graver	situation
was	 evident	 in	 a	 presentation	 about	 the	mortality	of	GBS	 in	Bangladesh	presented	 at	 the	 Inflammatory
Neuropathy	Consortium	meeting	of	2014	at	Dusseldorf	 [11].	 Ishaque	and	colleagues	from	the	Emerging
Diseases	and	Immunobiology	research	group	at	the	International	Centre	for	Diarrhoeal	Disease	Research
in	Bangladesh	 reported	a	high	mortality	 rate	 in	Bangladesh	of	12.4%	(61	out	of	491).	One	of	 the	most
disturbing	 results	 is	 that	 20%	 of	 the	 deceased	 GBS	 patients	 died	 because	 there	 was	 no	 mechanical
ventilator	available.
This	 study	 shows	 that	 there	 is	 a	 big	 difference	 between	 high-income	 and	 low-income	 countries,
probably	explained	by	the	different	standard	in	general,	supportive	and	intensive	care	and	the	availability
of	treatment.
Death	Causes	in	GBS
Winer	and	colleagues	and	the	Italian	GBS	Study	Group	reported	that	the	most	common	cause	of	death	was
acute	cardiac	arrest	preceded	by	autonomic	disturbances	[5,6].	Ropper,	Wijdicks	and	Truax	reported	that
the	 causes	 of	 death	 in	 GBS	 are	 pneumonia,	 adult	 respiratory	 distress	 syndrome	 following	 aspiration,
sepsis,	 myocardial	 infarction,	 pulmonary	 embolus	 and	 profound	 dysautonomia	 [4].	 Furthermore,	 they
stated	that	dysautonomia	can	be	life	threatening	but	only	rarely	leads	directly	to	death.	Lawn	and	Wijdicks
reported	 ventilator-associated	 pneumonia	 as	 a	 leading	 cause	 of	 death,	 followed	 by	 cardiac	 arrest	 (in
absence	of	dysautonomia)	[7].	The	most	common	causes	of	death	found	by	van	den	Berg	and	colleagues
were	 respiratory	 complications	 (pneumonia,	 respiratory	 failure),	 cardiovascular	 and	 autonomic
complications	[10].
Risk	Factors	of	Mortality	in	GBS
Only	a	few	studies	have	determined	the	risk	factors	of	death	in	patients	with	GBS.	All	studies	found	that
the	most	 important	 risk	 factor	 for	mortality	 from	GBS	 is	 older	 age	 [6,7,8,9,10,11].	Most	 studies	 also
found	that	GBS	fatalities	have	more	comorbidity,	more	often	need	mechanical	ventilation	and	have	more
severe	weakness	 at	 entry	 to	 the	 hospital	 [6,7,8,9,10,11].	 In	 a	 developing	 country	 like	Bangladesh,	 the
strongest	risk	factor	for	mortality	was	lack	of	ventilator	support	in	patients	with	respiratory	failure	[11].
Timing	of	Death	in	GBS
Winer	 and	 colleagues	 showed	 that	 the	majority	 of	 deceased	GBS	patients	 died	within	 an	 interval	 of	 4
weeks	 [5].	 Italian	GBS	study	group	confirmed	 this	 finding	and	stated	 that	 the	majority	of	GBS	patients
died	within	 the	 acute	 phase	 of	 the	 disease	with	 dysautonomia	 and	 cardiac	 arrest	 as	 leading	 causes	 of
death	[6].	 In	contrast,	Lawn	and	Wijdicks	described	that	only	a	minority	of	 the	fatal	GBS	patients	died
within	 the	first	28	days	[7].	 In	our	own	study	 two-thirds	of	 the	fatal	GBS	patients	died	 in	 the	recovery
phase	[10].	In	the	acute	phase	the	patient	died	of	cardiovascular	or	autonomic	complications,	in	contrast
with	 patients	 who	 died	 in	 the	 recovery	 phase.	 These	 patients	 died	 mostly	 from	 pneumonia	 or
cardiovascular	complications	[10].	 (See	Figure	54.1.)	 Important	 for	clinical	practice	 is	 the	 finding	 that
even	 in	 the	 recovery	phase	of	GBS	patients	are	at	 risk	of	dying.	This	 shift	 from	 the	majority	of	deaths
occurring	during	the	acute	phase	to	the	majority	of	deaths	occurring	in	a	later	stage	could	be	due	to	better
monitoring	 of	GBS	 patients	 in	 their	 acute	 phase	 of	 the	 disease	 at	 high	 care	 or	 intensive	 care	 units	 or
frequent	monitoring	on	a	neurology	ward.
How	to	Reduce	the	Mortality	of	GBS?
There	 is	 very	 little	 evidence	 for	measures	 that	 can	 prevent	 patients	 from	 dying	 from	GBS.	 It	 is	 clear,
however,	 that	GBS	patients	 are	 at	 risk	 of	 dying	 in	 every	phase	 of	 their	 disease,	 especially	 the	 elderly
patient,	patients	with	comorbidity	or	ventilated	GBS	patients.	Physicians	need	to	be	aware	that	patients
who	start	recovering	are	still	at	risk	of	dying.	Some	further	recommendations	may	be	helpful	to	reduce	the
mortality	rate	in	GBS,	although	none	of	these	have	been	evaluated	in	controlled	studies.
Standardized	and	 routine	monitoring	of	vital,	 respiratory	 function	and	weakness,	 in	 the	 acute	phase
every	2	to	4	hours
Checking	for	autonomic	dysfunction	and	swallowing	disturbances
Use	 of	 the	 Erasmus	 GBS	 Respiratory	 Insufficiency	 Score	 to	 predict	 the	 risk	 of	 respiratory
insufficiency.	 This	 can	 help	 physicians	 decide	whether	 the	 patient	 should	 be	 admitted	 to	 a	 general
ward,	high	care	or	intensive	care	[12].
Monitoring,	prevention	and	early	 treatment	of	 infection,	decubitus,	 thrombosis	and	contractures,	and
when	diagnosed	treatment	begun	as	soon	as	possible.
Use	of	step-down	units	for	patients	with	severe	weakness	or	a	trachea	cannula
Figure	54.1		Hospital	admission	and	transfers	in	patients	with	fatal	GBS.	Reproduced	with	permission	from	[10].
Summary	and	Conclusions
Probably	 due	 to	 improvements	 in	 general	 and	 intensive	 care	 of	 GBS	 patients	 the	 mortality	 rate	 has
decreased.	Although	dying	from	GBS	is	uncommon,	GBS	still	is	a	life-threatening	disease,	especially	in
the	elderly,	 in	ventilated	GBS	patients,	and	 in	GBS	patients	with	significant	comorbidity.	GBS	patients
can	 die	 in	 every	 phase	 of	 the	 disease.	 Every	 GBS	 patient	 deserves,	 therefore,	 intensive	 supportive
multidisciplinary	care,	especially	the	patients	at	risk.	There	still	is	a	higher	mortality	rate	in	developing
countries	compared	to	developed	countries	due	to	less	general	and	intensive	care.
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Treatment	of	GBS:	Times	Are	A-Changing:	From
Wait	and	See	to	Active	Interference	of	the	Immune
System
Pieter	A.	van	Doorn
Introduction
Over	the	past	100	years,	Guillain-Barré	syndrome	(GBS)	has	become	a	 treatable	disease.	Neurologists
are	 traditionally	 good	 in	 diagnosing	 a	 disease,	 but	 unfortunately	 treatment	 for	 many	 neuromuscular
diseases	largely	stays	behind.	This,	however,	is	not	the	case	for	GBS!	I	can	remember	very	well	the	year
1985,	when	 the	 landmark	paper	of	 the	North	American	GBS	plasma	exchange	 trial	was	published,	 just
when	I	started	my	residency	in	neurology	[1].	This	changed	the	perspective	on	treating	patients	with	GBS.
Nonetheless,	we	all	know	that	treatment	for	GBS	is	far	from	adequate	and	urgently	needs	to	be	improved.
It	 is	very	challenging	that	 the	knowledge	of	pathophysiological	processes	leading	to	GBS	has	exploded
over	 the	 past	 decade.	This	 hopefully	 helps	 to	 better	 select	 drugs	 or	 any	 other	 treatment	 regimen	 to	 be
tested.	With	the	help	of	proper	outcome	measures	and	using	up-to-date	trial	design,	it	is	to	be	hoped	that
the	 future	 for	GBS	patients	will	 be	much	better	 120	years	 after	 the	 syndrome	was	 first	 described.	My
personal	Top	10	papers	highlight	the	development	towards	a	better	treatment	for	GBS	(see	Figure	55.1).
Plasma	Exchange	Is	the	First	Proven	Effective	Treatment	for	GBS
The	Guillain-Barré	Syndrome	Study	Group.	Plasmapheresis	and	acute	Guillain-Barré
syndrome.	Neurology,	1985
About	70	years	after	the	famous	publication	by	Guillain,	Barré	and	Strohl	[2],	2	small	studies	reported	the
positive	effects	of	plasma	exchange	 (PE)	 in	patients	with	GBS	[3,4].	The	 first	 large	PE	 trial	had	been
conducted	 in	North	America	and	Canada	and	was	publised	 in	1985	 [1].	 I	 can	very	well	 remember	 the
publication	 of	 this	 landmark	 study.	 It	 showed	 that	 PE	 is	 the	 first	 proven	 effective	 treatment	 for	 GBS
patients	 being	 unable	 to	 walk,	 when	 PE	 starts	 within	 the	 first	 4	 weeks	 after	 onset	 of	 disease.	 It	 was
concluded	that	PE	hastens	recovery	compared	to	supportive	treatment	alone	and	especially	when	it	was
started	within	the	first	2	weeks.	Later	on	a	large	PE	trial	from	France	showed	similar	results	[5].	It	was	a
bit	surprising	that	no	difference	was	found	between	fresh	frozen	plasma	(FFP)	compared	to	albulin	as	a
replacement	 fluid	 for	 the	 PE	 procedure,	 because	 FFP	 is	 the	 source	 of	 IVIg,	 and	 FFP	 likely	 is	 also
effective	in	CIDP	[6].	The	PE	trials	used	some	different	exchange	regimens.	In	patients	unable	to	walk,	a
regimen	of	 five	 50-ml/kg	 exchanges	 over	 8–13	days	 seems	 appropriate.	One	other	 large	PE	 trial	 from
France	showed	that	2	PE	sessions	are	better	than	no	exchanges	in	GBS	patients	being	able	to	walk	[7].
Figure	55.1		My	personal	highlights	towards	a	better	treatment	for	GBS	patients.
IVIg	=	 intravenous	 immunoglobulin;	PE	=	 plasma	 exchange;	Methylpred	 =	methylprednisolone;	SID-GBS	=	 Second	 IVIg	 dose
randomized	 trial	 in	 GBS;	 I-SID-GBS	 =	 International	 second	 IVIg	 dose	 prospective	 study	 in	 GBS;	 ICA-GBS	 =	 inhibition	 of
complement	activation	in	GBS;	JET	=	Japanese	eculizumab	trial
*	=	North	American	PE	trial	was	followed	by	important	French	PE	trials
We	need	 to	 acknowledge	 that	PE	 is	 not	 an	 attractive	procedure	 to	be	performed	 in	many	groups	of
patients—for	 example	 young	 children—and	 that	 it	 is	 relatively	 contraindicated	 in	 individuals	 with
autonomic	failure.	Although	it	generally	is	less	expensive	than	IVIg,	it	remains	a	costly	procedure	and	it
requires	special	equipment	and	appropriately	trained	staff.	Therefore,	exchanging	multiple	small	volumes
of	 plasma	 wihout	 using	 a	 special	 apparatus	 potentially	 could	 be	 an	 attractive	 procedure	 for	 a	 large
population	 living	 in	 low-income	 countries.	 Such	 a	 study	 is	 now	 under	 consideration	 (Badrul	 Islam,
personal	information).	Currently,	both	the	effect	and	the	potential	side	effects	first	need	to	be	studied.
First	Paper	on	the	Potential	Effect	of	IVIg	in	GBS
Kleyweg	RP,	et	al.	Treatment	of	Guillain-Barré	syndrome	with	high-dose	gammaglobulin.
Neurology,	1988
Already	during	 the	 recruitment	phase	of	 the	North	American	PE	 trial,	 there	were	 some	pioneers	 in	 the
Netherlands	 who	 aimed	 to	 find	 another	 treatment	 for	 GBS	 and	 chronic	 inflammatory	 demyelinating
polyneuropathy	(CIDP)	[6,8].	This	was	largely	done	because	there	were	local	 logistical	problems	with
conducting	PE	as	a	regular	treatment	in	CIDP	at	that	time.	Here	in	Rotterdam,	as	far	as	I	know,	the	first
patients	 were	 treated	 with	 FFP	 instead	 of	 PE,	 and	 it	 appeared	 effective!	 Then	 a	 resident,	 I	 clearly
remember	 the	first	CIDP	patients	 receiving	 their	 regular	FFP	infusions.	This	 treatment	was	replaced	by
intravenous	immunoglobulin	(IVIg)	when	this	product	became	available	[6,9].	The	beneficial	therapeutic
effect	of	IVIg	in	CIDP	prompted	an	open	study	in	GBS.	The	first	study	included	8	GBS	patients.	It	was
observed	 that	 IVIg	 seemed	 to	be	beneficial	 in	patients	with	 severe	GBS	 [8].	 It	was	concluded	 that	 the
results	should	be	conformed	in	a	randomized	trial.
IVIg	Is	Effective	in	GBS!
van	der	Meché	FG	and	Schmitz	PI.	A	randomized	trial	comparing	intravenous	immune
globulin	and	plasma	exchange	in	Guillain-Barré	syndrome.	New	England	Journal	of
Medicine,	1992
The	 possible	 effect	 of	 IVIg	 in	 GBS	 was	 investigated	 in	 a	 randomized	 controlled	 trial	 (RCT)	 that
compared	IVIg	(0.4	g/kg	bodyweight	for	5	days)	with	standard	PE	treatment.	The	Dutch	GBS	study	group
led	by	Frans	van	der	Meché	started	this	RCT	in	June	1986	and	the	last	patient	entered	the	study	by	the	end
of	 1989.	After	 the	 inclusion	 of	 150	 patients	 and	 a	 follow-up	 of	 half	 a	 year,	 the	 study	was	 terminated
because	strength	had	improved	by	one	grade	or	more	on	the	GBS	diasbility	grade	after	4	weeks	in	34%	of
the	group	treated	with	PE,	compared	to	53%	in	the	group	treated	with	IVIg	(p	=	0.024).	The	IVIg	group
additionally	 had	 significantly	 fewer	 complications	 and	 less	 need	 for	 artificial	 ventilation	 [10].	 It	 was
concluded	 that	 IVIg	 is	 a	 practical,	 safe	 and	 effective	 treatment	 for	GBS.	 This	was	 a	major	 result	 and
would	finally	change	the	world’s	policy	to	treat	GBS!	However,	not	right	at	 that	moment	because	there
initially	was	a	lot	of	debate	whether	IVIg	really	would	be	as	effective	as	PE.	One	paper	indicated	that	a
proportion	of	GBS	patients	 required	a	second	course	of	 IVIg	because	of	a	 treatment-related	 fluctuation
(TRF)	[11].	In	the	IVIg/PE	trial,	the	percentage	of	patients	with	a	TRF,	however,	was	about	the	same	as
for	PE.	Additional	 reports	appeared	[12–14].	Finally,	other	studies	using	IVIg	 in	GBS	were	published.
The	Cochrane	review	concluded	that	IVIg	started	within	2	weeks	from	onset	hastens	recovery	as	much	as
PE,	 that	 adverse	 events	were	 not	 signifiantly	more	 or	 less	with	 IVIg	 compared	 to	 PE,	 but	 that	 IVIg	 is
significantly	much	more	likely	to	be	completed	than	PE	[15–17].
IVIg	currently	is	the	preferred	treatment	for	GBS.	However,	despite	standard	treatment	with	IVIg	(0.4
g/kg	bodyweight	for	5	days),	about	20%	of	patients	require	artificial	ventilation,	many	patients	still	have
severe	pain	for	a	prolonged	period	of	time	and	about	20%	are	still	unable	to	walk	after	half	a	year	[18].
Therefore,	treatment	for	patients	with	GBS	urgently	needs	to	be	improved.	Hopefully	a	better	and	more
individualised	treatment	will	become	available	in	the	coming	years.
Steroids	Are	Surprisingly	Ineffective	in	GBS
Guillain-Barré	Syndrome	Steroid	Trial	Group.	Double-blind	trial	of	intravenous
methylprednisolone	in	Guillain-Barré	syndrome.	The	Lancet,	1993
GBS	is	considered	to	be	caused	by	an	abberant	immune	response	often	related	to	a	preceeding	infection,
that	potentially	could	be	treated	with	corticosteroids,	like	in	CIDP.	Initial	reports	on	oral	steroids	in	GBS
were	not	very	promising.	However,	there	were	methodological	issues.	This	likely	was	the	main	reason	to
conduct	 a	 double-blind	 placebo-controlled	 RCT	 [19].	 The	 242	 patients	were	 randomized	 for	 steroids
(500	mg	methylprednisolone	for	5	days)	or	placebo	treatment.	Some	patients	additionally	received	PE.	It
was	 a	 disappointment	 that	 the	 study	 did	 not	 show	a	 beneficial	 effect	 of	 corticosteroids.	The	Cochrane
review	concluded	that	corticosteroids	given	alone	do	not	signifiantly	hasten	recovery	from	GBS	or	affect
longterm	outcome.	Additionally,	there	is	low-class	evidence	that	oral	corticosteroids	even	delay	recovery
[20].	 An	 important	 question	 is	 now	 whether	 one	 should	 avoid	 steroids	 in	 GBS	 under	 all	 condtions,
including	when	combined	with	IVIg.	Fortunately,	that	was	also	investigated	in	a	large	RCT.
IVIg	and	Steroids	Are	Likely	Not	More	Effective	Than	IVlg	Alone
van	Koningsveld	R,	et	al.	Effect	of	methylprednisolone	when	added	to	standard	treatment
with	intravenous	immunoglobulin	for	Guillain-Barré	syndrome:	randomised	trial.	The
Lancet,	2004
Because	we	hoped	that	we	could	improve	the	outcome	for	GBS	patients,	we	conducted	an	RCT	in	which
we	combined	IVIg	(0.4	g/kg	bodyweight	for	5	days)	with	methylprednisolone	(500	mg/day	for	5	days)	or
placebo	treatment.	We	started	that	study	before	 the	results	of	 the	methylprednisolone	study	were	known
[21].	In	the	MP-IVIg	trial,	225	were	randomized.	The	primary	outcome	criterion	was	that	the	percentage
of	patients	that	improved	at	least	one	grade	on	the	GBS	disability	scale	4	weeks	after	randomization	was
not	significantly	different	between	IVIg	+	MP	and	IVIg	+	placebo.	After	correction	for	known	prognostic
factors	 (a	 post-hoc	 analysis)	 it	 seems	 that	 there	 is	 a	 minor	 advantage	 for	 the	 combiation	 IVIg	 and
methylprednisolone,	but	only	for	an	endpoint	at	4	weeks.	The	overall	conclusion	was	that	the	results	of
the	 trial	 were	 negative,	 but	 that	 a	 small,	 short-time	 benefit	 of	 the	 combination	 IVIg	 and
methylprednisolone	 was	 not	 excluded	 [20].	 All	 together,	 it	 seems	 that	 steroids,	 including	 high-dose
steroids,	are	not	effective	in	GBS.	The	ineffectiveness	of	steroids	to	treat	GBS	remains	puzzling,	because
steroids	are	effective	in	CIDP.
Combination	of	PE	Followed	by	IVIg	Is	Not	Better
Plasma	Exchange/Sandoglobulin	Guillain-Barré	Syndrome	Trial	Group.	Randomised	trial	of
plasma	exchange,	intravenous	immunoglobulin,	and	combined	treatments	in	Guillain-Barré
syndrome.	The	Lancet,	1997
Because	 IVIg	 is	 insufficiently	 effective	 in	 a	 substantional	 portion	 of	 GBS	 patients,	 an	 international
consortium	lead	by	Professor	Hughes	conducted	an	RCT	in	383	adult	GBS	patients	who	were	randomized
for	 IVIg,	PE	and	PE	 followed	by	 IVIg	 [22].	This	 trial	unfortunately	did	not	 find	significant	differences
between	 any	 of	 these	 treatment	 groups.	 This	 is	 a	 very	 important	 study	 because	 it	 shows	 that	 the
combination	of	2	effective	treatments	is	not	necessarily	better	than	only	one	of	these	treatments	alone.	It
remains	a	question	whether	this	is	due	to	the	fact	that	the	second	treatment	was	started	too	late,	when	a	lot
of	nerve	damage	had	already	occurred.	It	has	been	one	of	the	reasons	we	took	care	in	the	design	of	the
second	dose	 IVIg	 trial	 (SID-GBS)	 since	we	decided	 to	 the	 start	 of	 the	 second	 IVIg	 course	or	 placebo
treatment	one	week	after	onset	of	the	first	standard	course	of	IVIg.
Is	More	IVIg	Better?
Kuitwaard	K.	Pharmacokinetics	of	intravenous	immunoglobulin	and	outcome	in	Guillain-
Barré	syndrome.	Annals	of	Neurology,	2009
The	dose	of	 IVIg	 in	 indiviual	patients	 is	currently	based	only	upon	bodyweight.	There	 is	 still	a	debate
about	whether	one	course	of	IVIg	(2	g/kg	administered	in	5	days)	is	adequate	for	all	GBS	patients.	It	is
would	be	preferrable	to	treat	individual	patients	more	based	upon	their	clinical	or	otherwise	biological
characteristics,	or	maybe	based	on	biomarkers	(if	available).	There	are	a	couple	of	arguments	suggesting
that	 some	 patients	 may	 require	 a	 repeated	 or	 otherwise	 higher	 IVIg	 dosage:	 (A)	 about	 10%	 of	 GBS
patients	 have	 a	 secondary	 deterioration	 (TRF)	 that	 improves	 after	 a	 second	 IVIg	 course	 [24];	 (B)	 one
important	study	showed	that	GBS	patients	having	a	higher	rise	in	their	IgG	levels	2	weeks	after	start	of
IVIg	treatment	(delta	IgG)	had	a	higher	chance	to	improve	better	and	faster	[23];	(C)	the	results	of	a	small
open	study	suggested	that	a	second	IVIg	course	might	have	been	beneficial	in	GBS	patients	who	seemed
unresponsive	to	a	standard	dosage	of	IVIg	[25].
Partially	based	upon	these	arguments,	we	started	the	second	dose	IVIg	randomized	placebo-controlled
trial	(SID-GBS)	in	GBS	patients	with	a	poor	prognosis	as	based	upon	the	mEGOS	prognostic	model	[26].
We	expect	that	the	results	of	this	RCT	will	be	available	in	2018.	The	international	version	of	this	study	(I-
SID	GBS)	is	conducted	as	part	of	the	prospective	International	GBS	Outcome	Study	(IGOS).	With	these	2
studies	we	aim	to	investigate	whether	a	second	course	of	IVIg	is	effective	when	started	one	week	after	the
start	of	the	first	IVIg	course,	when	irreversible	nerve	damage	likely	has	not	yet	occurred.	The	first	results
of	the	prospective	follow-up	study	are	expected	in	2017.
The	Importance	of	Supportive	Care
Hughes	RA,	et	al.	Supportive	care	for	patients	with	Guillain-Barré	syndrome.	Archives	of
Neurology,	2005
This	is	a	very	important	publication	because	it	focuses	just	on	supportive	care	for	GBS	patients	[27].	We
need	to	realize	that	good	general	medical	care	remains	essential,	irrespective	of	whatever	immunological
treatment	is	administered.	I	have	also	learned	a	lot	from	the	books	on	GBS	written	by	Richard	Hughes,
Eelco	Wijdicks,	Allan	Ropper	and	Garreth	Parry.	I	am	sure	that	these	books	have	largely	contribited	to
the	 clinical	 knowledge	 and	 understanding	 of	GBS	 of	many	 neurologists,	 intensive	 care	 physicians	 and
others	who	take	care	of	these	patients.	Further	reports	on	good	medical	care,	like	how	to	monitor	patients
in	 the	progressive	phase	of	 the	disease	when	 admitted	on	 a	 general	 neurological	ward,	when	 to	 admit
patients	 on	 an	 intensive	 care	 unit,	 how	 to	 treat	 severe	 pain	 and	 many	 other	 aspects	 of	 giving	 better
psychological	 support	 require	 a	 lot	 of	 attention	 and	 additional	 studies.	Hopefully,	 this	 part	 of	 treating
GBS	will	also	be	part	of	a	future	PNS/EAN	guideline.
Complement	Inhibition	Can	Be	the	Future	for	GBS
Halstead	SK,	et	al.	Eculizumab	prevents	anti-ganglioside	antibody-mediated	neuropathy	in
a	murine	model.	Brain,	2008
In	 this	 amazing	 study,	 built	 upon	 the	 shouders	 of	 a	 lot	 of	 other	 studies,	 in	 particular	 from	 the	Willison
group	 in	Glasgow,	 it	was	 shown	 that	 blockade	of	 complement	 activation	by	 eculizumab,	 a	monoclonal
antibody	 that	 prevents	 the	 formation	 of	membrane	 attack	 complex	 (MAC),	 completely	 inhibits	 clinical
disease	activity	in	mice	[28].	A	clinical	trial	in	humans	lead	by	Hugh	Willison	now	seeks	to	answer	the
question	of	whether	eculizumab	given	together	with	IVIg	is	of	benefit	to	GBS	patients.	The	results	of	the
‘inhibition	of	complement	activation	in	GBS’	(ICA-GBS)	are	eagerly	awaited.	Another	trial,	the	Japanese
eculizumab	trial	(JET)	using	the	same	protocol	has	started	in	Japan.	Inhibition	of	complement	activation
may	push	the	treatment	of	GBS	to	a	new	and	higher	level.
The	Importance	of	Using	Proper	Outcome	Measurements	in	Studying
the	Effect	of	Treatment
Vanhoutte	EK,	et	al.	Outcome	measures	in	inflammatory	peripheral	neuropathies
Neuromuscular	Disorders,	2013
The	Peripheral	Neuropathy	outcome	measures	Standardisation	(PeriNomS)	study,	is	a	large	international
study	 lead	 by	 Ingemar	 Merkies.	 It	 is	 in	 large	 part	 focussed	 on	 assessment	 scales	 in	 patients	 with
inflammatory	neuropathies,	GBS	in	particular.	Rasch-based	new	assessment	scales	will	hopefully	play	an
important	role	in	new	treatment	trials	in	GBS	and	other	immune-mediated	neuropathies.	It	 is	hoped	that
modern	clinimetrics	using	 linear	 scales	will	 finally	help	 to	assess	GBS	patients	 in	a	more	proper	way
than	we	now	generally	do	[29].	An	example	is	the	development	of	the	I-RODS	assessment	scale	[30].
Conclusion
Treatment	 trials	studying	new	drugs,	combinations	of	drugs	or	different	dosing	regimens,	but	also	 large
prospective	studies	like	the	IGOS,	led	by	Bart	Jacobs	are	essential	to	the	search	for	a	better	treatment	for
patients	with	GBS.	Using	modern	 statistics	 and	validated	 assessment	 scales	 is	 extremely	 important	 for
designing	new	treatment	studies	appropriately.	Covariate	adjustment	and	proportional	odds	analysis	can
potentially	help	us	conduct	trials	in	a	more	efficient	manner,	requiring	fewer	patients	to	be	randomized.
This	will	be	done	in	the	current	SID-GBS	trial.	New	treatment	trials,	including	the	studies	assessing	the
effect	of	complement	activation	blockage	(ICA-GBS	and	JET)	are	very	important	because,	unfortunately,
GBS	is	still	a	severe	disease,	100	years	after	the	publication	by	the	3	French	giants	[2].	Fortunately,	there
currently	 is	 substantial	 interest	 in	 researching	 inflammatory	 neuropathies,	 as	 demonstrated	 by	 the	 large
numbers	 of	 delegates	 attending	 the	 Peripheral	 Nerve	 Society	 /	 Inflammatory	 Neuropathy	 Consortium
(INC)	meetings.	With	all	these	new	developments,	it	seems	not	unlikely	that	the	future	for	GBS	patients
and	their	relatives	will	be	better	in	the	next	10	to	20	years.
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Intravenous	Immunoglobulin	(IVIg)	for	Guillain-
Barré	Syndrome:	The	Journey	and	Current
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Introduction
By	 the	 1980s,	 it	 was	 generally	 accepted	 that	 GBS,	 the	 ‘acute	 inflammatory	 demyelinating
polyradiculoneuropathy’	 (AIDP),	 represented	 a	 post-infectious	 immune-mediated	 neuropathy.	 This
hypothesis	 was	 supported	 by	 preceding	 infections	 and	 by	 the	 very	 early	 pathology	 showing	 extensive
lymphocyte	 infiltrations	 in	 roots	 and	 peripheral	 nerves,	 oedema,	 deposition	 of	 complement	 on	 outer
aspects	of	myelin	sheaths	followed	by	vesicular	disruption,	and	macrophages	infiltrating	Schwann	cells
and	acting	as	scavengers	by	engulfing	the	disintegrated	myelin	and	leaving	behind	a	segmentally	denuded
axon.	 Thus,	 the	 primary	 immune	 target	 epitope	 appeared	 to	 be	 localized	 in	 the	 outer	 Schwann	 cell
membrane	or	myelin.	Simultaneously,	nodes	of	Ranvier	became	widened	as	myelin	loops	lifted	off	from
their	 ‘paranodal’	 attachments	 [1,2].	 Degeneration	 of	 axons	 was	 considered	 a	 secondary	 event.	 The
observations	suggested	a	T	cell-dependent,	complement	and	macrophage-mediated	aetiology.	While	target
antigen(s)	remained	elusive,	humoral	factors	seemed	relevant.
In	1979,	Saida	 and	 colleagues	 reported	 an	EAN	model	 in	 rabbits	 induced	by	 sensitization	with	 the
myelin	 constituent	 galactocerebroside	 [3].	 The	 animals	 developed	 flaccid	 paralyses,	 and	 their	 nerve
pathology	showed	extensive	multifocal	demyelination	with	few	infiltrating	lymphocytes.	Subsequently,	the
investigators	injected	serum	from	these	rabbits	intraneurally	into	the	sciatic	nerves	of	Wistar	rats,	which
induced	vesicular	disruption	of	myelin	that	developed	before	the	recruitment	of	macrophages	[4].	A	year
later	my	colleagues	and	I	confirmed	the	observation	[5].	Using	this	paradigm,	we	and	others	observed	that
sera	from	a	proportion	(41–76%)	of	GBS	patients,	particularly	when	obtained	within	the	first	3	weeks	of
the	patients’	illness,	produced	focal	demyelination	and	electro-physiological	alterations	in	rat	nerve,	that
correlated	with	disease	severity	[6,7,8].	These	observations	lend	support	to	the	role	of	humoral	factors	in
the	pathogenesis	of	AIDP	and	GBS.
Plasmapheresis	Becomes	Standard	Therapy	for	GBS
The	Guillain-Barré	Syndrome	Study	Group.	Plasmapheresis	and	acute	Guillain-Barré
syndrome.	Neurology,	1985
Prior	 observations	 and	 anecdotal	 reports	 of	 patients	 with	 GBS	 who	 benefitted	 from	 therapeutic
plasmapheresis	(PE)	led	the	way	to	the	first	large	randomized	controlled	trial	(RCT)	comparing	PE	with
supportive	therapy	in	245	acutely	ill	and	severely	affected	GBS	patients	[9].	Results	showed	statistically
significant	differences	in	all	predefined	outcome	measures	in	favour	of	PE.	PE	was	particularly	effective
when	 started	within	7	days	of	disease	onset,	 and	 for	patients	who	had	 required	mechanical	ventilation
(MV)	after	 randomization.	 In	comparison	with	 standard	 supportive	care,	PE	hastened	 the	 recovery	and
shortened	the	duration	of	disability.	Its	use	in	severe	GBS	was	endorsed	by	a	NIH	consensus	conference
as	standard	therapy	[10],	and	was	reaffirmed	in	1986	by	results	of	a	second	large	French	RCT	[11].
IVIg	Comes	on	the	Scene
In	1980,	Imbach	and	colleagues	first	successfully	used	IVIg	at	an	empirical	dose	of	2g/kg	in	13	children
with	immune-thrombocytopenia	(ITP)	[12].	Once	these	observations	were	confirmed	in	adult	ITP	patients
[13],	the	way	was	clear	to	extend	IVIg	as	immunomodulatory	therapy	to	other	autoimmune	disorders.	In
1985,	 Vermeulen	 and	 colleagues	 reported	 that	 13	 out	 of	 17	 patients	 with	 chronic	 inflammatory
polyneuropathy	 (CIDP)	 had	 benefitted	 from	 infusions	 of	 fresh-frozen	 plasma	 (FFP).	 On	 average,
improvements	 lasted	 3	weeks,	 they	were	 reproducible,	 and	 functions	 stabilized	with	 repeat	 infusions.
Similar	improvements	occurred	in	8	out	of	9	CIDP	patients	after	infusions	of	polyclonal	gammaglobulin,
which	 accounts	 for	 the	 treatment	 effects	 of	 FFP	 [14].	 In	 a	 pilot	 study	 gammaglobulin,	 prescribed	 to	 8
patients	with	severe	GBS,	appeared	to	be	beneficial	[15].
Confirmation	of	the	Therapeutic	Efficacy	of	IVIg	for	GBS
van	der	Meché	FG,	et	al.	A	randomized	trial	comparing	immune	globulin	and	plasma
exchange	in	Guillain-Barré	syndrome.	New	England	Journal	of	Medicine,	1992
Encouraged	by	these	observations,	van	der	Meché	and	colleagues	initiated	an	RCT	comparing	IVIg	(0.4
g/kg	daily	for	5	days)	with	plasmapheresis	(PE,	200–250	mL/kg	in	5	sessions	over	7	to	14	days)	in	150
adult	 patients	 and	 children	 with	 severe	 GBS,	 treated	 within	 7	 days	 from	 onset	 [16].	 Outcome	 was
measured	 with	 the	 disability	 scale	 used	 in	 previous	 trials.	 Primary	 outcome	 measure	 (proportion	 of
patients	improved	by	one	or	more	functional	grades	at	4	weeks)	and	secondary	ones	(time	to	improve	one
functional	 grade	 and	 time	 to	 recover	 unaided	 walking)	 were	 the	 same	 as	 those	 used	 for	 the	 North
American	plasmapheresis	 trial	[9].	Ethical	concerns	ruled	out	a	comparison	with	placebo.	The	van	der
Meché	study	was	not	blinded,	leaving	room	for	bias.	Although	the	2	study	groups	appeared	appropriately
matched,	more	patients	in	the	PE	group	had	required	MV	and	for	a	longer	time,	and	more	had	very	low
amplitudes	of	the	distally	evoked	compound	muscle	action	potentials	(CMAPs),	both	shown	previously	to
be	associated	with	a	worse	prognosis.
According	 to	 predetermined	 rules,	 enrolment	 was	 stopped	 after	 the	 150th	 patient	 as	 the	 interim
analysis	of	the	primary	outcome	measure	significantly	favoured	IVIg.	Results	indicated	that	53%	patients
treated	with	IVIg	had	improved	by	one	or	more	functional	grades	at	4	weeks,	compared	to	34%	patients
treated	with	PE	(p	=	0.024).	The	analysis	of	secondary	outcome	measures	equally	favoured	IVIg.	Median
times	to	improve	one	functional	grade	were	27	days	for	the	IVIg	group	versus	41	days	for	the	PE	group	(p
=	0.05),	and	the	median	time	to	recover	unaided	walking	was	55	days	for	the	IVIg	group	versus	69	days
for	 the	PE	group	(p	=	0.07).	 IVIg	 treatments	were	well	 tolerated	and	more	 likely	 to	be	completed,	and
associated	medical	complications	were	significantly	less	frequent.
The	 trial	 results	 were	 met	 with	 great	 interest,	 but	 also	 raised	 concerns	 as	 observations	 with	 PE
differed	 substantially	 from	 those	 of	 the	 2	 prior	 large	 RCTs.	 Using	 the	 same	 outcome	 measures
—‘proportion	of	patients	improved	by	one	or	more	functional	grades	at	4	weeks’—the	earlier	trials	had
documented	a	response	rate	with	PE	of	59%	and	61%,	respectively,	differing	from	Dutch	trial	results.	The
issues	were	resolved	by	the	landmark	trial	initiated	and	conducted	by	Dr	Richard	Hughes	[17].
Plasma	Exchange/Sandoglobulin	Guillain-Barré	Syndrome	Trial	Group.	Randomised	trial	of
plasma	exchange,	intravenous	immune-globulin,	and	combined	treatments	in	Guillain-Barré
syndrome.	The	Lancet,	1997
The	 relative	 efficacy	 of	 plasma	 exchange	 (PE),	 intravenous	 immunoglobulin	 (Sandoglobulin)	 and	 the
combined	regimen	of	PE	immediately	followed	by	IVIg	were	compared	in	383	adult	patients	with	severe
GBS,	 who	 were	 randomized	 within	 14	 days	 from	 disease	 onset	 and	 studied	 by	 an	 international,
multicentre	RCT	[17].	The	‘disability	at	4	weeks’—the	primary	endpoint—was	assessed	by	an	examiner
who	 had	 no	 knowledge	 of	 the	 treatments,	 eliminating	 potential	 bias.	 The	 3	 study	 groups	 were	 evenly
matched	according	to	age	and	sex,	functional	impairments,	delay	of	randomized	treatments	from	onset	of
neuropathy,	and	baseline	characteristics	known	to	influence	prognosis.
On	analysis,	there	were	no	significant	differences	between	the	3	groups	in	the	major	outcome	criterion
—‘mean	disability	 grade	 improvement	 after	 4	weeks’.	The	difference	of	 improvement	between	 the	PE
group	 and	 the	 IVIg	 group	 was	 0.1	 grade	 (95%	 CI	 –0.23	 to	 0.42),	 where	 by	 the	 pre-set	 criterion	 for
equivalence	of	the	2	treatments	was	met.	Moreover,	differences	of	improvement	between	PE+	IVIg	group
and	PE	alone	of	0.20	grade	(95%	CI	–0.14	to	0.54)	and	IVIg	alone	0.29	grade	(95%	CI	–0.04	to	0.54)
respectively,	 were	 not	 significant.	 Furthermore,	 there	 were	 no	 significant	 differences	 between	 the
treatment	groups	in	regards	to	the	secondary	outcome	measures:	time	to	recover	unaided	walking;	median
time	to	discontinue	mechanical	ventilation;	and	pattern	of	recovery	over	48	weeks.	At	48	weeks,	16%	of
patients	 in	 each	 group	were	 left	 severely	 disabled	 and	 unable	 to	walk	 unaided,	 and	~5%	patients	 had
died.	The	median	times	to	hospital	discharge	and	to	return	to	work	did	not	differ	significantly	between	the
treatment	groups.
The	trial	results	documented	unequivocally	that	PE	and	IVIg	had	equivalent	efficacy	in	the	treatment	of
severe	 GBS,	 and	 that	 the	 combined	 treatment	 did	 not	 confer	 additional	 benefit.	 A	 regression	 analysis
confirmed	 that	older	age,	 small	distally	evoked	CMAP	amplitudes,	and	prior	gastrointestinal	 infections
adversely	affected	the	prognosis,	irrespective	of	the	treatment.
Adverse	effects	attributed	to	IVIg	(malaise,	nausea/vomiting,	rigor,	fever,	flu-like	symptoms,	myalgia,
chest	 pain,	 meningism,	 erythema	 at	 infusion	 site)	 were	 short	 lived	 and	 responded	 to	 symptomatic
treatment.	Complications	with	PE	were	potentially	more	serious,	and	25%	of	planned	PE	treatments	had
been	interrupted	versus	only	2.8%	of	IVIg	infusions.	Given	the	equivalent	efficacy	and	the	greater	ease	of
application,	IVIg	was	recommended	as	the	preferred	treatment.
Efficacy	of	IVIg	in	Children	with	GBS
Jones	HR	Childhood	Guillain-Barré	syndrome:	clinical	presentation,	diagnosis,	and
therapy.	Journal	of	Child	Neurology,	1996
In	childhood	GBS	is	much	less	common	but	may	affect	children	of	all	ages.	The	clinical	presentation	can
be	variable	and	a	diagnostic	challenge.	Most	children	have	a	relatively	limited	clinical	illness	and	remain
able	to	walk	unaided.	However,	nearly	25%	become	severely	ill	with	a	rapidly	ascending	quadriparesis,
facial	and	bulbar	weakness	requiring	intubation,	assisted	ventilation	and	intensive	monitoring.	Death	due
to	 sepsis	or	 autonomic	 failure	 is	 rare.	The	prognosis	 for	 children	with	GBS	 is	 excellent,	 as	nearly	 all
make	a	full	recovery.
Most	 controlled	 RCTs	 evaluating	 the	 efficacy	 of	 PE	 and	 IVIg	 had	 excluded	 children.	 Hence,
observations	 in	 severely	 affected	 adult	GBS	 patients	 have	 been	 extrapolated	 to	 children.	 This	may	 be
justified,	as	a	comparative	study	of	18	children	and	50	adults	 from	a	single	centre	 found	no	significant
differences	 in	 disease	 severity,	 need	 for	MV	 and	 duration	 of	 hospitalization	 [18].	 Immunomodulatory
treatments	are	used	primarily	for	children	who	have	lost	independent	ambulation.
Following	the	endorsement	of	PE	as	standard	treatment	for	severe	GBS	[9],	several	anecdotal	reports
of	small	case	series	using	historical	controls	documented	that	children	with	severe	GBS	benefitted	from
PE	[19].	Results	of	this	Dutch	RCT,	which	had	shown	equivalence	for	IVIg	and	PE	in	hastening	recovery
from	GBS,	 influenced	 the	choice	of	 therapy	 for	children	 [20].	From	 then	on,	 IVIg	 largely	 replaced	PE,
given	the	more	convenient	delivery.	Reports	of	uncontrolled	prospective	case	series	documented	benefit
from	IVIg	in	childhood	GBS	[21].	These	observations	were	confirmed	by	the	retrospective	analysis	of	a
larger	study,	which	compared	IVIg	to	supportive	care	in	75	children	with	GBS,	and	compared	2	dosing
regimes	 of	 IVIg	 [22].	 The	 study	 comprised	 3	 groups	 that	 were	 evenly	 matched	 in	 regards	 to	 disease
severity.	Twenty-four	children	received	IVIg	1g/kg	for	2	days,	23	children	IVIg	0.4g/kg	for	5	days,	and	28
children	 received	 supportive	 care.	 The	 primary	 outcome	 measures	 were	 ‘mean	 time	 to	 improve	 1
disability	grade’,	and	‘mean	grade	change	at	4	weeks’.	On	analysis,	the	mean	time	to	improve	1	disability
grade	was	 significantly	 shorter	with	 IVIg	 irrespective	of	dosing:	20.8	days	with	 IVIg	versus	62.4	days
with	 supportive	care	 (P	<	 0.01).	Moreover,	 at	 4	weeks	 improvement	with	 IVIg	was	 a	mean	1.0	 grade
versus	a	mean	0.35	grade	with	supportive	care	(P	<	0.01).	While	the	study	is	limited	by	its	retrospective
nature,	the	observed	large	differences	strongly	suggest	that	IVIg	benefits	childhood	GBS.	A	prospective
randomized	 study	compared	 IVIg	with	PE	 in	41	children	with	 severe	GBS	 requiring	MV	[23].	Twenty
children	randomized	to	IVIg	and	21	children	to	PE	treatment.	The	2	groups	were	balanced	in	regards	to
baseline	characteristics	and	motor	dysfunctions.	Primary	outcomes	measures	were	duration	of	MV,	length
of	stay	in	the	intensive	care	unit	(ICU),	and	ability	to	walk	within	4	weeks	from	discharge	from	the	ICU.
The	open	nature	of	 the	 trial	 left	 room	for	bias.	Results	 indicated	that	children	treated	with	PE	required
MV	for	a	median	11	days	(IQR	11.0	to	13.0)	versus	those	with	IVIg	for	a	median	13	days	(IQR	11.3	to
14.5)	P	=	0.037.	There	were	nonsignificant	differences	in	the	length	of	ICU	stay	and	in	the	outcome	at	4
weeks	 as	 20	 out	 of	 21	 children	 treated	 with	 PE	 and	 18	 out	 of	 20	 treated	 with	 IVIg	 had	 regained
independent	ambulation.	The	 trial	concluded	 that	PE	had	a	slight	but	significant	advantage	over	IVIg	 in
reducing	the	time	of	MV.	The	study	was	not	blinded,	which	could	have	introduced	bias.
A	second	prospective	randomized	multicentre	study	by	Korinthenberg	and	colleagues	sought	to	clarify
whether	 early	 treatment	with	 IVIg	mitigates	 the	 subsequent	disease	 severity	 [24].	Twenty-one	children,
who	were	able	to	walk	unaided,	were	randomized	to	IVIg	(1g/kg	over	2	days;	half	the	usual	dose)	or	no
treatment.	Concealed	randomization	resulted	in	unequal	allocation	of	14	participants	to	IVIg	and	only	7	to
no	 treatment.	 The	 2	 groups	 were	 otherwise	 matched.	 ‘Degree	 of	 disability	 at	 nadir’	 was	 the	 primary
outcome	measure.	Eleven	of	the	21	children	progressed	to	losing	the	ability	to	walk	unassisted,	7	out	of
14	 on	 IVIg	 and	 4	 out	 of	 7	 on	 no	 treatment,	 a	 nonsignificant	 difference	 (P	 =	 0.25).	 However,	 the
improvement	 in	 disability	 at	 4	 weeks	 was	 significantly	 greater	 in	 the	 group	 treated	 early	 than	 in	 the
untreated	participants	(the	mean	difference	(MD)	–1.42,	95%	CI	–2.57	to	–0.27).	The	same	investigators
assessed	 the	 effect	 of	 IVIg	 dosing	 in	 a	 second	 trial	 involving	 51	 children	 who	 were	 unable	 to	 walk
unaided:	25	participants	 randomized	 to	 IVIg	2g/kg	over	2	days,	and	26	 to	 IVIg	2g/kg	over	5	days.	The
primary	 outcome	 measure	 was	 ‘days	 to	 regain	 unaided	 walking’.	 Results	 showed	 no	 significant
differences	in	the	time	to	regain	unaided	walking	irrespective	of	IVIg	dosing:	median	19	days	for	IVIg	2
day	 group	 versus	median	 13	 days	 for	 IVIg	 5	 day	 group	 (log-rank	 test	 P	=	 0.94).	 The	median	 time	 to
improve	1	point	in	disability	score	was	5	days	in	both	groups.	Multivariate	analysis	showed	that	‘disease
severity	at	nadir’	was	the	only	prognostic	determinant	for	recovery.	Different	IVIg	dosing	regimes	did	not
influence	 recovery	 time	 or	 outcome.	 However,	 treatment-related	 fluctuations	 were	 significantly	 more
frequent	with	treatment	when	IVIg	2g/kg	was	given	over	2	days.
Despite	 efforts	 to	 arrive	 at	 objective	 guidance	 for	 the	 use	 of	 IVIg	 in	 childhood	 GBS,	 all	 studies
suffered	 from	 small	 enrolment	 and	 variable	 potential	 for	 bias.	 Nonetheless,	 observations	 point
consistently	to	a	beneficial	effect	of	IVIg	in	children.	These	underscore	the	current	guidelines	to	prescribe
immunomodulation	with	either	IVIg	or	PE	in	children	with	severe	GBS,	unable	to	walk	10	meters	without
assistance.	 There	 is	 limited	 evidence	 that	 children	 with	 milder	 disease,	 able	 to	 walk	 10	 meters
unassisted,	would	benefit	from	early	IVIg	treatment.	In	view	of	the	natural	speedy	recovery	and	excellent
outcome	in	childhood	GBS,	it	would	be	justified	to	monitor	such	children	closely	without	use	of	special
treatments.	 Anecdotal	 evidence,	 cited	 below,	 suggests	 that	 children	 suffering	 from	 acute	motor	 axonal
neuropathy	(AMAN)	might	benefit	from	IVIg	[25].
Efficacy	of	IVIg	in	Axonal	Forms	of	GBS
Shahrizaila	N,	et	al.	Antibodies	to	single	glycolipids	and	glycolipid	complexes	in	Guillain-
Barré	syndrome	subtypes.	Neurology,	2014;	Susuki	K,	et	al.	Dysfunction	of	nodes	of
Ranvier:	A	mechanism	of	anti-ganglioside	antibody-mediated	neuropathies.	Experimental
Neurology,	2012;	Kuwabara	S,	Yuki	N.	Axonal	Guillain-Barré	syndrome:	concepts	and
controversies.	Lancet	Neurology,	2013.
The	primary	axonal	 autoimmune	neuropathies	 constitute	 a	 spectrum	of	 clinical	disorders	with	 a	 shared
immunopathogenesis.	 The	 above	 papers	 by	 Shahrizaila,	 Susuki	 and	 Kuwabara	 and	 colleagues	 are
landmark	 publications	 in	 establishing	 this	 concept	 [26,27,28].	Most	 often,	 the	 triggering	 infections	 are
caused	 by	 strains	 of	 C.	 jejuni	 and	 Haemophilus	 influenzae,	 which	 express	 epitopes	 in
lipooligosaccharides	of	 their	cell-surface	 that	are	homologous	with	gangliosides	expressed	on	neurons.
Given	the	molecular	mimicry,	immune	responses	in	the	host	induce	anti-ganglioside	autoantibodies,	which
recognize	ganglioside	epitopes	in	the	axolemma	of	nerve	fibres	most	accessible	at	the	nodes	of	Ranvier
and	nerve	terminals.	Binding	of	autoantibodies	to	their	 targets	induces	complement-mediated	damage	to
nodal	and	paranodal	molecular	structures	and	to	terminal	axons	[29].	Blockade	or	disruption	of	sodium
channel	clusters	at	 the	nodes	of	Ranvier	causes	impaired	nerve	excitability,	conduction	block	(CB)	and
rapid	 loss	of	 function.	Depending	on	 the	degree	of	damage,	CB	may	be	 reversible	with	 resulting	early
clinical	 improvement.	 Alternatively,	 recruitment	 of	 macrophages	 and	 progression	 of	 complement-
mediated	pathology	causes	axonal	degeneration	and	consequently	protracted	recovery	[30].
The	 clinical	 manifestations	 of	 acute	 motor	 axonal	 neuropathy	 (AMAN),	 acute	 motor	 and	 sensory
axonal	neuropathy	(AMSAN),	acute	sensory	ataxic	neuropathy	(ASAN),	and	the	Fisher	syndrome	(FS)	are
each	associated	with	distinct	anti-ganglioside	autoantibody	profiles.	These	disorders	extend	the	spectrum
of	 GBS	 and	 make	 up	 between	 30%	 and	 67%	 of	 GBS	 cases	 in	 East	 Asia	 and	 in	 Central	 and	 South
America,	while	they	represent	less	than	10%	of	GBS	in	Europe	and	North	America	[31].	Previous	RCTs
that	examined	the	efficacy	of	IVIg	in	GBS	had	enrolled	participants	from	Europe	and	North	America,	most
of	whom	had	suffered	from	AIDP.	There	are	no	reported	RCTs	examining	IVIg	in	axonal	forms	of	GBS
and	 related	 conditions.	Few	 retrospective	 analyses	 have	 explored	 the	potential	 of	 benefit	 from	 IVIg	 in
children	and	adults	afflicted	with	AMAN	or	FS	[32,33,34].
Observations	in	Acute	Motor	Axonal	Neuropathy	(AMAN)
This	rapidly	evolving,	purely	motor	neuropathy,	AMAN,	is	commonly	preceded	by	a	diarrhoeal	 illness
caused	by	C.	 jejuni	 strains	 that	 induce	 IgG	 anti-ganglioside	 antibodies	 against	GM1,	GD1a,	GalNAc-
GD1a	and	GD1b,	a	pattern	characteristic	for	AMAN.	The	clinical	course	is	marked	by	an	acute	onset	of
flaccid	 weakness	 that	 initially	 affects	 the	 lower	 limbs,	 ascending	 upwards	 but	 often	 sparing	 cranial
nerves.	In	contrast	to	AIDP,	tendon	reflexes	may	be	preserved.	Usually,	patients	will	have	reached	their
nadir	within	days,	often	at	their	first	presentation	to	a	physician.	They	may	be	able	to	ambulate	or	be	bed-
bound,	 and	 approximately	 25%	 require	 assisted	 ventilation	 [35].	At	 times,	 recovery	 from	 paralysis	 in
AMAN	can	be	remarkably	fast,	within	days	from	onset,	which	is	due	to	resolution	of	conduction	block	at
the	 nodes	 of	Ranvier.	Alternatively,	 recovery	 is	more	 protracted	because	 of	more	 severe	 complement-
mediated	 damage	 to	 motor	 axons	 with	 ensuing	 axonal	 degeneration	 [30,36].	 Preceding	 diarrhoea	 is
considered	 a	 prognostic	 marker	 of	 less	 favourable	 outcome,	 yet	 recovery	 in	 children	 with	 AMAN	 is
usually	speedy	and	good	[37].
To	determine	incidence	and	prognosis	of	AIDP	and	AMAN	in	childhood	GBS	in	Japan,	data	from	31
children	with	GBS	were	analysed	retrospectively	[33].	According	to	electrodiagnostic	criteria	they	were
classified	as	AIDP	35%	(n	=	11),	AMAN	48%	(n	=	15),	and	undetermined	cases	16%	(n	=	 5).	The	2
defined	groups	did	not	differ	significantly	in	age,	sex	and	median	clinical	disability	at	nadir	(AIDP	4.0
(2–4)	 versus	 AMAN	 4.0	 (2–5)).	 Nearly	 half	 of	 the	 children	 with	 AMAN	 had	 suffered	 a	 preceding
gastroenteritis,	and	4	patients	had	required	MV.	Five	patients	in	each	group	were	only	mildly	affected	and
not	treated.	Six	AIDP	patients	(55%)	were	treated	with	IVIg,	and	8	AMAN	patients	(53%)	received	IVIg
and	2	PE.	At	6	months	all	children	with	AIDP	and	80%	AMAN	children	were	able	to	walk	unaided.	By	2
years	 all	 but	 1	 child	 with	 AMAN	 (93%)	 had	 regained	 independent	 ambulation.	 Hence,	 the	 authors
suggested,	that	the	long-term	prognosis	for	the	2	subtypes	of	childhood	GBS	may	be	similar.
The	 secondary	 analysis	 of	 participants	 in	 the	 original	 Dutch	 RCT	 of	 IVIg	 and	 PE	 in	 severe	 GBS
identified	27	participants	with	characteristics	of	AMAN:	16	had	 randomized	 to	 IVIg	and	11	 to	PE.	On
assessment	 at	 6	months	 14	 out	 of	 16	 participants	 treated	with	 IVIg	 had	 regained	 independent	walking
compared	 to	only	5	out	of	11	 treated	with	PE	(P	=	0.02).	The	authors	suggested	 that	 IVIg	might	be	 the
preferred	treatment	for	AMAN	[38,39].
The	retrospective	analysis	of	24	adult	AMAN	patients,	who	had	been	treated	either	with	IVIg	(n	=	10)
or	PE	(n	=	14)	came	to	the	same	conclusion	[32].	The	2	groups	did	not	differ	significantly	 in	age,	sex,
median	disability	 grades,	CMAP	 sum	 scores	 and	 frequency	of	C.	 jejuni	 infections.	 Those	 treated	with
IVIg	had	significantly	lower	disability	scores	at	1,	3	and	6	months	from	onset	of	treatment	(P	=	0.03),	and
they	 also	had	 a	higher	probability	 to	 regain	 independent	 ambulation	 at	 6	months	 (log	 rank	P	=	 0.044).
Moreover,	6	out	of	10	patients	treated	with	IVIg	had	shown	markedly	rapid	improvements	of	2	or	more
disability	 grades	 in	 the	 first	 4	weeks	 compared	 to	 only	 3	 out	 of	 14	 in	 the	 PE	 group	 (P	=	 0,03).	At	 6
months,	 all	 IVIg-treated	 patients	 had	 regained	 independent	 ambulation	 while	 4	 out	 of	 14	 PE-treated
patients	had	a	very	delayed	recovery	(p	=	0.07).	These	observations,	albeit	derived	from	a	small	number
of	AMAN	patients,	suggest	that	IVIg	may	be	the	preferred	treatment	modality	in	AMAN.
Observations	with	IVIg	in	the	Fisher	Syndrome
Ito	M,	et	al.	Bickerstaff’s	brainstem	encephalitis	and	Fisher	syndrome	form	a	continuous
spectrum.	Clinical	analysis	of	581	cases.	Journal	of	Neurology,	2008
Although	the	Fisher	syndrome	(FS)	is	a	unique	entity,	it	is	included	in	the	wider	spectrum	of	GBS	because
of	its	post-infectious	aetiology,	presence	of	pathogenic	anti-ganglioside	autoantibodies	against	GQ1b	and
GT1a	 in	 85%	 of	 cases,	 and	 observations	 of	 clinical	 overlap	 with	 GBS	 in	 ~7%	 of	 FS	 patients.	 Such
patients	 have	 a	 combined	 presentation	 of	 FS	 and	 AMAN,	 characterized	 by	 a	 descending	 pattern	 of
paralyses,	frequent	need	for	MV	and	a	less	favourable	prognosis	[40].
In	 Japan,	FS	 is	more	prevalent	 in	middle-aged	men	 (male	 to	 female	 ratio	 is	2:1).	A	 review	of	466
representative	FS	patients	indicated	that	most	patients	recalled	an	infectious	illness	within	the	preceding
week,	causing	either	only	upper	 respiratory	symptoms	 (64%),	or	only	diarrhoea	 (13%),	or	both	 (12%)
[41].	 Serologic	 and	 cultural	 evidence	 attested	 to	 a	 recent	 infection	with	H.	 influenzae	 or	C.	 jejuni	 in
some	of	the	patients,	yet	for	most	the	causative	agent	remained	undefined.	Initial	symptoms	were	abrupt
onset	 of	 diplopia	 or	 gait	 disturbance.	 All	 patients	 presented	 the	 classical	 triad	 of	 external
ophthalmoplegia,	 ataxia,	 and	 hypo-	 or	 areflexia.	 Blepharoptosis,	 mydriasis	 and	 facial	 weakness	 were
seen	in	one-third	of	patients,	while	mild	bulbar	and	limb	weakness	were	seen	in	one-quarter	of	patients.
At	 nadir,	 reached	 within	 a	 median	 4	 days	 (range	 1–20),	 nearly	 one-third	 of	 patients	 had	 complete
ophthalmoplegia	and	one-third	were	unable	to	walk	independently.
Although	half	of	 the	patients	 reported	mydriasis,	 loss	of	deep	sensation	was	rare	and	sensory	nerve
conduction	 studies	 were	 normal.	 Results	 of	 a	 body-sway	 analysis	 indicated	 dysfunction	 of	 group	 1a
sensory	neurons	 and	proprioceptive	 afferents.	Brain	MRI	 studies	were	normal	 in	 all	 but	1%	of	 the	FS
patients	in	whom	minor	abnormalities	were	found	in	the	brainstem.	CSF	albominocytological	dissociation
was	 present	 in	 76%	 of	 patients,	 and	 anti-GQ1b	 IgG	 antibodies	 and	 anti-GT1a	 IgG	 antibodies	 were
detected	in	86%	of	FS	patients	[41].	The	GQ1b	epitope	is	expressed	in	the	paranodal	regions	of	human
ocular	motor	nerves,	 in	muscle	spindles	and	 in	dorsal	 root	ganglia,	explaining	 the	clinical	presentation
[42,43].
FS	is	a	monophasic	illness,	characterized	by	spontaneous	recovery	and	generally	good	prognosis.	The
natural	history	and	course	of	recovery	have	been	delineated	from	a	study	of	28	consecutive	patients,	who
had	not	received	immunotherapy	and	were	followed	for	a	median	period	of	4	months	(range	1–185)	[44].
Earliest	signs	of	recovery	of	ataxia	and	ophthalmoplegia	were	noted	at	a	median	2	weeks	from	onset	of
neurologic	disease.	Ataxia	was	 fully	 reversed	by	a	median	32	days	 (8	 to	271),	while	 the	 resolution	of
ophthalmoparesis	required	a	median	88	days	(29–165).	By	6	months,	almost	all	patients	had	made	a	full
functional	recovery.
Excellent	natural	outcome	was	no	less	than	that	of	FS	treated	with	IVIg	or	PE.	A	retrospective	analysis
of	92	FS	patients	compared	outcomes	for	28	patients	treated	with	IVIg	with	those	of	23	patients	treated
with	PE,	and	those	of	41	FS	patients,	who	were	left	untreated	[34].	The	3	groups	were	evenly	matched
with	 the	exception	of	 the	frequency	of	complete	ophthalmoplegia,	which	was	significantly	higher	 in	 the
IVIg	 group	 (p	 =	 0.007).	 The	 time	 from	 onset	 of	 ataxia	 and	 ophthalmoplegia	 to	 the	 earliest	 signs	 of
improvement	was	significantly	shorter	in	the	IVIg	treated	group	compared	to	the	control	group	(ataxia	p	=
0.027;	ophthalmoplegia	p	=	0.04).	However,	 the	 times	 required	 for	 the	 full	 resolution	of	 the	symptoms
were	not	 significantly	different	between	 the	3	groups;	 this	was	also	 seen	 in	 a	 sub-analysis	of	 the	most
severely	affected	patients.	At	one	year	after	onset	of	the	neurological	symptoms	in	96%	FS	patients	had
fully	recovered.	The	study	concluded	that	IVIg	slightly	hastened	the	recovery	in	FS	patients	but	that	did
not	 affect	 the	 outcome.	 Interestingly,	 PE	 did	 not	 seem	 as	 effective	 in	 FS	 as	 had	 been	 observed	 in	 a
previous	study	[45].
In	view	of	 the	fairly	rapid	recovery	and	generally	excellent	prognosis	of	FS,	 there	is	consensus	that
IVIg	 treatments	 should	 be	 reserved	 for	 FS	 patients	 who	 are	 unable	 to	 ambulate	 or	 have	 overlapping
presentations	of	either	FS/GBS	or	of	FS/Bickerstaff	brainstem	encephalitis.
Potential	Mechanism	of	Action	of	IVIg	in	GBS
Buttman	M,	et	al.	Polyclonal	immunoglobulin	G	for	autoimmune	demyelinating	nervous
system	disorders.	Trends	in	Pharmacological	Sciences,	2013;	Shahrizaila	N,	Yuki	N.	The
role	of	immunotherapy	in	Guillain-Barré	syndrome:	understanding	the	mechanism	of	action.
Expert	Opinion	on	Pharmacotherapy,	2011;	Hughes	RA	et	al,	Intravenous	immunoglobulin
for	Guillain-Barré	syndrome,	Cochrane	Database	Syst	Rev,	2014
Intravenous	 immunoglobulin	 (IVIg)	 preparations	 comprise	 the	 pooled	 fraction	 of	 serum	 IgG	 from
thousands	 of	 healthy	 blood	 donors,	 generated	 by	 a	multistep	 purification	 process	 of	 cryoprecipitation,
followed	by	ethanol	fractionation	and/or	chromatography.	The	large	donor	pool	ensures	a	wide	spectrum
of	 natural	 and	 induced	 antibody	 activities,	 including	 antibodies	 directed	 against	 external	 antigens,
autoantibodies	 and	 anti-idiotypes.	 This	 polyclonal	 antibody	 repertoire	 is	 likely	 important	 for	 the
therapeutic	effects	of	IVIg	[46,47,48].	Various	measures	are	taken	for	the	inactivation	of	viruses	and	other
infectious	 agents,	 and	 for	 the	 depletion	 of	 ABO	 antibodies,	 to	 reduce	 the	 risk	 of	 contamination	 and
haemolytic	 reactions,	 respectively.	Concentrations	of	 IgA	are	kept	 to	a	minimum	(<	2.5%)	 to	avoid	 the
risk	for	anaphylactic	reactions	in	patients	with	IgA	deficiency	carrying	anti-IgA	antibodies.	Care	is	taken
to	 remove	 IgG	 aggregates	 to	 avoid	 cytokine	 release	 and	 overt	 immune	 stimulation.	 Thus,	 IVIg
preparations	 contain	 ~95%	 monomeric	 IgG,	 with	 a	 distribution	 of	 IgG	 subclasses	 equalling	 those	 of
normal	 serum.	Most	 commercial	 IVIg	 preparations	 also	 include	 stabilizers,	 such	 as	 sorbitol,	 glycine,
sucrose	or	L-proline,	which	may	potentially	contribute	 to	 the	adverse	effects,	such	as	headache,	nausea
and	fever.	 In	general,	 IVIg	 infusions	are	well	 tolerated,	with	side	effects	occurring	 in	 less	 than	10%	of
patients.	 The	 various	 proprietary	 IVIg	 preparations	 are	 considered	 as	 therapeutically	 equivalent	 and
comparable	in	safety	and	in	cost.
Mechanisms	by	Which	IVIg	Exerts	Anti-inflammatory	and
Immunomodulatory	Effects
Therapeutically	administered	high-dose	IVIg	can	interfere	with	the	adaptive	and	innate	 immune	systems
via	 antigen-specific	 (mediated	 by	 the	 antigen-binding	 IgG	 Fab	 region),	 and	 non-antigen-dependent
mechanisms	(mediated	via	the	IgG	constant	Fc	region).	Both	domains	participate	in	the	anti-inflammatory
and	 immunomodulatory	 activity	 of	 IVIg.	 It	 is	 likely	 that	 several	 mutually	 nonexclusive	 mechanisms
contribute	to	the	beneficial	effects.
Commercial	 preparations	 of	 IVIg	 contain	 a	multitude	 of	 highly	 specific	 antibodies	 generated	by	 the
adaptive	 immune	 system	of	 contributing	blood	donors	 after	 exposure	 to	 infectious	microbial	organisms
and	external	foreign	antigens,	as	well	as	natural	antibodies	and	anti-idiotypic	antibodies.	The	latter	are	of
particular	 importance	 as	 they	 recognize	 the	 antigen-detecting	 domains	 of	 other	 antibodies	 and	 are	 thus
potentially	able	to	block	or	neutralize	pathogenic	autoantibodies,	thereby	preventing	the	antibody-induced
activation	of	the	complement	cascade.	Natural	self-reacting	antibodies	are	an	integral	component	of	IVIg
and	 are	 believed	 to	 contribute	 to	 immunoregulatory	 effects	 of	 IgG	 by	 establishing	 normal	 immune
homeostasis	 [49].	 IVIg	 also	 contains	 neutralizing	 antibodies	 against	 pro-inflammatory	 cytokines.	 In
parallel,	Fc-mediated	mechanisms	play	a	major	role.	Saturation	of	neonatal	Fc	receptors	(FcRns)	by	IgG
may	accelerate	clearance	of	circulating	autoantibodies.	 IgG-mediated	blockade	of	activating	Fc-gamma
receptors	(FcγRs)	on	macrophages	may	lead	to	decreased	secretion	in	pro-inflammatory	cytokines,	as	is
found	in	serum	of	GBS	patients.	It	also	blocks	the	complement	pathway	and	thereby	prevents	the	C5b-9
membrane	 attack	 complex-mediated	 pathology.	Moreover,	 IVIg	 has	 profound	 effects	 on	 both	 T	 and	 B
lymphocytes,	 the	 key	 cellular	 components	 of	 the	 adaptive	 immune	 system,	 by	 suppressing	 pro-
inflammatory	 T	 cells,	 inhibiting	 cytotoxic	 T	 cells,	 upregulating	 T	 regulatory	 cells,	 and	 by	 inducting	 a
protective	 Th1/Th2	 shift.	 Importantly,	 IgG-induced	 upregulation	 of	 the	 inhibitory	 FcγRIIB	 receptor	 on
antigen	presenting	dendritic	cells	(DC)	modulates	T-cell	activation.	Furthermore,	upregulation	of	FcγRIIB
receptors	 on	 B	 cell	 surfaces	 results	 in	 diminished	 antigen-induced	B	 cell	 proliferation	 and	 decreased
antibody	production.	Moreover,	IgG-	mediated	cross-linking	of	FcγRIIB	receptors	on	B	cells	and	plasma
cells	induces	apoptosis,	thereby	maintaining	B-cell	and	plasma-cell	homeostasis.	In	addition,	IgG	exerts
anti-inflammatory	effects	by	downregulating	 the	expression	of	adhesion	molecules	on	endothelial	cells,
thereby	reducing	the	migration	of	activated	T	cells	into	the	endoneurium.
Despite	 solid	 evidence	 of	 the	 therapeutic	 efficacy	 of	 IVIg	 in	GBS,	 it	 remains	 unclear	which	 of	 the
above	outlined	pleiotropic	 immunomodulatory	mechanisms	are	operative	and	whether	 they	apply	 to	all
subtypes	of	GBS.	The	rabbit	model	of	AMAN	serves	 the	 in	vivo	study	of	effects	of	 IVIg	 in	 the	axonal
forms	of	GBS	[50].	The	mouse	diaphragm	nerve-muscle	preparation	serves	the	ex	vivo	study	of	effects	of
IVIg	on	the	anti-GQ1b	antibody-mediated	injury	at	neuromuscular	junctions	in	the	FS	[51].
IVIg	in	Evidence-Based	and	Individualized	Care	of	GBS
van	Doorn	PA,	et	al.	IVIg	treatment	and	prognosis	in	Guillain-Barré	syndrome.	Journal	of
Clinical	Immunology,	2010
Treatment	 of	GBS	 combines	multidisciplinary	 supportive	medical	 care	 and	 immunotherapy	 [52].	 Both
IVIg	and	PE	provide	equivalent	benefit	 to	hasten	 the	 recovery	and	 shorten	 the	duration	of	disability	 in
patients	with	severe	GBS	(updated	evidence	appears	in	Cochrane	Reviews,	2014).	IVIg	is	the	generally
preferred	 treatment	 because	 it	 is	 convenient	 and	 more	 available,	 and	 is	 more	 likely	 to	 be	 completed
according	to	protocol.	Immunotherapy	is	usually	started	when	the	patient	has	lost	the	ability	to	walk	10
meters	without	assistance	(GBS	disability	grade	≥3).	It	is	currently	not	known	whether	mild	GBS	would
benefit	 from	 IVIg.	 However,	 one	 RCT	 of	 PE	 included	 a	 group	 of	 91	 patients	 with	 mild	 GBS	 (GBS
disability	grade	2)	who	were	randomized	to	receive	2	PE	exchanges	or	no	treatment.	Onset	of	recovery
was	significantly	earlier	in	the	treated	group	[53].	Although	the	number	of	participants	in	this	comparison
was	small,	the	observations	support	early	treatment.
Randomized	controlled	trials	showed	that	IVIg	0.4g/kg	given	over	5	days	was	as	effective	as	a	course
of	5	PE	treatments	spread	over	2	weeks.	IVIg	is	generally	prescribed	at	an	empiric	dose	of	0.4g/kg/day
for	5	days,	or	else	with	an	equivalent	dose	of	1g/kg	for	2	days.	According	to	small	comparative	studies,
the	recovery	and	outcome	in	children	with	GBS	was	comparable	with	the	2	dosing	regimes	[24].	The	2-
day	 infusion	 regime	 is	 more	 convenient	 for	 children.	 In	 adult	 patients,	 particularly	 those	 with
hemodynamic	instability,	cardiovascular	risk	factors,	and	compromised	renal	function,	and	in	the	elderly,
one	 is	advised	 to	prescribe	a	slow	 infusion	rate	and	delivery	over	5	days.	A	randomized	double-blind
study	of	39	GBS	patients	compared	treatment	with	0.4g/kg/day	given	for	3	days	or	6	days.	Patients	treated
for	6	days	showed	a	trend	towards	better	outcome,	which	became	significant	for	ventilated	patients	[54].
Treatment-Related	Fluctuations	and	Variation	in	Treatment	Response
GBS	has	a	highly	variable	presentation	but	follows	a	monophasic	course.	Disease	nadir	is	reached	within
2	weeks	in	80%,	within	4	weeks	in	97%,	and	within	6	weeks	in	all	[55].	After	a	period	of	stabilization	or
early	 improvement	with	 IVIg,	approximately	10%	of	patients	experience	a	secondary	deterioration,	 so-
called	 treatment-related	 fluctuations	 (TRFs)	 [56,57,58].	 A	 prospective	 study	 of	 164	 GBS	 patients
identified	16	patients	with	GBS/TRFs.	Relapses	occurred	at	a	median	18	days	from	onset	of	weakness;	in
fact	the	great	majority	of	GBS/TRF	patients	relapsed	within	the	first	4	weeks,	and	5	(31%)	experienced	a
second	relapse.	All	TRFs	responded	to	repeat	courses	of	IVIg.	GBS/TRF	patients	were	severely	affected
and	 nearly	 half	 required	MV.	 In	 parallel,	 the	 investigators	 identified	 8	 (5%)	 patients	who	 represented
acute-onset	 CIDP.	 A-CIDP	 could	 be	 differentiated	 from	GBS/TRF.	 Patients	 with	 A-CIDP	 seldom	 had
cranial	 nerve	 dysfunction,	 had	 less	 weakness	 and	 disability,	 did	 not	 require	 MV,	 and	 had	 more
pronounced	signs	of	demyelination	on	electrophysiological	studies.	In	addition,	they	differed	significantly
by	 a	 later	 nadir,	 delayed	 first	worsening	 at	 ~	 4.5	weeks,	 and	 by	multiple	 exacerbations,	 all	 of	which
responded	to	IVIg.	Their	treatment	was	changed	to	a	long-term	CIDP	protocol	[58].
GBS/TRF	 patients	 likely	 have	 a	 longer-lasting	 active	 immune	 phase	 of	 their	 disease,	 and/or	 the
standard	 IVIg	 infusions	 were	 less	 effective.	 Response	 to	 immunomodulatory	 therapy	 is	 variable	 and
~20%	 GBS	 patients	 have	 a	 protracted	 disease	 course	 and	 are	 left	 severely	 disabled.	 Studying	 the
pharmacokinetics	of	IVIg	in	174	GBS	patients,	comparing	pretreatment	serum	IgG	levels	to	those	at	2	and
4	weeks,	3	months	and	6	months	after	a	standard	IVIg	dose,	it	was	found	that	the	increase	in	serum	IgG	at
2	 weeks	 varied	 markedly	 between	 patients.	 Patients	 with	 a	 low	 increase	 in	 serum	 IgG	 recovered
significantly	more	 slowly	and	 fewer	could	walk	at	6	months.	A	 low	 increase	 in	 serum	IgG	 levels	 at	2
weeks	was	an	independent	prognostic	marker	for	poor	outcome	[59].	This	raised	the	question	of	whether
such	patients	might	benefit	 from	a	higher	dose	and/or	second	course	of	IVIg.	Observations	from	a	pilot
study	of	4	GBS	patients	showed	this	to	be	the	case	[60].
Prognostic	Models	of	Outcome	and	Standardization	of	Outcome
Scales
van	Koningsveld	R,	et	al.	A	clinical	prognostic	scoring	system	for	Guillain-Barré	syndrome.
The	Lancet	Neurology,	2007
An	individualized	approach	to	therapy	for	GBS	is	highly	desirable	as	responses	to	treatment	as	well	as
outcome	vary	markedly	among	patients.	This	can	be	achieved	by	accurate	prediction	of	short	and	long-
term	outcome	at	 first	presentation.	Moreover,	by	predicting	risks	for	respiratory	 insufficiency	(Erasmus
GBS	Respiratory	Insufficiency	Score	[EGRIS])	[61]	and	cardiac	arrhythmias,	anticipatory	care	can	avoid
added	complications.	To	this	end,	validated	prognostic	models	(Erasmus	GBS	Outcome	Score	[EGOS])
[62]	 have	 been	 introduced	 into	 clinical	 care,	 which	 are	 derived	 from	 readily	 available	 clinical
parameters	and	are	easily	and	quickly	applied	at	the	bedside.	As	adjustment	of	treatment	to	the	individual
patient’s	need	will	be	most	important	in	the	early	phase	of	the	illness,	the	prognostic	model	was	further
modified	 [m	EGOS]	 to	 be	 used	 at	 admission	 and	 at	 day	 7.	 It	 allows	 the	 accurate	 prediction	 of	 poor
outcome	at	4	weeks,	3	months	and	6	months	of	GBS	with	high	discriminate	value	[63].	These	approaches
are	being	used	 in	clinical	 trials	and	will	 eventually	make	 it	possible	 to	 tailor	 therapy	according	 to	 the
needs	of	individual	patients.
SID-GBS	Trial
A	placebo-controlled	RCT	compares	 the	effects	of	a	second	course	of	 IVIg	given	shortly	after	 the	 first
course	 in	GBS	patients	with	 early	 projected	poor	 outcome	 (defined	 as	 an	mEGOS	 score	 of	 6–12	 at	 1
week)	and	was	launched	by	the	Inflammatory	Neuropathy	Consortium	in	2009	and	is	ongoing.
Newly	 introduced	 Rasch-transformed	 outcome	 scales	 for	 disability,	 the	 Inflammatory	 Rasch-built
Overall	Disability	Scale,	or	I-RODS,	and	for	impairment,	the	Rasch-transformed	MRC	sum	score,	or	RT-
MRC,	with	proven	greater	precision	will	be	used	in	future	therapeutic	trials.	Moreover,	the	significance
of	outcomes	will	be	calculated	and	expressed	as	minimal	clinically	important	difference	(MCID),	which
reflects	clinically	relevant	changes	at	the	individual-person	level	[64].
Adverse	Reactions	and	Risks	of	IVIg
Lünemann	JD,	et	al.	Intravenous	immunoglobulin	in	neurology—mode	of	action	and	clinical
efficacy.	Nature	Reviews	Neurology,	2015
IVIg	is	usually	well	tolerated,	with	adverse	reactions	occurring	in	no	more	than	10%	of	patients.	[65]	In
the	 largest	 RCT	 of	 GBS	 15	 out	 of	 258	 (5.8%)	 patients	 treated	 with	 Sandoglobulin	 experienced	 side
effects,	which	led	to	early	termination	of	the	infusion	in	7	patients	=	2.8%	(PSGBST	group	1997).	In	a
small	open	trial	of	IVIg	in	young	children	with	GBS,	treatment-related	adverse	events	occurred	in	4	out	of
11	 children,	 which	 included	 aseptic	 meningitis	 (1),	 recurrent	 fever	 (1)	 and	 reversible	 laboratory
abnormalities	(2)	[21].
Common	Infusion-Related	Reactions
Evidence-based	guidelines	for	the	use	of	IVIg	in	neuromuscular	disorders	(Therapeutics	and	Technology
Assessment	 Subcommittee	 of	 the	 American	 Academy	 of	 Neurology)	 list	 the	 prevalence	 of	 common
reported	 adverse	 events	 in	 therapeutic	 trials	 as	 follows:	 headaches	 (16.1%),	 fever	 (6.6%),	 mild
hypertension	(4.6%),	chills	(3.3%),	nausea	(3.2%),	asthenia	(1.4%),	arthralgia	(1.3%),	anorexia	(1.1%),
dizziness	(1.1%)	and	malaise	(1.1%)	[66].	Most	adverse	events	are	short-lived	and	respond	to	symptom
therapy.	Chest	and	back	pain,	or	shortness	of	breath	occurring	during	the	infusion,	resolve	by	stopping	the
infusion	 for	 30	 minutes	 and	 reducing	 the	 infusion	 rate.	 A	 slower	 rate	 of	 infusion	 is	 advised	 in	 older
patients	and	in	those	with	compromised	cardiovascular	functions,	as	the	excess	fluid	load	may	precipitate
congestive	heart	failure.	Post-infusion	fatigue,	fever	and	nausea	may	last	up	to	24	hours.
Rare,	More	Serious	Reactions
Migraine	 headache	 and	 aseptic	 meningitis	 can	 be	 triggered	 by	 IVIg	 in	 the	 predisposed	 individual.
Symptoms	of	meningeal	irritation	usually	subside	within	48	hours,	yet	hospitalization	and	strong	analgesia
are	often	required.	The	diagnosis	is	made	clinically	and	no	further	tests	are	necessary.	Pretreatment	with
steroids	or	nonsteroidal	anti-inflammatory	drugs	may	 lessen	 the	recurrence	with	repeat	 IVIg	 treatments.
Immobilized	 individuals	 or	 those	 prone	 to	 thrombophlebitis	 are	 at	 higher	 risk	 to	 develop	 a	 deep-vein
thrombosis.	Thromboembolic	events,	such	as	strokes,	pulmonary	embolism	or	myocardial	infarction	are
reported	but	are	rare.	The	main	causative	factor	is	an	increase	in	serum	viscosity	by	IVIg.	Skin	reactions
such	as	urticarial,	 lichenoid	 lesions,	eczema,	pruritus	of	 the	palms	and	petechiae	of	 the	extremities	can
develop	2–5	days	after	the	infusion	and	last	for	up	to	a	month.
Most	 serious	 anaphylactic	 reactions	 occur	 in	 patients	 with	 IgA	 deficiency	 (prevalence	 1:1000
population),	of	whom	~30%	have	anti-IgA	antibodies	that	can	cross-react	with	infused	IgA	contaminates
in	 the	 IVIg	 preparation,	 and	 can	 lead	 to	 the	 formation	 of	 macromolecular	 complexes.	 Fortunately	 the
complication	 is	 rare.	The	potential	 risk	 should	be	considered	at	 the	 start	of	each	 first	 infusion.	Rarely,
haemolytic	anaemia	may	be	provoked	by	haemolytic	antibody	contaminates	 in	 IVIg	preparations.	Acute
renal	 tubular	 necrosis	with	 resulting	 acute	 renal	 failure	 can	 occur	 in	 patients	with	 pre-existing	 kidney
disease,	especially	diabetic	nephropathy.
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Guillain-Barré	Syndrome,	Respiration	and	ITU
Robin	S.	Howard	and	Nicholas	P.	Hirsch
Introduction
Aristotle	 (384–322	 BC),	 reflecting	 the	 poetry	 of	 the	 physician	 Empedoches	 (500–430	 BC),	 linked
respiration	 to	 inward	 and	 outward	 movement	 of	 air	 through	 small	 pores	 in	 the	 skin.	 The	 concept	 of
alternating	 repulsion	and	attraction	between	elements	was	dominant	 in	Plato’s	 (427–327	BC)	dialogue,
the	Timaeus.	In	his	system	the	diaphragm	separated	the	uppermost,	‘better	soul’	(responsible	for	courage
and	spirit)	from	the	lower,	base	soul	responsible	for	our	animal	appetites	for	food,	drink	and	other	wants.
Aristotle	 did	 not	 link	 respiration	 to	 a	 particular	 organ	 and	 a	 specific	 movement	 of	 the	 thorax.	 He
maintained	that	the	‘use’	of	respiration	was	to	cool	the	innate	heat	of	the	body	generated	by	the	heart	and
to	keep	it	from	becoming	excessive.	He	considered	the	lungs	expanded	because	of	the	heat	generated	by
the	heart	and	that	the	cooling	caused	by	air	entering	led	to	the	lungs	shrinking.	The	diaphragm	had	no	role
in	respiration	and	the	thorax	moved	only	because	the	lung	expanded	and	deflated	[1,2].
Recognition	that	the	diaphragm	was	a	muscle	and	that	muscles	were	under	nervous	control	is	attributed
to	 the	 Alexandrian	 physicians	 Herophilus	 and	 Erasistramus	 (approx.	 300	 BC)	 who	 based	 their
observations	on	 the	 first	 animal	experiments;	 indeed,	 they	even	 taught	 that	 the	diaphragm	was	 the	main
muscle	 of	 respiration.	 Their	 work	 was	 later	 described	 in	 the	 writings	 of	 Galen	 (AD	 130–200)	 in
Pergamum	and	Rome	but	it	is	to	Galen	himself	that	we	owe	the	first	clear	description	of	the	workings	of
the	 respiratory	 pump.	 He	 undertook	 a	 meticulous	 description	 of	 experiments	 demonstrating	 that	 the
diaphragm	was	innervated	by	the	upper	cervical	cord	and	continued	to	move	the	rib	cage	in	response	to
spinal	section	below	this	level,	but	that	if	the	phrenic	nerve	is	sectioned	above	this	level	no	diaphragm
excursion	occurs.	It	is	said	that	Galen	was	a	skilled	clinician	who	taught	physicians	to	observe	the	motion
of	the	chest	wall	to	see	which	respiratory	muscles	were	being	used.	Derenne	and	colleagues	[1]	recount
the	history	of	an	athlete	named	Secundus,	with	a	weak	diaphragm,	whose	breathing	Galen	improved	by
putting	a	girdle	around	the	hypochondrium.
Guillain-Barré	syndrome	(GBS)	has	been	known	to	cause	weakness	of	the	respiratory	muscles	since
the	 original	 eponymous	 description	 by	 Landry	 in	 1859	 in	 which	 he	 described	 involvement	 of	 the
respiratory	 muscles	 and	 the	 eventual	 danger	 of	 asphyxia	 when	 the	 paralysis	 reached	 its	 maximum
intensity.	 Richard	 Hughes	 [3]	 draws	 attention	 to	 Landry’s	 prescient	 recognition	 of	 the	 presence	 of
diaphragmatic	weakness	by	observing	paradoxical	movement	of	the	abdomen.	Landry	observed:	“On	the
day	before	dying	of	 asphyxia	 the	patient	was	 lying	quietly	on	his	back	and	 there	was	hollowing	of	 the
abdomen	during	 inspiration	and	outward	movement	during	expiration.	This	paradoxical	movement	was
much	less	evident	when	the	patient	was	sitting	up”.
Osler	 (1892)	 also	 recognised	 that	 ‘acute	 ascending	 paralysis’	 was	 associated	 with	 respiratory
involvement	and	that	some	of	the	patients	died	from	this,	within	a	week	to	10	days	[4].	Gordon	Holmes
(1917)	described	12	cases	of	‘acute	febrile	polyneuropathy’	which	was	seen	at	Queen	Square	and	on	the
World	War	I	battlefields	in	France	[5].	Although	the	cases	were	all	associated	with	pyrexia	at	onset,	the
progressive	 motor	 and	 sensory	 impairments	 were	 characteristic	 of	 Guillain-Barré	 syndrome	 and	 he
recognised	 that	 “in	 two	 cases	which	died	 from	pulmonary	 complications	 the	paresis	 of	 the	 respiratory
movements	was	probably	a	contributory	factor	to	the	fatal	termination”.
Pinckney	 (1936)	 describes	 3	 similar	 cases	 in	 which	 diaphragm	 weakness	 or	 paralysis	 occurred,
although	only	one	of	the	patients	died	[6].	By	1943	the	diagnosis	was	more	clearly	understood	and	a	case
of	 relapsing	 GBS	 is	 described	 in	 a	New	 England	 Journal	 of	 Medicine	 (NEJM)	 clinicopathological
conference	[7].	Prior	to	death,	the	patient	is	reported	to	be	“unable	to	raise	secretions	or	to	swallow,	or	to
breathe	outside	the	respirator”.	We	can	find	no	earlier	reference	to	respiratory	support	for	this	condition,
although	the	first	NICU	was	said	to	have	been	established	by	Walter	Dandy	at	Johns	Hopkins	Hospital	in
1932	[8].	The	NEJM	report	is	also	striking	for	being	the	first	observation	of	a	critically	important	sign	of
incipient	 respiratory	 muscle	 insufficiency:	 “the	 fact	 that,	 in	 this	 case,	 the	 shoulders	 were	 severely
involved	 almost	 from	 the	 start	 made	 me	 a	 little	 cautious	 about	 the	 prognosis	 because	 the	 lesion	 was
getting	 closer	 to	 the	 fourth	 cervical	 segment,	 where	 the	 phrenic	 nerve	 comes	 off”.	 This	 remains	 an
important	 observation	 in	 routine	 clinical	 practice	 because	 shoulder	weakness	 indicates	 involvement	 of
C3/4	innervation	of	the	trapezius,	which	often	precedes	phrenic	nerve	impairment.
The	major	 stimulus	 to	 the	 development	 of	 intensive	 care	 came	 from	 the	 poliomyelitis	 epidemic	 in
Copenhagen	in	1952	and	a	later	one	in	London.	Lassen	reviewed	his	experience	in	Denmark	noting	that
“during	 the	11	years,	1934–44	respirator	 treatment	was	used	 in	76	cases	with	a	mean	mortality	 rate	of
80%.	Only	cuirass	respirators	were	used”	[9].	When	the	epidemic	occurred	available	ventilatory	support
was	 completely	 inadequate.	 In	 consultation	 with	 Dr	 Bjorn	 Ibsen,	 a	 Copenhagen	 anaesthetist,	 Lassen
undertook	 tracheostomy	 in	 those	 patients	 who	 could	 not	 maintain	 their	 airway	 because	 of	 excessive
secretions,	generally	due	to	acute	bulbar	poliomyelitis.	Positive	pressure	ventilation	was	then	delivered
manually	with	 a	 rubber	 bag.	At	 the	 height	 of	 the	 epidemic	 over	 300	 such	 patients	were	 admitted	 and
treated	 each	week	with	 continuous	manual	 ventilation	 being	 provided	 by	 teams	 of	medical	 and	 dental
students.	The	mortality	 fell	 from	over	80%	to	40%.	This	experience	 led	not	only	 to	 the	 introduction	of
intermittent	positive	pressure	ventilation	 (IPPV)	but	also	 to	 the	 idea	of	caring	 for	all	 sick	patients	 in	a
dedicated	ward	in	which	each	patient	could	have	their	own	nurse.	Thus,	 it	might	be	considered,	 that	 in
December	1953	the	specialty	of	intensive	care	medicine	was	born	[10].
The	 polio	 epidemic	 was	 also	 severe	 in	 London	 in	 1952.	 This	 led	 to	 the	 development	 of	 several
respiratory	isolation	units	across	the	city.	In	October	1953	an	intensive	care	unit	was	established	at	Queen
Square	 by	 Dr	Michael	 Kremer,	 and	 this	 continued	 to	 function	 after	 the	 polio	 epidemic.	 The	 unit	 was
subsequently	 led	by	Professor	 John	Marshall	 and	Dr	Atwood	 ‘Bobby’	Beaver.	Marshall	 described	 the
development	 of	 neurological	 intensive	 care	 to	 encompass	 the	management	 of	 temporary	 neuromuscular
paralysis	 [11].	 He	 described	 the	 ICU	 management	 of	 229	 patients	 over	 6	 years,	 including	 39	 with
polyneuritis.	 He	 notes	 “polyneuritis	 is	 in	 many	 ways	 a	 more	 gratifying	 condition	 to	 treat	 [than
poliomyelitis],	because	in	the	vast	majority	of	cases	there	is	no	residual	disability”.	This	important	paper
is	 remarkable	 in	 recognising	 many	 issues	 concerning	 the	 introduction	 of	 ventilatory	 care	 which	 have
become	 increasingly	 apparent	 over	 the	 intervening	 years.	 In	 particular	Marshall	 draws	 attention	 to	 the
rapid	 introduction	 of	 intermittent	 positive	 pressure	 respiration	 (IPPR),	 the	 importance	 of	 early
tracheostomy	 undertaken	 by	 a	 skilled	 operator,	 early	 recognition	 of	 CO2	 retention	 and	 incipient
ventilatory	failure,	the	importance	of	early	intervention	with	ventilatory	support	and	of	good	supportive
management	 including	 fluid	 and	 nutritional	 intake,	 metabolic,	 bowel	 and	 bladder	 care,	 the	 risk	 of
atelectasis	and	infection	and	the	importance	of	regular	nursing	and	physiotherapy	support.	This	important
paper	 also	describes	 the	difficulties	 in	providing	 respiratory	 support	 in	 patients	with	bulbar	weakness
using	a	cabinet	 (negative	pressure)	 respirator	and	recognises	 that	 IPPR	overcame	 these	difficulties	and
facilitated	nursing	and	physiotherapy.
In	1960,	Osler	and	Sidell	 reviewed	GBS	but	made	only	passing	reference	to	death	from	respiratory
failure,	describing	a	single	patient	who	was	a	‘respiratory	case’	from	admission	but	died	after	a	few	days
[12].	Marshall	 described	 the	Queen	 Square	 experience	 in	Brain,	 noting	 4	 of	 35	 patients	 died,	 3	 from
respiratory	 failure	 and	 one	 from	 cardiac	 arrest,	 but	 there	 is	 no	 description	 of	 those	 who	 received
respiratory	support	[13].	The	rapid	development	of	intensive	care	through	the	1960s	and	1970s	is	been
described	 in	 a	 number	 of	 papers,	 including	 those	 by	 Pontoppodou,	 Hilberman,	 McCleave	 and,	 more
recently,	Widjicks	[8,14,15,16].
The	intensive	care	management	of	acute	Guillain-Barré	syndrome	has	evolved	with	the	introduction	of
new	 modes	 of	 ventilation,	 better	 techniques	 of	 supportive	 care	 and	 the	 widespread	 availability	 of
intravenous	 immunoglobulin	 as	 a	 more	 convenient	 form	 of	 immunomodulatory	 treatment	 than	 plasma
exchange	 [17].	 In	 the	 UK,	 highly	 specialised	 neurological	 ICU	 has	 become	 easier	 to	 access	 with	 the
development	 of	 neuroscience	 units,	 although	 there	 is	 considerable	 variation	 in	 the	 provision	 of
neurological	 support	 for	 patients	 admitted	 to	 general	 ICUs.	 It	 remains	 uncertain	whether	 these	 changes
have	 led	 to	 a	 significant	 change	 in	 the	 pattern	 of	 referral	 for	 specialist	 care	 or	 an	 improvement	 in	 the
management	and	outcome	of	GBS.
In	a	previous	report	from	Queen	Square	ITU,	the	overall	mortality	in	79	patients	with	acute	GBS	was
5.1%	although	15%	remain	severely	disabled	at	6	months	and	10%	at	1	year	[18].	Several	large	series	of
patients	treated	for	GBS	on	ICU	have	subsequently	been	published.	The	mortality	has	varied	from	6.5%	to
12.2%	 but	 there	 are	 significant	 differences	 in	 the	 severity	 and	 clinical	 pattern	 of	 the	 cases	 seen	 and
treated	 [19,20].	 Most	 patients	 died	 from	 complications	 of	 intensive	 care	 and	 prolonged	 immobility,
including	 sepsis	 and	 pulmonary	 emboli.	Major	 complications,	 including	 pneumonia,	 sepsis,	 pulmonary
embolism	and	gastrointestinal	bleeding,	develop	in	60%	of	intubated	patients	[21].
We	undertook	a	retrospective	review	of	110	patients	with	acute	GBS	admitted	to	the	medical	ICU	at
Queen	Square	over	25	years	to	observe	any	change	in	the	patterns	of	referral	and	care	[22].	The	series
showed	 that	 patients	 referred	 over	 the	 last	 15	 years,	 when	 compared	 to	 the	 earlier	 cohort,	 were	 of	 a
similar	age	and	sex,	had	a	similar	incidence	and	range	of	ICU	complications	and	a	comparable	range	of
immunomodulation	treatment.	However,	patients	admitted	more	recently	were	transferred	to	the	ICU	later,
required	mechanical	 ventilation	 for	 longer	 periods	 and	 required	 longer	 ICU	 and	 hospital	 stays.	 In	 the
more	 recent	 group	 there	 was	 a	 much	 higher	 incidence	 of	 axonal	 neuropathy	 (51%	 >	 24%)	 but	 the
increased	 duration	 of	 ventilation	 and	 length	 of	 stay	 applied	 whether	 the	 primary	 neuropathy	 was
demyelinating	or	 axonal.	Despite	 the	delay	 in	 referral	 and	 the	 severity	of	 the	underlying	 condition,	 the
mortality	was	3	out	of	58	(5.2%)	compared	to	7	out	of	52	(13.5%)	and	the	rehabilitation	outcomes	were
similar.	There	was	no	late	mortality	after	‘step	down’	to	ward	neuro-rehabilitation	or	discharge	to	home
or	the	referring	hospital.
The	 results	 suggest	a	change	 in	 the	pattern	of	 referral,	 at	 least	 to	 this	 specialised	neurological	 ICU,
indicating	 that	 patients	 with	 acute	 GBS	 are	 now	 referred	 later	 and	 with	 more	 prolonged	 and	 severe
disease,	reflected	in	a	higher	proportion	of	severe	axonal	neuropathy	requiring	longer	ICU	and	hospital
stay.	 The	 mortality	 has	 reduced	 but	 the	 outcome	 is	 similar.	 The	 reasons	 for	 this	 apparent	 change	 in
practice	are	unclear	but	are	likely	to	reflect	easier	access	to	long-term	care	in	ICU	beds	in	the	admitting
hospital	and	to	immunomodulatory	treatment.
Respiratory	insufficiency	occurs	in	25%	of	patients	with	GBS	and	major	complications	are	common.
In	 a	 recent	 review	 undertaken	 in	 collaboration	 with	 the	 Intensive	 Care	 National	 Audit	 and	 Research
Centre	(ICNARC)	[23]	we	showed	that,	in	the	UK,	the	mortality	rate	in	ICU	is	7.7%	but	the	in-hospital
mortality	rate	after	ICU	step-down	is	16.7%.	Others	have	described	similarly	high	early	mortality	after
ICU	discharge	[19,24,25,26].	The	cause	of	this	alarming	mortality	rate	is	unclear,	but	poor	outcome	does
seem	 to	 be	 associated	with	 delayed	weaning	 and	 long-term	ventilatory	 impairment.	Weaning	 and	 step-
down	 care	 are	 critically	 important	 in	 determining	 long-term	 outcome	 after	 severe	 GBS.	 Prolonged
weaning	 requires	 specialist	 techniques	 of	 care	 and	 general	 medical	 ICUs	 do	 not	 always	 possess	 the
expertise	 or	 facilities	 for	 weaning	 patients	 with	 prolonged	 ventilatory	 problems	 secondary	 to	 severe
GBS.
To	study	these	issues	further	we	reviewed	20	patients	with	GBS,	managed	over	12	years	in	The	Lane
Fox	Unit	at	St.	Thomas’	Hospital,	a	specialist	tertiary	referral	respiratory	care	and	weaning	centre	[27].
The	mean	age	of	patients	was	59.3	years	with	a	marked	male	predominance.	All	had	tracheostomy	at	the
time	of	transfer.	The	duration	of	mechanical	ventilation	between	the	onset	and	the	time	of	transfer	varied
between	45	and	489	days.	The	time	from	admission	to	removal	of	the	tracheostomy	varied	from	1	to	118
days.	 19	 patients	 were	 successfully	 weaned	 from	 invasive	 ventilatory	 support,	 5	 required	 nocturnal
noninvasive	ventilatory	(NIV)	support	for	10	to	225	days,	1	continues	to	use	nocturnal	NIV	and	1	patient
died.	 Nineteen	 patients	 were	 successfully	 discharged.	 This	 study	 emphasises	 that,	 with	 appropriate
management,	 many	 patients	 with	 severe	 and	 prolonged	 residual	 disability	 due	 to	 GBS	 can	 make	 an
excellent	or	good	recovery	of	respiratory	function	with	meticulous	ongoing	care	and	rehabilitation,	often
despite	 severe	 residual	 limb	weakness	 and	 long	 periods	 of	 dependency.	This	 surprisingly	 high	 rate	 of
recovery	of	respiratory	and	bulbar	functional	following	acute	GBS,	even	with	severe	residual	weakness,
remains	a	curious	and	unexplained	phenomenon	of	the	condition.
There	is	debate	about	the	role	of	highly	specialised	neurological	intensive	care	and	this	discussion	has
obvious	 relevance	 to	 the	 future	care	of	GBS	 throughout	a	world	 in	which	 facilities	and	 resources	vary
enormously.	 It	 is	 uncertain	 if	 their	 primary	 role	 should	 lie	 in	 managing	 patients	 with	 common
presentations	 of	 acute	 neurological	 disorders	 or	 if	 the	 scarce	 resources	 should	 be	 focused	 on	 the
specialised	care	of	tertiary	referrals	of	the	most	complex	and	difficult	management	problems,	which	often
demand	extensive	 time	and	 resource	 input	 to	 achieve	 the	best	outcomes	 in	 relatively	 small	 numbers	of
patients.	If	this	is	the	case,	it	will	be	impossible	to	prove	such	units	improve	the	mortality	and	morbidity
rate	of	neurological	disorders.	However,	they	will	have	an	important	role	as	centres	of	last	resort	and	in
teaching,	research	and	establishing	guidelines	of	care.
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The	Other	Syndrome	of	Guillain-Barré	Syndrome:
Dysautonomia	and	Systemic	Effects
Eelco	F.	M.	Wijdicks
Introduction
I	suspect	the	neurologists	Georges	Guillain	and	Jean-Alexandre	Barré	did	not	consider	involvement	of	the
autonomic	 nerves	 or	 even	 systematic	 effects;	 at	 least,	 when	 reading	 their	 seminal	 paper	 or	 later
publications	on	variants	it	does	not	jump	off	the	page.	Why	would	they?	Professor	Guillain	strongly	felt
the	syndrome	he	described	with	Barré	(and	with	some	assistance	from	André	Strohl)	was	utterly	unique
because	 the	 course	 was	 benign	 and	 their	 patients	 fully	 recuperated.	 His	 syndrome	 (GBS)	 was	 much
different	from	the	fatal	Landry’s	ascending	paralysis	syndrome	and	he	was	unshakable	in	that	conviction
—no	need	to	ponder	a	more	serious	clinical	picture.
GBS	with	its	weakness	variants	is	now	100	years	old,	but	dysautonomia	has	not	even	reached	the	age
of	50.	First,	 there	was	the	typical	disconnect	with	the	proverbial	left	hand	(read	clinician)	not	knowing
what	the	right	hand	(read	pathologist)	was	doing.	One	of	the	first	autopsy	cases	showed	the	sympathetic
chain	was	involved	(“myelin	fragments	in	ballooned	Schwann	cells	…	Scattered	ganglion	cells	were	in	a
disintegrated	state”)	but	there	was	no	clinicopathologic	correlation	with	a	patient	dying	from	aspiration
pneumonia	 and	 sepsis	 [1].	 Perhaps	 it	 started	 with	 Mitchell	 and	 Meilman,	 who	 concluded	 there	 was
sympathetic	 hyperactivity	 on	 the	 basis	 of	 a	 high	 excretion	 of	 urinary	 catecholamines	 in	 a	 markedly
hypertensive	patient	with	GBS	[2].	Perhaps	the	observation	that	tweaked	their	syndrome	(GBS)	by	adding
involvement	of	the	autonomic	nervous	system	came	with	Lichtenfeld’s	paper	[3].
Now	we	know	from	case	reports	and	case	series—some	informative,	others	not—that	GBS	may	have
many	other	manifestations	and	vital	organs	can	become	compromised	[4,5].	We	also	know	that	some	are
therapy	related	(e.g.	IVIg),	that	others	are	rare	but	pop	up	in	the	literature	occasionally	(e.g.	membranous
nephropathy)	 or	 that	 manifestations	 are	 nonspecific	 and	 a	 result	 of	 failure	 to	 recognize	 and	 treat
dysautonomia	 (e.g.	 posterior	 reversible	 encephalopathy	 syndrome	 in	 dysautonomia	 -associated
hypertension).	 There	 is	 a	 good	 argument	 to	 be	 made	 that	 in	 the	 more	 severe	 cases	 of	 GBS	 there	 is
probably	another	‘hidden’	syndrome	(Figure	58.1).
Here,	I	will	interpret	a	collection	of	articles	published	over	the	years,	but	others	have	summarized	the
material	 in	 comprehensive	 topic	 reviews	 [6,7,8].	One	 can	 say	 these	 clinical	manifestations	 are	 a	 less
appreciated	part	of	this	acute	immune	mediated	inflammatory	disorder.
Figure	58.1		Systemic	effects	of	Guillain-Barré	syndrome.	©	2016	Mayo	Foundation	for	Medical	Education	and	Research
The	Many	Facets	of	Dysautonomia
One	of	 the	earlier	astute	observations	was	by	neurologist	Peter	Lichtenfeld	from	Mount	Sinai	Hospital,
New	York	in	1971	and	he	attributed	fatality	in	GBS	to	dysautonomia.	In	his	study	he	describes	how	4	of
28	patients	died	“during	or	 immediately	after	episodes	of	 severe	autonomic	dysfunction”	as	a	 result	of
“cardiac	arrest	following	several	hours	of	rapidly	fluctuating	autonomic	status”	or	were	“found	dead	after
extremely	high	blood	pressure	recordings	although	paralysis	was	not	severe”	or	“died	suddenly	after	the
development	of	 a	 cardiac	arrhythmia	preceded	by	electrographic	 abnormalities”	 [3].	His	 sound	advice
included	that	“patients	with	inadequate	sympathetic	responsiveness	must	be	positioned	carefully,	straining
at	 bowel	 movements	 must	 be	 avoided,	 respiratory	 pressures	 deliberately	 set	 and	 at	 the	 first	 sign	 of
autonomic	dysfunction	a	cardiac	monitor	employed”.
Dysautonomia	in	GBS	is	recognized	by	blood	pressure	fluctuations	and	exaggerated	drug	responses,
cardiac	 arrhythmias,	 hypersecretions,	 gastrointestinal	 dysfunction	 and	 bladder	 dysfunction.	 Curiously
profound	flushing	and	sweating	had	some	clinicians	considering	a	coexisting	pheochromocytoma,	and	of
course,	in	many	patients	urinary	catecholamines	were	increased.	Paroxysmal	or	sustained	hypertension	is
seen	 in	 nearly	 1	 in	 4	 patients	 with	 GBS	 but	 not	 always	 the	 more	 severely	 affected.	 Systolic	 blood
pressures	can	become	substantially	elevated	and	reach	values	that	may	not	only	cause	the	left	ventricle	to
acutely	 strain,	 but	 can	 even	 predispose	 the	 patient	 to	 develop	 posterior	 reversible	 encephalopathy
syndrome.	 Encephalopathy	 with	 new	 onset	 seizures	 or	 visual	 disturbances	 is	 totally	 unexpected	 in	 a
patient	with	GBS	 and	 therefore	 an	MRI	of	 the	 brain	 is	 essential	 to	 find	 its	 characteristic	white	matter
vasogenic	oedema.
Why	these	blood	pressure	fluctuations	occur	 is	not	entirely	known,	but	a	baroreflex	abnormality	has
been	postulated	 [9].	Baroreceptor	 sensitivity	might	be	altered	as	a	 result	of	vagal	nerve	demyelination
and	because	when	sympathetic	nerves	have	less	myelin,	it	results	in	a	sympathetic	overdrive.	Dysfunction
of	afferent	input	from	atrial	stretch	receptors	could	also	play	a	role	in	the	origin	of	blood	pressure	swings
[10].
These	blood	pressure	elevations	require	treatment,	but	treatment	might	lead	to	a	marked	hypotension
due	to	exaggerated	drug	sensitivity.	Clonidine,	sodium	nitroprusside,	or	a	calcium	channel	blocker	such	as
nicardipine	 have	 been	 used	 to	 treat	 severe	 hypertension,	 but	 simply	 controlling	 these	 responses	 with
multiple	doses	of	IV	morphine	is	just	as	effective	and	perhaps	safer.
The	whole	gamut	of	cardiac	arrhythmias	can	be	seen	in	GBS,	including	complete	heart	block	[11,12].
Sinus	 tachycardia	 and	 so-called	 vagal	 bradycardia	 spells	 are	 most	 frequent	 in	 patients	 with	 GBS.
Persistent	sinus	tachycardia	may	appear	at	any	time	during	the	illness	and	generally	is	not	associated	with
hypotension	or	chest	pain	but	slowing	of	rate	is	indicated	with	signs	of	myocardial	ischemia	on	EKG.	In
patients	 with	 hypotension,	 echocardiography	 is	 needed	 to	 look	 for	 stress	 cardiomyopathy	 [13].	 Vagal
spells	are	brief	salvos	of	bradycardia	or	sinus	arrest,	and	nursing	staff	know	that	tracheal	suctioning	is	a
common	trigger.	Vagal	spells	are	usually	a	feature	seen	in	the	worsening	and	plateau	phase	but	may	extend
into	the	recovery	phase.	These	bradycardic	spells	may	be	so	severe	that	they	can	lead	to	a	brief	pause.	A
pacemaker	may	 be	 considered	 if	 these	 episodes	 are	 symptomatic	 and	 recurrent	 [14].	 In	 some	patients,
atrioventricular	block	or	other	more	benign	arrhythmias	(e.g.	bigeminy)	become	apparent.
Bronchial	 function	 is	 also	 likely	 impaired	 in	Guillain-Barré	 syndrome,	because	bronchoconstriction
and	bronchodilatation	are	under	the	control	of	vagal	and	sympathetic	innervation.	There	is	some	evidence
that	 impaired	bronchoconstriction	and	dilation	due	 to	abnormal	 innervation	of	bronchial	smooth	muscle
can	 lead	 to	 profound	 impairment	 of	 clearing	 of	 already	 increased	 secretions	 and,	 in	 turn,	 lead	 to
atelectasis	of	large	lung	segments.
As	part	of	the	screening	for	dysautonomia,	patients	should	also	be	carefully	examined	for	development
of	adynamic	 ileus.	This	occurs	 in	about	1	 in	10	patients	with	severe	GBS	and	is	recognized	by	loss	of
abdominal	 sounds,	 expansion	 of	 the	 abdominal	 girth,	 and	 enlarged	 colonic	 loops	 on	 abdominal	 x-ray.
Perforation	 of	 the	 colon	 is	 a	 major	 complication	 which	 can	 substantially	 change	 the	 outcome	 of	 a
recoverable	neurologic	 illness.	The	 treatment	of	patients	with	 severe	adynamic	 ileus	 is	 rectal	 and	oral
suction	 tubes,	 and	 a	 therapeutic	 decompressive	 colonoscopy.	 Opiates	 should	 be	 stopped.	 Peripherally
acting	mu-opioid	 receptor	 antagonists	 in	 the	 future	may	offer	 the	 reversal	of	 ileus	without	 loss	of	pain
relief.	 The	 use	 of	 erythromycin,	metoclopramide	 or	 neostigmine	might	 be	 considered,	 but	 side	 effects
(cardiac	arrhythmias)	may	make	 it	a	much	 less	 favourable	choice.	 In	our	series	of	patients	with	severe
GBS,	adynamic	ileus	developed	in	15%,	but	only	a	few	instances	seemed	correlated	with	dysautonomia.
Pre-existing	 conditions,	 such	 as	 prior	 abdominal	 surgery,	 and	 incremental	 doses	 of	 opioids	 for	 pain
management,	were	dominant	causes	[15].
Fatality	 from	 dysautonomia	 is	 difficult	 to	 prove.	 We,	 and	 particularly	 the	 Massachusetts	 General
Hospital	 retrospective	 and	 prospective	 series	 [16],	 found	 none	 including	 among	 the	 more	 severely
affected	 patients	 who	 were	 ICU	 admissions.	 The	 Queen	 Square	 series	 mentioned	 in	 this	 book	 (see
Howard	and	Hirsh	chapter)	did	not	mention	a	single	fatal	case.	Still,	a	report	from	the	Dutch	GBS	group
with	a	large	number	of	patients	retrospectively	reviewed	between	1986	and	2008	noted	2	of	527	patients
died	 after	 severe	 autonomic	 dysfunction,	 one	 patient	 with	 severe	 hypertension	 and	 subarachnoid
haemorrhage	and	one	patient	whose	care	was	de-escalated	after	hypoxic-ischemic	encephalopathy.	Three
additional	patients	died	unexpectedly	of	cardiac	arrest	during	the	recovery	phase	[17].
Organ	Dysfunction
Any	organ	system	is	challenged	in	a	patient	with	severe	GBS	maintained	for	some	time	on	a	ventilator.
For	 sure	 any	 organ	 system	 can	 become	 critically	 involved	 when	 sepsis	 emerges.	 Some	 organs	 are
involved	(e.g.	liver)	because	an	infection	preceded	GBS	(e.g.	cytomegalovirus).	But	organ	systems	may
potentially	be	injured	as	part	of	the	immune	target,	and	in	some	inflammatory	lesions	have	been	found.
Cardiac	injury	is	likely	secondary	to	dysautonomia.	The	mechanism	of	stress	cardiomyopathy	in	GBS
could	 be	 explained	 by	 sympathetic	 overdrive	 resulting	 in	 marked	 reduction	 in	 ejection	 fraction	 from
sudden	 ventricular	 strain	 with	 hypertension.	 Morphologic	 EKG	 abnormalities	 are	 uncommon	 and
nonspecific	 in	GBS,	 but	when	 they	 are	 present,	 ST-segment	 abnormalities	 are	 frequent.	 It	 is	 uncertain
whether	they	represent	myocardial	damage.	Myocarditis	has	been	found	in	fatal	cases	that	went	to	autopsy
but	 this	 entity	 remains	 poorly	 understood.	 It	 might	 be	 difficult	 to	 sort	 it	 out	 from	 a	 co-existing	 viral
infection	 affecting	 the	 heart.	When	 I	 read	 through	many	 of	 these	 cases	 the	 full	 ICU	 course	 is	 not	 fully
known	and	little	has	been	published	lately.
Most	 fascinating	 is	 a	membranous	nephropathy	causing	 in	 some	patients	 a	mild	nephrotic	 syndrome
and	pitting	oedema.	The	cases	are	detected	if	attentive	physicians	note	the	urinalysis	results	with	marked
proteinuria	 and	 microscopic	 heamaturia	 [5].	 Reported	 renal	 biopsies	 (including	 one	 case	 of	 subacute
GBS	I	remember	clearly)	have	been	unquestionably	confirmative,	but	not	all	cases	in	the	literature	may	be
GBS	and	an	underlying	systemic	disorder	such	as	lymphoma	or	vasculitis	should	be	considered.
Transient	 abnormalities	 of	 transaminases	 (rarely	 double	 from	 baseline)	 have	 been	 found	 with	 no
evidence	of	viral	or	 toxic	hepatitis	other	 than	an	association	with	IVIg	[18].	Sucrose	containing	IVIg	is
more	likely	to	cause	these	largely	clinically	 insignificant	changes,	and	liver	function	abnormalities	may
coincide	 with	 worsening	 renal	 function	 but	 resolution	 is	 seen	 in	 2	 weeks.	 Immunoglobulins	 acting	 as
immune	 complexes	 is	 a	 speculative	 explanation	 for	 increased	 transaminases.	 In	 most	 practices	 liver
function	abnormalities	are	not	a	concern	with	IVIg.
Other	 systemic	 disorders—not	 explained	 by	 dysautonomia—have	 been	 reported	 over	 the	 years	 and
cases	have	included	SIADH,	hyperthyroidism	and	Addison’s	disease	[19].	Each	of	these	manifestations
remains	questionably	associated	with	GBS.
On	a	Personal	Note
The	early	observations	on	dysautonomia	in	the	1960s	were	far	from	alarmist,	and	I	have	seen	impressive
manifestations	 and	 mostly	 spontaneous	 wild	 blood	 pressure	 swings—one	moment	 in	 frank	 shock	 then
markedly	hypertensive	after	being	placed	in	 the	Trendelenburg	position.	Although	I	have	personally	not
encountered	 fatality	 or	 cardiac	 arrest	 associated	with	 dysautonomia	 and	 I	 have	not	 seen	 a	 patient	who
needed	a	pacemaker,	I	still	feel	very	uncomfortable	with	keeping	patients	with	GBS	and	dysautonomia	on
the	ward.	 The	 last	 patient	 I	 have	 seen	 at	 the	 time	 of	 this	writing	was	 improving	 from	GBS	 but	 had	 a
sustained	sinus	tachycardia	for	several	weeks	(Figure	58.2)	and	no	other	explanation.	 In	severe	GBS	a
neurointensivist	 will	 have	 to	 differentiate	 a	 veritable	 dysautonomia	 from	 early	 sepsis,	 pulmonary
embolus,	aspiration	pneumonia,	opioid	overuse	and	other	guises,	 including	urethra	obstruction.	Another
practical	 problem	 is	 that	 drugs	 to	 treat	 dysautonomia	 may	 worsen	 dysautonomia	 (glycopyrrolate	 for
increased	secretions,	neostigmine	for	ileus,	beta	blockers	for	tachycardia)	and	there	is	no	good	solution.
Acute	 autonomic	 failure	 in	 GBS	 usually	 resolves	 before	 full	 improvement	 in	 motor	 function.	Marked
orthostatic	hypotension	may	persist	during	the	recovery	phase.	Whether	this	is	due	to	persistent	autonomic
failure	or	a	result	of	long-standing	bed	rest	is	undetermined.	Dysautonomia	and	organ	dysfunction	plays
no	 small	 part	 in	 the	 syndrome	 of	 severely	 affected	 patients	 but	 all	 in	 all	 it	 is	 reassuring	 to	 know	 it
disappears	and	commonly	leaves	no	trace.
Figure	58.2		Asymptomatic	sinus	tachycardia	as	a	single	clinical	recognizable	sign	of	dysautonomia	in	Guillain-Barré	syndrome.
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Guillain-Barré	Syndrome:	The	Patient’s	Perspective
E.	Benson,	J.	Baer,	P.	Bloomquist,	L.	Butler,	G.	Sanders,	T.	Sammut,	M.
Tedesco	and	C.L.	Koski
As	physicians,	we	approach	a	patient	in	terms	of	diagnosis,	 treatments	available	and	eventual	outcome.
Guillain-Barré	syndrome	(GBS)	was	first	reported	in	the	early	19th	century	as	a	self-limiting,	progressive
weakness	with	preserved	cognition,	normal	bowel	and	bladder	function	[1],	loss	of	deep-tendon	reflexes
(DTRs)	 and	 abnormally	 elevated	 spinal	 fluid	 protein	with	 a	 normal	white	 blood	 cell	 count	 [2].	Other
variants,	such	as	the	Miller	Fisher	syndrome	of	external	ophthalmoplegia,	sluggish	pupil	reflex	and	DTR
loss	[3],	as	well	as	pure	sensory,	pure	motor,	autonomic	and	multiple	cranial	nerve	presentations,	were
subsequent	 identified.	Most	 research	 suggests	 that	 the	 aetiology	 of	 this	 syndrome	 is	 complement-fixing
antibody	 (Ab)	with	 specificity	 for	 elements	 of	 peripheral	 nerve	myelin	 or	 axolemma	 [4–6].	 Treatment
with	plasma	exchange	or	intravenous	immunoglobulin	shortens	the	clinical	course	and	reduces	the	time	on
the	ventilator,	 the	 time	 in	 the	 ICU	and	 the	 time	 to	 independent	walking	 [7].	This	 is	 particularly	 true	 in
patients	with	high-risk	factors	including	older	age	(>	60	years),	ventilator	dependence	within	a	week	of
onset,	 and	 preceding	 diarrheal	 illness	 [8,9].	 The	 patient’s	 perspective,	 although	 appreciative	 of	 these
advances,	 includes	 issues	 of	 communication;	 isolation;	 availability	 of	 accurate	 information;	 quality	 of
care;	 ability	 to	 participate	 in	 work,	 family	 and	 social	 activities;	 and	 their	 ultimate	 outcome,	 as
demonstrated	in	the	following	series	of	patient	stories	and	memories.
Bob	Benson	(Written	by	Estelle	Benson)
In	November	1979	51-year-old	Bob	Benson,	USA	had	an	upper	respiratory	tract	infection	which	developed	into	pneumonia.
Within	2	weeks,	he	had	trouble	walking,	holding	a	briefcase	and	turning	a	key	to	start	his	car.	His	signature	was	a	straight
line.	In	the	emergency	room	(ER)	a	spinal	tap	supported	a	diagnosis	of	GBS.	Bob	was	in	an	intensive	care	unit	(ICU)	for
four	weeks	and	 treated	with	prednisone.	To	help	him	sleep	and	ease	 the	pain,	he	had	wine	at	bedtime.	His	course	was
complicated	by	hallucinations.	From	ICU	Bob	was	transferred	to	a	step-down	unit	and	subsequently	a	rehabilitation	facility.
With	hard	work	and	a	great	attitude,	he	‘walked’	out	(barely)	after	four	months.
We	had	no	idea	what	this	condition	was	or	if	he	would	ever	get	better.	No	literature,	no	one	to	talk	to,	no	Internet!	We
vowed	to	do	something	about	this.	One	year	later,	eight	people	including	patients	and	doctors	met	around	our	dining	room
table	in	the	first	meeting	of	what	would	become	the	GBS/CIDP	Foundation	International!	I	started	with	a	one-page	newsletter
and	more	people	came.	Dr	Arthur	Asbury,	University	of	Pennsylvania,	expert	neurologist,	mentored	me.	For	one	of	 the
meetings	(all	at	my	home)	he	sent	two	of	his	neurology	residents	to	speak—David	Cornblath	and	Gareth	Parry!	Thirty-five
years	later,	look	where	we	are	now	with	more	than	150	chapters	worldwide!!!
Glennys	Sanders
In	August	1981,	at	age	37,	while	on	holiday,	I,	Glennys	Sanders,	UK,	experienced	fatigue,	neck	and	back	ache,	inability	to
open	bottles	and	climb	stairs	and	generalized	weakness.	Overnight	I	could	not	turn	over	in	bed,	walk	to	the	toilet	or	use	my
hands,	and	was	hospitalized.	I	was	intubated	day	2	of	a	6-week	ICU	stay	prior	to	transfer	to	a	hospital	closer	to	home	for
another	3	months.	Although	GBS	was	suspected,	neither	I	nor	my	family	knew	the	diagnosis	or	prognosis	until	weeks	later.
Throughout,	a	dedicated	and	caring	expert	staff	made	my	time	in	ICU	as	pleasant	as	possible,	despite	my	pneumonia	and
5	 near-death	 situations.	 The	 ventilator	was	 noisy.	 I	was	manually	 bagged	 during	 turning	 and	 bed	 linen	 changes.	 I	was
frightened,	 reliant	on	human	expertise	and	nasogastric	 tube	 feeding,	 could	not	 communicate	despite	an	alphabet	 chart
(only	 movement	 was	 to	 blink	 my	 eyes),	 and	 had	 concurrent	 hallucinations.	 No	 audio	 books,	 radio	 or	 television	 were
available.	I	was	unable	to	see	my	two	young	sons	because	of	ICU	policy.	Insertion	of	a	speaking	trachea	tube	resulted	in
enormous	 joy	 to	 be	 able	 to	 communicate.	 After	 Christmas,	 I	 transferred	 to	 Rehab.	 Hydrotherapy	 was	 immensely
beneficial.	I	relearned	to	swim,	beginning	with	13	floats	attached.	After	4	months,	when	I	was	able	to	independently	turn	over
in	bed,	I	was	discharged	to	outpatient	care.	The	Rehabilitation	Centre	was	4	1/2	hours	by	car	from	home.	Within	6	weeks	I
learned	to	drive	with	adaptations.	I	felt	independent	for	the	first	time	in	many	months.	Now	35	years	on,	I	live	a	relatively
normal	life,	albeit	slower	than	most	people	my	age.	I	am	unable	to	climb	stairs	but	run	a	home,	play	golf,	swim,	drive	and
travel	 alone.	 For	 30	 years	 I	 have	 voluntarily	 developed	 the	 GBS/CIDP	 British	 Support	 Group.	 In	 the	 beginning,	 Prof.
Richard	A.C.	Hughes	mentored	me,	and	gradually	chapters	throughout	the	UK	were	formed	and	I	became	the	International
Director	of	the	GBS/CIDP	Foundation	International.	For	my	efforts	Queen	Elizabeth	II	awarded	me	the	Member	of	British
Empire	medal.
Patricia	Bloomquist
In	 1990,	 I	 Patricia	 Bloomquist,	 31	 years	 old,	 Netherlands,	 experienced	 acute	 onset	 of	 severe	 lower	 back	 pain,	 oral
numbness,	and	total	malaise.	I	was	hospitalized	5	days	later	and	a	diagnosis	of	GBS	confirmed	by	spinal	tap	and	nerve
conduction	studies.	A	course	of	IVIg	was	given,	but	deterioration	continued,	requiring	intubation	and	mechanical	ventilation
for	35	days;	a	2-month	ICU	stay	was	complicated	with	pneumonia,	deep-vein	thrombosis	and	hallucinations;	and	a	4.5-
month	further	hospitalization	was	followed	by	outpatient	rehabilitation.	Six	to	eight	weeks	prior	to	my	neurological	symptoms
I	was	given	a	 tetanus	 immunization	and	developed	swollen	 lymph	nodes	after	4	weeks.	While	 in	 ICU	I	was	visited	by	a
recovered	GBS	patient	 found	by	my	parents.	This	 visit	 inspired	me	 to	 start	 a	 support	 group,	eventually	 leading	 to	my
involvement	with	the	GBS/CIDP	Foundation	(liaison,	regional	director,	board	member,	secretary	of	the	board	and	currently
vice	president).
GBS	has	had	a	great	impact	on	my	life.	Obviously,	the	first	years	(and	sometimes	still)	it	has	given	me	a	total	different
outlook	on	life.	After	25	years,	GBS	still	 is	a	big	part	of	my	life,	but	 in	a	good	way.	My	‘work’	 for	the	Foundation	and	the
Dutch	support	group	is	very	rewarding	and	fulfilling.	And	there	has	been	another	bonus:	because	of	GBS	I’ve	met	so	many
wonderful	people	that	I	wouldn’t	have	otherwise	met.
All	3	of	these	patients	noted	hallucinations	and	abnormal	dreams	that	have	been	described	in	as	many	as
19%	of	GBS	ICU	patients,	which	is	higher	than	the	3.6%	noted	in	other	ICU	patients.	This	phenomenon	is
linked	 to	 abnormalities	 in	 REM	 sleep,	 autonomic	 dysfunction	 and	 decreased	 levels	 of	 hypothalamic
hypocretin-1	[10],	suggesting	involvement	of	the	central	nervous	system.
Josua	Baer
In	1996,	 I,	Josua	Baer,	11	years	old,	USA,	following	a	flu-like	 illness,	developed	paraesthesia	and	mild	weakness	 in	my
legs.	The	family	doctor,	anticipating	recovery,	approved	a	family	vacation	to	Israel.	On	the	first	day,	I	was	unable	to	drink
from	a	straw,	developed	an	inability	to	whistle	and	fully	to	open	or	close	my	eyelids.	I	progressed	to	generalized	weakness
and	 unsteady	 gait,	 prompting	 hospitalization	 and	 diagnostic	 studies	 in	 Jerusalem	 that	 supported	 a	 diagnosis	 of	 Miller
Fisher	syndrome	with	GBS	overlap	reflecting	diffuse	motor	weakness.	Following	a	course	of	IVIg,	I	was	flown	home	to	the
United	 States	 unable	 to	 walk,	 with	 persistent	 double	 vision	 and	 loss	 of	 deep	 tendon	 reflexes,	 the	 last	 of	 which	 never
returned.	 I	 lost	20%	of	my	body	weight	and	was	 in	physical	 therapy	 for	10	months.	 I	 very	gradually	 regained	strength,
flexibility	 and	 stamina.	Support	 and	encouragement	 from	my	 family	 played	a	 large	part	 in	 the	 recovery.	Attendance	 in
school	in	the	fall	for	a	half	day	was	complicated	by	weakness	and	fatigue.	I	did	not	fit	in	with	my	class	and	was	not	able	to
make	new	friends	because	of	abnormal	thinness,	frequently	not	being	able	to	attend	a	full	day	of	school	and	an	inability	to
play	sports.	I	was	able	to	participate	full	time	the	second	half	of	the	year.	With	hard	work	I	achieved	full	recovery.
Stuart	Butler	(Written	by	Lisa	Butler,	Mother)
In	2001,	Stuart,	USA,	was	a	5-year-old	who	had	a	viral	infection	on	a	cruise.	Four	weeks	later	he	fell	on	the	playground	and
started	 to	 limp.	 Over	 5	 days	 the	 unsteadiness	 progressed.	 He	 was	 unable	 to	 walk	 40	 feet	 without	 support.	 He	 was
hospitalized	for	ataxia.	An	examination	showed	an	inability	to	raise	his	arms	over	shoulder	height	or	raise	his	legs	against
gravity.	The	weakness	and	associated	loss	of	DTRs	throughout	resulted	in	a	diagnosis	of	GBS,	supported	by	an	elevated
spinal	fluid	protein.	He	was	treated	with	IVIg	over	4	days	and	released	from	hospital	to	home	in	a	wheelchair.	Over	the	next
two	weeks	mild	improvement	was	followed	by	a	relapse,	and	nerve	conductions	showed	a	primary	axonal	variant	of	GBS.
He	was	 retreated	with	 IVIg	 2	months	 after	 initial	 symptoms	 and	 showed	 rapid	 improvement.	He	walked	 his	 first	 steps
independently	within	a	month.	Physical	therapy	including	aqua	therapy	was	continued	over	a	further	4	months.	He	currently
is	an	active	teenager	on	his	way	to	college	and	plays	competitive	water	polo.
Michael	Tedesco
I,	Michael	Tedesco,	32	years	old,	USA,	developed	flu-like	symptoms	in	March	of	2003	and	within	a	week	had	back	pain
with	difficulty	standing.	Nerve	conduction	studies	showed	prolonged	distal	 latencies	and	spinal	 fluid	 findings	supported	a
diagnosis	of	GBS.	During	hospitalization,	 increasing	weakness	and	difficulty	breathing	prompted	my	transfer	 to	 the	 ICU
and	intubation.	A	month	and	a	half	later,	following	two	courses	of	IVIg,	I	developed	some	movement	in	the	neck	and	trunk,
followed	by	movement	in	my	hands,	arms	and	eventually	legs.	After	3	months	I	was	weaned	from	the	ventilator	and	moved
to	a	rehab	unit	for	another	2	months.	I	stood	for	the	first	time	at	4	months.	At	my	weakest	I	had	lost	a	third	of	my	body
weight.	 I	was	discharged	5	months	 into	my	course,	 largely	confined	 to	a	wheelchair.	Gradually,	over	several	months	of
outpatient	rehab,	3	days	per	week,	I	discontinued	my	wheelchair,	progressed	to	a	walker,	a	cane	and	finally	no	support.	I
believe	my	mental	and	physical	commitment	to	a	full	 recovery	was	 instrumental	 in	my	outcome.	I	have	returned	to	my
investment	practice	and	enjoy	many	outdoor	physical	activities	including	surfing	(figure	59.1).
Figure	59.1		Michael	surfing	in	Fiji	2012
Trevor	Sammut
Trevor	Sammut,	Republic	of	Malta.	 In	November	of	2011,	as	a	30-year-old	man,	 I	was	struck	down	with	 food	poisoning
associated	with	 vomiting,	 abdominal	 pain	and	 runny	diarrhoea	 that	was	 treated	with	 two	different	 courses	of	 antibiotics.
Midway	through	the	second	week	I	was	unable	to	form	a	scoop	with	the	fingers	of	my	left	hand.	I	had	fatigue,	cramping	and
‘laziness’	 in	 my	 legs.	 I	 could	 not	 write	 despite	 resolution	 of	 the	 gastroenteritis.	 Difficulty	 standing	 up	 from	 a	 sofa	 and
climbing	up	and	down	one	 flight	of	stairs	prompted	an	emergency	 room	visit.	 I	entered	 the	hospital	 limping	at	9	pm	on
Sunday	20th	November	2011	and	was	wheelchair-dependent	within	 6	 hours.	 I	 had	good	 sensation	but	 prominent	 distal
weakness	in	both	upper	and	lower	extremities.	A	diagnosis	of	GBS	was	verified	with	a	 lumbar	puncture	and	NCSs.	IVIg
initially	stabilized	the	downward	course	and	after	10	days	allowed	me	to	begin	to	walk	a	few	steps	independently.	After	a	20-
day	hospitalization,	 I	 had	distal	 atrophy	and	shortened	ankle	 tendons.	 I	 underwent	physical	and	occupational	 therapy.	 I
psychologically	 fought	 real	 hard	 not	 to	 let	 GBS	 win	 over	 my	morale	 and	mind.	 At	 times	 GBS	 did	 win,	 as	 I	 definitely
imagined	myself	 permanently	 crippled	at	moments	of	weakness.	 I	 imagined	myself	 secretly	wheeling	myself	 to	a	high
bridge	 or	 a	 high	 location—to	 take	 a	 good	 view	 of	 course.	 My	 recovery	 was	 complicated	 by	 shock-like	 pain	 at	 night
originating	from	my	hips	down	my	legs.	Seven	months	later,	with	much	determination	and	effort,	I	can	open	a	garage-door
lock,	button	a	shirt	and	pants,	separate	my	fingers	from	one	another	and	walk	independently.	I	am	able	to	work	full	time	and
serve	as	a	liaison	for	the	GBS/CIDP	FI.	I	enjoy	my	life	and	my	family,	not	excluding	my	cat.
The	overall	incidence	of	GBS,	estimated	to	be	1.1/100,000	to	1.8/100,000	a	year,	is	increased	after	50
years	 of	 age	 to	 1.7/100,000	 to	 3.3/100,000	 a	 year	 [11].	 In	 this	 study,	 up	 to	 70%	 of	 cases	 reported	 a
preceding	 infection,	 either	 a	 URI	 or	 diarrheal	 illness,	 as	 was	 the	 case	 in	 all	 of	 the	 above	 series	 of
patients.	Only	1	of	this	series	was	in	their	sixth	decade	of	age,	most	were	in	the	fourth	decade	and	2	were
children	 ages	 5	 and	 11.	 Though	 not	 perhaps	 a	 representative	 sample	 age-wise	 of	 the	 GBS	 spectrum,
where	the	peak	incidence	is	between	50	and	60	years	of	age,	all	of	these	patients	ultimately	did	well	and
currently	enjoy	an	independent	life.	Two	were	empirically	treated	with	a	second	course	of	IVIg	because
of	relapse	or	lack	of	initial	improvement.	The	use	of	a	second	course	in	patients	with	risk	factors	for	a
poor	outcome	is	currently	being	studied	in	a	randomized	controlled	trial	in	the	Netherlands.	Some	of	these
patients	participated	in	rehabilitation	longer	than	others	and	one	had	significant	neurological	deficit	even
after	3	decades.	Nonetheless,	 the	overall	 response	was	good	and	2	currently	participate	 in	competitive
sports	requiring	good	balance,	strength	and	coordination.
Many	cited	the	importance	of	the	support	by	their	family.	I	feel	that	the	physician’s	role	is	not	only	to
diagnose	 and	 provide	 appropriate	 treatment	 but	 also	 to	 follow	 the	 patient	 during	 rehabilitation.
Documentation	of	 the	patient’s	 improvement	provides	a	different	 type	of	 support	 and	encouragement.	 It
also	identifies	any	relapse	that	might	require	additional	retreatment.	Knowing	and	working	with	more	than
300	 GBS	 patients	 in	 the	 past	 several	 years	 was	 perhaps	 the	most	 rewarding	 experience	 in	my	 entire
neurological	practice.
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Introduction
We	 are	 a	 group	 of	 medical	 students	 from	 Singapore	 in	 our	 third	 to	 final	 years	 of	 medical	 school
researching	Guillain-Barré	syndrome	(GBS)	under	the	supervision	of	Dr	Umapathi.	We	maintain	a	GBS
database	 and	 work	 on	 projects	 that	 cover	 clinical,	 electrophysiological,	 laboratory	 and	 serological
aspects	of	different	GBS	subtypes.	Here	we	share	our	perspectives	on	this	disorder	that	we	have	come	to
better	understand	in	the	course	of	our	research.
Our	First	Encounter	with	the	Enemy
Our	 first	 encounter	 with	 GBS	 was	 in	 a	 textbook,	 in	 a	 short	 paragraph	 buried	 amongst	 other	 medical
conditions.	Descriptors	like	‘uncommon’	and	‘autoimmune’	prompted	us	to	subconsciously	relegate	GBS
to	‘a	good-to-know,	but	not	a	must-know’	condition	for	the	examinations.	During	tutorials	on	the	approach
to	 patients	 with	 flaccid	 weakness,	 GBS	 would	 be	 briefly	 mentioned	 as	 a	 differential	 diagnosis	 with
minimal	elaboration,	 some	even	using	 the	 terms	 ‘acute	 inflammatory	demyelinating	neuropathy’	 (AIDP)
and	 ‘GBS’	 interchangeably.	 As	 we	 first	 embarked	 on	 our	 research	 journey,	 we	 learnt	 the	 global
importance	 of	 this	 most	 common	 cause	 of	 acute	 flaccid	 paralysis.	 However,	 it	 was	 only	 after	 our
encounter	with	Mr	T	that	we	appreciated	the	tremendous	impact	GBS	had	on	patients.
A	GBS	Patient’s	Experience
“It	 began	when	 I	 suddenly	 lost	my	 appetite,	 felt	 bloated	 and	 unwell,	 but	 couldn’t	 figure	 out	what	was
happening.”	Such	was	Mr	T’s	first	encounter	with	something	that	would	soon	change	his	life	forever.
At	60	years	old,	Mr	T	 led	an	active	 life,	worked	as	a	construction	company’s	 technical	officer	and
was	 happily	married	with	 children	 and	grandchildren.	When	his	 vague	 symptoms	 failed	 to	 resolve,	 he
consulted	a	general	practitioner	and	was	treated	for	indigestion.	He	did	not	get	better	and	instead	started
finding	 it	difficult	 to	walk	steadily	and	perform	simple	 tasks	 like	picking	up	a	cup.	His	hands	and	 feet
were	numb.	This	prompted	 a	visit	 to	 the	 emergency	department,	whereupon	he	was	 admitted.	He	 soon
developed	dysphagia	and	respiratory	muscle	paralysis,	 landing	him	in	 the	neurology	intensive	care	unit
(NICU)	for	7	weeks.	This	was	a	frightening	period	as	he	could	not	comprehend	what	was	happening	to
him.	He	was	eventually	diagnosed	with	GBS.	The	medical	team	provided	some	information	about	GBS	to
him,	 but	 much	 remained	 incomprehensible.	 Elderly	 people	 were	 supposed	 to,	 at	 some	 point	 in	 time,
develop	 heart	 failure,	 strokes	 or	 cancer,	 but	GBS?	None	 of	 his	 friends	 had	 the	 disease.	He	 had	 never
heard	of	GBS	before,	nor	of	the	nerve	conductions	studies	(NCS)	nor	intravenous	immunoglobulins	(IVIg)
which	 were	 soon	 to	 follow.	 Mr	 T	 remained	 hospitalised	 for	 2	 months	 and	 spent	 a	 further	 3	 at	 a
rehabilitation	hospital.
Mr	T	battled	with	GBS	on	multiple	fronts:	physically,	psychologically,	socially	and	financially.	The
disease	robbed	him	of	his	livelihood	and	he	grappled	with	the	loss	of	gainful	employment.	The	residual
weakness	 and	 unsteadiness	made	 it	 too	 dangerous	 for	 him	 to	 continue	 his	 physically	 demanding	work
inspecting	construction	 sites.	At	his	age,	 finding	a	new	 job	would	be	an	uphill	 struggle.	Hefty	medical
bills	further	compounded	the	stress,	and	the	previously	self-sufficient	Mr	T	had	to	seek	financial	support
from	his	children.
An	active	and	avid	basketball	player	prior	to	his	illness,	it	was	devastating	for	Mr	T	when	he	lost	his
ability	to	walk,	stand	and	sit	upright	over	a	few	days.	Having	to	rely	on	family	members	and	nurses	for
simple	 activities	 like	 dressing	 and	 bathing	 was	 humiliating.	 It	 was	 no	 mean	 feat	 to	 relearn	 to	 walk
independently,	but	he	succeeded	after	persevering	through	intense	rehabilitation.
To	Mr	T,	this	remains	an	incomplete	victory.	He	counts	himself	lucky	to	have	survived	and	regained
some	functional	independence;	however,	he	poignantly	points	out	that	going	back	to	his	previous	pursuits
remains	impossible.	Mr	T	hopes	doctors	will	continue	their	research	to	find	a	cure	for	 this	debilitating
condition.	He	still	dreams	of	being	able	play	basketball	again;	 to	do	so	would	be,	as	he	puts	 it,	 ‘better
than	winning	the	lottery’.
GBS	through	the	Caregiver’s	Eyes
“It	was	one	of	 the	hardest	and	most	emotionally	draining	times	of	my	life”	recounted	Mdm	T,	wife	and
sole	caregiver	of	Mr	T.	‘My	heart	ached	when	I	saw	him	in	the	NICU	with	tubes	and	machines	all	over.
He	was	so	thin,	weak	and	ill,	I	was	afraid	he	would	never	open	his	eyes	again’.	Mdm	T	had	many	fears
about	her	husband’s	condition.	She	felt	helpless	seeing	his	difficulty	coping	with	activities	of	daily	living
(ADLs),	but	stoically	batted	away	tears	to	maintain	a	strong	front	for	her	husband.
Mdm	T	had	been	through	a	lot	even	before	this	incident.	After	her	mother-in-law	suffered	a	stroke	31
years	 ago,	Mdm	 T	 quit	 her	 job	 to	 be	 her	 full-time	 caregiver	 as	 well	 as	 to	 raise	 her	 young	 children.
Although	it	was	a	trying	time,	she	attributes	her	ability	to	tide	through	Mr	T’s	illness	to	the	‘training’	she
got	when	caring	for	her	mother-in-law	and	young	children	simultaneously.	This	time,	she	had	to	care	for
both	Mr	T	 and	her	 2	 grandchildren	 as	 she	 shuttled	 between	 the	 kindergarten,	 hospital	 and	home	 every
single	day.
The	ordeal	continued	even	after	Mr	T	was	sent	home	from	the	rehabilitation	hospital.	Petite	Mdm	T
struggled	 to	 support	 him	 as	 he	walked	 and	 to	 deal	with	 her	 husband’s	 frustration	 over	 his	 inability	 to
perform	simple	tasks	such	as	bathing	independently,	something	they	took	for	granted	prior	to	his	illness.
Reflecting	on	the	entire	experience,	Mdm	T	explained,	“There	will	always	be	difficult	times	in	life	but
the	 important	 thing	 is	 to	 remain	 strong	 and	 keep	 pushing	 forward.	 Indulging	 in	 self-pity	will	 not	 help
matters.”
Mdm	T	is	extremely	thankful	for	her	husband’s	recovery,	knowing	some	patients	are	not	so	fortunate.
Mr	T	is	now	able	to	walk	independently	and	even	squat	down	to	carry	his	grandchildren!	He	is	able	to
perform	most	ADLs	independently,	albeit	with	some	limitation	of	movement	in	his	upper	limbs.	Mdm	T
smiled	 fondly	 when	 she	 recounted	 how	 the	 medical	 team	 supported	 her	 during	 those	 difficult	 weeks,
thanking	them	for	their	care,	comfort	and	concern	which	made	the	experience	more	bearable.
How	Do	Clinicians	Diagnose	GBS?
When	we	 first	 started	 learning	 to	 diagnose	 patients	with	GBS,	 it	 felt	 as	 if	we	were	 running	 through	 a
checklist.	 Reflexes	 decreased?	 Check.	 Ascending	 pattern	 of	 sensory	 loss?	 Check.	 Power	 decreased
distally	more	than	proximally?	Check.	Recent	onset	of	symptoms	and	a	flu	a	few	weeks	prior?	Splendid,
diagnosis	 of	GBS	made!	 Please	wait	while	 I	 order	 the	 appropriate	 tests	 to	 confirm	 the	 diagnosis	 and
admit	you	to	the	ward	for	appropriate	treatment.	Next	patient	please!
However,	as	we	delved	deeper	into	our	research,	we	encountered	patients	with	a	myriad	of	clinical
presentations.	With	time,	we	began	to	appreciate	the	approach	employed	by	clinicians.	Not	all	symptoms
or	signs	are	equal,	and	we	learnt	that	blindly	following	a	checklist	leaves	us	vulnerable	to	misdiagnosing
mimics	 such	 as	 thyrotoxic	 hypokalaemic	 periodic	 paralysis,	 acute	 myelopathy	 and	 acute	 beriberi
neuropathy	as	GBS.
We	 also	 began	 to	 appreciate	 the	 value	 of	 the	 various	 investigations	 involved.	 These	 include
electrophysiological	 studies,	 spinal	 fluid	 examination	 and	 anti-ganglioside	 antibodies.	While	we	 learnt
the	utility	of	these	tests	in	our	textbooks,	we	appreciated	their	limitations	in	practice.	This	made	us	realise
the	significance	of	research	in	advancing	knowledge	of	the	disease	at	an	electrophysiological,	serological
and	even	molecular	level.	Confining	ourselves	to	a	checklist	leaves	us	blinkered	and	does	a	disservice	to
those	whose	symptoms	are	still	evolving	or	lie	beyond	the	fringes	of	our	existing	knowledge.
Is	GBS	a	Single	Entity	or	a	Spectrum	of	Diseases?
Mr	T’s	illness	wore	many	masks.	He	initially	presented	with	what	appeared	to	be	Miller	Fisher	syndrome
(MFS)	but	unexpectedly	progressed	to	develop	additional	features.	He	was	later	diagnosed	to	have	acute
motor	and	sensory	axonal	neuropathy	(AMSAN).	As	we	looked	around,	we	found	other	patients	similarly
labelled	GBS	with	very	different	clinical	manifestations;	some	had	paraesthesias,	others	even	had	pain.
Through	 our	 database,	 we	 also	 encountered	 patients	 with	 central	 nervous	 system	 involvement	 namely
Bickerstaff	brainstem	encephalitis	(BBE).
Now,	 having	 been	 exposed	 to	 a	 myriad	 of	 presentations,	 we	 have	 learned	 to	 think	 of	 GBS	 as	 a
spectrum	of	subtypes	ranging	from	acute	 inflammatory	demyelinating	polyradiculoneuropathy	(AIDP)	 to
those	with	a	more	restricted	neurological	involvement	such	as	MFS.
How	Do	We	Sieve	through	the	Different	Subtypes	of	GBS?
With	such	a	spectrum	of	presentations,	how	does	one	differentiate	the	various	subtypes	of	GBS?	Through
our	observations	of	clinicians	at	work	and	our	research,	we	found	that	there	are	several	factors	useful	in
sorting	 this:	 demographics,	 antecedent	 infection,	 careful	 delineation	 of	 physical	 findings,	 serology	 and
electrodiagnosis,	especially	serial	studies	[1].
Some	forms	of	GBS	can	be	distinguished	on	clinical	grounds	from	‘classic’	GBS,	such	as	BBE,	MFS
and	the	pharyngeal-cervical-brachial	variant.	However,	subtypes	within	classic	GBS,	namely	AMAN	and
AIDP,	 are	 clinically	 indistinct.	 Serial	 NCS	 is	 the	 current	 gold	 standard	 [2,3,4].	 GBS,	 being	 an
autoimmune	 disease,	 also	 has	 a	 serological	 footprint.	Research	 in	 this	 area	 has	 shed	 light	 on	 both	 the
identification	of	subtypes	and	on	underlying	pathogenesis	at	a	molecular	 level.	For	instance,	anti-GQ1b
anti-ganglioside	 antibodies	 are	 present	 in	majority	 of	 patients	 afflicted	with	MFS;	 these	 patients	 often
have	ophthalmoplegia,	and	it	has	been	found	that	GQ1b	gangliosides	are	concentrated	in	the	oculomotor,
trochlear	and	abducens	nerves.	Likewise,	antibodies	to	GM1,	GM1b,	GD1a	and	GalNac-GD1a	are	raised
in	AMAN,	 and	 these	 have	 been	 implicated	 in	 paranodal	 injury.	Mr	 T’s	 serial	 nerve	 conduction	 study
showed	predominantly	 axonal	 changes	 and	 he	 had	 raised	 antibodies	 against	GQ1b	 and	GT1a.	He	was
therefore	assigned	the	subtype	of	AMSAN.
Despite	many	years	of	experience,	clinicians	and	researchers	still	encounter	difficulties	in	subtyping.
To	us	novices	in	the	world	of	GBS,	watching	our	mentors	think	of	novel	solutions	to	these	challenges	has
inspired	us	to	press	on	and	think	of	alternate	solutions	when	faced	with	a	scientific	or	clinical	problem.
We	also	learnt	that	dealing	with	complexity	is	one	of	the	skills	of	an	astute	clinician.	Our	study	of	GBS
has	honed	our	clinical	judgement,	matured	our	thinking	processes	and	enabled	us	to	feel	more	confident	in
dealing	with	complex	multi-system	disorders.	We	have	trained	our	minds	to	pick	out	the	defining	hallmark
of	each	condition:	the	‘black-white	stripes	that	differentiate	the	zebra	from	a	horse,’	as	our	mentor	often
quips.
Why	Subtype	GBS	at	All?
Does	it	really	matter	to	patients	like	Mr	T	if	he	has	AIDP	or	AMAN?	After	all,	the	mainstay	of	treatment
remains	 the	same,	with	 the	 focus	on	supportive	care	and	either	 IVIg	or	plasmapheresis	 to	minimise	 the
extent	 of	 autoimmune-mediated	 damage	 to	 peripheral	 nerve.	 Beyond	 the	 utility	 in	 prognosticating	 the
individual	patient’s	 expected	clinical	 course,	 the	distinction	does	not	generally	 affect	 clinical	practice.
This	question	kept	recurring	during	the	many	late	nights	we	spent	trying	to	make	sense	of	our	research	data
and	 derive	 better	ways	 of	 subtyping	GBS.	We	 learnt	 that	 our	 current	methods,	 while	 being	 constantly
improved,	 are	 still	 unable	 to	 consistently	 distinguish	 between	 subtypes.	 We	 encountered	 patients,
undifferentiated	 at	 presentation,	 who	 were	 later	 reclassified	 as	 our	 research	 entailed	 serial	 NCS	 and
long-term	follow-ups.	However,	repeat	NCS	and	serologies	are	not	feasible	for	patients	in	underserved
parts	of	the	world.
Nevertheless,	 questioning	 the	 purpose	 of	 our	 research	 is	 just	 as	 important,	 if	 not	more	 so,	 than	 the
research	 itself.	 As	 we	 tried	 to	 derive	 a	 greater	 meaning	 from	 our	 work,	 we	 eventually	 came	 to	 the
understanding	that	although	management	currently	remains	the	same,	the	pursuit	of	knowledge	is	an	end	in
its	own	right,	and	subsequent	generations	would	recoup	the	benefits	of	our	current	work.
The	Research	Process:	Entering	Uncharted	Waters
For	most	of	us,	this	was	our	maiden	foray	into	research	(we	now	realise	we	might	have	entered	the	pool
at	the	deep	end).	Before	this,	our	experience	with	research	was	mainly	limited	to	reading	journal	articles
and	making	sense	of	published	work.	As	we	marvelled	at	 the	intellectual	discussions	at	conferences	by
the	giants	of	GBS	research,	whom	we	had	only	read	about	previously,	a	flame	of	inspiration	was	ignited
within	all	of	us	to	aspire	to	make	a	contribution	to	the	understanding	of	GBS.
We	were	very	fortunate	to	be	exposed	to	both	research	and	clinical	work	early	in	our	medical	school
years.	Clinical	work	laid	the	foundation	of	our	understanding	of	GBS,	allowing	us	to	see	how	it	played
out	in	real	life,	while	research	armed	us	with	tools	to	delve	deeper.	On	the	other	hand,	research	was	not	a
bed	of	roses	as	our	idealistic	selves	soon	realised;	there	were	so	many	aspects	we	had	not	considered,
from	fastidiously	maintaining	a	database	to	securing	adequate	funding.	We	also	learnt	valuable	skills	such
as	manuscript	preparation	and	cogent	presentation	of	data.	We	have	not	figured	it	all	out	yet	(and	perhaps
never	will),	but	the	seeds	of	a	future	in	research	have	been	planted.
The	Future	of	GBS	Treatment
We	 hold	 the	 same	 hope	 as	 Mr	 T	 to	 find	 a	 cure	 for	 GBS	 and	 read	 with	 excitement	 some	 of	 the
developments	 in	GBS.	We	 now	know	 that	 neuronal	 injury	 is	 a	 complement-mediated	 process	 [5]	with
immunologic	targets	differing	amongst	subtypes,	such	as	Schwann	cells	in	AIDP	and	nodal	and	paranodal
axolemma	 in	 AMAN	 [6].	 Further,	 histological-serological-molecular	 correlation	 may	 facilitate	 the
development	of	treatment	options,	beyond	IVIg	and	plasmapheresis.	It	 is	with	great	anticipation	that	we
look	towards	a	future	where	more	targeted	treatment	can	help	patients	like	Mr	T	recover	faster	and	better;
and	we	hope	we	may	be	able	to	play	a	role	in	making	this	dream	a	reality.
Our	Takeaways
The	conundrum	 that	 is	GBS	 is	 a	 lesson	 in	humility	and	patience	 for	us.	 It	has	 taught	us	 respect	 for	 the
scientific	 method.	 Our	 initial	 lofty	 aspirations	 of	 making	 the	 next	 breakthrough	 in	 GBS	 by	 the	 end	 of
medical	school	evolved	into	smaller,	more	deliberate	steps	at	improving	understanding	of	this	disease	by
working	with	the	global	community	of	GBS	researchers.	The	immediate	benefits	of	our	work	may	not	yet
be	clear,	 but	 it	 is	our	hope	 that	 fellow	medical	 students,	 doctors	 and	 scientists	 around	 the	world,	who
share	this	common	passion	for	GBS	research,	are	encouraged	that	their	efforts	are	never	in	vain.
It	is	also	important	we	do	not	lose	sight	of	our	goal	of	research:	to	alleviate	the	suffering	of	patients
like	Mr	T.	We	have	learnt	the	importance	of	establishing	prompt	diagnoses,	subtyping	accurately,	applying
current	 evidence-based	 therapeutic	 and	 supportive	 protocols,	 deepening	 our	 understanding	 of	 the
immunopathology	 of	 GBS	 and	 designing	 new,	 inexpensive,	 accessible	 and	 more	 effective	 therapeutic
approaches.	What	we	know	of	GBS	in	the	future	will	likely	be	different	from	what	we	believe	we	now
know;	the	last	100	years	is	proof	of	that.	With	so	much	still	a	work	in	progress,	we	realise	it	is	important
to	 keep	 an	 open	 mind	 to	 new	 solutions,	 yet	 not	 forget	 the	 art	 of	 applying	 our	 currently	 imperfect
knowledge	in	clinical	practice.
Finally,	 it	 has	 been	 our	 greatest	 privilege	 to	 have	 been	mentored	 and	 taught	 by	 experts	 in	 the	 field
which,	 coupled	 with	 the	 lessons	 Mr	 T	 has	 imparted	 to	 us,	 continue	 to	 guide	 us	 in	 our	 journey	 in
understanding	GBS.
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Top	10	Moments	in	Research:	A	PhD	Student’s
Journey
Madeleine	E.	Cunningham
Introduction
As	I	am	sure	is	the	case	for	many	young	researchers	entering	the	field	of	Guillain-Barré	research,	when
the	day	came	to	start	my	PhD	I	had	not	even	heard	of	a	ganglioside	and	had	only	a	vague	recollection	of	a
lecture	mentioning	Guillain-Barré	syndrome	(GBS).	So	I	had	a	lot	of	reading	to	do.	Some	papers	became
staple	 reading	material,	 necessary	 both	 to	 learning	 the	 general	 nature	 of	my	 subject	matter,	 but	 also	 to
refer	to	for	the	nitty-gritty	details	needed	to	make	sense	of	my	own	data.	Here,	I	have	compiled	a	list	of
my	top	10	favourite	papers,	some	of	which	helped	me	understand	the	world	of	GBS	research	and	some	of
which	helped	me	understand	my	own	PhD.	All	of	them	are	wonderful	examples	of	how	different	areas	of
research	have	combined	to	forward	our	understanding	of	GBS	over	the	last	century.
McKhann	GM,	et	al.	Clinical	and	electrophysiological	aspects	of	acute
paralytic	disease	of	children	and	young	adults	in	northern	China.	The
Lancet,	1991
My	thesis	focused	on	acute	motor	axonal	neuropathy	(AMAN);	therefore	one	of	my	first	looked-to	papers
was	 that	 of	McKhann	 and	 colleagues’	 clinical	 and	 electrophysiological	 description	 of	 axonal	 GBS	 in
children	[1].	Until	 their	ground-breaking	work,	GBS	was	thought	of	as	demyelinating,	synonymous	with
what	 is	 now	 referred	 to	 as	 acute	 inflammatory	 demyelinating	 polyneuropathy	 (AIDP).	 This	 paper
described	a	paralytic	 syndrome	which	occurred	 in	 rural	China,	 similar	 to	GBS	 in	all	 features	with	 the
exception	of	the	electrophysiological	tests	[1].	These	tests	indicated	not	a	demyelinating	disease,	but	one
which	appeared	to	affect	motor	neuron	axons.	This	syndrome	was	also	seasonal,	a	feature	not	believed	to
be	commonly	seen	with	GBS	at	 the	 time.	This	was	 the	first	 indication	not	only	 that	GBS	could	also	be
axonal,	but	also	that	it	can	be	linked	to	seasonal	outbreaks	of	illness.
Ilyas	AA,	et	al.	Serum	antibodies	to	gangliosides	in	Guillain-Barré
syndrome.	Annals	of	Neurology,	1988
One	of	the	first	things	I	was	ever	told	about	GBS	is	that	it	is	an	autoimmune	disease,	caused	by	antibodies
targeting	 peripheral	 nerves.	 Of	 course	 this	 only	 begins	 to	 scratch	 the	 surface	 of	 GBS	 pathogenesis.
However,	 until	 the	 work	 of	 Ilyas	 and	 colleagues	 in	 1988	 the	 target	 for	 this	 autoimmune	 attack	 was
unknown.	They	were	the	first	 to	demonstrate	that	antibodies	against	peripheral	nerve	gangliosides	were
present	in	the	serum	of	GBS	patients	[2].	Since	then,	many	other	studies	have	confirmed	this	using	various
solid-phase	assays.	Some	subtypes	of	GBS	were	identified	as	being	associated	with	specific	ganglioside
antibodies,	 building	 the	 case	 for	 these	 antibodies	 being	biomarkers	 for	 disease.	The	 antigen	 for	AIDP,
however,	still	remains	elusive.
Yuki	N,	et	al.	Animal	model	of	axonal	Guillain-Barré	syndrome	induced
by	sensitization	with	GM1	ganglioside.	Annals	of	Neurology,	2001
While	anti-ganglioside	antibodies	were	associated	with	GBS	patients,	before	2001	it	was	still	debated
whether	 the	 antibodies	 were	 pathogenic	 or	 simply	 biomarkers	 of	 disease.	 Evidence	 in	 support	 of	 the
former	 came	with	 the	 development	 of	 the	 first	 animal	model	 of	AMAN.	When	 Japanese	white	 rabbits
were	 inoculated	 with	 GM1	 ganglioside,	 they	 began	 to	 develop	 limb	 weakness	 or	 flaccid	 paralysis,
accompanied	by	an	anti-GM1	antibody	response	in	their	serum	[3].	Animal	models	are	an	essential	step
in	understanding	molecular	pathogenesis	of	any	disease	and	in	this	particular	case	they	served	to	confirm
the	importance	of	an	autoimmune	response	to	ganglioside	as	a	triggering	step	in	the	process.
Takamiya	K,	et	al.	Mice	with	disrupted	GM2/GD2	synthase	gene	lack
complex	gangliosides	but	exhibit	only	subtle	defects	in	their	nervous
system.	Proceedings	of	the	National	Academy	of	Sciences	USA,	1996
The	generation	of	mice	 lacking	 the	enzymes	 responsible	 for	 synthesizing	ganglioside	plays	an	essential
role	in	our	story.	GalNAcT-/-	mice	generated	by	Takamiya	and	colleagues	lack	all	complex	gangliosides,
a	subset	of	gangliosides	whose	production	is	dependent	on	the	GalNAcT	enzyme	[4].	The	generation	of
these	mice,	who	develop	 an	 age-dependent	 degenerative	phenotype,	 led	 to	 further	 understanding	of	 the
roles	of	gangliosides	in	nervous	system	maintenance.	On	a	personal	level	they	have	served	me	faithfully
as	 negative	 controls	 in	 many	 of	 my	 studies	 which	 require	 an	 interaction	 between	 antibody	 and
ganglioside.	 One	 of	 their	 most	 useful	 roles,	 however,	 has	 been	 their	 involvement	 in	 ganglioside
immunisation	studies.
Bowes	T,	et	al.	Tolerance	to	self	gangliosides	is	the	major	factor
restricting	the	antibody	response	to	lipopolysaccharide	core
oligosaccharides	in	Campylobacter	jejuni	strains	associated	with
Guillain-Barré	syndrome.	Infection	and	Immunity,	2002
While	antibodies	against	gangliosides	had	been	generated	previously	in	wild	type	mice,	GalNAcT-/-mice
produce	a	much	greater	anti-ganglioside	antibody	response	than	their	wild	type	counterparts	[5].	For	our
lab,	 this	has	 led	 to	 the	use	of	 these	mice	as	hosts	 for	generating	many	of	our	 in-house	anti-ganglioside
antibodies.	 The	 incorporation	 of	 liposomes	 into	 our	 immunisations,	 as	 described	 by	 Bowes	 and
colleagues,	have	proved	to	be	an	effective	way	of	introducing	gangliosides	into	the	mice	in	a	way	which
at	 least	 in	part	mimics	the	way	gangliosides	are	presented	in	the	membrane,	especially	when	some	ova
protein	 is	 introduced	 to	 elicit	 T	 cell	 help	 [6].	 This	 protocol	 has	 been	 used	 to	 make	 many	 in-house
monoclonal	antibodies	against	gangliosides,	and,	more	recently,	antibodies	to	other	lipids.
Greenshields	KN,	et	al.	The	neuropathic	potential	of	anti-GM1
autoantibodies	is	regulated	by	the	local	glycolipid	environment	in
mice.	Journal	of	Clinical	Investigation,	2009
The	discovery	that	antibodies	against	gangliosides	are	often	found	in	patients’	sera	was	only	the	beginning
of	 a	 very	 complex	 (no	 pun	 intended)	 story.	 It	 has	 become	 increasingly	 clear	 that	 the	 organisation	 of
gangliosides	in	the	plasma	membrane	is	incredibly	important	in	GBS.	Kaida	and	colleagues	demonstrated
that	 a	 proportion	 of	 GBS	 patients	 had	 antibodies	 against	 neoepitopes	 formed	 by	 a	 combination	 (or
complex)	of	ganglioside	antigens,	an	observation	Alan	Pestronk	previously	made	about	GM1	and	other
lipids	 in	patients	with	multifocal	motor	neuropathy	 [7,8].	The	 studies	by	Greenshields	 and	co-workers
showed	that	despite	binding	to	GM1	in	solid-phase	assays,	surrounding	gangliosides	such	as	GD1a	may
block	the	binding	of	certain	GM1	antibodies	in	the	living	plasma	membrane,	preventing	injury	[9].	These
studies,	particularly	appropriate	to	this	chapter	as	they	were	done	during	her	PhD,	demonstrated	that	this
organisation	of	gangliosides	is	incredibly	important	for	pathogenicity.
Yao	D,	et	al.	Neuronal	expression	of	GalNAc	transferase	is	sufficient
to	prevent	the	age-related	neurodegenerative	phenotype	of	complex
ganglioside-deficient	mice.	Journal	of	Neuroscience,	2014
A	development	which	 greatly	 served	my	 PhD	was	 the	 generation	 of	 new	 transgenic	mice,	which	 only
expressed	the	usually	ubiquitous	gangliosides	on	neuronal	or	glial	membranes	[10].	These	mice	are	not
only	useful	for	the	study	of	ganglioside	function,	they	are	great	tools	for	the	study	of	GBS.	For	unknown
reasons,	 antibodies	directed	 against	 gangliosides	only	 result	 in	 injury	 to	peripheral	 nerves,	 despite	 the
fact	that	gangliosides	are	expressed	on	most	cell	types	in	the	body.	Therefore	the	production	of	these	mice
can	allow	more	effective	targeting	of	anti-ganglioside	antibody-mediated	attack	to	disease-relevant	sites.
For	me,	whose	focus	was	the	neuromuscular	junction,	this	allowed	the	comparison	of	binding	and	injury
at	the	perisynaptic	Schwann	cells	or	the	motor	nerve	terminal.	It	also	meant	restricting	in	vivo	binding	of
anti-ganglioside	antibody	to	neuronal	or	glial	sites.
Daniotti	JL	and	Iglesias-Bartolome	R.	Metabolic	pathways	and
intracellular	trafficking	of	gangliosides.	International	Union	of
Biochemistry	and	Molecular	Biology	Life,	2011
Gangliosides	have	very	dynamic	existences.	They	are	formed	in	the	Golgi	complex	and	transported	to	the
outer	leaflet	of	the	plasma	membrane,	where	they	are	thought	to	exist	in	the	already-dynamic	lipid	rafts.
However,	they	also	can	be	re-endocytosed	and	post-modified	or	even	degraded	into	their	constituent	parts
[11].	This	review	details	the	comings	and	goings	of	gangliosides	and	how	their	endocytic	pathways	can
change	 in	different	cell	 types	and	 in	 response	 to	different	 ligands,	 including	 toxins	and	antibodies.	The
movements	of	gangliosides	in	this	way	led	to	the	idea	that	the	anti-ganglioside	antibodies,	so	relevant	to
patient	disease,	may	be	internalised	along	with	the	gangliosides.
Fewou	SN,	et	al.	Anti-ganglioside	antibody	internalization	attenuates
motor	nerve	terminal	injury	in	a	mouse	model	of	acute	motor	axonal
neuropathy.	Journal	of	Clinical	Investigation,	2012
As	we	come	further	down	the	 list,	 the	papers	are	particularly	personal	choices,	whose	work	either	has
directly	 influenced	 the	background	or	was	 essential	 to	 the	methods	 employed	during	my	PhD.	My	next
choice	 heavily	 influenced	 the	 direction	which	my	 PhD	 studies	 took.	 This	 paper	was	 the	 first	 to	 show
explicitly	 that	 antibodies	 against	 gangliosides	 can	 bind	 the	 axonal	 component	 of	 the	 neuromuscular
junction	and	become	 internalised	at	 this	 site	 [12].	This	observation	 is	one	which	has	a	 lot	of	potential
implications.	 First	 of	 all,	 it	 provides	 an	 explanation	 as	 to	 why	 the	motor	 nerve	 terminal	 is	 relatively
spared	 in	 patient	 disease,	when	 there	 is	 such	 a	wealth	 of	 evidence	 showing	 its	 destruction	 in	 ex	 vivo
tissue	in	response	to	anti-ganglioside	antibody	and	complement.	Second,	since	it	seems	to	act	as	a	vacuum
for	anti-ganglioside	antibody,	could	this	be	enough	to	affect	the	amount	of	antibody	which	is	circulating?
That	was	the	question	I	wished	to	answer	in	my	PhD.
Fabian	RH.	Retrograde	axonal	transport	and	transcytosis	of
immunoglobulins:	implications	for	the	pathogenesis	of	autoimmune
motor	neuron	disease.	Advances	in	Neurology,	1991
While	the	observation	of	peripheral	antibody	being	taken	up	at	the	nerve	terminal	is	not	a	new	one,	it	has
never	been	considered	as	an	important	factor	in	the	field	of	GBS	research.	Previous	studies	which	looked
at	antibodies	against	nonspecific	 synaptic	membrane	components	 indicated	 that	 this	uptake	at	 the	nerve
terminal	is	not	the	end	of	the	road	for	these	antibodies.	In	fact,	immunoglobulins	which	are	taken	up	at	the
motor	 endplate	 may	 be	 retrogradely	 transported	 to	 the	 spinal	 cord	 [13].	 Does	 this	 happen	 with	 anti-
ganglioside	antibodies	as	well?	If	so,	what	influence	could	those	antibodies	have	once	in	the	CNS?	These
were	further	questions	which	I	sought	to	answer	within	the	constraints	of	my	3-year	PhD.	Some	have	been
answered	in	part	and	some	remain	unanswered.
Conclusion
From	starting	out	my	project,	 completely	overwhelmed	by	 the	 expanse	of	new	 information	 I	 needed	 to
retain,	eventually	finding	my	niche	within	the	field,	and	coming	out	the	other	end	with	a	PhD,	it	has	been	a
long	 journey.	That	 journey	 is	 reflected	 in	my	 top	10	papers	which	helped	me	build	my	knowledge	and
shape	 the	 direction	 of	 my	 studies.	 You	 may	 have	 noticed	 that	 4/10	 of	 my	 papers	 have	 a	 distinct
Glaswegian	quality	about	them.	From	this	you	may	have	guessed	that	my	PhD	was	carried	out	in	Glasgow
in	the	lab	of	Professor	Hugh	Willison.	It	is	not	that	I	am	biased	(well	maybe	a	little),	just	simply	that	these
papers	 are	 very	 personal	 to	my	 journey,	 often	 describing	methods	 or	 resources	 critical	 to	my	PhD,	 or
work	which	I	took	forward	in	my	own	research.
Figure	61.1	 	Neuromuscular	 junction	 labelled	with	 anti-ganglioside	antibody.	 α-Bungarotoxin	 labels	 the	 post-synaptic	 nicotinic
acetylcholine	receptors	(nAChRs),	while	the	axon	and	Schwann	cells	(SCs)	express	CFP	and	GFP,	respectively.
While	any	PhD	attempts	to	address	several	questions,	it	will	inevitably	throw	up	several	more	which
remain	unanswered	when	the	time	comes	to	submit.	These	questions	are	left	to	future	PhD	students	who
will	 find	 their	own	 top	10	papers	 in	 their	own	personal	 journey	 in	GBS	research.	 I	 leave	you	with	an
image	of	my	wee	pal,	the	NMJ,	taken	during	my	PhD	(figure	61.1).	I	must	say	it	was	difficult	to	choose
only	one.
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A	Bibliometric	Assessment	of	Guillain-Barré
Syndrome:	A	Librarian’s	Perspective
Susan	Ashworth
Introduction
Citation	 analysis	 is	 not	 an	 exact	 science	 and	 what	 is	 presented	 here	 is	 one	 interpretation	 of	 the	 top
research	and	researchers	 in	Guillain-Barré	syndrome.	There	will	be	other	 interpretations	depending	on
the	tool	or	the	methodology	used	to	derive	the	citation	analysis.	There	are	a	number	of	different	tools	that
can	 be	 used;	 the	 tools	which	 are	 commonly	 available	 in	 higher	 education	 are	Web	 of	 Science	 (WoS),
Scopus	and	Google	Scholar.	These	databases	each	give	different	citation	counts	for	the	same	article	(WoS
and	Scopus	may	 not	 differ	 significantly;	Google	 Scholar	 usually	 returns	 a	 higher	 number	 of	 citations).
This	begs	the	question	as	to	whether	every	citation	is	equal.	WoS	and	Scopus	have	strict	inclusion	criteria
for	journals	in	their	database,	and	citations	to	articles	come	from	the	same	range	of	high-quality	journals,
arguably	presenting	a	clearer	picture	of	academic	impact;	Google	Scholar	includes	citations	from	a	much
wider	range	of	sources,	for	example	from	student	dissertations,	so	arguably	academic	impact	is	diluted.
In	this	case,	the	Web	of	Science	Core	Collection	(the	citation	indexes)	has	been	used	as	the	basis	for
analysis.	WoS	 is	 an	online,	multidisciplinary	 indexing	and	abstracting	database	which	also	 indexes	 the
citations	within	and	to	articles.
Earliest	Publications
The	earliest	paper	related	to	GBS	which	is	indexed	in	WoS	was	published	in	the	Journal	of	Nervous	and
Mental	Disease	in	1900	(alongside	2	other	papers	in	the	same	volume).
Knapp	PC,	Thomas	JJ.	Landry’s	paralysis.	Journal	of	Nervous	and	Mental	Disease,	1900
This	paper	has	been	cited	just	4	times,	and	early	publications	in	WoS	on	Landry’s	paralysis	received	very
few	 citations.	 There	 were	 far	 fewer	 journal	 articles	 published	 in	 the	 early	 20th	 century	 than	 today.
Bornmann	and	Mutz	(2014)	have	identified	that	global	scientific	publication	is	growing	at	a	rate	of	around
3%	every	year	and	that	the	volume	of	publication	approximately	doubles	every	24	years	[1].
Top	Publications
The	search	conducted	on	WoS	was	for	the	keyword	‘Guillain’,	which	returned	9,190	resultsa,	and	papers
were	listed	in	order	of	times	cited	from	highest	to	lowest.	This	search	was	chosen	as	the	most	appropriate
based	 on	 tests	 using	 a	 number	 of	 different	 variations–for	 example,	 searches	 for	Guillain-Barré	missed
those	articles	where	Barré	 is	spelt	as	Barr	or	Barri.	 ‘Guillain’	 is	a	broad	search	 term	and	some	of	 the
papers	 found	are	peripheral	 to	GBS.	 I	consulted	with	staff	 from	the	Institute	of	 Infection,	 Immunity	and
Inflammation	at	the	University	of	Glasgow	to	identify	these	peripheral	papers	and,	after	consultation,	the
following	papers	are	my	Top	10.
All	Publications
1.	 van	der	Meché	FG,	Schmitz	PI	 (1992)	A	 randomized	 trial	 comparing	 intravenous	 immune	globulin
and	 plasma-exchange	 in	 Guillain-Barré	 syndrome.	 N	 Engl	 J	 Med	 326(17):	 1123–29.
(10.1056/NEJM199204233261705)
2.	 Asbury	 AK,	 Cornblath	 DR	 (1990)	 Assessment	 of	 current	 diagnostic-criteria	 for	 Guillain-Barré
syndrome.	Ann	Neurol	27(Suppl):	S21–S24.	(10.1002/ana.410270707)
3.	 Hughes	 RAC,	 Cornblath	 DR	 (2005)	 Guillain-Barré	 syndrome.	 Lancet	 366(9497):	 1653–66.
(10.1016/S0140-6736(05)67665-9)
4.	 Haymaker	 WE,	 Kernohan	 JW	 (1949)	 The	 Landry-Guillain-Barré	 syndrome;	 a	 clinicopathologic
report	 of	 50	 fatal	 cases	 and	 a	 critique	 of	 the	 literature.	 Medicine	 (Baltimore)	 28(1):	 59–141.
(10.1097/00005792-194902010-00003)
5.	 Ropper	 AH	 (1992)	 The	 Guillain-Barré-syndrome.	 N	 Engl	 J	 Med	 326(17):	 1130–36.
(10.1056/NEJM199204233261706)
6.	 Plasma	 Exchange/Sandoglobulin	 GBS	 Trial	 Group.	 (1997)	 Randomised	 trial	 of	 plasma	 exchange,
intravenous	 immunoglobulin,	 and	 combined	 treatments	 in	 Guillain-Barré	 syndrome.	 Plasma
Exchange/Sandoglobulin	 Guillain-Barré	 Syndrome	 Trial	 Group.	 Lancet	 349(9047):	 225–30.
(10.1016/S0140-6736(96)09095-2)
7.	 Chiba	A,	Kusunoki	S,	Obata	H,	Machinami	R,	Kanazawa	I	(1993)	Serum	anti-GQ1b	IgG	antibody	is
associated	with	 ophthalmoplegia	 in	Miller	 Fisher	 syndrome	 and	Guillain-Barré	 syndrome:	 clinical
and	immunohistochemical	studies.	Neurology	43(10):	1911–17.	(10.1212/WNL.43.10.1911)
8.	 Ho	TW,	Mishu	B,	Li	CY,	Gao	CY,	Cornblath	DR,	Griffin	JW,	Asbury	AK,	Blaser	MJ,	McKhann	GM
(1995)	Guillain-Barré	syndrome	in	Northern	China:	 relationship	 to	Campylobacter	 jejuni	 infection
and	anti-glycolipid	antibodies.	Brain	118(3):	597–605.	(10.1093/brain/118.3.597)
9.	 Rees	JH,	Soudain	SE,	Gregson	NA,	Hughes	RA	(1995)	Campylobacter-jejuni	infection	and	Guillain-
Barré	syndrome.	N	Engl	J	Med	333(21):	1374–79.	(10.1056/NEJM199511233332102)
10.	 Schonberger	 LB,	 Bregman	 DJ,	 Sullivan-Bolyai	 JZ,	 Keenlyside	 RA,	 Ziegler	 DW,	 Retailliau	 HF,
Eddins	 DL,	 Bryan	 JA	 (1979)	 Guillain-Barré	 syndrome	 following	 vaccination	 in	 the	 National
Influenza	Immunization	Program,	United	States,	1976–1977.	Am	J	Epidemiol	110(2):	105–123.
All	Publications	by	Authors
The	‘analyse	results’	feature	in	WoS	allows	analysis	of	the	9,190	results	returned	by	a	search	for	Guillain;
this	includes	an	analysis	by	authors;	the	top	10	most	prolific	authors	are	listed	in	Table	62.1.
The	‘create	citation	report’	feature	in	WoS	then	enables	ranking	of	the	top	10	most	published	authors
by	H-Index	(the	point	at	which	the	author	has	published	n	publications,	each	of	which	has	been	cited	at
least	n	times).	See	Table	62.2.
All	Publications	by	Citation
WoS	provides	the	sum	of	the	times	cited	for	each	author’s	papers	and	provides	the	sum	of	the	times	cited
without	self-citation.	This	enables	us	to	see	which	authors	have	cited	themselves	most	often	(there	could
be	very	good	reasons	for	this,	for	example,	a	researcher	building	on	previous	knowledge;	the	researcher’s
work	is	at	the	cutting	edge	of	their	field,	and	so	forth	[2]).	See	Table	62.3.
Table	62.1		Top	10	most	prolific	authors
Table	62.2		Top	10	most	published	authors	by	H-Index
Table	62.3		Top	authors	by	self-citation
Top	10,	Articles	Only
The	search	for	‘Guillain’	includes	a	wide	range	of	document	types;	WoS	allows	searches	to	be	refined	by
document	type	such	as	articles,	review	articles,	meeting	abstracts,	letters,	editorial	material,	proceedings
papers,	book	chapters,	etc.
Refining	 the	 search	 to	 include	 only	 articles	 gives	 5,657	 articles.	 Again	 I	 consulted	with	 academic
colleagues	to	determine	which	articles	are	peripheral	to	Guillain-Barré	syndrome	and	produced	my	Top
10	articles:
Articles
1.	 van	der	Meché	FG,	Schmitz	PI	 (1992)	A	 randomized	 trial	 comparing	 intravenous	 immune	globulin
and	 plasma-exchange	 in	 Guillain-Barré	 syndrome.	 N	 Engl	 J	 Med	 326(17):	 1123–29.
(10.1056/NEJM199204233261705).
2.	 Plasma	 Exchange/Sandoglobulin	 GBS	 Trial	 Group.	 (1997)	 Randomised	 trial	 of	 plasma	 exchange,
intravenous	 immunoglobulin,	 and	 combined	 treatments	 in	 Guillain-Barré	 syndrome.	 Plasma
Exchange/Sandoglobulin	 Guillain-Barré	 Syndrome	 Trial	 Group.	 Lancet	 349(9047):	 225–30.
(10.1016/S0140-6736(96)09095-2)
3.	 Chiba	A,	Kusunoki	S,	Obata	H,	Machinami	R,	Kanazawa	I	(1993)	Serum	anti-GQ1b	IgG	antibody	is
associated	with	 ophthalmoplegia	 in	Miller	 Fisher	 syndrome	 and	Guillain-Barré	 syndrome:	 clinical
and	immunohistochemical	studies.	Neurology	43(10):	1911–17.	(10.1212/WNL.43.10.1911)
4.	 Ho	TW,	Mishu	B,	Li	CY,	Gao	CY,	Cornblath	DR,	Griffin	JW,	Asbury	AK,	Blaser	MJ,	McKhann	GM
(1995)	Guillain-Barré	syndrome	 in	Northern	China;	 relationship	 to	Campylobacter-jejuni	 infection
and	anti-glycolipid	antibodies.	Brain	118(3):	597–605.	(10.1093/brain/118.3.597)
5.	 Rees	 JH,	 Soudain	 SE,	 Gregson	 NA,	 Hughes	 RAC	 (1995)	 Campylobacter-jejuni	 infection	 and
Guillain-Barré	syndrome.	N	Engl	J	Med	333(21):	1374–79.	(10.1056/NEJM199511233332102)
6.	 Schonberger	 LB,	 Bregman	 DJ,	 Sullivan-Bolyai	 JZ,	 Keenlyside	 RA,	 Ziegler	 DW,	 Retailliau	 HF,
Eddins	 DL,	 Bryan	 JA	 (1979)	 Guillain-Barré	 syndrome	 following	 vaccination	 in	 the	 National
Influenza	Immunization	Program,	United	States,	1976–1977.	Am	J	Epidemiol	110(2):	105–23.
7.	 Feasby	TE,	Gilbert	 JJ,	Brown	WF,	Bolton	CF,	Hahn	AF,	Koopman	WF,	Zochodne	DW	(1986)	An
acute	 axonal	 form	 of	 Guillain-Barré	 polyneuropathy.	 Brain	 109(6):	 1115–26.
(10.1093/brain/109.6.1115)
8.	 McKhann	GM,	Cornblath	DR,	Griffin	JW,	Ho	TW,	Li	CY,	Jiang	Z,	Wu	HS,	Zhaori	G,	Liu	Y,	Jou	LP,	et
al.	(1993)	Acute	motor	axonal	neuropathy:	a	frequent	cause	of	acute	flaccid	paralysis	in	China.	Ann
Neurol	33(4):	333–42.	(10.1002/ana.410330402).
9.	 Hadden	 RD,	 Cornblath	 DR,	 Hughes	 RA,	 Zielasek	 J,	 Hartung	 HP,	 Toyka	 KV,	 Swan	 AV	 (1998)
Electrophysiological	 classification	 of	Guillain-Barré	 syndrome:	 clinical	 associations	 and	 outcome.
Plasma	Exchange/Sandoglobulin	Guillain-Barré	Syndrome	Trial	Group.	Ann	Neurol	44(5):	 780–88
(10.1002/ana.410440512).
10.	 Jacobs	BC,	Rothbarth	PH,	van	der	Meché	FG,	Herbrink	P,	Schmitz	PI,	de	Klerk	MA,	van	Doorn	PA
(1998)	 The	 spectrum	 of	 antecedent	 infections	 in	 Guillain-Barré	 syndrome:	 a	 case-control	 study.
Neurology	51(4):	1110–15.	(10.1212/WNL.51.4.1110)
Articles	Only,	Publications	by	Authors
For	the	10	most	prolific	authors,	articles	only,	see	Table	62.4.	To	see	these	ranked	by	H-Index,	see	Table
62.5.	To	see	them	ranked	by	self-citation,	see	Table	62.6.
Top	Review	Articles
Limiting	 the	 ‘Guillain’	 search	 to	 reviews	 gives	 1,028	 reviews.	My	Top	 10	most	 highly	 cited	 reviews
(again	after	academic	consultation)	are	as	follows.
1.	 Hughes	 RAC,	 Cornblath	 DR	 (2005)	 Guillain-Barré	 syndrome.	 Lancet	 366(9497):	 1653–66.
(10.1016/S0140-6736(05)67665-9)
2.	 Haymaker	W,	Kernohan	JW	(1949)	The	Landry-Guillain-Barré	syndrome:	a	clinicopathologic	report
of	 50	 fatal	 cases	 and	 a	 critique	 of	 the	 literature.	Medicine	 28(1):	 59–141.	 (10.1097/00005792-
194902010-00003)b
3.	 Ropper	 AH	 (1992)	 The	 Guillain-Barré-syndrome.	 N	 Engl	 J	 Med	 326(17):	 1130–36.
(10.1056/NEJM199204233261706)
4.	 Willison	HJ,	Yuki	N	(2002)	Peripheral	neuropathies	and	anti-glycolipid	antibodies.	Brain	125(12):
2591–25.	(10.1093/brain/awf272)
5.	 Nachamkin	 I,	Allos	BM,	Ho	T	 (1998)	Campylobacter	 species	 and	Guillain-Barré	 syndrome.	Clin
Microbiol	Rev	11(3):	555–67.
6.	 Hartung	HP,	 Pollard	 JD,	 Harvey	GK,	 Toyka	KV	 (1995)	 Immunopathogenesis	 and	 treatment	 of	 the
Guillain-Barré	syndrome.	Muscle	Nerve	18(2):	137–53.	(10.1002/mus.880180202)
7.	 Hughes	RAC,	Hadden	RD,	Gregson	NA,	Smith	KJ	(1999)	Pathogenesis	of	Guillain-Barré	syndrome.
J	Neuroimmunol	100(1–2):	74–97.	(10.1016/S0165-5728(99)00195-2)
8.	 Van	Doorn	PA,	Ruts	L,	Jacobs	BC	(2008)	Clinical	features,	pathogenesis,	and	treatment	of	Guillain-
Barré	syndrome.	Lancet	Neurol	7(10):	939–50.	(10.1016/S1474-4422(08)70215-1)
9.	 Kiefer	R,	Kieseier	BC,	Stoll	G,	Hartung	HP	 (2001)	The	 role	of	macrophages	 in	 immune-mediated
damage	 to	 the	 peripheral	 nervous	 system.	 Prog	 Neurobiol	 64(2):	 109–27.	 (10.1016/S0301-
0082(00)00060-5)
10.	 Dalakas	 MC	 (2004)	 Intravenous	 immunoglobulin	 in	 autoimmune	 neuromuscular	 diseases.	 JAMA
291(19):	2367–75.	(10.1001/jama.291.19.2367)
Table	62.4		Top	10	most	published	authors,	articles	only
Table	62.5		Top	10	most	published	authors	by	H-Index,	articles	only
Table	62.6		Top	authors	by	self-citation,	articles	only
The	top	review	article	authors,	as	measured	with	the	H-Index	is	shown	in	Table	62.7.
The	top	review	article	authors,	by	self-citation,	appears	in	Table	62.8.
Table	62.7		Top	review	article	authors	by	H-Index
Table	62.8		Top	review	article	authors	by	self-citation
Normalisation
There	has	not	been	any	normalisation	applied	to	take	account	of	date	of	publication	(the	longer	a	paper
has	been	published	the	more	time	it	has	to	accrue	citations).	Reviews	also	tend	to	attract	more	citations
than	original	research.	All	of	 the	papers	I	have	selected	have	been	cited	over	a	hundred	times,	most	of
them	several	hundred	times.
Impact
Citations	are	one	measure	of	impact,	which	is	largely	academic.	Governments	and	research	funders	are
increasingly	 interested	 in	wider	 impacts	 such	 as	 the	 impact	 of	 research	 on	 the	 economy,	 or	 on	 society
more	generally,	or	on	the	culture.	There	are	a	new	group	of	metrics	which	are	designed	to	try	to	measure
this	 wider	 impact;	 these	 are	 referred	 to	 as	 altmetrics	 or	 alternative	 metrics.	 Altmetrics	 are	 seen	 as
complementary	 to	 traditional	 citation	 analysis	 and	 include	 article	 views,	 downloads,	 and	 mentions	 in
social	 media,	 news	 media	 and	 policy	 documents.	 Altmetrics	 can	 provide	 real-time	 and	 immediate
feedback	on	 the	attention	being	paid	 to	 scholarly	content	and	can	be	very	useful	 in	particular	 for	early
career	 researchers	 whose	 research	may	 not	 yet	 be	 cited.	 One	 example	 of	 the	 use	 of	 altmetrics	 is	 the
University	 of	 Glasgow’s	 institutional	 repository,	 Enlighten.	 The	 altmetrics.com	 API	 tool	 has	 been
embedded	 into	 the	 repository	 and	 uses	 a	 journal	 article’s	 DOI	 or	 PubMed	 ID	 to	 provide	 a	 ‘donut’
visualisation	 of	 sources	 discussing	 papers	 published	 by	University	 of	Glasgow	 authors,	with	 a	 link	 to
further	details	available.
	
	
a	All	searches	were	conducted	on	8th	December	2015.
b	This	paper	is	categorised	as	a	review	in	WoS	but	appears	to	be	an	original	article.
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Ten	Papers	That	Set	the	Future
Simon	Rinaldi
An	Introduction	to	the	Future
It	 is	 notoriously	 difficult	 to	 make	 predictions,	 especially	 about	 the	 future,	 as	 Niels	 Bohr	 (may	 have)
previously	noted.	Nevertheless,	this	final	chapter	speculates	on	the	directions	GBS	research	and	treatment
might	 take	 in	 its	 second	 100	 years,	 drawing	 on	 some	 ground-breaking	 approaches	 and	 observations
described	in	the	existing	literature.	I	await	with	interest	the	publication	of	GBS200	as	the	gold	standard
test	for	the	clarity	of	my	crystal	ball.
Take	Care	of	the	Chickens—Prevention	Is	Better	Than	Cure
Baker	MG,	et	al.	Declining	Guillain-Barré	syndrome	after	campylobacteriosis	control,	New
Zealand,	1988–2010.	Emerging	Infectious	Diseases,	2012
It	 may	 seem	 curious	 to	 start	 this	 chapter	 with	 a	 paper	 that	 reports	 on	 nothing	more	 cutting	 edge	 than
epidemiological	 incidence	 data,	 yet	 this	 2012	 publication	 by	 Baker	 and	 colleagues	 [1]	 in	Wellington,
New	Zealand,	highlights	the	way	in	which	existing	knowledge	might	be	used	with	substantial	effect	in	the
future.	It	has	long	been	appreciated	that	Campylobacter	jejuni	is	the	most	commonly	identified	prodromal
infection	 in	 GBS.	 This	 study	 simply	 showed	 that	 population-level	 efforts	 to	 reduce	 Campylobacter
contamination	of	poultry	meat	have	a	significant	effect	on	preventing	GBS,	reducing	its	incidence	by	13%.
Likewise,	 influenza	 immunisation	 programmes	 have	 been	 shown	 to	 have	 a	 longer-term	 benefit	 in
preventing	GBS,	which	outweighs	the	smaller,	short-term	risk	of	disease	induction	[2].	Moving	forward,
the	 combination	 of	 an	 increased	 understanding	 of	 environmental	 risk	 factors,	 greater	 international
collaboration	 (catalysed	by	 the	 success	of	 the	 International	GBS	Outcome	Study,	 IGOS)	 [3],	 improved
statistical	rigour,	and	evidence-based	public	health	policies	offer	a	clear	hope	of	substantially	reducing
the	incidence	of	GBS.	Much	as	the	improvements	in	sanitation	at	the	start	of	the	last	century,	rather	than
the	later	development	of	antibiotics,	contributed	most	to	the	reduction	in	death	from	infectious	diseases,
simple	 population-level	measures	may	 offer	 as	much	 as	 personalised,	 targeted	 immunotherapies	 in	 the
second	century	of	GBS.
Gen	and	Other	Omics
International	Human	Genome	Sequencing	Consortium.	A	physical	map	of	the	human
genome.	Nature,	2001
It	 is	 clear	 (at	 least	 to	 me!)	 that	 in	 addition	 to	 environmental	 factors,	 genetic	 influences	 must	 also	 be
involved	 in	GBS	 susceptibility.	This	 is	 supported	 by	 the	 observations	 that	 the	 disease	 recurs	 at	 a	 rate
much	 higher	 than	 expected	 by	 chance,	 but	 often	with	 different	 serological	 findings,	 and	 that	 even	with
exposure	 to	 identical	 infectious	 agents,	 only	 a	 small	 proportion	 of	 patients	will	 subsequently	 develop
GBS.	As	an	autoimmune	condition,	the	usual	candidate	genes,	and	some	more	unusual	immune-associated
targets,	have	been	investigated,	but	no	consistent	disease	associations	have	been	identified	[4].	Does	this
mean	that	the	search	for	genetic	factors	will	be	abandoned?	It	seems	unlikely.	The	continuing	evolution	of
genetic	 (and	 bio-informatics)	 techniques,	 boosted	 significantly	 during	 the	 completion	 of	 the	 Human
Genome	Project	[5],	even	now	facilitate	much	more	extensive	studies.	It	 is	already	possible	to	perform
genome-wide	 association	 studies	 looking	 for	 single	 nucleotide	 polymorphisms	 (SNPs)	 across	 many
thousands	of	genes,	and	 indeed,	 this	 is	one	of	 the	proposed	facets	of	 the	current	 IGOS	project.	Similar
studies	 have	 already	 benefited	 from	 the	 SNP	 datasets	 made	 freely	 available	 via	 the	 internationally
collaborative	HapMap	Project.	The	observation	 that	 large	proportions	of	SNP	hits	 occur	 in	noncoding
regions	 surely	 foreshadows	 an	 increasing	 awareness	 and	understanding	of	 their	 importance	 in	 disease.
With	 the	 decreasing	 cost,	 and	 increasing	 speed,	 of	whole	 exome	 and	 even	whole	 genome	 sequencing,
future	studies	will	be	able	to	draw	upon	ever	more	extensive	genetic	data,	offering	new	and	unexpected
insights	into	disease	pathogenesis,	and	implicating	critical	processes	both	within	and	outside	the	immune
system	amenable	 to	 therapeutic	 intervention.	 Indeed,	others	have	already	predicted	a	next	generation	of
medicine	 where	 individual	 patients’	 genomes	 are	 used	 to	 personalise	 treatments,	 based	 on	 a	 precise
understanding	of	their	given	disease	process.
Jinek	M,	et	al.	A	programmable	dual-RNA-guided	DNA	endonuclease	in	adaptive	bacterial
immunity.	Science,	2012
Alongside	an	increased	capability	to	read	and	decode	genetic	data	there	has	developed	a	vastly	improved
power	 to	 manipulate	 genes.	 Cre-recombinase	 systems,	 allowing	 triggered	 activation	 or	 inhibition	 of
defined	 genes	 in	 specific	 cells,	 are	 already	 in	 widespread	 use	 in	 biomedical	 research.	 The	 current
pinnacle	of	genetic	manipulation	is,	however,	currently	best	demonstrated	by	the	application	of	CRISPR
technology	first	outlined	by	Jinek	and	colleagues	[6]	in	2012.	In	essence,	the	use	of	guide	RNAs	allows
an	 endonuclease	 to	 cut	 DNA	 at	 defined	 points,	 facilitating	 the	 relatively	 simple,	 and	 cost-effective,
removal,	addition	or	replacement	of	particular	nucleotide	sequences.	The	implications	for	many	diseases,
including	GBS,	are	potentially	enormous.	Cell-	and	animal-based	disease	models	could	have	individual
genes	 modified	 to	 assess	 their	 influence	 on	 key	 aspects	 of	 the	 disease	 process.	 Ultimately,	 similar
technology	could	be	applied	 to	patients,	with	 the	enticing	possibility	of	genetically	engineered	cellular
robots	being	designed	 to	manipulate	 specific	aspects	of	 the	 immune	 response,	enhance	nerve	 repair,	or
interfere	with	other	pathologically	relevant	processes.
In	 many	 ways,	 however,	 obtaining	 and	 analysing	 the	 genetic	 data	 itself	 is	 likely	 to	 be	 one	 of	 the
simpler	 tasks	 undertaken	 by	 GBS	 researchers	 of	 the	 future.	 It	 is	 now	 appreciated	 that	 much	 of	 the
complexity	 of	 the	 human	 ‘biome’	 is	 not	 revealed	by	 study	of	 the	 genes	 themselves.	Epigenetic	 factors,
transcriptional	control,	post-translational	protein	modifications,	lipids	and	carbohydrates	have	all	already
been	shown	to	be	important	in	health	and	disease.	Large-scale	collaborations,	with	ongoing	advances	in
biochemical	techniques,	will	ensure	that	the	genomics	revolution	will	be	followed	by	similar	advances	in
transcriptomics,	proteomics	and	glycolipidomics.	With	cognition	network	technologies	such	as	Definiens
already	operational	[7],	the	insights	offered	by	such	increasingly	complex	datasets	seem	more	likely	to	be
successfully	revealed	by	computer	thinking,	rather	than	by	the	direct	application	of	scientists’	little	grey
cells.
Membranomics—Studies	of	the	Membrane	Microenvironment
Lloyd	KO,	et	al.	Cell	surface	accessibility	of	individual	gangliosides	in	malignant	melanoma
cells	to	antibodies	is	influenced	by	the	total	ganglioside	composition	of	the	cells.	Cancer
Research,	1992
It	was	momentarily	pleasing	to	think	I	had	created	a	neologism	that	might	be	increasingly	used	in	future
years,	but	a	quick	visit	to	Google	confirms,	of	course,	that	‘membranomics’	is	already	an	established	term
and	even	had	its	own	international	symposium	in	2010	[8].	Away	from	semantics,	 that	 the	physical	and
biochemical	properties	of	 the	cell	membrane	as	a	whole	have	relevance	 to	GBS	was	foreshadowed	as
long	 ago	 as	 1992.	 Lloyd	 and	 colleagues,	 studying	 melanoma	 cells,	 realised	 that	 the	 ability	 of	 a
ganglioside	 antibody	 to	 interact	 with	 its	 membrane	 target	 was	 markedly	 influenced	 by	 the	 overall
ganglioside	 composition	 of	 the	 cell	membrane	 [9].	Over	 a	 decade	 later,	 researchers	working	 in	Hugh
Willison’s	 lab,	 including	 myself,	 demonstrated	 a	 similar	 phenomenon	 with	 anti-GM1	 antibodies	 [10],
known	 to	 be	 associated	with	 the	 acute	motor	 axonal	 neuropathy	 (AMAN)	 subtype	 of	 GBS.	While	 all
GM1-antibodies	studied,	including	those	derived	from	patients,	were	able	to	bind	purified	GM1	in	solid
phase	 assays	 (typically	 ELISA),	 a	 proportion	 were	 unable	 to	 bind	 when	 GM1	was	mixed	 with	 other
gangliosides,	 notably	 GD1a,	 a	 pattern	 we	 termed	 ‘complex	 attenuated’.	 It	 became	 apparent	 that	 these
observations	 had	 direct	 relevance	 to	 the	 pathogenic	 potential	 of	 the	 antibodies.	 Using	 ex	 vivo
preparations	 of	 neuromuscular	 tissue,	 we	 demonstrated	 that	 the	 complex	 attenuated	 antibodies	 were
pathologically	inert,	whereas	complex	independent	clones—able	to	bind	GM1	regardless	of	the	presence
or	 absence	 of	 other	 glycolipids—caused	 complement	 dependent	 structural	 and	 functional	 injury	 at	 the
neuromuscular	junction.	The	implication	is	that	the	precise	density,	orientation	and	interactions	of	target
antigens	 within	 the	 cell	 membrane	 have	 a	 critical	 role	 in	 modulating	 antibody	 interactions.	 These
observations	built	upon	the	then-recent	discovery	by	Kaida	and	Kusunoki	of	GBS-associated	antibodies
only	 able	 to	 bind	 specific	 heterodimeric	 combinations	 of	 gangliosides,	 which	 they	 had	 named
‘ganglioside	complex	antibodies’	[11].
In	yet	another	exposition	of	the	importance	of	the	dynamism	of	the	cell	membrane,	Simon	Fewou	and
Rhona	McGonigal,	working	on	neighbouring	benches	in	Hugh’s	lab,	showed	that	antibody	internalisation
substantially	reduced	complement	activation	and	played	a	crucial	role	in	preventing	nerve	injury	[12,13].
Internalisation	was	particularly	active	at	the	nerve	terminal,	but	much	attenuated	at	the	nodes	of	Ranvier,
providing	 a	 potential	 explanation	 for	 the	 topographically	 focussed	 pathophysiological	 effects	 of
antibodies	directed	against	widely	expressed	membrane	glycolipids.	It	is	now	evident	that	internalisation
can	 significantly	 influence	 circulating	 levels	 of	 antibody,	 as	 discussed	 below,	 and	 this	 too	 is	 likely	 to
prove	an	important	area	of	future	study.
Binnig	G,	et	al.	Atomic	force	microscope.	Physical	Review	Letters,	1986
Given	 the	 obvious	 importance	 of	 the	 membrane	 microenvironment	 in	 GBS	 pathology,	 how	 will	 the
scientists	 of	 the	 future	 study	 this	 important	 area?	 Antibodies	 cannot	 be	 relied	 upon	 to	 unambiguously
indicate	the	presence	or	absence	of	an	antigen	within	the	cell	membrane,	and	the	cis	interactions	between
neighbouring	 molecules	 in	 the	 lipid	 bilayer	 cannot	 be	 visualised	 by	 the	 light	 or	 even	 by	 electron
microscope.	Technologies	already	exist	to	address	this	but	have	so	far	been	little	utilised	in	this	field.
One	 particular	 technique	which	 shows	 promise	 in	 this	 area	 is	 that	 of	 atomic	 force	microscopy.	By
measuring	the	atomic-level	physical,	electrical	and	magnetic	interactions	at	the	probe	tip,	the	atomic	force
microscope,	 first	 developed	 by	 Binnig	 and	 colleagues	 at	 IBM,	 allows	 surfaces	 to	 be	 resolved	 at
nanometre	resolution	[14].	As	well	as	determining	the	precise	orientation	and	interactions	of	molecules
within	the	lipid	bilayer,	modifications	to	the	methodology	allow	the	strength	and	nature	of	ligand-receptor
interactions	to	be	assessed	and	manipulated	in	their	natural	environment.	Such	imaging	has	the	potential	to
reveal	 why	 certain	 cells	 are	 sensitive	 to	 immunological	 attack	 whereas	 others	 are	 resistant,	 and	 may
uncover	alternative	means	by	which	this	sensitivity	can	be	modified.
GBS	in	a	Dish	and	the	Rise	of	the	Robots
Takahashi	K	and	Yamanaka	S.	Induction	of	pluripotent	stem	cells	from	mouse	embryonic
and	adult	fibroblast	cultures	by	defined	factors.	Cell,	2006
Professor	Yamanaka’s	pioneering	work	in	demonstrating	that	self-renewing,	pluripotent	stem	cells	can	be
generated	from	adult	cells	[15]	has	already	begun	a	revolution	in	biomedical	science	which	seems	very
likely	 to	 continue	 well	 into	 the	 second	 century	 of	 GBS.	 In	 the	 original	 methodology,	 pluripotency-
associated	genes	are	introduced	into	adult	cells	using	viral	vectors.	By	this	process,	patient-	and	disease-
specific	 induced	 pluripotent	 stem	 cells	 (iPSCs)	 are	 produced.	 These	 cells	 should	 be	 immunologically
inert	if	transplanted	back	into	the	individual	they	are	derived	from,	and	thus	have	great	potential	for	use	as
disease-modifying	 and	 repair-promoting	 agents.	 Although	 therapeutic	 uses	 are	 currently	 limited	 by
concerns	 over	 oncogenicity,	methodological	 advances	 are	 likely	 to	make	 this	 increasingly	 plausible	 in
coming	years.
Chambers	SM,	et	al.	Highly	efficient	neural	conversion	of	human	ES	and	iPS	cells	by	dual
inhibition	of	SMAD	signaling.	Nature	Biotechnology,	2009
In	 neuropathy	 research,	 the	 ability	 to	 reliably	 and	 efficiently	 generate	 neural	 cells	 from	 iPSCs,	 made
possible	through	the	techniques	pioneered	by	the	Lorenz	Studer	Lab	at	Sloan	Kettering	[16],	will	enable
stem	cell-derived	tissue	to	be	used	to	address	questions	regarding	disease	mechanisms	and	to	provide	a
biologically	relevant,	high-throughput	screening	platform	for	potential	new	therapies.
As	previously	discussed,	the	complexity	of	the	nerve	membrane	microenvironment	cannot	be	easily	or
accurately	recapitulated	by	current	assays.	The	use	of	in	vivo	or	ex	vivo	animal	neuromuscular	tissue	has
previously	 been	 used	 to	 study	 antigen-antibody	 interactions	 and	 pathological	 events,	 but	 even	 this
platform	 has	 important	 differences	 compared	 to	 its	 human	 equivalent,	 with	 rodents	 notably	 entirely
lacking	some	types	of	glycolipid.	Human	nerve	biopsy	tissue	is	available	in	only	limited	quantities,	and
cannot	 be	 easily	 studied	 in	 a	 live	 state.	 Unfortunately,	 fixation	 procedures	 are	 known	 to	 disrupt	 the
membrane	 antigen	 profile.	 By	 utilising	 Yamanaka	 and	 Studer’s	 methodologies,	 we	 have	 been	 able	 to
generate	myelinating	 sensory	nerve	 co-cultures	with	neurons	derived	 from	human	 iPSCs	 (Figure	 63.1).
Nodes	of	Ranvier,	recently	identified	as	targets	for	neuropathy-associated	antibodies,	form	spontaneously
in	 this	 system.	The	methodology	 is	 now	being	 optimised	 for	 iPSC-derived	 human	Schwann	 cells,	 thus
generating	 a	 human-specific	 membrane	 antigen	 environment	 for	 use	 in	 forthcoming	 studies.	 Future
developments	 in	 these	 techniques	will	 also	allow	 the	generation	of	other	 components	of	 the	peripheral
nerve	system.	Indeed,	co-cultures	of	muscle	cells	and	iPSC-derived	motor	neurons	have	just	been	used	to
generate	motor	units	in	microfluidic	chambers.	A	major	benefit	of	this	methodology	will	be	the	ability	to
study	pathological	processes	in	disease-relevant,	live	cells,	in	real	time.
The	 potential	 ability	 to	 recreate	multiple	 examples	 of	 human	GBS	 across	 tissue	 culture	 plates	will
soon	 be	 exploited.	 The	 increasing	 availability	 of	 iPSCs	 generated	 from	 GBS	 patients	 and	 multiple
controls	will	 facilitate	 assessment	of	 the	 importance	of	 the	polygenetic	background	on	GBS	pathology.
Very	high	 throughput	 studies	 driven	by	 robotic	management	 of	 culture	 conditions	will	 enable	 the	 rapid
evaluation	of	strategies	aimed	at	ameliorating	the	disease	process	and/or	facilitating	improved	recovery,
whilst	 no	doubt	making	 the	PhD	student	obsolete.	Some	of	 these	 approaches	may	even	 incorporate	 the
previously	described	capacity	to	genetically	or	otherwise	manipulate	neural	or	immune	cells,	generating
specially	programmed	effector	cells	for	therapeutic	use.
Immunoengineering
Bettelli	E,	et	al.	Reciprocal	developmental	pathways	for	the	generation	of	pathogenic
effector	TH17	and	regulatory	T	cells.	Nature,	2006
Betelli	and	colleagues’	2006	study	acts	as	a	marker	of	our	increasing	understanding	of	the	complexities	of
the	 immune	 response	 [17].	The	 discovery	 of	 a	whole	 new	 class	 of	T	 cells	was	 in	 itself	 a	 remarkable
development.	 The	 observation	 that	 the	 precursors	 of	 these	 Th17-type	 pro-inflammatory	 cells	 could	 in
certain	circumstances	 instead	produce	 regulatory	anti-inflammatory	cells	 is	perhaps	even	more	exciting
[17].	 It	 is	 now	 apparent	 that	 transdifferentiation	 occurs	 between	 the	 multiple	 types	 of	 mature	 cells,
opening	up	the	possibility	that	neuroimmunologists	of	the	future	will	be	able	to	specifically	switch	off	the
disease-causing	 components	 of	 an	 autoimmune	 response,	 while	 simultaneously	 enhancing	 the	 anti-
inflammatory	aspects	of	the	immune	system	itself.
Figure	63.1		Human-induced	pluripotent	stem	cell	myelinating	culture	methodology
(A)	 Schematic	 of	 hiPSC-myelinating	 co-culture	 methodology.	 (B)	 hiPSCs	 differentiated	 to	 sensory	 neurons	 form	 ganglia-like
clusters	 (cell	 bodies	 labelled	 with	 Brn3a,	 purple)	 and	 extend	 axons	 (labelled	 with	 neurofilament,	 green).	 The	 addition	 of	 (C)
Schwann	cells	results	in	(D)	myelination	(myelin	basic	protein,	MBP)	and	the	formation	of	nodes	of	Ranvier	with	clustered	sodium
channels	(NavP)	and	appropriately	localised	paranodal	proteins	(Caspr).
Corti	D,	et	al.	A	neutralizing	antibody	selected	from	plasma	cells	that	binds	to	group	1	and
group	2	influenza	A	hemagglutinins.	Science,	2011
The	work	 of	 Corti	 and	 colleagues	 has	 already	 shown	 that	 it	 is	 possible	 to	 isolate	 and	 interrogate	 the
function	 of	 individual	 antibody-producing	 cells	 [18].	A	 future	 ability	 to	 target	 specific	 subsets	 in	 vivo
would	clearly	have	therapeutic	value,	but	even	the	current	technology	offers	the	ability	to	dissect	out	and
study	 pathogenically	 relevant	 clones	 from	 within	 the	 polyclonal	 background.	 The	 implication,	 from
studies	of	antibody	internalisation	on	an	organism-wide	scale,	is	that	the	circulating	levels	of	pathogenic
antibody	may	 be	 below	 the	 limits	 of	 detection,	 such	 that	 their	 identification	 and	 characterisation	will
depend	on	this	ability	to	capture	and	culture	the	cells	producing	them.
Maude	SL,	et	al.	Chimeric	antigen	receptor	T	cells	for	sustained	remissions	in	leukemia.
New	England	Journal	of	Medicine,	2014
As	well	as	being	important	in	autoimmune	pathology,	monoclonal	antibodies	have	been	at	the	forefront	of
recent	 advances	 in	 biological	 therapies	which	 seem	 likely	 to	 continue	 into	 the	 next	 100	 years	 of	GBS
research.	Already,	stepwise	improvements	in	the	therapeutic	monoclonals	have	produced	numerous	agents
capable	of	modulating	different	aspects	of	the	immune	response,	and	a	trial	of	the	complement	inhibitor
eculizumab	for	GBS	has	already	begun	[20].
The	 engineered	 antibodies	 of	 the	 future	 could	 affect	 blocking	 rather	 than	 destructive	 processes,	 be
conjugated	to	drugs	to	deliver	directed	therapies,	or	have	their	binding	sites	alone	incorporated	into	other
molecular	scaffolds.	The	potential	power	of	 this	 latter	approach	has	 recently	been	demonstrated	by	 the
use	of	chimeric	antigen	receptor-T	cells	in	the	treatment	of	‘incurable’	childhood	leukaemia	[19].
Conclusion
The	future	of	GBS	will	surely	involve	an	exponential	increase	in	our	knowledge	of	disease	processes	and
our	 ability	 to	 precisely	 modulate	 these	 for	 therapeutic	 effect.	 New	 research	 techniques	 will	 generate
enormous	 datasets	 likely	 to	 require	 an	 equivalent	 expansion	 in	 bioinformatic	 processing	 to	 fully
understand.	To	exploit	these	developments	in	a	full	and	timely	manner,	we	must	ensure	that	direct	clinical
research	undergoes	a	similar	revolution.	A	future	where	it	is	the	expectation,	rather	than	the	exception,	for
each	GBS	patient	to	enter	an	informative	clinical	trial,	is	one	we	must	strive	to	realise.
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	Appendix
Sur	Un	Syndrome	De	Radiculo-Nevrite	Avec
Hyperalbuminose	Du	Liquide	Cephalo-Rachidien
Sans	Reaction	Cellulaire.	Remarques	Sur	Les
Caracteres	Cliniques	Et	Graphiques	Des	Reflexes
Tendineux
Par	MM.	Georges	Guillain,	J.-A.	Barre	et	A.	Strohl.
Nous	attirons	 l’attention,	dans	 la	présente	note,	 sur	un	syndrome	clinique	que	nous	avons	observé	chez
deux	malades,	 syndrome	 caractérisé	 par	 des	 troubles	moteurs,	 l’abolition	 des	 réflexes	 tendineux	 avec
conservation	des	reflexes	cutanés,	des	paresthésies	avec	troubles	légers	de	la	sensibilité	objective,	des
douleurs	 à	 la	 pression	 des	 masses	 musculaires,	 des	 modifications	 peu	 accentuées	 des	 réactions
électriques	 des	 nerfs	 et	 des	muscles,	 de	 l’hyper	 albuminose	 très	 notable	 du	 liquide	 céphalo-rachidien
avec	 absence	 de	 réaction	 cytologique	 (dissociation	 albumino-cytologique).	 Ce	 syndrome	 nous	 a	 paru
dépendre	 d’une	 atteinte	 concomitante	 des	 racines	 rachidiennes,	 des	 nerfs	 et	 des	 muscles,
vraisemblablement	de	nature	 infectieuse	ou	toxique.	Il	doit	être	différencié	des	radiculites	simples,	des
polynévrites	pures	et	des	polymyosites.	Des	recherches	expérimentales	par	la	méthode	graphique	sur	la
vitesse	des	reflexes	et	leur	temps	perdu,	sur	les	modalités,	la	contractilité	musculaire,	montrent	la	réalité
de	 la	 participation,	 dans	 ce	 syndrome,	 de	 tout	 l’appareil	 moteur	 neuromusculaire	 périphérique.	 Nous
insistons	 particulièrement	 aussi	 sur	 l’hyperalbuminose	 du	 liquide	 céphalo-rachidien	 sans	 réaction
cytologique,	fait	qui,	a	notre	connaissance,	n’a	pas	été	mentionne	dans	des	cas	semblables.
OBS.	1.	–	Le	soldat	D	…,	du	…	hussards,	âgé	de	vingt-cinq	ans,	entre,
le	20	aout	1916,	au	Centre	neurologique	de	la	VI	Armée	pour	des
troubles	moteurs	des	membres	inferieurs	et	supérieurs.	L’affection	a
débuté	vers	le	25	juillet	par	des	fourmillements	des	pieds	et	de	la
faiblesse	des	membres	inferieurs	l’obligeant	a	s’arrêter	au	bout	de	200
a	300	mètres	de	marche,	puis	des	fourmillements	sont	apparus	les
jours	suivants	aux	membres	supérieurs	et	sur	la	partie	inférieure	de	la
face;	la	force	musculaire	s’est	affaiblie	aux	membres	supérieurs.
Ces	différents	 troubles	 se	 sont	 développés	 sans	 cause	 apparente:	 le	malade	n’avait	 eu	 aucune	maladie
infectieuse	 récente,	 aucune	 angine	même	 légère,	 Il	 n’avait	 présenté	 aucun	 symptôme	 d’une	 intoxication
alimentaire,	 il	 n’avait	 pas	 eu	 de	 grandes	 fatigues.	 Nous	 ajouterons	 que,	 dans	 ses	 antécédents
pathologiques,	on	ne	retrouvait	aucun	fait	 important,	 le	malade	niait	 toute	 infection	syphilitique	et	 toute
habitude	alcoolique.
Le	premier	examen	du	25	Aout	nous	a	permis	de	constater	la	symptomatologie	suivante.
La	force	musculaire	est	diminuée	d’une	façon	globale	aux	membres	supérieurs	et	inferieurs	sans	que,
toutefois,	il	existe	une	paralysie	totale;	cette	diminution	de	la	force	musculaire	est	surtout	accentuée	aux
extrémités	ou	l’on	constate	une	très	grande	faiblesse	de	la	flexion	et	de	l’extension	des	orteils,	du	pied	sur
la	jambe,	des	doigts,	de	la	main	sur	l’avant-bras.
Les	muscles	du	tronc	sont	faibles,	ainsi	le	malade,	étant	couché	ne	peut	s’asseoir	spontanément	sans
prendre	de	point	d’appui.
La	marche	est	possible	durant	quelques	pas,	on	 remarque	alors	une	certaine	 instabilité	 et	 la	 station
debout	sur	un	pied	ne	peut	être	maintenue.
Il	n’existe	aucun	trouble	de	la	musculature	faciale.
L’examen	 électrique	 montre	 qu’aux	 membres	 supérieurs	 l’excitabilité	 faradique	 est	 normale	 et
l’excitabilité	 galvanique	 bonne	 pour	 tous	 les	 muscles	 avec	 secousses	 vives;	 il	 n’y	 a	 pas	 d’inversion
polaire;	ou	constate	seulement	une	légère	hypoexcitabilité	de	l’extenseur	des	doigts;	parfois	la	secousse
est	 légèrement	 ralentie;	 on	 constate	 de	 l’inversion	polaire	 pour	 le	 jumeau	 externe,	mais	 la	 réaction	de
dégénérescence	est	très	incomplète.
Les	 réflexes	 rotuliens,	achilléens,	medio-plantaires	 recherchés	par	 le	marteau	percuteur	sont	abolis,
de	même	que	les	réflexes	antibrachiaux,	radio-et	cubito-pronateurs,	olécraniens.
Le	réflexe	cutané	plantaire	amène	la	flexion	franche	des	orteils	avec	contraction	à	distance	du	tenseur
du	 fascia	 lata.	 Les	 reflexes	 crémasteriens	 et	 cutanés	 abdominaux	 sont	 normaux.	 On	 ne	 constate	 aucun
réflexe	de	défense	soit	par	pincement	du	cou-de-pied,	soit	par	hyperflexion	des	orteils.
L’excitabilité	neuromusculaire	au	marteau	percuteur	est	conservée.
Le	malade	se	plaint	toujours	de	fourmillements	dans	les	deux	pieds	jusqu’au	dessus	des	malléoles	et
dans	 les	 deux	mains	 jusqu’au-dessus	du	poignet.	 Il	 n’y	 a	 pas	 de	 troubles	 nettement	 appréciables	 de	 la
sensibilité	 objective,	 sinon	 une	 légère	 hypoesthésie	 tactile,	 thermique	 et	 douloureuse	 aux	 pieds	 et	 aux
mains.	Les	masses	musculaires	des	membres	supérieurs	et	inférieurs	sont	douloureuses	à	la	pression.
Les	pupilles,	égales,	réagissent	à	la	lumière	et	à	l’accommodation.
Il	n’y	a	pas	de	troubles	sphinctériens.
Aucune	fièvre,	aucun	trouble	respiratoire	ou	gastro-intestinal,	le	pouls	est	normal.
Les	 urines,	 examinées	 au	Laboratoire	 de	Bactériologie	 et	 de	Chimie	 de	 l’Armée,	 ne	 contiennent	 ni
sucre,	ni	albumine,	ni	indoxyle;	les	éléments	chimiques	sont	dans	leur	proportion	normale.
La	ponction	lombaire	montre	un	liquide	céphalo-rachidien	clair,	non	hypertendu,	hyperalbumineux	(2
gr.	5	d’albumine	par	litre)	sans	réaction	leucocytaire	(2	à	4	lymphocytes	par	champ).
La	réaction	de	Wassermann	dans	le	sang	est	négative.
Un	ensemencement	du	pharynx	et	du	mucus	nasal	montre,	l’absence	de	tout	bacille	diphtérique.
Le	traitement	consiste	en	un	repos	absolu	au	lit,	des	frictions	sur	les	membres	supérieurs	et	inférieurs,
des	injections	de	strychnine,	de	salicylate	de	soude	et	de	salol	à	l’intérieur.
Le	27	aout,	les	fourmillements	ont	diminué	aux	membres	inferieurs.
Le	2	 septembre,	 on	 constate	 une	 certaine	 amélioration	 de	 la	 force	 musculaire,	 et	 il	 n’y	 a	 plus	 de
fourmillements	dans	les	pieds;	ceux-ci	persistent	aux	mains;	 les	réflexes	tendineux	sont	toujours	abolis.
Une	 nouvelle	 ponction	 lombaire	montre,	 comme	 au	 précèdent	 examen,	 une	 très	 forte	 hyperalbuminose
sans	réaction	leucocytaire	appréciable.
Le	19	septembre,	 les	 troubles	moteurs	sont	 très	améliorés;	 le	malade	est	capable	de	marcher	durant
une	 heure,	 il	 peut	 se	 tenir	 sur	 un	 seul	 pied;	 les	 paresthésies	 ont	 complètement	 disparu	 aux	 membres
inferieurs,	 elles	 persistent	 encore,	 quoique	 atténuées,	 au	 niveau	 des	 mains;	 les	 réflexes	 tendineux
cliniquement	 sont	 abolis,	 les	 réflexes	 de	 défense	 nuls,	 les	 réflexes	 cutanés	 normaux;	 l’excitabilité
neuromusculaire	au	marteau	percuteur	parait	normale	aux	membres	supérieurs	et	inférieurs	et	à	la	face.
Le	malade,	s’améliorant	progressivement,	fut	envoyé	en	convalescence	le	30	septembre.
OBS.	II.	–	Le	soldat	D	…,	du	…	régiment	d’infanterie,	âgé	de	trente-cinq
ans,	entre,	le	5	septembre	1916,	au	Centre	neurologique	de	la	VI	Armée
pour	des	troubles	moteurs	des	membres	inferieurs	qui	se	sont
montrés	dans	les	circonstances	suivantes.
Le	28	 aout,	 Après	 une	marche	 de	 15	 kilomètres,	 il	 ressent	 une	 fatigue	 anormale,	 de	 la	 céphalée,	 des
douleurs	erratiques	dans	les	membres	supérieurs	et	 inferieurs,	 il	se	couche,	ne	peut	dormir	et	frissonne
une	partie	de	la	nuit.	Le	lendemain	matin	il	marche	avec	de	grandes	difficultés	pour	se	rendre	à	la	visite,
il	 est	 exempté	 de	 service	 durant	 quatre	 jours	 consécutifs.	 L’état	 parétique	 a	 débuté	 par	 les	 membres
inferieurs	et	a	atteint	ensuite	 les	membres	 supérieurs.	Le	quatrième	 jour	 il	veut	partir	vers	cinq	heures
avec	ses	camarades,	s’équipe	mais	tombe	à	la	renverse	avec	sa	musette	et	ne	peut	se	relever.	Transporté	à
un	poste	de	secours,	il	est	ensuite	évacué	au	Centre	neurologique	de	l’Armée.	Ces	différents	troubles	se
sont	développés	sans	cause	apparente,	il	n’avait	eu	aucune	maladie	infectieuse	récente,	n’avait	présenté
aucun	symptôme	d’une	intoxication	alimentaire	ou	autre;	il	convient	d’ajouter	qu’il	est	très	affirmatif	sur
ce	fait	qu’il	n’a	jamais	contracté	la	syphilis.
Le	5	septembre,	nous	avons	constaté	la	symptomatologie	suivante.
Le	malade	esquisse	avec	efforts	de	petits	mouvements	de	flexion	et	d’extension	des	orteils,	de	flexion
de	la	jambe	sur	la	cuisse	et	de	la	cuisse	sur	le	basin.	La	même	difficulté	existe	pour	les	mouvements	des
membres	 supérieurs	ou	 les	 troubles	prédominent	nettement	 à	 la	périphérie.	La	 tête	est	généralement	en
rotation	à	gauche	et	le	malade	éprouve	de	la	difficulté	pour	la	tourner	à	droite;	il	peut	ouvrir	et	fermer	la
bouche,	mais	lentement	et	incomplètement.
L’examen	des	 réactions	 électriques	montre	 une	 légère	 hyperexcitabilité	 des	 nerfs	 et	 des	muscles	 au
courant	 faradique.	Au	courant	galvanique	 l’excitabilité	est	 légèrement	accrue,	 surtout	pour	 les	nerfs	du
membre	supérieur;	il	n’y	a	pas	de	réaction	de	dégénérescence.
Les	reflexes	rotuliens	sont	très	difficiles	à	rechercher	à	cause	de	l’hypertonie	musculaire,	ils	semblent
exister.	 Les	 reflexes	 achilléens	 et	 medio-plantaires	 sont	 abolis.	 L’état	 des	 reflexes	 des	 membres
supérieurs	 ne	 peut	 être	 déterminé	 à	 cause	 de	 l’hypertonie	 et	 de	 l’impossibilité	 d’une	 résolution
musculaire	complète.	Les	réflexes	cutanés	plantaires	amènent	la	flexion	franche	des	orteils;	les	reflexes
crémastériens	 et	 cutanés	 abdominaux	 sont	 normaux.	On	 ne	 constate	 aucun	 reflexe	 de	 défense,	 soit	 par
pincement	 du	 dos	 du	 pied,	 soit	 par	 hyperflexion	 des	 orteils,	 mais	 le	 malade	 perçoit	 les	 sensations
provoquées	par	ces	excitations.
L’excitabilité	neuromusculaire	au	marteau	percuteur	est	conservée.
Le	 malade	 se	 plaint	 de	 fourmillements	 aux	 extrémités,	 il	 n’existe	 pas	 de	 trouble	 de	 la	 sensibilité
objective	sinon	une	légère	hypoesthésie	tactile,	douloureuse	et	thermique	aux	pieds	et	aux	mains.
Les	masses	musculaires	 du	mollet	 et	 de	 l’avant-bras	 sont	 douloureuses	 à	 la	 pression.	 Les	 pupilles
égales	 réagissent	 à	 la	 lumière	 et	 à	 l’accommodation.	 Le	malade	 urine	 seul,	 il	 sent	 le	 besoin	mais	 ne
perçoit	pas	l’écoulement	des	urines.
Il	n’a	pas	de	fièvre,	pas	de	signe	de	Kernig,	pas	de	nausées,	pas	de	vomissements.
Les	 urines	 examinées	 au	 Laboratoire	 de	 Bactériologie	 et	 de	 Chimie	 de	 l’Armée	 ne	 contiennent	 ni
sucre,	ni	albumine,	ni	indoxyle;	les	éléments	chimiques	sont	dans	leur	proportion	normale.
Il	 convient	 de	 noter	 une	 éruption	 cutanée	 apparue	 depuis	 trois	 ou	 quatre	 jours,	 localisée
principalement	à	la	partie	supérieure	du	thorax	et	à	la	région	abdominale	inferieure,	éruption	caractérisée
par	des	taches	érythémateuses,	papuleuses.	En	dehors	des	zones	que	nous	avons	signalées,	des	éléments
éruptifs	sont	dissémines	sur	le	reste	du	thorax	et	de	l’abdomen;	aucun	élément	ne	se	voit	sur	les	membres
supérieurs	et	inferieurs.
La	ponction	lombaire	montre	un	liquide	céphalo-rachidien	clair,	non	apparemment	hypertendu,	hyper
albumineux	(plus	de	0	gr.	85	d’albumine	au	 rachi	albuminimètre	de	Sicard),	 sans	 réaction	 leucocytaire
notable	(3	à	4	lymphocytes	par	champ).
Les	 symptômes	 constatés	 au	 premier	 examen	 ont	 eu	 une	 légère	 tendance	 à	 l’amélioration.	 Au	 20
septembre,	 on	 constatait	 encore	 cependant	 la	 faiblesse	 des	 muscles	 de	 la	 périphérie	 des	 membres,
l’abolition	de	tous	les	reflexes	tendineux	à	l’exception	du	reflexe	antibrachial	gauche,	la	conversation	des
reflexes	cutanés,	 la	douleur	des	masses	musculaires	à	 la	pression,	 les	paresthésies	des	extrémités	avec
hypoesthésie	légère.	On	observait	aussi	par	intermittences	dans	les	muscles	du	mollet	et	de	la	cuisse	de
petites	 secousses	 myocloniques.	 Une	 nouvelle	 ponction	 lombaire	 a	 permis	 de	 noter	 les	 mêmes
particularités	 qu’au	 précèdent	 examen:	 liquide	 clair,	 non	 hypertendu,	 avec	 une	 hyper	 albuminose	 très
accentuée	sans	réaction	leucocytaire	(3	ou	4	lymphocytes	par	champ).
Le	malade	a	été	évacué	sur	l’arrière	le	1er	octobre.
Les	deux	observations	que	nous	venons	de	relater	sont	tout	à	fait	semblables.	Chez	ces	deux	malades,
sans	cause	apparente	décelable,	s’est	développé	un	syndrome	clinique	caractérisé,	comme	nous	le	disions
au	 début,	 par	 des	 troubles	 moteurs	 atteignant	 l’ensemble	 des	 muscles	 des	 membres	 supérieurs	 et
inferieurs	et	prédominant	aux	extrémités	de	ceux-ci,	l’abolition	des	reflexes	tendineux	avec	conservation
de	 tous	 les	 reflexes	 cutanés,	 des	 paresthésies	 avec	 troubles	 légers	 des	 sensibilités	 objectives,	 des
douleurs	à	la	pression	des	masses	musculaires,	des	modifications	minimes	des	réactions	électriques	des
nerfs	et	des	muscles,	des	troubles	assez	spéciaux	du	liquide	céphalo-rachidien	caractérisés	par	une	forte
hyper	albuminose	sans	réaction	cytologique.
L’hyper	 albuminose	 accentuée	 du	 liquide	 céphalo-rachidien	 sans	 réaction	 cellulaire	 est	 une
particularité	 qui	 nous	parait	 importante	 à	 signaler.	Cette	 dissociation	 albumino	 cytologique	 (Sicard	 et-
Foix)	 est	 observée	 le	 plus	 souvent	 dans	 certaines	 compressions	médullaire,	 dans	 le	mal	 de	Pott,	 dans
certains	 cas	 de	 syphilis	 du	 névraxe,	mais	 on	 ne	 l’a	 pas	 décrite,	 nous	 semble-t-il,	 dans	 les	 radiculites
pures	et	les	polynévrites.
Chez	 le	 second	 de	 nos	 malades	 se	 surajoutait	 à	 l’élément	 paralytique	 une	 certaine	 hypertonie	 des
muscles	qui	mérite	d’être	mise	en	relief.	Le	malade	étant	au	repos,	la	consistance	de	tous	les	muscles	est
nettement	 supérieure	 à	 celle	 des	muscles	 d’un	 individu	 sain	 dans	 la	même	 situation.	 Les	mouvements
passifs	gardent	 toute	 leur	amplitude	normale.	Les	mouvements	volontaires	 limités,	comme	nous	 l’avons
dit,	se	font	avec	une	certaine	raideur	et	lenteur.	Les	reflexes	tendineux	sont	difficiles	à	mettre	en	évidence,
les	muscles	dont	la	contraction	est	sollicitée	se	trouvant	pour	ainsi	dire	bridés	par	l’état	de	contraction
continue	des	antagonistes.	Malgré	cet	ensemble	de	caractères	qu’on	rencontre	assez	fréquemment	dans	les
méningites,	le	malade	peut	être	assis	en	gardant	les	membres	supérieurs	presque	complètement	étendus,	et
la	légère	flexion	des	genoux	qui	se	produit	alors	est	vaincue	par	une	pression	insignifiante.	Les	membres
inférieurs	relevés	et	mis	presque	à	angle	droit	avec	le	tronc	se	fléchissent	comme	ceux	d’un	sujet	normal.
Le	 signe	 de	 Kernig	 n’existe	 par	 conséquent	 pas	 chez	 notre	 malade.	 Cet	 état	 d’hypertonie	 n’est	 donc
nullement	 en	 rapport	 avec	 une	 méningite,	 mais	 avec	 un	 état	 spécial	 de	 la	 contractilité	 musculaire
paraissant	dépendre	d’une	lésion	du	nerf	périphérique.	Nous	avons	d’ailleurs	déjà	insisté	sur	ce	fait	que
les	états	d’hypertonie	peuvent	se	rencontrer	au	cours	de	certaines	névrites	périphériques	et	de	blessures
incomplètes	des	nerfs,	et	spécifié	à	cette	occasion	que	les	contractures	fréquemment	observées	au	cours
de	 certaines	 paralysies	 faciales	 ne	 sont	 pas	 une	 exception	 dans	 les	 lésions	 périphériques	 des	 nerfs,
comme	on	le	croyait	classiquement.
L’ensemble	 des	 troubles	 observés	 chez	 ces	 deux	malades	 appartient	 à	 la	 pathologie	 simultanée	des
racines	rachidiennes,	des	nerfs	périphériques	et	des	muscles.	L’hyper	albuminose	considérable	du	liquide
céphalo-rachidien	 témoigne	 de	 la	 participation	 méningée;	 les	 caractères	 des	 troubles	 paralytiques
prédominant	aux	extrémités	et	les	douleurs	des	masses	musculaires	à	la	pression	montrent	la	participation
névritique	et	musculaire.	D’ailleurs,	 il	nous	 semble	que	c’est	 avec	une	 schématisation	 trop	grande	que
l’on	 isole	 en	 neurologie	 les	 polynévrites	 et	 les	 polymyosites	 ;	 dans	 un	 très	 grand	 nombre	 de	 cas	 de
polynévrites	infectieuses	ou	toxiques,	les	terminaisons	nerveuses	intramusculaires,	les	fibres	musculaires
elles-mêmes	 peuvent	 être	 atteintes	 et	 en	 réalité	 il	 peut	 s’agir	 très	 souvent	 beaucoup	 plus	 de	 poly-
neuromyosites	que	de	polynévrites	pures.
Chez	notre	premier	malade	des	recherches	expérimentales	par	la	méthode	graphique	nous	ont	permis
d’apporter	 certains	 caractères	 nouveaux	 dans	 l’étude	 des	 reflexes	 et	 de	 la	 contractilité	musculaire.	 La
méthode	 graphique	 peut	 donner	 des	 éléments	 importants	 pour	 l’interprétation	 des	 symptômes	 et	 des
lésions.
Chez	ce	malade,	alors	que	les	reflexes	tendineux	ont	paru,	à	l’examen	clinique,	abolis	durant	tout	le
cours	de	 la	maladie,	 l’inscription	graphique	du	gonflement	des	muscles	quadriceps	 fémoral	et	 jumeaux
sous	l’influence	d’une	percussion	portant	sur	les	tendons	de	ces	muscles	ou	leurs	masses	musculaires	ont
montré	 des	 particularités	 intéressantes.	 C’est	 ainsi	 que,	 dès	 le	 début	 de	 la	 maladie,	 la	 recherche	 du
réflexe	 rotulien	 amène	 une	 contraction	 que	 l’on	 voit	 nettement	 sur	 la	 figure	 1	 après	 la	 secousse
mécanique.	Cette	 contraction,	 notablement	 plus	 faible	 que	 celle	 obtenue	 chez	 un	 sujet	 sain,	 se	 produit
après	un	temps	perdu	de	0’’056	environ	et	n’est	pas	suivie	d’une	deuxième	contraction	plus	ample	et	plus
longue	 qui	 caractérise	 dans	 la	 courbe	 du	 reflexe	 normal	 la	 partie	 de	 la	 réponse	musculaire	 d’origine
véritablement	“reflexe“	C’est	a	peine	si	0’’152	après	le	début	de	l’excitation	on	remarque	un	très	léger
soulèvement	de	la	courbe	indiquant	le	vestige	de	la	contraction	reflexe.	Le	réflexe	rotulien	est	ainsi	resté
presque	entièrement	 réduit	à	une	contraction	 idio-musculaire	 jusqu’a	 la	guérison	de	 la	maladie.	Durant
cette	 période	 la	 percussion	 de	 la	masse	 du	quadriceps	 provoquait	 une	 belle	 contraction	musculaire	 se
produisant	 avec	 un	 retard	 de	 0’051,	 suivie	 elle-même	 d’une	 deuxième	 contraction	 ayant	 tous	 les
caractères	d’une	secousse	d’origine	reflexe	(fig.1)	et	se	produisant	0’’150	après	le	début	de	l’excitation.
Le	 muscle,	 qui	 ne	 répond	 que	 faiblement	 et	 partiellement	 à	 une	 excitation	 mécanique	 portée	 sur	 son
tendon	 et	 transmise	 par	 propagation	 aux	 fibres	musculaires,	 présente,	 lorsqu’il	 est	 percuté	 directement
une	double	contraction	a	peu	près	normale.	Il	semble	être	le	siège	d’une	hypoexcitabilité	mécanique	qui
ne	le	rend	excitable	que	pour	des	déformations	brusques	portées	sur	le	corps	même	du	muscle.
Figure	1.1	 	 R,	 R,	 R,	 courbe	myographique	 du	 quadriceps	 fémoral	 au	 cours	 du	 réflexe	 rotulien,	 ayec	 le	 signal	 de	 Desprez
indiquant	le	moment	de	la	percussion	et	le	temps	en	1/100	de	seconde.
I,	I,	I,	les	memes	tracés	pour	la	percussion	directe	du	muscle	quadriceps	fémoral.
Enregistrement	du	21	aout	1916.
On	remarque	l’absence	presque	totale	de	contraction	«	reflexé	»	qui	suit	la	percussion	du	tendon	rotulien,	alors	qu’elle	existe	très
nettement	pour	la	percussion	directe	du	muscle.
Le	reflexe	achilléen	s’est	montré,	au	début,	également	très	modifié	et	réduit	presque	entièrement	à	la
secousse	 mécanique.	 Celle-ci	 (fig.2)	 d’amplitude	 très	 faible,	 se	 produit	 après	 un	 temps	 perdu
extrêmement	 long,	 soit	 environ	 0’’110,	 et	 n’est	 suivie	 d’aucune	 contraction	 d’origine	 reflexe.	Mais,	 à
l’encontre	de	ce	qui	s’est	passé	pour	le	reflexe	rotulien,	ces	altérations	ont	rétrocédé	en	partie,	et,	déjà	le
5	 septembre	 (fig.3),	 une	nouvelle	 inscription	du	 reflexe	permettait	 de	déceler	une	 secousse	musculaire
plus	ample,	plus	vive,	plus	rapide	(0’’055),	suivie	d’une	deuxième	secousse	reconnaissable	comme	étant
de	nature	réflexe	et	survenant	après	un	retard	de	0’’140.	La	secousse	neuromusculaire	des	jumeaux	suivait
une	évolution	parallèle	et	reprenait	progressivement	une	forme	se	rapprochant	de	la	normale.
Figure	1.2		A,	courbe	myographique	du	jumeau	interne	au	cours	du	réflexe	achilléen.
M,	la	meme	au	cours	du	réflexe	médio-plantaire.
Enregistrement	du	21	aout	1916.
La	première	élévation	de	la	courbe	A	est	une	secousse	mécanique,	la	deuxième	est	une	contraction	«	musculaire	».	La	partie	«
reflexé	»,	qui	n’existe	pas	dans	le	cas	du	réflexe	achilleen	est	visible	quoique	très	faible	sur	la	courbe	du	reflexé	médio-plantaire.
Figure	1.3		A,	courbe	myographique	du	iumeau	externe	au	cours	du	réflexe	achilleen.
Enregistrement	du	5	septembre	1916.
Le	réflexe	se	présente	avec	ses	trois	élévations	caractéristiques.	Toutefois	la	contraction	«	musculaire	»	et	surtout	Ja	contraclion
‘	«	reflexé	»	sont	plus	faibles	que	chez	un	sujet	normal.
Il	est	intéressant	de	remarquer	que,	tandis	qu’au	début	de	la	maladie,	la	percussion	du	tendon	d’Achille	et
celle	 des	 jumeaux	 ne	 provoquait	 qu’une	 secousse	 musculaire,	 à	 ce	 moment-la	 déjà,	 la	 recherche	 du
réflexe	medio-plantaire	amenait	une	deuxième	contraction	ayant	0’144	de	retard	et	que	l’on	doit	regarder
comme	une	contraction	reflexe	(fig.	2)	d’intensité	faible	mais	très	nette.
En	somme,	tandis	que	le	simple	examen	clinique	ne	permet	que	de	constater	l’abolition	des	reflexes
tendineux,	l’analyse	détaillée	des	courbes	myographiques,	en	nous	révélant	sur	quels	éléments	du	reflexe
portent	 les	 altérations,	 nous	 conduit	 à	une	 série	de	 remarques	dignes	d’intérêt.	D’abord,	 la	 disparition
complète	 de	 la	 partie	 reflexe	 de	 la	 courbe	 myographique,	 ou,	 lorsqu’elle	 subsiste,	 ses	 caractères
morphologiques	 d’amplitude	 extrêmement	 réduite	 et	 de	 grande	 lenteur,	 enfin	 son	 temps	 perdu
considérable,	 presque	 double	 de	 la	 normale,	 nous	montrent	 l’altération	 profonde	 et	 prédominante	 des
conducteurs	 nerveux	 ou	 de	 la	 partie	 central	 du	 reflexe.	Mais,	 de	 plus,	 la	 secousse	musculaire	 parait
également	modifiée,	diminuée	de	hauteur,	 ralentie,	et	 retardée	dans	son	apparition,	elle	nous	permet	de
penser	 que	 l’élément	 musculaire	 a	 également	 été	 touché	 par	 le	 processus	 d’intoxication.	 Enfin,	 la
comparaison	des	courbes	obtenues	après	percussion	du	tendon	rotulien	et	du	tendon	achilléen	permet	de
constater	une	évolution	différente	pour	ces	deux	reflexes.	Tandis	que	le	premier	a	été	aboli	rapidement	et
n’a	montré	jusqu’au	moment	ou	le	malade	a	quitté	l’hôpital,	aucune	tendance	à	la	réapparition,	le	second,
quoique	 paraissant	 aboli	 cliniquement,	 a	 pu	 être	 enregistré	 avec	 des	 caractères	 se	 rapprochant
progressivement	de	la	normale.	Nous	insistons	sur	ce	fait	important	que	la	méthode	graphique	permet
beaucoup	mieux	que	 l’examen	avec	 le	marteau	percuteur	d’avoir	des	notions	précises	sur	 l’état	des
reflexes	tendineux.
La	pathogénie	du	syndrome	de	radiculo-névrite	observé	chez	nos	malades	n’a	pu	être	précisée.	Une
infection	 on	 une	 intoxication	 doivent	 sans	 doute	 être	 invoquées,	mais	 nous	 n’avons	 pu	 les	 déceler.	 Le
pronostic	ne	parait	pas	être	 très	grave,	 si	nous	en	 jugeons	par	 l’évolution	de	 l’affection	chez	nos	deux
malades,	le	premier	était	presque	guéri	et	le	second	en	voie	d’amélioration	quand	ils	furent	évacués	de
l’Armée.
-----------------------------
(1)	Cette	observation	a	été	succinctement	analysé	par	l’un	de	nous	à	une	réunion	médicale	de	la	VI	Armée
a	Villers-Cotterets	au	mois	d’aout	1915










